PROSPECTUS

For Health, Vigour and Happiness

ACME

Serving Nation Since 1954

ISO 9001:2008 Certified Company

Good to Great

"পুঁজিবাজারে বিনিয়োগ ঝুঁকিপূর্ণ। জেনে ও বুঝে বিনিয়োগ করুন"

"Investment in capital market involves certain degree of risks. The investors are required to read the prospectus and risk factors carefully, assess their own financial conditions and risk taking ability before making their investment decisions."

PROSPECTUS

of

The ACME Laboratories Ltd.

Issue Size

Public Offering of **50,000,000** Ordinary Shares, of this 50,000,000 ordinary shares 50% i.e. 25,000,000 Ordinary Shares are reserved for Eligible Institutional Investors and 10% i.e. 5,000,000 Ordinary Shares for Mutual Funds at a cut off price of Tk. 85.20 and remaining 40% i.e. 20,000,000 Ordinary Shares at a Discounted Price of Tk. 77.00 per share for General Public, **ক্ষতিগ্রস্থ ক্ষুদ্র বিনিয়োগকারী** and NRB of Tk. 10.00 each totaling Tk. 4,096,000,000

Opening date of subscription: 11 April, 2016
Closing date of subscription: 21 April, 2016
For Non-Resident Bangladeshis quota, subscription closes on: 21 April, 2016

MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
ICB Capital Management Limited Green City Edge (5th & 6th Floor), 89 Kakrail, Dhaka-1000, www.icml.com.bd	**Prime Finance Capital Management Limited** PFI Tower (6th Floor), 56-57 Dilkusha C/A, Dhaka-1000, Fax: +88 02 9584922, www.primefincap.com

CREDIT RATING BY

Credit Rating Information and Services Limited (CRISL)

Based on Financial Statements of 30 June 2015

Date of Rating: October 15, 2015		
	Long Term	Short Term
Rating	**A+**	**ST-3**
Validity	**October 14, 2016**	**April 14, 2016**

Date of Issue of Prospectus: 16 March 2016

Preliminary Information and Declarations

Issuer Company	Contact person	Telephone and Fax Number
The ACME Laboratories Ltd. Court de la ACME 1/4, Kallayanpur, Mirpur Road, Dhaka-1207 E-mail:headoffice@acmeglobal.com; Web: www.acmeglobal.com	**Mr. Md. Zahangir Alam, FCMA** Chief Financial Officer	Tel: +880-2-9004194-6, FAX: +880-2-9016872, +880-2-9039399

Manager to the Issue	Contact person	Telephone and Fax Number
ICB Capital Management Ltd. Green City Edge (5th & 6th Floor), 89 Kakrail, Dhaka-1000. E-mail:ceocmcl@accesstel.net; Web: www.icml.com.bd	**Mrs. Nasrin Sultana** Chief Executive Officer	Tel: +880-2-8300421, +880-2-8300395, +880-2-8300555, +880-2-8300367 FAX: +880-2-8300396

Underwriters	Contact person	Telephone and Fax Number
ICB Capital Management Ltd. Green City Edge (5th & 6th Floor), 89 Kakrail, Dhaka-1000. E-mail:ceocmcl@accesstel.net; Web: www.icml.com.bd	**Mrs. Nasrin Sultana** Chief Executive Officer	Tel: +880-2-8300421, +880-2-8300395, +880-2-8300555, +880-2-8300367 FAX: +880-2-8300396
Prime Finance Capital Management Ltd. PFI Tower (6th Floor), 56-57 Dilkusha C/A, Dhaka-1000 E-mail: info@primefincap.com; Web: www.primefincap.com	**Dr. Mosharaf Hossain, FCA** Chief Executive Officer	Tel: +880-2- 9584874, +880-2-9584876-7 FAX: +880-2-9584922
Southeast Bank Capital Services Ltd. Eunoos Trade Center, (Level-9), 52-53, Dilkusha C/A, Dhaka-1000 E-mail:alamgir_dbl@yahoo.com; Web: www.southestbank.com.bd	**Mr. Md. Alamgir Hossain** Sr. Assistant Vice President	Tel: +880-2-9574171 (Ext-103), +880-2-9574167 FAX: +880-2-9574169
Swadesh Investment Management Ltd. Suite 01, Level 11, Unique Trade Centre, 8 Panthapath, Karwan Bazar, Dhaka-1215 E-mail:mamunahmed@msn.com; Web: www.swadesh.com.bd	**Mr. Mamun Ahmed** Managing Director	Tel: +880-2- 01713400500 FAX: +880-2-81558344
IDLC Investments Ltd. Eunoos Trade Centre (Level 21), 52-53 Dilkusha C/A, Dhaka-1000. E-mail:merbank@idlc.com; Web: www.idlc.com	**Mr. Md. Moniruzzaman, CFA** Managing Director	Tel: +880-2-9571170 FAX: +880-2-9571171
EBL Investments Ltd. 59, Motijheel C/A, 1st Floor, Dhaka-1000 E-mail:info@eblinvestments.com; Web: www.eblinvestments.com	**Mr. Md. Tanvir Hashem** Manager	Tel: +880-2-7118975 FAX: +880-2-7120251
First Security Islami Capital & Investment Ltd. Al Amin Center, (12th Floor), 25/A, Dilkusha C/A, Dhaka-1000 E-mail:info@fsicibd.com; Web: www.fsicibd.com	**Mr. M. Anwar Husain** Chief Executive Officer	Tel: +880-2-9555077 FAX: +880-2-9515917
IL Capital Ltd. Printers Building (13th Floor), 5, Rajuk Avenue, Dhaka-1000 E-mail: info@il-capital.com; Web: www.il-capital.com	**Mr. Saad Muhammad Faisal** Chief Executive Officer	Tel: +880-2-9515573 FAX: +880-2-7117559
PLFS Investments Ltd. Paramount Heights (13th Floor), 65/2/1 Box Culvert Road, PuranaPaltan, Dhaka-1000 E-mail:plfsilbd@gmail.com; Web: www.plfsil.plfsbd.com	**Mr. Nripendra Chandra Pandit** Chief Executive Officer (C.C)	Tel: +880-2-9551036, +880-2-9551041 FAX: +880-2-7125396
Roots Investment Limited Diganto Tower, 1st Floor, 12/1, R.K. Mission Road, Motijheel, Dhaka, 1203 E-mail:info@rootsinvestment.com Web: www.rootsinvestment.com	**Mr. Nomanur Rashid** Senior Vice President	Tel: +880-2-01712990348, +880-2- 01833148258 FAX: +880-2-7116908

Sonali Investment Ltd. Sara Tower (11th Floor), 11/A Toyenbee Circular Road, Motijheel C/A, Dhaka – 1000 E-mail:sonaliinvestmentltd@gmail.com; Web: www.silbd.com	**Mr. Surajit Kumar Saha** Chief Executive Officer (In charge)	Tel: +880-2-9568777, +880-2-9556940, +880-2-9575975 FAX: +880-2-9556940 – Ext. 126
BetaOne Investment Ltd. Green Delta AIMS Tower (Level-4), 51-52, Mohakhali C/A, Dhaka-1212. E-mail:info@betaone.com.bd; Web: www.betaone.com.bd	**Mr. Mohammed Atiquzzaman** Managing Director	Tel: +880-2-9887337 FAX: +880-2-9880733

Auditor	Contact person	Telephone and Fax Number
Pinaki & Company Chartered Accountants (An Independent Associate Member of Thakur, Vaidyanath Aiyar& Co., Chartered Accountants, New Delhi, India) Ahsandell, 2/A Mymensing Road (2nd Floor), Shahbag, Dhaka-1000 E-mail: pinaki_co@yahoo.com; Web: N/A	**Mr. Pinkai Das, FCA** Partner	Tel: +880-2-9660944, 9665095 FAX: +880-2-9672726,

Credit Rating Company	Contact person	Telephone and Fax Number
Credit Rating Information & Services Ltd. (CRISL) Nakshi Homes (4th& 5th floor), 6/1A, Segunbagicha Dhaka-1000. E-mail: crisldhk@crislbd.com; Web: www.crislbd.com	**Ms. Dil Khadija Banu** Analysts	Tel: +880-2-9530991-4, FAX: +880-2-9530995,

Valuer	Contact person	Telephone and Fax Number
Masih Muhith Haque & Co. Chartered Accountants Level 13, UTC Building, 8 Panthopoth, Dhaka-1215 E-mail:masihmuhithsyl@gmail.com; Web: www.masihmuhith.com	**Mr. Mohammed Forkan Uddin, FCA** Partner	Tel: +88 02 9144357, 9130675 FAX: +88 02 8119252,

"A person interested to get a prospectus may obtain from the issuer and the issue manager"

"If you have any query about this document, you may consult the issuer, issue manager and underwriter"

"CONSENT OF THE BANGLADESH SECURITIES AND EXCHANGE COMMISSION HAS BEEN OBTAINED TO THE ISSUE/OFFER OF THESE SECURITIES UNDER THE SECURITIES AND EXCHANGE ORDINANCE, 1969, AND RELEVANT PROVISIONS OF THE BANGLADESH SECURITIES AND EXCHANGE COMMISSION (PUBLIC ISSUE) RULES, 2015. IT MUST BE DISTINCTLY UNDERSTOOD THAT IN GIVING THIS CONSENT THE COMMISSION DOES NOT TAKE ANY RESPONSIBILITY FOR THE FINANCIAL SOUNDNESS OF THE ISSUER COMPANY, ANY OF ITS PROJECTS OR THE ISSUE PRICE OF ITS SECURITIES OR FOR THE CORRECTNESS OF ANY OF THE STATEMENTS MADE OR OPINION EXPRESSED WITH REGARD TO THEM. SUCH RESPONSIBILITY LIES WITH THE ISSUER, ITS DIRECTORS, CHIEF EXECUTIVE OFFICER, MANAGING DIRECTOR, CHIEF FINANCIAL OFFICER, COMPANY SECRETARY, ISSUE MANAGER, ISSUE MANAGER'S CHIEF EXECUTIVE OFFICER, UNDERWRITERS, AUDITOR(S), VALUER AND/OR CREDIT RATING COMPANY (IF ANY)."

Risks in relation to the First Issue

"This being the first issue of the issuer, there has been no formal market for the securities of the issuer. The face value of the securities is Tk. 10.00 (ten) and the issue price is Tk. 85.20, i.e. '8.52 times for EIIs including Mutual Fund and Tk. 77.00, i.e. '7.7 times for General Public, ক্ষতিগ্রস্থ ক্ষুদ্র বিনিয়োগকারী and NRB' of the face value. The issue price has been determined and justified by the issuer and the issue manager/bidding by the eligible investors as stated under the paragraph on "Justification of Issue Price" should not be taken to be indicative of the market price of the securities after listing. No assurance can be given regarding an active or sustained trading of the securities or the price after listing."

General Risk

"Investment in securities involves a degree of risk and investors should not invest any funds in this offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offer. For taking an investment decision, investors must rely on their own examination of the issuer and the offer including the risks involved. The securities have not been recommended by the Bangladesh Securities and Exchange Commission (BSEC) nor does BSEC guarantee the accuracy or adequacy of this document. Specific attention of investors is invited to the statement of 'risk factors' given on page number(s) 213-227"

The ACME Laboratories Limited's Absolute Responsibility

"The issuer, having made all reasonable inquiries, accepts responsibility for and confirms that this prospectus contains all material information with regard to the issuer and the issue, that the information contained in the prospectus are true, fair and correct in all material aspects and are not misleading in any respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which make this document as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect."

AVAILABILITY OF PROSPECTUS

The Prospectus and Abridge version of prospectus of The ACME Laboratories Ltd. are available in hard and soft forms at the following addresses:

Issuer Company	Contact person	Telephone and Fax Number
The ACME Laboratories Ltd. Court de la ACME 1/4,Kallayanpur, Mirpur Road, Dhaka-1207 E-mail:headoffice@acmeglobal.com;www.acmeglobal.com	**Mr. Md. Zahangir Alam, FCMA** Chief Financial Officer	Tel: +88 02 9004194-6, FAX: +88 02 9016872, +88 02 9039399

Manager to the Issue	Contact person	Telephone and Fax Number
ICB Capital Management Ltd. Green City Edge (5th & 6th Floor), 89 Kakrail, Dhaka-1000. E-mail: ceocmcl@accesstel.net; www.icml.com.bd	**Mrs. Nasrin Sultana** Chief Executive Officer	Tel: +880-2-8300421, +880-2-8300395, +880-2-8300555, +880-2-8300367 FAX: +88 02 8300396

Stock Exchanges	Contact person	Telephone Number
Dhaka Stock Exchange Ltd (DSE) DSE Library, Research and Information Department 9/F, Motijheel C/A, Dhaka-1000. E-mail: research@dsebd.org; web: www.dsebd.org	**Mr. Md. Afzalur Rahman** Manager	+88 02 9564601-7 +88 02 9666944-8 Fax: +88 02 9569755 +88 02 9564727
Chittagong Stock Exchange Ltd (CSE) CSE Building, 1080, Sk. Mujib Road Agrabad, Chittagong -4100 **Dhaka Liaison Office:** Eunoos Trade Center (Level-15) 52-53 Dilkusha C/A, Dhaka-1000. E-mail: jabed@cse.com.bd; Web: www.cse.com.bd	**Mr. Mohammed Jabed Sarwar** Assistant Manager	+88 031 714632-3 +88031 720871 Fax: +88 031 714101 +880-2-9513911-15

Prospectus would also be available on the web site of BSEC (www.sec.gov.bd), DSE (www.dsebd.org), CSE (www.cse.com.bd), The ACME Laboratories Ltd. (www.acmeglobal.com), Issue Manager (www.icml.com.bd) and Public Reference Room of the Bangladesh Securities and Exchange Commission (BSEC) for reading and studying.

Names and dates of the newspapers where abridged version of prospectus was published

Sl. No.	Name of the News paper	Date of Publication	Page number of the newspaper
01	The Daily Samakal	16 March 2016	17
02	The Daily Ittefaq	16 March 2016	17
03	The Daily Financial Express	16 March 2016	21
04	The Daily New Age	16 March 2016	11

Definitions and Acronyms/Elaborations

Unless the context otherwise indicates, requires or implies, the following terms shall have the meanings set forth below in this Draft Prospectus. References to statutes, rules, regulations, guidelines and policies will be deemed to include all amendments and modifications notified thereto.

A	
AAMC	Association of Assets Management Companies
AAS	Atomic Absorption Spectrophotometer
ACME	The ACME Laboratories Ltd.
AIDS	Acquired Immune Deficiency Syndrome
Allotment	Letter of Allotment of Shares
"Articles" or "Articles of Association" or "AoA"	The Articles of Association of The ACME Laboratories Ltd., as amended
API	Active Pharmaceutical Ingredient
Audit Committee	The audit committee, a sub-committee of the Board of Directors of The ACME Laboratories Ltd.
B	
BAB	Bangladesh Accreditation Board
BAS	Bangladesh Accounting Standards
BFRS	Bangladesh Financial Reporting Standards
BFS	Blow Fill Seal (a saline unit of the Company)
Bidders	The Eligible Institutional Investors who have participated in the bidding
BIA	Bangladesh Insurance Association
BLFCA	Bangladesh Leasing and Finance Companies Association
BMBA	Bangladesh Merchant Bankers Association
BO	Beneficiary Owner
"Board" or "Board of Directors" or "our Board"	The Board of Directors of The ACME Laboratories Ltd., as duly constituted from time to time including any committees thereof
Book-Building Method	The process by which an issuer attempts to determine the price to offer its security based on demand from Eligible Institutional Investors (EIIs)
BSEC	Bangladesh Securities and Exchange Commission
C	
CAGR	Compound Annual Growth Rate
CDBL	Central Depository Bangladesh Limited
CFC	Chlorofluorocarbon
cGMP	Current Good Manufacturing Practices

CIB	Credit Information Bureau
Commission	Bangladesh Securities and Exchange Commission
CRISL	Credit Rating Information and Services Limited
CSE	Chittagong Stock Exchange Limited
CSR	Corporate Social Responsibility
Cut-off Price	The lowest price offered by the bidders at which the total issue could be exhausted
D	
DGDA	Directorate General of Drug Administration & Licensing Authority (Drugs)
DoE	Directorate of Environment
DPI	Dry Powder Inhaler
DSE	Dhaka Stock Exchange Limited
E	
EIIs	Eligible Institutional Investors
E-mail	Electronic Mail
EMS	Express Mail Service
ETP	Effluent Treatment Plant
F	
FC Account	Foreign Currency Account
FTIR	Fourier Transform Infrared Spectrophotometer
Floor Price	The lowest price of the price band within which the Eligible Institutional Investors shall bid for security under book-building method
G	
GC	Gas Chromatography
GCC	Gulf Cooperation Council
GLP	Good Laboratory Practices
GU	General Unit
H	
HFA	Hydro Fluoro Alkanes
HIV	Human Immunodeficiency Virus
HSBC	The Hongkong and Shanghai Banking Corporation
HPLC	High Performance Liquid Chromatography
HVAC	Heating, Ventilation and Air Conditioning
I	
IAS	International Accounting Standards
ICAB	The Institute of Chartered Accountants of Bangladesh

ICB	Investment Corporation of Bangladesh
ICDDR,B	International Centre for Diarrhoeal Disease Research, Bangladesh
ICML	ICB Capital Management Limited
IMS	Intercontinental Marketing Services (an USA based healthcare market surveyor entity)
Indicative Price	The price which the issuer indicate in the draft prospectus taking input from the eligible institutional investors on which the bidders bid for final determination of price.
IPO	Initial Public Offering
IPDC	Industrial Promotion and Development Company
ISO	International Standardization Organization
Issue	Public Issue of Shares
IV	Intravenous
K	
KRA	Key Result Area
L	
LDC	Least Development Country
LTU	Large Taxpayer Unit
LVP	Large Volume Parenteral
M	
MDG	Millennium Development Goal
MDI	Meter Dosage Inhaler
MNC	Multinational Company
MP	Market Price
"Memorandum" or "Memorandum of Association" or "MoA"	The Memorandum of Association of The ACME Laboratories Ltd., as amended
MS –Word	Microsoft word
N	
NAV	Net Asset Value
NBR	National Board of Revenue
NGO	Non-Government Organization
NRB	Non-Resident Bangladeshi
O	
Offering Price	Price of the Share of The ACME Laboratories Ltd. being offered
"Our Company" or "the Company" or "the Issuer"	The ACME Laboratories Limited, a public limited company incorporated under the Companies Act

P	
Price Discovery	A method of determining the price for a specific security through demand and supply factors related to the market
Q	
QA	Quality Assurance
QC	Quality Control
R	
R & D	Research & Development
REB	Rural Electrification Board
Registered Office	Head Office of the Company
RJSC	Registrar of Joint Stock Companies and Firms
Road Show	Presentation by an issuer of security to potential investors about its issuance of security
S	
Securities	Share of The ACME Laboratories Ltd.
Securities Market	The Share Market of Bangladesh
SDU	Solid Dosage Unit
SFT	Square Feet
SOP	Standard Operating Procedure
Sponsors	The Sponsors Shareholder of The ACME Laboratories Ltd.
STD Account	Short Term Deposit Account
Stock Holder	Share Holder
Subscription	Application Money
SVP	Small Volume Parenteral (a Drop and Injectable unit of the Company)
T	
TGA	Therapeutic Goods Administration
The Company/Issuer	The ACME Laboratories Ltd.
TOC	Total Organic Carbon
TRIPS	Trade-Related aspects of Intellectual Property Rights
TT	Telephonic Transfer
U	
UKMHRA	Medicine and Healthcare Products Regulatory Agency of United Kingdom
USFDA	Food and Drug Administration of United States of America
US DOLLAR	United States Dollar
UK	United Kingdom
UK POUND	United Kingdom Pound

UN	United Nation
UNDP	United Nation Development Program
V	
VAT	Value Added Tax
W	
WDV	Written Down Value
WHO	World Health Organization
WSP	Water Soluble Powder

CORPORATE OFFICE
Court de la ACME

GENERAL UNIT

TABLE OF CONTENTS

	Particulars	Page
CHAPTER I	**EXECUTIVE SUMMARY**	
	About the industry	1-2
	About the Issuer	2
	Financial Information	3
	Features of the issue and its objects	3-4
	Legal and Other Information	4
	Promoters' background	4
	Capital structure and history of capital raising	5
	Summary of Valuation Report of Securities	5
CHAPTER II	**CONDITIONS IMPOSED BY THE COMMISSION**	
	Disclosure in respect of issuance of security in Dematerialized form	6
	Condition under 2CC of the Securities & Exchange Ordinance 1969	6-12
	Consent to commence bidding	13-14
CHAPTER III	**DECLARATION AND DUE DILIGENCE CERTIFICATES**	
	Declaration about the responsibility of the directors, including Managing Director of the Issuer in respect of the prospectus	15
	Due Diligence Certificate by the Issue Manager	16-17
	Due Diligence Certificate by the Underwriters	18-29
CHAPTER IV	**ABOUT THE ISSUER**	
	Particulars of the Company	30-31
	Name of the Sponsors and Directors	31
	Particulars of the Auditors and Registrar to the Issue	32
	Name of the Stock Exchanges where the Securities to be listed	32
CHAPTER V	**CORPORATE DIRECTORY OF THE ISSUER**	33
CHAPTER VI	**DESCRIPTION OF THE ISSUER**	
	Summary of the Industry	34-36
	Summary of consolidated financial, operating and other Information	36
	General Information	37-45
	Capital Structure	45-54
	Description of the Business	54-93
	Description of Property	94-136
	Plan of Operation and Discussion of Financial Condition	137-164
CHAPTER VII	**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION**	
	Overview of business and strategies	165-166
	SWOT analysis	167
	Analysis of the financial statements of last five years with reason(s) of fluctuating revenue/sales, other income, total income, cost of material, finance cost, depreciation and amortization expense, other expense; changes of inventories, net profit before & after tax, EPS etc.	167-169
	Known trends demands, commitments, events or uncertainties that are likely to have an effect on the company's business.	169
	Trends or expected fluctuations in liquidity	169
	Off-balance sheet arrangements those have or likely to have a current or future effect on financial condition.	169-170

CHAPTER VIII	**DIRECTORS AND OFFICERS**	
	Particulars of Directors	171
	Directorship tenure in the Company	172-174
	Short Bio Data of the Directors and Others	174-181
CHAPTER IX	**CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**	181-183
CHAPTER X	**EXECUTIVE COMPENSATION**	184
CHAPTER XI	**OPTIONS GRANTED TO DIRECTORS, OFFICERS AND EMPLOYEES**	185
CHAPTER XII	**TRANSACTION WITH THE DIRECTORS AND SUBSCRIBERS TO THE MEMORANDUM**	185-186
CHAPTER XIII	**OWNERSHIP OF THE COMPANY'S SECURITIES**	186-194
CHAPTER XIV	**CORPORATE GOVERNANCE**	195-203
CHAPTER XV	**VALUATION REPORT OF SECURITIES PREPARED BY THE ISSUE MANAGER**	204-208
CHAPTER XVI	**DEBT SECURITIES**	209
CHAPTER XVII	**PARTIES INVOLVED AND THEIR RESPONSIBILITIES**	209-210
CHAPTER XVIII	**MATERIAL CONTRACTS**	210-211
CHAPTER XIX	**OUTSTANDING LITIGATIONS, FINE OR PENALTY**	211-212
CHAPTER XX	**RISK FACTORS AND MANAGEMENT'S PERCEPTIONS ABOUT THE RISKS**	213-227
CHAPTER XXI	**DESCRIPTION OF THE ISSUE**	228-242
CHAPTER XXII	**USE OF PROCEEDS**	243-265
CHAPTER XXIII	**LOCK-IN**	265-270
CHAPTER XXIV	**MARKETS FOR THE SECURITIES BEING OFFERED**	271
CHAPTER XXV	**DESCRIPTION OF SECURITIES OUTSTANDING OR BEING OFFERED**	272-273
CHAPTER XXVI	**FINANCIAL STATEMENTS**	274-346
CHAPTER XXVII	**CREDIT RATING REPORT**	347-367
CHAPTER XXVIII	**PUBLIC ISSUE APPLICATION PROCEDURE: AS DESCRIBED IN THE CONSENT LETTER**	368-372
CHAPTER XXIX	**OTHERS**	
	Auditors Additional Disclosure	373-383
	Additional Disclosure of the Management	384-386
	Audited Financial Statements for the year ended 30 June 2015	387-427

CHAPTER I: EXECUTIVE SUMMARY

About the industry

Pharmaceuticals products are met one of the basic needs for all living being. It is one of the fastest growing industries in the world. According to IMS (an USA based healthcare market surveyor entity), by 2017 demand of pharma products will be USD 1,200 billion, which was USD 965 billion in the year 2012.

According to the same source, in the year 2014 Bangladesh pharma market size was Tk. 10,600 crore with a growth percentage 8.48. For the year ended 30 June 2014, ACME's domestic sales was Tk. 985.46 crore and export sales was Tk. 36.33 crore totaling Tk. 1021.79 crore with a growth 14.11%, 7.63% and 13.87% respectively. According to IMS, in the year 2015 Bangladesh pharma market size was Tk. 12,000 crore. Insiders of the industry apprehend that by the year 2020 Bangladesh pharma market size will be Tk. 20,000 crore. They also apprehend that pharma products are going to be added into the Bangladesh export basket in a big way within couple of years.

Pharmaceutical Industry of Bangladesh has come a long way in the past four decades and has already established itself in domestic as well as international market. The industry contributes about 1% of the total GDP and the second largest industry in terms of contribution to government's exchequer. Bangladesh pharmaceutical industry is now heading towards self–sufficiency in meeting local demand. There are more than 437 registered small, medium, large scale, local and multinational companies operating in the country producing around 97% of the total internal demand. The remaining 3% basically constitute import of much-specialized products like vaccines, anti-cancer products and hormone drugs.

Bangladesh pharma industry is enjoying good number of macroeconomic factors as competitive advantages like favorable government policy, comfortable size of local market for 16 crore population, cheap labor, available technological know-how, low power costs, low costs white-collar labor etc. Population growth rate, growing income level of people and increase in modern health-care facilities, health awareness of the mass people, contract manufacturing service and export of pharmaceutical products are major drivers for future growth in pharma market in Bangladesh.

Therapeutic class wise industry sales of pharma product in the year 2014 & 2015

(Amount in BDT Crore)

Sl. #	Name of the Therapeutic class	30 June 2015		30 June 2014	
		Sales	Market share	Sales	Market share
1	Alimentary T. & Metabolism	4,145.64	34.68	3,635.51	34.34
2	Systemic Anti-Infectives	2,197.38	18.38	2,045.58	19.32
3	Nervous System	1,242.44	10.39	1,138.74	10.76
4	Cardiovascular System	1,153.32	9.65	988.34	9.34
5	Respiratory System	1,051.38	8.79	881.82	8.33
6	Musculo-Skeletal System	654.66	5.48	576.17	5.44
7	G.U.System & Sex Hormones	354.00	2.96	285.72	2.70
8	Dermatological	288.04	2.41	247.00	2.33
9	Blood + B. Forming Organs	247.27	2.07	223.41	2.11
10	Sensory Organs	185.12	1.55	160.34	1.51
11	Systemic Hormones	137.41	1.15	119.72	1.13

Sl. #	Name of the Therapeutic class	30 June 2015		30 June 2014	
		Sales	Market share	Sales	Market share
12	Hospital Solutions	127.06	1.06	128.88	1.22
13	Parasitology	113.56	0.95	109.70	1.04
14	Antineoplast+Immunomodul	34.47	0.29	28.51	0.27
15	Various	22.96	0.19	16.58	0.16
16	Diagnostic Agents	0.13	0.00	0.34	0.00

Sources: IMS Global Health

About the Issuer

The ACME Laboratories Ltd. started its commercial operation in the year 1954 as a proprietorship concern. Later on, the enterprise converted into a private limited company on 17 March 1976 vides registration no. C-4745/163 of 1975-76 under the Companies Act-1913 and it was converted into a public limited company on 30 November 2011. In the way of its over six decades journey, it has transformed itself from good to better and it has been moving towards the great from better through converting into a public limited Company. Right now, it is peeping into the Capital Market.

The Company is engaged in manufacturing, marketing and distribution of generic pharmaceuticals finished formulation products which includes human drugs dosage forms like tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatin, sachet products, IV infusion; veterinary drugs dosage forms like bolus, liquid, injection, water soluble powder, premix and herbal drugs dosage form like liquid, capsule, tablet, cream & ointment. The products of the Company are sold in domestic and international markets.

ACME's Strategies

ACME's key strategic objectives are to

1) Ensure health, vigour and happiness for all;
2) Ensure stable and long-term return to our investors;
3) Maintain state-of-the-art manufacturing facilities for ensuring best quality products to the customers;
4) Obtain word class accreditation by proper execution of ISO 9001:2008 standard, WHO cGMP standard and best practices that are proven effective;
5) Expand existing and develop new large scale projects to diverse the product range and related diversification;
6) Strengthening our existing market share, cope with the changing scenario in the pharma industry to ensure higher prescription rates, transparency and improved products and services for our existing and potential customers;
7) Comprehensive marketing and distribution network (Both in domestic and international markets);
8) Excellent relationship with health care professionals, chemists and other concerned stakeholders;
9) Seek new ways of working to improve efficiency and ensure sustainability.

Financial Information

(Amount in BDT)

Particulars	For the year ended 30 June / as at 30 June				
	2014	2013	2012	2011	2010
Revenue	10,217,931,465	8,973,319,332	8,838,091,913	6,996,750,681	5,557,237,718
Gross Profit	3,980,138,911	3,252,298,522	3,140,612,811	2,455,959,940	1,907,611,158
Net Profit Before Tax	1,204,844,233	810,707,935	802,304,895	584,141,913	364,490,469
Net Profit After Tax	893,890,898	505,695,794	476,128,396	344,151,300	227,806,543
Total Assets	22,179,571,084	16,573,644,043	12,732,360,252	9,809,814,023	4,237,525,961
Shareholders' Equity	10,692,163,182	9,517,448,502	6,609,452,889	5,823,832,008	1,209,557,215
Number of Shares	161,601,700	155,631,100	116,000,000	116,000,000	10,000,000
NAV Per Share	66.16	61.15	56.98	50.21	1,209.56
Earnings Per Share	5.65	4.19	4.10	2.97	1.96

Features of the issue and its objects

The ACME Laboratories Ltd. intended to issue 50,000,000 Ordinary Shares face value Tk. 10 each through Initial Public Offering (IPO) under Book Building Method.

In this regard, the Company has conducted a Road Show on 13 October 2014 for Price Discovering of its security under Book building Method. Total 76 (Seventy Six) Eligible Institutional Investors (EIIs) in 6 (six) categories have given their Indicative Prices. The Issuer in consultation with the Issue Manager quoted the Indicative Price at Tk. 71.00 (Seventy One), from the Indicative Price range Tk. 71.00 to Tk. 86.00, which is supported by 46 (Forty Six) EIIs in 6 (six) categories, against the requirement of at least 20 (twenty) EIIs including at least 3 (Three) quotations covering 10% of the total issue size as per Rule 8(B)(16)(4)(b) of the Securities and Exchange Commission (Public Issue) Rules, 2006 which absorbed 14,716,300 Ordinary Shares out of offering shares.

The summary of bidding process participated by the Eligible Institutional Investors (EIIs)

Face Value	BDT 10.00
Indicative Price	BDT 71.00
Price Band (20% Downward and Upward of the Indicative Price)	BDT 56.80 to BDT 85.20
Total Participants in the Bid	193
Total no. of Bids	275
Highest Bidding Price	BDT 85.20
Lowest Bidding Price	BDT 57.00
Weighted average and Cut-off Price (applicable for EIIs quota allotment including Mutual Fund)	BDT 85.20
Discounted price (applicable for general public, **ক্ষতিগ্রস্থ ক্ষুদ্র বিনিয়োগকারী,** NRB)	BDT 77.00

Both of the weighted average and cut-off price have been determined at Tk. 85.20 through the electronic bidding process under Book Building System of Stock Exchanges in Bangladesh. Total 193 Eligible Institutional Investors (EIIs) have successfully participated in the Price Discovery Process. Amongst them, 178 EIIs have subscribed 50% of the public offer i.e. 25,000,000 Ordinary Shares of Tk. 10/- each at a weighted average and cut-off price of Tk. 85.20 each including a premium of Tk. 75.20 per share as specified in **'List of EII Allotment'** under the head of '**Description of the Issue**' of this Prospectus.

Offer Price

As per Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015, the cut-off price has been determined at Tk. 85.20 per share including a premium of Tk. 75.20 per share, as 50% of the public offer exhausted at weighted average and cut-off price at Tk. 85.20 per share and 10% will offer for Mutual Fund at a cut off price of Tk. 85.20 per share and general public, NRBs and **ক্ষতিগ্রস্থ ক্ষুদ্র বিনিয়োগকারী** shall buy securities of the Company at a discounted price of Tk. 77.00 per share.

Objective of the Issue

ACME has a succeeding expansion plan to develop three new projects namely Steroid & Hormone Project, Oncology Project and Ayurvedic, Modern Herbal & Nutraceuticals Project by using IPO proceeds.

Legal and other Information

The legal and other information against the issuer or any of its Directors are available in the Chapter XIX, page no. 211 under the head of **'Outstanding litigations, fine or penalty'** of the prospectus.

Promoters' background

Late Hamidur Rahman Sinha, founder of the Company, established The ACME Laboratories in the 1954 as a proprietorship concern. Later on, the enterprise converted into a private limited company on 17 March 1976 vides registration no. C-4745/163 of 1975-76 under the Companies Act-1913. At that time Sinha family held 83.33 percent share of the Company and following promoters were contributed to ACME's journey. Among them two promoters namely Mr. Mizanur Rahman Sinha and Mrs. Jahanara Mizan Sinha are still serving the Company as members of the Board whose background are discussed in the Chapter **'Directors' and Officers'** page no. 174 under the head of short bio data of the directors and others. Mr. Nasir-ur-Rahman Sinha, Mrs. Parvin Akhter Nasir and Mrs. Khurshid Jahan Dabir are current shareholders of the Company. Shares of the other promoters were transferred and/or transmitted among the other shareholders of the Company.

Sl. No.	Name
1	Late Hamidur Rahman Sinha
2	Mr. Masudul Haque
3	Mr. Masum Rahman
4	Mr. Nasir-ur-Rahman Sinha
5	Mr. Mizanur Rahman Sinha
6	Capt. (Rtd.) Anisur Rahman Sinha
7	Mrs. Sitara Hossain
8	Mrs. Parvin Akhter Nasir
9	Mrs. Jahanara Mizan
10	Mrs. Khurshid Jahan Dabir
11	Mrs. Nazma Rahman
12	Mrs. Laizu Dabir

Capital structure and history of capital raising

Authorized Capital

Particulars	No. of Ordinary Shares	Nominal Value in BDT	Total Amount in BDT
Authorized Capital	500,000,000	10	5,000,000,000

Paid-up Capital

Date of allotment	No. of Shares	Amount in BDT
17.03.1976	600	6,000
16.05.1976	2,000	20,000
16.05.1976	27,500	275,000
10.08.1986	300,000	3,000,000
29.11.2006	9,669,900	96,699,000
05.05.2011	106,000,000	1,060,000,000
20.05.2013	39,631,100	396,311,000
26.11.2013	59,70,600	59,706,000
Total 161,601,700 Ordinary Shares @Tk. 10.00 each		**1,616,017,000**

Paid-up capital before and after the Public Issue

Particulars of Paid-up Capital	No. of Ordinary Shares	Amount in BDT
Before Initial Public Offerings	**161,601,700**	**1,616,017,000**
Initial Public Offering through Book Building Method	500,000,00	500,000,000
After Initial Public Offerings	**211,601,700**	**2,116,017,000**

Summary of Valuation Report of securities

Sl. #	Particulars	Amount in BDT
Method-1 (a)	Net Assets Value per Share at current cost as at 30 June 2015	70.37
Method-1 (b)	Net Assets Value per Share at historical cost as at 30 June 2015	37.45
Method-2	Earnings based value per share as at 30 June 2015	110.34
Method-3	Average Market Price Per Share of Similar Stock	271.59

CHAPTER II: CONDITIONS IMPOSED BY THE COMMISSION

DISCLOSURE IN RESPECT OF ISSUANCE OF SECURITY IN DEMATERIALIZED FORM

As per provisions of the Depository Act, 1999 and regulations made there under, share of the Company will be issued in dematerialized form only and for this purpose The ACME Laboratories Ltd. will sign an agreement with the Central Depository Bangladesh Limited (CDBL). Therefore, all transfers, transmissions, splitting or conversions will take place on the CDBL system and any further issuance of shares (including rights and bonus) will also be issued in dematerialized form only.

CONDITIONS UNDER 2CC OF THE SECURITIES AND EXCHANGE ORDINANCE, 1969

PART–A

1. The abridged version of the prospectus, as approved by the Commission, shall be published by the issuer in 4 (Four) national daily newspapers (two in Bangla and two in English), within 02 (two) working days of issuance of this consent letter. The issuer shall post the full prospectus, vetted by Commission, in the issuer's website and shall also put on the websites of the Commission, stock exchanges, and the issue manager, within 03 (three) working days from the date of issuance of this letter and shall remain posted till the closure of the subscription list. The issuer shall submit to the Commission, the stock exchanges and the issue manager a diskette containing the text of the vetted prospectus in "MS-Word" format.

2. The company shall submit **40 (Forty)** copies of the printed prospectus to the Commission for official record within **05 (Five) working days** from the date of publication of the abridged version of the prospectus in the newspaper.

3. The issuer company and the issue manager shall ensure transmission of the prospectus and its abridged version for NRBs through email to the Bangladesh Embassies and Missions abroad within **05 (Five) working days** from the date of publication of the abridged version of the prospectus in the newspaper. A compliance report shall be submitted in this respect to the Commission jointly by the issuer and the Issue Manager within **02 (Two) working** days from the date of said transmission of the prospectus.

4. The following declaration shall be made by the company in the prospectus, namely: -

   "**Declaration about Listing of Shares with the stock exchange (s):**

   None of the stock exchange(s), if for any reason, grants listing within **75 (Seventy Five) days** from the closure of subscription, any allotment in terms of this prospectus shall be void and the company shall refund the subscription money within **15 (Fifteen) days** from the date of refusal for listing by the stock exchanges or from the date of expiry of the said **75 (Seventy Five) days**, as the case may be.

   In case of non-refund of the subscription money within the aforesaid **15 (Fifteen) days**, the Directors of the company, in addition to the issuer company, shall be collectively and severally liable for refund of the subscription money, with interest at the rate of **2% (two percent)** above the bank rate, to the subscribers concerned.

   The issue manager, in addition to the issuer company, shall ensure due compliance of the above mentioned conditions and shall submit compliance report thereon to the Commission within **07 (Seven) days** of expiry of the aforesaid **15 (Fifteen) days** time period allowed for refund of the subscription money."

5. The IPO shall stand cancelled in case of under-subscription in any categories above 35%. In such an event, the issuer and issue manager shall inform the Commission **within 02 (two) working days** and release the subscription money within 10 (ten) working days after receiving verification report from CDBL and the information from exchanges regarding subscription.

6. **20% of the securities for general public shall be reserved for ক্ষতিগ্রস্থ ক্ষুদ্র বিনিয়োগকারী. In case of over subscription in the general public category, the issuer and the issue manager shall jointly conduct an open lottery. In case of over subscription by the Mutual Funds, securities reserved for them shall be allotted on pro-rata basis.**

7. All applicants under general public category shall apply for minimum market lot of 100 shares worth Taka 7,700/- (Taka seven thousand seven hundred only) for a market lot or its multiples.

8. **An applicant cannot submit more than two applications, one in his/her own name and the other jointly with another person. In case, an applicant submits more than two applications, all applications will be treated as invalid and will not be considered for allotment purpose. In addition, 15% (fifteen) of the application money will be forfeited by the Commission and the balance amount will be refunded to the applicant.**

9. **The applicants who have applied for more than two applications using same bank account, their application will not be considered for lottery and the Commission will forfeit 15% of their subscription money.**

10. **Making any false statement in the application or supplying of incorrect information therein or suppressing any relevant information in the application shall make the application liable to rejection and subject to forfeiture of 25% of the application money and/or forfeiture of share (unit) before or after issuance of the same by the issuer. The said forfeited application money or share (unit) will be deposited in account of the Bangladesh Securities and Exchange Commission (BSEC). This is in addition to any other penalties as may be provided for by the law.**

11. The company shall furnish the list of allotees to the Commission and the stock exchange(s) simultaneously in which the shares will be listed, within **24 (Twenty Four) hours** of allotment.

12. Shares not allotted at the time of according this consent, but allotted after listing, in favor of sponsors, directors or shareholders having 5% or more shares through stock dividends, shall be subject to a lock-in period of 02 (two) years from the date of issuance of the prospectus.

13. **If any share of Sponsors/Directors/Promoters is in paper format, it shall be handed over to securities custodian registered with the Commission and shall remain held till completion of lock-in period and the name of the securities custodian shall be furnished to the Commission jointly by the issuer and issue manager, along with a confirmation thereof from the custodian, within one week of listing of the shares with the stock exchange(s). Or they (shares of Sponsors/ Directors/ Promoters) can be demated and shall remain in lock-in under CDBL system and issuer shall submit a dematerialization confirmation report generated by CDBL and attested by Managing Director of the company along with the lock-in confirmation to the Commission within one week of listing of the shares with the stock exchange(s). In respect of shares other than Sponsors/Directors/Promoters the issuer will ensure their lock-in of those shares and submit a statement to this effect to the Commission.**

14. **25% of the shares allotted to eligible investors (including Mutual Fund), shall be locked-in for 3 (three) months and other 25% of the shares allotted to them, shall be locked-in for 6 (six) months.**

15. **The company shall not declare any dividend/bonus shares before listing of its securities with any exchange from the date of this consent for raising of capital.**

PART–B

Application Process

Step-1 (Applicant)

1. An applicant for public issue of securities shall submit application/buy instruction to the Stockbroker/ Merchant Banker where the applicant maintains customer account, within the cut-off date (i.e. the subscription closing date), which shall be the **25th (twenty fifth) working day** from the date of publication of abridged version of prospectus.

2. The application/buy instruction may be submitted in prescribed paper or electronic form, which shall contain the Customer ID, Name, BO Account Number, Number of Securities applied for, Total Amount and Category of the Applicant. At the same time:

    a) Other than non-resident Bangladeshi (NRB) and Foreign applicants shall make the application money and service charge available in respective customer account maintained with the Stockbroker/Merchant Banker. No margin facility, advance or deferred payment is permissible for this purpose. In case the application is made through a margin account, the application money shall be deposited separately and the Stockbroker/Merchant Banker shall keep the amount segregated from the margin account, which shall be refundable to the applicant, if become unsuccessful.

    b) Non-resident Bangladeshi (NRB) and Foreign applicants shall submit bank drafts (FDD), issued in favor of the Issuer for an amount equivalent to the application money, with their application to the concerned Stockbroker/Merchant Banker. A Non-resident Bangladeshi (NRB) and Foreign applicant may also submit a single draft against 02(two) applications made by him/her, i.e. one in his/her own name and the other jointly with another person. The draft (FDD) shall be issued by the Bank where the applicant maintains NITA/Foreign Currency account debiting the same account. No banker shall issue more than two drafts from any NITA/Foreign Currency account for any public issue. At the same time, the applicant shall make the service charge available in respective customer account maintained with the Stockbroker/Merchant Banker.

Step-2 (Intermediary)

3. The Stockbroker/Merchant Banker shall maintain a separate bank account only for this purpose namely "Public Issue Application Account". The Stockbroker/Merchant Banker shall:

    a) post the amount separately in the customer account (other than NRB and Foreign applicants), and upon availability of fund, block the amount equivalent to the application money;

b) accumulate all the application/buy instructions received up to the cut-off date, deposit the amount in the "Public Issue Application Account" maintained with its bank within the first banking hour of **next working day** of the cut-off date. In case of application submitted by the Stock-dealer or the Merchant Banker's own portfolio, the application amount should also be transferred to the "Public Issue Application Account";

c) instruct the banker to block the account for an amount equivalent to the aggregate application money and to issue a certificate in this regard.

4. Banker of the Stockbroker/Merchant Banker shall block the account as requested for, issue a certificate confirming the same and handover it to the respective Stockbroker/Merchant Banker.

5. For Non-resident Bangladeshi (NRB) and Foreign applicants, the Stockbroker/Merchant Banker shall prepare a list containing the draft information against the respective applicant's particulars.

6. The Stockbroker/Merchant Banker shall prepare category wise lists of the applicants containing Customer ID, Name, BO Account Number and Number of Securities applied for, and **within 03 (three) working days** from the cut-off date, send to the respective Exchange, the lists of applicants in electronic (text format with tilde '~' separator) format, the certificate(s) issued by its banker, the drafts received from Non-resident Bangladeshi (NRB) and Foreign applicants and a copy of the list containing the draft information.

7. **On the next working day**, the Exchanges shall provide the Issuer with the information received from the Stockbroker/Merchant Bankers, the drafts submitted by Non-resident Bangladeshi (NRB) and Foreign applicants and the list containing the draft information. Exchanges shall verify and preserve the bankers' certificates in their custody.

8. The application/buy instructions shall be preserved by the Stockbroker/Merchant Bankers up to 6 months from listing of the securities with exchange.

Step-3 (Issuer)

9. The Issuer shall prepare consolidated list of the applications and send the applicants' BOIDs in electronic (text) format in a CDROM to CDBL for verification. The Issuer shall post the consolidated list of applicants on its website and websites of the Exchanges. CDBL shall verify the BOIDs as to whether the BO accounts of the applicants are active or not.

10. **On the next working day**, CDBL shall provide the Issuer with an updated database of the applicants containing BO Account Number, Name, Addresses, Parents' Name, Joint Account and Bank Account information along with the verification report.

11. After receiving verification report and information from CDBL, the Issuer shall scrutinize the applications, prepare category wise consolidated lists of valid and invalid applications and submit report of final status of subscription to the Commission and the Exchanges **within 10 (ten) working days** from the date of receiving information from the Exchanges.

12. The Issuer and the issue manager shall conduct category wise lottery with the valid applications **within 03 (three) working days** from the date of reporting to the Commission and the Exchanges, if do not receive any observation from the Commission or the Exchanges.

13. The Issuer and issue manager shall arrange posting the lottery result on their websites within **06 (six) hours** and on the websites of the Commission and Exchanges within **12 (twelve) hours** of lottery.

14. Within **02 (two) working days** of conducting lottery, the Issuer shall:

    a) send category wise lists of the successful and unsuccessful applicants in electronic (text format with tilde '~' separator) format to the respective Exchange.

    b) send category wise lists of unsuccessful applicants who are subject to penal provisions as per conditions of the Consent Letter issued by the Commission in electronic (text format with tilde '~' separator) format to the Commission and Exchanges mentioning the penalty amount against each applicant.

    c) issue allotment letters in the names of successful applicants in electronic format with digital signatures and send those to respective Exchange in electronic form.

    d) send consolidated allotment data (BOID and number of securities) in electronic text format in a CDROM to CDBL to credit the allotted shares to the respective BO accounts.

Step-4 (Intermediary)

15. **On the next working day**, Exchanges shall distribute the information and allotment letters to the Stockbroker/Merchant Bankers concerned in electronic format and instruct them to:

    a) remit the amount of successful (other than NRB and Foreign) applicants to the Issuer's respective Escrow Account opened for subscription purpose, and unblock the amount of unsuccessful applicants;

    b) send the penalty amount of other than NRB and Foreign applicants who are subject to penal provisions to the Issuer's respective Escrow Accounts along with a list and unblock the balance application money;

16. **On the next working day** of receiving the documents from the Exchanges, the Stockbrokers/Merchant Banker shall request its banker to:

    a) release the amount blocked for unsuccessful (other than NRB and foreign) applicants;

    b) remit the aggregate amount of successful applicants and the penalty amount of unsuccessful applicants (other than NRB and foreign) who are subject to penal provisions to the respective 'Escrow' accounts of the Issuer opened for subscription purpose.

17. **On the next working day** of receiving request from the Stockbrokers/Merchant Bankers, their bankers shall unblock the amount blocked in the account(s) and remit the amount as requested for to the Issuer's 'Escrow' account.

18. **Simultaneously**, the stockbrokers/Merchant Bankers shall release the application money blocked in the customer accounts; inform the successful applicants about allotment of securities and the unsuccessful applicants about releasing their blocked amounts and send documents to the Exchange evidencing details of the remittances made to the respective 'Escrow' accounts of the Issuer. The unblocked amounts of unsuccessful applicants shall be placed as per their instructions. The Stockbroker/Merchant Banker shall be entitled to recover the withdrawal charges, if any, from the applicant who wants to withdraw the application money, up to an amount of Tk.5.00 (five) per withdrawal.

19. All drafts submitted by NRB or Foreign applicants shall be deposited in the Issuer's respective 'Escrow' accounts and refund shall be made by the Issuer by refund warrants through concerned stockbroker or merchant banker or transfer to the applicant's bank account through banking channel within 10 (ten) working days from the date of lottery.

Miscellaneous:

20. The Issuer, Issue Manager(s), Stockbrokers and Merchant Bankers shall ensure compliance of the above.

21. The bank drafts (FDD) shall be issued considering TT Clean exchange rate of Sonali Bank Ltd. on the date of publication of abridged version of prospectus.

22. Amount deposited and blocked in the "Public Issue Application Account" shall not be withdrawn or transferred during the blocking period. Amount deposited by the applicants shall not be used by the Stockbrokers/Merchant Bankers for any purpose other than public issue application.

23. The Issuer shall pay the costs related to data transmission, if claimed by the Exchange concerned up to an amount of Tk.2,00,000.00 (taka two lac) for a public issue.

24. The Stockbroker/Merchant Bankers shall be entitled to a service charge of Tk.5.00 (taka five) only per application irrespective of the amount or category. The service charge shall be paid by the applicant at the time of submitting application.

25. The Stockbroker/Merchant Banker shall provide the Issuer with a statement of the remittance and drafts sent.

26. The Issuer shall accumulate the penalty amount recovered and send it to the Commission through a bank draft/payment order issued in favor of the Bangladesh Securities and Exchange Commission.

27. The concerned Exchange are authorized to settle any complaints and take necessary actions against any Stockbroker/Merchant Banker in case of violation of any provision of the public issue application process with intimation to the Commission.

PART–C

1. The issue manager shall carefully examine and compare the published prospectus and its abridged version on the date of publication with the copies vetted by the Commission. If any discrepancy is found, both the issuer and the issue manager shall jointly publish a corrigendum immediately in the same newspapers concerned, simultaneously endorsing copies thereof to the Commission and the stock exchanges concerned. In this regard, the issue manager shall submit a compliance report to the Commission within 5 working days from the date of such publications.

2. The fund collected through Public Offering shall not be utilized prior to listing with stock exchanges and that utilization of the said fund shall be effected through banking channel, i.e. through account payee cheque, pay order or bank drafts etc.

3. **The company shall furnish status report on utilization of Public Offering proceeds audited by foreign affiliated auditors and authenticated by the board of directors to the Commission and the exchanges within 15 (Fifteen) days of the closing of each month until such fund is fully utilized, as mentioned in the schedule contained in the prospectus, and in the event of any irregularity or inconsistency, the Commission may employ or engage any person, at issuer's cost, to examine whether the issuer has utilized the proceeds for the purpose disclosed in the prospectus.**

4. **While auditing the utilization of IPO proceeds, the auditors will perform their jobs under the following terms of reference (TOR) and confirm the same in their report/certificate:**

    (a) Whether IPO proceeds have been utilized for the purposes/heads as specified in the prospectus;

    (b) Whether IPO proceeds have been utilized in line with the condition (if any) of the Commission's consent letter;

    (c) Whether utilization of IPO proceeds have been completed within the time schedule/implementation schedule as specified in the published prospectus;

    (d) Whether utilization of IPO proceeds is accurate and for the purpose of the company as mentioned/specified in the published prospectus; and

    (e) The auditors should also confirm that:(i)assets have been procured/imported/constructed maintaining proper/required procedure as well as at reasonable price; and (ii) auditors' report has been made on verification of all necessary documents/papers/vouchers in support of IPO proceeds making reconciliation with Bank Statement.

5. All transactions, excluding petty cash expenses, shall be effected through the company's bank account(s).

6. Proceeds of the public offering shall not be transferred to any other bank account before listing with exchanges and used for any purpose other than those specified in the prospectus. Any deviation in this respect must have prior approval of the shareholders in the shareholders meeting under intimation to the Commission and the exchanges.

7. If any quarter or half-year of the financial year ends after publication of the abridged version of prospectus and before listing of its securities with any exchange, the company shall disseminate/transmit/submit the said quarterly/half yearly financial statements in accordance with the Commission's Notification SEC/CMRRCD/2008-183/admin/03-34 dated September 27, 2009 and Rules 13 of the Securities and Exchange Rules, 1987.

8. In the event of arising issues concerning Price Sensitive Information as defined under the সিকিউরিটিজ ও এক্সচেঞ্জ কমিশন (সুবিধাভোগী ব্যবসা নিষিদ্ধকরণ) বিধিমালা ১৯৯৫ after publication of the abridged version of prospectus and before listing of its securities with any exchange, the company shall disseminate/transmit/submit the information as price sensitive in accordance with the Commission's Notification No. SEC/SRMI/200-953/1950 dated October 24, 2000.

PART–D

1. As per provision of the Depository Act, 1999 & regulations made there under, shares will only be issued in dematerialized condition. All transfer/transmission/splitting will take place in the Central Depository Bangladesh Ltd. (CDBL) system and any further issuance of shares (Including rights/bonus) will be made in dematerialized form only.

2. The issuer and the issue manager shall ensure due compliance of all the above conditions, the 'Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015' and the listing regulations of the exchanges.

3. The Commission may impose further conditions/restrictions etc. from time to time as and when considered necessary which shall also be binding upon the issuer company.

Consent to commence bidding by the eligible institutional investors for price discovery of issuance of 50,000,000 Ordinary Shares of The ACME Laboratories Ltd.

The Commission hereby accords its consent, vide letter no. BSEC/CUBB-03/2014/1, Dated: January 03, 2016 under section 2A, sub-sections (2)(a) and (2)(b), read with section 2B of the Securities and Exchange Ordinance, 1969 and the Securities and Exchange Commission (Public issue) Rules 2006, based on all the above documents and information provided to BSEC, to commence bidding by the eligible institutional investors for price discovery of issue of 50,000,000 ordinary shares of The ACME Laboratories Ltd. (hereinafter referred to as Issuer* or 'company') through public offer, subject to the following conditions imposed under section-2CC of the said Ordinance:

1. The indicative price Tk. 71.00 (taka seventy one) only shall be the basis for formal price building with an upward and downward band of 20% (twenty percent) of indicative price within which eligible institutional investors shall bid for the allocated amount of security:
2. If institutional quota is not cleared at 20% (twenty percent) below indicative price, the issue will be considered cancelled unless the floor price is further lowered within the face value of security, provided that. the issuer's chance to lower the price shall not be more than once;
3. Prospectus will have to be posted on the Websites of the Commission, stock exchanges, issue manager and issuer at least two weeks prior to the start of the bidding to facilitate investors to know about the company and all aspect of offering.

   Associations (Stock Exchanges, BMBA, BAB, BLFCA, BlA, AAMC) shall ensure dissemination of hard copy of draft prospectus among their respective members;
4. No institutional investor shall be allowed to quote for more than 5% (five percent) of the total security offered for sale, subject to maximum of 5 (five) bids:
5. Institutional bidding period will be 48 (forty eight) hours which may be changed by the approval of the Commission:
6. The Company and the Issue Manager shall submit the status of bidding and the Cut-off price along with the final draft prospectus, simultaneously to the Commission and the stock exchanges within 05(five) working days from the closing day of bidding;
7. The bidding will be handled through a uniform and integrated automated system of the stock exchanges, or any other organization as decided by the Commission, especially developed for book building method;
8. The volume and value of bid at different prices will be displayed on the monitor of the said system without identifying the bidder;
9. The institutional bidders will be allotted security on pro-rate basis at the weighted average price of the bids that would clear the total number of securities being issued to them;
10. Institutional bidders shall deposit their bid with 20% (twenty percent) of the amount of bid in advance to the designated bank account and the rest amount to settle the dues against security to be issued to them shall be deposited within 5 (five) working days prior to the date of opening subscription for general investors;

11. In case of failure to deposit remaining amount that is required to be paid by institutional bidders for full settlement of the security to be issued in their favor, 50% (fifty percent) of bid money deposited by them shall be forfeited by the Commission. The securities earmarked for the bidder who defaulted in making payment shall be added to the general investor quota;
12. General investors, which include mutual funds and NRBs, shall buy at the cut-off price;
13. There shall be a time gap of 15 (fifteen) working days or as may be determined by the Commission between closure of bidding by eligible institutional investors and subscription opening for general investors,
14. Subscription for general investors shall remain open for the period as specified by the Commission;
15. General investors shall place their application through Stock Brokers and Merchant bankers:
16. All application money shall be kept in a separate escrow account opened with a designated bank with prior intimation to the Commission. Issuer will not be allowed to utilize such money until all the process of issue is completed and Commission's consent to this effect is obtained:
17. There shall be lock-in of 4 (four) months from the first trading day on the security issued to the eligible institutional investors:
18. Within 5 (five) working days of completion of the bidding process, the issuer and issue manager shall submit to the Commission, the following papers/documents for final approval of the prospectus:
    i. 10(ten) copies of draft prospectus duly signed by the issuer and issue manager containing among others, the cut-off price and weighted average price as discovered through the bidding process, date of opening and closing of subscription for the general investors, number of shares to be allotted to each category of investors and a statement of shares to be allotted to each of the eligible institutional investors:
    ii. Statement of the designated bank account evidencing deposit of money paid in advance by the eligible institutional investors;
    iii. Hard copy and soft copy of the bidding results;
19. The company along with the Issue Manager and Registrar to the Issue shall ensure due compliance of the above and the securities and Exchange Commission (Public issue) Rules, 2006.

Allocation of Shares of 'The ACME Laboratories Limited'

Further to the letter no. BSEC/CI/BB-03/2014/1 dated January 03, 2016 regarding consent to commence bidding by the eligible institutional investors, an additional letter no. BSEC/CI/BB-3/2014/107; dated: February 17, 2016 was issued by Bangladesh Securities and Exchange Commission to allocate the shares in the following manner as per Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015:

Eligible investors (EIs)		**General public**	
Mutual Funds	**Other EIs**	**NRB**	**Others**
10% At the cut-off price	50% At the cut-off price	10% At 10% discount (at nearest integer) from the cut-off price	30% At 10% discount (at nearest integer) from the cut-off price

CHAPTER III: DECLARATIONS & DUE DILIGENCE CERTIFICATES

Annexure-A

Declaration about the responsibility of the Directors including the Managing Director of The ACME Laboratories Ltd. in respect of the Prospectus

[Rule 4 (1) (d)]

This Prospectus has been prepared, seen and approved by us, and we, individually and collectively, accept full responsibility for the authenticity and accuracy of the statements made, information given in the Prospectus, Documents, Financial Statements, Exhibits, Annexes, Papers submitted to the Commission in support thereof, and confirm, after making all reasonable inquiries that all conditions concerning this Public Issue and Prospectus have been met and that there are no other information or documents the omission of which make any information or statements therein misleading for which the Commission may take any civil, criminal or administrative action against any or all of us as it may deem fit.

We also confirm that full and fair disclosure has been made in this Prospectus to enable the investors to make a well-informed decision for investment.

Sd/- **(Afzalur Rahman Sinha)** Chairman	Sd/- **(Mizanur Rahman Sinha)** **Managing Director	Sd/- (**Dr. Jabilur Rahman Sinha)** Director
Sd/- (**Jahanara Mizan Sinha)** Director	Sd/- **(Nagina Afzal Sinha)** Director	Sd/- **(Syed Shahed Reza)** Independent Director
	Sd/- **(Fouzia Haque, FCA)** Independent Director	

**** Managing Director of the company is also a shareholder of the company**

Annexure - B

Due Diligence Certificate by Issue Manager
[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Issue of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 by The ACME Laboratories Limited.

Dear Sir,
We, the issue manager to the above-mentioned forthcoming issue, state and confirm as follows:

(1) We have examined all the documents submitted with the application for the above mentioned public issue, visited the premises of the issuer and interviewed the Chairperson, Directors and key management personnel of the issuer in connection with the finalization of the prospectus pertaining to the said issue;

(2) On the basis of such examination and the discussions with the directors, officers and auditors of the issuer, other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer.

WE CONFIRM THAT:

(a) The prospectus filed with the Commission is in conformity with the documents, materials and papers relevant to the issue;

(b) All the legal requirements relating to the issue as also in the rules, notification, guidelines, instructions, etc. framed/issued by the Commission, other competent authorities in this behalf and the Government have been duly complied with;

(c) The disclosures made in prospectus are true, fair and adequate to enable the investors to make a well informed decision for investment in the proposed issue and such disclosures are in accordance with the requirements of the Companies Act, 1994 and the relevant provisions of the Bangladesh Securities Exchange Commission (Public Issue) Rules, 2015 and other applicable laws;

(d) Besides ourselves, all the intermediaries named in the prospectus is registered with the Commission and that till date such registrations are valid;

(e) We have satisfied ourselves about the capability of the underwriters to fulfill their underwriting commitments;

(f) The proposed activities of the issuer for which the funds are being raised in the present issue fall within the 'main objects' listed in the object clause of the Memorandum of Association or other charter of the issuer and that the activities which have been carried out till now are valid in terms of the object clause of its Memorandum of Association;

(g) Necessary arrangements have been made to ensure that the moneys to be received pursuant to the issue shall be kept in a separate bank account and shall be used for the purposes disclosed in the use of proceeds section of the prospectus;

(h) All the applicable disclosures mandated in the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 have been made in addition to other disclosures which, in our view, are fair and adequate to enable the investor to make a well informed decision;

(i) We enclose a note explaining how the process of due diligence has been exercised by us in view of the nature of current business background of the issuer, situation at which the proposed business stands, the risk factors, sponsors experiences etc. We also confirm that the due diligence related process, documents and approval memos shall be kept in record by us for the next 5 (five) years after the IPO for any further inspection by the Commission.

(j) We enclose a checklist confirming rule-wise compliance with the applicable provisions of the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 containing details such as the rule number, its text, the status of compliance, page numbers of the prospectus where the rules has been complied with and our comments, if any;

(k) We also declare that we have managed the public issue of following issuers in the last 05 (five) years:

Serial No.	Issue Month/Year (July to June)	Issue FY	Issue Price	Dividend Payment History
1	No issue has been approved	**2010-11**	N/A	N/A
2	Bangladesh Shipping Corporation (RPO)	**2011-12**	500.00	2015- 10% B, 2014-10% C, 2013- 20% C, 15% B, 2012- 20% C, 10% B
	GSP Finance Company (Bangladesh) Limited		25.00	2014-55% B, 2013- 12% B, 2011- 10% B
	Bangladesh Submarine Cable Company Limited		35.00	2015- 20% B, 2014-20% B, 5% C, 2013- 15% B,
3	Orion Pharma Limited	**2012-13**	60.00	2014- 15% C, 2013- 15% C, 2012- 20% C, 20% B.
	Bengal Windsor Thermoplastics Limited		40.00	2014- 10% B, 2013- 23% C, 2012- 8% B, 14% C
4	Apollo Ispat Complex Limited	**2013-14**	22.00	2015- 3% C, 12% B, 2014- 14% B
	Shurwid Industries Limited		10.00	2014- 15% B
	Saif Powertec Limited		30.00	2015- 29% B, 2014- 27% B
	Western Marin Shipward Limited		35.00	2014- 5%C, 10%B
5	National Feed Mills Limited	**2014-15**	10.00	2014- 10%B
	Hamid Fabrics Limited		35.00	2015- 15%C, 5%B, 2014- 10%C, 10%B

For Manager to the Issue

Sd/-
(Nasrin Sultana)
Chief Executive Officer
ICB Capital Management Limited

Dhaka,
Date: February 8, 2016

Due diligence certificate by the underwriter (ICB Capital Management Limited)

[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,
We, the under-noted Underwriter to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 131.86 (One hundred thirty one point eight six) crore and we have the capacity to underwrite a total amount of Tk. 659.30 (Taka six hundred fifty nine point three zero) crore as per relevant legal requirements. We have committed to underwrite for up to Tk. 696,320,000 (Sixty Nine crore Sixty Three lac and Twenty thousand) for the upcoming issues.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of the Company	Amount Underwritten (in Tk.)
1	Doreen Power Generations and Systems Limited	145,000,000.00
2	Bangladesh National Insurance Company Limited	13,275,000.00
3	Energypac Power Generation Limited	7,812,500.00
4	IDLC Finance Limited	150,000,000.00
5	GPH Ispat Limited	210,000,000.00
Total=		**526,087,500.00**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-
(Nasrin Sultana)
Chief Executive Officer
ICB Capital Management Limited

Date: February 18, 2016

Due diligence certificate by the underwriter (PLFS Investments Limited)

[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,
We, the under-noted Underwriter to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 241,500,000.00 (Twenty Four Core Fifteen Lac) and we have the capacity to underwrite a total amount of Tk. 1,207,500,000 (One Hundred Twenty Core Seventy Five Lac) as per relevant legal requirements. We have committed to underwrite for up to Tk. 40,960,000 (Four Core Nine Lac Sixty Thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of the Company	Amount Underwritten (in Tk.)
1.	Doreen Power Generations & Systems Limited (IPO)	41,470,000
2.	Fortune Shoes Limited (IPO)	20,000,000
3.	Pacific Denims Limited (IPO)	18,750,000
4.	Shamsul Alamin Real Estate Limited (IPO)	7,758,630
Total=		**87,978,630**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) this underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-
Nripendra Chandra Pandit
Chief Executive Officer (C.C.)
PLFS Investments Limited

Date: February 18, 2016

Due diligence certificate by the Underwriter (IL Capital Limited)

[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,
We, the under-noted Underwriter(s) to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 256.066 Million (Taka Two hundred Fifty Six Million sixty six thousand) and we have the capacity to underwrite a total amount of Tk. 1,250 million (Taka twelve hundred fifty million) as per relevant legal requirements. We have committed to underwrite for up to Tk. 180,224,000 (Eighteen crore Two lac and Twenty Four thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of the Company	Amount Underwritten (in Tk.)
1	Delta Hospital Limited	6,557,550.00
2	Energypac Power Generation Limited	7,812,500.00
Total		**14,370,050.00**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) this underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-
Chief Executive Officer
IL Capital Limited

Date: 06/02/2016

Due diligence certificate by the Underwriter (Roots Investment Limited)

[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,
We, the under-noted Underwriter(s) to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 135 million (thirteen crore fifty lac) and we have the capacity to underwrite a total amount of Tk. 675 million (sixty seven crore fifty lac) as per relevant legal requirements. We have committed to underwrite for up to Tk. 40,960,000 (Four Core Nine Lac Sixty Thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of the Company	Amount Underwritten (In Taka)
1	Fiber Shine Limited	10,000,000.00
2	Summit Shipping Limited	52,500,000.00
3	Alliance Holdings Limited	16,940,000.00
4	Bangladesh Thai Aluminium Ltd	30,000,000.00
5	Republic Insurance Company Limited	45,000,000.00
6	Mohammed Elias Brothers Poy Manufacturing Co. Limited	10,000,000.00
7	SBS Cables Limited	28,050,000.00
8	Supreme seed Company Limited	11,000,000.00
9	Beach Hatchery Limited	50,000,000.00
10	Energypac Power Generation Limited.	7,812,500.00
11	IDLC Finance limited	30,000,000.00
	Total	**291,302,500.00**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-
Chief Executive Officer
Md. Shah Alam
Roots Investment Limited

Date: 22/02/2016

Due Diligence Certificate by the Underwriter (Sonali Investment Limited)
[Rule 4 (1) (d)]

To
Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir

We, the under-noted Underwriter to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, it's directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 2,000,000,000 (Two hundred crore only) and we have the capacity to underwrite a total amount of Tk. 10,000,000,000 (one thousand crore only) as per relevant legal requirement. We have committed to underwrite for up to Tk. 98,304,000 (Nine crore Eighty Three lac Four thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of the Company	Amount Underwritten (in Tk.)
01	Express Insurance Limited	50,000,000.00
02	Evince Textiles Limited	20,000,000.00
	Total	**7,00,00,000.00**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15(fifteen) days of calling up there of by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

For the Underwriter

Sd/-
(Surajit Kumar Saha)
Chief Executive Officer (In Charge)
Sonali Investment Limited

Dated: March 10, 2016

Due Diligence Certificate by the Underwriter (IDLC Investments Limited)

[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,

We, the under-noted Underwriter(s) to the above mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, it's directors and officers, and other agencies, independent verification of the statements concerning objects of the issue, and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at BDT 1,400 million (One thousand and four hundred million) and we have the capacity to underwrite a total amount of BDT 7,000 million (Seven thousand million) as per relevant legal requirements. We have committed to underwrite for up to BDT 40,960,000 (Four Core Nine Lac Sixty Thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

i. Energypac Power Generation Limited = 157.29 million
ii. IDLC Finance Limited (Right Issue) = 1,363.67 million

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

For the Underwriter

Sd/-
Md. Moniruzzaman
Managing Director
IDLC Investments Limited

Date : February 18, 2016

Due Diligence Certificate by the Underwriter (EBL Investments Ltd.)

[Rule 4 (1) (d)]

To:

The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,

We, the under-noted Underwriter(s) to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 30 crore (Thirty Crore) and we have the capacity to underwrite a total amount of Tk. 150 Crore (One Hundred and Fifty Crore) as per relevant legal requirements. We have committed to underwrite for up to Tk. 40,960,000 (Four Core Nine Lac Sixty Thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of The Company	Amount Underwritten (in Tk.)
1	Silco Pharmaceuticals Limited	50,000,000
2	Supreme Seed Company Ltd.	22,000,000
3	Pacific Denims Limited	75,000,000
4	Cutting Edge Industries Ltd.	16,500,000
5	SBS Cables Ltd.	41,922,000
6	ADN Telecom Limited	38,700,000
7	IDLC Finance Ltd	50,000,000
8	Nurani Dyeing & Sweater Limited	107,500,000
9	Fortune Shoes Ltd.	20,000,000
	Total	**421,622,000**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-

Moinul Hossain Asif
Managing Director
EBL Investments Ltd.

Place: Dhaka
Dated: 18 February 2016

Due Diligence Certificate by the Underwriter (BetaOne Investment Ltd.)
[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,
We, the under-noted Underwriter(s) to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 25,00,00,000 (twenty five crore) and we have the capacity to underwrite a total amount of Tk. 1,25,00,00,000 (one hundred twenty five crore) as per relevant legal requirements. We have committed to underwrite for up to Tk 49,152,000 (Four crore Ninety One lac Fifty Two thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of the Company	Amount Underwritten (in Tk.)
1	Ananda Shipyard & Slipways Limited	9,100,000.00
2	Supreme Seed Company Limited	33,000,000.00
3	South Asia Insurance Company Limited	30,000,000.00
4	SBS Cables Limited	29,410,000.00
5	CARE Specialized Hospital and Research Centre Ltd.	40,000,000.00
6	IDLC Finance Limited	30,000,000.00
7	GPH Ispat Limited	420,000,000.00
8	Baraka Patenga Power Limited	38,250,000.00
9	Delta Hospital Limited	13,115,075.00
Total		**642,875,075**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-
Mohammed Atiquzzaman
Managing Director
BetaOne Investment Ltd.

Date: February 18, 2016

Due Diligence Certificate by the Underwriter (Prime Finance Capital Management Limited)

[Rule 4 (1) (d)]

To

The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,

We, the under-noted Underwriter(s) to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 2,032,800,000 (Taka two billion thirty two million eight hundred thousand) and we have the capacity to underwrite a total amount of Tk. 10,068,719,220 (Taka ten billion sixty eight million seven hundred nineteen thousand two hundred and twenty) as per relevant legal requirements. We have committed to underwrite for up to Tk. 49,152,000 (Four crore Ninety One lac Fifty Two thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl.	Name of the issue	Amount underwritten
1	Royal Denim Limited	5,500,000
2	M.L Dyeing Limited	100,000,000
3	Rupsha Fish & Allied Industries Limited	25,000,000
4	GQ Ball Pen Industries Limited	50,100,000
5	Bangladesh National Insurance Company Limited	61,950,000
6	IFCO Garments & Textiles Ltd.	17,500,000
7	Care Specialized Hospital and Research Centre Limited	75,900,000
8	IDLC Finance Limited	70,000,000
9	Bangas Limited	131,778,890
10	Summit Alliance Port Limited	103,057,395
11	Bangladesh Thai Aluminium Limited	10,000,000
12	Dhaka Regency Hotel Limited	25,000,000
13	VFS Thread Dyeing Limited	40,000,000
Total		**715,786,285**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-

M. Mosharraf Hossain FCA, PhD
Managing Director & CEO
Prime Finance Capital Management Limited

Date: 18 February 2016

Due Diligence Certificate by the Underwriter (First Security Islami Capital & Investment Limited)
[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,
We, the under-noted Underwriter(s) to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 53, 50, 00,000 (Fifty Three Crore Fifty Lac Only) and we have the capacity to underwrite a total amount of Tk. 267,50,00,000 (Two Hundred and Sixty Seven Crore Fifty Lac Only) as per relevant legal requirements. We have committed to underwrite for up to Tk. 40,960,000 (Four Core Nine Lac Sixty Thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of the Company	Amount Underwritten (in Tk.)
1	Reliance Finance Limited	20,00,00,000.00
2	Summit Shipping Limited	5,25,00,000.00
3	Rupsha Fish & Industries Limited	100,000,000.00
4	Rhymer Chemical Industries Limited	8,00,00,000.00
5	Express Insurance Limited	5,00,00,000.00
6	Alliance Holdings Limited	4,23,50,000.00
7	Galaxy Sweater & Yarn Dying Limited	15,00,00,000.00
8	Dhaka Regency Hotel & Resort Limited	5,00,00,000.00
Total=		**72,48,50,000.00**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-
Chief Executive Officer
First Security Islami Capital & Investment Limited Date: February 18, 2016

Due Diligence Certificate by the Underwriter (Southeast Bank Capital Services Limited)
[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,

We, the under-noted Underwriter to the above mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, it's directors and officers, and other agencies, independent verification of the statements concerning object of the issue and the contents of the documents and other materials furnished by the issuer company;

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our Present Paid-up capital stands at Tk. 150,00,00,000 (One hundred and fifty crore) only and we have the capacity to underwrite a total amount of Tk. 750,00,00,000 as per relevant legal requirements. We have committed to underwrite for up to Tk. 98,304,000 (Nine crore Eighty Three lac Four thousand) for the upcoming issue.

(b) At present, the fallowing underwriting obligation are pending for us :

Sl. No.	Name of the company	Amount underwritten (in Tk.)
01	Express Insurance Limited	5,73,25,000
02	IDLC Finance Limited	3,00,00,000
03	Amulet Pharmaceuticals Limited	2,00,00,000
04	Dhaka Regency Hotel Limited	2,50,00,000
	Total	**13,23,25,000**

(c) all information as are relevant to our underwriting decision have been received by us and that the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and (e) this underwriting commitment is unequivocal and irrevocable.

For Southeast Bank Capital Services Limited

Sd/-
Muhammad Shahjahan
Managing Director (CC)
Southeast Bank Capital Services Limited

Place : Dhaka
Date : February 22, 2016

Due diligence certificate by the Underwriter (Swadesh Investment Management Limited)
[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Offer of 50,000,000 Ordinary Shares of Tk. 4,096,000,000 of The ACME Laboratories Limited.

Dear Sir,

We, the under-noted Underwriter(s) to the above-mentioned forthcoming issue, state individually and collectively as follows:

(1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and

(2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

(a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 45.00 Crores(Taka Forty Five Crores Only) and we have the capacity to underwrite a total amount of Tk. 225 Crores (Taka Two Hundred Twenty Five Crores) as per relevant legal requirements. We have committed to underwrite for up to Tk. 57,344,000 (Five crores Seventy Three Lac Forty Four Thousand) for the upcoming issue.

(b) At present, the following underwriting obligations are pending for us:

Sl. No.	Name of the company	Amount Underwritten (In Tk.)
1	BMSL Investment Limited	75,000,000.00
2	Reliance Finance Limited (REFL)	170,000,000.00
3	Ananda Shipyard & Slipways Limited	13,636,000.00
4	Aman Cotton Fibrous Limited	37,500,000.00
5	Rupsha Fish & Allied Industries Ltd	25,000,000.00
6	Genuity Systems Limited	31,250,000.00
7	Simtexs Industries Ltd	60,000,000.00
8	Dragon Sweater and Spinning Ltd.	20,000,000.00
9	Bangladesh Thai Aluminium Ltd.	50,000,000.00
10	The Dacca Dyeing & Manufacturing Co. Ltd.	250,000,000.00
Total		**732,386,000.00**

(c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;

(d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and

(e) This underwriting commitment is unequivocal and irrevocable.

The Underwriter:

Sd/-
(Mamun Ahmed) **Date: February 18, 2016**
Managing Director
Swadesh Investment Management Limited

CHAPTER IV: ABOUT THE ISSUER

Name of the issuer, dates of incorporation and commencement of its commercial operations, its logo, addresses of its registered office, other offices and plants, telephone number, fax number, contact person, website address and e-mail address

Corporate and Plant

Name of the Issuer	:	The ACME Laboratories Ltd.
Date of Incorporation as a Private Limited Company	:	17 March 1976
Commercial Operation (As a proprietorship)	:	1954
The Logo of the Issuer	:	
Addresses of Registered Office	:	Court de la ACME 1/4, Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh
Plants	:	Dhulivita, Dhamrai, Dhaka, Bangladesh.
Telephone and Fax number	:	Tel: +88 02 9004194-6, FAX: +88 02 9016872, +88 02 9039399
Contact Person	:	Mr. Md. Zahangir Alam, FCMA Chief Financial Officer
Website and E-mail Address	:	www.acmeglobal.com; headoffice@acmeglobal.com

Sales Center

Name of companies Sales Center	Address, Telephone and Fax numbers
Rangpur Sales Center	House # 162/1, Road # 18, R.K. Shatgara Road, Islambagh, Upashar, Rangpur. Tel: 0521-62164
Bogra Sales Center	Fuldigi, Holding # 1887/A, Dhaka Rangpur Highway, Fuldigi, Bogra. Tel: 051-66570.
Rajshahi Sales Center	268 Shagorpara, (Bot Tola Moor), Ghoramara, Rajshahi. Tel: 0721-774806
Jessore Sales Center	58, Upa-Shahar, Sector-2, Jessore. Mobile: 01711-823032
Khulna Sales Center	43, Yousuf Row, Mirzapur, Khulna. Tel: 041-721594
Barisal Sales Center	433, N Hossain Avenue, Police Line Road, Barisal, Tel & Fax: 0431-2174906
Mymensingh Sales Center	258/1 Taltola, Dholadia, Mymensingh. Tel: 091-54416
Dhaka City North	Jadhur Char, Hemayetpur, Savar, Dhaka.Tel: 7742892
Dhaka City South	Jadhur Char, Hemayetpur, Savar, Dhaka.Tel: 7742892
Sylhet Sales Center	17/B, Housing Estate, Amborkhana, Sylhet. Tel: 0821-716810
Comilla Sales Center	Prity Bhovan, 97 Ga, Gangchar, West Side of Harun School, Chandpur, Comilla. Tel: 081-76207
Chittagong Sales Center	Dhuppul Bazar, S.M Hachari, South Burichar, P.O. Nor Ali Bari, Hathazari, Chittagong. Tel: 031-651056,
Chowmuhani Sales Center	Kachari Bari Mosjid Road, Chowmuhani. Tel: 0321-51940
Chakaria Sales Center	Thana Road, Chakaria Pourashava Chiringa, Cox Bazar, Chakaria. Tel: 03422-56016
Central Sales Center	Jadhur Char, Hemayetpur, Savar, Dhaka. Tel: 7741742, 7741743

Name of companies Sales Center	Address, Telephone and Fax numbers
Faridpur Sales Center	27/19/2, Mollah Bari Road, Goalchamot, Faridpur. Tel: 0631-61044
Savar Sales Center	Jadhur Char, Hemayetpur, Savar, Dhaka. Mobile: 01711-823035
Narayangonj Sales Center	Dhaka Narayangonj Link Road, Kutubpur, Fatulla, Narayangonj. Tel: 7613696
Dinajpur Sales Center	House # 132, Block-1, Road # 4, Word # 1, Upashahar, Dinajpur. Tel: 0531-62062
B. Baria Sales Center	1081/1, West Medda, B. Baria. Mobile: 01730002865

The names of the sponsors and directors of the issuer;

The company started its commercial operation in the year 1954 as a proprietorship concern. Later on, the enterprise converted into a private limited company on 17 March 1976 and the name of the sponsors on that time and existing directors are presented below:

Sponsors of the company

Sl. No.	Name
1	Late Hamidur Rahman Sinha
2	Mr. Masudul Haque
3	Mr. Masum Rahman
4	Mr. Nasir-ur-Rahman Sinha
5	Mr. Mizanur Rahman Sinha
6	Capt. (Rtd.) Anisur Rahman Sinha
7	Mrs. Sitara Hossain
8	Mrs. Parvin Akhter Nasir
9	Mrs. Jahanara Mizan
10	Mrs. Khurshid Jahan Dabir
11	Mrs. Nazma Rahman
12	Mrs. Laizu Dabir

Directors of the Company

Sl. #	Name	Status
01	Mr. Afzalur Rahman Sinha	Chairman
02	Mr. Mizanur Rahman Sinha	Managing Director
03	Dr. Jabilur Rahman Sinha	Deputy Managing Director
04	Mrs. Jahanara Mizan Sinha	Director
05	Mrs. Nagina Afzal Sinha	Director
06	Syed Shahed Reza	Independent Director
07	Ms. Fouzia Haque, FCA	Independent Director

The name, logo and address of the auditors and registrar to the issue, along with their telephone numbers, fax numbers, contact persons, website and e-mail addresses

Particulars	Name & Address	Logo	Contact person	Telephone and Fax Number
Auditor	**Pinaki & Company** Chartered Accountants (An Independent Associate Member of Thakur, Vaidyanath Aiyar & Co., Chartered Accountants, New Delhi, India) Ahsandell, 2n/A Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000 E-mail: pinaki_co@yahoo.com; Web: N/A		Mr. Pinaki Das, FCA Partner	Tel: +88 02 9660944, 96650 FAX: +88 02 9672726,
Registrar to the Issue	**Prime Finance Capital Management Ltd.** PFI Tower (6th Floor), 56-57 Dilkusha C/A, Dhaka-1000 E-mail: info@primefincap.com; www.primefincap.com		Dr. Mosharaf Hossain, FCA Chief Executive Officer	Te: +880-2- 9584874, +880-2-9584876-7 FAX: +880 2 9584922

The name(s) of the stock exchanges where the specified securities are proposed to be listed

SL #	Name of the Exchange	Logo	Address
1	Dhaka Stock Exchange Limited (DSE)		9/F, Motijheel C/A, Dhaka-1000.
2	Chittagong Stock Exchange Limited (CSE)	CHITTAGONG STOCK EXCHANGE	CSE Building, 1080 Sheikh Mujib Road, Chittagong.

CHAPTER V: CORPORATE DIRECTORY OF THE ISSUER

Date of Incorporation as a Private Limited Company	:	17 March 1976
Commercial Operation (As a proprietorship concern)	:	1954
Change of Denomination from Tk. 100 to Tk. 10 per share Date of Conversion into a Public Limited Company	:	30 November 2011
Date of Amalgamation of The ACME Specialized Pharmaceutical Limited with The ACME Laboratories Ltd.	:	20 November 2013
Authorized Capital	:	Tk. 5,000,000,000.00
Issued, Subscribed & Paid-up Capital	:	Tk. 1,616,017,000.00
Addresses of the Registered Office	:	Court de la ACME 1/4, Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh
Plants	:	Dhulivita, Dhamrai, Dhaka, Bangladesh.
Telephone and Fax number	:	Tel: +88 02 9004194-6, FAX: +88 02 9016872
Website and E-mail Address	:	www.acmeglobal.com; headoffice@acmeglobal.com
Compliance Officer	:	Mr. Md. Rafiqul Islam, ACS Company Secretary

CHAPTER VI: DESCRIPTION OF THE ACME LABORATORIES LTD.

Summary

Summary of the Industry of the Issuer

Basically, Bangladesh Pharmaceutical industry finished formulation based, heavily technology driven, dynamic in nature and vertically integrated i.e. most of the Companies under this industry cover activities like manufacturing, promotion, sales and distribution. As such, value addition of this industry is comparatively high. Before era of 1982 market of the industry were dominated by multinational companies. But, 1982's drug policy opened the door for national companies. Now, scenario just reverse, local companies are dominating the market.

It is one of the fastest growing sectors in the country with an annual average two-digit growth rate over the last five years. It is the second largest industry in terms of contribution to government's exchequer and contributes about 1% of the total GDP. According to IMS in 2015, the market size of the industry was Tk. 12,000 crore (approx). If we calculate per day per person consumption, it stands Tk. 2.05. Therefore, the industry has an ample opportunity to grow more.

Figure 1: Therapeutic class wise market size of pharma product in the year 2014 and 2015 was as follows:

(Amount in BDT Crore)

Sl. #	Name of the Therapeutic class	30 June 2015		30 June 2014	
		Sales	Market share	Sales	Market share
1	Alimentary T.& Metabolism	4,145.64	34.68	3,635.51	34.34
2	Systemic Anti-Infectives	2,197.38	18.38	2,045.58	19.32
3	Nervous System	1,242.44	10.39	1,138.74	10.76
4	Cardiovascular System	1,153.32	9.65	988.34	9.34
5	Respiratory System	1,051.38	8.79	881.82	8.33
6	Musculo-Skeletal System	654.66	5.48	576.17	5.44
7	G.U.System & Sex Hormones	354.00	2.96	285.72	2.70
8	Dermatologicals	288.04	2.41	247.00	2.33
9	Blood + B.Forming Organs	247.27	2.07	223.41	2.11
10	Sensory Organs	185.12	1.55	160.34	1.51
11	Systemic Hormones	137.41	1.15	119.72	1.13
12	Hospital Solutions	127.06	1.06	128.88	1.22
13	Parasitology	113.56	0.95	109.70	1.04
14	Antineoplast + Immunomodul	34.47	0.29	28.51	0.27
15	Various	22.96	0.19	16.58	0.16
16	Diagnostic Agents	0.13	0.00	0.34	0.00

Sources: IMS Global Health

There are several strong competitive macro economic factors are enjoying by Bangladesh pharma industry like favorable government policy, availability of technological know-how, comfortable local market size for 16 crore population, low white collar professional costs etc. There are more than 437 registered small, medium, large, local and multinational companies operating in the country producing around 97% of the total internal demand. To meet the remaining 3% high-tech products and to develop stronger long-term competencies, most of the top ranking pharma companies of the country are relentlessly investing resources and trying to adopt high-end technologies. Due to some factors like, requirement of initial high capital expenditure, application of sophisticated technology, requirement of huge working capital and application indirect marketing approach, Bangladesh pharmaceuticals industry have been enjoying inherent entrant barrier.

Considering glorious success and prospect of the industry, to expand the value chain further, government has taken necessary steps to set up a full-fledge Active Pharmaceutical Ingredients (API) Park, containing 42 plots, at Munshigonj district. Most of the top ranking pharmaceutical Companies are applied for more than one plot each. With the development of diversified knowledge, science and technology, throughout the world, this industry is growing very rapidly. With the passage of time disease pattern is changing frequently i.e. more and more new disease have been being emerging consequence of which is rapid diversification and high growth in global Pharma market. It is useful to briefly look back 100 years at the evolution of the disease process.

Pre First World War, infectious and parasitic diseases were the most common illnesses and killers and global life expectancy was around 44 years of age. In the 1920s up until the 1960s, infectious disease were still prevalent, but as vaccines and more powerful antibiotics were introduced emergence of chronic diseases like diabetes mellitus, hepatic, renal, cardio-vascular and cancer, with the expectancy of life, in the developed countries, then increased to around 68 years.

During the 1970s and 1980s, there were still increase in diabetics, hepatic, renal, ischemic heart diseases, cancers and cerebral vascular disease, but during this time emergence of new viruses such as HIV and AIDS occurred. Despite this, life expectancy increased to approximately 73 years.

Now a day, those who do not die of the above noted diseases, are likely to suffer from some sort of ageing disease, such as Alzheimer's and/or stroke. Alternatively, one may develop a disease associated with pollution, such as bronchitis or asthma. The good news is however, that life expectancy has now increased to 76 years (65 years in Bangladesh).

What this illustrates is that, disease progression has changed quite remarkably over the last 100 years, and the pharmaceutical industry has had to change its approach to diseases as a result of that.

Pharma market growth over the last couple of decades has been fuelled by demographics and ever increasing an ageing population. Attitude and entitlement has also been changed. Patients now have better access to information about drugs and not surprisingly, they ask their physician for the newest and latest drugs, which just happens to be the most expensive in most cases.

Despite of prolonged global recession, World Pharmaceutical market is growing consistently, particularly the market of without prescribed products and Chronic care products, which registered tremendous growth during the last couple of years.

Business environment of the Issuer

The ACME Laboratories Ltd. started its commercial operation in the year 1954 as a proprietorship concern. Later on, the enterprise converted into a private limited company on 17 March 1976 vides registration no. C-4745/163 of 1975-76 under the Companies Act-1913 and it was converted into a public limited company on 30 November 2011. In the way of its over six decades journey it has transformed itself from good to better and it has been moving towards the great from better through converting into a public limited Company. Right now, it is peeping into the Capital Market.

The Company is engaged in manufacturing, marketing and distribution of generic pharmaceuticals finished formulation products which includes human drugs dosages form like tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatin, sachet products, IV infusion; veterinary drugs dosages form like bolus, liquid, injection, water soluble powder, premix and herbal drugs dosages form like liquid, capsule, tablet, cream & ointment. The products of the company are sold in domestic and international markets.

The erstwhile 'The ACME Specialized Pharmaceuticals Ltd.' (Present Solid Dosage Unit) was engaged in manufacturing of non-penicillin & non-cephalosporin solid dosage generic pharmaceuticals formulation products including dosages form like tablet, capsule and dry syrup, liquid in hard gelatine, sachet products and was enjoying Tax Holiday period from 29 September 2011 to 28 September 2016.

ACME has an outstanding record of all around excellence and growth in the relevant business activities. It is one of the leading manufacturer and exporter of Human, Herbal and Animal Health Pharmaceutical Products in Bangladesh. Since very inception of the journey, it has been working relentlessly with a vision to ensure Health, Vigour and Happiness for all. The quality slogan of the Company is: "Perpetual Quest for Excellence". The ACME Laboratories Ltd. is committed to maintain state-of-the-art manufacturing facilities for ensuring best quality products to the customers. ACME is committed to achieve excellence by proper execution of ISO 9001:2008 standard, WHO cGMP standard and best practices that are proven effective.

In the year 1999, the company was awarded ISO 9001:1994 certification. In this year the company launched its veterinary division. The company added Dry Powder Inhaler (DPI) and Suppository to its product line in the year 2003 and Metered Dosage Inhaler (MDI) added its product line in the year 2004. The ACME Laboratories Ltd. was awarded 'Enterprise of the Year – 2006' organized by DHL and the Daily Star. In the year 2006 the company started marketing Baby Zink, which was a R&D of ACME and ICDDR,B. The company added IV Infusion products in its products line in the year 2007. In this year, the company started operation of its warehouse complex including central warehouse at Hemayetpur, Savar, Dhaka.

In the year 2008, in the way of success, ACME group built another milestone in its core business activities by establishing The ACME Specialized Pharmaceutical Limited, the then subsidiary of The ACME Laboratories Ltd., in order to cater upcoming national and global demand of various type of products and also to meet the challenges of 21st century. Naturally as a follow up, the Board of Directors of the Company decided to amalgamate the same through vide EGM dated 27 April 2013. By this time The Honorable High Court Division of The Honorable Supreme Court of Bangladesh has given their verdict in favour of Amalgamation Scheme on 20 November 2013. The Amalgamation paves the way for availing International Accreditation benefit for the products now being produced in present solid dosage unit (Former ASPL) with International GMP compliance as earlier enjoyed by the company.

As a part of continuous improvement policy, the company renewed and upgraded its ISO Certification to ISO 9001:2008 in the year 2009. In the year 2010, the company started functioning of its own distribution hub at Bogra. Full-fledged operations of Rangpur, Barishal and Mymensingh depots have started during the year. In the year 2011, the company upgraded its MDI facility to HFA based from CFC based in order to make the project more environments friendly. During the year 2013- 2014, the company has successfully completed and launched separate Cephalosporin facility. BFS (LVP & SVP) were launched in October 2014.

Since very inception of its journey ACME has been enjoying continuous growth and strengthening its position in the Bangladesh and Global phama market. Up to 30 June 2014 ACME introduced 504 human products including herbal products covers 13 dosages form under 17 therapeutics classes and 168 veterinary products including herbal products covers 6 dosages form under 18 therapeutics classes. For the year ended 30 June 2014, its revenue stood at Tk. 10,217,931,465 representing growth 13.87 percent and earned net profit after tax Tk. 893,890,898. It's last five years Compound Annual Growth Rate of revenue stood at 16.45 percent.

(ii) Summary of consolidated financial, operating and other information

This information is not applicable for the Issuer since it has no subsidiary and associates company.

General Information

Name and address, telephone and fax numbers of the registered office, corporate head office, other offices, factory, business premises and outlets of the Issuer are as follows:

Corporate and factory

Registered and Corporate Head Office	:	Court de la ACME 1/4, Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh Tel: +88 02 9004194-6, FAX: +88 02 9016872
Factory	:	Dhulivita, Dhamrai, Dhaka, Bangladesh. Phone: +88 02 7730881-2 +88 02 7330816-7 Fax: +88 02 7730141
Business Premises	:	The Corporate Head office and other offices are considered as business premises of the company.

Other offices (Sales Centers/Dispatch Outlets)

Name of companies Sales Center	Address, Telephone and Fax numbers
Rangpur Sales Center	House # 162/1, Road #18, R.K. Shatgara Road, Islambagh, Upashar, Rangpur. Tel: 0521-62164
Bogra Sales Center	Fuldigi, Holding # 1887/A, Dhaka Rangpur Highway, Fuldigi, Bogra. Tel: 051-66570.
Rajshahi Sales Center	268 Shagorpara, (Bot Tola Moor), Ghoramara, Rajshahi. Tel: 0721-774806
Jessore Sales Center	58, Upa-Shahar, Sector-2, Jessore. Mobile: 01711-823032
Khulna Sales Center	43, Yousuf Row, Mirzapur, Khulna. Tel: 041-721594
Barisal Sales Center	433, N Hossain Avenue, Police Line Road, Barisal, Tel & Fax: 0431-2174906
Mymensingh Sales Center	258/1 Taltola, Dholadia, Mymensingh. Tel: 091-54416
Dhaka City North	Jadhur Char, Hemayetpur, Savar, Dhaka.Tel: 7742892
Dhaka City South	Jadhur Char, Hemayetpur, Savar, Dhaka.Tel: 7742892
Sylhet Sales Center	17/B, Housing Estate, Amborkhana, Sylhet. Tel: 0821-716810
Comilla Sales Center	Prity Bhovan, 97 Ga, Gangchar, West Side of Harun School, Chandpur, Comilla.Tel: 081-76207
Chittagong Sales Center	Dhuppul Bazar, S.M Hachari, South Burichar, P.O. Nor Ali Bari, Hathazari, Chittagong.Tel: 031-651056,
Chowmuhani Sales Center	Kachari Bari Mosjid Road, Chowmuhani. Tel: 0321-51940
Chakaria Sales Center	Thana Road, Chakaria Pourashava Chiringa, Cox Bazar, Chakaria. Tel: 03422-56016
Central Sales Center	Jadhur Char, Hemayetpur, Savar, Dhaka. Tel: 7741742, 7741743
Faridpur Sales Center	27/19/2, Mollah Bari Road, Goalchamot, Faridpur. Tel: 0631-61044
Savar Sales Center	Jadhur Char, Hemayetpur, Savar, Dhaka.Mobile: 01711-823035
Narayangonj Sales Center	Dhaka Narayangonj Link Road, Kutubpur, Fatulla, Narayangonj. Tel: 7613696
Dinajpur Sales Center	House # 132, Block-1, Road # 4, Word # 1, Upashahar, Dinajpur. Tel: 0531-62062
B. Baria Sales Center	1081/1, West Medda, B. Baria.Mobile: 01730002865

The Board of Directors of the Issuer

Sl. no.	Name	Position
1	Mr. Afzalur Rahman Sinha	Chairman
2	Mr. Mizanur Rahman Sinha	Managing Director
3	Dr. Jabilur Rahman Sinha	Deputy Managing Director
4	Mrs. Jahanara Mizan Sinha	Director
5	Mrs. Nagina Afzal Sinha	Director
6	Syed Shahed Reza	Director (Independent)
7	Ms. Fouzia Haque, FCA	Director (Independent)

Names, addresses, telephone numbers, fax numbers and e-mail addresses of the Chairman, Managing Director, whole time Directors, etc. of the Issuer

Sl	Name	Position	Address	Telephone number, Fax number and e-mail address
1	Mr. Afzalur Rahman Sinha	Chairman	Court de la ACME, 1/4,Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh	PABX:+88 02 9004194-6, FAX: +88 02 9016872 E-mail:asinha.chairman@acmeglobal.com
2	Mr. Mizanur Rahman Sinha	Managing Director	Court de la ACME, 1/4,Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh	PABX:+88 02 9004194-6, FAX: +88 02 9016872 E-mail:msinha.md@acmeglobal.com
3	Dr. Jabilur Rahman Sinha	Deputy Managing Director	Court de la ACME, 1/4,Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh	PABX:+88 02 9004194-6, FAX: +88 02 9016872 E-mail:jsinha.dmd@acmeglobal.com
4	Mrs. Jahanara Mizan Sinha	Director	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	PABX:+88 02 9004194-6, FAX: +88 02 9039399, E-mail: jmsinha.director@acmeglobal.com
5	Mrs. Nagina Afzal Sinha	Director	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	PABX:+88 02 9004194-6, FAX: +88 02 9039399, E-mail: nasinha.director@acmeglobal.com
6	Syed Shahed Reza	Independent Director	Apt. # A4, House No. 26, Road No. 130, Gulshan - 01, Dhaka	PABX:+88 02 9004194-6, FAX: +88 02 9039399 E-mail: nocban@gmail.com
7	Ms. Fouzia Haque	Independent Director	House No. 7/2, Block-D, Lalmatia, Dhaka	PABX:+88 02 9004194-6, FAX: +88 02 9039399 E-mail: haque.fouzia@gmail.com

Names, addresses, telephone numbers, fax numbers and e-mail addresses of the CFO, Company Secretary, Legal Advisor, Auditors and Compliance Officer

Name	Position	Address	Telephone, Fax number and e-mail
Mr. Md. Zahangir Alam, FCMA	Chief Financial Officer	Court de la ACME, 1/4,Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh	Tel: +88 02 9004194-6, FAX: +88 02 9016872, +88 02 9039399 E-mail:zalam.accounts@acmeglobal.com
Mr. Md. Rafiqul Islam, ACS	Company Secretary	Court de la ACME, 1/4,Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh	Tel: +88 02 9004194-6, FAX: +88 02 9016872, +88 02 9039399, E-mail:rislam.cs@acmeglobal.com

Name	Position	Address	Telephone, Fax number and e-mail
A.M. Amin Uddin and Associates	Lawyer (Legal Advisor)	Home Tech Tower, 100 Azimpur Road (1st Floor) Opposite to China Building, Dhaka-1205	Tel: 01720032442 E-mail :aminuddingandassociates@gmail.com
Pinaki & Company Chartered Accountants (An Independent Associate Member of Thakur, Vaidyanath Aiyar & Co., Chartered Accountants, New Delhi, India)	Auditor	Ahsandell, 2/A Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000	Tel: +88 02 9660944, 9665095 FAX: +88 02 9672726, E-mail: pinaki_co@yahoo.com;
Mr. Md. Rafiqul Islam, ACS	Compliance Officer	Court de la ACME, 1/4,Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh	Tel: +88 02 9004194-6, FAX: +88 02 9016872,+88 02 9039399, E-mail:rislam.cs@acmeglobal.com

Names, addresses, telephone numbers, fax numbers, contact person, website addresses and e-mail addresses of the issue manager(s), registrar to the issue etc.

Name	Address	Contact person	Telephone, Fax number, e-mail and Web.
Manager to the Issue			
ICB Capital Management Ltd.	Green City Edge (5th & 6th Floor), 89 Kakrail, Dhaka-1000.	Mrs. Nasrin Sultana Chief Executive Officer	Tel: +880-2-8300421, +880-2-8300395, +880-2-8300555, +880-2-8300367 FAX: +88 02 8300396 E-mail: ceocmcl@accesstel.net; Web: www.icml.com.bd
Registrar to the Issue			
Prime Finance Capital Management Ltd.	PFI Tower (6th flr.), 56-57 Dilkusha C/A, Dhaka-1000.	Dr. Mosharaf Hossain, FCA Chief Executive Officer	Te: +880-2- 9584874, +880-2-9584876-7 FAX: 88-02-9584922 E-mail: info@primefincap.com Web: www.primefincap.com

Details of Credit Rating

Name of Credit rating agency ***: Credit Rating Information and Services Limited (CRISL)***
Financial Year ***: For the year ended 30 June 2015***

Rating obtained ***:***

Date of Rating: October 15, 2015		
	Long Term	Short Term
Rating	**A+**	**ST-3**
Validity	**October 14, 2016**	**April 14, 2016**

Rationale of the ratings obtained

CRISL has reaffirmed the Long term rating to 'A+' (pronounced as single A plus) and Short term rating to 'ST-3' of 'The ACME Laboratories Limited' (ALL) based on its financials and other relevant quantitative and qualitative information up to the date of rating.

These ratings reflect that the company has been operating with average business and financial performance, State-Of-The-Art technology, sound production facilities, good number of products in the market, regular loan repayment history etc. These rating strengths are partially offset by moderately debt based capital structure, long cash conversion cycle, risk of foreign exchange, competition, TRIPS Agreement expiration etc.

ALL, the flagship company of renowned ACME Group, is a front footed pharmaceutical company, which has been involved in the manufacturing and marketing of Pharmaceutical finished products since 1954. The company mainly engaged in manufacturing human, herbal & ayurvedic products and veterinary products. Over its period of operation, the company has launched more than 700 products in different dosages form in the market. Moreover, after meeting local demand, it entered into the foreign market in the year 1999. During 2014-15, the average capacity and capacity utilization of ALL increased to some extent. The company distributes the products through its own distribution channel throughout the country. The reported turnover of the company stood at Tk. 11,496.41 mil. and Tk. 10,217.93 mil. in FY 2014-15 and FY 2013-14 respectively with a growth of 12.51%. The profit after tax of ALL stood at Tk. 921.92 mil. and Tk. 893.89 mil. in FY 2014-15 and FY 2013-14 respectively.

Entities rated in this category are adjudged to offer adequate safety for timely repayment of financial obligations. This level of rating indicates a corporate entity with an adequate credit profile. Risk factors are more variable and greater in periods of economic stress than those rated in the higher categories. The Short Term rating indicates good certainty of timely payment. Liquidity factors and company fundamentals are sound. Although ongoing funding needs may enlarge total financing requirements, access to capital and financial markets is good.

CRISL also placed the company with "Positive Outlook" with an expectation of no extreme changes in economic or company situation within the rating validity period.

Observations and risk factors stated in the Credit Rating Report:

Observations

Rating Comforts:	**Rating Concerns:**
▪ Average business and financial performance ▪ Wide distribution network ▪ Experienced corporate management ▪ Sound production facilities ▪ State-Of-The-Art technology ▪ Good number of products in the market ▪ Adequate ETP facility ▪ Regular loan repayment history	▪ Moderate debt based capital structure ▪ Moderate liquidity ▪ Increase in cost of goods sold ▪ Long cash conversion cycle ▪ TRIPS Agreement expiration risk ▪ Foreign currency risk ▪ Competition risk

Business Opportunity:	Business Challenges:
▪ Cheap skilled human resource base ▪ Launching of new products ▪ Establishment of backward supply linkage ▪ Exploring more export markets ▪ Immense opportunity of penetration in foreign market ▪ Friendly government drug policy	▪ Limited scope of local raw material sources ▪ Severe competition in local market ▪ Maintenance of international standard

Risk factors

1. Operational & Maintenance Risk
2. Quality Control Risk
3. Raw Material Supply Risk
4. Power Supply Risk
5. Competition Risk
6. Foreign Exchange Risk
7. TRIPS Agreement Expiration Risk

Name of the Credit rating Agency : Credit Rating Information and Services Limited (CRISL)
Financial Year : For the year ended 30 June 2014

Rating obtained :

Date of Rating: September 21, 2014		
	Long Term	Short Term
Rating	**A+**	**ST-3**
Validity	**September 20, 2014**	**March 20, 2015**

Rationale of the ratings obtained

CRISL has reaffirmed the Long term rating to 'A+' (pronounced as single A plus) and Short term rating to 'ST-3' of The ACME Laboratories Limited (ALL) based on its financials and other relevant quantitative and qualitative information up to the date of rating.

These ratings reflect that the company has been operating with average business and financial performance, improving cost efficiency, sound production facilities, good number of products, regular debt repayment history, etc. These rating strengths are partially offset by moderately debt based capital structure, moderate liquidity, long cash conversion cycle, exposure to foreign exchange risk, exposure to market risk, etc.

ALL, the flagship company of renowned ACME Group, is a front footed pharmaceutical company, which has been involved in the manufacturing and marketing of Pharmaceutical finished products since 1954. The company mainly engaged in manufacturing human, herbal & ayurvedic products and veterinary products. Over its period of operation, the company has launched more than 600 products in the market. Moreover, after meeting local demand, it entered into the foreign market in the year 1999. During 2013-14, the average capacity and capacity utilization of ALL increased to some extent. The company distributes the products through its own distribution channel throughout the country. The reported turnover of the company stood at Tk. 10,217.93 mil. and Tk. 9,809.27 mil. in FY 2013-14 and FY 2012-13 respectively with a growth of 4.17%. The profit after tax of ALL stood at Tk. 893.89 mil. and Tk. 533.52 mil. in FY 2013-14 and FY 2012-13 respectively.

Entities rated in this category are adjudged to offer adequate safety for timely repayment of financial obligations. This level of rating indicates a corporate entity with an adequate credit profile. Risk factors are more variable and greater in periods of economic stress than those rated in the higher categories. The Short Term rating indicates good certainty of timely payment. Liquidity factors and company fundamentals are sound. Although ongoing funding needs may enlarge total financing requirements, access to capital and financial markets is good.

CRISL also placed the company with "Positive Outlook" with an expectation of no extreme changes in economic or company situation within the rating validity period.

Observations and risk factors stated in the Credit Rating Report:

Observations

Rating Comforts:	**Rating Concerns:**
▪ Average business and financial performance ▪ Improved in cost efficiency ▪ Wide distribution network ▪ Experienced corporate management ▪ Sound production facilities ▪ Good number of products in the market ▪ Adequate ETP facility ▪ Regular debt repayment history	▪ Moderate debt based capital structure ▪ Moderate liquidity ▪ Long cash conversion cycle ▪ Exposed to foreign currency risk ▪ Exposed to market risk ▪ Exposed to price volatility risk
Business Opportunity:	**Business Challenges:**
▪ Cheap skilled human resource base ▪ Launching of new products ▪ Establishment of backward supply linkage ▪ Exploring more export markets ▪ Immense opportunity of penetration in foreign market	▪ Limited scope of local raw material sources ▪ Severe competition in local market ▪ Maintaining international standard ▪ Limited control over product pricing ▪ Continuously changing quality standard

Risk factors

1. Operational & Maintenance Risk
2. Quality Control Risk
3. Raw Material Supply Risk
4. Power Supply Risk
5. Market Risk
6. Foreign Exchange Risk

Name of the Credit rating Agency : Credit Rating Information and Services Limited (CRISL)
Financial Year : For the year ended 30 June 2012

Rating obtained :

Date of Rating: June 27, 2013		
	Long Term	Short Term
Rating	**A+**	**ST-3**
Validity	**June 26, 2014**	**December 26, 2013**

Rationale of the ratings obtained

CRISL has reaffirmed the Long term rating to 'A+' (pronounced as single A plus) and Short term rating to 'ST-3' of The ACME Laboratories Limited (ALL) based on its financials and other relevant quantitative and qualitative information up to the date of rating.

These ratings reflect that the company has been operating with an equity based capital structure, improving cost efficiency, increasing capacity utilization, sound production facilities, good number of products, regular debt repayment history, etc. These rating strengths are partially offset by moderate liquidity, long cash conversion cycle, exposure to foreign exchange risk, exposure to raw material supply risk, etc.

ALL, the flagship company of renowned ACME Group, is a front footed pharmaceutical company, which has been involved in the manufacturing and marketing of Pharmaceutical finished products since 1954. The company mainly engaged in manufacturing human, herbal & ayurvedic products. Over its period of operation, the company has launched more than 590 products in the market. Moreover, after meeting local demand, it entered into the foreign market in the year 1999. During 2012, the average capacity and capacity utilization of ALL increased to some extent.

The company distributes the products through its own distribution channel throughout the country. The reported turnover of the company stood at Tk. 9,483.85 mil. and Tk. 6,996.75 mil. in FY 2011-12 and FY 2010-11 respectively with a growth of 35.55%. The profit after tax of ALL stood at Tk. 476.20 mil. and Tk. 344.15 mil. in FY 2011-12 and FY 2010-11 respectively.

Entities rated in this category are adjudged to offer adequate safety for timely repayment of financial obligations. This level of rating indicates a corporate entity with an adequate credit profile. Risk factors are more variable and greater in periods of economic stress than those rated in the higher categories. The Short Term rating indicates good certainty of timely payment. Liquidity factors and company fundamentals are sound. Although ongoing funding needs may enlarge total financing requirements, access to financial markets is good.

CRISL also placed the company with "Stable Outlook" with an expectation of no extreme changes in economic or company situation within the rating validity period.

Observations and risk factors stated in the Credit Rating Report:
Observations:

Rating Comforts: ▪ Equity based capital structure ▪ Improving cost efficiency ▪ Increasing capacity utilization ▪ Experienced corporate management ▪ Sound production facilities ▪ Good number of products in the market ▪ Adequate ETP facility ▪ Regular debt repayment history ▪ Standby power back up facility	**Rating Concerns:** ▪ Moderate liquidity ▪ Long cash conversion cycle ▪ Exposed to foreign exchange risk ▪ Exposed to quality control risk ▪ Exposed to raw material supply risk
Business Opportunity: ▪ Cheap skilled human resource base ▪ Launching of new products ▪ Establishment of backward supply linkage ▪ Exploring more export market ▪ Immense opportunity of penetration in foreign market	**Business Challenges:** ▪ Limited scope of local raw material sources ▪ Severe competition in local market ▪ Maintaining international standard ▪ Limited control over product pricing ▪ Continuous changing quality standard

Risk factors

- Operational & Maintenance Risk
- Quality Control Risk
- Raw Material Supply Risk
- Power Supply Risk
- Foreign Exchange Risk

The names, addresses, telephone numbers, fax numbers, contact persons and e-mail addresses of the underwriters and the amount underwritten by them

Sl. #	Name and Address of the underwriters	Contact person	Telephone and Fax No.	No. of Shares Underwritten	Amount in Tk.
1	**ICB Capital Management Ltd.** Green City Edge (5th & 6th Floor), 89 Kakrail,Dhaka-1000. E-mail: ceocmcl@accesstel.net; Web: www.icml.com.bd	**Mrs. Nasrin Sultana** Chief Executive Officer	Tel: +880-2-8300421, +880-2-8300395, +880-2-8300555, +880-2-8300367 FAX: +88 02 8300396	8,500,000	696,320,000
2	**Prime Finance Capital Management Ltd.** PFI Tower (6th Floor), 56-57 Dilkusha C/A, Dhaka-1000 E-mail: info@primefincap.com; Web: www.primefincap.com	**Dr. Mosharaf Hossain, FCA** Chief Executive Officer	Te: +880-2- 9584874, +880-2-9584876-7 FAX: +880 2 9584922	600,000	49,152,000
3	**Southeast Bank Capital Services Ltd.** Eunoos Trade Center, (Level-9), 52-53, Dilkusha C/A, Dhaka-1000 E-mail:alamgir_dbl@yahoo.com; Web: www.southestbank.com.bd	**Mr. Md. Alamgir Hossain** Sr. Assistant Vice President	Tel: +880-2-9574171 (Ext-103), +880-2-9574167 FAX: +880 2 9574169	1,200,000	98,304,000
4	**Swadesh Investment Management Ltd.** Suite 01, Level 11, Unique Trade Centre, 8 Panthapath, Karwan Bazar, Dhaka-1215 E-mail:mamunahmed@msn.com; Web: www.swadesh.com.bd	**Mr. Mamun Ahmed** Managing Director	Tel: +880-2- 01713400500 FAX: +88 02 81558344	700,000	57,344,000
5	**IDLC Investments Ltd.** Eunoos Trade Centre (Level 21), 52-53 Dilkusha C/A, Dhaka-1000 Bangladesh. E-mail:merbank@idlc.com; Web: www.idlc.com	**Mr. Md. Moniruzzaman, CFA** Managing Director	Tel: +880-2-9571170 FAX: +880 2 9571171	500,000	40,960,000
6	**EBL Investments Ltd.** 59, Motijheel C/A, 1st Floor, Dhaka-1000 E-mail:info@eblinvestments.com; Web: www.eblinvestments.com	**Mr. Md. Tanvir Hashem** Manager	Tel: +880-2-7118975 FAX: +880 2 7120251	500,000	40,960,000
7	**First Security Islami Capital & Investment Ltd.** Al Amin Center, (12th Floor), 25/A, Dilkusha C/A, Dhaka-1000 E-mail:info@fsicibd.com; Web: www.fsicibd.com	**Mr. M. Anwar Husain** Chief Executive Officer	Tel: +880-2-9555077 FAX: +880 2 9515917	500,000	40,960,000
8	**PLFS Investments Ltd.** Paramount Heights (13th Floor), 65/2/1 Box Culvert Road, PuranaPaltan, Dhaka-1000 E-mail:plfsilbd@gmail.com; Web: www.plfsil.plfsbd.com	**Mr. Nripendra Chandra Pandit** Chief Executive Officer (C.C)	Tel: +880-2-9551036, +880-2-9551041 FAX: +880 2 7125396	500,000	40,960,000
9	**IL Capital Ltd.** Printers Building (13th Floor), 5, Rajuk Avenue, Dhaka-1000 E-mail: info@il-capital.com; Web: www.il-capital.com	**Mr. Saad Muhammad Faisal** Chief Executive Officer	Tel: +880-2-9515573 FAX: +880 2 7117559	2,200,000	180,224,000
10	**Sonali Investment Ltd.** Sara Tower (11th Floor), 11/A Toyenbee Circular Road, Motijheel C/A, Dhaka – 1000 E-mail:sonaliinvestmentltd@gmail.com; Web: www.silbd.com	**Mr. Surajit Kumar Saha** Chief Executive Officer (In charge)	Tel: +880-2-9568777, +880-2-9556940, +880-2-9575975 FAX: +880 2 9556940 – Ext. 126	1,200,000	98,304,000
11	**Roots Investment Limited** Diganto Tower, 1st Floor, 12/1, R.K. Mission Road, Motijheel, Dhaka, 1203 E-mail:info@rootsinvestment.com Web:www.rootsinvestment.com	**Mr. Nomanur Rashid** Senior Vice President	Tel: +880-2-01712990348, +880-2- 01833148258 FAX: +880 2 7116908	500,000	40,960,000
12	**BetaOne Investment Ltd.** Green Delta AIMS Tower (Level-4), 51-52, Mohakhali C/A, Dhaka-1212. E-mail: info@betaone.com.bd; Web: www.betaone.com.bd	**Mr. Mohammed Atiquzzaman** Managing Director	Tel: +880-2-9887337 FAX: +880 2 9880733	600,000	49,152,000
Total				17,500,000	1,433,600,000

Declaration by the Underwriters

We the underwriter(s) have sufficient resources as per the regulatory requirements to discharge our respective obligations.

For Underwriter(s)

Sd/-
(**Managing Director/ Chief Executive Officer**)

ICB Capital Management Ltd.	Roots Investment Limited
Southeast Bank Capital Services Ltd.	Sonali Investment Ltd.
Swadesh Investment Management Ltd.	EBL Investments Ltd.
IL Capital Ltd.	First Security Islami Capital & Investment Ltd.
PLFS Investments Ltd.	BetaOne Investment Ltd.
Prime Finance Capital Management Ltd.	

Declaration by the IDLC Investments Ltd.

We are one of the underwriters of the Initial Public Offering (IPO) of The ACME Laboratories Limited. We will underwrite 500,000 ordinary shares totaling to BDT 40,960,000 (300,000 ordinary shares from EI portion at BDT 85.20 each and 200,000 ordinary shares from General Public portion at BDT 77.00 each) on a firm commitment basis. In this connection, we hereby declare that:

We have sufficient resources as per the regulatory requirements to discharge our respective obligations.
For Underwriter

Sd/-
Place: Dhaka
Date: February 18, 2016

Md. Moniruzzaman
Managing Director
IDLC Investments Limited

Major Terms and Conditions of the Underwriting Agreements

1. The Issuer shall within 10 (Ten) days of the closure of subscription call upon the underwriter in writing with a copy of said writing to the Bangladesh Securities and Exchange Commission, to subscribe for the shares not subscribed by the closing date and to pay for in cash in full for such unsubscribed shares within 15(Fifteen) days of the date of said notice and the said amount shall have to be credited into shares subscription account within the said period.
2. In any case within 7 (Seven) days after the expiry of the aforesaid 15(Fifteen) days, the Company shall send proof of subscription and Deposit of Money by the underwriter to the Commission.

Capital Structure

Authorized, issued, subscribed and paid up capital (number and class of securities, allotment dates, nominal price, issue price and form of consideration)

Particulars	No. of Ordinary Shares	Nominal Value per Share in BDT	Paid-up Capital Amount in BDT
Authorized Capital	500,000,000	10	5,000,000,000.00
Before Initial Public Offering:			
Issued, subscribed and paid-up	161,601,700	10	1,616,017,000.00
Initial Public Offerings through Book Building Method	50,000,000	10	500,000,000.00
Post Initial Public Offering:			
Issued, subscribed and paid-up	**211,601,700**	10	**2,116,017,000.00**

The Company has raised its paid-up capital in following phases

Date of allotment	Mode of Consideration			Nominal Price	Issue Price	Amount in BDT
	In Cash	Other than Cash	Bonus Share			
17.03.1976	600	-	-	10/-	10/-	6,000
16.05.1976	2,000	-	-	10/-	10/-	20,000
16.05.1976	-	27,500	-	10/-	10/-	275,000
10.08.1986	300,000	-	-	10/-	10/-	3,000,000
29.11.2006	9,669,900	-	-	10/-	10/-	96,699,000
05.05.2011	-	-	106,000,000	10/-	10/-	1,060,000,000
20.05.2013	39,631,100	-	-	10/-	52/-	396,311,000
26.11.2013	-	59,70,600	-	10/-	10/-	59,706,000
Total	**161,601,700 Ordinary Shares @Tk. 10.00 each**					**1,616,017,000**

Size of the present Issue, with break-up (number of securities, description, nominal value and issue amount)

Particulars		No. of Ordinary Shares	Nominal value per share	Premium per share	Issue price per Share	Total Amount in BDT
Initial Public Offering through Book Building Method	For EIIs	30,000,000	10	75.20	85.20	2,556,000,000
	For General Public	20,000,000	10	67.00	77.00	1,540,000,000
Total		50,000,000	-			4,096,000,000

Paid-up capital before and after the present issue and share premium account (before and after the issue)

Particulars	No. of Ordinary Shares	Paid-up Capital Amount in BDT	Share Premium Amount in BDT
Before Initial Public Offerings	161,601,700	1,616,017,000	1,605,066,569
Initial Public Offering through Book Building Method	500,000,00	500,000,000	3,596,000,000
After Initial Public Offerings	**211,601,700**	**2,116,017,000**	**5,201,066,569**

Category wise shareholding structure with percentage before and after the present issue

Sl. No.	Category of Shareholders	No. of Ordinary Shares Hold		Percentage of Holding	
		Pre-IPO	Post-IPO	Pre-IPO	Post-IPO
1	Sponsors	121,970,600	121,970,600	75.48	57.64
2	Institutional	38,476,100	63,476,100	23.81	30.00
3	Mutual fund	-	5,000,000	-	2.36
4	Individual	1,155,000	16,155,000	0.71	7.64
5	Non Resident Bangladeshis (NRBs)	-	5,000,000	-	2.36

Shares have been issued for consideration in other than cash at any point of time, details in a separate table, indicating the date of issue, persons to whom those are issued, relationship with the issuer, issue price and whether any benefits have been accrued to the issuer out of the issue

Consideration Other than cash			Allotment date	Name of the Allottee's	Relationship with the issuer	Issue price after split (Tk.)	Reason for the issue
Total	Consideration and valuation	Per Shareholder after split					
2,750 or 27,500 (after split)	For acquisition of entire business, the said Ordinary Shares issued to its sponsors against the net assets value.	5,000	16.05.1976	Late Hamidur Sinha	Subscriber to the memorandum	10	Acquisition of Business
		2,500	16.05.1976	Mr. Nasir-Ur-Rahman Sinha	Shareholder	10	
		2,500	16.05.1976	Mr. Mizanur Rahman Sinha	Managing Director	10	
		800	16.05.1976	Capt. (Rtd.) Anisur Rahman Sinha	Subscriber to the memorandum	10	
		2,500	16.05.1976	Mrs. Sitara Hossain	Subscriber to the memorandum	10	
		600	16.05.1976	Mrs. Parveen Akhter Nasir	Shareholder	10	
		600	16.05.1976	Mrs. Jahanara Mizan	Director	10	
		700	16.05.1976	Khurshid Jahan Dabir	Shareholder	10	
		700	16.05.1976	Nazma Rahman	Shareholder	10	
		800	16.05.1976	Laizu Dabir	Shareholder	10	
		3,800	16.05.1976	Dr. Jabilur Rahman Sinha	Deputy Managing Director	10	
		4,000	16.05.1976	Mrs. Hasina Jabil	Shareholder	10	
		1,000	16.05.1976	Mr. Afzalur Rahman Sinha	Chairman	10	
		2,000	16.05.1976	Mrs. Nagina Afzal	Director	10	
5,970,600	To acquire its Subsidiary the company issued one Ordinary share for every five Ordinary Shares of its subsidiary as purchase consideration.	2,336,115	26.11.2013	Mr. Mizanur Rahman Sinha	Managing Director	10	Amalgamation
		301,480	26.11.2013	Dr. Jabilur Rahman Sinha	Deputy Managing Director	10	
		1,443,736	26.11.2013	Mr. Afzalur Rahman Sinha	Chairman	10	
		100,493	26.11.2013	Mrs. Parveen Akhter Nasir	Shareholder	10	
		80,394	26.11.2013	Mrs. Jahanara Mizan Sinha	Director	10	
		100,493	26.11.2013	Mrs. Hasina Jabil Sinha	Shareholder	10	
		984,833	26.11.2013	Mrs. Nagina Afzal Sinha	Director	10	
		100,493	26.11.2013	Mr. Motiur Rahman Sinha	Shareholder	10	
		80,394	26.11.2013	Ms. Tasneem Sinha	Shareholder	10	
		200,986	26.11.2013	Mr. Nasir-Ur-Rahman Sinha	Shareholder	10	
		80,394	26.11.2013	Mr. Tanveer Sinha	Shareholder	10	
		80,394	26.11.2013	Mrs. Sabrina Sinha	Shareholder	10	
		80,395	26.11.2013	Mr. Fahim Sinha	Shareholder	10	

No benefits have been accrued to the issuer out of the issue.

Shares have been allotted in terms of merger, amalgamation or acquisition details of the scheme and shares allotted

The Company has not issued any shares in terms of merger or acquisition scheme. However, the company issued shares in terms of amalgamation scheme. Details of which are stated below:

The ACME Specialized Pharmaceuticals Ltd. amalgamated with The ACME Laboratories Ltd. in pursuant of Extra Ordinary General Meeting dated: 27 April 2013, both the Companies applied for approval to the Hon'ble High Court Division of the Supreme Court of Bangladesh. Hon'ble High Court Division of the Supreme Court of Bangladesh approved the appeal vide: dated 20th November 2013. As per the direction of the approved scheme by the Hon'ble High Court, The ACME Laboratories Ltd. issued and allotted one new Ordinary Share with a face value Tk. 10 per share for every five shares with a face value Tk. 10 per share held by shareholders of The ACME Specialized Pharmaceuticals Ltd. as purchase consideration. Consequently, total 5,970,600 numbers of Ordinary Shares were issued.

Information regarding where the issuer has issued equity shares under one or more employee stock option schemes, including the price at which such equity shares were issued

The Company did not issue any equity shares under stock option to its employees' stock option schemes to its employee.

If the issuer has made any issue of specified securities at a price lower than the issue price during the preceding two years, specific details of the names of the persons to whom such specified securities have been issued, relation with the issuer, reasons for such issue and the price thereof

In the year 2013, Company issued 39,631,100 Ordinary shares @ Tk. 52 each and in the year 2014, issued 5,970,600 shares @ Tk. 10 each respectively. Details of which are given below:

Date of allotment	Name of the Issued person	No. of shares allotted	Issue price	Relation with the issuer	Reasons for issue
20-May-13	GSP Finance Company (Bangladesh) Limited	769,200	Tk. 52	Shareholder	Capital raising
	Dr. Syed Anwarul Hafiz	500,000	Tk. 52	Shareholder	
	Khadim Ceramics Ltd. Unit-2	500,000	Tk. 52	Shareholder	
	Alpha Capital Management Ltd.	500,000	Tk. 52	Shareholder	
	Popular Life Insurance Company Limited	1,000,000	Tk. 52	Shareholder	
	Dhaka Bank Limited	500,000	Tk. 52	Shareholder	
	Bank Asia Limited	1,000,000	Tk. 52	Shareholder	
	Green Delta Insurance Company Ltd.	500,000	Tk. 52	Shareholder	
	Southeast Bank Limited	2,884,600	Tk. 52	Shareholder	
	Pioneer Insurance Company Limited	1,000,000	Tk. 52	Shareholder	
	Pragati Life Insurance Ltd.	300,000	Tk. 52	Shareholder	
	United Commercial Bank Limited	7,692,300	Tk. 52	Shareholder	
	Investment Corporation of Bangladesh	5,800,000	Tk. 52	Shareholder	
	ICB Unit Fund	5,800,000	Tk. 52	Shareholder	
	Bangladesh Shilpa Rin Sangstha (BDBL)	1,000,000	Tk. 52	Shareholder	
	ICB Capital Management Ltd.	1,900,000	Tk. 52	Shareholder	
	ICB Securities Trading Company Limited	950,000	Tk. 52	Shareholder	
	Bangladesh Fund	4,800,000	Tk. 52	Shareholder	
	Federal Insurance Company Limited	500,000	Tk. 52	Shareholder	
	Md. Ruhul Amin - ICML A/C	25,000	Tk. 52	Shareholder	

Date of allotment	Name of the Issued person	No. of shares allotted	Issue price	Relation with the issuer	Reasons for issue
20-May-13	A. S. M. Masudur Rahman - ICML A/C	50,000	Tk. 52	Shareholder	
	Md. Omar Siddique - ICML A/C	25,000	Tk. 52	Shareholder	
	Md. Hasibur Rahman - ICML A/C	60,000	Tk. 52	Shareholder	
	Sanowar Habib Sinha - ICML A/C	20,000	Tk. 52	Shareholder	
	Sarwar Habib Sinha - ICML A/C	20,000	Tk. 52	Shareholder	
	Golam Rabbani Bhuiyan - ICML A/C	20,000	Tk. 52	Shareholder	
	Md. Minar Hossain Khan - ICML A/C	20,000	Tk. 52	Shareholder	
	Md. Omar Khayam Bhuiyan - ICML A/C	20,000	Tk. 52	Shareholder	
	Suladhar Tarafder - ICML A/C	20,000	Tk. 52	Shareholder	
	Pralay Kumar Paul Chowdhury - ICML A/C	25,000	Tk. 52	Shareholder	
	Abu Reza Khan - ICML A/C	20,000	Tk. 52	Shareholder	
	Mojibur Rahman - ICML A/C	20,000	Tk. 52	Shareholder	
	Muhammed Ali	50,000	Tk. 52	Shareholder	
	Shahnoor Chowdhury	50,000	Tk. 52	Shareholder	
	The ACME Laboratories Ltd. Employees Provident Fund	1,000,000	Tk. 52	Shareholder	
	Muhammed Shahidul Islam	100,000	Tk. 52	Shareholder	
	ICB Portfolio Khulna	80,000	Tk. 52	Shareholder	
	Farzana Abedin	20,000	Tk. 52	Shareholder	
	Md. Asaduzzaman Mia	60,000	Tk. 52	Shareholder	
	Partho Kumar Bagchi	5,000	Tk. 52	Shareholder	
	G.K.M. Siddiquer Rahman	10,000	Tk. 52	Shareholder	
	Chowdhury Rishad Nighar	10,000	Tk. 52	Shareholder	
	Dr. Chowdhury Rifat Nighar	2,500	Tk. 52	Shareholder	
	Dr. Chowdhury Akram Uz Zaman	2,500	Tk. 52	Shareholder	
	Total	**39,631,100**			
26-Nov-13	Mr. Mizanur Rahman Sinha	2,336,115	Tk. 10	Managing Director	Amalgamation
	Dr. Jabilur Rahman Sinha	301,480	Tk. 10	Deputy Managing Director	
	Mr. Afzalur Rahman Sinha	1,443,736	Tk. 10	Chairman	
	Mrs. Parveen Akhter Nasir	100,493	Tk. 10	Shareholder	
	Mrs. Jahanara Mizan Sinha	80,394	Tk. 10	Director	
	Mrs. Hasina Jabil Sinha	100,493	Tk. 10	Shareholder	
	Mrs. Nagina Afzal Sinha	984,833	Tk. 10	Director	
	Mr. Motiur Rahman Sinha	100,493	Tk. 10	Shareholder	
	Ms. Tasneem Sinha	80,394	Tk. 10	Shareholder	
	Mr. Nasir-Ur-Rahman Sinha	200,986	Tk. 10	Shareholder	
	Mr. Tanveer Sinha	80,394	Tk. 10	Shareholder	
	Mrs. Sabrina Sinha	80,394	Tk. 10	Shareholder	
	Mr. Fahim Sinha	80,395	Tk. 10	Shareholder	
	Total	**5,970,600**			

The decision or intention, negotiation and consideration of the issuer to alter the capital structure by way of issue of specified securities in any manner within a period of one year from the date of listing of the present issue

The Company has no such decision or plan, contract, negotiation and consideration to alter its capital structure by way of issue of specified securities in any manner within a period of one year from the date of listing of the present issue.

Total shareholding of the sponsors and directors in a tabular form, clearly stating the names, nature of issue, date of allotment, number of shares, face value, issue price, consideration , date when the shares were made fully paid up, percentage of the total pre and post issue capital, the lock in period and the number and percentage of pledged shares, if any, held by each of them

Name of the Sponsor and Directors	Position in the Company	Number of shares held	Face Value	Issue price	Nature of issue	Consideration	Date of Allotment and Acquisition & date of share fully paid-up	% of share holding before public issue	% of share holding after public issue	Lock-in period from the date of issuance of prospectus	percentage of pledged shares
Mr. Nasir-Ur-Rahman Sinha	Shareholder (Sponsor)	6,160,405	10	10	Ordinary share	Cash= Tk. 59,569,190 Other than cash = Tk. 2,034,860	17.03.1976 16.05.1976 10.08.1989 20.05.2002 29.11.2006 05.05.2011 26.11.2013 01.09.2015	3.812	2.911	3 (Three) Years	N/A
Mr. Afzalur Rahman Sinha	Chairman	17,214,336	10	10	Ordinary share	Cash = Tk. 157,696,000 Other than cash = 14,447,360	16.05.1976 07.06.1980 10.08.1989 28.05.2002 29.11.2006 05.05.2011 26.11.2013 24.02.2015 02.06.2015 01.09.2015	10.652	8.135	3 (Three) Years	N/A
Mr. Mizanur Rahman Sinha	Managing Director	20,426,565	10	10	Ordinary share	Cash = Tk. 180,879,500 Other than cash = Tk. 23,386,150	17.03.1976 16.05.1976 07.06.1980 10.08.1989 20.05.2002 29.11.2006 05.05.2011 26.11.2013 24.02.2015 02.06.2015 01.09.2015	12.640	9.653	3 (Three) Years	N/A

Name of the Sponsor and Directors	Position in the Company	Number of shares held	Face Value	Issue price	Nature of Issue	Consideration	Date of Allotment and Acquisition & date of share fully paid-up	% of share holding before public issue	% of share holding after public issue	Lock-in period from the date of issuance of prospectus	percentage of pledged shares
Dr. Jabilur Rahman Sinha	Deputy Managing Director	4,860,696	10	10	Ordinary share	Cash = Tk. 45,554,160 Other than cash = Tk. 3,052,800	16.05.1976 29.11.2006 05.05.2011 26.11.2013 01.09.2015	3.008	2.297	3 (Three) Years	N/A
Mrs. Jahanara Mizan Sinha	Director	10,519,744	10	10	Ordinary share	Cash = Tk. 104,387,500 Other than cash = Tk. 809,940	17.03.1976 16.05.1976 07.06.1980 10.08.1989 29.11.2006 05.05.2011 26.11.2013	6.510	4.971	3 (Three) Years	N/A
Mrs. Nagina Afzal Sinha	Director	11,888,433	10	10	Ordinary share	Cash =Tk. 109,016,000 Other than cash = Tk. 9,868,330	16.05.1976 10.08.1989 29.11.2006 05.05.2011 26.11.2013	7.357	5.618	3 (Three) Years	N/A
Mrs. Parveen Akhter Nasir	Shareholder (Sponsor)	5,401,517	10	10	Ordinary share	Cash =Tk. 53,004,240 Other than cash = Tk. 1,010,930	17.03.1976 16.05.1976 07.06.1980 10.08.1989 29.11.2006 05.05.2011 26.11.2013	3.34	2.553	3 (Three) Years	N/A
Syed Shahed Reza	Independent Director	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Ms. Fouzia Haque, FCA	Independent Director	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

The details of the aggregate shareholding of the sponsors and directors, the aggregate number of specified securities purchased or sold or otherwise transferred by the sponsor and/or by the directors of the issuer and their related parties within six months immediate preceding the date of filing the prospectus;

The shares of Late Hamidur Rahman Sinha were transmitted to his legal wills on the following way:

Names of the Sponsors and Directors	No. of Shares received by way of transmission	Date of Transmission
Mr. Nasir-Ur-Rahman Sinha	1,450	01.09.2015
Mr. Afzalur Rahman Sinha	1,450	01.09.2015
Mr. Mizanur Rahman Sinha	1,450	01.09.2015
Dr. Jabilur Rahman Sinha	1,450	01.09.2015

The name and address of any person who owns, beneficially or of record, 5% or more of the securities of the issuer, indicating the amount of securities owned, whether they are owned beneficially represented by such ownership including number of equity shares which they would be entitled to upon exercise of warrant, option or right to convert any convertible instrument.

Sl. no	Name of the Security holder	Address	Quantity of Securities Owned	Type of Ownership	Security holding percentage
1	Mr. Afzalur Rahman Sinha	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	17,214,336	Shareholder director	10.652
2	Mr. Mizanur Rahman Sinha	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	20,426,565	Shareholder director	12.640
3	Mrs. Jahanara Mizan Sinha	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	10,519,744	Shareholder director	6.510
4	Mrs. Nagina Afzal Sinha	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	11,888,433	Shareholder director	7.357

As far as the existing information is concern, there is no event or intent of exercising warrant, option or right to convert any convertible instrument.

The number of securities of the issuer owned by each of the top ten salaried officers, and all other officers or employees as group, indicating the percentage of outstanding shares represented by the securities owned.

Securities owned by the top ten salaried officers

Sl.	Name of the Officers	Position	Number of Share Owned	Percentage of ownership
1	Mr. Afzalur Rahman Sinha	Chairman	17,214,336	10.652
2	Mr. Mizanur Rahman Sinha	Managing Director	20,426,565	12.640
3	Dr. Jabilur Rahman Sinha	Deputy Managing Director	4,860,696	3.008
4	Mr. Md. Hasibur Rahman	Additional Deputy Managing Director	60,180	0.037
5	Mr. Nasir-Ur-Rahman Sinha**	Shareholder	6,160,405	3.812
6	Ms. Tasneem Sinha*	Shareholder	280,394	0.173
7	Mr. Ansar Uddin Sinha*	Shareholder	2,900,000	1.79
8	Mr. Tanveer Sinha*	Shareholder	280,394	0.173
9	Ms. Sabrina Sinha*	Shareholder	280,394	0.173
10	Mr. Reza –Ur- Rahman Sinha*	Shareholder	4,400,000	2.72
11	Mr. Motiur Rahman Sinha*	Shareholder	1,400,000	0.87
12	Mr. Fahim Sinha*	Shareholder	280,395	0.173

** In the 41st Board Meeting dated 25th June 2014 Mr. Nasir-Ur-Rahman Sinha, former Chairman and Mrs. Parveen Akhter Nasir, former Director resigned from their position.

* In the 41st Board Meeting dated 25th June 2014, the Payee Sponsor Directors were voluntarily resigned from their position.

Note: Serial no. 9 to 12 enjoyed equal amount of remuneration.

Description of the Business

The date on which the issuer company was incorporated and the date on which it commenced operation and nature of business which the company and its subsidiaries are engaged in or propose to engage in;

The ACME Laboratories Ltd. started its commercial operation in the year 1954 as a proprietorship concern. Later on, the enterprise converted into a private limited company on 17 March 1976 and it was converted into a public limited company on 30 November 2011.

The Company is engaged in manufacturing, marketing and distribution of generic pharmaceuticals formulation products which includes human drugs dosages form like tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, sachet products, IV infusion; veterinary drugs dosages form like bolus, liquid, injection, water soluble powder, premix and herbal drugs dosages form like liquid, capsule, tablet, cream & ointment. The products of the company are sold in domestic and international markets.

Right now, the Company has no subsidiary concern.

Location of the project

The Registered office of the company is located at Court de la ACME, 1/4, Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh and its factory is located at Dhulivita, Dhamrai, Dhaka, Bangladesh.

Plant, machinery, technology, process etc.

ACME is vertically integrated generic pharmaceuticals formulation products manufacturer, marketer, promoter and distributor. Its manufacturing process heavily technology driven, dynamic in nature and using highly sophisticated state-of-the –art cutting edge technology.

The plant adheres to GMP standard, hygiene and safety. The facilities are unique for Integrated Building Management System (IBMS), World-class Structural Design, Dust-free Environment, well-designed HVAC System, Zero Cross-contamination, Vacuum Transfer Close System, Different Storage Conditions, High-tech Chemical & Microbiological Laboratories, Modern R&D facility, Most up-to-date Purified Water Generation plant, Fire Management System and Eco-friendly Effluent Treatment Plant.

ACME maintains Total Quality System, which includes Strict Monitoring, End-to-end Regulation. State-of-the-art Equipment, True Measurements, Equipment Calibration, Trained professionals.

Details of the major events in the history of the issuer, including details of capacity/ facility creation, launching of plant, products, marketing, change in ownership and/ or key management personnel etc.;

Formation of the Company and changes of its status

- In 1954, year of foundation of ACME as proprietorship firm
- In 1976, the firm converted into a Private Limited Company
- In 2011, ACME converted into a Public limited Company
- In 2013, the Company raised paid up capital amounting BDT 2060 million by issuing 39.63 million Ordinary shares

Details of capacity/facility creation, Launching of plant, products and marketing

- In 1983, Started commercial operation in modern facilities after BMRE project at Dhamrai
- In 1995, ACME started its first journey to International Operation by exporting medicines to Bhutan
- In 1999, ISO 9001:1994 certification for its Quality Management System & In the same year launched Veterinary Division
- In 2006, ACME completed 18-storied corporate office
- In 2007, Inclusion veterinary section under QMS scope of ISO 9001:2000
- In 2009, Up-gradation of QMS as per latest version of ISO 9001:2008
- In 2011, launched Modern new state of the ART facilities ASPL for solid Dosages
- In 2012, ASPL achieved certification of ISO 9001-2008 for the new state–of–the art solid dosages
- In 2013, ASPL amalgamated with The ACME Laboratories Ltd.
- In 2014, the Company started its commercial operation in following facilities:
  - Cephalosporin unit which is one of the largest state of the art Cephalosporin facilities in the Country
  - Liquid in hard gelatin products facilities
  - Parenteral Products facility under BFS technology which is highly automated facility

Changes in Ownership and/or key Management Personnel

- In 1995, Mr. Mizanur Rahman Sinha became Managing Director of the Company
- In 2014, Mr. Afzalur Rahman Sinha became Chairman of the Company.

Principal products or services of the issuer and markets for such products or services. Past trends and future prospects regarding exports (if applicable) and local market, demand and supply forecasts for the sector in which the product is included with source of data;

ACME produces a good number of products under three manufacturing division namely Human products division, Herbal & Ayurvedic products division and Veterinary products division. All the products of ACME categorized under Non-Biological Products and Biological Products. List of the products are mentioned below**:**

List of Non-Biological Products

[As approved by Directorate General of Drug Administration & Licensing Authority (Drugs), Government of the People's Republic of Bangladesh]

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
1.	A-Cal 250 mg. Tablet	Calcium Carbonate BP	Tablet	625.00 mg. (Equivalent to 250.00 mg Elemental Calcium)	036-279-062	12.11.2015
2.	A-Cal 500 mg. Tablet	Calcium Carbonate Heavy BP	Tablet	1250.00 mg. (Equivalent to 500.00 mg Elemental Calcium)	036-280-062	13.11.2015
3.	A-Calm Tablet	Tolperisone Hydrochloride INN	Tablet	50.00 mg	036-498-070	29.05.2016
4.	A-Card 20 mg. Tablet	Isosorbide Mononitrate (as Diluted Isosorbide Mononitrate) BP	Tablet	20.00 mg.	036-298-040	20.01.2017
5.	Acemox Tablet	Acetazolamide BP	Tablet	250.00 mg.	036-69-042	19.01.2017
6.	Acivir-200 Tablet	Aciclovir BP	Tablet	200.00 mg.	036-768-032	22.06.2018
7.	Acivir-400 Tablet	Aciclovir BP	Tablet	400.00 mg.	036-769-032	22.06.2018
8.	Acivir Suspension	Aciclovir BP	Suspension	4.000 g./100 ml	036-770-032	22.06.2018
9.	Aclobet Cream	Clobetasol Propionate (Micronized) BP	Cream	0.005 g/10 gm	036-626-071	13.11.2015
10.	Aclobet Ointment	Clobetasol Propionate (Micronized) BP	Ointment	0.005 g/10 gm	036-622-071	13.09.2015
11.	ACME's Milk of Magnesia	Magnesium Hydroxide Paste 30% Mg(OH)2 USP	Suspension	26.70 gm/100 ml	036-142-007	10.05.2018
12.	ACME's Milk of Magnesia Plus Suspension	Liquid Paraffin BP + Magnesium Hydroxide Paste, 34% BP + Magnesium Hydroxide Dried Gel, 96% BP	Suspension	30.00 ml + 7.060 g + 5.000 g/120 ml	036-597-060	27.01.2020
13.	ACME's Orsaline (Oral Rehydration Salts)	Sodium Chloride BP + Potassium Chloride BP + Trisodium Citrate Dihydrate BP + Anhydrous Glucose BP	Sachet	1.30 gm + 0.75 gm + 1.45 gm + 6.75 gm/Sachet ORS	036-793-079	14.05.2019
14.	Acmegra-25 Tablet	Sildenafil Citrate INN	Tablet	35.125 mg. (Equivalent to 25 mg Sildenafil)	036-752-043	12.05.2018
15.	Acmegra-50 Tablet	Sildenafil Citrate INN	Tablet	70.25 mg. (Equivalent to 50 mg Sildenafil)	036-753-043	12.05.2018
16.	Acmegra-100 Tablet	Sildenafil Citrate INN	Tablet	140.50 mg.(Equivalent to 100 mg Sildenafil)	036-754-043	12.05.2018
17.	Acnegel	Adapalene INN + Hydrous Benzoyl Peroxide, 70% USP	Gel	0.015 g + 0.536 g/15 gm	036-621-071	13.09.2015
18.	A-Cof Syrup	Dextromethorphan Hydrobromide USP + Pseudoephedrine Hydrochloride USP + Triprolidine Hydrochloride USP	Syrup	0.200 gm + 0.600 gm + 0.025 gm/ 100 ml	036-495-031	16.04.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
19.	A-Cold Syrup	Bromhexine Hydrochloride BP	Syrup	80.00 mg/100 ml	036-301-031	20.01.2017
20.	A-Colit Tablet (Export)	Lithium Carbonate BP	Tablet	300.00 mg	036-661-028	24.08.2016
21.	A-Fenac 25 mg. Tablet	Diclofenac Sodium BP	Tablet	25.00 mg.	036-90-064	02.05.2018
22.	A-Fenac 50 mg. Tablet	Diclofenac Sodium BP	Tablet	50.00 mg.	036-116-064	03.02.2016
23.	A-Fenac K 50 mg. Tablet	Diclofenac Potassium BP	Tablet	50.00 mg.	036-206-064	22.09.2018
24.	A-Fenac SR 100 mg. Tablet	Diclofenac Sodium BP	Tablet	100.00 mg.	036-144-064	07.08.2018
25.	A-Fenac - 12.5 Suppository	Diclofenac Sodium (Injectable Grade) BP	Suppository	12.50 mg.	036-323-064	18.02.2017
26.	A-Fenac - 50 Suppository	Diclofenac Sodium (Injectable Grade) BP	Suppository	50.00 mg.	036-322-064	18.02.2017
27.	A-Fenac Gel	Diclofenac Diethylamine BP	Gel	1.160 gm/100 gm. (Equivalent to 1.00 gm. Diclofenac Sodium/100 gm.)	036-455-071	02.01.2016
28.	A-Fenac Plus Gel	Diclofenac Diethylamine BP + Methyl Salicylate BP + Menthol BP	Gel	0.348 g (Equivalent to 0.3 g Diclofenac Sodium) + 3.000 g + 1.500 g/30 gm	036-744-071	01.01.2018
29.	Alanil 120 Tablet	Fexofenadine Hydrochloride USP	Tablet	120.00 mg	036-698-021	18.12.2016
30.	Alanil 180 Tablet	Fexofenadine Hydrochloride USP	Tablet	180.00 mg	036-704-021	15.01.2017
31.	Alanil Suspension	Fexofenadine Hydrochloride (Micronized) USP	Suspension	0.300 gm/50 ml	036-699-021	18.12.2016
32.	Alercon Nasal Spray	Olopatadine Hydrochloride INN	Nasal Spray	0.1596 g (Eqv. to 0.1439 g Olopatadine)	036-677-050	11.10.2016
33.	A-Meb 135 Tablet	Mebeverine Hydrochloride BP	Tablet	135.00 mg.	036-750-011	12.05.2018
34.	A-Metrine 0.125 mg. Tablet	Methylergometrine Maleate USP	Tablet	0.125 mg.	036-526-049	20.08.2017
35.	A-Migel Oral Gel	Miconazole USP	Oral Gel	0.300 g/15 g	036-611-073	31.03.2020
36.	Amlopin 5 Tablet	Amlodipine Besylate BP	Tablet	6.94 mg. (Equivalent to 5.00 mg. Amlodipine)	036-169-022	12.08.2016
37.	Amlopin 10 Tablet	Amlodipine Besylate BP	Tablet	13.88 mg (Equivalent to 10.00 mg Amlodipine)	036-170-022	12.08.2016
38.	Amloten 25 Tablet	Amlodipine Besylate BP + Atenolol BP	Tablet	6.94 mg (Equivalent to 5 mg Amlodipine) + 25.00 mg	036-541-022	24.02.2018
39.	Angirid MR Tablet	Trimetazidine Hydrochloride BP	Tablet	35.00 mg	036-590-040	24.11.2019
40.	Angist SR Tablet	Nitroglycerin SR Granules (2.06% W/W) Ph. Grade	Tablet	126.22 mg (Equivalent to 2.6 mg of Nitroglycerin USP)	036-501-071	29.05.2016
41.	Anticoc Oral Solution	Toltrazuril INN	Oral Solution	2.500 gm.	036-798(V)-077	04.03.2019
42.	A-Phyline 100 Tablet	Aminophylline BP	Tablet	100.00 mg.	036-527-044	20.08.2017
43.	Apitac-100 Tablet	Aceclofenac BP	Tablet	100.00 mg	036-464-064	02.01.2016
44.	Arth-A Tablet	Glucosamine Hydrochloride USP + Chondroitin Sulfate USP	Tablet	250.00 mg.+ 200.00 mg	036-413-064	12.04.2019
45.	Ascon -100 HFA Inhalation Aerosol	Anhydrous Beclomethasone Dipropionate (Micronised) BP	HFA Inhaler Aerosol	100.00 mcg/Actuation	036-708-044	30.05.2017
46.	Ascon -250 HFA Inhalation Aerosol	Anhydrous Beclomethasone Dipropionate (Micronised) BP	HFA Inhaler Aerosol	25.00 mg/100 Actuation	036-667-044	24.08.2016
47.	A-Spasm Tablet	Oxyphenonium Bromide INN	Tablet	5.00 mg.	036-122-011	14.05.2016
48.	Azelec 20% Cream	Azelaic Acid (Micronised) INN	Cream	20.00 gm./ 100 gm.	036-406-071	12.04.2019
49.	Azepam Tablet	Diazepam BP	Tablet	5.00 mg.	036-360-057	03.01.2018

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
50.	Azolin Nasal Drops	Oxymetazoline Hydrochloride USP	Nasal Drops	0.005 gm./10 ml.	036-648-052	10.04.2016
51.	Azolin Nasal Paediatric Drops	Oxymetazoline Hydrochloride USP	Nasal Drops	0.0025 gm./10 ml.	036-634-052	10.04.2016
52.	Baby Zinc 20 mg. Dispersible Tablet	Zinc Sulfate Monohydrate (Zn= 36.18%) USP	Dispersible Tablet	55.28 mg (Equivalent to 20.00 mg elemental Zinc)	036-445-062	19.08.2020
53.	Beclomet 0.05% Nasal Spray	Beclomethasone Dipropionate, Superfine BP	Nasal Spray	0.011 g/22 g Solution	036-728-050	17.10.2017
54.	Ben-A 200 mg. Tablet (Export)	Albendazole USP	Tablet	200.00 mg.	036-172-008	25.11.2016
55.	Ben-A 400 mg. Tablet	Albendazole Micronized, USP	Tablet	400.00 mg.	036-173-008	25.11.2016
56.	Ben-A Suspension	Albendazole USP	Suspension	0.400 gm/ 10 ml	036-576-008	06.07.2019
57.	Benazol VET Bolus	Albendazole Micronized, USP	Bolus	600.00 mg.	036-218(V)-077	01.09.2018
58.	Benzyl Lotion 25%	Benzyl Benzoate BP	Lotion	25.000 gm/100 ml	036-520-071	20.08.2017
59.	Bet-A Tablet	Betamethasone BP	Tablet	0.50 mg	036-647-072	10.04.2016
60.	Bet-A Cream	Betamethasone Valerate Micronised, BP	Cream	120.00 mg. (Equivalent to 100 mg Betamethasone)/100 gm.	036-233-071	22.09.2018
61.	Bet - A Ointment	Betamethasone Valerate Micronised, BP	Ointment	0.018 gm (Equivalent to 0.015 gm Betamethasone BP)/15 gm.	036-613-071	05.06.2020
62.	Bet - CL Cream	Betamethasone Dipropionate, Micronised BP + Clotrimazole, Micronised BP	Cream	0.0065 gm (Equivalent to 0.005 gm Betamethasone BP) + 0.100 gm./10 gm.	036-614-071	05.06.2020
63.	Bet-CL Ointment	Betamethasone Valerate, Micronised BP + Clotrimazole, Micronised BP	Ointment	0.012 g (Equivalent to 0.010 gm Betamethasone) + 0.100 g/10 g	036-654-071	01.06.2016
64.	Betabis -2.5 Tablet	Bisoprolol Hemifumarate USP	Tablet	2.50 mg	036-693-022	18.12.2016
65.	Betabis -5 Tablet	Bisoprolol Hemifumarate USP	Tablet	5 mg	036-694-022	18.12.2016
66.	Betaone 25 Tablet	Metoprolol Tartrate USP	Tablet	25 mg	036-808-022	22.03.2019
67.	Betaone 50 Tablet	Metoprolol Tartrate USP	Tablet	50 mg	036-655-022	24.08.2016
68.	Bloatstop Emulsion	Simethicone Emulsion USP	Emulsion	3.333 g (Equivalent to Simethicone 1.000g)/100 ml	036-610(V)-077	31.03.2020
69.	BS Ointment	Benzoic Acid, Microfine BP + Salicylic Acid, Microfine BP	Ointment	6.000 gm + 3.000 gm/100 gm	036-522-071	20.08.2017
70.	Burncare Cream	Silver Sulfadiazine, Micronized USP	Cream	0.250 gm/25 gm	036-757-071	12.05.2018
71.	Carvipress 6.25 Tablet	Carvedilol BP	Tablet	6.25 mg	036-452-022	29.10.2015
72.	Carvipress 12.50 Tablet	Carvedilol BP	Tablet	12.50 mg	036-453-022	29.10.2015
73.	Carvipress-25 Tablet	Carvedilol BP	Tablet	25.00 mg	036-465-022	02.01.2016
74.	Cetizin Tablet	Cetirizine Dihydrochloride BP	Tablet	10.00 mg.	036-205-021	22.09.2018
75.	Cinazin Tablet 15 mg.	Cinnarizine BP	Tablet	15.00 mg.	036-152-021	12.02.2019
76.	Cinazin Plus Tablet	Cinnarizine BP + Dimenhydrinate USP	Tablet	20.00 mg + 40.00 mg	036-598-021	27.01.2020
77.	Clotrim Cream	Clotrimazole Micronized USP	Cream	1.00 gm./ 100 gm.	036-102-071	13.05.2019
78.	Clotrim VT	Clotrimazole Microfine BP	Vaginal Tablet	200.00 mg	036-532-020	27.10.2017
79.	Clotrim Vaginal Suppository	Clotrimazole Microfine BP	Vaginal Suppository	200.00 mg	036-511-020	20.12.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
80.	Cofrid Syrup	Guaiphenesin BP + Pseudoephedrine Hydrochloride BP + Triprolidine Hydrochloride BP	Syrup	2.000 gm. + 0.600 gm + 0.025 gm/ 100 ml.	036-201-031	21.03.2018
81.	Cosium Tablet	Clobazam BP	Tablet	10.00 mg.	036-89-046	02.05.2018
82.	Co-Valtin 5/80 Tablet	Amlodipine Besilate BP + Valsartan BP	Tablet	6.90 mg (Equivalent to 5 mg Amlodipine) + 80.00 mg	036-788-022	04.12.2018
83.	Co-Valtin 5/160 Tablet	Amlodipine Besilate BP + Valsartan BP	Tablet	6.90 mg (Equivalent to 5 mg Amlodipine) + 160.00 mg	036-789-022	04.12.2018
84.	Dactus-1 Tablet	Glimepiride BP	Tablet	1.00 mg.	036-380-015	19.11.2018
85.	Dactus-2 Tablet	Glimepiride BP	Tablet	2.00 mg.	036-381-015	19.11.2018
86.	Dactus-3 Tablet	Glimepiride BP	Tablet	3.00 mg.	036-569-015	30.05.2019
87.	Daomin Tablet	Metformin Hydrochloride BP	Tablet	500.00 mg.	036-117-015	03.02.2016
88.	Daomin 850 mg. Tablet	Metformin Hydrochloride BP	Tablet	850.00 mg.	036-243-015	23.10.2019
89.	Daomin 1000 Tablet	Metformin Hydrochloride BP	Tablet	1000.00 mg	036-612-015	05.06.2015
90.	Daomin XR 500 Tablet	Metformin Hydrochloride BP	Tablet	500.00 mg	036-702-015	15.01.2017
91.	Daomin XR 1000 Tablet	Metformin Hydrochloride BP	Tablet	1000.00 mg	036-703-015	15.01.2017
92.	Darifen ER 7.5 Tablet	Darifenacin Hydrobromide INN	Tablet	8.93 mg (Equivalent to Darifenacin 7.50 mg)	036-619-049	29.08.2015
93.	Darifen ER 15 Tablet	Darifenacin Hydrobromide INN	Tablet	17.85 mg (Equivalent to Darifenacin 15 mg)	036-620-049	13.09.2015
94.	Dclot-75 Tablet	Clopidogrel Bisulphate USP	Tablet	97.86 mg (Equivalent to 75.mg Clopidogrel)	036-437-026	11.02.2020
95.	Defaz Tablet	Folic Acid BP + Zinc Sulphate Monohydrate USP	Tablet	5.00 mg + 54.90 mg (Equivalent to 20.00 mg Elemental Zinc)	036-581-045	06.07.2019
96.	Defaz CI Capsule	Carbonyl Iron, Folic Acid & Zinc Sulfate Blended Pellets	Capsule	435.00 mg (Eqv. to Elemental Iron 50 mg + Folic Acid 500 mcg & Elemental Zinc 22.5 mg)	036-603-045	27.01.2020
97.	Dirovet Bolus	Metronidazole BP	Bolus	2000.00 mg.	036-419(V)-077	20.08.2019
98.	Dirozyl 200 Tablet	Metronidazole BP	Tablet	200.00 mg.	036-91-027	02.05.2018
99.	Dirozyl 400 Tablet	Metronidazole BP	Tablet	400.00 mg.	036-51-027	04.05.2018
100.	Dirozyl – 500 Suppository	Metronidazole Microfined BP	Suppository	500.00 mg.	036-325-027	18.02.2017
101.	Dirozyl Suspension	Benzoyl Metronidazole BP	Suspension	6.43 gm (Equivalent to Metronidazole BP 4.00 gm)/ 100 ml	036-22-027	03.01.2018
102.	Dolonil 100 SR Tablet	Tramadol Hydrochloride BP	Tablet	100.00 mg	036-523-065	20.08.2017
103.	Dolonil 50 Capsule	Tramadol Hydrochloride BP	Capsule	50.00 mg	036-524-065	20.08.2017
104.	Don-A 10 mg. Tablet	Domperidone Maleate BP	Tablet	12.73 mg. (Equivalent to 10.00 mg Domperidone)	036-296-018	30.11.2016
105.	Don-A 15 Suppository	Domperidone Microfine BP	Suppository	15.00 mg.	036-412-018	12.04.2019
106.	Don-A 30 Suppository	Domperidone BP	Suppository	30.00 mg.	036-400-018	19.03.2019
107.	Don-A Suspension	Domperidone BP	Suspension	0.100 gm/100 ml	036-297-018	30.11.2016
108.	Don-A Paediatric Drops	Domperidone BP	Paediatric Drops	0.075 gm/15 ml	036-547-018	23.12.2018
109.	Don-A Paediatric Suspension	Domperidone BP	Paediatric Suspension	0.100 gm/ 100 ml	036-359-018	03.01.2018
110.	Dot 40 mg. Tablet	Drotaverine Hydrochloride INN	Tablet	40.00 mg.	036-341-048	19.07.2017
111.	Dulox- 20 Tablet	Duloxetine Hydrochloride INN	Tablet	22.45 mg (Equivalent to 20.00 mg Duloxetine)	036-459-014	02.01.2016
112.	Dulox -30 Tablet	Duloxetine Hydrochloride INN	Tablet	33.67 mg (Equivalent to 30. mg Duloxetine)	036-460-014	02.01.2016
113.	Doxy-A Vet WSP	Doxycycline Hydrochloride BP	WSP	10.00 gm/100 gm	036-265(V)-077	30.08.2015
114.	Ecosprin Tablet 75 mg. (E/C)	Aspirin (Acetyl Salicylic Acid) BP	Tablet	75.00 mg.	036-151-026	02.01.2019
115.	Ecosprin 300 mg. Tablet	Aspirin (Crystalline Powder) BP	Tablet	300.00 mg.	036-81-006	28.02.2018

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
116.	Ecosprin Plus Tablet	Clopidogrel Bisulphate USP + Aspirin BP	Tablet	97.53 mg (Equivalent to Clopidogrel 75.00 mg) + 75.00 mg	036-438-026	07.05.2020
117.	Ecosprin 100 E/C Tablet	Aspirin BP	Tablet	100.00 mg	036-796-026	02.02.2019
118.	Ecosprin 150 E/C Tablet	Aspirin BP	Tablet	150.00 mg	036-781-026	18.09.2018
119.	Ecosprin E/C 150 Tablet (Export)	Aspirin BP	Tablet	150.00 mg	036-546-026	16.11.2018
120.	Edemide Tablet	Spironolactone BP + Furosemide BP	Tablet	50.00 mg.+ 20.00 mg.	036-347-042	19.07.2017
121.	Edemide 40 Tablet	Spironolactone BP + Frusemide BP	Tablet	50.00 mg + 40.00 mg	036-580-042	06.07.2019
122.	Electro-K Tablet	Potassium Chloride BP	Tablet	600.00 mg.	036-92-062	22.05.2019
123.	Electro-K Syrup	Potassium Chloride USP	Syrup	10.00 gm/100 ml.	036-06-062	08.12.2019
124.	Elodep-5 Tablet	Escitalopram Oxalate USP	Tablet	6.40 mg (Equivalent to Escitalopram 5 mg)	036-761-014	22.06.2018
125.	Elodep-10 Tablet	Escitalopram Oxalate USP	Tablet	12.80 mg (Equivalent to Escitalopram 10 mg)	036-762-014	22.06.2018
126.	Enocam Tablet 20 mg	Tenoxicam BP	Tablet	20.00 mg	036-623-064	13.11.2015
127.	Etogesic SR Tablet	Etodolac USP	Tablet	600 mg	036-692-064	18.12.2016
128.	Famodin 20 mg. Tablet	Famotidine USP	Tablet	20.00 mg.	036-148-055	02.01.2019
129.	Famodin 40 mg. Tablet	Famotidine USP	Tablet	40.00 mg.	036-149-055	02.01.2019
130.	Fast Tablet	Paracetamol BP	Tablet	500.00 mg.	036-42-006	25.08.2015
131.	Fast Plus Tablet	Paracetamol BP + Caffeine BP	Tablet	500.00 mg + 65.00 mg	036-469-006	04.01.2016
132.	Fast ER Tablet	Paracetamol BP	Tablet	665.00 mg	036-660-006	24.08.2016
133.	Fast-M Tablet	Paracetamol BP + DL- Methionine BP	Tablet	500.00 mg + 100.00 mg	036-755-006	12.05.2018
134.	Fast – 125 Suppository	Paracetamol Microfine BP	Suppository	125.00 mg.	036-321-006	18.02.2017
135.	Fast-250 Suppository	Paracetamol Microfine BP	Suppository	250.00 mg.	036-320-006	18.02.2017
136.	Fast- 500 Suppository	Paracetamol Microfine BP	Suppository	500.00 mg	036-472-006	22.02.2016
137.	Fast Syrup	Paracetamol BP	Syrup	2.400 gm/100 ml	036-710-006	19.06.2017
138.	Fast Suspension	Paracetamol Micronised BP	Suspension	2.400 gm/100 ml.	036-241-006	23.10.2019
139.	Fast Paediatric Drops	Paracetamol BP	Paediatric Drops	1.2000 gm/15 ml	036-641-006	10.04.2016
140.	Fast Vet Bolus	Paracetamol BP	Bolus	2.00 gm/ Bolus	036-476(V)-077	22.02.2016
141.	Fastdol Tablet	Paracetamol BP + Tramadol Hydrochloride BP	Tablet	325.00 mg + 37.50 mg	036-709-006	19.06.2017
142.	Fenazol Vet Bolus	Fenbendazole BP	Bolus	250.00 mg	036-816(V)-077	14.05.2019
143.	Ferocit-TR Capsule	Ferrous Sulphate + Folic Acid Blended Pellets	Capsule	435 mg (Eqv. to Dried Ferrous Sulphate 150 mg & Folic Acid 0.5 mg in SR form)	036-177-045	09.09.2017
144.	Ferocit-Z Capsule	Dried Ferrous Sulphate BP + Zinc Sulphate Monohydrate USP + Folic Acid BP	Capsule	150.00 mg. + 61.800 mg. + 0.500 mg.	036-261-045	30.08.2015
145.	Ferroglobin Syrup	Ferrous Sulphate USP	Syrup	4.00 gm/ 100 ml	036-75-045	28.01.2018
146.	Flatunil Paediatric Drops	Simethicone Emulsion (30%) USP	Paediatric Drops	22.334 g (Equivalent to Simethicone 6.700 g)/100 ml	036-792-007	04.12.2018
147.	Fluticon-50 DPI	Fluticasone Propionate, Microfine BP	Rotacapsule	0.05 mg.	036-330-044	18.02.2017

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
148.	Fluticon-100 DPI	Fluticasone Propionate, Microfine BP	Rotacapsule	0.10 mg.	036-331-044	18.02.2017
149.	Fluticon-250 DPI	Fluticasone Propionate, Microfine BP	Rotacapsule	0.25 mg.	036-398-044	19.03.2019
150.	Fluticon-500 DPI	Fluticasone Propionate, Microfine BP	Rotacapsule	0.500 mg.	036-399-044	19.03.2019
151.	Fluticon Nasal Spray	Fluticasone Propionate, Superfine BP	Nasal Spray	0.00675 gm/13.5 gm	036-638-050	10.04.2016
152.	Fluticon Nasal Spray 0.05%	Fluticasone Propionate, Microfine BP	Nasal Spray	0.05 gm./ 100 ml.	036-345-050	19.07.2017
153.	Fluzin 5 Tablet	Flunarizine Dihydrochloride BP	Tablet	5.90 mg (Equivalent to Flunarizine 5 mg)	036-672-047	11.10.2016
154.	Fluzin 10 Tablet	Flunarizine Dihydrochloride BP	Tablet	11.80 mg (Equivalent to Flunarizine 10 mg)	036-673-047	11.10.2016
155.	FMD Cure Solution	Natril Carbonas (Sodium Carbonate) BP	Solution	4.000 gm/ 100 ml	036-535(V)-077	02.12.2017
156.	Gabon Tablet	Gabapentin USP	Tablet	300.00 mg	036-674-046	11.10.2016
157.	Genlet Solution 2%	Gentian Violet BP	Solution	2.000 gm.	036-521-071	20.08.2017
158.	Gliclid Tablet	Gliclazide BP	Tablet	80.00 mg	036-260-015	30.08.2015
159.	Gliclid - 30 MR Tablet	Gliclazide BP	Tablet	30.00 mg	036-772-015	22.06.2018
160.						
161.	Glipimet Tablet (Export)	Glimepiride BP + Metformin Hydrochloride BP	Tablet	2.00 mg + 500.00 mg	036-745-015	01.01.2018
162.	Gluconil Tablet	Glibenclamide (Microfine) BP	Tablet	5.00 mg.	036-77-015	26.02.2018
163.	Goustat F/C Tablet	Febuxostat INN	Tablet	40.00 mg	036-705-076	28.03.2017
164.	Histalex Tablet	Chlorpheniramine Maleate BP	Tablet	4.00 mg.	036-123-021	16.12.2016
165.	Histalex Syrup	Chlorpheniramine Maleate BP	Syrup	40.00 mg / 100 ml	036-19-021	28.04.2018
166.	Hycine 10 Tablet	Hyoscine - N Butylbromide BP	Tablet	10.00 mg	036-525-064	20.08.2017
167.	Ibsan 300 Tablet	Irbesartan USP	Tablet	300.00 mg	036-806-022	04.03.2019
168.	Ibsan 150 mg. Tablet (Export)	Irbesartan USP	Tablet	150.00 mg	036-356-022	10.08.2017
169.	Indo-A 25 Capsule	Indomethacin USP	Capsule	25.00 mg.	036-727-064	12.09.2017
170.	Indo-A 100 Suppository	Indomethacin BP	Suppository	100.00 mg.	036-319-064	18.02.2017
171.	Janmet-500 Tablet	Sitagliptin Phosphate Monohydrate INN + Metformin Hydrochloride BP	Tablet	64.25 mg (Equivalent to Sitagliptin 50 mg) + 500 mg	036-685-015	23.10.2016
172.	Janmet-1000 Tablet	Sitagliptin Phosphate Monohydrate INN + Metformin Hydrochloride BP	Tablet	64.25 mg (Equivalent to Sitagliptin 50 mg) + 1000 mg	036-686-015	23.10.2016
173.	Janvia-50 F/C Tablet	Sitagliptin Phosphate Monohydrate INN	Tablet	64.25 mg (Equivalent. to Sitagliptin 50 mg)	036-675-015	11.10.2016
174.	Janvia-100 F/C Tablet	Sitagliptin Phosphate Monohydrate INN	Tablet	128.50 mg (Eqv. to Sitagliptin 100 mg)	036-676-015	11.10.2016
175.	Ketifen Tablet	Ketotifen Fumarate BP	Tablet	1.38 mg. (Equivalent to 1.00 mg Ketotifen)	036-156-021	17.03.2020
176.	Ketifen Syrup	Ketotifen Fumarate BP	Syrup	27.60 mg (Equivalent to 20 mg Ketotifen)/ 100 ml.	036-358-021	03.01.2018

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
177.	Keto-A 50 Tablet	Ketoprofen BP	Tablet	50.00 mg.	036-200-064	21.03.2018
178.	Keto-A 100 Tablet	Ketoprofen BP	Tablet	100.00 mg.	036-199-064	21.03.2018
179.	Keto-A 100 Suppository	Ketoprofen Micronised BP	Suppository	100.00 mg.	036-324-064	18.02.2017
180.	Keto-A Vet Bolus	Ketoprofen BP	Bolus	400.00 mg.	036-729(V)-077	17.10.2017
181.	Keto-D Tablet	Dexketoprofen Trometamol INN	Tablet	36.90 mg (Equivalent to 25 mg Dexketoprofen)	036-571-064	30.05.2019
182.	Kidcal Chewable Tablet	Calcium Carbonate Heavy BP	Tablet	625.00 mg. (Equivalent to 250 mg Elemental Calcium)	036-338-062	06.05.2017
183.	Lacitab Tablet- 2	Lacidipine BP	Tablet	2.00 mg	036-574-022	06.07.2019
184.	Lacitab Tablet- 4	Lacidipine BP	Tablet	4.00 mg	036-575-022	06.07.2019
185.	Lacosam-50 Tablet	Lacosamide INN	Tablet	50.00 mg.	036-765-013	22.06.2018
186.	Lacosam-100 Tablet	Lacosamide INN	Tablet	100.00 mg.	036-766-013	22.06.2018
187.	Lansodin 15 mg. Capsule	Enteric Coated Granules of Lansoprazole Ph. Grade	Capsule	175.00 mg (Containing 15 mg of Lansoprazole INN)	036-281-067	13.11.2015
188.	Lansodin 30 mg. Capsule	Enteric Coated Granules of Lansoprazole Ph. Grade	Capsule	350.00 mg (Containing 30 mg of Lansoprazole INN)	036-282-067	13.11.2015
189.	Leanxit Tablet	Flupentixol Dihydrochloride Ph. Eur. + Melitracen Hydrochloride INN	Tablet	0.5814 mg. (Eqv. to 0.5 mg Flupentixol) + 11.24 mg. (Eqv. to 10 mg Melitracen)	036-371-028	11.08.2018
190.	Leptic-0.5 Tablet	Clonazepam USP	Tablet	0.50 mg.	036-461-046	29.10.2015
191.	Leptic-2 Tablet	Clonazepam USP	Tablet	2.00 mg.	036-462-046	29.10.2015
192.	Levanid Vet Bolus	Tetramisole Hydrochloride BP + Oxyclozanide BP	Bolus	2.00 gm. + 1.40 gm.	036-222(V)-077	01.09.2018
193.	Levavet Bolus	Levamisole Hydrochloride BP	Bolus	708.00 mg. (Equivalent to Levamisole 600 mg)	036-216(V)-077	01.09.2018
194.	Levopa 110 Tablet	Levodopa BP + Carbidopa BP	Tablet	100.00 mg + 10.00 mg	036-624-025	13.11.2015
195.	Levopa 275 Tablet	Levodopa BP + Carbidopa BP	Tablet	250.00 mg + 25.00 mg	036-625-025	13.11.2015
196.	Lincol Linctus	Liquid Sucrose (67.5%) BP + Glycerol BP	Linctus	(38.600 ml + 15.000 ml)/100 ml	036-730-031	17.10.2017
197.	Lipidof-200 Capsule	Fenofibrate (Micronised) BP	Capsule	200.00 mg.	036-372-061	21.09.2018
198.	Lipril 5 Tablet	Lisinopril Dihydrate USP	Tablet	5.45 mg (Equivalent to 5.00 mg Lisinopril)	036-157-061	12.05.2016
199.	Lipril 10 Tablet	Lisinopril Dihydrate USP	Tablet	10.90 mg. (Equivalent to 10 mg Lisinopril)	036-158-061	12.05.2016
200.	Liptor-10 Tablet	Atorvastatin Calcium INN	Tablet	10.82 mg (Equivalent to 10.00 mg Atorvastatin)	036-470-061	22.02.2016
201.	Liptor-20 Tablet	Atorvastatin Calcium INN	Tablet	21.64 mg (Equivalent to 20.00 mg Atorvastatin)	036-471-061	22.02.2016
202.	Liptor- 40 Tablet	Atorvastatin Calcium INN	Tablet	43.40 mg (Equivalent to 40.00 mg Atorvastatin)	036-618-061	29.08.2015

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
203.	Lopamid Capsule	Loperamide Hydrochloride USP	Capsule	2.00 mg.	036-85-016	26.02.2018
204.	Losart-25 Tablet	Losartan Potassium USP	Tablet	25.00 mg.	036-334-022	06.05.2017
205.	Losart-50 Tablet	Losartan Potassium USP	Tablet	50.00 mg.	036-335-022	06.05.2017
206.	Losart-100 Tablet	Losartan Potassium USP	Tablet	100.00 mg.	036-649-022	01.06.2016
207.	Losart Plus Tablet	Losartan Potassium USP + Hydrochlorothiazide BP	Tablet	50 mg + 12.50 mg	036-473-022	22.02.2016
208.	Losart Plus 100/12.5 Tablet	Losartan Potassium USP + Hydrochlorothiazide BP	Tablet	100 mg + 12.50 mg	036-650-022	01.06.2016
209.	Losart Plus 100/25 Tablet	Losartan Potassium USP + Hydrochlorothiazide BP	Tablet	100 mg + 25.00 mg	036-651-022	01.06.2016
210.	LT-Vet Bolus	Triclabendazole INN + Levamisole Hydrochloride BP	Bolus	900.00 mg +708.00 mg (Equivalent to 600.00 mg Levamisole)	036-434(V)-077	02.01.2020
211.	Magvet Suspension	Magnesium Hydroxide Paste, 34% BP + Magnesium Hydroxide Dried Gel, 96% BP	Suspension	(29.415 g + 31.250 g)/500 ml	036-606(V)-077	27.01.2020
212.	Maxima - 20 Capsule	Esomeprazole Pellet 8.5% w/w INN	Capsule	235.30 mg (Equivalent to 20 mg Esomeprazole)	036-439-067	14.03.2020
213.	Maxima - 40 Capsule	Esomeprazole Pellet 8.5% w/w INN	Capsule	470.60 mg (Equivalent to 40 mg Esomeprazole)	036-440-067	14.03.2020
214.	Mebolin Tablet	Mebhydrolin Napadisylate BPC	Tablet	76.00 mg. (Eqv. to 50 mg Mebhydrolin)	036-104-021	13.05.2019
215.	Megafil- 5 Tablet	Tadalafil INN	Tablet	5.00 mg	036-731-043	17.10.2017
216.	Megafil- 10 Tablet	Tadalafil INN	Tablet	10.00 mg	036-510-043	04.09.2016
217.	Megafil- 20 Tablet	Tadalafil INN	Tablet	20.00 mg	036-628-043	13.11.2015
218.	Mel-Vet Bolus	Meloxicam BP	Bolus	100 mg	036-688(V)-077	23.10.2016
219.	Milast-A Tablet	Roflumilast INN	Tablet	500.00 mcg	036-790-044	04.12.2018
220.	Misoclear 600 Tablet	Misoprostol 1% HPMC Dispersion BP	Tablet	60.00 mg (Eqv. to 600 mcg Misoprostol)	036-756-049	12.05.2018
221.	Misofenac -50 Tablet	Diclofenac Sodium BP + Misoprostol INN	Tablet	50.00 mg + 200 mcg	036-458-064	02.01.2016
222.	Misofenac- 75 Tablet	Diclofenac Sodium BP + Misoprostol INN	Tablet	75.00 mg + 200 mcg	036-435-064	02.01.2015
223.	Mizolam -7.5 Tablet	Midazolam BP	Tablet	7.50 mg	036-444-057	19.08.2015

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
224.	Monas - 4 mg. Tablet	Montelukast Sodium INN	Tablet	4.20 mg. (Equivalent to 4.00 mg Montelukast)	036-318-044	16.01.2017
225.	Monas – 5 mg. Tablet	Montelukast Sodium INN	Tablet	5.20 mg. (Equivalent to 5.00 mg Montelukast)	036-317-044	16.01.2017
226.	Monas – 10 mg. Tablet	Montelukast Sodium INN	Tablet	10.40 mg. (Equivalent to 10.00 mg Montelukast)	036-316-044	16.01.2017
227.	Muterol -10 Tablet	Bambuterol Hydrochloride BP	Tablet	10.00 mg	036-492-044	16.04.2016
228.	Muterol- 20 Tablet	Bambuterol Hydrochloride BP	Tablet	20.00 mg	036-493-044	16.04.2016
229.	Muterol Oral Solution	Bambuterol Hydrochloride BP	Oral Solution	0.100 gm/100 ml	036-494-044	16.04.2016
230.	Naligram Tablet	Nalidixic Acid BP	Tablet	500.00 mg.	036-74-023	30.11.2017
231.	Naligram Suspension	Nalidixic Acid (Microcrystalline Powder) BP	Suspension	6.00 gm/100 ml.	036-71-023	27.02.2017
232.	Napro-A Tablet	Naproxen BP	Tablet	250.00 mg.	036-203-064	12.05.2018
233.	Napro-A Tablet 500 mg.	Naproxen BP	Tablet	500.00 mg.	036-291-064	25.08.2016
234.	Napro-A Plus 375 Tablet	Naproxen BP + Esomeprazole Magnesium Trihydrate BP	Tablet	375.00 mg. + 22.30 mg (Eqv. to Esomeprazole 20 mg)	036-720-064	30.05.2017
235.	Napro-A Plus 500 Tablet	Naproxen BP + Esomeprazole Magnesium Trihydrate BP	Tablet	500.00 mg. + 22.30 mg (Eqv. to Esomeprazole 20 mg)	036-721-064	30.05.2017
236.	Neo-Trax Tablet	Levamisole Hydrochloride BP	Tablet	47.20 mg (Equivalent to Levamisole Base 40.00 mg)	036-27-008	28.04.2018
237.	Neo-Trax Syrup	Levamisole Hydrochloride BP	Syrup	944.00 mg (Equivalent to 800 mg Levamisole Base)	036-11-008	28.04.2018
238.	Neotrax Vet WSP	Levamisole Hydrochloride BP	WSP	6.00 gm/ 20 gm.	036-306(V)-077	20.01.2017
239.	Neotrax Vet Syrup 1%	Levamisole Hydrochloride BP	Syrup	1180.00 mg (Eqv. to 1000 mg Levamisole)/ 100 ml	036-244(V)-077	23.10.2019
240.	Neugalin-50 Capsule	Pregabalin INN	Capsule	50.00 mg	036-714-046	30.05.2017
241.	Neugalin-75 Capsule	Pregabalin INN	Capsule	75.00 mg	036-715-046	30.05.2017
242.	Neugalin-150 Capsule	Pregabalin INN	Capsule	150.00 mg	036-716-046	30.05.2017
243.	Nidozox 500 Tablet	Nitazoxanide INN	Tablet	500.00 mg	036-562-027	31.03.2019
244.	Nidozox Suspension	Nitazoxanide (Micronised) INN	Suspension	600 mg/30 ml	036-563-027	31.03.2019
245.	Nifin Tablet	Nifedipine USP	Tablet	10.00 mg.	036-95-022	12.05.2019
246.	Nigofon Vet Powder	Trichlorfon USP	Powder	100.00 gm/100 gm Sachet	036-818(V)-077	14.05.2019

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
247.	Norflu Tablet 10 mg.	Fluphenazine Hydrochloride BP + Nortiptylene Hydrochloride BP	Tablet	0.50 mg. + 11.39 mg. (Equivalent to 10.00 mg Nortiptylene)	036-240-028	13.07.2019
248.	Nil Pain Cream	Methyl Salicylate BP + Menthol BP	Cream	(7.500 g + 2.000 g)/25g	036-662-071	24.08.2016
249.	Nutramid Tablet	Metoclopramide Hydrochloride BP	Tablet	10.54 mg. (Equivalent to 10.00 mg Metoclopramide)	036-71-018	20.08.2017
250.	Nutramid Syrup	Metoclopramide Hydrochloride BP	Syrup	105.40 mg (Equivalent to Metoclopramide 100 mg)/100 ml	036-98-018	12.05.2019
251.	Oratics Oral Gel	Benzocaine USP	Gel	1.000 gm/5gm	036-717-071	30.05.2017
252.	Orbapin 5/20 Tablet	Amlodipine Besilate BP + Olmesartan Medoxomil INN	Tablet	6.935 mg (Equivalent to Amlodipine 5 mg) + 20.00 mg	036-791-022	04.12.2018
253.	Orbas-20 Tablet	Olmesartan Medoxomil INN	Tablet	20.00 mg.	036-763-022	22.06.2018
254.	Orbas-40 Tablet	Olmesartan Medoxomil INN	Tablet	40.00 mg.	036-764-022	22.06.2018
255.	Orbas Plus 20/12.5 Tablet	Olmesartan Medoxomil INN + Hydrochlorothiazide BP	Tablet	20.00 mg + 12.50 mg	036-807-022	04.03.2019
256.	Orin Tablet	Loratadine Micronised INN	Tablet	10.00 mg.	036-259-021	30.08.2015
257.	Orin Suspension	Loratadine INN	Suspension	0.100 gm/100 ml.	036-258-021	30.08.2015
258.	Orinex Tablet	Desloratadine INN	Tablet	5.00 mg	036-558-021	31.03.2019
259.	Oxecone Tablet	Dried Aluminium Hydroxide Gel BP + Magnesium Hydroxide BP	Tablet	250.00 mg. + 400.00 mg	036-76-007	26.02.2018
260.	Oxecone-M Tablet	Magaldrate USP	Tablet	440.00 mg. (Equivalent to 400 mg Anhydrous Magaldrate)	036-166-007	04.02.2017
261.	Oxecone-S Tablet	Dried Aluminium Hydroxide Gel BP + Magnesium Hydroxide BP + Simethicone USP	Tablet	400.00 mg. + 400.00 mg. + 30.00 mg.	036-146-007	08.12.2018
262.	Oxecone Suspension	Magnesium Hydroxide BP + Aluminium Hydroxide Compressed Gel (Al2O310%) USP	Suspension	2.50 gm. + 40.00 gm. (Eqv. to Al2O3 BP 4.00 gm)/ 100 ml.	036-07-007	28.04.2018
263.	Oxecone-M Suspension	Magaldrate USP	Suspension	8.889 gm (Equivalent to 8.00 gm Magaldrate Anhydrous)/ 100 ml	036-165-007	15.04.2016
264.	Oxecone-S Suspension	Aluminium Hydroxide Compressed Gel (Al2O310%) BP + Magnesium Hydroxide BP + Simethicone Emulsion 30% USP	Suspension	40.00 gm (Equivalent to 8.0 gm of Dried Aluminium Hydroxide Gel) + 8.00 gm + 2.00 gm. (Equivalent to Simethicone 0.6 gm)/ 100 ml.	036-147-007	08.12.2018
265.	Oxecone - MS Suspension	Magaldrate USP + Simethicone Emulsion (30%) USP	Suspension	9.600 gm + 1.333 gm (Eqv. to 0.400 gm Simethicone)/100 ml	036-510-007	20.12.2016
266.	Pavigard Tablet	Pitavastatin Calcium INN	Tablet	2.09 mg (Eqv. to Pitavastatin 2 mg)	036-687-061	23.10.2016
267.	Peravet WSP	Piperazine Citrate USP	WSP	100.00 gm./100 gm.	036-305(V)-077	20.01.2017
268.	Periset F/C Tablet	Ondansetron Hydrochloride USP	F/C Tablet	9.98 mg (Equivalent to 8 mg Ondansetron)	036-631-018	10.04.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
269.	Periset Oral Solution	Ondansetron Hydrochloride USP	Oral Solution	0.050 gm (Eqv. to 0.040 gm of Ondansetron)/50 ml	036-722-018	19.06.2017
270.	Periset Suppository	Ondansetron Hydrochloride USP	Suppository	19.96 mg (Eqv. to Ondansetron 16 mg)	036-784-018	18.09.2018
271.	Permin Cream	Permethrin INN	Cream	5.00 gm./ 100 gm.	036-357-071	10.08.2017
272.	Phenadryl syrup	Diphenhydramine Hydrochloride BP	Syrup	200 mg./100 ml.	036-47-021	25.08.2015
273.	Picidin Tablet	Procyclidine Hydrochloride USP	Tablet	5.00 mg	036-706-025	28.03.2017
274.	Pilestop Tablet	Diosmin BP + Hesperidin INN	Tablet	450.00 mg + 50.00 mg	036-491-075	16.04.2016
275.	Povid Lotion 10%	Povidone – Iodine USP	Lotion	10.00 gm (Eqv. to 1.00 gm Iodine)	036-531-071	27.10.2017
276.	PPI-20 Capsule	Omeprazole, Enteric Coated Pellets 8.5% W/W Ph. Grade	Capsule	240.00 mg. (Containing Omeprazole BP 20 mg)	036-141-067	08.03.2018
277.	PPI 40 mg. Capsule	Omeprazole Enteric Coated Pellets 8.5% W/W Ph. Grade	Capsule	480.02 mg. (Eqv. to Omeprazole BP 40 mg)	036-242-067	23.10.2019
278.	Prasugen-5 Tablet	Prasugrel Hydrochloride INN	Tablet	5.49 mg (Eqv. to 5 mg Prasugrel)	036-695-026	18.12.2016
279.	Prasugen-10 Tablet	Prasugrel Hydrochloride INN	Tablet	10.98 mg (Eqv. to 10 mg Prasugrel)	036-696-026	18.12.2016
280.	Profen Film Coated Tablet 400 mg.	Ibuprofen (Tablet Grade) BP	Tablet	400.00 mg.	036-231-064	22.09.2018
281.	Profen Suspension 100 mg./5 ml	Ibuprofen, Microfine BP	Suspension	2000.00 mg./100 ml.	036-232-064	22.09.2018
282.	Pronil Tablet	Secnidazole Anhydrous INN	Tablet	500.00 mg.	036-249-027	31.05.2015
283.	Pronil DS Tablet	Secnidazole Anhydrous INN	Tablet	1000.00 mg.	036-250-027	31.05.2020
284.	Protocid 20 Tablet	Pantoprazole Sodium Sesquihydrate INN	Tablet	22.60 mg (Eqv. to 20 mg Pantoprazole)	036-567-067	31.03.2019
285.	Protocid 40 Tablet	Pantoprazole Sodium Sesquihydrate INN	Tablet	45.20 mg (Eqv. to 40 mg Pantoprazole)	036-568-067	31.03.2019
286.	Prozar Tablet (Export)	Amlodipine Besilate BP + Losartan Potassium USP	Tablet	6.935 mg (Equivalent to Amlodipine 5 mg) + 50 mg	036-767-022	22.06.2018
287.	Rabizol-20 Tablet	Rabeprazole Sodium INN	Tablet	20.00 mg	036-659-067	24.08.2016
288.	Ranidin Tablet 150 mg.	Ranitidine Hydrochloride USP	Tablet	167.40 mg. (Equivalent to 150 mg Ranitidine)	036-65-055	23.11.2015
289.	Ranidin Tablet 300 mg. (Film Coated)	Ranitidine Hydrochloride USP	Tablet	334.80 mg. (Equivalent to 300 mg Ranitidine)	036-145-055	07.08.2018
290.	Ranidin Syrup 1.5 gm/100 ml	Ranitidine Hydrochloride USP	Syrup	1.680 gm (Equivalent to Ranitidine 1.500 gm)/ 100 ml	036-548-055	16.11.2018
291.	Rhinozol 0.05% Paediatric Nasal Drop	Xylometazoline Hydrochloride USP	Nasal Drop	50.00 mg./ 100 ml.	036-121-050	14.05.2016
292.	Rhinozol 0.1% Nasal Drop	Xylometazoline Hydrochloride USP	Nasal Drop	100.00 mg/ 100 ml.	036-120-050	14.05.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
293.	Rifew 5 Capsule (Export)	Enalapril Maleate BP	Capsule	5.00 mg.	036-804-022	04.03.2019
294.	Rizat-5 Tablet	Rizatriptan Benzoate INN	Tablet	7.265 mg. (Equivalent to 5.00 mg Rizatriptan)	036-382-047	19.11.2018
295.	Rostab 5 Tablet	Rosuvastatin Calcium INN	Tablet	5.20 mg (Eqv. to 5 mg Rosuvastatin)	036-805-061	04.03.2019
296.	Rostab 10 Tablet	Rosuvastatin Calcium INN	Tablet	10.40 mg (Eqv. to 10 mg Rosuvastatin)	036-656-061	24.08.2016
297.	Rostab 20 Tablet	Rosuvastatin Calcium INN	Tablet	20.80 mg (Eqv. to 20 mg Rosuvastatin)	036-657-061	24.08.2016
298.	Rostab 40 Tablet	Rosuvastatin Calcium INN	Tablet	41.60 mg (Eqv. to 40 mg Rosuvastatin)	036-658-061	24.08.2016
299.	Rupastin-10 Tablet	Rupatadine Fumarate INN	Tablet	12.80 mg. (Eqv. to 10 mg Rupatadine)	036-751-021	12.05.2018
300.	Salflu-100 DPI	Salmeterol Xinafoate, Microfined BP + Fluticasone Propionate, Microfined BP	Capsule	0.05 mg. + 0.10 mg.	036-367-044	23.06.2019
301.	Salflu – 250 DPI	Salmeterol Xinafoate, Microfined BP + Fluticasone Propionate, Microfined BP	Capsule	0.05 mg. + 0.25 mg.	036-401-044	19.03.2019
302.	Salflu – 500 DPI	Salmeterol Xinafoate, Microfined BP + Fluticasone Propionate, Microfined BP	Capsule	0.05 mg. + 0.50 mg.	036-402-044	19.03.2019
303.	Salflu-50 HFA Inhalation Aerosol	Salmeterol Xinafoate, Micronised BP + Fluticasone Propionate, Micronised BP	Inhalation Aerosol	36.32 mcg (Eqv. to 25 mcg Salmeterol) + 50.00 mcg/actuation	036-707-044	30.05.2017
304.	Salflu-125 HFA Inhalation Aerosol	Salmeterol Xinafoate, Micronised BP + Fluticasone Propionate, Micronised BP	Inhalation Aerosol	3.632 mg (Eqv. to 2.50 mg Salmeterol) + 12.50 mg/100 actuations	036-665-044	24.08.2016
305.	Salflu-250 HFA Inhalation Areosol	Salmeterol Xinafoate, Micronised BP + Fluticasone Propionate, Micronised BP	Inhalation Aerosol	3.632 mg (Eqv. to 2.50 mg Salmeterol) + 25.00 mg/100 actuations	036-666-044	24.08.2016
306.	Salmolin Tablet	Salbutamol Sulphate BP	Tablet	4.80 mg. (Equivalent to 4 mg Salbutamol)	036-94-044	12.05.2019
307.	Salmolin Syrup	Salbutamol Sulphate BP	Syrup	48 mg (Eqv. to 40 mg Salbutamol)/ 100 ml.	036-101-044	13.05.2019
308.	Salmolin - L 1 Tablet	Levosalbutamol Sulphate INN	Tablet	1.205 mg (Eqv. to Levosalbutamol 1 mg)	036-564-044	31.03.2019
309.	Salmolin - L 2 Tablet	Levosalbutamol Sulphate INN	Tablet	2.41 mg (Eqv. to Levosalbutamol 2 mg)	036-565-044	31.03.2019
310.	Salmolin - L Syrup 1 mg/5 ml	Levosalbutamol Sulphate INN	Syrup	0.0241 gm (Equivalent to Levosalbutamol 0.020 gm.)/ 100 ml	036-566-044	31.03.2019
311.	Salmolin – 200 DPI	Salbutamol Sulphate, Microfine BP	Capsule	0.24 mg (Eqv. to 0.20 mg Salbutamol)	036-328-044	18.02.2017
312.	Salmolin HFA Inhalation Aerosol	Salbutamol Sulphate (Superfine) BP	Inhalation Aerosol	12.00 mg (Eqv. to Salbutamol 10 mg)/ 100 actuations	036-759-044	22.06.2018

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
313.	Salmolin Respirator Solution	Salbutamol Sulphate BP	Respirator Solution	0.120 gm (Equivalent to 0.100 gm Salbutamol)/20 ml	036-633-044	10.04.2016
314.	Salpium HFA Inhalation Aerosol	Salbutamol Sulphate (Superfine) BP + Ipratropium Bromide (Superfine) BP	Inhalation Aerosol	12.00 mg (Eqv. to 10 mg Salbutamol) + 2.00 mg/100 actuations	036-760-044	22.06.2018
315.	Setorib 60 Tablet	Etoricoxib INN	Tablet	60.00 mg	036-599-064	27.01.2020
316.	Setorib 90 Tablet	Etoricoxib INN	Tablet	90.00 mg	036-600-064	27.01.2020
317.	Setorib 120 Tablet	Etoricoxib INN	Tablet	120.00 mg	036-601-064	27.01.2020
318.	Sevel Tablet	Sevelamer Hydrochloride INN	Tablet	400.00 mg	036-627-062	13.11.2015
319.	Simvatin Tablet 20 mg.	Simvastatin USP	Tablet	20.00 mg.	036-248-061	14.03.2015
320.	Sizomax 1 Tablet	Risperidone BP	Tablet	1.00 mg.	036-773-028	22.06.2018
321.	Sizomax 2 Tablet	Risperidone BP	Tablet	2.00 mg.	036-774-028	22.06.2018
322.	Sizomax 4 Tablet	Risperidone BP	Tablet	4.00 mg.	036-775-028	22.06.2018
323.	Sizopra -10 Tablet	Aripiprazole INN	Tablet	10.00 mg	036-499-028	29.05.2016
324.	Sizopra -15 Tablet	Aripiprazole INN	Tablet	15.00 mg	036-500-028	29.05.2016
325.	Skelofen 5 Tablet	Baclofen USP	Tablet	5.00 mg	036-719-070	30.05.2017
326.	Skelofen Tablet	Baclofen USP	Tablet	10.00 mg	036-668-070	24.08.2016
327.	Sono- 1 Tablet	Eszopiclone INN	Tablet	1.00 mg	036-502-057	29.05.2016
328.	Sono -2 Tablet	Eszopiclone INN	Tablet	2.00 mg	036-503-057	29.05.2016
329.	Steron Tablet 0.5 mg.	Dexamethasone Micronised BP	Tablet	0.50 mg.	036-162-072	23.12.2015
330.	Steron Vet Bolus	Dexamethasone (Micronized) BP	Bolus	10.00 mg	036-678(V)-077	11.10.2016
331.	Sucrol Tablet	Aspartame NF	Tablet	18.00 mg.	036-134-075	27.09.2017
332.	Sulfasol Vet Bolus	Sulfadimidine BP	Bolus	5.00 gm/ bolus	036-475(V)-077	22.02.2016
333.	Tacrol - 0.03% Ointment	Tacrolimus INN	Ointment	0.030 gm./ 100 gm.	036-387-071	19.11.2018
334.	Tenil 3 mg. Tablet	Bromazepam BP	Tablet	3.00 mg.	036-285-057	19.12.2015
335.	Tenoloc - 50 mg. Tablet	Atenolol BP	Tablet	50.00 mg.	036-72-022	07.11.2017
336.	Tenoloc - 100 mg. Tablet	Atenolol BP	Tablet	100.00 mg.	036-73-022	07.12.2017
337.	Thenglate SR 250 Tablet	Theophylline Anhydrous USP	Tablet	250.00 mg.	036-424-044	07.11.2019
338.	Thenglate SR 400 Tablet	Theophylline Anhydrous USP	Tablet	400.00 mg.	036-425-044	07.11.2015

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
339.	Thenglate Syrup	Theophylline Sodium Glycinate USP	Syrup	2.40 gm./100 ml.	036-83-044	26.02.2018
340.	Thyrolar 25 Tablet	Levothyroxine Sodium USP	Tablet	0.025 mg	036-594-074	27.01.2020
341.	Thyrolar 50 Tablet	Levothyroxine Sodium USP	Tablet	0.050 mg	036-595-074	27.01.2020
342.	Thyroler 100 Tablet	Levothyroxine Sodium USP	Tablet	0.100mg	036-596-074	27.01.2020
343.	Tinium - 50 Tablet	Tiemonium Methylsulphate INN	Tablet	50.00 mg	036-490-011	16.04.2016
344.	Topium DPI	Tiotropium Bromide Microfine INN	Capsule	22.50 mcg (Equivalent to 18.00 mcg Tiotropium)	036-474-044	22.02.2016
345.	Tracid- 500 Tablet	Tranexamic Acid BP	Tablet	500.00 mg	036-482-019	07.03.2016
346.	Trasin 1 Tablet (Export)	Terazosin Hydrochloride USP	Tablet	1.20 mg (Equivalent to Terazosin 1 mg)	036-801-022	04.03.2019
347.	Trasin 2 Tablet	Terazosin Hydrochloride USP	Tablet	2.40 mg (Equivalent to Terazosin 2 mg)	036-802-022	04.03.2019
348.	Trasin 5 Tablet	Terazosin Hydrochloride USP	Tablet	6.00 mg (Equivalent to Terazosin 5 mg)	036-803-022	04.03.2019
349.	Tulos Syrup	Lactulose Concentrated Solution (67% w/v) BP	Syrup	131.83 gm./100 ml.	036-385-060	19.11.2018
350.	Tycon Cream	Tioconazole BP	Cream	1.00 gm./ 100 gm.	036-407-071	12.04.2019
351.	Tycon Vaginal Suppository	Tioconazole Microfine BP	Suppository	0.300 gm.	036-408-071	12.04.2019
352.	Uliv-150 Tablet	Ursodeoxycholic Acid BP	Tablet	150.00 mg	036-442-075	19.08.2015
353.	Uliv-300 Tablet	Ursodeoxycholic Acid BP	Tablet	300.00 mg	036-443-075	19.08.2015
354.	Unipril-1.25 Tablet	Ramipril BP	Tablet	1.25 mg	036-718-022	30.05.2017
355.	Unipril 2.5 Tablet	Ramipril BP	Tablet	2.50 mg.	036-578-022	06.07.2019
356.	Unipril 5 Tablet	Ramipril BP	Tablet	5.00 mg.	036-579-022	06.07.2019
357.	Valtin-80 Tablet	Valsartan USP	Tablet	80.00 mg.	036-782-022	16.02.2019
358.	Valtin-160 Tablet	Valsartan USP	Tablet	160.00 mg.	036-783-022	16.02.2019
359.	Versil Tablet	Perindopril Erbumine BP	Tablet	4.00 mg.	036-671-022	11.10.2016
360.	Vildapin-50 Tablet	Vildagliptin INN	Tablet	50.00 mg	036-711-015	30.05.2017
361.	Vildapin Plus 500 Tablet	Vildagliptin INN + Metformin Hydrochloride BP	Tablet	50.00 mg + 500.00 mg	036-712-015	30.05.2017
362.	Vildapin Plus 850 Tablet	Vildagliptin INN + Metformin Hydrochloride BP	Tablet	50.00 mg + 850.00 mg	036-713-015	30.05.2017
363.	Vinpoton-5 Tablet	Vinpocetin BP	Tablet	5.00 mg.	036-771-036	22.06.2018
364.	Vir Tablet	Entecavir INN	Tablet	0.50 mg	036-697-032	18.12.2016
365.	Winop-10 Tablet	Ketorolac Tromethamine USP	Tablet	10.00 mg	036-479-064	07.03.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
366.	X-Cold Syrup	Ambroxol Hydrochloride BP	Syrup	300.00 mg/ 100 ml	036-540-031	24.02.2018
367.	X-Cold Paediatric Drops	Ambroxol Hydrochloride BP	Paediatric Drops	0.090 g/ 15 ml	036-573-031	06.07.2019
368.	Zero Tablet	Sucralose USPNF	Tablet	8.00 mg	036-536-075	02.12.2017
369.	Zis Syrup	Zinc Sulphate Monohydrate USP	Syrup	222.30 mg (Equivalent to 81 mg Elemental Zinc)/100 ml	036-267-062	02.10.2015
370.	Zis DS Syrup	Zinc Sulphate Monohydrate USP	Syrup	548.88 mg (Equivalent to 200 mg Elemental Zinc)/100 ml	036-284-062	19.12.2015
371.	Zis-Vet Bolus	Zinc Sulfate Monohydrate USP	Bolus	549.00 mg (Eqv. to Elemental Zinc 200 mg)	036-689(V)-077	23.10.2016
372.	Zymovet Powder	Ammonium Bicarbonate BP + Sodium Bicarbonate BPC+ Nux Vomica BP+ Ginger Powder BP+ Gentian Powder Pure BP	Powder	25.00 gm + 65.00 gm + 7.00 gm + 1.50 gm + 1.50 gm/100 gm	036-217(V)-077	02.09.2018

HUMAN
&
HERBAL PRODUCTS

VETERINARY PRODUCTS

List of Biological Products

[As approved by Directorate General of Drug Administration & Licensing Authority (Drugs), Government of the People's Republic of Bangladesh]

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
1.	A-B1 Tablet	Thiamine Hydrochloride BP	Tablet	100.00 mg.	036-159-078	23.12.2015
2.	A-Cal D Tablet	Calcium Carbonate BP + Cholecalciferol (Vitamin D3) BP	Tablet	1250 mg (Eqv. to 500 mg Elemental Calcium) + 2 mg (Eqv. to 200 IU Vitamin D3)	036-537-062	24.02.2018
3.	Acelex 250 mg. Capsule	Cephalexin Monohydrate (Compacted) BP	Capsule	263.00 mg. (Eqv. to 250.00 mg Cephalexin)	036-113-023	03.02.2016
4.	Acelex 500 mg. Capsule	Cephalexin Monohydrate (Compacted) BP	Capsule	526.00 mg. (Eqv. to 500.00 mg Cephalexin)	036-150-023	02.01.2019
5.	Acelex Powder for Suspension	Cephalexin Monohydrate (Micronised) BP	Suspension	2.651 gm (Eqv. to 2.50 gm Cephalexin)/100 ml	036-114-023	03.02.2016
6.	Aclobet-N Cream	Clobetasol Propionate, Micronized BP + Neomycin Sulphate, Micronized USP + Nystatin, Micronized USP	Cream	0.0075 g + 0.0750 g + 0.2600 g (Equivalent to 15,00,000 Units of Nystatin)/15 g	036-643-071	10.04.2016
7.	Aclobet-N Ointment	Clobetasol Propionate, Micronized BP + Neomycin Sulphate, Micronized USP + Nystatin, Micronized USP	Ointment	0.0075 g + 0.0750 g + 0.2600 g (Equivalent to 15,00,000 Units of Nystatin)/15 g	036-644-071	10.04.2016
8.	A-Clox Capsule	Cloxacillin Sodium (Compacted) BP	Capsule	545.00 mg. (Equivalent to 500.00 mg Cloxacillin)	036-86-023	27.02.2018
9.	A-Clox Powder for Paediatric Drop	Cloxacillin Sodium Micronised BP	Paediatric Drop	10.90 gm (Equivalent to 10 gm Cloxacillin)	036-187-023	27.01.2018
10.	A-Clox Powder for Syrup	Cloxacillin Sodium Micronised BP	Syrup	2.725 gm (Equivalent to 2.5 gm Cloxacillin)	036-70-023	19.01.2017
11.	A-Clox Injection 250 mg.	Cloxacillin Sodium Sterile BP	Injection	272.50 mg (Equivalent to 250.00 mg Cloxacillin Sterile)/Vial	036-126-023	28.04.2017
12.	A-Clox Injection 500 mg.	Cloxacillin Sodium Sterile BP	Injection	545.00 mg. (Equivalent to 500.00 mg Cloxacillin)/Vial	036-127-023	28.04.2017
13.	ACME's PEG Diluent (Export)	Polyethylene Glycol 400 BP + Citric Acid Monohydrate BP	Diluent	4.000 gm + 5.000 gm	036-800-075	02.02.2019
14.	ACME's Water for Injection	Water for Injection BP	WFI	5 ml. & 10 ml.	036-130-079	28.04.2017
15.	Acmecilin Capsule	Ampicillin Trihydrate BP	Capsule	287.50 mg. (Equivalent to 250.00 mg Ampicillin)	036-29-023	25.08.2015
16.	Acmecilin Injection 250 mg.	Ampicillin Sodium Sterile BP	Injection	265.00 mg (Eqv. to 250.00 mg Ampicillin)/Vial	036-124-023	28.04.2017
17.	Acmecilin Injection 500 mg.	Ampicillin Sodium Sterile (Lyophilized) BP	Injection	530.00 mg. (Eqv. to 500.00 mg Ampicillin)/Vial	036-125-023	28.04.2017
18.	Acmecilin Powder for Suspension	Ampicillin Trihydrate Micronised BP	Suspension	2.875 g (Equivalent to 2.5 g Ampicillin)/100 ml	036-31-023	28.04.2018
19.	A-Fenac Injection 3 ml.	Diclofenac Sodium BP	Injection	75.00 mg./3 ml	036-129-064	28.04.2017
20.	A-Fenac Plus IM Injection 2 ml.	Diclofenac Sodium BP + Lidocaine Hydrochloride BP	Injection	75.00 mg. + 20.00 mg./ 2 ml.	036-185-064	27.01.2018
21.	A-Flox 250 mg. Capsule	Flucloxacillin Sodium (Compacted) BP	Capsule	272.50 mg. (Equivalent to 250.00 mg Flucloxacillin)	036-194-023	21.03.2018
22.	A-Flox 500 mg. Capsule	Flucloxacillin Sodium (Compacted) BP	Capsule	545.00 mg. (Equivalent to 500.00 mg Flucloxacillin)	036-193-023	21.03.2018
23.	A-Flox 250 mg. Injection	Flucloxacillin Sodium Sterile BP	Injection	272.50 mg. (Eqv. to 250.00 mg Flucloxacillin)/Vial	036-196-023	21.03.2018
24.	A-Flox 500 mg. Injection	Flucloxacillin Sodium sterile BP	Injection	545.00 mg. (Eqv. to 500.00 mg Flucloxacillin)/Vial	036-195-023	21.03.2018

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
25.	A-Flox Powder for Syrup	Flucloxacillin Sodium (Micronised) BP	Powder for Syrup	2.723 gm (Eqv. to 2.50 gm Flucloxacillin)/100 ml	036-197-023	21.03.2018
26.	Alclor 500 Capsule	Cefaclor Monohydrate USP	Capsule	525.00 mg (Equivalent to 500 mg of Cefaclor)	036-635-023	10.04.2016
27.	Alclor Paediatric Drop	Cefaclor Monohydrate, Micronized USP	Paediatric Drop	1.575 gm (Equivalent to 1.500 gm of Cefaclor)/15 ml	036-637-023	10.04.2016
28.	Alclor Powder for Suspension	Cefaclor Monohydrate, Micronized USP	Powder for Suspension	2.625 gm (Equivalent to 2.500 gm of Cefaclor)	036-636-023	10.04.2016
29.	Alercon Opthalmic Drop	Olopatadine Hydrochloride INN	Eye Drop	0.0056 gm/ 5 ml	036-561-052	31.03.2019
30.	Alercon DS Eye Drops	Olopatadine Hydrochloride USP	Eye Drop	11.10 mg/ 5 ml	036-799-052	02.02.2019
31.	Alin Vet WSP	Tiamulin Hydrogen Fumarate BP	WSP	45.000 g/100 g Powder	036-681(V)-077	11.10.2016
32.	A-Mectin Vet Injection	Ivermectin BP	Injection	1.000 gm/ 100 ml	036-504(V)-077	29.05.2016
33.	A-Mectin Plus-5 Vet Injection	Ivermectin BP + Clorsulon USP	Injection	0.050 g + 0.500 g/5 ml	036-734(V)-077	17.10.2017
34.	A-Mectin Plus-30 Vet Injection	Ivermectin BP + Clorsulon USP	Injection	0.300 g + 3.000 g/30 ml	036-735(V)-077	17.10.2017
35.	Aminomix IV Infusion	Amino Acids + Carbohydrate + Electrolytes	Infusion	-	036-725-003	12.09.2017
36.	Aminoplex IV Infusion	Amino Acids + Carbohydrate + Electrolytes	Infusion	-	036-726-003	12.09.2017
37.	Anora Bolus (VET)	Cobalt Sulphate Heptahydrate BP + Ferrous Sulphate Dried BP + Thiamine Mononitrate DC USP + Vitamin B12 (1%) (Lutavit B12 1%) USP + Choline Bitartrate BP	Bolus	51.546 mg (Equivalent to 50.00 mg Cobalt) + 100.00 mg + 25.00 mg + 2.00 mg (Equivalent to 20.00 mcg Cyanocobalamine) + 9.10 mg	036-315(V)-077	20.01.2017
38.	Anora DS Vet Bolus	Cobalt Sulphate Heptahydrate Ph. Grade + Dried Ferrous Sulphate BP + Thiamine Mononitrate USP + Vitamin B12 (Cyanocobalamin) 1% BP + Choline Bitartrate USP	Bolus	181.37 mg (Equivalent to 100 mg Cobalt Sulphate) + 200.00 mg + 50.00 mg + 4.00 mg (Equivalent to 40 mcg Vitamin B12) + 18.20 mg	036-776(V)-077	22.06.2018
39.	Antox Tablet	β-Carotene Dry Powder USP + Ascorbic Acid DC (98%) BP + Vitamin E Acetate (As Dry Powder 50%) BP	Tablet	30.00 mg (Eqv. to 6 mg β-Carotene) + 222.22 mg (Eqv. to 200 mg Ascorbic Acid) + 100 mg (Eqv. to 50 mg Vitamin E)	036-198-078	21.03.2018
40.	A-Phenicol Opthalmic Drop	Chloramphenicol Micronised BP	Eye Drop	500.00 mg/ 100 ml.	036-139-052	08.03.2018
41.	A-Phenicol Eye Ointment	Chloramphenicol, Levo Micronised Sterile BP	Eye Ointment	1.00 gm./100 gm.	036-133-052	13.07.2017
42.	A-Phenicol-D Eye Drop	Dexamethasone Sodium Phosphate BP + Chloramphenicol BP	Eye Drop	0.0065 g (Eqv. to 0.005 gm of Dexamethasone) + 0.0250 g/ 5 ml	036-645-052	10.04.2016
43.	A-Sol Injection (Vet)	Butaphosphan INN + Cyanocobalamin (Vitamin B12) BP	Injection	10 gm + 0.005 gm/ 100 ml	036-463(V)-077	29.10.2015
44.	Asta-Vet Injection	Pheniramine Maleate BP	Injection	2275.00 mg/100 ml.	036-264(V)-077	30.08.2015
45.	A-Tetra 500 mg. Tablet	Tetracycline Hydrochloride BP	Tablet	540.00 mg. (Equivalent to 500.00 mg Tetracycline)	036-182-023	09.07.2017
46.	A-Tetra Capsule 500 mg.	Tetracycline Hydrochloride BP	Capsule	540.00 mg. (Equivalent to 500.00 mg Tetracycline)	036-236-023	01.03.2019
47.	Ativet Liquid	Trimethoprim BP + Sulphadiazine BP	Liquid	4.80 gm.+ 24.00 gm./ 60 ml.	036-254(V)-077	31.05.2020

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
48.	Aximin 200 Tablet	Rifaximin BP	Tablet	200.00 mg	036-814-023	14.05.2019
49.	Aximin 550 Tablet	Rifaximin BP	Tablet	550.00 mg	036-815-023	14.05.2019
50.	Azin 250 mg. Capsule	Azithromycin Dihydrate (Compacted) USP	Capsule	262.02 mg. (Equivalent to 250.00 mg Azithromycin)	036-164-023	12.05.2016
51.	Azin 500 Tablet	Azithromycin Dihydrate Compacted USP	Tablet	534.52 mg. (Equivalent to 500.00 mg Azithromycin)	036-239-023	13.07.2019
52.	Azin Powder for Suspension	Azithromycin Dihydrate (Micronised) USP	Suspension	4.192 gm (Equivalent to 4 gm Azithromycin)/100 ml	036-175-023	09.07.2017
53.	A-Zyme Tablet	Pancreatin BP	Tablet	325.00 mg.	036-154-051	17.03.2020
54.	Babecure Injection Vet	Imidocarb Dipropionate INN	Injection	0.240 g/2 ml Ampoule	036-609(V)-077	31.03.2020
55.	Catnil Eye Drop	Adenosine BP + Cytochrome C Ph. Grade + Sodium Succinate Ph. Grade + Nicotinamide BP	Eye Drop	10.00 mg + 2.50 mg + 3.00 mg + 50.00 mg/5 ml	036-550-052	16.11.2018
56.	Cecon Tablet	Ascorbic Acid BP + Sodium Ascorbate Powder BP	Tablet	125.00 mg. + 140.60 mg (Equivalent to 125.00 mg Ascorbic Acid)	036-79-078	27.02.2018
57.	Cino Plus Suppository	Cinchocaine Hydrochloride Micronised BP + Hydrocortisone Base Micronised BP + Framycetin Sulphate Micronised BP + Aesculin Micronised INN	Suppository	5.00 mg. + 5.00 mg. + 10.00 mg. + 10.00 mg.	036-423-075	20.08.2019
58.	Cipro-A Tablet 250 mg.	Ciprofloxacin Hydrochloride USP	Tablet	291.10 mg (Equivalent to 250.00 mg Ciprofloxacin)	036-155-023	17.03.2020
59.	Cipro-A 500 mg. Tablet	Ciprofloxacin Hydrochloride USP	Tablet	583.00 mg. (Equivalent to 500.00 mg Ciprofloxacin)	036-167-023	12.08.2016
60.	Cipro-A 750 mg. Tablet	Ciprofloxacin Hydrochloride USP	Tablet	874.50 mg (Equivalent to 750 mg Ciprofloxacin)	036-340-023	06.05.2017
61.	Cipro-A Suspension	Ciprofloxacin Pellets, 20% Ph. Grade	Suspension	15.00 g (Eqv. to Ciprofloxacin USP 3 g)/60 ml	036-512-023	24.08.2016
62.	Cipro-A 200 mg IV Infusion	Ciprofloxacin Lactate Ph. Grade	Infusion	254.40 mg (Eqv. to Ciprofloxacin USP 200 mg)/100 ml	036-509-023	08.10.2016
63.	Cipro-A Eye Drop	Ciprofloxacin Hydrochloride USP	Eye Drop	352.94 mg. (Equivalent to 300.00 mg Ciprofloxacin)/100 ml.	036-171-052	12.08.2016
64.	Cipro-D Eye Drop	Ciprofloxacin Hydrochloride USP + Dexamethasone (Micronized) BP	Eye Drop	0.0175 g (Equivalent to 0.015 g of Ciprofloxacin) + 0.005 g/ 5 ml	036-646-052	10.04.2016
65.	Cipro-A Vet 750 Bolus	Ciprofloxacin Hydrochloride USP	Bolus	873.30 mg (Eqv. to 750 mg Ciprofloxacin)	036-747(V)-077	12.05.2018
66.	Cipro-A Vet 1000 Bolus	Ciprofloxacin Hydrochloride USP	Bolus	1164.40 mg (Equivalent to 1000 mg Ciprofloxacin)	036-748(V)-077	12.05.2018
67.	Cipro-A Vet Oral Solution	Ciprofloxacin Hydrochloride BP	Oral Solution	11.644 gm (Equivalent to 10.00 gm Ciprofloxacin) /100 ml	036-313(V)-077	20.01.2017
68.	Cipro-A Vet 10 ml Injection	Ciprofloxacin Lactate INN	Injection	0.635 gm (Eqv. to 0.500 gm Ciprofloxacin)/10 ml	036-810(V)-077	22.03.2019

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
69.	Cipro-A Vet 30 ml Injection	Ciprofloxacin Lactate INN	Injection	1.905 gm (Equivalent to 1.500 gm Ciprofloxacin)/30 ml	036-811(V)-077	22.03.2019
70.	Cipro-A Vet Injection	Ciprofloxacin Lactate Ph. Grade	Injection	3.175 gm (Eqv. to 2.5 gm Ciprofloxacin)/50 ml vial	036-519(V)-077	27.03.2017
71.	Cipro-A Vet 100 ml Injection	Ciprofloxacin Lactate INN	Injection	6.350 gm (Eqv. to 5.000 gm Ciprofloxacin)/100 ml	036-812(V)-077	22.03.2019
72.	Claricin 250 mg. Tablet	Clarithromycin USP	Tablet	250.00 mg.	036-190-023	27.01.2018
73.	Claricin 500 mg. Tablet	Clarithromycin USP	Tablet	500.00 mg.	036-246-023	14.03.2020
74.	COCCIOFF WSP	Amprolium USP + Sulfaquinoxaline Sodium Pharma Grade + Mendione Sodium Bisulphite (Vitamin -K) USP	WSP	10.200 g + 10.200 g + 0.100 g/100 g	036-608(V)-077	27.01.2020
75.	Combipen 4 Lacs Injection	Fortified Procaine Penicillin Sterile BP	Injection	372.00 mg. (Eqv. to Benzyl Penicillin 1 lac and Procaine Penicillin 3 lacs)/ Vial	036-184-023	09.07.2017
76.	Combipen Vet 40 Lac Injection	Fortified Procaine Penicillin Sterile BP	Injection	3.910 gm (Eqv. to 40,00,000 units of Procaine Penicillin and Benzyl Penicillin Sodium mixture at 3:1 ratio)/Vial	036-421(V)-077	20.08.2019
77.	Combipen Vet 8 Lacs	Fortified Procaine Penicillin Sterile Powder (Potency: 1080 Units/mg) BP	Powder for Injection	0.714 g (Eqv. to 6,00,000 Units of Procaine Penicillin and 2,00,000 Units of Benzyl Penicillin Sodium)/Vial	036-607(V)-077	27.01.2020
78.	CP 200 Tablet	Cefpodoxime Proxetil USP	Tablet	260.00 mg(Equivalent to 200 mg Cefpodoxime)	036-448-023	29.10.2015
79.	CP Paediatric Drops	Cefpodoxime Proxetil (Micronised) USP	Paediatric Drops	0.390 gm (Equivalent to 0.300 gm Cefpodoxime)/ 15 ml	036-542-023	24.02.2018
80.	CP Suspension	Cefpodoxime Proxetil USP	Suspension	1.040 gm (Equivalent to 0.800 gm Cefpodoxime)/ 100 ml	036-449-023	29.10.2015
81.	CP-DS Suspension	Cefpodoxime Proxetil, Micronized USP	Powder for Suspension	1.040 gm (Eqv. to 0.800 gm Cefpodoxime)/50 ml	036-701-023	18.12.2016
82.	Decam Vet Injection	Calcium Gluconate BP + Dextrose BP + Magnesium Hypophosphite BP	Injection	20.80 gm. + 20.00 gm. + 5.00 gm./ 100 ml	036-422(V)-077	20.08.2019
83.	Dermupin Ointment	Mupirocin USP	Ointment	0.200 gm/10g	036-700-071	18.12.2016
84.	Dirozyl 500 IV Infusion	Metronidazole BP	Infusion	0.500 gm/100 ml	036-508-027	08.10.2016
85.	Dolonil 100 Injection	Tramadol Hydrochloride BP	Injection	100.00 mg/2 ml	036-529-065	20.08.2017
86.	Dot Injection 2 ml	Drotaverine Hydrochloride INN	Injection	40.00 mg./ 2 ml.	036-349-011	19.07.2017
87.	Doxy-A Capsule	Doxycycline Hydrochloride BP	Capsule	115.00 mg (Equivalent to 100 mg Doxycycline)	036-115-023	03.02.2016
88.	Doxy-A Vet WSP	Doxycycline Hydrochloride BP	WSP	10.00 gm./ 100 gm.	036-265(V)-077	30.08.2015
89.	Doxy-N Vet WSP	Neomycin Sulfate USP + Doxycycline Hydrochloride BP	WSP	24.390 g (Eqv. to 15.000 g Neomycin) + 17.310. g (Eqv. 15.000 g Doxycycline)	036-684(V)-077	11.10.2016
90.	Drop V-Plex	Multivitamin & Multimineral	Paediatric Drop	-	036-87-078	06.04.2018
91.	Enrovet Oral Solution	Enrofloxacin INN	Oral Solution	10.00 gm./100 ml.	036-283(V)-077	13.11.2015

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
92.	Eraprim (Vet) WSP	Erythromycin Thiocyanate INN + Sulphadiazine BP + Trimethoprim BP	WSP	18.000 g + 15.000 g + 3.000 g/100 g	036-669(V)-077	11.10.2016
93.	Erocin Tablet 250 mg.	Erythromycin Stearate USP	Tablet	347.50 mg (Equivalent to 250 mg Erythromycin)	036-293-023	30.11.2016
94.	Erocin F/C Tablet 500 mg.	Erythromycin Stearate USP	Tablet	695.00 mg. (Equivalent to 500 mg Erythromycin)	036-294-023	30.11.2016
95.	Erocin Powder for Oral Suspension	Erythromycin Ethylsuccinate, Microfine USP	Powder for Suspension	2.936 gm (Equivalent to 2.5 gm Erythromycin)/100 ml	036-295-023	30.11.2016
96.	E-Tab	Vitamin E Acetate 50% DP USP	Tablet	400.00 mg.(Equivalent to 200 IU Vitamin E)	036-174-078	09.07.2017
97.	E-Vet WSP	Alpha Tocopherol Acetate (Lutavit E 50S) Feed Grade/BP	WSP	2.00 gm./20 gm.	036-290(V)-077	18.06.2016
98.	E-Vet Plus 30 Injection	Vitamin E Acetate (Oily) BP + Sodium Selenite BP	Injection	1.500 g + 0.015 g/30 ml	036-682(V)-077	11.10.2016
99.	Eyefen Eye Drops	Bromfenac Sodium INN	Eye Drops	5.175 mg (Eqv. to 4.50 mg Bromfenac)	036-786-052	18.09.2018
100.	Eyemox 0.5% Eye Drop	Moxifloxacin Hydrochloride INN	Eye Drops	0.545 gm (Equivalent to 0.50 gm Moxifloxacin)/ 100 ml	036-457-052	02.01.2016
101.	Famicef 1.5 Injection	Sterile Cefuroxime Sodium Powder (Lyophilized) USP	Injection	1.610 gm (Eqv. to 1.500 gm Cefuroxime)/Vial	036-585-023	21.10.2019
102.	Famicef 250 Tablet	Cefuroxime Axetil USP	Tablet	300.00 mg(Equivalent to 250.00 mg Cefuroxime)	036-450-023	29.10.2015
103.	Famicef 500 Tablet	Cefuroxime Axetil (Potency 80% as Cefuroxime) USP	Tablet	625.00 mg (Equivalent to 500.00 mg Cefuroxime)	036-513-023	27.03.2017
104.	Famicef Suspension	Cefuroxime Axetil USP	Suspension	3.000 gm (Eqv. to 2.50 gm Cefuroxime)/100 ml	036-451-023	29.10.2015
105.	Famicef 750 Injection	Sterile Cefuroxime Sodium Powder (Lyophilized) USP	Injection	787.50 mg (Eqv. to 750.00 mg Cefuroxime)/Vial	036-517-023	27.03.2017
106.	Famicef DS Suspension	Cefuroxime Axetil USP	Suspension	6.000 gm (Eqv. to 5.00 gm Cefuroxime)/100 ml	036-477-023	22.02.2016
107.	Ferocit Tablet	Ferrous Fumarate BP + Folic Acid BP	Tablet	200.00 mg + 200.00 mcg	036-80-045	26.02.2018
108.	Ferovet Oral Solution (Vet)	Ferrous Sulphate Heptahydrate BP + Copper Sulphate Pentahydrate BP + Zinc Sulphate Monohydrate USP + Cobalt Sulphate Heptahydrate Ph. Grade + Cyanocobalamin (Vitamin B12) BP	Oral Solution	91.48 mg (Eqv. to 50 mg Ferrous Sulphate) + 31.28 mg (Eqv. to 20 mg Copper Sulphate) + 22.23 mg (Eqv. to 20 mg Zinc Sulphate) + 47.69 mg (Eqv. to 10 mg Elemental Cobalt) + 10 mg	036-530(V)-077	20.08.2017
109.	Feziplex Syrup	Iron (III) Hydroxide Polymaltose Complex INN + Thiamine HCl BP + Riboflavin Sodium Phosphate BP + Pyridoxine Hydrochloride BP + Nicotinamide BP + Zinc Sulfate Monohydrate USP	Syrup	4 g (Eqv. to 1 g Elemental Iron) + 0.100 g + 0.055 g (Eqv. to 0.040 g Riboflavin) + 0.040 g + 0.400 g + 0.519 g (Eqv. to 0.200 g Elemental Zinc)/100 ml	036-484-045	07.03.2016
110.	Fix-A Capsule	Cefixime Trihydrate Compacted USP	Capsule	233.00 mg. (Equivalent to 200 mg Anhydrous Cefixime)	036-268-023	02.10.2015

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
111.	Fix-A Powder for Syrup	Cefixime Trihydrate (Micronised) USP	Powder for Syrup	2.24 g (Eqv. to 2 g Anhydrous Cefixime)	036-192-023	27.01.2018
112.	Fix-A Paediatric Drops	Cefixime Trihydrate, Micronised USP	Paediatric Drop	2.800 g (Eqv. to 2.500 g Cefixime)/100 ml	036-817-023	14.05.2019
113.	Fix-A DS Capsule	Cefixime Trihydrate (Compacted) USP	Capsule	448.00 mg (Equivalent to 400 mg Cefixime)	036-544-023	24.02.2018
114.	Fix-A DS Powder for Suspension	Cefixime Trihydrate, Micronized USP	Powder for Suspension	2.240 g (Eqv. to Cefixime 2 g)	036-741-023	17.10.2017
115.	Floxigem Tablet	Gemifloxacin Mesylate INN	Tablet	399.00 mg (Eqv. to Gemifloxacin 320 mg)	036-785-023	18.09.2018
116.	Floxipar-200 Tablet	Sparfloxacin INN	Tablet	200.00 mg.	036-287-023	19.12.2015
117.	Fluconal Tablet	Fluconazole BP	Tablet	50.00 mg.	036-207-020	22.09.2018
118.	Fluconal Tablet 150 mg.	Fluconazole BP	Tablet	150.00 mg.	036-257-020	05.08.2020
119.	Fluconal Dry Powder for Suspension	Fluconazole, Microfine BP	Powder for Suspension	1000.00 mg/100 ml.	036-237-020	01.03.2019
120.	Fulspec 500 mg IV Injection	Sterile Mixture of Meropenem and Sodium Carbonate USP	Injection	642.00 mg(Equivalent to Meropenem 500.00 mg)/Vial	036-552-023	23.12.2018
121.	Fulspec 1 gm IV Injection	Sterile Mixture of Meropenem and Sodium Carbonate USP	Injection	1.284 gm (Equivalent to Meropenem 1.00 gm)/Vial	036-553-023	23.12.2018
122.	Genta- 10 Injection (Vet)	Gentamicin Sulfate USP	Injection	16.950 gm (Eqv. to 10 gm Gentamicin)/100 ml	036-486(V)-077	07.03.2016
123.	Gentacin Eye Ointment	Gentamicin Sulphate Microfine Sterile USP	Eye Ointment	507.00 mg (Equivalent to 300 mg Gentamicin Base)/100 gm	036-106-052	12.03.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
124.	Glucolyte Vet Premix	Sodium Bicarbonate BP + Sodium Chloride BP + Potassium Chloride BP + Vitamin A (Lutavit A 500S) BP	Premix	50.00 gm + 26.60 gm. + 5.00 gm. + 200.00 IU/ 100 gm.	036-211(V)-077	01.09.2018
125.	Iron + Folic Acid Tablet (UNICEF Supply)	Ferrous Fumarate BP + Folic Acid BP	Tablet	184.80 mg (Eqv. to 60 mg Elemental Iron) + 0.40 mg.	036-332-045	18.02.2017
126.	Keto-A Injection 100 mg/2 ml	Ketoprofen BP	Injection	5000.00 mg/100 ml	036-224-064	22.09.2018
127.	Keto-A Vet Injection	Ketoprofen BP	Injection	1.000 g/10 ml	036-593(V)-077	24.11.2019
128.	Ketosamin Tablet (Export)	Amino Acids	Tablet	-	036-746-003	01.01.2018
129.	Leo-250 Tablet	Levofloxacin Hemihydrate USP	Tablet	260.40 mg (Equivalent to 250.00 mg Levofloxacin)	036-379-023	15.10.2018
130.	Leo-500 Tablet	Levofloxacin Hemihydrate USP	Tablet	520.80 mg (Equivalent to 500.00 mg Levofloxacin Anhydrous)	036-373-023	21.09.2018
131.	Leo- 750 Tablet	Levofloxacin Hemihydrate INN	Tablet	768.00 mg (Equivalent to 750.00 mg Levofloxacin)	036-468-023	22.02.2016
132.	Leo 0.5% Sterile Eye Drops	Levofloxacin Hemihydrate INN	Eye Drops	26.90 mg (Eqv. to 25 mg Levofloxacin)/5 ml	036-605-052	27.01.2020
133.	Leo 500 IV Infusion	Levofloxacin Hemihydrate USP	Infusion	512.45 mg (Equivalent to 500 mg Levofloxacin)/100 ml	036-506-023	08.10.2016
134.	Lifil-E 200 Capsule	All-rac-Alpha-Tocopheryl Acetate BP	Capsule	200.00 mg	036-794-078	14.05.2019
135.	Lifil-E 400 Capsule	All-rac-Alpha-Tocopheryl Acetate BP	Capsule	400.00 mg	036-795-078	14.05.2019
136.	Lincocin-150 Capsule	Clindamycin Hydrochloride BP	Capsule	169.50 mg (Eqv. to Clindamycin 150 mg)	036-679-023	11.10.2016
137.	Lincocin 300 Capsule	Clindamycin Hydrochloride BP	Capsule	339.00 mg (Eqv. to Clindamycin 300 mg)	036-680-023	11.10.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
138.	Lincocin Plus Gel	Clindamycin Phosphate USP + Tretinoin USP	Gel	0.180 gm + 0.00375 gm/15 gm	036-809-071	22.03.2019
139.	Maxima Injection 40 mg./vial	Esomeprazole Sodium Sterile INN	Injection	42.50 mg (Equivalent to 40 mg Esomeprazole) /Vial	036-496-067	16.04.2016
140.	MB-12 Tablet	Mecobalamin INN	Tablet	0.50 mg.	036-456-078	02.01.2016
141.	MB-12 Tablet (Export)	Mecobalamin INN	Tablet	1.50 mg.	036-743-078	01.01.2018
142.	MB-12 Injection	Mecobalamin INN	Injection	0.50 mg/ml Ampoule	036-478-078	22.02.2016
143.	Mediprist Tablet	Mifepristone INN	Tablet	200.00 mg	036-797-049	02.02.2019
144.	Mel-Vet Injection	Meloxicam BP	Injection	0.050 g/10 ml	036-690(V)-077	23.10.2016
145.	Mel-Vet 30 Injection	Meloxicam BP	Injection	0.150 g/30 ml	036-758(V)-077	12.05.2018
146.	Mel-Vet Plus 5 ml Injection	Meloxicam BP + Paracetamol BP	Injection	0.100 g + 0.750 g/5 ml	036-777(V)-077	22.06.2018
147.	Mel-Vet Plus 10 ml Injection	Meloxicam BP + Paracetamol BP	Injection	0.200 g + 1.500 g/10 ml	036-778(V)-077	22.06.2018
148.	Momneed Capsule	Carbonyl Iron + Folic Acid + Vitamin B Complex + Vitamin C + Zinc Sulphate Blended Pellets Ph. Grade	Capsule	50 mg + 0.5 mg + 61.8 mg + 2 mg + 2 mg + 1 mg + 10 mg + 50 mg	036-572-045	30.05.2019
149.	Moxilin Capsule	Amoxycillin Trihydrate BP	Capsule	287.50 mg (Equivalent to 250 mg Amoxycillin)	036-30-023	25.08.2015
150.	Moxilin 500 mg. Capsule	Amoxycillin Trihydrate (Compacted) BP	Capsule	575.00 mg (Equivalent to 500.00 mg Amoxycillin)	036-245-023	23.10.2019
151.	Moxilin Powder for Paediatric Drop	Amoxycillin Trihydrate (Micronised) BP	Paediatric Drops	11.50 gm (Equivalent to 10 gm Amoxycillin)/100 ml	036-188-023	27.01.2018
152.	Moxilin Powder for Suspension	Amoxycillin Trihydrate (Micronised) BP	Suspension	2.875 g (Equivalent to 2.5 g Amoxycillin)/100 ml	036-67-023	28.04.2018
153.	Moxilin Injection 250 mg.	Amoxycillin Sodium Sterile Crystalline BP	Injection	265.96 mg (Equivalent to 250 mg Amoxycillin)/Vial	036-131-023	28.04.2017
154.	Moxilin Injection 500 mg.	Amoxycillin Sodium Sterile BP	Injection	531.92 mg (Equivalent to 500 mg Amoxycillin)/Vial	036-132-023	13.07.2017
155.	Moxilin vet Bolus	Amoxicillin Trihydrate BP	Bolus	1.150 g (Eqv. to Amoxicillin 1 g)	036-653(V)-077	01.06.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
156.	Moxilin 15% Vet WSP	Amoxycillin Trihydrate (Micronised) BP	WSP	17.65 gm (Equivalent to 15.0 gm. Amoxycillin)/100 gm	036-312 (V)-077	20.01.2017
157.	Moxilin DS Suspension	Amoxicillin Trihydrate, Microfine BP	Suspension	5.750 gm (Equivalent to 5 gm Amoxicillin)/100 ml	036-446-023	29.10.2015
158.	Moxilin Vet DS WSP	Amoxicillin Trihydrate BP	WSP	34.500 gm (Eqv. to 30 gm Amoxicillin BP)/100 gm	036-617(V)-077	05.06.2020
159.	Moxilin Plus WSP (VET)	Amoxicillin Trihydrate BP + Colistin Sulphate (Potency: 19,000 IU/mg) BP	WSP	15.000 g+ 6.316 g (Eqv. to 12,00,00,000 IU Colistin Sulphate)	036-691(V)-077	23.10.2016
160.	Moxilin Vet LA Injection	Amoxicillin Trihydrate Sterile BP	Injection	17.250 gm (Equivalent to Amoxicillin 15 gm)/100 ml	036-518(V)-077	27.03.2017
161.	Nalphin - 10 Injection	Nalbuphine Hydrochloride INN	Injection	10.00 mg/ml Ampoule	036-466-065	02.01.2016
162.	Nalphin - 20 Injection	Nalbuphine Hydrochloride INN	Injection	20.00 mg/ml Ampoule	036-467-065	02.01.2016
163.	Nalphin Injection	Nalbuphine Hydrochloride	Injection	20.00 mg/2 ml	036-742-065	17.10.2017
164.	Neobet Cream	Neomycin Sulphate (Micronised) USP + Betamethasone Valerate (Micronised) USP	Cream	500.00 mg + 121.50 mg/ 100 gm	036-108-071	24.11.2019
165.	Neobet-E-Eye Ointment.	Neomycin Sulphate (Micronised) Sterile USP + Betamethasone Sodium Phosphate (Micronised) Sterile USP	Eye Ointment	500.00 mg + 100.00 mg/ 100 gm	036-105-052	24.11.2019
166.	Neobet Eye, Ear & Nasal Drop	Betamethasone Sodium Phosphate BP + Neomycin Sulphate BP	Eye, Ear & Nasal Drop	0.0065 g (Equivalent to 0.005 g of Betamethasone) + 0.025 g	036-642-050	10.04.2016
167.	Neotracin Ointment	Neomycin Sulphate Micronised USP + Bacitracin Zinc Micronised BP	Ointment	0.500 gm + 0.909 gm/ 100 gm	036-137-071	08.03.2018
168.	Neotracin Powder	Neomycin Sulphate Micronised BP + Bacitracin Zinc Micronised BP	Powder	0.500 gm + 0.456 gm/ 100 gm	036-263-071	30.08.2015
169.	Nitrox-A Injection (Vet)	Nitroxynil BP	Injection	3.400 gm/10 ml Vial	036-555(V)-077	23.12.2018
170.	Norvet Liquid	Norfloxacin BP	Liquid	10 gm/100 ml	036-252(V)-077	31.05.2020
171.	Nutrum 50+ Tablet	Multivitamin & Multimineral A-Z Tablet	Tablet	-	036-414-078	12.04.2019
172.	Nutrum Bone Tablet	Multivitamin + Multimineral	Tablet	-	036-505-078	29.05.2016
173.	Nutrum Eye Capsule	Ascorbic Acid (Vitamin C) BP + Vitamin E Acetate DC, 50% Ph. Grade + Lutein 5% Ph. Grade + Cupric Oxide Ph. Grade + Zinc Oxide BP	Capsule	60 mg + 60 mg (Eqv. to 30 mg Vitamin E BP) + 120 mg (Eqv. to 6 mg Lutein USP) + 2.51 mg (Eqv. to 2 mg Copper) + 18.68 mg (Eqv. to 15 mg Zinc)	036-749-052	12.05.2018
174.	Nutrum Gold Tablet	Multivitamin & Multimineral A-Z Tablet	Tablet	-	036-415-078	12.04.2019
175.	Nutrum Junior Tablet (Export)	Multivitamin + Multimineral	Tablet	-	036-604-078	27.01.2015

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
176.	Nutrum Junior Syrup	Multivitamin + Multimineral	Syrup	-	036-516-078	27.03.2017
177.	Nutrum PN Tablet	Prenatal Multivitamin & Multimineral A-Z Tablet	Tablet	-	036-378-078	15.10.2018
178.	Nutrum PN Tablet (Export)	Prenatal Multivitamin & Multimineral A-Z Tablet	Tablet	-	036-813-078	22.03.2019
179.	Nutrum Super Tablet	Super Anti-Oxidant Vitamin Plus Multimineral Tablet	Tablet	-	036-377-078	15.10.2018
180.	NVP F/C Tablet	Meclizine Hydrochloride USP + Pyridoxine Hydrochloride USP	Tablet	25.00 mg + 50.00 mg	036-549-018	23.12.2018
181.	Nystat Tablet	Nystatin (Potency 4180 u/mg) USP	Tablet	119.62 mg (Eqv. to 500,000 units of Nystatin)	036-118-020	03.02.2016
182.	Nystat Oral Suspension	Nystatin (5000 u/mg) USP	Suspension	2.00 gm/100 ml	036-119-020	03.02.2016
183.	Nystat Vaginal Tablet	Nystatin Micronised (Potency 4180 u/mg) USP	Vaginal Tablet	23.94 mg	036-140-020	08.03.2018
184.	Opcol Eye Drops	Polyethylene Glycol 400 USP + Propylene Glycol BP	Eye Drops	40.00 mg + 30.00 mg/10 ml	036-787-052	18.09.2018
185.	Oxecylin Capsule	Oxytetracycline Hydrochloride BP	Capsule	270.00 mg (Equivalent to 250.00 mg Oxytetracycline)	036-28-023	30.06.2016
186.	Peflox Vet WSP	Pefloxacin Mesilate Dihydrate BP	WSP	13.960 g (Eqv. to Pefloxacin 10 g)/100 gm	036-683(V)-077	11.10.2016
187.	Periset Injection	Ondansetron Hydrochloride USP	Injection	9.98 mg (Equivalent to 8 mg Ondansetron)/4 ml	036-632-018	10.04.2016
188.	Phenadryl-10 Vet Injection	Diphenhydramine Hydrochloride BP	Injection	0.200 g/10 ml	036-732(V)-077	17.10.2017
189.	Phenadryl-30 Vet Injection	Diphenhydramine Hydrochloride BP	Injection	0.600 g/30 ml	036-733(V)-077	17.10.2017
190.	Pizo-A Tablet	Pizotifen Malate BP	Tablet	0.725 mg (Equivalent to 0.50 mg Pizotifen)	036-262-047	30.08.2015
191.	Pizo-A Tablet 1.5 mg	Pizotifen Malate BP	Tablet	2.175 mg (Equivalent to 1.5 mg Pizotifen)	036-292-047	30.11.2016
192.	Politrim Tablet	Sulphamethoxazole BP + Trimethoprim BP	Tablet	400.00 mg + 80.00 mg	036-32-023	19.04.2018
193.	Politrim Suspension	Sulphamethoxazole BP + Trimethoprim BP	Suspension	4.00 gm + 800.00 mg/ 100 ml	036-20-023	28.04.2018
194.	Politrim DS Tablet	Sulphamethoxazole BP + Trimethoprim BP	Tablet	800.00 mg + 160.00 mg	036-160-023	23.12.2015
195.	Politrim Vet Bolus	Sulphamethoxazole BP + Trimethoprim BP	Bolus	1000.00 mg + 200.00 mg	036-420(V)-077	20.08.2019
196.	Politrim VET Injection	Sulphamethoxazole BP + Trimethoprim BP	Injection	20.00 gm + 4.000 gm/100 ml	036-588(V)-077	21.10.2019
197.	PPI IV Injection	Sterile Omeprazole Sodium (Lyophilized) BP	Injection	130.00 mg (Equivalent to 40.00 mg Omeprazole)/Vial	036-554-067	23.12.2018
198.	Protocid IV Injection	Sterile Pantoprazole Sodium Powder (Lyophilized) INN	Injection	0.134 g (Equivalent to Pantoprazole 0.040 g)	036-584-067	15.07.2019
199.	Ranidin Injection 2 ml.	Ranitidine Hydrochloride USP	Injection	55.80 mg (Equivalent to 50.00 mg Ranitidine)/2 ml	036-168-055	12.08.2016
200.	SCZ Vet WSP	Sulphaclozine Sodium Monohydrate INN	WSP	3.00 gm/10 gm	036-288(V)-077	19.12.2015

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
201.	Sefril 250 mg. Capsule	Cephradine (Compacted) BP	Capsule	250.00 mg	036-97-023	23.05.2019
202.	Sefril 500 mg Capsule	Cephradine (Compacted) BP	Capsule	500.00 mg	036-111-023	03.02.2016
203.	Sefril Powder for Paediatric Drop	Cephradine (Micronised) BP	Paediatric Drop	10.00 gm/100 ml	036-186-023	27.07.2018
204.	Sefril Powder for Suspension	Cephradine, Microfine USP	Suspension	2.50 gm/100 ml	036-112-023	03.02.2016
205.	Sefril Injection 500 mg.	Cephradine with L-Arginine, Sterile USP	Injection	846.77 mg (Equivalent to 500.00 mg Cephradine)/Vial	036-225-023	22.09.2018
206.	Sefril -1.0 gm Injection	Cephradine with L-Arginine, Sterile for Injection USP	Injection	1531.96 mg (Equivalent to 1000.00 mg Cephradine)/Vial	036-339-023	06.05.2017
207.	Sefril DS Suspension	Cefradine (Micronized) BP	Suspension	5.000 gm/100 ml	036-447-023	29.10.2015
208.	SP-Vet 0.5 Injection	Fortified Procaine Penicillin Sterile BP + Streptomycin Sulphate Sterile USP	Injection	390.25 mg (Eqv. to 4,00,000 units of Procaine Penicillin Sterile and Benzyl Penicillin Sodium Sterile mixture at 3:1 ratio) + 670.00 mg (Eqv. to 0.5 gm Streptomycin Base)/ Vial	036-411(V)-077	19.03.2019
209.	SP-Vet Injection 2.5 gm.	Fortified Procaine Penicillin Sterile BP + Streptomycin Sulphate Sterile USP	Injection	1951.25 mg (Eqv. to 20,00,000 units of Procaine Penicillin Sterile and Benzyl Penicillin Sodium Sterile mixture at 3:1 ratio) + 3350.00 mg (Eqv. to 2.5 gm Streptomycin Base)/Vial	036-351(V)-077	19.07.2017
210.	SP-Vet LA 10 ml	Penicillin G Procaine sterile powder (1000 Penicillin G unit per mg.) USP + Penicillin G Benzathine sterile powder (1200 Penicillin G unit per mg) USP + Dihydrostreptomycin Sulfate sterile powder USP	Injection	1.500 g (Eqv. to 15,00,000 IU Procaine Penicillin G + 0.8334 g (Eqv. to 10,00,000 IU Benzathine Penicillin G) + 2.000 g/10 ml vial	036-779(V)-077	22.06.2018
211.	SP-Vet LA 50 ml	Penicillin G Procaine sterile powder (1000 Penicillin G unit per mg.) USP + Penicillin G Benzathine sterile powder (1200 Penicillin G unit per mg) USP + Dihydrostreptomycin Sulfate sterile powder USP	Injection	7.500 g (Eqv. to 75,00,000 IU Procaine Penicillin G + 4.167 g (Eqv. to 50,00,000 IU Benzathine Penicillin G) + 10.000 g/50 ml vial	036-780(V)-077	22.06.2018
212.	Steron Injection	Dexamethasone Sodium Phosphate BP	Injection	0.005 g/1 ml ampoule	036-639-072	10.04.2016
213.	Steron Eye Drop	Dexamethasone Sodium Phosphate BP	Eye Drop	0.0065 g (Eqv. to 0.005 g of Dexamethasone)/5 ml	036-640-052	10.04.2016
214.	Steron-T Eye Drops	Tobramycin USP + Dexamethasone, sterile (Microfine) USP	Eye Drops	0.015 g + 0.005 g/5 ml	036-652-052	01.06.2016
215.	Steron Vet-10 Injection	Dexamethasone Sodium Phosphate BP	Injection	2.00 mg/ml	036-670(V)-077	11.10.2016
216.	Sulfasol Vet Injection	Sulfadimidine Sodium (Potency 98.29%) BP	Injection	33.88 gm/100 ml	036-436(V)-077	02.01.2020
217.	Sulpha Vet WSP	Sulphanilamide BP	WSP	10.00 gm	036-311(V)-077	20.01.2017

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
218.	Sulphadin Vet Bolus	Sulphadiazine BP + Sulphadimidine BP + Sulphapyridine BP	Bolus	1.666 gm + 1.666 gm + 1.666 gm	036-209(V)-077	01.09.2018
219.	Sulphadin-S Vet Bolus	Sulphadiazine BP + Sulphadimidine BP + Sulphapyridine BP + Streptomycin Sulphate (740 mcg/mg potency) BP	Bolus	1.5830 gm +1.5830 gm + 1.5830 gm + 0.3378 gm (Eqv. to Streptomycin Sulphate 0.250 gm)	036-212(V)-077	01.09.2018
220.	Superpime 500 IM/IV Injection	Cefepime Hydrochloride with Sterile Arginine USP	Injection	980.00 mg (Equivalent to 500.00 mg Cefepime)/Vial	036-428-023	07.11.2019
221.	Superpime 1.0 gm IM/IV Injection	Cefepime Hydrochloride with Sterile Arginine USP	Injection	1.960 gm (Equivalent to 1.0 gm Cefepime)/Vial	036-429-023	07.11.2019
222.	Superpime 2.0 gm IV Injection	Cefepime Hydrochloride with Arginine Sterile USP	Injection	3.920 gm (Equivalent to 2.0 gm Cefepime)/Vial	036-430-023	07.11.2019
223.	Taxim -250 mg. IM/IV Injection	Cefotaxime Sodium Sterile USP	Injection	262.65 mg (Equivalent to 250 mg Cefotaxime Sterile)/Vial	036-269-023	02.10.2015
224.	Taxim - 500 mg. IM/IV Injection	Cefotaxime Sodium Sterile USP	Injection	525.30 mg (Equivalent to 500 mg. Cefotaxime)/Vial	036-270-023	02.10.2015
225.	Taxim -1.0 gm. IM/IV Injection	Cefotaxime Sodium Sterile USP	Injection	1050.60 mg (Equivalent to 1000 mg Cefotaxime Sterile)/Vial	036-271-023	02.10.2015
226.	Tetravet Bolus	Oxytetracycline Hydrochloride BP	Bolus	540.00 mg (Eqv. to Oxytetracycline 500 mg)	036-219(V)-077	22.09.2018
227.	Tetravet WSP	Oxytetracycline Hydrochloride BP	WSP	50.00 gm/100 gm	036-253(V)-077	31.05.2020
228.	Tetravet 200 WSP	Oxytetracycline Hydrochloride USP	WSP	23.80 gm (Eqv. to 20 gm Oxytetracycline)/100 gm	036-314(V)-077	20.01.2017
229.	Tetravet Injection	Oxytetracycline Hydrochloride (Injectable Grade) USP	Injection	517.00 mg (Equivalent to 500 mg Oxytetracycline)/10 ml	036-366(V)-077	06.06.2018
230.	Tetravet- 100 Injection	Oxytetracycline Hydrochloride USP	Injection	10.800 gm (Equivalent to 10.00 gm Oxytetracycline)/ 100 ml	036-485(V)-077	07.03.2016
231.	Tetravet-LA Injection	Oxytetracycline Dihydrate (Injectable Grade) USP	Injection	2.00 gm/10 ml	036-352(V)-077	19.07.2017
232.	Tinium Injection	Tiemonium Methylsulfate INN	Injection	5.00 mg/ 2 ml Ampoule	036-507-011	08.10.2016
233.	TPC Tablet	Thiamine Hydrochloride (Vitamin B1) BP + Pyridoxine Hydrochloride (Vitamin B6) BP + Cyanocobalamin (Vitamin B12) BP	Tablet	100.00 mg + 200.00 mg + 200.00 mcg	036-514-078	27.03.2017
234.	TPC Injection	Thiamine Hydrochloride (Vitamin B1) BP + Pyridoxine Hydrochloride (Vitamin B6) BP + Cyanocobalamin (Vitamin B12) BP	Injection	100.00 mg + 100.00 mg + 100.00 mcg/3 ml	036-515-078	27.03.2017
235.	Tracid -500 Injection	Tranexamic Acid BP	Injection	500.00 mg/5 ml	036-483-019	07.03.2016
236.	Tracid-10 Vet Injection	Tranexamic Acid BP	Injection	1.000 g/10 ml	036-736(V)-077	17.10.2017
237.	Tracid-30 Vet Injection	Tranexamic Acid BP	Injection	3.000 g/30 ml	036-737(V)-077	17.10.2017
238.	Trizidim IV/IM- 250 Injection	Ceftazidime Pentahydrate Buffered with Sodium Carbonate, Sterile USP	Injection	320.70 mg (Equivalent to 250 mg Ceftazidime)/Vial	036-487-023	22.03.2016
239.	Trizidim IV/IM- 500 Injection	Ceftazidime Pentahydrate Buffered with Sodium Carbonate, Sterile USP	Injection	641.40 mg (Equivalent to 500.00 mg Ceftazidime)/Vial	036-488-023	22.03.2016

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
240.	Trizidim IV/IM- 1.0 gm. Injection	Ceftazidime Pentahydrate Buffered with Sodium Carbonate, Sterile USP	Injection	1282.80 mg (Equivalent to 1000.00 mg Ceftazidime)/Vial	036-489-023	22.03.2016
241.	Trizon IM 250 mg. Injection	Ceftriaxone Sodium Sterile USP	Injection	298.24 mg (Equivalent to 250 mg Ceftriaxone)/Vial	036-228-023	23.09.2018
242.	Trizon IM 500 mg. Injection	Ceftriaxone Sodium Sterile USP	Injection	595.00 mg (Equivalent to 500 mg Ceftriaxone)/Vial	036-227-023	22.09.2018
243.	Trizon IM 1.0 gm. Injection	Ceftriaxone Sodium Sterile USP	Injection	1190.00 mg (Equivalent to 1 g Ceftriaxone sterile)/Vial	036-226-023	22.09.2018
244.	Trizon IV 250 mg. Injection	Ceftriaxone Sodium Sterile USP	Injection	298.24 mg (Equivalent to 250 mg Ceftriaxone)/Vial	036-229-023	22.09.2018
245.	Trizon IV 500 mg. Injection	Ceftriaxone Sodium Sterile USP	Injection	595.00 mg (Equivalent to 500 mg. Ceftriaxone)/Vial	036-230-023	22.09.2018
246.	Trizon IV 1.0 gm. Injection	Ceftriaxone Sodium Sterile USP	Injection	1190.48 mg (Equivalent to 1 g Ceftriaxone)/Vial	036-234-023	22.09.2018
247.	Trizon 2 gm. IV Injection	Ceftriaxone Sodium Sterile USP	Injection	2380 mg (Equivalent to 2000 mg Ceftriaxone)/Vial	036-389-023	19.11.2018
248.	Trizon VET 1 gm. Injection	Ceftriaxone Sodium Sterile USP	Injection	1.190 gm (Equivalent to 1.000 gm Ceftriaxone USP)/Vial	036-616(V)-077	05.06.2020
249.	Trizon VET 2 gm. Injection	Ceftriaxone Sodium Sterile USP	Injection	2.380 gm (Equivalent to 2.000 gm Ceftriaxone USP)/Vial	036-615(V)-077	05.06.2020
250.	Tropin Vet Injection	Atropine Sulphate BP	Injection	0.010 gm/10 ml	036-587(V)-077	21.10.2019
251.	Twicef- 500 Capsule	Cefadroxil Monohydrate (Compacted) BP	Capsule	525.00 mg (Equivalent to 500 mg Cefadroxil Base)	036-374-023	21.09.2018
252.	Twicef Suspension	Cefadroxil Monohydrate (Micronized) BP	Suspension	2.625 gm (Equivalent to 2.50 gm Cefadroxil Base)/100 ml	036-375-023	21.09.2018
253.	Twicef DS Suspension	Cefadroxil Monohydrate Microfine USP	Suspension	5.248 gm (Eqv. to 5.00 gm Cefadroxil)/100 ml	036-497-023	29.05.2016
254.	Tylovet WSP	Tylosin Tartrate BP	WSP	21.64 gm (Equivalent to 20 gm of Tylosin)/100 gm	036-255(V)-077	31.05.2020
255.	Tylovet Injection	Tylosin BP	Injection	2.00 gm/10 ml	036-630(V)-077	13.11.2015
256.	Vita - ADE Oral Liquid (Vet)	Vitamin-A Propionate (2.5 Mio.I.U/gm) USP + Vitamin D3 Oily Feed (40 Mio. I.U/gm) USP + Vitamin-E Acetate Liquid (96%) USP	Liquid	4000.00 mg + 200.00 mg + 2000.00 mg/100 ml	036-221(V)-077	01.09.2018
257.	Vita-ADE Vet Injection	Vitamin-A Palmitate (1.7 mio.i.u./gm) Ph. Eur. + Vitamin D3 Oily (40 mio.i.u. /gm) Ph. Eur. + Vitamin E Acetate Liquid 96% Ph. Eur	Injection	4.71 gm + 0.10 gm + 2.00 gm/100 ml	036-350(V)-077	19.07.2017
258.	Vita-ADE Forte-10 Vet Injection	Vitamin A Palmitate (Oily), 1 MIU/g BP + Vitamin D3 (Oily), 1 MIU/g BP + Vitamin E Acetate (Oily) BP	Injection	5.000 g (Eqv. to 50,00,000 IU Vitamin A) + 0.750 g (Eqv. to 7,50,000 IU Vitamin D3) + 0.500 g (Eqv. to 500 mg Vitamin E)/10 ml	036-738(V)-077	17.10.2017

SL.	Brand Name	Generic Name	Dosages Form	Strength	DAR No.	Valid up to
259.	Vita-ADE Forte-30 Vet Injection	Vitamin A Palmitate (Oily), 1 MIU/g BP + Vitamin D3 (Oily), 1 MIU/g BP + Vitamin E Acetate (Oily) BP	Injection	15.000 g (Eqv. to 150,00,000 IU Vitamin A) + 2.250 g (Eqv. to 22,50,000 IU Vitamin D3) + 1.500 g (Eqv. to 1500 mg Vitamin E)/30 ml	036-739(V)-077	17.10.2017
260.	Vita-ADE Forte-100 Vet Injection	Vitamin A Palmitate (Oily), 1 MIU/g BP + Vitamin D3 (Oily), 1 MIU/g BP + Vitamin E Acetate (Oily) BP	Injection	50.000 g (Eqv. to 50,000,000 IU Vitamin A) + 7.500 g (Eqv. to 7,500,000 IU Vitamin D3) + 5.000 g (Eqv. to 5,000 mg Vitamin E)/100 ml	036-740(V)-077	17.10.2017
261.	V-Plex Tablet	Vitamin B Complex [Thiamine Hydrochloride (B1) BP + Riboflavin (B2) BP + Pyridoxine Hydrochloride (B6) BP + Nicotinamide BP]	Tablet	5.00 mg + 2.00 mg + 2.00 mg + 20.00 mg	036-88-078	28.04.2018
262.	V-Plex Capsule	Vitamin B Complex [Riboflavin (B2) BP + Pyridoxine Hydrochloride (B6) BP + Thiamine Hydrochloride (B1) BP + Nicotinamide BP]	Capsule	2.00 mg + 2.00 mg + 5.00 mg + 20.00 mg	036-45-078	01.12.2018
263.	V-Plex Syrup	Vitamin B Complex [Thiamine Hydrochloride (B1) BP + Riboflavin Sodium 5-Phosphate (B2) BP + Pyridoxine Hydrochloride (B6) BP + Nicotinamide BP]	Syrup	100.00 mg + 54.80 mg + 40.00 mg + 400 mg /100 ml	036-143-078	14.06.2018
264.	V-Plex Injection 2 ml.	Vitamin B Complex [Thiamine hydrochloride (B1) + Riboflavin Phosphate Sodium (B2) BP + Nicotinamide BP + Pyridoxine Hydrochloride (B6) BP + D-Panthenol (Dexapanthenol) BP	Injection	50.00 mg + 5.48 mg + 100.00 mg + 10.00 mg + 5.00 mg/2 ml	036-128-078	28.04.2017
265.	V-Plex Plus Tablet	Multivitamin + Multimineral	Tablet	_	036-153-078	12.02.2019
266.	V-Plex Vet Injection	Vitamin B Complex [Thiamine Hydrochloride (B1) USP + Riboflavin 5-Phosphate Sodium (B2) USP + Pyridoxine Hydrochloride (B6) USP + Nicotinamide USP + Dexapanthenol USP]	Injection	25.0 mg + 2.74 mg (Eqv. to 2 mg Base) + 5.0 mg + 50.0 mg + 2.5 mg/ ml	036-308(V)-077	20.01.2017
267.	V-Plex Vet Plus Injection	Multivitamin + Multimineral	Injection	-	036-589(V)-077	21.10.2019
268.	Winop- 10 Injection	Ketorolac Tromethamine USP	Injection	10.00 mg/ml Ampoule	036-480-064	07.03.2016
269.	Winop- 30 Injection	Ketorolac Tromethamine USP	Injection	30.00 mg/ml Ampoule	036-481-064	07.03.2016
270.	Winop 0.5% Opthalmic Solution	Ketorolac Tromethamine USP	Opthalmic Solution	0.025 gm/5 ml	036-543-052	24.02.2018
271.	Winop- 60 Injection	Ketorolac Tromethamine USP	Injection	60.00 mg/2 ml	036-586-064	21.10.2019
272.	Z-Plex Syrup	Thiamine Hydrochloride BP + Riboflavin- 5 Phosphate Sodium BP + Pyridoxine Hydrochloride BP + Nicotinamide BP + Zinc Sulphate Monohydrate USP	Syrup	100.00 mg + 55.00 mg Eqv. to 40 mg Riboflavin) + 40.00 mg + 400.00 mg + 549.00 mg (Eqv. to 200 mg Elemental Zinc)/ 100 ml	036-534-078	16.11.2018

Market

All of the products' markets are throughout the Bangladesh and approximately 170 products are exporting outside the country.

Past trends and future prospects regarding exports (if applicable) and local market, demand and supply forecasts for the sector in which the product is included with source of data;

Last 5 years sales of The ACME Laboratories Ltd. **(Amount in BDT)**

Year/Sales	2013-2014	2012-2013	2011-2012	2010-2011	2009-2010
Domestic Sales	9,854,662,369	8,635,790,556	8,645,975,391	6,742,610,671	5,332,867,274
Export Sales	363,269,096	337,528,776	192,116,522	254,140,010	224,370,444
Total Sales	**10,217,931,465**	**8,973,319,332**	**8,838,091,913**	**6,996,750,681**	**5,557,237,718**

Pharmaceuticals products are met one of the basic needs for all living being. It is one of the fastest growing industries in the world. According to IMS by 2017, demand of pharma products will be USD 1,200 billion.

According to the same source, in the year 2014 Bangladesh pharma market size was Tk. 10,600 crore with a growth percentage 8.48. For the year ended 30 June 2014, ACME's domestic sales was Tk 985.46 crore and export sales was Tk. 36.33 crore totaling Tk. 1021.79 crore with a growth 14.11%, 7.63% and 13.87% respectively. According to IMS in the year 2015, Bangladesh pharma market size was Tk. 12,000 crore (based on 520 Chemist shop of urban area in Bangladesh).

Relative contribution of Products/Services contributing more than 10% of the total revenue

There is no product that account for more than 10% of the Company's total revenue.

Associates, subsidiary/related holding Company & their core areas of business

Presently there are no associates, subsidiary and holding company of The ACME Laboratories Ltd.

How the products or services are distributed with details of the distribution channel. Export possibilities and export obligation, if any

ACME has its own distribution network to distribute its products throughout the country. All products produced in the factory, are brought to the central depot at Hemayetpur, Savar, before a fleet of 100 vehicles of the company distribute the products to 19 other sales centers/depots located across the country. Part of the sales network is outsourced. Company's product distribution systems are depicted below:



Export Possibilities and Obligation:

The company currently exports approximately 170 pharmaceutical products to different countries in Southeast Asia, Africa and Central America. At present, the company is successfully exporting its quality products to Sri Lanka, Nepal, Bhutan, Myanmar, Thailand, Vietnam, Philippines, Cambodia, Hong Kong, Mongolia, Lao PDR, Ethiopia, Kenya, Nigeria, Somalia, Guatemala and Fiji. In addition to human pharmaceuticals, the company is exporting its animal-health products to Myanmar, Sri Lanka and exploring the opportunities of Herbal & Ayurvedic products in South Asia and Africa. The company has further market exploration plan to USA, Europe and Latin America and working for accreditation of WHO and UNICEF.

Competitive conditions in business with names, percentage and volume of market share of major competitors;

Based on 520 Chemist shop of urban area in Bangladesh, IMS in its report dated 30 June 2015 and 30 June 2014 reported the following top fifteen competitors and their market share in values and percentage-

Name of the Competitors	Market share (30 June 2015)			Market share (30 June 2014)		
	Values (in BDT)	(%)	Position	Values (in BDT)	(%)	Position
Square Pharmaceuticals Ltd.	21,930,698,095	18.32	1	20,535,593,231	19.36	1
Incepta Pharmaceuticals Ltd.	12,355,658,045	10.32	2	10,997,050,969	10.37	2
Beximco Pharmaceuticals Ltd.	10,216,986,848	8.53	3	9,136,028,090	8.61	3
Opsonin Pharma Ltd.	6,602,671,150	5.52	4	5,808,271,991	5.47	4
Renata Ltd.	5,997,526,422	5.01	5	5,401,738,911	5.09	5

Name of the Competitors	Market share (30 June 2015)			Market share (30 June 2014)		
	Values (in BDT)	(%)	Position	Values (in BDT)	(%)	Position
Eskayef Bangladesh Ltd.	5,373,278,479	4.49	7	4,778,901,308	4.5	6
Aristopharma Ltd.	5,485,190,024	4.58	6	4,569,297,391	4.3	7
ACI Ltd.	4,969,069,843	4.15	8	4,492,884,433	4.23	8
The ACME Laboratories Ltd.	4,624,965,118	3.86	9	4,164,590,747	3.92	9
Drug International Ltd.	3,629,945,107	3.03	11	2,927,676,165	2.76	10
Healthcare Pharmaceuticals Ltd.	3,662,648,632	3.06	10	2,648,498,978	2.49	11
Novo Nordisk	2,168,873,133	1.81	14	2,033,517,241	1.91	12
Sanofi Aventis (BD) Ltd.	2,398,799,630	2.00	13	2,028,118,828	1.91	13
General Pharmaceuticals Ltd.	2,419,756,889	2.02	12	1,908,761,946	1.8	14
Popular Pharmaceuticals Ltd.	2,113,164,442	1.77	16	1,779,422,868	1.67	15

Apart from this, as per annual report of the major listed companies and audited financial statements of The ACME Laboratories Ltd. the sales amounts are presented below:

Sl No.	Name of the Company	2014	Year End
1	Square Pharmaceuticals Ltd.	20,910,773,826	31 March
2	Beximco Pharmaceuticals Ltd.	11,206,885,677	31 December
3	Renata Limited	11,107,281,260	31 December
4	The ACME Laboratories Ltd.	10,217,931,465	30 June
5	ACI Ltd. (Pharma)	5,744,012,657	31 December
6	The IBN SINA Pharmaceutical Industry Ltd.	2,678,909,367	31 December
7	Becon Pharmaceuticals Limited	1,690,363,446	30 June
8	Orion Pharma Ltd.	1,652,879,840	31 December
9	Central Pharmaceuticals Ltd.	654,288,520	30 June

There is no data available regarding market shares of the respective listed company in their annual report.

Sources and availability of raw materials and the Names and address of the principal suppliers and contingency plan in the case of disruption

Most of the raw materials and some primary packing materials of the Company are procured from aboard. The names of main suppliers are mentioned below:

SL.	Suppliers Name	Address	Materials
1	Korea Aluminum co. Limited	457, kwang duk-ri, doan-myun, jeung pyeong-kun, Chung-Buk, South Korea.	Alu-Alu Foil, Packing Material
2	Evervictory Pharm Co. Limited	Flat 01, 2/F, on ning building, 425-431 king'sRoad, north point, China.	Riboflavin, Sulphadimidine, sulphanilamide, Amprolium HCL, Ascorbic Acid
3	Nectar Life sciences Limited	110, Industrial Area, Phase-1, Chandigarh- 160 002, India.	Cefixime Trihydrate, Cefuroxime Axetil, Pantoprazole Sodium Sterile
4	Aarti Drugs Ltd.	109-D, Mahendra Industrial Estate, Road No. 29, Sion (E), Bombay -400022, India	Aceclofenac, Benzoyl Metronidazole, Ciprofloxacin HCL
5	Shandong Pharmaceuticals Glass Co. Limited	Add: Buxia Road, Yiyuan country, Zibo city, Shandong provience, China.	Packing Material (Bottles, Vials)
6	United Pharma & Chemical Co. Limited	Add: Flat/RM 1005, wing yue bldg., 60-64 des voeux road west, Hongkong, China.	Lactic acid, Choline bitartrate, Azelaic Acid, Clotrimazole, Boron Citrate Blend.
7	BASF South East asia Pte Ltd.	7 temasek Boulevard 35-01 suntec tower one, Singapore 038987	Lutein Xylometazolin HCL, kolidon CL Lutavit E, D-panthenol, Povidon
8	Qilu Antibiotics Pharmacuticals Co. Limited	849 dongjia town, licheng district, jinan city 250105, China.	Ceftriaxone Sodium Sterile
9	Starway Pharm Co. Limited	Add: Flat RM 1202, 12/F, at tower, 180 electric road, north point, China.	Erythromycin thiocyane inn, Tylosin tartrate powder
10	Roquette Freres	62080 Lestrem CEDEX, France.	Pregelatinized Maize Starch, Maize starch
11	Caprihans India Limited	Block D, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mombai 400 018, India	PVC flim for blister pack
12	Shanghai, Modern Pharmaceutical Co. Ltd., China	Room 402, Building No. 6, No. 1320, West Beijing Road, Shanghai, 200040, Chaina	Azithromycin Dihydrate USP (Com.), Azithromycin Dihydrate B. Less
13	Molkerel Meggle Wasserburg GMBH & CO. KG.	Megglestr, 6-12, D-83512 Wasserburg, Germany.	Lactose Monohydrate

Contingency plan in case of Disruption of supplier

ACME is a vertically integrated finished formulation pharmaceuticals product manufacturer, promoter, distributor and seller. Its business is product wise brand driven in nature. But a key part of its business model is managing a complex supply chain management. To ensure each brand growth, it is indispensible to make available of all ingredients with right quality, right quantity, from right sources. Being a member of highly regulated industry, we have to keep familiarity with at least three process firstly is it coming from validated sources, secondly is it processed in a right way and finally how it is reaching to the final consumers.

To meet the Good Manufacturing Practice (GMP) ACME always conducts vendors audit and selects several validated vendors, which helps to tackle disruption of supply and minimize the risk of short supply. Industry analysts say, threat of disruption of supply of raw materials will be further reduced after establishing API Park at Gazaria, Munshigonj.

Sources of and requirement for power, gas and water or any other utilities

Power	Water	Gas
In order to generate electricity the company has **7 gas** generators with a capacity 8.91 MW (1.6 MW 3 nos. 1.03 MW 3 nos, 1.02 MW 1 no.) and 7 diesel generators with capacity 7.736 MW (1.6 MW 3 nos. 1.056 MW 1 no., 1.12 MW 1 no., 0.4 MW 1 no. 0.36 MW 1 no.) Total capacity is 16.646 MW. In addition the company has **REB connection** that is mainly used for off time lighting purpose.	Water is drawn by own deep Tube well and stored in central storage tank **(300,000 liter capacity)** for distribution throughout the site.	The gas required for both official and manufacturing purpose is supplied from **Titas Gas Transmission & Distribution Company Limited.**

Contingency plan in case of Disruption of utilities

To tackle the disruption of utilities, Company has installed two types of generators i.e. as mentioned in aforesaid table, 7 nos gas combustion generators with a total capacity 8.91 MW and 7 nos diesel combustion generators with a total capacity 7.736 MW. Besides, as contingency plan, the Company has applied for 15 MW electricity from 33 KVA line to REB out of which approval of 5 MW were obtained from concerned authority and approval for the remaining 10 MW hopefully will be obtained by 2016.

Names, address(s), telephone number, web address, e-mail and fax number of the customers who account for 10% or more of the company's products with the amount and percentage thereof

The Company has no such customer who contributes 10% or more of the total revenue.

Names, address(s), telephone number, web address, e-mail and fax number of the suppliers from whom account for 10% or more of its raw materials/finished goods with the amount and percentage thereof

The Company has no such Supplier from whom the Company purchases 10% or more of its raw material/Finished goods.

Description of any contract which the issuer has with its principal suppliers or customers showing the total amount and quality of transaction for which the contract is made and the duration of the contract. If there is not any of such contract, a declaration is to be disclosed duly signed by the CEO/MD, CFO and Chairman on behalf of the Board of Directors

The Company has no such contract with principal suppliers or Customers.

Declaration regarding Contract with Principal suppliers or customers

We, on behalf of the Board of Directors certify that The ACME Laboratories Ltd. did not enter into any contract with its principal suppliers or customers.

Sd/-	Sd/-	Sd/-
Md. Zahangir Alam, FCMA	Mizanur Rahman Sinha	Afzalur Rahman Sinha
Chief Financial Officer	Managing Director	Chairman

Description of licenses, registration, NOC and permissions obtained by the Company with issue, renewal and expiry dates

Name of the Issues (Licenses, registration, NOC and permissions obtained)	Issue Date	Renewal date	Expiry date
Drug Manufacturing License from Ministry of Health and family Wealth fare, Directorate General of Drug Administration	29.04.1972 17.09.1980	29.04.2014	28.04.2016
Valid Trade license from Dhaka CITY corporation, North	25-07-2013	27-07-2015	30-06-2016
Fire License from Bangladesh Fire Service and Civil Defence (Dhaka Division)	01-07-1999	22-07-2015	30-06-2016
Factory License from কল-কারখানা অধিদপ্তর	19-05-1959	29-12-2015	31-12-2016
IRC from Controller office of Import and Export, Dhaka	28-11-1994	02-07-2015	30-06-2016
ERC from Controller office of Import and Export, Dhaka	08-09-1994	02107-2015	30-06-2016
Environment clearance from পরিবেশ অধিদপ্তর, Dhaka district	03-07-2001	10-12-2015	02-07-2016
Board of Investment (BOI) registration no. 30030401081	15-04-2013	N/A	N/A

Description of any material patents, trademarks, licenses or royalty agreements

The Company has not entered into any such agreements other than the following Certificates, details of which are as follows:

i. ISO Certification: The Company has been certified under ISO 9001:2008, the registration is valid up to 28 November 2016.

ii. Certificate of Good Manufacturing Practice (GMP): The Company has been issued GMP certificate, considering the format recommended by the World Health Organization, by Directorate General of Drug Administration on 06 March 2013 and 26 August 2014. These certificates are valid for next two years from the date of issue.

iii. We have applied 171 products for trademarks registration to the Department of Patents, Designs and Trademarks under Ministry of Industry. Among which 101 products have already been registered and accordingly published in the Trade Marks Journal No-259 dated 28 February 2011 under the directions of the Registrar, Department of Patents, Designs and Trade Marks, Dhaka, Bangladesh and remaining 70 products are in process for trade mark registration.

Number of total employees and number of full-time employees

During the year 01 July 2013 to 30 June 2014, there were 6,711 employees employed in the company with remuneration above Tk. 3,000.00 per month, among them 4,306 employees employed for the full year and remaining 2,405 employees employed less than full year. Mentionable that, there were no employees having salary of below Tk. 3,000.00 (three thousand) only per month.

Brief Description of Business strategy

ACME's key strategic objectives are to:

1) Ensure health, vigour and happiness for all;
2) Ensure stable and long-term return to our investors;
3) Maintain state-of-the-art manufacturing facilities for ensuring best quality products to the customers;

4) Obtain word class accreditation by proper execution of ISO 9001:2008 standard, WHO cGMP standard and best practices that are proven effective;
5) Expand existing and develop new large scale projects to diverse the product range and related diversification;
6) Strengthening our existing market share, cope with the changing scenario in the pharma industry to ensure higher prescription rates, transparency and improved products and services for our existing and potential customers;
7) Comprehensive marketing and distribution network (Both in domestic and international markets);
8) Excellent relationship with health care professionals, chemists and other concerned stakeholders;
9) Seek new ways of working to improve efficiency and ensure sustainability.

A table containing the existing installed capacities for each product or service, capacity utilization for these products or services in the previous years, projected capacities for existing as well as proposed products or services and the assumptions for future capacity utilization for the next three years in respect of existing as well as proposed products or services. If the projected capacity utilization is higher than the actual average capacity utilization, rational to achieve the projected level;

With regard to above, a table is presented in the following page:

Total actual capacity and its utilization

Quantity in Thousand

Products	Unit	Installed Capacity			Capacity utilization for this Products			Actual Capacity Utilization (%)		
		Jul'12 to Jun'13	Jul'13 to Jun'14	Jul'14 to Jun'15	Jul'12 to Jun'13	Jul'13 to Jun'14	Jul'14 to Jun'15	Jul'12 to Jun'13	Jul'13 to Jun'14	Jul'14 to Jun'15
HUMAN										
Tablet	Pcs	1,411,000	3,086,237	3,368,590	1,695,264	1,953,640	2,199,808	120.15%	63.30%	65.30%
Capsule	Pcs	224,100	630,486	630,486	271,001	319,640	348,051	120.93%	50.70%	55.20%
Liquid	Bottle	62,250	62,250	87,234	39,622	46,571	51,959	63.65%	74.81%	59.56%
Dry Syrup	Bottle	7,470	18,409	18,409	5,562	6,712	8,574	74.46%	36.46%	46.58%
Ointment	Tube	3,984	3,984	6,158	1,356	1,640	1,894	34.04%	41.16%	30.76%
Cream	Tube	17,928	17,928	17,928	3,225	4,238	4,920	17.99%	23.64%	27.44%
Suppository	Pcs	14,940	14,940	32,660	12,973	15,297	21,770	86.83%	102.39%	66.66%
Inhaler (DPI)	Pcs	22,410	22,410	66,690	19,445	24,530	27,738	86.77%	109.46%	41.59%
Inhaler (MDI)	Canister	498	498	1,457	341	410	487	68.47%	82.33%	33.42%
Eye/Ear/Nasal Drop	Phials	6,640	6,640	10,136	6,265	7,607	9,091	94.35%	114.56%	89.69%
Injection (Amps)	Pcs	24,900	24,900	35,380	18,176	24,244	30,518	73.00%	97.37%	86.26%
Injection (Vial)	Pcs	13,280	18,424	15,350	10,676	14,374	9,176	80.39%	78.02%	59.78%
Infusion	Pcs	-	-	4,680	-	-	2,001	-	-	42.76%
Sachet	Pcs	-	-	28,201	-	-	8,223	-	-	29.16%
HERBAL										
Capsule	Pcs	32,370	32,370	32,370	4,629	8,145	9,235	14.30%	25.16%	28.53%
Liquid	Pcs	7,470	7,470	8,708	4,410	5,189	6,460	59.04%	69.46%	74.18%
Tablet	Pcs	29,880	29,880	29,880	8,343	12,354	11,126	27.92%	41.35%	37.24%
VETERINARY										
Bolus	Pcs	174,300	174,300	217,445	86,434	98,758	118,482	49.59%	56.66%	54.49%
Liquid	Pcs	4,980	4,980	5,212	2,681	3,025	3,748	53.84%	60.74%	71.91%
Premix	Pcs	14,940	14,940	27,587	12,045	13,255	14,448	80.62%	88.72%	52.37%
Water Soluble Powder	Pcs	5,976	5,976	8,579	2,722	3,228	3,836	45.55%	54.02%	44.71%
Injection	Vial	12,700	12,700	12,487	6,438	8,996	11,305	50.69%	70.83%	90.53%

Capacity is calculated considering 240 days per year, 2 shifts per day and 8 hours per shift. If needed, to meet the market demand the company runs three shifts production. That is why in some areas actual utilization of capacity shows more than 100%.

Estimated capacity and its utilization

Products	Unit	Projected Capacities for Existing and Proposed			Projected Capacity utilization			Projected Capacity Utilization (%)		
		Jul'15 to Jun'16	Jul'16 to Jun'17	Jul'17 to Jun'18	Jul'15 to Jun'16	Jul'16 to Jun'17	Jul'17 to Jun'18	Jul'15 to Jun'16	Jul'16 to Jun'17	Jul'17 to Jun'18
HUMAN										
Tablet	Pcs	* 3,537,020	3,537,020	**** 4,072,081	2,507,781	2,833,793	3,258,862	70.90%	80.12%	80.03%
Capsule	Pcs	630,486	*** 662,010	**** 708,380	382,856	424,970	480,216	60.72%	64.19%	67.79%
Liquid	Bottle	87,234	*** 183,138	183,138	56,635	63,431	73,580	64.92%	34.64%	40.18%
Dry Syrup	Bottle	18,409	18,409	18,409	10,117	12,343	14,565	54.96%	67.05%	79.12%
Ointment	Tube	6,158	6,158	**** 7,394	2,197	2,505	2,931	35.68%	40.68%	39.64%
Cream	Tube	17,928	*** 28,728	**** 30,488	5,756	6,792	7,743	32.11%	23.64%	25.40%
Suppository	Pcs	32,660	32,660	32,660	21,267	24,882	28,614	65.12%	76.18%	87.61%
Inhaler (DPI)	Pcs	66,690	66,690	66,690	31,621	35,416	40,020	47.41%	53.11%	60.01%
Inhaler (MDI)	Canister	1,457	1,457	**** 2,371	584	707	834	40.08%	48.52%	35.18%
Eye/Ear/Nasal Drop	Phials	** 19,736	19,736	**** 21,598	10,818	12,765	14,807	54.81%	64.68%	68.56%
Injection (Amps)	Pcs	35,380	35,380	**** 38,380	32,654	34,246	37,596	92.29%	96.79%	97.96%
Injection (Vial)	Pcs	15,350	15,350	**** 18,150	9,727	10,700	11,877	63.37%	69.71%	65.44%
Infusion	Pcs	4,680	4,680	4,680	2,455	2,801	3,468	52.46%	59.85%	74.10%
Sachet	Pcs	28,201	28,201	28,201	8,865	10,045	12,402	31.44%	35.62%	43.98%
HERBAL										
Capsule	Pcs	32,370	32,370	32,370	9,789	10,181	10,690	30.24%	31.45%	33.02%
Liquid	Pcs	8,708	8,708	8,708	7,429	8,566	9,519	85.31%	98.37%	109.31%
Tablet	Pcs	29,880	29,880	29,880	11,571	12,150	13,122	38.72%	40.66%	43.92%
VETERINARY										
Bolus	Pcs	239,190	239,190	239,190	142,178	172,035	206,442	59.44%	71.92%	86.31%
Liquid	Pcs	5,873	5,873	5,873	4,498	5,578	6,305	76.59%	94.98%	107.36%
Premix	Pcs	27,587	27,587	27,587	15,315	16,540	17,698	55.52%	59.96%	64.15%
Water Soluble Powder	Pcs	9,180	9,180	9,180	4,833	5,800	7,134	52.65%	63.18%	77.71%
Injection	Vial	12,487	12,487	12,487	11,079	11,411	11,982	88.72%	91.38%	

Capacity is calculated considering 240 days per year, 2 shifts per day and 8 hours per shift. If needed, to meet the market demand the company runs three shifts production. That is why in some areas actual utilization of capacity shows more than 100%. Assumptions for future capacity utilization are:

* New Granulation and Tableting machine installed

** New SVP machine installed

*** Liquid & Semi Solid to be started

**** Steroid & Hormone project to be started

Projected capacity utilization will be higher than the actual average capacity utilization due to installation of above four projects as well as increase in the market demand for medicine. The company will utilized its remaining capacity to meet the additional market demand for existing products as well as new products.

Description of Property

Location and area of the land, Building, Principal Plants and other property of the company and the condition thereof;

The written down value of Property, Plant & Equipments owned by the company as per audited accounts as on 30 June 2014 are stated below:

Name of the Assets	30 June 2014
Land & Land Development	4,029,795,161
Building	3,924,985,578
Machinery & Equipment	1,974,170,597
Furniture & Fixture	101,726,732
Motor Vehicles	220,253,907
Utilities, Electrical Installation & Eng.	1,067,915,835
Office Equipmentl	40,279,355
Books and Periodicals	2,031,573
Machinery in Transit	1,440,380,565
Construction work in Progress	2,710,357,783
Total	**15,511,897,086**

Location and area of the land are stated below:

SL No.	Location	Total Areas of Land (Decimal)
1	Head office, Dhaka	62.00
2	Factory, Dhamrai, Dhaka	1,008.18
3	Hemayetpur, Dhaka	294.83
4	Kalampur, Dhaka	950.20
5	Sales Centre	417.56
Total		**2,732.77**

Building, Principal Plants (Solid Dosage unit, LVP & SVP and Liquid & Semisolid unit, Cephalosporin unit, General unit and Herbal, Nutraceuticals & Ayurvedic unit) and other property of the company are located in the above-mentioned land and all of them are in working condition.

Whether the property is owned by the company or taken on lease;

All the assets mentioned above are owned by the Company, among which 61 and 2 total 63 number vehicles procured under finance lease from IDLC Finance Ltd. and IPDC of Bangladesh Ltd. respectively. Besides, 12 machineries procured under sale & lease back from National Finance Ltd., which has already been repaid on 11 September 2014.

Dates of purchase, last payment date of current rent (খাজনা) and mutation date of lands, deed value and other costs including details of land development cost, if any and current use thereof;

The names of the persons from whom the lands has been acquired/ proposed to be acquired along with the cost of acquisition and relation, if any, of such persons to the issuer or any sponsor or director thereof;

Details of whether the issuer has received all the approvals pertaining to use of the land, if required;

Details requirement of the above are presented below:

SOLID DOSAGES UNIT

METTLER TOLEDO
PDI-015
V20
Volumetric KF Titrator
Measured value
99.3mV
Drift

SL No.	Location	Tota Area of Land (Decimal)	Total Deed Value (Tk.)	Total Registration & Other Cost (Tk.)	Total Land Development Cost (Tk.)	Total (Tk.)
1	Head office,Dhaka	62.00	2,740,008	746,347	11,045,768	14,532,123
2	Factory, Dhamrai, Dhaka	1,008.18	107,749,500	17,324,049	90,532,090	215,605,640
3	Hemayetpur, Dhaka	294.83	14,775,002	2,406,915	17,542,977	34,724,894
4	Kalampur, Dhaka	950.20	3,445,762	995,845	6,551,897	10,993,504
5	Sales Centre	417.56	82,795,300	12,427,575	34,845,658	130,068,533
	TOTAL	**2,732.77**	**211,505,572**	**33,900,732**	**160,518,390**	**405,924,694**

Detail descriptions of the above land are given below:

Schedule of Land at Kallayanpur (Head Office, Dhaka)

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese (Decimal)	Last Payment Date of Rent	Mutation done	Mutation Date	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's relation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
1	Kallayanpur	7999	14-12-1994	ACME LAB	Mrs. Sultana Chowdury	22	22.04.15	22	10.07.14	N/A	972,268	Corporate Office	No relation	No lease agreement	Not mortgaged
2	Kallayanpur	710	31-10-1994	ACME LAB	1. Sayed Abdur razzak 2. Mrs Sadat Sultana Mazumder	31	22.04.15	31	10.07.14	N/A	1,370,000	Corporate Office	do	do	do
3	Kallayanpur	1343	20-02-1995	ACME LAB	Mrs. Sadat Sultana Mazumder	9	22.04.15	9	10.07.14	N/A	397,740	Corporate Office	do	do	do
Total						**62**					**2,740,008**				

Schedule of Land at Dhamrai, Dhaka (Factory)

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese(Decimal)	Last Payment Date of Rent	Mutation done	Mutation Date	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's relation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
1	Dhamrai	196	14.01.80	ACMELAB	Md. Chand Miah.	26	09.09.14	26	10.04.10	N/A	39,500	Factory & Warehouse	No relation	No lease agreement	Agrani,Ramna
2	Dhamrai	5880	10.12.80	ACMELAB	1. Abdul Quddus 2. Monzu Miah	12.5	09.09.14	12.5	10.04.10	N/A	25,000	Factory & Warehouse	do	do	Agrani,Ramna
3	Dhamrai	5870	10.12.80	ACMELAB	1. Azufa Khatun 2. Zaytunnesa 3. Taramonnesa 4. Asia Khatun	14	09.09.14	14	10.04.10	N/A	25,000	Factory & Warehouse	do	do	Agrani,Ramna
4	Dhamrai	5873	10.12.80	ACMELAB	1. Abdul Monnaf 2. Md .Siraz Miah	12.5	09.09.14	12.5	10.04.10	N/A	25,000	Factory & Warehouse	do	do	Agrani,Ramna
5	Dhamrai	1714	17.03.80	ACMELAB	Chand Miah	25	09.09.14	25	10.04.10	N/A	39,000	Factory & Warehouse	do	do	Agrani,Ramna
6	Dhamrai	4985	20.06.05	ACMELAB	Noor Mohammad	50	09.09.14	50	04.12.11	N/A	310,000	Factory & Warehouse	do	do	Not mortgaged
7	Dhamrai	3208	21.04.05	ACMELAB	Md. Mosaddek Hossin	33	09.09.14	33	04.12.11	N/A	202,000	Factory & Warehouse	do	do	do
8	Dhamrai	4800	26.07.06	ACMELAB	Md.Zabed Ali	40	09.09.14	40	04.12.11	N/A	500,000	Factory & Warehouse	do	do	do
9	Dhamrai	11319	22.09.11	ACMELAB	1. Golam Kabir 2. Mahamudur Rahman 3. Ahamadur Rahman 4.Golam Rahman Humyan 5. Mohidur Rahman Rumayn	60	09.09.14	57	12.11.12	3	4,653,224	Factory & Warehouse	do	do	Standard Chartered Bank & HSBC
				ACMELAB		25	09.09.14	23	12.11.12	2	1,938,843	Factory & Warehouse	do	do	
				ACMELAB		95.52	09.09.14	94	12.11.12	1.52	7,407,933	Factory & Warehouse	do	do	
10	Dhamrai	2963	5.04.09	ACMELAB	ASPL	129	09.09.14	129	16.02.14	0	45,150,000	Factory & Warehouse	do	do	Standard Chartered Bank & HSBC
11	Dhamrai	do	do	ACMELAB	ASPL	55	09.09.14	55		N/A	19,250,000	Factory & Warehouse	do	do	
12	Dhamrai	4512	13.05.09	ACMELAB	ASPL	22.1	09.09.14	22.1	16.02.14		600,000	Factory & Warehouse	do	do	Not mortgaged
13	Dhamrai	2963	05.04.09	ACMELAB	ASPL	45	09.09.14	45		N/A	15,750,000	Factory & Warehouse	do	do	Standard Chartered Bank & HSBC
14	Dhamrai	4511	13.05.09	ACMELAB	ASPL	7.4	09.09.14	7.4	16.02.14	N/A	200,000	Factory & Warehouse	do	do	Not mortgaged
15	Dhamrai	2962	05.04.09	ACMELAB	ASPL	9	09.09.14	9	16.02.14	0	3,150,000	Factory & Warehouse	do	do	Standard Chartered Bank & HSBC
16	Dhamrai	6353	24.08.03	ACMELAB	Md Zabed Ali	6	10.09.14	73	04.12.12	3.5	24,000	Factory & Warehouse	do	do	Not mortgaged
17	Dhamrai	2705	24.03.02	ACMELAB	Md. Hayet Ali	8.5	10.09.14		04.12.12	N/A	12,000	Factory & Warehouse	do	do	do
18	Dhamrai	1139	02.02.02	ACMELAB	Md. Eashaque Miah	8	10.09.14		04.12.12	N/A	12,000	Factory & Warehouse	do	do	do
19	Dhamrai	8295	05.10.02	ACMELAB	1 Md. Gani Miah 2.Mrs. Ayotennesa	6	10.09.14		04.12.12	N/A	24,000	Factory & Warehouse	do	do	do
20	Dhamrai	7818	17.09.02	ACMELAB	Md. Tara Miah	6	10.09.14		04.12.12	N/A	30,000	Factory & Warehouse	do	do	do

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese(Decimal)	Last Payment Date of Rent	Mutation done	Mutation Date	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's relation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
21	Dhamrai	8296	05.10.02	ACMELAB	1.Gani Miah 2.Ms.Moni Akther	6	10.09.14		04.12.12	N/A	24,000	Factory & Warehouse	No relation	No lease agreement	Not mortgaged
22	Dhamrai	2616	31.03.01	ACMELAB	Md. Abdul Hakim Mollah	16	10.09.14		04.12.12	N/A	50,000	Factory & Warehouse	do	do	do
23	Dhamrai	709	19.01.02	ACMELAB	1. Md.Abdul Mozid Mondol 2. Md.Abdul Vashon 3. Md.Shaheb Ali	10	10.09.14		04.12.12	N/A	12,000	Factory & Warehouse	do	do	do
24	Dhamrai	3048	15.04.01	ACMELAB	Md. Nasiruddin Mollah	5	10.09.14		04.12.12	N/A	12,000	Factory & Warehouse	do	do	do
25	Dhamrai	4544	10.06.01	ACMELAB	Md. Motahar Hossain	5	10.09.14		04.12.12	N/A	12,000	Factory & Warehouse	do	do	do
26	Dhamrai	1676	10.02.11	ACMELAB	1. Golam Kabir 2. Golam Sarower	56	10.09.14	56	05.05.11	N/A	2,285,714	Factory & Warehouse	do	do	do
27	Dhamrai	Do	do	ACMELAB	do	68	10.09.14	68	05.05.11	N/A	2,775,510	Factory & Warehouse	do	do	do
28	Dhamrai	Do	do	ACMELAB	do	60	10.09.14	50	05.05.11	10	2,448,980	Factory & Warehouse	do	do	do
29	Dhamrai	Do	do	ACMELAB	do	12	10.09.14	12	05.05.11	N/A	489,796	Factory & Warehouse	do	do	do
30	Dhamrai	7682	02.10.93	ACMELAB	1. Taraban Bibi 2. Jhalu Bibi 3. Julakha Bibi	2.5	10.09.14	2.5	18.05.14	N/A	2,000	Factory & Warehouse	do	do	do
31	Dhamrai	6042	17.08.93	ACMELAB	Md. Badruddin	9.5	10.09.14	9.5		N/A	35,000	Factory & Warehouse	do	do	do
32	Dhamrai	6677	05.09.93	ACMELAB	1. Md. Adom Ali 2. Md. Mathap Ali 3. Sanwar Ali	7	10.09.14	7	18.05.14	N/A	35,000	Factory & Warehouse	do	do	do
33	Dhamrai	5585	04.08.93	ACMELAB	Md. Ayen Ali	3.33	10.09.14	3.33	18.05.14	N/A	10,000	Factory & Warehouse	do	do	do
34	Dhamrai	5584	04.08.93	ACMELAB	Md. Hayet Ali	3.33	10.09.14	3.33	18.05.14	N/A	10,000	Factory & Warehouse	do	do	do
35	Dhamrai	5582	04.08.93	ACMELAB	Md. Akali Mollah	6.67	10.09.14	6.67	18.05.14	N/A	10,000	Factory & Warehouse	do	do	do
36	Dhamrai	5667	05.08.93	ACMELAB	Abdus Salam	3.33	10.09.14	3.33	18.05.14	N/A	10,000	Factory & Warehouse	do	do	do
37	Dhamrai	6043	17.08.93	ACMELAB	1. Md. Fazlul Haque 2. Md. Abu Hanif 3. Mrs. Morufa Khatun 4. Mrs. Noor Zahan Begum 5. Mrs. Razia Khatun	39	10.09.14	37	18.05.14	2	160,000	Factory & Warehouse	do	do	do
Total						**1008.18**					**107,749,500**				

Schedule of Land at Hemayetpur, Dhaka

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese (Decimal)	Last Payment Date of Rent	Mutation done	Mutation Date	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's rellation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
1	Hemayetpur	13183	14.05.07	ACMELAB	Mrs. Hazara Begum Md.Abdul Malek	0.5	30.04.14	-	-	0.5	25,000	Depot (Central, Dhaka- North, South & Saver)	No relation	No lease agreement	Not mortgage
2	Hemayetpur	12690	15.06.o6	ACMELAB	Mrs. Zoygun Bibi	4	30.04.14	4	25.07.06	N/A	200,000	Do	do	do	do
3	Hemayetpur	5292	19.03.06	ACMELAB	Mrs. Nazma Begum	4	30.04.14	4	03.0.06	N/A	200,000	Do	do	do	do
4	Hemayetpur	27164	27.12.05	ACMELAB	1. Md. Tara Gazi 2. Rahima Begum	5	30.04.14	5	25.01.06	N/A	250,000	Do	do	do	do
5	Hemayetpur	3357	23.02.06	ACMELAB	1. Md. Abdul Hakem 2. Imtiaz Ahmed 3. Md. Azizul Haque 4. Md. Safiullah Mazuder 5. Md Samsul Alam 6. Md.Akram Hossain 7. GNR.Md.Habibur Rah.	26	30.04.14	26	19.03.06	N/A	1,300,000	Do	do	do	do
				ACMELAB		14	30.04.14	14	19.03.06	N/A	700,000	Do	do	do	do
6	Hemayetpur	4770	13.03.06	ACMELAB	1. Abdur Razzak Mredha 2. Mrs. Rowsanara Begum	21.17	30.04.14	21.17	03.04.06	N/A	1,053,337	Do	do	do	City Bank
				ACMELAB	3. Md. Arifur Rahman mreda 4. Md. Masudur Rahman	25.83	30.04.14	25.83	03.04.06	N/A	1,285,200	Do	do	do	
				ACMELAB	5. Rabia Khatun (Lovly) 6. Rasheda Sultana	21	30.04.14	21	03.04.06	N/A	1,044,879	Do	do	do	
				ACMELAB	7. Abdul Karim Bhuewa 8. Md. Sirazul Islam	17	30.04.14	17	03.04.06	N/A	845,854	Do	do	do	
				ACMELAB	9. Babul Ahmed Talukder 10. Nasima Sultana (Mukti)	17.5	30.04.14	17.5	03.04.06	N/A	870,732	Do	do	do	
7	Hemayetpur	25077	28.11.05	ACMELAB	1. Md. Wahidur Rahman	4.19	30.04.14	4.16	21.12.05	0.03	212,526	Do	do	do	Standard Chartered Bank
				ACMELAB	2. Mohammad Shaidullah	3	30.04.14	3	21.12.05	N/A	152,167	Do	do	do	
				ACMELAB	3. Mrs. Shamsunnahar	4.5	30.04.14	4.5	21.12.05	N/A	228,250	Do	do	do	
				ACMELAB	4. Md. Arif billah 5. Md. Rana Akteruzzman	16	30.04.14	16	21.12.05	N/A	811,556	Do	do	do	
				ACMELAB	6. Md. Iftaker Billah	39	30.04.14	39	21.12.05	N/A	1,978,167	Do	do	do	
				ACMELAB	7. Obayedur Rahman 8. Md. Mhahabub Alam	1	30.04.14	1	21.12.05	N/A	50,722	Do	do	do	
				ACMELAB		23	30.04.14	23	21.12.05	N/A	1,166,612	Do	do	do	
8	Hemayetpur	22230	26.09.06	ACMELAB	1. Hasin Ahmed 2. Md. Abdul Motin Patwary	9	30.04.14	9	08.10.06	N/A	450,000	Do	do	do	Not mortgage
9	Hemayetpur	2280	31.01.07	ACMELAB	Mohammad Hamud Billah Power to Md. Shidullah	4.14	30.04.14	4.17	13.03.07	N/A	200,000	Do	do	do	do
10	Hemayetpur	16527	26.07.06	ACMELAB	Md. Sukum Ali	2	30.04.14	2	21.08.06	N/A	100,000	Do	do	do	do
				ACMELAB		2	30.04.14	2	21.08.06	N/A	100,000	Do	do	do	do
11	Hemayetpur	18246	13.08.06	ACMELAB	Md. Azizul Hossian	1.17	30.04.14	1.17	03.09.06	N/A	58,500	Do	do	do	City Bank
				ACMELAB		14	30.04.14	14	03.09.06	N/A	700,000	Do	do	do	
				ACMELAB		8.83	30.04.14	8.83	03.09.06	N/A	441,500	Do	do	do	
				ACMELAB		3.5	30.04.14	3.5	03.09.06	N/A	175,000	Do	do	do	
				ACMELAB		3.5	30.04.14	3.5	03.09.06	N/A	175,000	Do	do	do	
Total						**294.83**					**14,775,002**				

Schedule of Land at Kalampur, Dhaka

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese (Decimal)	Last Payment Date of Rent	Mutation done	Mutation Date	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's rellation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
1	Kalampur	719	05.02.07	ACMELAB	Mrs. Hazara bagum	9.0	09.09.14	9	22.09.11	N/A	50,000	Vacant Land	No relation	No lease agreement	Not mortgage
2	Kalampur	1999	04.03.08	ACMELAB	1. Mrs. falani begum 2. Raza miah 3. Mrs. Mazada begum 4. Md. Nazar ali	9.0	09.09.14	9	22.09.11	N/A	80,000	Vacant Land	do	do	do
3	Kalampur	318	12.05.05	ACMELAB	1. Md. Monser ali 2. Md. Bador ali	9.0	09.09.14	9	22.09.11	N/A	24,000	Vacant Land	do	do	do
4	Kalampur	7573	10.10.05	ACMELAB	Mrs. Zahanara begum	16.0	09.09.14	16	22.09.11	N/A	50,000	Vacant Land	do	do	do
5	Kalampur	6036	13.09.06	ACMELAB	1. Md. Moslemuddin 2. Rokman ali 3. Rahimuddin	15.8	09.09.14	15.75	22.09.11	N/A	50,000	Vacant Land	do	do	do
6	Kalampur	7883	21.11.07	ACMELAB	1. Mrs.parveen akter 2. Sharmeen akther	3.0	09.09.14	2.9	22.09.11	0.05	20,000	Vacant Land	do	do	do
7	Kalampur	317	12.01.05	ACMELAB	Md. Dudu miah	16.0	09.09.14	16	22.09.11	N/A	50,000	Vacant Land	do	do	do
8	Kalampur	5711	28.06.05	ACMELAB	Md. Iqbal sobhan	10.5	09.09.14	10.5	22.09.11	N/A	70,000	Vacant Land	do	do	do
9	Kalampur	7572	10.10.05	ACMELAB	Md. Abdul khaleque	10.5	09.09.14	10.5	22.09.11	N/A	30,000	Vacant Land	do	do	do
10	Kalampur	4178	30.05.05	ACMELAB	Md. Kafiluddin	9.7	09.09.14	9.66	22.09.11	N/A	28,473	Vacant Land	do	do	do
				ACMELAB		9.0	09.09.14	9	22.09.11	N/A	26,527	Vacant Land	do	do	do
11	Kalampur	767	02.02.05	ACMELAB	1. Md. Moslemuddin 2. Md. Rokman ali 3. Md. Abdur rahim	5.5	09.09.14	5.5	22.09.11	N/A	24,000	Vacant Land	do	do	do
12	Kalampur	9562	13.12.04	ACMELAB	Mrs. Zahanara begum	10.0	09.09.14	10	22.09.11	N/A	40,000	Vacant Land	do	do	do
13	Kalampur	1235	01.03.06	ACMELAB	Md. Zahagir alam	3.5	09.09.14	3.5	22.09.11	N/A	12,000	Vacant Land	do	do	do
14	Kalampur	9934	07.12.04	ACMELAB	Md. Muzibor rahman	10.0	09.09.14	10	22.09.11	N/A	30,000	Vacant Land	do	do	do
15	Kalampur	123	05.01.05	ACMELAB	Md. Babul miah	4.0	09.09.14	4	22.09.11	N/A	10,667	Vacant Land	do	do	do
				ACMELAB		5.0	09.09.14	5	22.09.11	N/A	13,333	Vacant Land	do	do	do
16	Kalampur	6664	04.10.06	ACMELAB	Mohammad ali Md. Azhar ali	3.0	09.09.14	0	22.09.11	3	10,000	Vacant Land	do	do	do
17	Kalampur	10167	28.12.04	ACMELAB	Md. Khorshed alam	11.0	09.09.14	11	22.09.11	N/A	40,000	Vacant Land	do	do	do
18	Kalampur	10168	28.12.04	ACMELAB	Mohammad ali	21.0	09.09.14	21	22.09.11	N/A	60,000	Vacant Land	do	do	do
19	Kalampur	316	12.01.05	ACMELAB	1.Md Hasen ali 2.Md. Kholilur rahman 3.Md. Chan miah	22.0	09.09.14	22	22.09.11	N/A	70,000	Vacant Land	do	do	do

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese (Decimal)	Last Payment Date of Rent	Mutation done	Mutation Date	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's rellation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
20	Kalampur	3071	18.04.05	ACMELAB	Md. Easob ali	7.0	09.09.14	7	22.09.11	N/A	24,000	Vacant Land	do	do	do
21	Kalampur	2253	20.03.05	ACMELAB	Md. Ranzon ali	13.0	09.09.14	13	22.09.11	N/A	41,935	Vacant Land	do	do	do
				ACMELAB		18.0	09.09.14	18	22.09.11	N/A	58,065	Vacant Land	do	do	do
22	Kalampur	9591	13.12.04	ACMELAB	Md. Hasen ali	12.0	09.09.14	12	22.09.11	N/A	45,000	Vacant Land	do	do	do
23	Kalampur	4074	26.05.05	ACMELAB	Md. Khorshed alam	8.0	09.09.14	8	22.09.11	N/A	24,000	Vacant Land	do	do	do
24	Kalampur	7627	17.10.05	ACMELAB	1. Md. Pochu miha	5.0	09.09.14	5	22.09.11	N/A	14,583	Vacant Land	do	do	do
				ACMELAB	2. Tara miah	7.0	09.09.14	6	22.09.11	1	20,417	Vacant Land	do	do	do
25	Kalampur	766	02.02.05	ACMELAB	Md. Solimuddin	30.0	09.09.14	30	22.09.11	0	100,000	Vacant Land	do	do	do
26	Kalampur	2961	15.05.06	ACMELAB	Md. Nasimuddin	2.5	09.09.14	2	22.09.11	0.25	7,143	Vacant Land	do	do	do
				ACMELAB		1.0	09.09.14	1	22.09.11	N/A	2,857	Vacant Land	do	do	do
27	Kalampur	332	12.01.05	ACMELAB	Md. Poran ali	11.8	09.09.14	11.75	22.09.11	N/A	40,000	Vacant Land	do	do	do
28	Kalampur	5519	27.05.05	ACMELAB	Md. Nathu miah	19.5	09.09.14	19.5	22.09.11	N/A	60,166	Vacant Land	do	do	do
				ACMELAB		14.5	09.09.14	14.5	22.09.11	N/A	44,172	Vacant Land	do	do	do
				ACMELAB		3.8	09.09.14	3.75	22.09.11	N/A	11,424	Vacant Land	do	do	do
29	Kalampur	5518	27.02.05	ACMELAB	1. Md. Nathu miah 2. Monowara khatoon	14.5	09.09.14	14.5	22.09.11	N/A	45,000	Vacant Land	do	do	do
30	Kalampur	4322	02.06.05	ACMELAB	Mrs. Varla khatoon	43.0	09.09.14	43	22.09.11	N/A	140,000	Vacant Land	do	do	do
31	Kalampur	267	07.01.10	ACMELAB	Hazi Md Azaharul Islam	6.7	09.09.14	6.67	22.09.11	N/A	125,000	Vacant Land	do	do	do
32	Kalampur	9563	13.12.04	ACMELAB	1. Mohammad ali 2. Mrs Khatun nessa	18.0	09.09.14	18	22.09.11	N/A	70,000	Vacant Land	do	do	do
33	Kalampur	4301	02.06.05	ACMELAB	Md. Tula miah	11.5	09.09.14	11.5	22.09.11	N/A	30,000	Vacant Land	do	do	do
34	kalampur	4709	14.06.05	ACMELAB	Md. Sukur masud	28	09.09.14	28	22.09.11	N/A	84,000	Vacant Land	do	do	do
				ACMELAB		22	09.09.14	22	22.09.11	N/A	66,000	Vacant Land	do	do	do
35	Kalampur	5079	22.06.05	ACMELAB	Mrs. Amana begum	13	09.09.14	13	22.09.11	N/A	40,000	Vacant Land	do	do	do
36	Kalampur	772	02.02.05	ACMELAB	1. Md. Abdul Mazid 2. Md.Tofazzal hossin 3. Mrs.Mazada Khatun 4. Mrs. Zarena Khatun 5. Mrs. Hazara khatun	16	09.09.14	16	22.09.11	N/A	50,000	Vacant Land	do	do	do
37	Kalampur	769	02.02.05	ACMELAB	1. Md. Rukman Ali 2. Md. Rahimuddin	10	09.09.14	10	22.09.11	N/A	24,000	Vacant Land	do	do	do
38	Kalampur	1027	04.02.08	ACMELAB	Md. Lokman hossain Abdur Rahim	5	09.09.14	5	22.09.11	N/A	45,000	Vacant Land	do	do	do
39	Kalampur	9561	13.12.04	ACMELAB	Md. Fazal haque	11.5	09.09.14	11.5	22.09.11	N/A	30,000	Vacant Land	do	do	do
40	Kalampur	4311	02.03.05	ACMELAB	1. Md.Nobu miah 2. Md.Modhu miah	9.66	09.09.14	9.66	22.09.11	N/A	24,000	Vacant Land	do	do	do

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese (Decimal)	Last Payment Date of Rent	Mutation done	Mutation Date	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's rellation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
41	Kalampur	4312	02.06.05	ACMELAB	1. Md. Tula tunmiah 2. Mrs.Sabura khatun 3. Mrs.Jumala khatun 4. Mrs.Hamala khatun 5. Mrs.Zohua khatun 6. Mrs.Jamala khatun	4.84	09.09.14	4.84	22.09.11	N/A	12,000	Vacant Land	do	do	do
42	Kalampur	4321	02.06.05	ACMELAB	1. Md. Badsha miah 2. Mrs.Vaila khatun	21	09.09.14	21	22.09.11	N/A	64,068	Vacant Land	do	do	do
				ACMELAB		19	09.09.14	19	22.09.11	N/A	57,966	Vacant Land	do	do	do
				ACMELAB		19	09.09.14	19	22.09.11	N/A	57,966	Vacant Land	do	do	do
43	Kalampur	9560	13.12.04	ACMELAB	Md.Monser ali Md.Badaruddin	9	09.09.14	9	23.07.12	N/A	30,000	Vacant Land	do	do	do
44	Kalampur	7195	19.09.05	ACMELAB	Md. Azharul Islam	9.33	09.09.14	12.33	22.09.11	N/A	29,063	Vacant Land	do	do	do
				ACMELAB		6.67	09.09.14	6.67		N/A	20,937	Vacant Land	do	do	do
45	Kalampur	758	02.02.05	ACMELAB	1. Md. Hayet ali	13	09.09.14	13	22.09.11	N/A	44,390	Vacant Land	do	do	do
				ACMELAB	2. Md. Sahyeb ali	28	09.09.14	28	22.09.11	N/A	95,610	Vacant Land	do	do	do
46	Kalampur	9590	13.12.04	ACMELAB	Md. Hazrat ali	8	09.09.14	8	22.09.01	N/A	20,000	Vacant Land	do	do	do
				ACMELAB		23	09.09.14	23	23.07.12	N/A	57,500	Vacant Land	do	do	do
				ACMELAB		9	09.09.14	9	23.07.12	N/A	22,500	Vacant Land	do	do	do
47	Kalampur	10166	28.12.04	ACMELAB	1. Md. Nazor ali 2. Mrs. Falani begum 3. Mrs. Mazada begum	8	09.09.14	8	22.09.11	N/A	24,000	Vacant Land	do	do	do
48	Kalampur	3072	18.04.05	ACMELAB	Md. Aynal haque	10	09.09.14	10	22.09.11	N/A	29,412	Vacant Land	do	do	do
				ACMELAB		7	09.09.14	7	22.09.11	N/A	20,588	Vacant Land	do	do	do
49	Kalampur	7001	03.09.05	ACMELAB	Mrs. Tajmahal bibi	23	09.09.14	23	22.09.11	N/A	70,000	Vacant Land	do	do	do
50	Kalampur	7576	10.10.05	ACMELAB	Mrs. Sahanara begum	18	09.09.14	18	22.09.11	N/A	50,000	Vacant Land	do	do	do
51	Kalampur	86	04.01.05	ACMELAB	Md. Mohiuddin	12	09.09.14	12	23.07.12	N/A	39,344	Vacant Land	do	do	do
				ACMELAB		12	09.09.14	12	23.07.12	N/A	39,344	Vacant Land	do	do	do
				ACMELAB		3.75	09.09.14	3.5	22.09.11	0.25	12,296	Vacant Land	do	do	do
				ACMELAB		19.5	09.09.14	19.5	23.07.12	N/A	63,934	Vacant Land	do	do	do
				ACMELAB		29	09.09.14	29	23.07.12	N/A	95,082	Vacant Land	do	do	do
52	Kalampur	9564	13.12.04	ACMELAB	Md. Dudu miah	12.5	09.09.14	12.5	22.09.11	N/A	40,123	Vacant Land	do	do	do
				ACMELAB		28	09.09.14	28	22.09.11	N/A	89,877	Vacant Land	do	do	do
53	Kalampur	11660		ACMELAB	Shamsunnahar	2	09.09.14	2	05.03.15	N/A	17,333	Vacant Land	do	do	do
				ACMELAB		1	09.09.14	0		1	8,667	Vacant Land	do	do	do
54	Kalampur	11661	30.12.83	ACMELAB	Mrs. Parveen Akther	2	09.09.14	0	05.03.15	2	18,000	Vacant Land	do	do	do
55	Kalampur	759	02.02.05	ACMELAB	Md. Shaheb Ali	15	09.09.14	15	23.07.12	N/A	50,000	Vacant Land	do	do	do
56	Kalampur	5002	20.04.14	ACMELAB	Mrs. Parveen Atther	1.88	09.09.14	1.88	17.11.14	N/A	108,462	Vacant Land	do	do	do
				ACMELAB		1.76	09.09.14	1.76		N/A	101,538	Vacant Land	do	do	do
Total						**950.20**					**3,445,762**				

Schedule of Land of all sales center

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese (Decimal)	Last Payment Date of Rent	Mutation Date	Mutation Done	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's rellation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
1	Bogura	3631	25.02.03	ACMELAB	Md. Mokbul Hossain	3	26.02.12	22.09.15			50,000	Depot	No relation	No lease agreement	
2	Bogura	21653	22.02.02	ACMELAB	Dr. Shamim Ahmed Chow.	9.75	26.08.04	22.09.15			195,000	Depot	do	do	
3	Bogura	13757	21.07.02	ACMELAB	1. Mrs. Tahera Akther Chow 2. Shahim Ahmed Chow. 3. Tuhin Ahmed Chow 4. Munzila Chow.	14.25	26.08.04	22.09.15	27	N/A	285,000	Depot	do	do	IPDC
4	Rangpur	4576	08.04.02	ACMELAB	Md. Shamsul Haque	15	25.09.03	20.04.15	15	N/A	600,000	Depot	do	do	Not mortgaged
5	Rajshahi	1864	11.03.03	ACMELAB	Dr. Iqbal Bari	13.81	30.03.03	26.04.15	13.81	N/A	1,200,000	Vacant Land	do	do	do
6	Dinajpur	11771	14.12.11	ACMELAB	Md. Monsur Ali	26	24.01.12	18.08.14	26	N/A	9,050,000	Vacant Land	do	do	do
7	Dinajpur	8760	12.12.09	ACMELAB	1. Mrs Nazrin Nena 2. Md. Shah Alam 3. Md.Zahurul Islam	32	20.06.12	18.08.14	32	N/A	2,720,000	Vacant Land	do	do	do
7	Sylhet	11841/11	05.07.11	ACMELAB	1. Saddam Hossin Pabal 2. Safayet Hossin Sakel	18	19.09.11	27.04.15	18	N/A	4,165,200	Vacant Land	do	do	do
8	Sylhet	do	do	ACMELAB	Do	12	19.09.11	27.04.15	12	N/A	2,776,800	Vacant Land	do	do	do
9	Faridpur	2263	24.02.10	ACMELAB	1. Mrs.Sufia Begum 2. Mrs.Salina Parveen	18.68	21.04.11	05.05.15	18.68	N/A	5,680,000	Vacant Land	do	do	do
10	Jessore	13328	5.12.03	ACMELAB	Mr. Nasiruddin	14.81	12.09.04	19.08.14	14.81	N/A	304,000	Vacant Land	do	do	do
11	Barisal	6347	16.10.02	ACMELAB	1. Md. Anwar Pasha 2. Rafique Pasha 3. Md. Soliaiman Pasha 4. Zohora noor 5. Khadaza Noor 6. Fatama Noor 7. Mrs.Khairunnesa	1.20	30.11.02	14.08.15	15	N/A	84,112	Depot	do	do	do
12	Barisal	do	do	ACMELAB	Do	7.50	30.11.02	14.08.15			525,700		do	do	do
13	Barisal	do	do	ACMELAB	Do	6.30	30.11.02	14.08.15			441,588		do	do	do
14	Mymensing	6403	21.07.08	ACMELAB	Md. Hamidul Haque	11	23.12.09	31.12.15	18	N/A	3,300,000	Depot	do	do	do
15	Mymensing	do	do	ACMELAB	do	7	23.12.09	31.12.15			2,100,000	Depot	do	do	do

Sl. No.	Location	Sale Deed No.	Reg. date	Purchaser	Name of Seller	Land purchese (Decimal)	Last Payment Date of Rent	Mutation Date	Mutation Done	Under Prosess (Decimal)	Deed Value in BDT	Current Use of Land	Seller's rellation with sponsor/ director	Expiration of Lease Date / Lease Agreement	Mortgage
16	Narayangonj	10871	14.09.09	ACMELAB	Sayed Amzed Hossain	4	06.05.10	20.04.15	4	N/A	2,200,000	Depot	do	do	IPDC
17	Narayangonj	do	do	ACMELAB	do	17	06.05.10	20.04.15	17	N/A	9,350,000	Depot	do	do	
18	Khulna	130/14	15.01.14	ACMELAB	Tanjima Jesmin	9.26	22.10.14	07.10.15	16.26	N/A	3,453,365	Vacant Land	do	19.02.2110	Not mortgaged
19	Khulna	do	do	ACMELAB	Do	7	22.10.14	07.10.15		N/A	2,610,535	Vacant Land	do		do
20	B.Baria	7619/12	24.05.12	ACMELAB	Uttara Bank	32	05.07.12	21.04.15	32	N/A	1,839,719	Vacant Land	do	No lease agreement	do
21	B.Baria	do	do	ACMELAB	do	59	05.07.12	21.04.15	59	N/A	3,391,982	Vacant Land	do	do	do
22	B.Baria	do	do	ACMELAB	do	23	05.07.12	21.04.15	23	N/A	1,322,299	Vacant Land	do	do	do
23	Chokoria	7550	26.12.13	ACMELAB	1. Imrul Alam Chow. 2. Tasneem Alam Karim	38	19.02.14	19.02.14	38	N/A	9,000,000	Vacant Land	do	do	do
24	Comilla	9085	15.07.12	ACMELAB	Md. Zahirul Islam	14	07.10.12	14.07.14	14	N/A	13,650,000	Vacant Land	do	do	do
25	Narayangonj	11445	7.10.13	ACMELAB	Md. Motiur Rahman	4	08.05.15	02.06.15	-	4	2,500,000	Depot	do	do	do
Total						**417.56**					**82,795,300**				

The issuer has received all the approvals pertaining to use of the land.

The company procured **2,716.51** decimals land in different places in Bangladesh by various registered kobla deeds and made development thereon and **16.26** decimals land of Khulna Development Authority procured from Mrs. Tanjima Jesmin, W/O: Mr. Md. Munir Sattar, 140, Tootpara Taltola, Hospital Road, GPO Khulna – 9100, District – Khulna by way of registered permanent lease deed dated: 21 January 2014. Some of them are covered by boundary wall and some are barbed wire fence. Out of total land mutation has been completed and rent paid up to the year 2014 for 2,698.67 decimals land. Mutation yet to be completed for 34.10 decimals of land details of which are given below:

Sl.	Location of Land	Area in decimal	Date of execution of title deed	Reason for non execution or mutation	Updated status
1	Kalampur (Paruhala), Dhamrai	0.05	15.05.06	Applied for mutation 18.65 decimals land but mutated 18.60 decimals land in the name of the company. Mutation for remaining 0.05 decimals land is under process.	Under process
2	Kalampur (Paruhala), Dhamrai	3	04.01.05	Applied for mutation 46 decimals land but mutated 43 decimals land in the name of the company. Mutation for remaining 3 decimals land is under process.	Under process
3	Kalampur (Paruhala), Dhamrai	1	13.12.04	Applied for mutation 12 decimals land but mutated 11 decimals land in the name of the company. Mutation for remaining 1 decimal land is under process.	Under process
4	Kalampur (Paruhala), Dhamrai	0.25	04.01.05	Applied for mutation 3.25 decimals land but mutated 3 decimals land in the name of the company. Mutation for remaining 0.25 decimal land is under process.	Under process
5	Kalampur (Paruhala), Dhamrai	0.25	15.05.06	Applied for mutation 76.25 decimals land but mutated 76 decimals land in the name of the company. Mutation for remaining 0.25 decimal land is under process.	Under process
6	Kalampur (Paruhala), Dhamrai	1	04.01.05	3 decimals of land have not been mutated erroneously. Mutation activities in under process.	Under process
7	Kalampur (Paruhala), Dhamrai	2	13.12.04		
8	Narayangonj	4	7.10.13	Applied for mutation	Applied for mutation
9	Hemayetpur	0.5	14.05.07	Mutation yet to be completed for 0.5 decimalland.	Under process
10	Hemayetpur	0.03	28.11.05	Applied for mutation 90.69 decimals land but mutated 90.66 decimals land in the name of the company. Mutation for remaining 0.03 decimal land is under process.	Under process
11	Dhamrai	3	22.09.11	Applied for mutation 180.52 decimals land but mutated 174 decimals land in the name of the company. Mutation for remaining 6.52 decimal land is under process.	Under process
12	Dhamrai	2	Do		
13	Dhamrai	1.52	Do		

Sl.	Location of Land	Area in decimal	Date of execution of title deed	Reason for non execution or mutation	Updated status
14	Dhamrai	3.5	24.08.03	Applied for mutation 76.50 decimals land but mutated 73 decimals land in the name of the company. Mutation for remaining 3.50 decimal land is under process	Under process
15	Dhamrai		24.03.02		
16	Dhamrai		02.02.02		
17	Dhamrai		05.10.02		
18	Dhamrai		17.09.02		
19	Dhamrai		05.10.02		
20	Dhamrai		31.03.01		
21	Dhamrai		19.01.02		
22	Dhamrai		15.04.01		
23	Dhamrai		10.06.01		
24	Dhamrai	10	10.02.11	Applied for mutation 60 decimals land but mutated 50 decimals land in the name of the company. Mutation for remaining 10 decimal land is under process	Under process
25	Dhamrai	2	17.08.93	Applied for mutation 39 decimals land but mutated 37 decimals land in the name of the company. Mutation for remaining 2 decimal land is under process.	Under process

However, the Company has absolute physical position of the total 2,732.77 decimal land in different places of the Country as stated herein above.

Apart from above, the ACME Laboratories Ltd. has provided an advance amounting Tk. 85,200,000 for acquisition of land as disclosed note # 13 in the audited financial statements for the year ended 30 June 2014, regarding this further disclosure is available in query # 14 of the auditor's additional disclosure. Mentionable here that for the Advance against land at Dhamrai registration for 190 decimals already have completed on dated 29 June 2015 for amounting Tk. 80,000,000 and regarding B. Baria land registration process is in final stage.

If the property is owned by the issuer, whether there is a mortgage or other type of charge on the property, with name of the mortgagee;

Sl No.	Name of Mortgagee	Deed No.	Date	Description of land/Plot No.	Area in Decimal
1	Agrani Bank Ltd., Ramna Corporate Branch	196	14/01/1980	RS Dag No. - 512	26.00
		5880	10/12/1980	RS Dag No. - 513	12.50
		5870	10/12/1980	RS Dag No. - 513	14.00
		5873	10/12/1980	RS Dag No. - 513	12.50
		1714	17/03/1980	RS Dag No. - 514	25.00
		Sub Total			**90.00**
2	Standard Chartered Bank, Bangladesh	25077	28/11/2005	RS Dag No. - 353	4.19
				RS Dag No. - 354	3.00
				RS Dag No. - 355	4.50
				RS Dag No. - 356	16.00
				RS Dag No. - 236	39.00
				RS Dag No. - 242	1.00
				RS Dag No. - 337	23.00
		Sub Total			**90.69**
3	Standard Chartered Bank, Bangladesh and HSBC, Bangladesh	11319	22/09/2011	RS Dag No. - 528	60.00
				RS Dag No. - 529	25.00
				RS Dag No. - 536	5.00
					90.00
		2963	05/04/2009	RS Dag No. - 507	45.00
				RS Dag No. - 510	129.00
				RS Dag No. - 593	33.00
		2962	05/04/2009	RS Dag No. - 509	9.00
					216.00
		Sub Total			**306.00**
4	The City Bank Ltd., Dhanmondi Branch	18246	13/08/2006	RS Dag No. - 230	1.17
				RS Dag No. - 231	14.00
				RS Dag No. - 232	8.83
				RS Dag No. - 357	3.50
				RS Dag No. - 358	3.50
		4770	13/03/2006	RS Dag No. - 232	21.17
				RS Dag No. - 233	25.83
				RS Dag No. - 239	21.00
				RS Dag No. - 238	17.00
				RS Dag No. - 235	17.50
		Sub Total			**133.50**
5	IPDC of Bangladesh Ltd.	3631	25/02/2003	SA Dag No. - 924	3.00
		21653	22/02/2002	RS Dag No. - 2563	9.75
		13757	21/07/2002	RS Dag No. - 2562	14.25
		Bogra Land			**27.00**
		10871	14/09/2009	RS Dag No. - 40	4.00
				RS Dag No. - 33	17.00
		Narayangonj Land			**21.00**

If the property is taken on lease, the expiration dates of the lease with name of the lessor, principal terms and conditions of the lease agreements and details of payment

Operating lease agreement during last five years

The company has established various Depots on leased accommodation. Relevant information on the operating lease agreement with the landlord is as follows:

(Amount in BDT)

Sl.	Particulars of Rental Premises	Period of Agreement	Amount	Total Monthly Amount
01	Rajshahi Sales Centre: F 1282, Sagar Para, P.S- Boalia, Rajshahi.	01-07-2014 to 30.06.2017	-	52,000.00
02	Jessore Sales Centre: 58 Upa shahar, Sector-2, P.S.- Kotwali, Jessore.	01.07.2013 to 30.06.2018	35,000.00	45,000.00
	House # 59, Sector-2, Upa shahar, Jessore.	01.12.2009 to 30.11.2014	10,000.00	
03	Khulna Sales Centre: 43, Yusuf Row, Mirjapur, Khulna.	01.10.2012 to 30.09.2014	15,000.00	70,000.00
		01.10.2012 to 30.09.2014	10,000.00	
		01.09.2012 to 30.09.2014	10,000.00	
		01.10.2012 to 30.09.2014	15,000.00	
		01.10.2012 to 30.09.2014	10,000.00	
		01.10.2012 to 30.09.2014	10,000.00	
04	Faridpur Sales Centre: 27/19/2, Molla Bari Sarak, Goal Chamat, Faridpur.	01.01.2013 to 31.12.2014	-	42,000.00
05	Narayangonj Sales Centre: Sosta Pur, P.O.- Fatullah, P.S.- Fatullah, Narayanganj.	01.09.2013 to 31.12.2015	104,000.00	104,000.00
06	Chakoria Sales Center: North Rampur, Thana- Satkania, District- Chittagong.	01.06.2013 to 31.05.2018		55,000.00
07	Chittagong Sales Center: Dhup pole, South Buri Char, Thana- Hathazari, Dist. Chittagong.	01.09.2012 to 31.08.2017		1,60,000.00
08	Dinajpur Sales Centre: Block # 1, House # 132, Road # 4, Ward # 01, Upa Shahar, Dinajpur.	01.10.2011 to 30.09.2014	-	38,000.00
09	Brahman Baria Sales Centre: Ghatura, P.S.-B. Baria, B. Baria.	01.10.2010 to 30.09.2015	48,000.00	56,500.00
	Vill: Austogram, P.S.-B. Baria, B. Baria.	01.03.2012 to 30.09.2015	8,500.00	
10	Rangpur Sales Centre: House No. 86, R.K. Road No. 02, Islambag, Post-Upa Shahar, Rangpur.	01.06.2010 to 01.06.2013	55,000.00	75,000.00
		01.09.2011 to 01.06.2013	20,000.00	
11	Bogra Sales Centre: Orchid, Holding No. - 528, Doctor Ishaque Lane, Sutrapur, Bogra.	01.06.2009 to 31.05.2014	-	50,000.00
12	Mymensingh Sales Centre: Dholadia (Near Taltola Bazar) Mymensingh.	01.08.2013 to 31.07.2014	-	105,000.00
13	Barisal Sales Centre: N. Hossain Villa, Police Line Road, Barisal	01.09.2011 to 31.08.2014	33,300.00	94,775.00
		01.10.2011 to 30.09.2014	61,475.00	
Total				**9,47,275.00**

The company also procured 63 vehicles under finance lease from IDLC Finance Ltd. (61 nos) and IPDC of Bangladesh Ltd. (2 nos) respectively. Besides, 12 machineries procured under sale & lease back from National Finance Ltd., which has already been repaid on 11 September 2014. Details of which are given below:

Lease Commitment

The ACME Laboratories Ltd. entered into the following lease commitment during the last five years. The status and outstanding as on 30 June 2014 are presented below:

(Amount in BDT)

SL.	NBFI	Total Amount (Sanctioned)	Rate of Interest (%)	Sanction Date	Expiration Date	Monthly / Quarterly Installment	Outstanding Balance as on 30 June 2014	Remarks
1	IDLC Finance Ltd.	6,415,306.00	13.50	24-Aug-09	25-Aug-13	400,957.00	Nil	N/A
2	IDLC Finance Ltd.	9,022,270.00	13.50	27-Jan-10	05-Feb-14	563,892.00	Nil	N/A
3	IDLC Finance Ltd.	1,932,780.00	13.60	08-Dec-09	15-Dec-13	120,799.00	Nil	N/A
4	IDLC Finance Ltd.	6,278,280.00	13.50	20-Apr-10	25-Apr-14	392,385.00	Nil	N/A
5	IDLC Finance Ltd.	5,140,272.00	13.50	20-Apr-10	25-Apr-14	321,267.00	Nil	N/A
6	IDLC Finance Ltd.	5,474,027.00	13.50	26-Oct-10	05-Nov-14	342,127.00	684,249.00	N/A
7	IDLC Finance Ltd.	10,046,333.00	13.50	13-Jul-10	15-Jul-14	627,896.00	627,893.00	N/A
8	IDLC Finance Ltd.	1,748,514.00	13.50	24-Nov-10	25-Nov-14	109,282.00	218,566.00	N/A
9	IDLC Finance Ltd.	21,962,939.00	15.00	27-Mar-11	25-Mar-15	1,372,684.00	4,118,047.00	N/A
10	IDLC Finance Ltd.	10,157,910.00	16.00	26-Apr-11	05-May-15	634,869.00	2,539,482.00	N/A
11	IDLC Finance Ltd.	38,205,010.00	16.00	12-May-11	25-May-15	2,387,813.00	9,551,254.00	N/A
12	IDLC Finance Ltd.	5,243,581.00	16.00	22-Jun-11	25-Jun-15	327,724.00	1,310,893.00	N/A
13	IDLC Finance Ltd.	1,997,904.00	16.00	22-Jun-11	15-Jul-15	124,869.00	624,345.00	N/A
14	IDLC Finance Ltd.	5,624,222.00	16.00	02-Aug-11	05-Aug-15	351,514.00	1,757,568.00	N/A
15	IDLC Finance Ltd.	3,041,354.00	16.00	23-Aug-11	05-Sep-15	190,085.00	950,419.00	N/A
16	IDLC Finance Ltd.	27,932,820.00	16.00	18-Jan-12	25-Jan-16	1,745,801.00	12,220,611.00	N/A
17	IDLC Finance Ltd.	28,144,783.00	16.00	04-Dec-12	05-Dec-16	1,759,049.00	17,590,489.00	N/A
18	IDLC Finance Ltd.	6,672,951.00	16.00	04-Dec-12	05-Dec-16	417,059.00	4,170,597.00	N/A
19	IDLC Finance Ltd.	6,251,388.00	16.00	28-Nov-13	05-Dec-17	390,712.00	5,469,964.00	N/A
20	IDLC Finance Ltd.	5,148,030.00	16.00	18-Nov-13	25-Nov-17	321,752.00	4,504,526.00	N/A
21	IDLC Finance Ltd.	5,725,378.00	15.50	30-Apr-14	05-May-18	357,836.00	5,725,378.00	N/A
22	IDLC Finance Ltd.	12,849,157.00	15.50	13-Mar-14	25-Mar-18	803,072.00	12,046,085.00	N/A
23	IPDC of Bangladesh Ltd.	3,380,000.00	14.50	14-Jul-11	05-Sep-15	286,541.00	1,289,178.00	N/A
24	IPDC of Bangladesh Ltd.	3,450,000.00	14.50	14-Jul-11	05-Sep-15	292,475.00	1,315,877.00	N/A
25	National Finance Ltd.	100,000,000.00	19.00	14-Feb-12	20-Feb-17	2,594,055.00	64,731,754.00	Subsequently repaid on 11 September '14

Dates of purchase of plant and machineries along with sellers name, address, years of sale, condition when purchased, country of origin and remaining economic life, purchase price and written down value

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Tabletting Machine	1	31-Dec-13	Fluidpack	1-4116,Phase Iv,G.I.D.C.,Vataw,Ahmedabad,India	Not Sold	Brand new	India	13.33	12.83	5,972,912.40	5,524,944.22
Hplc	1	31-Dec-13	Perkin Elmer	Peddnelmer Singapur Pte Ltd,26 Ayer Rajahcresent #08-01,Singapur 139959	Not Sold	Brand new	USA	13.33	12.83	5,673,296.90	5,247,799.79
Total Organic Carbon(Toc) Analyzer	1	31-Dec-13	Shimadzu (Asia Pacific) Pte Ltd	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	Japan	13.33	12.83	3,075,800.30	2,845,115.29
Hplc	1	31-Dec-13	Ameritech Scentific Corporation	3632 Pin Street,Irvine,Ca 92606-2620 U.S.A.	Not Sold	Brand new	U.S.A.	13.33	12.83	3,681,244.50	3,405,151.36
Hmg Stability Chember	1	31-Dec-13	Thermolab Scientific Equipments Pvt. Ltd	1/A,Ojha Niwas,Patel Estate Marg,Jogeshwari(W),Mumbai,Maharashtra-400102	Not Sold	Brand new	India	13.33	12.83	2,317,126.60	2,143,342.39
Total Organic Carbon(Toc) Analyzer	1	30-Jun-14	Shimadzu (Asia Pacific) Pte Ltd	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	Japan	13.33	13.33	2,581,430.20	2,580,886.51
Autoclave	1	30-Jun-14	Zirbus Technology	Hilfe Gottes 1,37539 Bad Grund	Not Sold	Brand new	Germany	13.33	13.33	22,858,939.00	22,854,124.56
Jacketed Vessel	1	30-Jun-14	S.K.Pharma Machinery Pvt.Ltd	Plot No.1806/13,Gidc-Umbergaon,Valsad Dist.Gujarat-396171,India	Not Sold	Brand new	India	13.33	13.33	5,301,445.90	5,300,329.34
Hardness Tester	1	30-Jun-14	Erweka	Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	13.33	1,434,499.90	1,434,291.39
Hardness Tester	1	30-Jun-14	Erweka	Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	13.33	1,434,499.90	1,434,291.39
Powder Fill.& Rubber Stopering Mach	1	30-Jun-14	Pharmec Technologies Co.Ltd	Room 1402,No.8 Building,313 Ninggud Road,Yangpu District,Shanghi 200090,China	Not Sold	Brand new	China	13.33	13.33	4,331,152.70	4,330,240.49
Powder Fill.& Rubber Stopering Mach	1	30-Jun-14	Pharmec Technologies Co.Ltd	Room 1402,No.8 Building,313 Ninggud Road,Yangpu District,Shanghi 200090,China	Not Sold	Brand new	China	13.33	13.33	4,331,152.70	4,330,240.49
Capsule Filling & Sealing Machine	1	30-Jun-14	Anchor Mark Pvt.Ltd	Plot No.101A,Kandivili Co-Operative Indi Estate Ltd.,Charkop,Kandivli (W),Mumbai-400067,India	Not Sold	Brand new	India	13.33	13.33	7,911,011.70	7,909,345.52
Sticker Labelling Machine	1	30-Jun-14	Npm Machinery Pvt.Ltd	Survey No.252,Opp.Iocl Petrol Pump,Changodar,Ahmedabad-382 213,Gujarat,India	Not Sold	Brand new	India	13.33	13.33	1,445,504.10	1,445,199.66
High Speed Mixer Granulat	1	30-Jun-14	Nin Machinery Technology Co.Ltd	No.210-8,Xialiao,Houbi Dist.,Tainan City 73150,Taiwan	Not Sold	Brand new	India	13.33	13.33	17,080,345.00	17,076,747.62
Tabletting Machine	1	30-Jun-14	Ptk Co.,Ltd.	No.3005 Gimpo Goldvalley,Hakun-Ri,Yangchon-Eup,Gimpo City,Gyeonggi-Do,Korea 415-843	Not Sold	Brand new	Taiwan	13.33	13.33	14,758,710.00	14,755,601.59
Blender	1	30-Jun-14	Pharmaceuticals And Medical Supply Limited Partnership	551/32-39 Soi Sansuk,Sathupradith Rd.,Chongnonsee,Yannawa,Bangkok 10120,Thailand	Not Sold	Brand new	Thailand	13.33	13.33	2,870,041.80	2,869,437.33
Blister Packing Machine	1	30-Jun-14	Buchon Machinery Co. Ltd	1381-10,Chong Wang-Dong,Shi Heung-City,Kyung Gi-Do,South Korea	Not Sold	Brand new	South Korea	13.33	13.33	6,640,103.00	6,638,704.49
Sterility Testing Device	1	30-Jun-14	Sartorius Stedim Biotech Gmbh	D-37070 Goettingen,Fed.Rep.Of Germany	Not Sold	Brand new	Germany	13.33	13.33	2,911,154.90	2,910,541.77
Sterility Testing Device	1	30-Jun-14	Sartorius Stedim Biotech Gmbh	D-37070 Goettingen,Fed.Rep.Of Germany	Not Sold	Brand new	Germany	13.33	13.33	2,911,154.90	2,910,541.77
Ampoule Inspection Machine	1	30-Jun-14	Shanghai Puxi Ltd	10A No.89,Fumin Road,Shanghai-200040,China	Not Sold	Brand new	China	13.33	13.33	2,344,811.90	2,344,318.05

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Sugar Crushing Machine	1	30-Jun-14	Jiangyin Longchang Machinery Manufacturing Co.Ltd	No.128,Zhuhuang Road,Zhutang Town,Jiangyin,Wuxi,Jiangsu,P.R.China	Not Sold	Brand new	China	13.33	13.33	1,496,196.50	1,495,881.38
Pre-Fabricated Building	1	30-Jun-14	Fabtech Technologies International Ltd	Office-615,Janki Centre,Veera Desai Road,Andheri (W),Mumbai 400053,India	Not Sold	Brand new	India	13.33	13.33	61,513,140.00	61,500,184.41
Validator	1	30-Jun-14	Ellab A/S	Trollesmindealle 25,Dk-3400 Hillerroed Denmark	Not Sold	Brand new	Denmark	13.33	13.33	4,373,222.20	4,372,301.13
Powder Filling Machine	1	30-Jun-14	Brothers Pharamamach (India)Pvt.Ltd.	Plot No. 2,Phase Ii,G.I.D.C. Vatva,Ahmedabad 382 445,India	Not Sold	Brand new	India	13.33	13.33	19,271,104.00	19,267,045.22
Potentiometer Titrator	1	30-Jun-14	Methm Middle East	P.O.Box 120747,Sharjah-U.A.E	Not Sold	Brand new	UAE	13.33	13.33	1,507,206.90	1,506,889.46
Autoclave	1	30-Jun-14	Zirbus Technology	Hilfe Gottes 1,37539 Bad Grund	Not Sold	Brand new	Germany	13.33	13.33	5,850,578.80	5,849,346.58
Double Door Autoclave,Steam	1	30-Jun-14	Zirbus Technology	Hilfe Gottes 1,37539 Bad Grund	Not Sold	Brand new	Germany	13.33	13.33	1,218,876.20	1,218,619.49
Disintegration Tester	1	30-Jun-14	Distek,Inc	121 North Center Drive,North Brunswick,Nj 08902 U.S.A.	Not Sold	Brand new	U.S.A.	13.33	13.33	1,473,592.60	1,473,282.24
Dissolution Tester	1	30-Jun-14	Distek,Inc	121 North Center Drive,North Brunswick,Nj 08902 U.S.A.	Not Sold	Brand new	U.S.A.	13.33	13.33	2,677,723.90	2,677,159.93
Fabric Washing Machine	1	30-Jun-14	Girbau Middle East	P.O.Box-17881,Jebel Ali,Dubai,Uae	Not Sold	Brand new	U.A.E	13.33	13.33	1,982,219.80	1,981,802.31
High Pressure Liquid Chromotography	1	30-Jun-14	Perkin Elmer	Peddnelmer Singapur Pte Ltd,26 Ayer Rajahcresent #08-01,Singapur 139959	Not Sold	Brand new	Singapur	13.33	13.33	3,064,731.30	3,064,085.82
Powder Filling Machine	1	30-Jun-14	Romaco	40067 Pianoro Fraz.Rastignano (Bo)-Italy	Not Sold	Brand new	Italy	13.33	13.33	157,147,831.00	157,114,733.31
Sifter	1	30-Jun-14	Zhejiang Canaan Technology Ltd	Linpu Road,Dong'Ou Industrial Park Wenzhou,Zhejiang,China	Not Sold	Brand new	China	13.33	13.33	2,658,383.40	2,657,823.50
Blender	1	30-Jun-14	Zhejiang Canaan Technology Ltd	Linpu Road,Dong'Ou Industrial Park Wenzhou,Zhejiang,China	Not Sold	Brand new	China	13.33	13.33	11,958,525.00	11,956,006.36
Lifter	1	30-Jun-14	Zhejiang Canaan Technology Ltd	Linpu Road,Dong'Ou Industrial Park Wenzhou,Zhejiang,China	Not Sold	Brand new	China	13.33	13.33	2,434,257.30	2,433,744.61
Sifter	1	30-Jun-14	Zhejiang Canaan Technology Ltd	Linpu Road,Dong'Ou Industrial Park Wenzhou,Zhejiang,China	Not Sold	Brand new	China	13.33	13.33	3,263,314.00	3,262,626.70
Capsule Filling & Sealing Machine	1	30-Jun-14	Ippr Engineering International Corp.	5 Xisanhuanbei Road,Beijing,China 100089	Not Sold	Brand new	China	13.33	13.33	5,471,788.50	5,470,636.06
Flim Coating Unit	1	30-Jun-14	Ganson Ltd.	157/158A,Akber Camp Road,Sandoz Baug,Kolshet,Ihane 400 607,Maharastra State,India	Not Sold	Brand new	India	13.33	13.33	8,911,724.30	8,909,847.36
Bottle Washing Machine	1	30-Jun-14	Laxmi Pharma Machines	Plot No.A-75,Bileshwar Industrial Estate,Opp.G.V.M.M.,Nr.Ring Road,Odhav-Kathwada,Road,Odhav,Ahmedabad-382 415,Guirat,India	Not Sold	Brand new	India	13.33	13.33	5,277,228.90	5,276,117.44
Water Purifier	1	30-Jun-14	Pharmatec Gmbh	Elisabeth-Boer-Strabe 3,D-01099 Dresden,Germany	Not Sold	Brand new	Germany	13.33	13.33	69,639,685.00	69,625,017.84
Water Purifier	1	30-Jun-14	Watertown Pharmaceutical Equipment Co.Ltd	No.6969 Changdong Highway,Xilicheng Section,Jingyue Development Area,Changchun,China 130119	Not Sold	Brand new	China	13.33	13.33	29,905,858.00	29,899,559.38
Tray Dryer	1	30-Jun-14	Changzhoy Yutong Drying Equipment Co.Ltd	Shun Xi Road,Jiao Xi Town,Changzhou,China	Not Sold	Brand new	China	13.33	13.33	2,077,652.80	2,077,215.22

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Cap Sealing Machine	1	31-Dec-07	Excelsior Trading Corporation Ltd	345,Segun Bagcha,G.P.O.Box No.6 Dhaka	Not Sold	Brand new	China	13.33	6.83	2,360,855.00	944,342.95
Bottle Washing Machine	1	31-Dec-03	Keller Machine Co.	Dkb/1413/02/01/0282 Date26/09/2002	Not Sold	Brand new	China	13.33	2.83	437,231.00	43,726.86
Bottle Washing Machine	1	30-May-06	Keller Machine Co.	B-10,Talbag,Thana Road,Savar,Dhaka	Not Sold	Brand new	China	13.33	5.24	250,000.00	81,250.00
Bottle Washing Machine	1	31-Dec-12	Laxmi Pharma Machines	Plot No-75,Bileshwar Industrial Estate,Opp.G.V.M.M.Nr.Ring Road,Odhav-Kathwada Road,Odhav,Ahmedabad-382415,Gujarat	Not Sold	Brand new	India	13.33	11.83	3,068,787.00	2,627,464.89
Bottle Dryer	1	31-Aug-06	Bright Trading Corporation	1219/C,Khilgaon Chowrasta,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	5.49	452,500.00	147,058.21
Hapa(2) Colour Foil Printing Machine	1	31-Dec-08	Hepa Ag	Chriesbaumstrasse4,Ch-8604 Volketswil,Switzerland	Not Sold	Brand new	Switzerland	13.33	7.83	8,341,783.00	4,587,979.11
Ointment Vacuum Emulsifier	1	31-Jul-09	Gmp China Ltd	No.8 Jinliang Road,Zhuqiao,Nanhui,Shanghai 201323,China	Not Sold	Brand new	China	13.33	8.41	4,087,825.00	2,554,890.05
Jacketed Vessel	1	31-Dec-04	Fd&C Equipments Private Ltd	F-116,S.I.T.E.Karachi-75730	Not Sold	Brand new	Pakistan	13.33	3.83	2,780,836.00	486,643.13
Jacketed Vessel	1	31-Dec-12	Skilltech Traders	40A(Park),Rajangianda Market,Mirpur-14,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	11.83	1,364,698.00	1,159,993.85
Jacketed Vessel	1	31-Dec-13	Skilltech Traders	40A(Park),Rajangianda Market,Mirpur-14,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	12.83	1,364,716.00	1,262,362.13
Powder Filling Machine	1	31-Jul-02	Rings Auto Pack	Nelson,Bb9 Old,England	Not Sold	Brand new	UK	13.33	1.41	861,806.00	21,550.81
Powder Filling Machine	1	31-Dec-11	Shanghai Light Industrial Equipment (Group)Co.Ltd	433 Xie Tu Road Shanghai 200023,China	Not Sold	Brand new	China	13.33	10.83	4,215,361.00	3,266,904.97
Planetary Mixture	1	31-Dec-01	Saizoner Mixer	Amex/D/C/006925 Date 10/09/2000	Not Sold	Brand new	Local	13.33	0.83	2,257,863.00	-
Planetary Mixture	1	31-Dec-05	Ganson Ltd.	157/158A,Akber Camp Road,Sandoz Baug,Kolshet,Ihane 400 607,Maharastra State,India	Not Sold	Brand new	India	13.33	4.83	5,051,301.00	1,262,821.17
Flim Coating Unit	1	31-Dec-05	Ganson Ltd.	157/158A,Akber Camp Road,Sandoz Baug,Kolshet,Ihane 400 607,Maharastra State,India	Not Sold	Brand new	India	13.33	4.83	12,515,146.00	3,128,786.02
Flim Coating Unit	1	31-Jul-09	Ideal Cures Pvt. Ltd	Plot No-24,Sector Ii,The Vasai Taluka Ind.Estate,Gaurai Pada,Vasai(E),Dist Thana-401 208,Maharashtra,India	Not Sold	Brand new	India	13.33	8.41	964,876.00	603,046.13
Tabletting Machine	1	31-Dec-00	Vinayak Exports	11,Ashokwadi,Nirala House,N.H.No-8,Amraiwadi,Ahmedabad-380 026,India	Not Sold	Brand new	India	13.33	(0.17)	1,546,556.20	-
Tabletting Machine	1	31-Dec-03	Vinayak Exports	Scb/2486/02/01/2537 Date 18/12/2002	Not Sold	Brand new	Local	13.33	2.83	5,334,514.00	133,357.19
Tabletting Machine	1	31-Dec-06	Chamunda Pharma Machinery Pvt Ltd.	Chamunda Estate,House-Iv,Gidc,Vatva,Cross Road,Ahmedabad-382445,India	Not Sold	Brand new	India	13.33	5.83	1,886,060.00	612,965.21
Tabletting Machine	1	31-Dec-06	Cmc Machinery	Plot No-3604/3605,Phase Iv,Vatva,Ahmedabad-380 015,India	Not Sold	Brand new	India	13.33	5.83	7,758,402.00	2,521,481.94
Tabletting Machine	1	31-Dec-06	Cmc Machinery	Plot No-3604/3605,Phase Iv,Vatva,Ahmedabad-380 015,India	Not Sold	Brand new	India	13.33	5.83	8,838,112.00	2,872,389.83
Tabletting Machine	1	31-Dec-08	Gmp China Ltd	No.8 Jinliang Road,Zhuqiao,Nanhui,Shanghai 201323,China	Not Sold	Brand new	China	13.33	7.83	10,009,668.00	5,167,449.37
Tabletting Machine	1	31-Dec-06	Chamunda Pharma Machinery Pvt Ltd.	Chamunda Estate,House-Iv,Gidc,Vatva,Cross Road,Ahmedabad-382445,India	Not Sold	Brand new	India	13.33	5.83	2,112,387.00	686,525.99

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Tabletting Machine	1	30-Jun-11	Fluidpack	116,Phese Iv,G.I.D.C.,Vatwa,Ahmedabad	Not Sold	Brand new	India	13.33	10.33	4,748,936.50	3,324,256.40
Fluid Bed Dryer	1	31-Dec-00	Alliance Engineering Company	Not Available	Not Sold	Brand new	India	13.33	(0.17)	1,997,389.00	-
Fluid Bed Dryer	1	31-Dec-05	Ganson Ltd.	157/158A,Akber Camp Road,Sandoz Baug,Kolshet,Ihane 400 607,Maharastra State,India	Not Sold	Brand new	India	13.33	4.83	4,849,150.00	1,212,289.89
Fluid Bed Dryer	1	31-Dec-05	Ganson Ltd.	157/158A,Akber Camp Road,Sandoz Baug,Kolshet,Ihane 400 607,Maharastra State,India	Not Sold	Brand new	India	13.33	4.83	4,849,150.00	1,212,289.89
Multi Column Distillation Plant	1	31-Dec-04	Klenzaids Contamination Controls (P) Ltd	A-21,Midc,Street 3,Andheri(E),Mumbai 400 093,India	Not Sold	Brand new	India	13.33	3.83	2,415,779.00	422,765.83
Multi Column Distillation Plant	1	31-Dec-06	Gmp China Ltd	No.8 Jinliang Road,Zhuqiao,Nanhui,Shanghai 201323,China	Not Sold	Brand new	China	13.33	5.83	4,901,050.00	1,592,839.11
Capsule Filling & Sealing Machine	1	31-Dec-95	Precision Weighing Solution Co	House-191,Road-01,New Dohs Mohakhali,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	(5.18)	1,143,053.50	(0.04)
Ointment Filling Machine	1	31-Jul-09	Gmp China Ltd	No.8 Jinliang Road,Zhuqiao,Nanhui,Shanghai 201323,China	Not Sold	Brand new	China	13.33	8.41	3,270,266.00	2,043,916.02
Ampoule Filling & Sealing Machine	1	31-Jul-02	Rota Verpackungstechnik Gmbh & Co	Kg.Postfach 1131.D79656 Wehr	Not Sold	Brand new	Germany	13.33	1.41	11,631,843.00	290,798.91
Powder Fill.& Rubber Stopering Mach	1	31-Dec-07	Excelsior Trading Corporation Ltd	345,Segun Bagcha,G.P.O.Box No.6 Dhaka	Not Sold	Brand new	China	13.33	6.83	4,384,445.00	1,753,780.84
Automatic Labelling Machine	1	31-Dec-07	The United Engineering Company	Hazra Road,Calcutta-700 029	Not Sold	Brand new	India	13.33	6.83	959,803.00	383,922.91
Jet Washing Machine For Vial & Amp.	1	31-Dec-06	Project Consultancy Services	Room No-203,Jindai Towers,2J/1A/3,Darga Road,Kolkata-700 017	Not Sold	Brand new	India	13.33	5.83	1,276,544.00	414,875.08
Jet Washing Machine For Vial & Amp.	1	31-Dec-06	Project Consultancy Services	Room No-203,Jindai Towers,2J/1A/3,Darga Road,Kolkata-700 017	Not Sold	Brand new	India	13.33	5.83	1,351,546.00	439,252.02
Dry Sterilizer	1	31-Dec-02	Sanamij	Vismbloem 65,3068 Jg Rotterdam,Holland	Not Sold	Brand new	Holland	13.33	1.83	4,686,859.00	117,176.83
Dry Sterilizer	1	31-Dec-03	Sanamij	Scb/2486/02/01/1345 Date 09/07/2002	Not Sold	Brand new	Holland	13.33	2.83	5,467,186.00	546,718.02
Dry Sterilizer	1	31-Dec-03	Sanamij	Scb/2486/03/01/0945 Date 20/04/2003	Not Sold	Brand new	Holland	13.33	2.83	662,523.00	66,254.91
Dry Sterilizer	1	31-Dec-06	Fd Enterprise Corporation	No.5,Lane 132,Chi-Lin Road,Tao-Yuan,Taiwan 338	Not Sold	Brand new	Tiwan	13.33	5.83	4,763,129.00	1,548,014.14
Double Door Autoclave,Steam	1	31-Dec-06	Machine Fabric	B/12,Arjun Center,B.S.D.Marg,Govandi,Mumbai-400 088,India	Not Sold	Brand new	India	13.33	5.83	2,606,011.00	846,952.08
Double Door Autoclave,Steam	1	31-Dec-07	Gmp China Ltd	No.8 Jinliang Road,Zhuqiao,Nanhui,Shanghai 201323,China	Not Sold	Brand new	China	13.33	6.83	1,661,967.00	664,783.20
Double Door Autoclave,Steam	1	31-Dec-07	Human Engineering Co	3Rd Fl.Keeyoung,Bldg#700-1,Daerim3-Dong,Youngdeungpo-Gu,150814,Korea	Not Sold	Brand new	Korea	13.33	6.83	311,878.00	124,750.06
Blister Packing Machine	1	31-Dec-97	Precision Weighing Solution Co	House-191,Road-01,New Dohs Mohakhali,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	(3.18)	3,840,000.00	-
Blister Packing Machine	1	31-Dec-03	Precision Weighing Solution Co	Dkb/1413/02/01/0138 Date10/07/2002	Not Sold	Brand new	Not Available	13.33	2.83	5,616,748.00	561,675.95
Blister Packing Machine	1	31-Dec-03	Precision Weighing Solution Co	Dkb/1413/02/01/0138 Date10/07/2002	Not Sold	Brand new	Not Available	13.33	2.83	5,616,748.00	561,675.95
Blister Packing Machine	1	31-Dec-05	Buchon Machinery Co. Ltd	1381-10,Chong Wang-Dong,Shi Heung-City,Kyung Gi-Do,South Korea	Not Sold	Brand new	South Koria	13.33	4.83	6,309,838.00	2,997,172.06

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Blister Packing Machine	1	31-Mar-06	Buchon Machinery Co. Ltd	1381-10,Chong Wang-Dong,Shi Heung-City,Kyung Gi-Do,South Korea	Not Sold	Brand new	Korea	13.33	5.08	7,119,690.00	3,381,851.11
Blister Packing Machine	1	31-Dec-08	Buchon Machinery Co. Ltd	1381-10,Chong Wang-Dong,Shi Heung-City,Kyung Gi-Do,South Korea	Not Sold	Brand new	South Koria	13.33	7.83	26,409,048.00	13,582,421.15
Blister Packing Machine	1	30-Jun-12	Buchon Machinery Co. Ltd	1381-10,Chong Wang-Dong,Shi Heung-City,Kyung Gi-Do,South Korea	Not Sold	Brand new	Korea	13.33	11.33	16,501,371.00	12,788,562.08
Liquid Filling Sealing & Leb. Line	1	31-Dec-01	National Pharma Machinery	Gota,Ahmedabad ,India	Not Sold	Brand new	India	13.33	0.83	3,193,728.00	-
Liquid Filling Sealing & Leb. Line	1	31-Dec-06	National Pharma Machinery	Gota,Ahmedabad ,India	Not Sold	Brand new	India	13.33	5.83	4,371,662.00	2,076,537.14
Liquid Filling Sealing & Leb. Line	1	31-Dec-12	Konark Machine Tools	1,Anand Nagar,Nr Ramdev Pir Mandir,Chandlodia,Ahmedabad,India	Not Sold	Brand new	India	13.33	11.83	6,830,074.00	5,805,562.19
Dehumidifire	1	31-Dec-04	Bry-Air(Asia)Pvt	20 Rajpur Road,Delhi 110 054,India	Not Sold	Brand new	India	13.33	3.83	1,121,797.00	196,312.09
Defoiler	1	30-Jun-13	Target Innovations	13,Chase International,P.E.Jose Vaz Road,Vasco Da Gama,Goa,India	Not Sold	Brand new	India	13.33	12.33	466,070.50	396,160.38
Water Purifier	1	31-Dec-07	Imperial Corporation Ltd.	House#8,Road#11,Sector-7,Uttara Model Town,Dhaka,Bangladesh	Not Sold	Brand new	Germany	13.33	6.83	2,490,182.00	996,070.14
Water Purifier	1	31-Dec-11	Ion Exchange(India) Ltd	Tiecicon House,Dr.E.Moses Road,Mahalaxmi,Mumbai 400 011,India	Not Sold	Brand new	INDIA	13.33	10.83	3,125,919.00	2,422,587.03
Automatic Suppository Machine	1	31-Jul-02	Sarong Spa Machinery And Packing Industry	C.C.I.A.A.Reggio E.N.184340,Italy	Not Sold	Brand new	Italy	13.33	1.41	14,439,387.00	360,984.99
Automatic Suppository Machine	1	31-Dec-12	Sarong	42046 Reggiolo (Re),Italy,Via C,Colombo 18	Not Sold	Brand new	Italy	13.33	11.83	68,166,887.00	57,941,853.20
Semi-Automatic Metered Dose Inheler	1	31-Dec-03	Not Available	Dkb/1413/02/01/0250 Date17/09/2002	Not Sold	Brand new	Not Available	13.33	2.83	5,515,694.00	551,569.98
Micronizer-Lab	1	31-Dec-03	Not Available	Scb/2486/02/01/1975 Date 30/09/2002	Not Sold	Brand new	Not Available	13.33	2.83	2,182,867.00	218,286.99
Mixing Vessel For Inheler	1	31-Dec-03	Scanchem International	Scb/2486/02/01/1975 Date 30/09/2002	Not Sold	Brand new	Not Available	13.33	2.83	914,079.00	91,407.03
Mixing Vessel For Inheler	1	30-Jun-11	Scanchem International	A/44 Anand,4Th Floor,17 Juhu Lane Andheri(West),Mumbai 400058,India	Not Sold	Brand new	India	13.33	10.33	4,630,327.50	3,241,227.69
Mixing Vessel For Inheler	1	30-Jun-11	Scanchem International	A/44 Anand,4Th Floor,17 Juhu Lane Andheri(West),Mumbai 400058,India	Not Sold	Brand new	India	13.33	10.33	2,878,898.50	2,015,230.34
Container Clean Machine	1	31-Dec-03	Not Available	Scb/2486/02/01/1975 Date 30/09/2002	Not Sold	Brand new	Not Available	13.33	2.83	130,986.00	13,098.02
Auto Fill & Seal Machine-Premix	1	31-Dec-03	Chung Shan Machinery Works Co. Ltd	Scb/2486/02/01/2285 Date 14/11/2002	Not Sold	Brand new	Not Available	13.33	2.83	503,086.00	50,313.81
Auto Fill & Seal Machine-Premix	1	31-Dec-08	Chung Shan Machinery Works Co. Ltd	521 Ltu Lin Village,Shui Shang,60843 Chia Yi Hsien,Taiwan	Not Sold	Brand new	Tiwan	13.33	7.83	4,016,826.00	2,058,623.02
Pre-Fabricated Building	1	31-Jul-03	Precisa Techno Trade	Not Available	Not Sold	Brand new	Local	13.33	2.41	100,000.00	47,500.00
Pre-Fabricated Building	1	31-Dec-06	Jiangsu Gusu Purifying Co. Ltd	No.262 Jin Xian Road,Jin Jin Ba Town,Wu Jiang City,Su Zhou City,Jiangsu Province,China	Not Sold	Brand new	China	13.33	5.83	7,567,571.00	3,594,595.08
Hapa(2) Colour Foil Print	1	31-Dec-06	Hapa Ag	Chriesbaumstrasse4,Ch-8604 Volketswil,Switzerland	Not Sold	Brand new	Switzerland	13.33	5.83	15,206,795.00	7,223,225.16
Hapa(2) Colour Foil Print	1	31-Dec-08	Hapa Ag	Chriesbaumstrasse4,Ch-8604 Volketswil,Switzerland	Not Sold	Brand new	Switzerland	13.33	7.83	8,341,783.00	3,962,345.11
High Speed Mixer Granulat	1	31-Dec-06	Tapaya Engineering Works Pvt. Ltd.	A/212,Road No.30,Wagle Industrial Estate,Thane-400 604,India	Not Sold	Brand new	India	13.33	5.83	4,005,022.00	1,902,383.14

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Autoclave	1	31-Dec-11	De Lama	Via Plemonte,21-27028 San Martino Siccomario (Pv) Italy	Not Sold	Brand new	Italy	13.33	10.83	11,154,194.00	8,644,499.19
Autoclave	1	31-Dec-11	De Lama	Via Plemonte,21-27028 San Martino Siccomario (Pv) Italy	Not Sold	Brand new	Italy	13.33	10.83	12,371,010.00	9,587,532.11
Hplc	1	30-Jun-11	Dionex Softron Gmbh	Dornierstrasse 4,D-82110 Germering,Germany	Not Sold	Brand new	Germany	13.33	10.33	2,824,695.40	1,977,287.34
Hplc	1	30-Jun-11	Dionex Softron Gmbh	Dornierstrasse 4,D-82110 Germering,Germany	Not Sold	Brand new	Germany	13.33	10.33	3,983,847.50	2,788,691.69
High Pressure Liquid Chromotography	1	31-Dec-04	Not Available	L/C No-Scb/2486/02/01/2135 Date 24/10/2002	Not Sold	Brand new	Not Available	13.33	3.83	2,158,550.60	377,749.48
High Pressure Liquid Chromotography	1	31-Dec-06	Watev Gesellschaft Mbh	L/C No-Scb/2486/05/01/2765 Date 28/12/2005	Not Sold	Brand new	USA	13.33	5.83	3,349,212.00	1,088,493.05
High Pressure Liquid Chromotography	1	31-Dec-06	Shimadzu Asia Pacific Pte Ltd.	16 Science Park Drive #01-01,The Pasteur,Singapore Science Park,Singapore 118227	Not Sold	Brand new	Singapore	13.33	5.83	1,047,481.20	340,432.16
High Pressure Liquid Chromotography	1	31-Mar-06	Shimadzu Asia Pacific Pte Ltd.	16 Science Park Drive #01-01,The Pasteur,Singapore Science Park,Singapore 118227	Not Sold	Brand new	Singapore	13.33	5.08	2,565,987.70	833,946.67
High Pressure Liquid Chromotography	1	30-Jun-10	Shimadzu Asia Pacific Pte Ltd.	16 Science Park Drive #01-01,The Pasteur,Singapore Science Park,Singapore 118227	Not Sold	Brand new	Japan	13.33	9.33	3,648,723.60	2,280,453.49
Gas Layer Chromatography (Glc)	1	31-Dec-07	Shimadzu Asia Pacific Pte Ltd.	16 Science Park Drive #01-01,The Pasteur,Singapore Science Park,Singapore 118227	Not Sold	Brand new	Singapore	13.33	6.83	2,906,008.90	1,162,401.04
Atomic Absorption Spectrometer Sys.	1	31-Dec-04	Not available	L/C No-Scb/2486/03/01/3163 Date 15/11/2003	Not Sold	Brand new	Not Available	13.33	3.83	2,155,300.40	377,172.60
Hmg Stability Chember	1	31-Dec-08	Hmg India	201,Country Park,Opp.Tata Ssl Ltd,Dattapada Road,Borivali(E)Mumbai 400066	Not Sold	Brand new	India	13.33	7.83	1,326,678.62	679,928.25
Hmg Stability Chember	1	30-Jun-10	Thermollab Scientific Equipments Pvt. Ltd	218,Sterling Chambers.56.Mogra Village Andheri(East),Mumbai 400069,India	Not Sold	Brand new	India	13.33	9.33	1,156,002.00	722,501.94
Hmg Stability Chember	1	30-Jun-11	Thermollab Scientific Equipments Pvt. Ltd	1/A,Ojha Niwas,Patel Estate Marg,Jogeshwari(W),Mumbai,Maharashtra-400102	Not Sold	Brand new	India	13.33	10.33	726,786.61	508,750.61
Hmg Stability Chember	1	30-Jun-13	Sheldon Manufacturing Inc.	300 North 26Th Avenue,P.O.Box-627,Cornelius,Oregon 97113 U.S.A	Not Sold	Brand new	USA	13.33	12.33	1,749,892.00	1,487,408.04
Vortex Mixture	1	23-Feb-14	Diamed	205 Shahid Syed Nazrul Islam Sharani,Dhaka,Bangladesh	Not Sold	Brand new	Germany	13.33	12.98	1,167,600.00	1,136,123.00
Paste Preparation Tank	1	1-Oct-11	Yenchen Machinery Co. Ltd.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	835,984.58	614,796.99
Paste Preparation Tank	1	1-Oct-11	Yenchen Machinery Co. Ltd.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	1,096,703.20	806,533.82
Tabletting Machine	1	1-Oct-11	Pharmatech Korea	21, Majun-Dong, Seo-Gu, Incheon City, Korea, 404-820, South Korea.	Not Sold	Brand new	South Korea	13.33	10.58	23,239,144.00	17,090,453.85
Tabletting Machine	1	1-Oct-11	Enovak Industrial Solver	75, Green Road, Farmgate, Tejgaon, Dhaka.	Not Sold	Brand new	Local	13.33	10.58	1,592,794.10	1,171,367.33
Tabletting Machine	1	1-Oct-11	Sejong Pharmatech Co. Ltd.	419-4, Chungchun-Dong, Pupyung-Gu, Incheon-City, South Korea.	Not Sold	Brand new	South Korea	13.33	10.58	18,123,275.00	13,336,283.56
Tabletting Machine	1	1-Oct-11	Sejong Pharmatech Co. Ltd.	419-4, Chungchun-Dong, Pupyung-Gu, Incheon-City, South Korea.	Not Sold	Brand new	South Korea	13.33	10.58	18,123,275.00	13,336,283.56
Flim Coating Unit	1	1-Oct-11	Pharmaceuticals And Medical Supply Limited	419-4, Chungchun-Dong, Pupyung-Gu, Incheon-City, South Korea.	Not Sold	Brand new	South Korea	13.33	10.58	24,969,499.00	18,362,985.76

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Flim Coating Unit	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	18,344,958.00	13,491,187.76
Flim Coating Unit	1	1-Oct-11	Nr Industries Co. Ltd.	768 Mu 3 Soi Tanpuying, Teparuk Road, Ampur Muang, Samutprakarn 10270, Thailand	Not Sold	Brand new	Thailand	13.33	10.58	1,472,826.50	1,083,141.16
High Speed Mixer Granulat	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	7,466,481.70	5,490,975.08
High Speed Mixer Granulat	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	21,457,814.00	17,170,446.04
Fluid Bed Dryer	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	13,402,952.00	9,856,754.28
Fluid Bed Dryer	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	26,501,348.00	19,489,532.97
Fluid Bed Dryer	1	1-Oct-11	Nr Industries Co. Ltd.	768 Mu 3 Soi Tanpuying, Teparuk Road, Ampur Muang, Samutprakarn 10270, Thailand	Not Sold	Brand new	Thailand	13.33	10.58	4,615,933.50	3,394,634.42
Cone Mill	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	1,798,190.10	1,322,418.96
Cone Mill	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	3,291,653.30	2,420,736.69
Washing In Place Equipment	1	1-Oct-11	Yenchen Machinery Co. Ltd.	38, Huaya 1St Road, Kueishan Township, Taoyuan Country, 333 Taiwan.	Not Sold	Brand new	Taiwan	13.33	10.58	1,197,787.70	880,873.04
Washing In Place Equipment	1	1-Oct-11	Yenchen Machinery Co. Ltd.	38, Huaya 1St Road, Kueishan Township, Taoyuan Country, 333 Taiwan.	Not Sold	Brand new	Taiwan	13.33	10.58	1,197,787.70	880,873.04
Vaccum Suction Device	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	2,478,042.70	1,822,393.89
Vaccum Suction Device	1	1-Oct-11	Yenchen Machinery Co.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	2,840,094.40	2,088,652.76
Planetary Mixture	1	1-Oct-11	Nr Industries Co. Ltd.	768 Mu 3 Soi Tanpuying, Teparuk Road, Ampur Muang, Samutprakarn 10270, Thailand	Not Sold	Brand new	Thailand	13.33	10.58	3,443,687.00	2,532,544.81
Blender	1	1-Oct-11	Nr Industries Co. Ltd.	768 Mu 3 Soi Tanpuying, Teparuk Road, Ampur Muang, Samutprakarn 10270, Thailand	Not Sold	Brand new	Thailand	13.33	10.58	4,174,180.10	3,069,761.61
Roller Compactor	1	1-Oct-11	Yenchen Machinery Co. Ltd.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	7,037,566.50	5,175,543.69
Blender	1	1-Oct-11	Pharmaceuticals And Medical Supply Limited	Linpu Road,Dong'Ou Industrial Park Wenzhou,Zhejiang,China	Not Sold	Brand new	China	13.33	10.58	14,478,170.00	10,647,487.47
Blender	1	1-Oct-11	Pharmaceuticals And Medical Supply Limited	Linpu Road,Dong'Ou Industrial Park Wenzhou,Zhejiang,China	Not Sold	Brand new	China	13.33	10.58	13,480,821.00	9,914,020.41
Bin Washing & Drying Machine	1	1-Oct-11	Yenchen Machinery Co. Ltd.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	8,534,463.60	6,276,386.77
Hot Air Oven	1	1-Oct-11	Changzhou Yutong Drying Equipment Co. Ltd.	Shun Xi Road,Jiao Xi Town,Changhou,China	Not Sold	Brand new	China	13.33	10.58	1,854,538.20	1,363,858.29
Hot Air Oven	1	1-Oct-11	Changzhou Yutong Drying Equipment Co. Ltd.	Shun Xi Road,Jiao Xi Town,Changhou,China	Not Sold	Brand new	China	13.33	10.58	2,440,181.90	1,794,550.43
Hot Air Oven	1	1-Oct-11	Changzhou Yutong Drying Equipment Co. Ltd.	Shun Xi Road,Jiao Xi Town,Changhou,China	Not Sold	Brand new	China	13.33	10.58	5,146,580.50	3,784,881.07

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Blister Packing Machine	1	1-Oct-11	Buchon Machinery Co. Ltd.	1381-10 Jeongwang-Dong, Siheung-Si, Gyeonggi-Do,South Koria	Not Sold	Brand new	Koria	13.33	10.58	13,491,098.00	10,045,764.66
Blister Packing Machine	1	1-Oct-11	Buchon Machinery Co. Ltd.	1381-10 Jeongwang-Dong, Siheung-Si, Gyeonggi-Do,South Koria	Not Sold	Brand new	Koria	13.33	10.58	12,813,718.00	9,423,421.78
Blister Packing Machine	1	1-Oct-11	Buchon Machinery Co. Ltd.	1381-10 Jeongwang-Dong, Siheung-Si, Gyeonggi-Do,South Koria	Not Sold	Brand new	Koria	13.33	10.58	12,813,718.00	9,423,421.78
Blister Packing Machine	1	1-Oct-11	Buchon Machinery Co. Ltd.	1381-10 Jeongwang-Dong, Siheung-Si, Gyeonggi-Do,South Koria	Not Sold	Brand new	Koria	13.33	10.58	12,813,718.00	9,423,421.78
Strip Packing Machine	1	1-Oct-11	Kwang Dah Enterprises Co. Ltd.	70, Keng Chou Road Wuku Hsien 24815, Taiwan	Not Sold	Brand new	TAIWAN	13.33	10.58	6,922,890.40	5,091,208.98
Powder Fill.& Rubber Stopering Mach	1	1-Oct-11	F.D Enterprise Corporation	No.68,Jin-Hua Road,Lu-Ju,Tao-Yuan Taiwan 33848	Not Sold	Brand new	TAIWAN	13.33	10.58	11,086,850.00	8,153,454.27
Automatic Vacuum Conveyer	1	1-Oct-11	F.D Enterprise Corporation	No.68,Jin-Hua Road,Lu-Ju,Tao-Yuan Taiwan 33848	Not Sold	Brand new	TAIWAN	13.33	10.58	1,151,922.90	847,143.30
Auto Plugging Machine	1	1-Oct-11	F.D Enterprise Corporation	No.68,Jin-Hua Road,Lu-Ju,Tao-Yuan Taiwan 33848	Not Sold	Brand new	TAIWAN	13.33	10.58	4,549,681.70	3,345,911.75
Cap Sealing Machine	1	1-Oct-11	F.D Enterprise Corporation	No.68,Jin-Hua Road,Lu-Ju,Tao-Yuan Taiwan 33848	Not Sold	Brand new	TAIWAN	13.33	10.58	6,519,552.70	4,794,587.70
Bottle Washing Machine	1	1-Oct-11	National Pharma Machinery	Gota,Ahmedabad ,India	Not Sold	Brand new	India	13.33	10.58	2,691,174.30	1,979,134.42
Capsule Filling & Sealing Machine	1	1-Oct-11	Pam Pharmaceuticals & Allied Mmachinery Company Pvt. Ltd.	127, Kandivli Ind. Estate, Kandivli West, Mumbai-400 067, India.	Not Sold	Brand new	India	13.33	10.58	19,075,279.00	14,028,278.13
Auto Weight Checker & Controller	1	1-Oct-11	Pam Pharmaceuticals & Allied Mmachinery Company Pvt. Ltd.	127, Kandivli Ind. Estate, Kandivli West, Mumbai-400 067, India.	Not Sold	Brand new	India	13.33	10.58	3,665,851.20	2,695,928.07
Auto Weight Checker & Controller	1	1-Oct-11	F.D Enterprise Corporation	No.68,Jin-Hua Road,Lu-Ju,Tao-Yuan Taiwan 33848	Not Sold	Brand new	TAIWAN	13.33	10.58	1,566,283.70	1,151,871.14
Hplc	1	1-Oct-11	Shimadzu (Asia Pacific) Pte Ltd.	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	Japan	13.33	10.58	2,654,977.20	1,952,514.48
Gas Layer Chromatography (Glc)	1	1-Oct-11	Shimadzu (Asia Pacific) Pte Ltd.	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	Japan	13.33	10.58	5,735,785.90	4,218,192.53
Total Organic Carbon(Toc) Analyzer	1	1-Oct-11	Shimadzu (Asia Pacific) Pte Ltd.	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	Japan	13.33	10.58	3,026,629.90	2,225,834.06
Potentiometer Titrator	1	1-Oct-11	Mettler-Toledo Ag	Sonnenbergstrasse 74,8603 Schwerzenboch,Switzerlond	Not Sold	Brand new	Switzerland/China/Japan/Uk	13.33	10.58	1,148,324.90	844,497.28
Hand Pallet Truck	1	1-Oct-11	Jungheinrich Lift Truck Singapore Pte Ltd.	14, Kwong Min Road, Singpore, 628715.	Not Sold	Brand new	Switzerland/China/Japan/Uk	13.33	10.58	3,491,458.20	2,567,676.54
Hand Pallet Truck	1	1-Oct-11	Jungheinrich Lift Truck Singapore Pte Ltd.	14, Kwong Min Road, Singpore, 628715.	Not Sold	Brand new	singapore	13.33	10.58	3,491,458.20	2,567,676.54
Autoclave	1	1-Oct-11	Astell Scientific Ltd.	Powerscroft Road Sidcup, Kent Da14 5Dt United Kingdom	Not Sold	Brand new	UK	13.33	10.58	1,344,993.70	989,130.78
Air Sampler,Ariemometer,Tripod.	1	1-Oct-11	Sartorius Stedim	August-Spindler-Str.11,37079 Gottingen,Deutschland	Not Sold	Brand new	European	13.33	10.58	1,079,305.70	793,739.41
Hmg Stability Chember	1	1-Oct-11	Cvallo S.R.L	Via Mulino 5/B-20090 Buccinasco(Mi) , Italy	Not Sold	Brand new	Italy	13.33	10.58	1,734,644.50	1,275,686.47
Hmg Stability Chember	1	1-Oct-11	Cvallo S.R.L	Via Mulino 5/B-20090 Buccinasco(Mi) , Italy	Not Sold	Brand new	Italy	13.33	10.58	1,734,644.50	1,275,686.47

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Hplc System-Quaternary Gradient	1	1-Oct-11	Shimadzu (Asia Pacific) Pte Ltd.	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	Japan	13.33	10.58	4,804,174.40	3,533,069.92
Hplc System-Quaternary Gradient	1	1-Oct-11	Shimadzu (Asia Pacific) Pte Ltd.	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	Japan	13.33	10.58	4,804,174.40	3,533,069.92
Transfer Pump	1	30-Jun-14	S.K.Pharma Machinery Pvt.Ltd	Plot No.1806/13,Gidc-Umbergaon,Valsad Dist.Gujarat-396171,India	Not Sold	Brand new	India	13.33	13.33	1,617,389.60	1,617,048.95
Jacketed Vessel	1	30-Jun-14	S.K.Pharma Machinery Pvt.Ltd	Plot No.1806/13,Gidc-Umbergaon,Valsad Dist.Gujarat-396171,India	Not Sold	Brand new	India	13.33	13.33	5,301,445.90	5,300,329.34
Blender	1	30-Jun-14	Zhejiang Canaan Technology Ltd	Linpu Road,Dong'Ou Industrial Park Wenzhou,Zhejiang,China	Not Sold	Brand new	China	13.33	13.33	2,182,750.20	2,182,290.48
Multi Column Distillation Plant	1	30-Jun-14	Bochi Labortechnik Ag	Meierseggstrasse 40,P.O.Box Ch-9230 Flawil 1,Switzerland	Not Sold	Brand new	switzerland	13.33	13.33	2,090,506.90	2,090,066.61
Blister Packing Machine	1	30-Jun-14	Buchon Machinery Co. Ltd	1381-10,Chong Wang-Dong,Shi Heung-City,Kyung Gi-Do,South Korea	Not Sold	Brand new	South Korea	13.33	13.33	11,068,027.00	11,065,695.91
Dispensing Booth	1	30-Jun-14	Suzhou Industrial Park Hjclean Tech.Co.	15 A,Chuang Tou Industrial Area,Yang He Road,Suzhou,China	Not Sold	Brand new	China	13.33	13.33	11,615,178.00	11,612,731.67
Tray Dryer	1	30-Jun-14	Jiangyin Longchang Machinery Manufacturing Co.Ltd	No.128,Zhuhuang Road,Zhutang Town,Jiangyin,Wuxi,Jiangsu,P.R.China	Not Sold	Brand new	China	13.33	13.33	1,094,689.30	1,094,458.74
Tray Dryer	1	30-Jun-14	Changzhoy Yutong Drying Equipment Co.Ltd	Shun Xi Road,Jiao Xi Town,Changzhou,China	Not Sold	Brand new	China	13.33	13.33	3,005,963.10	3,005,330.00
Tray Dryer	1	30-Jun-14	Changzhoy Yutong Drying Equipment Co.Ltd	Shun Xi Road,Jiao Xi Town,Changzhou,China	Not Sold	Brand new	China	13.33	13.33	4,508,935.60	4,507,985.95
Capsule Filling & Sealing Machine	1	30-Jun-14	Acg Pam Pharma Technologies Pvt	Pam House,Plot 127,Kandivli Industrial Estate,Charkop,Kandivali(West),Mumbai-400067,India	Not Sold	Brand new	INDIA	13.33	13.33	713,718.85	713,718.85
Hapa(2) Colour Foil Printing Machine	1	30-Jun-14	Hapa Ag	Chriesbaumstrasse4,Ch-8604 Volketswil,Switzerland	Not Sold	Brand new	SWITZERLAND	13.33	13.33	40,991,189.42	40,991,189.42
Blister Packing Machine	1	30-Jun-14	Romaco Pharmatechnik	Postfach 43 01 46,D-76216 Karisuhe	Not Sold	Brand new	Germany	13.33	13.33	71,560,826.66	71,560,826.66
Hplc System	1	30-Jun-14	Shimadzu (Asia Pacific) Pte Ltd	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	JAPAN	13.33	13.33	9,115,479.61	9,115,479.61
Rapid Mixer Granulator	1	30-Jun-14	Gansons Ltd.India	157/153A Akber Camp Road,Sandoz Baug,Kolshet,Thane 400 607,Maharashtra State ,India	Not Sold	Brand new	INDIA	13.33	13.33	46,537,156.18	46,537,156.18
Tablet Coating Machine	1	30-Jun-14	Pam-Glatt Pharma Tech.Pvt.Ltd	Survey No-14 And 16 Jankar Ind.Estate,J.M.Compound Kashimira,Thane-401104,Maharahstra,India	Not Sold	Brand new	INDIA	13.33	13.33	27,874,467.43	27,874,467.43
Potentiometric Titrator	1	30-Jun-14	Mettler-Toledo Ag	Im Langacher 44,8606 Greifensee,Seitzerland	Not Sold	Brand new	SWITZERLAND	13.33	13.33	1,654,243.74	1,654,243.74
Dissolution Tester	1	30-Jun-14	Erweka	Ottostrasse 20-22 D-63150 Heusenstamm	Not Sold	Brand new	Germany	13.33	13.33	3,499,292.76	3,499,292.76
Blister Packing Machine	1	30-Jun-14	Romaco Pharmatechnik	Postfach 43 01 46,D-76216 Karisuhe	Not Sold	Brand new	Germany	13.33	13.33	140,382,461.27	140,382,461.27
Tablet Pressing Machine	1	30-Jun-14	Bosch Packaging Technology Ltd	Manesty Kitling Road,Knowsley,Merseyside L34 9Js,U.K.	Not Sold	Brand new	U.K.	13.33	13.33	97,483,879.83	97,483,879.83
Dissolution Tester	1	30-Jun-14	Erweka	Ottostrasse 20-22 D-63150 Heusenstamm	Not Sold	Brand new	Germany	13.33	13.33	5,133,005.26	5,133,005.26
Capsule & Tablet Deblistering Machine	1	30-Jun-14	Pingyang Shida Import And Export. Trading Co. Ltd	No.70-1 Xingbei Road,Doubei Village Songbu Office,Wanquan Town,Pingyang,China	Not Sold	Brand new	CHINA	13.33	13.33	1,288,269.68	1,288,269.68

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Reach Truck	1	30-Jun-14	Toyota Tsusho Corporation	9-8 Meteki,4-Chome,Nagoya,Japan	Not Sold	Brand new	JAPAN	13.33	13.33	4,671,424.11	4,671,424.11
Hplc System	1	30-Jun-14	Shimadzu (Asia Pacific) Pte Ltd	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	JAPAN	13.33	13.33	2,963,159.11	2,963,159.11
Hplc System	1	30-Jun-14	Shimadzu (Asia Pacific) Pte Ltd	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	JAPAN	13.33	13.33	3,464,617.48	3,464,617.48
Blister Packing Machine	1	30-Jun-14	Hoong-A Corporation	83-4,Todang-Dong,Wonmi-Ku,Buchon City,Kyunggi Do,South Korea	Not Sold	Brand new	KOREA	13.33	13.33	30,658,919.73	30,658,919.73
Liq. In Hard Gelatin Cap Filling & Sealing Machine	1	30-Jun-14	Acg Pam Pharma Technologies Pvt	Pam House,Plot 127,Kandivli Industrial Estate,Charkop,Kandivali(West),Mumbai-400067,India	Not Sold	Brand new	INDIA	13.33	13.33	51,137,484.47	51,137,484.47
Bin Washing & Drying Machine	1	30-Jun-14	Yenchen Machinery Co.Ltd.	No.38,Huaya Est Rd.Taoyuan County 333,Taiwan	Not Sold	Brand new	TAIWAN	13.33	13.33	13,842,920.69	13,842,920.69
Hot Air Oven	1	30-Jun-14	Changzhou Yutong Drying Equipment Co.Ltd	Shun Xi Road,Jion Xi Town,Tangzhou,China	Not Sold	Brand new	CHINA	13.33	13.33	2,740,732.95	2,740,732.95
Bin Blender	1	30-Jun-14	Pms	551/32-39 Soi Sansuk Sathupradith Rd,Bangkok 10120,Thailand	Not Sold	Brand new	THAILAND	13.33	13.33	14,091,448.71	14,091,448.71
Container Filling Caping Sealing & Leveling Machine	1	30-Jun-14	Ippr Engineering International Corp.	5 Xisanhuanbei Road,Beijing China	Not Sold	Brand new	CHINA	13.33	13.33	13,278,750.64	13,278,750.64
Loading Autoclave	1	30-Jun-14	Zirbus	Hilfe Gottes 1,37539 Bad Grund	Not Sold	Brand new	Germany	13.33	13.33	4,968,639.16	4,968,639.16
Sachet Packing Machine	1	30-Jun-14	Auto Science Technology Co.Ltd	No.16,Alley 1,Lake 573,Pindong Rd.,Pin-Chien City,Taur Yuan Hsien,Taiwan	Not Sold	Brand new	TAIWAN	13.33	13.33	9,207,323.11	9,207,323.11
Air Displacement Unit(Dust Collect)	2	31-Dec-05 to 01-Oct-11	Pam Pharmaceuticals & Allied Mmachinery Company Pvt. Ltd.	127, Kandivli Ind. Estate, Kandivli West, Mumbai-400 067, India.	Not Sold	Brand new	India	13.33	4.83 to 10.58	301,203.00	164,173.46
Air Sampler,Ariemometer,Tripod.	3	31-May-10 to 30-Jun-14	Partical Measuring Systems	5475 Airport Boulevard,Boulder,Colorada-80301-2339	Not Sold	Brand new	India	13.33	9.25 to 13.33	1,812,402.14	1,774,916.27
Alu. Foil Sealer Machine	4	31-Jul-03 to 15-Nov-11	Matey Engineering Works	73,North Jatrabari,Dhaka	Not Sold	Brand new	Local	13.33	2.41 to 10.71	199,000.00	97,750.00
Aluminium Tray	2	31-Jan-99 to 31-Jan-99	Myth Industries	1219/C,Khilgaon Chowrasta,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	60,000.00	-
Ampule & Vial Crashing Machine	1	30-Sep-07 to 30-Sep-07	Bappa Karigori Ltd.	63/15 Mohakhali C/A,Dhaka	Not Sold	Brand new	Local	13.33	6.58 to 6.58	55,000.00	22,000.00
Analytical Balance	7	31-Aug-96 to 30-Jun-14	Sartorius Stedim Biotech Gmbh	D-37070 Goettingen,Fed.Rep.Of Germany	Not Sold	Brand new	Germany	13.33	0 to 13.33	6,354,930.39	6,152,449.13
Auto Imprinter	3	01-Oct-11 to 01-Oct-11	F.D Enterprise Corporation	No.68,Jin-Hua Road,Lu-Ju,Tao-Yuan Taiwan 33848	Not Sold	Brand new	TAIWAN	13.33	10.58 to 10.58	1,194,666.99	878,578.03
Automatic Refractrometer	2	31-Dec-05 to 01-Oct-11	Mettler-Toledo Ag	Sonnenbergstrasse 74,8603 Schwerzenboch,Switzerlond	Not Sold	Brand new	Switzerland/China/Japan/Uk	13.33	4.83 to 10.58	1,364,262.27	784,863.70
Balance And Weighting Scale	149	30-Sep-03 to 16-Jun-14	Blue Ribbon Associates	Multiplan Center,Suite-18,Level-11,69-71 New Elephant Road,Dhaka,Bangladesh	Not Sold	Brand new	POLAND	13.33	2.57 to 13.29	12,733,864.27	7,636,731.56
Batch Printing Machine	2	29-Feb-04 to 29-Feb-04	Dreks Associates	Not Available	Not Sold	Brand new	Not Available	13.33	2.99 to 2.99	67,000.00	11,714.42
Binocular (Microscope)	3	30-Nov-97 to 01-Oct-11	Olympus	4918 River Vally Road-12-01/04 Vally Point Office Tower Singapur 248373	Not Sold	Brand new	Japan	13.33	0 to 10.58	1,545,079.40	1,086,897.97

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Bio Test Anemo Meter	1	31-Dec-05 to 31-Dec-05	Not Available	Not Available	Not Sold	Brand new	Not Available	13.33	4.83 to 4.83	25,000.00	6,250.00
Biosafety Cabinet	1	30-Jun-14 to 30-Jun-14	Labconco Corporation	8811 Prospect Avenue,Kansas City,Mo 64132-2696 Usa	Not Sold	Brand new	USA	13.33	13.33 to 13.33	1,039,677.80	1,039,458.83
Blender	6	30-Sep-03 to 17-Apr-14	Myth Industries	1219/C,Khilgaon Chowrasta,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	2.57 to 13.13	2,205,000.00	1,292,442.71
Blister Sealer	1	31-Dec-06 to 31-Dec-06	Keller Machine Co.	B-10,Talbag,Thana Road,Savar,Dhaka	Not Sold	Brand new	Not Available	13.33	5.83 to 5.83	285,000.00	92,625.00
Bod Analyser	1	13-Sep-12 to 13-Sep-12	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	USA	13.33	11.54 to 11.54	628,626.00	534,332.02
Bottle Dryer	1	04-Mar-98 to 04-Mar-98	Myth Industries	1219/C,Khilgaon Chowrasta,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	30,000.00	-
Bucket & Trolley	19	01-Oct-11 to 31-Dec-12	Advance Enineering Workshop	Hazi Aksar Ali Road -Boro Dewra Tongi,Gazipur	Not Sold	Brand new	Bangladesh	13.33	10.58 to 11.83	493,939.98	382,653.72
Cap Sealing Machine	12	31-Jul-03 to 30-Jun-14	Wenzhou Best International Trade Co.Ltd	401 Shengtai Building Liming,East Rd,Wenzhou,China	Not Sold	Brand new	China	13.33	2.41 to 13.33	1,260,871.54	897,794.73
Capsule Dedusting & Polishing Machi	2	31-Dec-05 to 01-Oct-11	Pam Pharmaceuticals & Allied Mmachinery Company Pvt. Ltd.	127, Kandivli Ind. Estate, Kandivli West, Mumbai-400 067, India.	Not Sold	Brand new	India	13.33	4.83 to 10.58	743,080.70	378,042.30
Capsule Filling & Sealing Machine	1	31-Dec-11 to 31-Dec-11	Acg Pam Pharma Technologies Pvt Ltd	Pam House,Plot-127,Kandivill Industrial Plote,Mumbai-400067,India	Not Sold	Brand new	India	13.33	10.83 to 10.83	272,167.50	210,928.68
Carton Over Printing Machine	21	31-Dec-03 to 30-Jun-14	Pharmachine India	20,Suyog Industrial Estate,L.B.S. Marg,Vikhroli West,Mumbai-400 083,India	Not Sold	Brand new	India	13.33	2.83 to 13.33	4,550,733.25	2,762,371.44
Centrifuge	1	30-Jun-14 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK	13.33	13.33 to 13.33	562,574.89	562,456.40
Centrifuge Machine	1	01-Oct-11 to 01-Oct-11	Techcomp Ltd.	Em Macau,Rua De Pequim Ns 202A-246,Centro Financeiro K10	Not Sold	Brand new	Australia	13.33	10.58 to 10.58	676,884.64	497,792.25
Cod Analyser	1	13-Sep-12 to 13-Sep-12	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	USA	13.33	11.54 to 11.54	115,087.00	97,823.20
Collaid Mill (Homoginiger)	1	31-Dec-00 to 31-Dec-00	Vinayak Exports	11,Ashokwadi,Nirala House,N.H.No-8,Amraiwadi,Ahmedabad-380 026,India	Not Sold	Brand new	India	13.33	-	189,680.00	-
Colony Counter	2	30-Jun-14 to 30-Jun-14	Ultra Violet Products Ltd	Unit 1,Trinity Hall,Farm Estate,Nuffield Road,Cambridge Cb4 1Tg,Uk	Not Sold	Brand new	UK	13.33	13.33 to 13.33	1,028,913.96	1,028,697.26
Condenser	2	29-May-14 to 29-May-14	Skilltech Traders	40A(Park),Rajangianda Market,Mirpur-14,Dhaka,Bangladesh	Not Sold	Brand new	LOCAL	13.33	13.24 to 13.24	265,000.00	263,158.17
Conductivity Meter	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	248,906.77	248,906.77
Continuous Poly Bag Sealing Machine	24	31-Mar-04 to 11-Nov-12	Kai Enterprise	Block-A,Islampur,Medical Road,Dhamrai,Dhaka,Bangladesh	Not Sold	Brand new	China	13.33	3.08 to 11.7	478,700.00	268,953.29
Conveyor Table	28	31-Jul-02 to 11-Mar-14	Multi Engineering Services	Telirchala,Mouchak,Kaliakoir,Gazipur,Bangladesh	Not Sold	Brand new	LOCAL	13.33	1.41 to 13.03	4,960,104.74	3,603,640.25
Cube Mixer Type-Kb 15S	1	31-Dec-03 to 31-Dec-03	Not available	Scb/2486/03/01/1608 Date 19/06/2003	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	154,202.00	15,421.94
D. I. Plant	1	31-May-03 to 31-May-03	Mark Industries (Pvt) Ltd	348/1,Dilu Road Dhaka	Not Sold	Brand new	Not Available	13.33	2.24 to 2.24	60,000.00	1,500.00

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Deblistering Machine	3	01-Oct-11 to 30-Jun-13	Target Innovations	13,Chase International,P.E.Jose Vaz Road,Vasco Da Gama,Goa,India	Not Sold	Brand new	India	13.33	10.58 to 12.33	913,993.64	696,845.93
Deduster	2	31-Dec-00 to 31-Dec-00	Vinayak Exports	11,Ashokwadi,Nirala House,N.H.No-8,Amraiwadi,Ahmedabad-380 026,India	Not Sold	Brand new	India	13.33	-	176,145.00	-
Defoiler	2	31-Jul-09 to 31-Dec-11	Target Innovations	13,Chase International,P.E.Jose Vaz Road,Vasco Da Gama,Goa,India	Not Sold	Brand new	India	13.33	8.41 to 10.83	442,670.20	309,226.09
De-Foiling	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	449,589.32	449,589.32
Dehumidifire	28	31-Dec-95 to 14-Aug-12	Shameem & Company	166,Mirpur Road,Kalabagan,Dhaka	Not Sold	Brand new	BANGLADESH	13.33	0 to 11.45	2,133,000.00	616,950.00
Dial Calipar Slide Caliper	7	31-Dec-96 to 06-Sep-12	Rotex International	Mamun Plaza,Shop#120,31,Hatkhola Road,Dhaha	Not Sold	Brand new	Japan	13.33	0 to 11.52	56,400.00	37,973.25
Die Punch Holder	4	31-May-06 to 31-May-06	Bright Trading Corporation	1219/C,Khilgaon Chowrasta,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	5.24 to 5.24	8,000.00	2,600.00
Dies & Punches	1	31-Dec-00 to 31-Dec-00	Not available	Not available	Not Sold	Brand new	Not Available	13.33	-	271,952.14	-
Digital Metal Detector	5	31-Dec-08 to 01-Oct-11	Flowaire International Llp	153,Bukit Batok Street 11*02-284 Singapur-650153	Not Sold	Brand new	UK	13.33	7.83 to 10.58	5,166,507.65	3,577,767.04
Disintegration Tester	8	31-Dec-07 to 31-Dec-13	Copley Scientific Ltd	Colwic Quays Business Park,Private Road No-2,Colwick ,Nottingham,Ng4 2Jy Uk	Not Sold	Brand new	UK	13.33	6.83 to 12.83	4,973,394.77	3,476,104.80
Dispensing Booth	14	31-Dec-03 to 01-Oct-11	Utopia-Aire Pte Ltd.	No. 7 Kaki Bukit Place Eunos Teachpark,Singapur,416185	Not Sold	Brand new	Malaysia	13.33	2.83 to 10.58	9,557,646.96	4,758,214.69
Dissolution Tester	4	30-Jun-11 to 01-Oct-11	Copley Scientific	Colwic Quays Business Park,Private Road No-2,Colwick ,Nottingham,Ng4 2Jy Uk	Not Sold	Brand new	UK	13.33	10.33 to 10.58	5,461,001.80	3,952,965.96
Dissolved Oxygen Meter	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	225,636.21	225,636.21
Do Meter	1	13-Sep-12 to 13-Sep-12	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	USA	13.33	11.54 to 11.54	72,534.00	61,653.98
Drum Mixer	1	31-May-96 to 31-May-96	Myth Industries	1219/C,Khilgaon Chowrasta,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	85,000.00	-
Drum Pump Motor & Tube	2	31-Dec-03 to 31-Dec-03	Not available	Amx/2421/02/01/0951 Date 17/10/2002	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	109,096.00	10,911.92
Drum Pump,Air,Tube & Berrel Adapter	3	31-Dec-03 to 31-Dec-03	Not available	Amx/2421/02/01/0951 Date 17/10/2002	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	87,935.00	8,794.95
Dry Granulator Type-Tg 2000	1	31-Dec-03 to 31-Dec-03	Not available	Scb/2486/03/01/1608 Date 19/06/2003	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	442,712.00	44,275.83
Drying Cabinet	1	30-Jun-14 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK	13.33	13.33 to 13.33	540,532.58	540,418.74
Dust Extractor	7	31-Dec-00 to 12-Jun-12	Enovak Industrial Solver	Hossain Tower,75 Green Road,Farmgate,Dhaka	Not Sold	Brand new	Not Available	13.33	0 to 11.28	665,339.00	412,282.00
Electric Heater	1	23-Aug-12 to 23-Aug-12	Paradise Scientific Company	Mamun Plaza,31 Shahid Nazrul Islam Sharak (Hatkhola Road),Dhaha	Not Sold	Brand new	China	13.33	11.48 to 11.48	4,500.00	3,824.21
Electric Oven	1	31-Aug-08 to 31-Aug-08	Termaks As	Line 79 N-5057 Bergen	Not Sold	Brand new	Norway	13.33	7.5 to 7.5	791,353.60	405,565.80

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Electronic Balance	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	292,161.58	292,161.58
Evaporator	1	31-Jan-14 to 31-Jan-14	Sciencetec	75, Science Laboratory, Bs Bhaban, Dhanmondi, Dhaka.	Not Sold	Brand new	Not Available	13.33	12.92 to 12.92	520,500.00	499,896.88
Fabric Steam Drier	9	28-Feb-99 to 01-Oct-11	Foshan Goworld Laundry Equioment Co. Ltd.	Shenning Second Road,Foshan City,Guangdong Province,China	Not Sold	Brand new	China	13.33	0 to 10.58	1,571,729.50	859,401.05
Fabric Steam Iron	9	30-Apr-09 to 08-Nov-13	New Alook Electric Co.	Aziz Electrical Market,125 Nawabpur Road,Dhaka,Bangladesh	Not Sold	Brand new	KOREA	13.33	8.16 to 12.69	48,100.00	38,128.04
Fabric Washing Machine	9	28-Feb-99 to 01-Oct-11	Foshan Goworld Laundry Equioment Co. Ltd.	Shenning Second Road,Foshan City,Guangdong Province,China	Not Sold	Brand new	China	13.33	0 to 10.58	2,493,332.09	1,603,729.67
Filter Bag Drying System	1	01-Oct-11 to 01-Oct-11	Girbau Middle East Fzco	Girbau Middle East Fzco Reginal Office P.O Box 17881,Jabel Ali Dubai,Uae	Not Sold	Brand new	Spain	13.33	10.58 to 10.58	514,976.28	378,722.13
Filter Bag Washing System	1	01-Oct-11 to 01-Oct-11	Girbau Middle East Fzco	Girbau Middle East Fzco Reginal Office P.O Box 17881,Jabel Ali Dubai,Uae	Not Sold	Brand new	Spain	13.33	10.58 to 10.58	632,248.14	464,965.84
Filter Integrity Test System	1	30-Jun-13 to 30-Jun-13	Sartorius Stedim Biotech Gmbh	August-Spindler-Str.11,37079 Gottingen,Deutschland	Not Sold	Brand new	Germany	13.33	12.33 to 12.33	1,396,252.00	1,186,814.04
Filter Press & Transfer Pump	20	31-Dec-96 to 30-Jun-14	Matey Engineering Works	73,North Jatrabari,Dhaka	Not Sold	Brand new	Germany	13.33	0 to 13.33	3,653,038.00	1,566,274.56
Flame Photo Meter	2	31-Dec-05 to 31-Jan-14	Sciencetec	75, Science Laboratory, Bs Bhaban, Dhanmondi, Dhaka.	Not Sold	Brand new	Not Available	13.33	4.83 to 12.92	865,000.00	759,718.75
Flask Shaker	1	30-Jun-11 to 30-Jun-11	Puriest Pharma. Technology Co Ltd	B 410,Yingjiachuntian,175 No.Jinsheng Rd. Vanjing,China 211101,China	Not Sold	Brand new	China	13.33	10.33 to 10.33	178,484.53	124,940.39
Flux Pump	2	31-Dec-96 to 31-Dec-08	Flux-Gerate Gmbh	Talweg 12 ,D-75433 Maulbronn	Not Sold	Brand new	Germany	13.33	0 to 7.83	466,243.04	171,700.91
Friability Tester	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	383,387.17	383,387.17
Fume Hood	5	31-Dec-05 to 30-Jun-14	Labconco Corporation	8811 Prospect Avenue,Kansas City,Mo 64132-2696 Usa	Not Sold	Brand new	USA	13.33	4.83 to 13.33	2,792,215.02	2,475,308.20
Glass Condenser-Mdi	1	31-Dec-03 to 31-Dec-03	Scanchem International	A-44 Anand,17,Juhu Lane,Andheri (West)Mumbai-400 058,India	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	63,800.00	6,380.00
Hand Pallet Truck	13	01-Oct-11 to 30-May-13	Energypac	79,Shahid Tajuddin Ahmed Sharoni,Tejgaon Dhaka	Not Sold	Brand new	Not Available	13.33	10.58 to 12.25	897,253.53	696,888.55
Hand Pump & Scoop	12	31-Dec-03 to 31-Dec-03	Not available	Amx/2421/02/01/0951 Date 17/10/2002	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	105,368.00	10,566.92
Hardness Tester	8	31-Dec-07 to 30-Jun-14	Pharma Test	Siemensstrasse 5,D-63512 Hainburg/Germany	Not Sold	Brand new	Germany	13.33	6.83 to 13.33	5,224,014.21	3,958,719.21
Heating Mantle-Mdi	2	31-Dec-03 to 01-Oct-11	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK/EC	13.33	2.83 to 10.58	55,774.37	37,770.97
Hemacytometer	1	30-Nov-97 to 30-Nov-97	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	8,250.00	-
Herbs Cutting Machine	1	30-Jun-12 to 30-Jun-12	Pingyang Shida Imp And Exp Trading Co Ltd	Not available	Not Sold	Brand new	China	13.33	11.33 to 11.33	741,961.00	575,019.97
Herbs Grinding Machine	1	30-Jun-12 to 30-Jun-12	Pingyang Shida Imp And Exp Trading Co Ltd	Not available	Not Sold	Brand new	China	13.33	11.33 to 11.33	741,962.00	575,020.94

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Herbs Washing Machine	1	30-Jun-12 to 30-Jun-12	Pingyang Shida Imp And Exp Trading Co Ltd	Not available	Not Sold	Brand new	China	13.33	11.33 to 11.33	577,081.20	447,238.16
Hfa Gas Cylinder	10	27-Jun-12 to 27-Jun-12	Brenntag Bangladesh Services Ltd	Lalif Tower,7Th Floor,47 Kawran Bazar ,Tejgaon,Dhaka	Not Sold	Brand new	Not Available	13.33	11.32 to 11.32	425,000.00	329,362.08
High Pressure Liquid Chromotography	1	31-Dec-99 to 31-Dec-99	Not available	Not available	Not Sold	Brand new	Not Available	13.33	-	1,775,695.00	-
Holler Machine	1	31-Oct-03 to 31-Oct-03	Sultan Mill & Machinery Store	203/1,Nabab Pur Road,Dhaka	Not Sold	Brand new	Not Available	13.33	2.66 to 2.66	19,700.00	1,964.21
Hot Air Dryer	5	31-May-96 to 31-Dec-08	Atlas Copco	Not available	Not Sold	Brand new	Belgium	13.33	0 to 7.83	1,696,092.00	692,809.04
Hot Air Oven	6	01-Oct-11 to 30-May-13	Skilltech Traders	40A (Park), Raganigandha Market,Mirpur 14 -Dhaka	Not Sold	Brand new	Local	13.33	10.58 to 12.25	1,292,424.14	983,270.20
Hotplate With Magnetic Stirrer	1	30-Jun-14 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK	13.33	13.33 to 13.33	40,940.92	40,932.30
Hplc Grade Water Purifier	1	31-Jan-14 to 31-Jan-14	Sciencetec	75,Science Laboratory Road,Bs Bhabon Dhaka	Not Sold	Brand new	Germany	13.33	12.92 to 12.92	474,000.00	455,237.50
Imaje Ink Jet Printer	16	31-Jul-02 to 26-Sep-12	Sincos Engineers Ltd	Yakub South Centre (3Rd Floor),156 Lake Circus,Kalabagan,Dhaka,Bangladesh	Not Sold	Brand new	Not Available	13.33	1.41 to 11.57	16,543,875.05	9,665,407.46
Impulse Sealer	1	31-Dec-99 to 31-Dec-99	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	2,500.00	-
Incubator/Sterilization	5	30-Nov-07 to 01-Oct-11	Memmert	Memmert P.O. Box 1720 D-91107 Schwebach,Germany	Not Sold	Brand new	Germany	13.33	6.74 to 10.58	2,122,430.74	1,345,103.99
Industrial Rack	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	2,699,871.56	2,699,871.56
Jacketed Vessel	6	30-Apr-03 to 03-Jun-12	Skilltech Traders	40A(Park),Rajangianda Market,Mirpur-14,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	2.15 to 11.26	1,128,450.00	514,557.52
Karl Fischer Titrator	2	31-Dec-07 to 30-Jun-14	Metrohm Middle East Fzc	P.O.Box 120747,Sharjah-U.A.E	Not Sold	Brand new	U.A.E	13.33	6.83 to 13.33	2,004,827.73	1,705,934.45
Lable Over Printing Machine	9	31-Dec-95 to 30-Jun-14	Pack Leader Machinery Inc.	No.60,32 Nd Road Taichung Industrial Park Taichung City 40768,Taiwan	Not Sold	Brand new	TAIWAN	13.33	0 to 13.33	4,145,923.11	3,214,408.28
Laboratory Kneader Type-Lk5	1	31-Dec-03 to 31-Dec-03	Not available	Scb/2486/03/01/1608 Date 19/06/2003	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	594,910.00	59,493.90
Laminar Airflow Cabinet	17	31-Dec-02 to 30-Jun-14	Hiclean Tech.Co.Ltd	Room 1501,15/F,Spa Center,53-55 Lockhart Road,Wanchai,Hong Kong	Not Sold	Brand new	China	13.33	1.83 to 13.33	10,818,242.47	7,500,891.10
Laser Airborne Particle Counter	4	31-Dec-95 to 01-Oct-11	Particle Measuring Systems	5475 Airport Boulder, Colorado 80301,Usa	Not Sold	Brand new	USA	13.33	0 to 10.58	2,883,417.66	1,387,311.18
Leaflet Folding Machine	7	31-Dec-00 to 30-Jun-14	Origami Machines Pvt Ltd	Sr.No.11,Vadgaon (Kh) Lagadmala,Sinhgad Road,Pune-411041,India	Not Sold	Brand new	India	13.33	0 to 13.33	3,658,671.71	2,514,501.09
Leakage Testing Chamber	3	30-Jun-06 to 01-Oct-11	Erweka	Erweka Gmbh Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	5.32 to 10.58	801,001.44	560,541.57
Leakage Testing Device	2	30-Jun-11 to 31-Dec-13	Erweka	Erweka Gmbh Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	10.33 to 12.83	2,324,609.16	2,036,365.29
Lift	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	2,854,598.20	2,854,598.20

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Liquid Filling Machine	10	04-May-96 to 31-Dec-08	Mark Industries (Pvt) Ltd	348/1,Dilu Road Dhaka	Not Sold	Brand new	Local	13.33	0 to 7.83	711,000.00	265,850.00
Liquid Filling Sealing & Leb. Line	2	01-Oct-11 to 30-Jun-12	Jintan Weilong Filling M/C Co.Ltd	No.9,Hongshan Road,Jincheng Industrial Mpark,Jintan,Changzhou 213200,China	Not Sold	Brand new	China	13.33	10.58 to 11.33	2,588,151.50	1,921,332.81
Liquid Filter Machine	2	31-May-97 to 31-Jul-03	Mark Industries (Pvt) Ltd	348/1,Dilu Road Dhaka	Not Sold	Brand new	Not Available	13.33	0 to 2.41	116,000.00	5,800.00
Liquid Particle Counter	4	30-Jun-11 to 30-Jun-14	Partical Measuring Systems	5475 Airport Boulevard,Boulder,Colorada-80301-2339	Not Sold	Brand new	Not Available	13.33	10.33 to 13.33	5,171,002.23	4,759,925.04
Magnetic Stirrer	1	30-Jun-14 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK	13.33	13.33 to 13.33	584,023.75	584,023.75
Magnetic Stirrer With Hotplate	1	30-Jun-14 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK	13.33	13.33 to 13.33	88,943.40	88,943.40
Mechanical Shaker	1	30-Jun-14 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	Uk	13.33	13.33 to 13.33	325,877.88	325,877.88
Melting Points Apparatus	4	31-Dec-08 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK	13.33	7.83 to 13.33	2,737,939.58	2,141,597.22
Membraance Filter Holder	1	01-Oct-11 to 01-Oct-11	Sartorius Stedim	August-Spindler-Str.11,37079 Gottingen,Deutschland	Not Sold	Brand new	European	13.33	10.58 to 10.58	369,211.60	271,524.37
Memo Titrator	1	30-Jun-01 to 30-Jun-01	Methorn Ag	Not available	Not Sold	Brand new	Switzerland	13.33	0.32 to 0.32	1,065,750.00	-
Micro Biologial Incubator	4	31-Dec-99 to 30-Jun-14	Memmert	Co Kg,P.O. Box 1720,D-91107 Schwabach,Germany	Not Sold	Brand new	Germany	13.33	0 to 13.33	1,335,653.27	1,035,435.15
Mosture Analyzer	7	30-Apr-08 to 12-Dec-13	Precision Weighing Solution Co	House-191,Road-01,New Dohs Mohakhali,Dhaka,Bangladesh	Not Sold	Brand new	Japan	13.33	7.16 to 12.78	2,974,778.49	1,981,551.86
Motor Drive Type-Ar 402	1	31-Dec-03 to 31-Dec-03	Not available	Scb/2486/03/01/1608 Date 19/06/2003	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	115,575.00	11,558.95
Movable Basin	8	30-Jun-12 to 31-Jan-13	Skilltech Traders	40A (Park), Raganigandha Market,Mirpur 14 -Dhaka	Not Sold	Brand new	Local	13.33	11.33 to 11.92	147,950.00	123,997.44
Muffle France	3	01-Oct-11 to 30-Jun-14	Naberthern	Bahnhofstrabe 20,28865 Lilienthal/Bremen,Germany	Not Sold	Brand new	Germany	13.33	10.58 to 13.33	947,141.62	823,076.31
Multi Column Distillation Plant	1	31-Dec-95 to 31-Dec-95	Precision Weighing Solution Co	House-191,Road-01,New Dohs Mohakhali,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	139,455.00	-
Multi Mill	4	31-Jul-03 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	2.41 to 13.33	1,181,769.70	950,873.87
Multi Range Conductivity Meter	3	31-Dec-02 to 01-Oct-11	Mettler-Toledo Ag	Sonnenbergstrasse 74,8603 Schwerzenboch,Switzerlond	Not Sold	Brand new	Switzerland/China/Japan/Uk	13.33	1.83 to 10.58	317,777.92	185,045.01
Liquid Filter Machine	1	30-Jun-14 to 30-Jun-14	Mark Industries (Pvt) Ltd	348/1,Dilu Road Dhaka	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	43,186,486.00	42,667,727.00
Nitrogen Gas Cylinder Regulator	9	01-Oct-11 to 01-Oct-11	Boc Bangladesh Ltd.	285,Tajuddin Road Dhaka	Not Sold	Brand new	Bangladesh	13.33	10.58 to 10.58	514,956.10	378,707.31
Nominal Aperture	18	18-Oct-11 to 18-Oct-11	Bangladesh Scientific Instrument Company	107,Motijheel C/A,Dhaka	Not Sold	Brand new	Not Available	13.33	10.63 to 10.63	320,400.00	235,627.56
Osmometer	2	31-Dec-08 to 30-Jun-14	Gonotec Gmbh	Eisenacher Str 56 D-10823 Berlin	Not Sold	Brand new	Germany	13.33	7.83 to 13.33	1,908,486.57	1,383,429.63

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Particle Counter	1	30-Jun-14 to 30-Jun-14	Particle Measuring Systems	5475 Airport Boulder, Colorado 80301,Usa	Not Sold	Brand new	USA	13.33	13.33 to 13.33	995,331.08	995,331.08
Pass Box	15	31-Dec-07 to 01-Oct-11	Utopia -Aire Pte Ltd.	No.7 Kaki Bukit Place Eunos Techpark, Singapore-416185	Not Sold	Brand new	Malayshia	13.33	6.83 to 10.58	4,034,157.99	2,886,726.90
Penetrometer	1	30-Jun-11 to 30-Jun-11	Petrotest Instrumants Gmbh & Co. Kg	Ludwig Erhard Ring 13 15327 Dahlewitz	Not Sold	Brand new	Germany	13.33	10.33 to 10.33	727,506.23	509,254.24
Ph-Meter	15	30-Apr-08 to 04-Jun-14	Technoworth Associates Ltd.	78,Motijeeel C/A,Dhaka	Not Sold	Brand new	USA	13.33	7.16 to 13.26	1,363,000.86	1,013,250.20
Plastic Pallet	2	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	30,194,303.02	30,194,303.02
Polorimeter	4	31-Dec-08 to 30-Jun-14	Optical Activity Ltd	Old Station Road,Ramsey,Cambridgeshire,Pe26 1Nf,England	Not Sold	Brand new	England	13.33	7.83 to 13.33	3,688,255.85	2,844,178.74
Pre-Fabricated Building	1	31-Mar-03 to 31-Mar-03	Shanghi Tian Chou Air-Conditioning Clarifacation Equipent Ao Ltd	429 Min Feng Road,Cao Lu Industrial Park,Pudong New Area,Shanghai 201209,P.R.China	Not Sold	Brand new	China	13.33	2.07 to 2.07	4,023,963.00	402,398.91
Printer (Inkjet & Data)	2	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	2,587,547.75	2,587,547.75
Propellent Filter Unit For Inheller	2	31-Dec-02 to 31-Dec-02	Pall Pharmalab Filtration Pvt. Ltd	Santej Vadsar Road,Santej-382 721,Near Ahmedabad,Gujarat,India	Not Sold	Brand new	India	13.33	1.83 to 1.83	179,644.00	4,482.29
Refrigerator Type Auto Drier	2	31-Dec-03 to 31-Dec-03	Not available	Dkb/1413/02/01/0214 Date20/08/2002	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	566,012.00	14,161.63
S. S. Trolly	5	01-Oct-11 to 23-Jan-12	Skilltech Traders	40A (Park), Raganigandha Market,Mirpur 14 -Dhaka	Not Sold	Brand new	Local	13.33	10.58 to 10.89	201,119.14	149,781.36
S.S. Tank With Trolly	6	31-Aug-05 to 31-Mar-14	Pharmapack Engineering	Plot-8,Block-C,Rajuk Industrial Area,Fisons Road,Cherag Ali,Tongi-1711,Gazipur,Bangladesh	Not Sold	Brand new	LOCAL	13.33	4.49 to 13.08	453,000.00	224,021.59
S.S.Bucket	18	30-Jun-05 to 30-Jun-14	Bright Trading Corporation	1219/C,Khilgaon Chowrasta,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	4.32 to 13.33	164,371.00	104,856.68
S.S.Pressure Vassel	10	30-Nov-06 to 12-Nov-13	Skilltech Traders	40A(Park),Rajangianda Market,Mirpur-14,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	5.74 to 12.7	710,000.00	374,750.00
Sampling Thieves	10	31-Jul-12 to 31-Jul-12	Pharmamech Engineering Ltd.	38/5 North Auchpara Khapara Road Tongi-1711	Not Sold	Brand new	Bangladesh	13.33	11.41 to 11.41	109,000.00	88,335.43
Seiving/Shifter	20	31-Oct-05 to 01-Oct-11	Yenchen Machinery Co. Ltd.	No.38,Huaya 1St Rd, Kueishan Township,Taoyuan County,333 Taiwan	Not Sold	Brand new	TAIWAN	13.33	4.66 to 10.58	3,951,940.30	2,883,974.44
Sewing Machine	5	28-Nov-11 to 23-Aug-12	Olympia M/C Store	175,Nawabpur Road,Dhaka	Not Sold	Brand new	TAIWAN	13.33	10.74 to 11.48	27,900.00	22,632.62
Sieve Shakers "Spartan"	2	01-Oct-11 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK	13.33	10.58 to 13.33	749,392.57	654,002.17
Spectrophoto Meter	10	26-Dec-96 to 30-Jun-14	Shimadzu (Asia Pacific) Pte Ltd	79 Science Park Drive #02-01/08,Cintech Iv,Singapur Science Park 1, Singapore 118264	Not Sold	Brand new	Singapore	13.33	0 to 13.33	17,747,235.34	12,537,304.90
Ss Stol	209	31-Dec-12 to 07-Dec-13	Skilltech Traders	40A (Park), Raganigandha Market,Mirpur 14 -Dhaka	Not Sold	Brand new	Local	13.33	11.83 to 12.77	462,052.00	436,651.57
Stacker	2	01-Oct-11 to 01-Oct-11	Jungheinrich Lift Truck Singapore Pte Ltd.	14, Kwong Min Road, Singpore, 628715.	Not Sold	Brand new	Singapore	13.33	10.58 to 10.58	1,973,432.88	1,451,295.44
Stainless Steel Vat	583	31-Dec-98 to 18-Jun-14	Skilltech Traders	40A(Park),Rajangianda Market,Mirpur-14,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	0 to 13.3	19,868,487.03	11,880,564.93

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Standard Weight	8	01-Oct-11 to 25-Jun-14	F.M.Traders	House-24,Road-8,Sector-11,Uttara,Dhaka	Not Sold	Brand new	Local	13.33	10.58 to 13.32	499,713.83	432,011.18
Steam Vessel	1	21-Sep-11 to 21-Sep-11	Bright Trading Corporation	1219/C,Khilgaon Chowrasta,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	10.55 to 10.55	975,000.00	755,625.00
Stirrer	14	30-Apr-07 to 31-Dec-12	Ika India Private Ltd	Survey No-129/1,Bangalore-560060 Karnataka,India	Not Sold	Brand new	India	13.33	6.16 to 11.83	2,141,575.23	1,186,107.53
Stirrer Valander	1	31-Dec-99 to 31-Dec-99	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	50,000.00	-
Strip Packing Machine	3	31-Dec-95 to 31-Dec-03	Not available	Not available	Not Sold	Brand new	Not Available	13.33	0 to 2.83	920,111.16	85,528.97
Sugar Crushing Machine	1	01-Oct-11 to 01-Oct-11	Gmp China Ltd.	No.8 Jinliang Road,Zhuqiao,Nanhui,Shanghai 201323,China	Not Sold	Brand new	China	13.33	10.58 to 10.58	1,181,848.50	869,151.08
Suppository Disintegration Tester	1	31-Dec-02 to 31-Dec-02	Erweka	Erweka Gmbh Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	1.83 to 1.83	475,327.00	11,877.20
Suppository Hardness Tester	1	31-Dec-02 to 31-Dec-02	Erweka	Erweka Gmbh Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	1.83 to 1.83	177,270.00	4,434.90
Suppository Melting Point Tester	1	31-Dec-02 to 31-Dec-02	Erweka	Erweka Gmbh Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	1.83 to 1.83	92,927.00	2,317.20
Suppository Penetration Tester	1	31-Dec-02 to 31-Dec-02	Erweka	Erweka Gmbh Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	1.83 to 1.83	216,303.00	5,404.11
Table Balance	2	31-Jul-98 to 31-Jul-98	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	1,099.00	1.00
Tablet Compression (R&D Model)	1	31-Dec-06 to 31-Dec-06	Karnavata Engineering Ltd	S.No342,Nani Kadi Mehsana(N.G)382715,India	Not Sold	Brand new	India	13.33	5.83 to 5.83	781,341.40	253,932.56
Tablet Friability Tester	8	31-Jan-01 to 30-Jun-14	Pharma Test	Siemensstrasse 5,D-63512 Hainburg/Germany	Not Sold	Brand new	Germany	13.33	0 to 13.33	2,267,589.87	1,741,587.25
Tap Density Tester	4	31-Dec-05 to 30-Jun-14	Erweka	Postfach 1253 D-63130 Heusenstamm	Not Sold	Brand new	Germany	13.33	4.83 to 13.33	1,141,317.49	1,012,727.27
Temparature Meter	1	31-Mar-05 to 31-Mar-05	Chemie International	B,20/28 Babor Road,Mohammadpur,Dhaka	Not Sold	Brand new	USA	13.33	4.08 to 4.08	42,000.00	10,500.00
Thermostatic Water Bath	4	31-Jan-98 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	Uk	13.33	0 to 13.33	422,634.31	343,801.41
Tilting Kettle	6	01-Oct-11 to 01-Oct-11	Sukorun (Xiamen Electricity And Machinary Co.Ltd.	Room:A434 Lotus Mall Commerce Center No.28,Xianglianli Of Siming District ,Xiaman,China	Not Sold	Brand new	China	13.33	10.58 to 10.58	2,283,716.88	1,679,483.44
Tool Clean-Xi	1	01-Oct-11 to 01-Oct-11	Eliza Tool	Plot#09,Gala#02,102 And 202,Rajvidesh Building,Prime Industrial Complex, Sativili Road,Waliv, Vasai Road(East Vasai 401 208,Thane India	Not Sold	Brand new	India	13.33	10.58 to 10.58	472,947.94	347,813.81
Tool Storage Cabinet	8	01-Oct-11 to 01-Oct-11	Eliza Tool	Plot#09,Gala#02,102 And 202,Rajvidesh Building,Prime Industrial Complex, Sativili Road,Waliv, Vasai Road(East Vasai 401 208,Thane India	Not Sold	Brand new	India	13.33	10.58 to 10.58	3,152,984.56	2,318,757.31

Name of Machinary	Nos. of machine	Date of purchase	Name of supplier	Address of supplier	Year of Sale	Condition	Country of origin	Useful Economic Life at purchase	Estimated Remaining Useful Life	Total purchase price with other cost* (Amount in BDT)	Written down value (Amount in BDT)
Tools Inspection Kit	1	01-Oct-11 to 01-Oct-11	Eliza Tool	Plot#09,Gala#02,102 And 202,Rajvidesh Building,Prime Industrial Complex, Sativili Road,Waliv, Vasai Road(East Vasai 401 208,Thane India	Not Sold	Brand new	India	13.33	10.58 to 10.58	472,947.94	347,813.81
Tray Dryer	1	31-Dec-03 to 31-Dec-03	Precision Weighing Solution Co	House-191,Road-01,New Dohs Mohakhali,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	2.83 to 2.83	50,000.00	5,000.00
Turbidity Meter	2	24-Jun-12 to 31-Jan-14	Tecnoworth	78,Motijheel,Dhaka	Not Sold	Brand new	USA	13.33	11.31 to 12.92	278,753.00	250,104.44
Turn Table	1	01-Oct-11 to 01-Oct-11	F.D Enterprise Corporation	No.68,Jin-Hua Road,Lu-Ju,Tao-Yuan Taiwan 33848	Not Sold	Brand new	TAIWAN	13.33	10.58 to 10.58	385,355.99	283,397.22
Ultra Voilate Apparators & Accesso.	1	31-Dec-96 to 31-Dec-96	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	-	191,612.43	-
Ultrasonic Bath	4	30-Jun-11 to 30-Jun-14	Fisher Scientific Uk	Bishop Meadow Road,Loughborough,Leics Le11 5Rg,Uk	Not Sold	Brand new	UK	13.33	10.33 to 13.33	1,514,934.58	1,190,628.89
Ultrasonic Cleaning Unit/Bath	2	30-Jun-14 to 30-Jun-14	Technoworth Associates Ltd.	House-60,Road-10,Block-D,Banani,Dhaka,Bangladesh	Not Sold	Brand new	Local	13.33	13.33 to 13.33	808,844.24	808,844.24
Universal Gearing Type-Ug	1	31-Dec-03 to 31-Dec-03	Not available	Scb/2486/03/01/1608 Date 19/06/2003	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	157,972.00	15,796.04
Universal Oven	6	31-Dec-03 to 30-Jun-14	Memmert	Co Kg,P.O. Box 1720,D-91107 Schwabach,Germany	Not Sold	Brand new	Germany	13.33	2.83 to 13.33	1,331,150.59	1,272,408.02
Uv-Chamber & Sample Applicator For Tlc	1	01-Oct-11 to 01-Oct-11	Camag	Sonnenbergstrasse 74,8603 Schwerzenboch,Switzerlond	Not Sold	Brand new	Switzerland	13.33	10.58 to 10.58	1,202,277.96	440,032.11
Uv-Spectrophotometer	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	889,107.82	889,107.82
Vacum Oven	3	31-Dec-03 to 30-Jun-14	Memmert	Co Kg,P.O. Box 1720,D-91107 Schwabach,Germany	Not Sold	Brand new	Germany	13.33	2.83 to 13.33	2,186,315.21	1,582,144.84
Validator	1	30-Jun-10 to 30-Jun-10	Ge Inftaatructure Sensing	1100 Technology Park Drive,Billerica,Ma.01321	Not Sold	Brand new	USA	13.33	9.33 to 9.33	4,243,796.90	3,089,511.00
Viscometer	6	31-Dec-08 to 30-Jun-14	Brook Field Engineering Laboratories, Inc.	11 Commerce Bl Vd-Middleton,Ma 02346,U.S.A.	Not Sold	Brand new	USA	13.33	7.83 to 13.33	2,926,451.32	2,300,731.56
Volumetric Kf Titration	2	01-Oct-11 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	10.58 to 13.33	1,677,945.33	1,481,145.39
Vortex Mixture	2	01-Oct-11 to 04-Jun-14	Technoworth Associates Ltd.	78,Motijeeel C/A,Dhaka	Not Sold	Brand new	ITALY	13.33	10.58 to 13.26	76,264.56	63,480.34
Water Firtration System	1	01-Oct-11 to 01-Oct-11	Termo Fisher Scientific Llc	275Road Asheville, Nc 28804,Usa	Not Sold	Brand new	USA	13.33	10.58 to 10.58	689,382.52	506,983.41
Water Purifier	1	14-Dec-11 to 14-Dec-11	Enovak Industrial Solver	75,Green Road,Farmgate,Dhaka	Not Sold	Brand new	Local	13.33	10.78 to 10.78	275,000.00	213,125.00
Wet Granulator Type-Fgs	1	31-Dec-03 to 31-Dec-03	Not available	Scb/2486/03/01/1608 Date 19/06/2003	Not Sold	Brand new	Not Available	13.33	2.83 to 2.83	489,366.00	48,939.00
Wood Cutter Machine	1	31-May-03 to 31-May-03	Popular Metal & Electric	366,Mirhazir Bagh,West Jatrabari,Dhaka	Not Sold	Brand new	Not Available	13.33	2.24 to 2.24	60,000.00	6,000.00
Zone Reader	1	30-Jun-14 to 30-Jun-14	Not available	Not available	Not Sold	Brand new	Not Available	13.33	13.33 to 13.33	633,600.40	633,600.40

*Total Purchase Price with other cost includes invoice value including import duties and non-refundable purchase taxes, bank charge, insurance permium, carrige, clearing & forwarding agent's commission.

Details of the machineries required to be bought by the issuer, cost of the machineries, name of the suppliers, date of placement of order and the date or expected date of supply, etc.

The company has a plan to procure following machinery & equipment by using IPO Proceeds

Steroid & Hormone Project :

Machinery & Equipment								
Particulars	**Qty.**	**Name of the Supplier**	**Estimated Date of Placement of order**	**Estimated Year of Purchase**	**Estimated Year of Delivery**	**Total Amount in USD**	**Total Amount (In BDT crore)**	**Estimated life at the time of Acquisition**
Tablet & Capsule								
Rapid Mixture Granulator, Wet Granulator	1	Not Yet Decided	2016	2017	2017	187,500	1.575	13.33
60 kg FBD (Flued Bed Dryer)	1	Not Yet Decided	2016	2017	2017	62,500	0.525	13.33
Dry mill	1	Not Yet Decided	2016	2017	2017	35,000	0.294	13.33
Vibratory Sifter	2	Not Yet Decided	2016	2017	2017	31,500	0.265	13.33
IBC (Intermediate Bulk Container)	1	Not Yet Decided	2016	2017	2017	62,500	0.525	13.33
IBC (Intermediate Bulk Container) Bin	10	Not Yet Decided	2016	2017	2017	62,500	0.525	13.33
IBC (Intermediate Bulk Container) Bin	1	Not Yet Decided	2016	2017	2017	26,250	0.221	13.33
Tablet Press Machine	2	Not Yet Decided	2016	2017	2017	1,000,000	8.400	13.33
Capsule Filling+Polishing	2	Not Yet Decided	2016	2017	2017	375,000	3.150	13.33
Vacuum Transfer	4	Not Yet Decided	2016	2017	2017	25,000	0.210	13.33
Coating Machine	2	Not Yet Decided	2016	2017	2017	315,000	2.646	13.33
Blister Machine (Primary Packing)	2	Not Yet Decided	2016	2017	2017	625,000	5.250	13.33
Injectable								
Sterile Compounding	1	Not Yet Decided	2016	2017	2017	106,250	0.893	13.33
Mobile LAF (Laminar Air Flow)	1	Not Yet Decided	2016	2017	2017	12,500	0.105	13.33

Particulars	Qty.	Name of the Supplier	Estimated Date of Placement of order	Estimated Year of Purchase	Estimated Year of Delivery	Total Amount in USD	Total Amount (In BDT crore)	Estimated life at the time of Acquisition
Container Washing m/c	1	Not Yet Decided	2016	2017	2017	187,500	1.575	13.33
Sterilization Tunnel	1	Not Yet Decided	2016	2017	2017	647,500	5.439	13.33
Sterile Filling/Sealing m/c	1	Not Yet Decided	2016	2017	2017	500,000	4.200	13.33
Inspection table	1	Not Yet Decided	2016	2017	2017	1,250	0.011	13.33
Sterile Labeling m/c	1	Not Yet Decided	2016	2017	2017	62,500	0.525	13.33
Fixed LAF (Laminar Air Flow)	1	Not Yet Decided	2016	2017	2017	2,500	0.021	13.33
Autoclave	1	Not Yet Decided	2016	2017	2017	265,625	2.231	13.33
Cream & Ointment								
Compounding vessel	3	Not Yet Decided	2016	2017	2017	225,000	1.890	13.33
Planetary mixer	1	Not Yet Decided	2016	2017	2017	31,250	0.263	13.33
Filling Machine	1	Not Yet Decided	2016	2017	2017	562,500	4.725	13.33
Nasal spray (steroid) line								
Bottle Washing	1	Not Yet Decided	2016	2017	2017	50,000	0.420	13.33
DHS (Dry Heat Sterilizer)	1	Not Yet Decided	2016	2017	2017	125,000	1.050	13.33
Processing Vessel	1	Not Yet Decided	2016	2017	2017	75,000	0.630	13.33
Buffer tank with 4 wheel	1	Not Yet Decided	2016	2017	2017	37,500	0.315	13.33
Filling & crimping machine automatic	1	Not Yet Decided	2016	2017	2017	62,500	0.525	13.33
Sticker Labeling machine auto	1	Not Yet Decided	2016	2017	2017	37,500	0.315	13.33
Batch coding & mini carton	1	Not Yet Decided	2016	2017	2017	3,750	0.032	13.33
Image printer	1	Not Yet Decided	2016	2017	2017	10,000	0.084	13.33
Master carton self adhesive closer	1	Not Yet Decided	2016	2017	2017	6,250	0.053	13.33
MDI inhaler (steroid) line								
Preparation Vessel	2	Not Yet Decided	2016	2017	2017	150,000	1.260	13.33
Can Cleaner	1	Not Yet Decided	2016	2017	2017	125,000	1.050	13.33
Filling Machine	2	Not Yet Decided	2016	2017	2017	75,000	0.630	13.33
Vacuum Crimper	1	Not Yet Decided	2016	2017	2017	12,500	0.105	13.33
Propellant Filler	1	Not Yet Decided	2016	2017	2017	25,000	0.210	13.33
Spray checking and sticker labeling	1	Not Yet Decided	2016	2017	2017	12,500	0.105	13.33
Eye drop								
Compounding Vessel	2	Not Yet Decided	2016	2017	2017	150,000	1.260	13.33
Filling & Sealing Machine	2	Not Yet Decided	2016	2017	2017	125,000	1.050	13.33
Lotion								
Mixture	2	Not Yet Decided	2016	2017	2017	125,000	1.050	13.33
Filling Machine	2	Not Yet Decided	2016	2017	2017	75,000	0.630	13.33
QC & Microbiology	1	Not Yet Decided	2016	2017	2017	375,000	3.000	13.33
Laundry								
Dress Washing & Drying Machine	2	Not Yet Decided	2016	2017	2017	55,000	0.462	13.33
Sterile Dress Holding Cabinet	2	Not Yet Decided	2016	2017	2017	20,000	0.168	13.33
Machinery & Equipment Total :							**59.86**	

Oncology Project :

Machinery & Equipment								
Particulars	**Qty.**	**Name of the Supplier**	**Estimated Date of placement of order**	**Estimated Year of Purchase**	**Estimated Year of Delivery**	**Total Amount in USD**	**Total Amount (In BDT crore)**	**Estimated life at the time of Acquasition**
Tablet & Capsule								
Rapid Mixture Granulator, Wet Granulator	1	Not Yet Decided	2017	2018	2018	187,500	1.575	13.33
60 kg FBD (Flued Bed Dryer)	1	Not Yet Decided	2017	2018	2018	62,500	0.525	13.33
Dry mill	1	Not Yet Decided	2017	2018	2018	35,000	0.294	13.33
Vibratory Sifter	2	Not Yet Decided	2017	2018	2018	31,500	0.265	13.33
IBC (Intermediate Bulk Container) Blender	1	Not Yet Decided	2017	2018	2018	62,500	0.525	13.33
IBC (Intermediate Bulk Container) Bin	3	Not Yet Decided	2017	2018	2018	19,875	0.167	13.33
IBC (Intermediate Bulk Container) Bin	1	Not Yet Decided	2017	2018	2018	26,250	0.221	13.33
Tablet Press	2	Not Yet Decided	2017	2018	2018	1,000,000	8.400	13.33
Capsule Filling+Polishing	2	Not Yet Decided	2017	2018	2018	375,000	3.150	13.33
Vacuum Transfer	3	Not Yet Decided	2017	2018	2018	18,750	0.158	13.33
Coating Machine	1	Not Yet Decided	2017	2018	2018	157,500	1.323	13.33
Blister	1	Not Yet Decided	2017	2018	2018	312,500	2.625	13.33
Injectable								
Sterile Compounding	1	Not Yet Decided	2017	2018	2018	106,250	0.893	13.33
Mobile LAF (Laminar Air Flow)	1	Not Yet Decided	2017	2018	2018	12,500	0.105	13.33
Container Washing m/c	1	Not Yet Decided	2017	2018	2018	187,500	1.575	13.33
Sterilization Tunnel	1	Not Yet Decided	2017	2018	2018	562,500	4.725	13.33
Sterile Filling/Sealing m/c	1	Not Yet Decided	2017	2018	2018	500,000	4.200	13.33
Inspection table	1	Not Yet Decided	2017	2018	2018	1,250	0.011	13.33
Sterile Labeling m/c	1	Not Yet Decided	2017	2018	2018	62,500	0.525	13.33
Fixed LAF (Laminar Air Flow)	1	Not Yet Decided	2017	2018	2018	2,500	0.021	13.33
Autoclave	1	Not Yet Decided	2017	2018	2018	250,000	2.100	13.33
QC & Microbiology	1	Not Yet Decided	2017	2018	2018	312,500	2.625	13.33
Laundry								
Dress Washing & Drying Machine	2	Not Yet Decided	2017	2018	2018	55,000	0.462	13.33
Sterile Dress Holding Cabinet	3	Not Yet Decided	2017	2018	2018	28,125	0.236	13.33
Machinery & Equipment Total :							**36.70**	

Utility								
Heating, Ventilating and Air Conditioning System (HVAC)- Air Handling Unit, Chiller, Pump, Ducting etc.	1	Not Yet Decided	2017	2018	2018	2,500,000	21.000	13.33
Building Management System (BMS)- Access Control, Alam Monitor, Control Panel, CCTV set up cost, Security Automation, PA System, Security and Observation.	1	Not Yet Decided	2017	2018	2018	375,000	3.000	13.33
Central Vacuum	2	Not Yet Decided	2017	2018	2018	10,000	0.084	13.33
Air Compressor	1	Not Yet Decided	2017	2018	2018	25,000	0.210	13.33

Particulars	Qty.	Name of the Supplier	Estimated Date of placement of order	Estimated Year of Purchase	Estimated Year of Delivery	Total Amount in USD	Total Amount (In BDT crore)	Estimated life at the time of Acquasition
Purified Water & Water for Injection Generation	1	Not Yet Decided	2017	2018	2018	562,500	4.725	13.33
Purified Water & Water for Injection Distribution	1	Not Yet Decided	2017	2018	2018	562,500	4.725	13.33
Lift	4	Not Yet Decided	2017	2018	2018	150,000	1.260	13.33
Utility Total :							**35.00**	

Warehouse								
Particulars	**Qty.**	**Name of the Supplier**	**Estimated Date of placement of order**	**Estimated Year of Purchase**	**Estimated Year of Delivery**	**Total Amount in USD**	**Total Amount (In BDT crore)**	**Estimated life at the time of Acquasition**
Dispensing Booth	2	Not Yet Decided	2017	2018	2018	62,500	0.525	13.33
Weighting balances	5	Not Yet Decided	2017	2018	2018	20,000	0.168	13.33
Rack	1	Not Yet Decided	2017	2018	2018	125,000	1.050	13.33
Fork lift	3	Not Yet Decided	2017	2018	2018	112,500	0.945	13.33
Reach truck	2	Not Yet Decided	2017	2018	2018	150,000	1.260	13.33
Pallet	1	Not Yet Decided	2017	2018	2018	125,000	1.050	13.33
Warehouse Total :							**5.00**	

Ayurvedic, Modern Herbal & Nutraceuticals Project :

Machinery & Equipment								
Particulars	**Qty.**	**Name of the Supplier**	**Estimated Date of placement of order**	**Estimated Year of Purchase**	**Estimated Year of Delivery**	**Total Amount in USD**	**Total Amount (In BDT crore)**	**Estimated life at the time of Acquasition**
Herbs Processing								
Herbs Extraction Plant	2	Not Yet Decided	2017	2018	2018	625,000	5.250	13.33
Herbs processing plant	1	Not Yet Decided	2017	2018	2018	437,500	3.675	13.33
Herbs Softener	1	Not Yet Decided	2017	2018	2018	43,875	0.369	13.33
Herbs Cutting machine	1	Not Yet Decided	2017	2018	2018	24,375	0.205	13.33
Herbs Washing Machine	1	Not Yet Decided	2017	2018	2018	24,375	0.205	13.33
Herbs Crushing Machine	1	Not Yet Decided	2017	2018	2018	29,250	0.246	13.33
Herbs Grinding Machine	1	Not Yet Decided	2017	2018	2018	19,500	0.164	13.33
Vacuum Dryer	1	Not Yet Decided	2017	2018	2018	58,500	0.491	13.33
Pulverizer	1	Not Yet Decided	2017	2018	2018	34,125	0.287	13.33
Spray Dryer	1	Not Yet Decided	2017	2018	2018	938	0.008	13.33
Granulation								
Fluid Bed Dryer	1	Not Yet Decided	2017	2018	2018	200,000	1.680	13.33
Rapid Mixer Granulator	1	Not Yet Decided	2017	2018	2018	200,000	1.680	13.33
Co Mill	1	Not Yet Decided	2017	2018	2018	18,750	0.158	13.33
Vibratory Sifter	1	Not Yet Decided	2017	2018	2018	18,750	0.158	13.33
Roller Compactor	1	Not Yet Decided	2017	2018	2018	100,000	0.840	13.33
Blender	1	Not Yet Decided	2017	2018	2018	75,000	0.630	13.33
Tablet Pressing								
Tablet Press machine	1	Not Yet Decided	2017	2018	2018	250,000	2.100	13.33
Coating machine	1	Not Yet Decided	2017	2018	2018	250,000	2.100	13.33
Lifting Column	1	Not Yet Decided	2017	2018	2018	97,500	0.819	13.33
Tablet Bin	8	Not Yet Decided	2017	2018	2018	54,600	0.459	13.33

Particulars	Qty.	Name of the Supplier	Estimated Date of placement of order	Estimated Year of Purchase	Estimated Year of Delivery	Total Amount in USD	Total Amount (In BDT crore)	Estimated life at the time of Acquasition
Capsule Filling								
Capsule Filling machine	1	Not Yet Decided	2017	2018	2018	250,000	2.100	13.33
Lifting Column	1	Not Yet Decided	2017	2018	2018	97,500	0.819	13.33
Capsule bin	8	Not Yet Decided	2017	2018	2018	54,600	0.459	13.33
Syrup Filling								
Bottle Washing machine	2	Not Yet Decided	2017	2018	2018	200,000	1.680	13.33
Bottle Dryer	1	Not Yet Decided	2017	2018	2018	93,750	0.788	13.33
Syrup Manufacturing Vessel	2	Not Yet Decided	2017	2018	2018	500,000	4.200	13.33
Syrup Storage Vessel	2	Not Yet Decided	2017	2018	2018	487,500	4.095	13.33
Sugar melting vessel	1	Not Yet Decided	2017	2018	2018	100,000	0.840	13.33
Sugar storage vessel	1	Not Yet Decided	2017	2018	2018	125,000	1.050	13.33
CMC melting vessel	2	Not Yet Decided	2017	2018	2018	150,000	1.260	13.33
Turn Table	1	Not Yet Decided	2017	2018	2018	687,500	5.775	13.33
Inspection Machine (before Filling)	2	Not Yet Decided	2017	2018	2018			
Syrup Filling machine	2	Not Yet Decided	2017	2018	2018			
Capping Machine	2	Not Yet Decided	2017	2018	2018			
Inspection Machine (after capping)	2	Not Yet Decided	2017	2018	2018			
Labeling machine	2	Not Yet Decided	2017	2018	2018			
Ink Jet Printer	2	Not Yet Decided	2017	2018	2018	17,500	0.140	13.33
Cream & Ointment								
Emulsifier	1	Not Yet Decided	2017	2018	2018	150,000	1.260	13.33
Oil Phase vessel	1	Not Yet Decided	2017	2018	2018			
Wax Phase Vessel	1	Not Yet Decided	2017	2018	2018			
Tube Filling machine	1	Not Yet Decided	2017	2018	2018			
Rub filling machine	1	Not Yet Decided	2017	2018	2018			
Ink Jet Printer	1	Not Yet Decided	2017	2018	2018	8,750	0.070	13.33
Sachet Filling								
Sachet Filling Machine	1	Not Yet Decided	2017	2018	2018	150,000	1.260	13.33
Ink Jet Printer	1	Not Yet Decided	2017	2018	2018	8,750	0.070	13.33
Bin	5	Not Yet Decided	2017	2018	2018	34,125	0.287	13.33
Common Use								
Clean Room Equipments	1	Not Yet Decided	2017	2018	2018	48,750	0.410	13.33
SS Furniture & Utensils	1	Not Yet Decided	2017	2018	2018	75,000	0.600	13.33
IPQC instruments	1	Not Yet Decided	2017	2018	2018	62,500	0.500	13.33
IPQC Furniture	1	Not Yet Decided	2017	2018	2018	31,250	0.250	13.33
Bin washing & drying machine	1	Not Yet Decided	2017	2018	2018	48,750	0.410	13.33
De-blistering machine	1	Not Yet Decided	2017	2018	2018	4,875	0.041	13.33
Batch Printing machine	1	Not Yet Decided	2017	2018	2018	4,875	0.041	13.33
Leaflet folding machine	1	Not Yet Decided	2017	2018	2018	4,875	0.041	13.33
Soft Gelatin								
Soft Gelatin Filling Machine	1	Not Yet Decided	2017	2018	2018	125,000	1.050	13.33
Drying Machine	1	Not Yet Decided	2017	2018	2018	48,750	0.410	13.33
Bin	5	Not Yet Decided	2017	2018	2018	34,375	0.289	13.33
Hard Gelatin								
Hard Gelatin Filling Machine	1	Not Yet Decided	2017	2018	2018	125,000	1.050	13.33
Bin	5	Not Yet Decided	2017	2018	2018	34,375	0.289	13.33
Primary Packing								
Blister Pack machine for Tablet	1	Not Yet Decided	2017	2018	2018	375,000	3.150	13.33
Blister Pack machine for Capsule	1	Not Yet Decided	2017	2018	2018	375,000	3.150	13.33
Blister Pack machine for Gelatin	1	Not Yet Decided	2017	2018	2018	237,500	1.995	13.33
Blister Pack machine for Tube	1	Not Yet Decided	2017	2018	2018	237,500	1.995	13.33
Container Filling Line (Tab/Cap)	1	Not Yet Decided	2017	2018	2018	375,000	3.150	13.33
Container Filling Line (cream/oil)	1	Not Yet Decided	2017	2018	2018	375,000	3.150	13.33

Particulars	Qty.	Name of the Supplier	Estimated Date of placement of order	Estimated Year of Purchase	Estimated Year of Delivery	Total Amount in USD	Total Amount (In BDT crore)	Estimated life at the time of Acquasition
Secondary Packing								
Conveyor belt	8	Not Yet Decided	2017	2018	2018	30,000	0.240	13.33
Ink Jet Printer	8	Not Yet Decided	2017	2018	2018	70,000	0.560	13.33
Sticker labeling machine	2	Not Yet Decided	2017	2018	2018	37,500	0.315	13.33
Shrink Warf machine	1	Not Yet Decided	2017	2018	2018	37,500	0.315	13.33
SS Table	8	Not Yet Decided	2017	2018	2018	2,500	0.020	13.33
SS Cabinet	8	Not Yet Decided	2017	2018	2018	4,000	0.032	13.33
Hydraulic trolley	5	Not Yet Decided	2017	2018	2018	12,500	0.100	13.33
Vacuum Cleaner	5	Not Yet Decided	2017	2018	2018	12,500	0.100	13.33
QC Instruments								
Validation instruments	1	Not Yet Decided	2017	2018	2018	125,000	1.000	13.33
Lab Furniture	1	Not Yet Decided	2017	2018	2018	50,000	0.400	13.33
QC Instruments	1	Not Yet Decided	2017	2018	2018	1,250,000	10.000	13.33
Others								
Laundry equipments	1	Not Yet Decided	2017	2018	2018	62,500	0.500	13.33
Office and others furniture	1	Not Yet Decided	2017	2018	2018	62,500	0.500	13.33
Contingency	1	Not Yet Decided	2017	2018	2018	250,000	2.000	13.33
Machinery & Equipment Total :							**85.72**	

Utility								
Heating, Ventilating and Air Conditioning System (HVAC)- Air Handling Unit, Chiller, Pump, Ducting etc.	1	Not Yet Decided	2017	2018	2018	2,812,500	22.500	13.33
Lift	1	Not Yet Decided	2017	2018	2018	150,000	1.200	13.33
Canteen Furniture & Facility	1	Not Yet Decided	2017	2018	2018	12,500	0.100	13.33
Air Compressor	1	Not Yet Decided	2017	2018	2018	100,000	0.800	13.33
Generator	1	Not Yet Decided	2017	2018	2018	750,000	6.000	13.33
Boiler	1	Not Yet Decided	2017	2018	2018	250,000	2.000	13.33
Water System	1	Not Yet Decided	2017	2018	2018	250,000	2.000	13.33
Fork Lift	1	Not Yet Decided	2017	2018	2018	25,000	0.200	13.33
Electrical Work	1	Not Yet Decided	2017	2018	2018	625,000	5.000	13.33
Split type A/C	1	Not Yet Decided	2017	2018	2018	75,000	0.600	13.33
Utility Total :							**40.40**	

Warehouse								
Particulars	**Qty.**	**Name of the Supplier**	**Estimated Date of placement of order**	**Estimated Year of Purchase**	**Estimated Year of Delivery**	**Total Amount in USD**	**Total Amount (In BDT crore)**	**Estimated life at the time of Acquasition**
Racks	1	Not Yet Decided	2017	2018	2018	62,500	0.500	13.33
Pallets	1	Not Yet Decided	2017	2018	2018	12,500	0.100	13.33
Balance	1	Not Yet Decided	2017	2018	2018	62,500	0.500	13.33
Warehouse Total :							**1.10**	

In case the machineries are yet to be delivered, the date of quotations relied upon for the cost estimates given shall also be mentioned

As at 30 June 2014, Cost accumulated against machinery import is Tk. 250,557,321 for which letter of credit are opened details are given below:

Sl. No.	Name of Machinery	Date of Quotation	Estimated Total Value
1	Water Shower Sterilizer	27-Jul-11	11,445,929
2	Lika Plastic Pallet	31-Dec-12	20,601,735
3	Bus Bar Trunking System	1-Sep-13	28,973,395
4	Low Voltage Switch Gear	1-Sep-13	31,142,216
5	Walk In Type Stability Chamber	20-May-12	3,234,152
6	Dry Heat Sterilizer	6-Feb-13	25,614,673
7	Ultrasonic Ampoule Washing Machine	28-May-13	9,377,314
8	Automatic Container Rotary Washing Machine	28-Aug-13	4,804,819
9	Rhine Brand Cargo/Passenger Lift	11-Dec-13	5,156,030
10	Rhine Brand Cargo/Passenger Lift	11-Dec-13	2,677,668
11	Rhine Brand Cargo/Passenger Lift	11-Dec-13	3,076,259
12	Hot Water Generation System	25-Nov-13	746,057
13	Manufacturing Vessele	27-Jan-14	30,244,887
14	Steam Boiler	11-Sep-13	625,451
15	Wooden Plastic Platform	31-Mar-14	6,867,250
16	Laboratory Furniture	2-Aug-14	1,131,933
17	Automatic Bang Washing Machine	10-Mar-13	1,528,949
18	Laundry Equipment	4-Aug-14	1,398,952
19	Central Air Conditioning System	19-Apr-14	920,467
20	Central Air Conditioning System	19-Apr-14	16,540,595
21	Air Handing Unit	19-Apr-14	43,663,281
22	Air Handing Unit	19-Apr-14	785,310
Total			**250,557,321**

If plant is purchased in brand new condition then it should be mentioned;

The company purchased all the Plants in brand new condition. In this connection, Auditor's certificate is as follows:

Auditors' Disclosure:

During the course of our audit, we have examined the relevant papers of plant and machinery and observed that, no re-conditioned or second-hand plant & machinery is used by The ACME Laboratories Limited (including those acquired as a result of amalgamation of The ACME Specialized Pharmaceuticals Limited).

Sd/-
PINAKI & COMPANY
Chartered Accountants

Date, Dhaka;
June 8, 2015

Details of the second hand or reconditioned machineries bought or proposed to be bought, if any, including the age of the machineries, balance estimated useful life, etc. as per PSI certificates of the said machineries as submitted to the Commission;

The company uses no re-conditioned or second-hand plant & machinery. It has also no proposal to buy second hand or reconditioned machineries.

BLOW FILL SEAL (BFS)- LVP & SVP
AND
LIQUID & SEMI-SOLID UNITS



A world class facility to manufacture lifesaving Intravenous Fluids

A Physical verification report by the Issue Manager(s) regarding the properties as submitted to the Commission

V I S I T R E P O R T

Particulars			
Name of Company	:	**The ACME Laboratories Limited**	
Head Office	:	Court de la ACME, 1/ 4, Kallayanpur, Mirpur Road, Dhaka-1207.	
FactoryAddress	:	Dhulivita, Dhamrai, Dhaka, Bangladesh.	
Date of Visit	:	6 February 2016	
Visited by	:	1. Nasrin Sultana	Chief Executive Officer ICB Capital Management Ltd.
		2. Mujibur Rahman Khan	Deputy Chief Executive Officer ICB Capital Management Ltd.
Accompanied by	:	1. Mr. Zahangir Alam, FCMA	Chief Financial Officer The ACME Laboratories Limited
		2.Mr. Rafiqul Islam, ACS	Company Secretary The ACME Laboratories Limited

Description of Head Office	
Nature of Business	Pharmaceuticals Company
Location& Area of Land	1/ 4, Kallayanpur, Mirpur Road, Dhaka. Total area of land 62 decimals.
Building and Civil Construction in details	18 storied modern building consist of total area 145,195 square feet.
Building facilities and Condition	Well equipped, necessary safety measures including fire hydrant system are in place. Besides, as a part of risk management process the corporate building are insured.
No. of Departments	8

Description of Factory	
Factory location& Area of Land	Dhulivita, Dhamrai, Dhaka, Bangladesh. Total area of land 10.08 acres.
Factory Building, Civil Construction and Condition	There are 5 separate manufacturing plants at factory building namely Solid Dosage unit; BFS (LVP& SVP) and Liquid & Semisolid unit, Cephalosporin unit, General unit and Herbal, Nutraceuticals & Ayurvedic unit. At factory sight, there are three quality operation units. Besides, Engineering, Factory Administration, Warehouse building also available at site. Total consist of 900,000 sqft (approx.).
No. of Plants	6 (Considering LVP& SVP and Liquid & Semisolid unit as two seperate plants)
ETP	A modern ETP covering area 8,232 sqft.
Machinery and Utilities	In the prospectus the issuer mentioned, they bought all the machineries at brand new condition. After visiting the factory site we are absolutely convince with their reports.

Description of Sales Centre	
No. of Sales Centre	20
Ownership of the Sales Centre	The Company operates its distribution activities through 20 Sales Centre located all over the country. Out of which 9 owns by the Company.
Building, Civil Construction and Condition	Most of the buildings are multistoried, well equipped, and newly built.

Remarks:	
The issuer has been running its business for more than 6 decades and in course of visit, we found that all the manufacturing units are functioning as usual.	
Signed by	
Sd/- **(Nasrin Sultana)** Chief Executive Officer	**Sd/-** **(Mujibur Rahman Khan)** Deputy Chief Executive Officer

If the issuer is entitled to any intellectual property right or intangible asset, full description of the property, whether the same are legally held by the issuer and whether all formalities in this regard have been complied with

ACME owns software, which was recognized as an Intangible Asset in the Financial Statements under the head of Non Current Assets. The cost of acquiring and developing computer software for internal use as well as for external users are capitalized as Intangible Asset. In this regard, the company had entered into a sub-licence agreement with IBCS-PRIMAX Software (Bangladesh) Ltd. vide agreement no. BA-OPN-FUDA-821159-28-AUG-06, dated May 15, 2008 to use the software. Details of the asset are discussed in the notes no. 7 of the Financial Statements.

Full description of other properties of the issuer

Total properties of the ACME are categorized as Land, Building, Vehicles, Machinery & Equipment, Utilities, Electrical equipment and office Equipment, among which major of them are shortly described in above and summary of remaining categories are given below:

(Amount in BDT)

Sl No.	Name of the Assets	No. of Assets	WDV as at 30 June 2014
1	Vehicle	232	220,253,907
2	Furniture and fixture	N/A	101,726,732
3	Office Equipment	N/A	40,279,355
4	Utilities, Electrical Installation & Eng.	N/A	1,067,915,835

In addition to above, ACME has an Investment Property for which the company follows fair value model as subsequent measurement. During the year 2013-2014, the valuation was conducted by an Independent valuer name MASIH MUHITH HAQUE & CO. Chartered Accountants.

The details of the building are stated in the following table-

(Amount in BDT)

SL No.	Location	Particulars	Area (sft)	Rate per sft	Estimated Life	Unexpired Life	Estimated Fair Value as at 30.06.2014
	Building – A						
1	Foundation	Civil Construction	14,650	578.075	40	36	8,468,799
2	Ground Floor	Civil Construction	14,650	593.275	40	36	8,691,479
3	Foundation (Pile Foundation for 3 Storied Building)	Civil Construction	1,800	1,156,288	40	36	2,081,318
	Building – A						
4	Ground Floor	Civil Construction	1,800	2,047.934	40	36	3,686,281
5	1st Floor	Civil Construction	1,800	1,809.513	40	36	3,257,123
Total			**34,700.00**				**26,185,000**

Plan of Operation and Discussion of Financial Condition

The company's revenues and results from operations, Statement of Financial position, Changes in Financial Position and Statement of Cash Flows for the last five years are mentioned below:

Revenue and Results from operation:

(Amount in BDT)

Particulars	2013-2014	2012-2013	2011-2012	2010-2011	2009-2010
Revenue	10,217,931,465	8,973,319,332	8,838,091,913	6,996,750,681	5,557,237,718
Cost of Goods Sold	6,237,792,554	5,721,020,810	5,697,479,102	4,540,790,741	3,649,626,560
Gross Profit/(Loss)	3,980,138,911	3,252,298,522	3,140,612,811	2,455,959,940	1,907,611,158
Other income	108,071,977	20,146,796	17,992,913	12,096,145	19,644,640
Net Profit before tax	1,204,844,233	810,707,935	802,304,895	584,141,913	364,490,469
Provision for Income Tax:					
Current Tax expense	426,636,328	304,015,476	305,940,093	218,905,630	136,683,926
Deferred Tax (income)/expense	(115,682,993)	996,665	20,236,406	21,084,983	-
Net Profit after tax	**893,890,898**	**505,695,794**	**476,128,396**	**344,151,300**	**227,806,543**
Gain/(Loss) on Marketable Securities (Unrealized)	841,041	-	-	-	-
Total Comprehensive Income for the year	**894,731,939**	**505,695,794**	**476,128,396**	**344,151,300**	**227,806,543**

A. Statement of Financial Position

Particulars	As at 30.06.2014	As at 30.06.2013	As at 30.06.2012	As at 30.06.2011	As at 30.06.2010
Assets					
Non-Current Assets :	**15,544,508,282**	**8,684,201,210**	**6,993,694,379**	**6,140,710,979**	**1,548,636,643**
Property, Plant and Equipment	15,511,897,086	8,306,210,678	6,615,633,325	5,762,752,567	1,197,143,553
Intangible Assets	286,875	338,132	408,654	528,472	20,000
Investment in Shares	6,139,321	351,467,400	351,467,400	351,467,400	351,467,400
Preliminary Expenses	-	-	-	5,690	5,690
Investment Property	26,185,000	26,185,000	26,185,000	25,956,850	-
Current Assets:	**6,635,062,802**	**7,889,442,833**	**5,738,665,873**	**3,669,103,044**	**2,688,889,318**
Inventories	2,223,003,434	1,886,267,051	1,781,058,760	1,271,611,575	811,183,318
Trade Receivable	644,867,067	471,021,187	393,373,660	228,023,633	166,006,224
Other Receivable	74,526,105	76,067,715	56,095,089	14,340,585	6,462,000
Advance, Deposits & Pre-Payments	1,097,408,239	2,347,694,271	2,126,780,980	1,202,554,410	1,276,005,733
Advance Income Tax	1,334,147,374	1,273,276,904	905,905,040	666,301,708	
Material In Transit	294,476,484	162,465,596	309,970,102	173,392,545	335,888,303
Term Deposit	553,201,740	1,220,000,000	-	-	
Cash and Cash Equivalents	413,432,359	452,650,109	165,482,242	112,878,588	93,343,740
TOTAL ASSETS	**22,179,571,084**	**16,573,644,043**	**12,732,360,252**	**9,809,814,023**	**4,237,525,961**
EQUITY AND LIABILITIES					
Shareholders Equity:	**10,692,163,182**	**9,517,448,502**	**6,609,452,889**	**5,823,832,008**	**1,209,557,215**
Share Capital	1,616,017,000	1,556,311,000	1,160,000,000	1,160,000,000	100,000,000
Share Premium	1,605,066,569	1,605,066,569	-	-	-
Revaluation Surplus	5,429,804,848	4,488,695,133	4,559,559,835	4,321,826,996	-
Capital Reserve	-	40,166,723	40,166,723	40,166,723	40,166,723
Share Money Deposit	-	500,000,000	-	-	-
Gain/(Loss) on Marketable Securities (Unrealized)	841,041	-	-	-	-
Tax Holiday Reserve	91,006,996	-	-	-	-
Retained Earnings	1,949,426,728	1,327,209,077	849,726,331	301,838,289	1,069,390,492
Non Current Liabilities:	**3,057,678,428**	**1,128,412,130**	**631,726,945**	**491,432,627**	**160,194,313**
Long Term Loan- Net off Current Maturity	3,018,088,196	1,003,604,234	507,915,714	387,857,802	160,194,313
Provision For Gratuity	30,465,330	-	-	-	-
Deferred Tax Liability	9,124,902	124,807,896	123,811,231	103,574,825	-
Current Liabilities :	**8,429,729,474**	**5,927,783,411**	**5,491,180,418**	**3,494,549,388**	**2,867,774,433**
Loans & Overdrafts	4,874,126,240	3,614,173,307	3,578,565,702	2,288,385,645	2,109,966,973
Current Maturity of Long Term Loans	1,014,864,198	384,236,310	269,275,732	212,521,282	95,900,321
UNDP Grant	-	-	-	29,540,983	16,398,545
Trade Payable	528,302,125	506,963,399	615,283,214	283,312,919	227,239,956
Provision for Income Tax	1,245,658,922	1,168,807,914	864,792,438	558,852,345	339,946,715
Liability for Expenses and Others	160,054,589	154,524,731	163,263,332	121,936,214	78,321,923
Dividend Payable	606,723,400	99,077,750	-	-	-
TOTAL EQUITY AND LIABILITY	**22,179,571,084**	**16,573,644,043**	**12,732,360,252**	**9,809,814,023**	**4,237,525,961**

B. Statement of Changes in Financial Position

For the Year Ended 30 June 2010 to 30 June 2014

(Amount in Taka)

Particulars	Share capital	Share Premium	Capital Reserve**	Share money Deposit *	Tax Holiday Reserve	Gain/(Loss) on Marketable securities (Unrealized)	Revaluation Surplus	Retained earnings	Total
Balance as at July 01, 2009	100,000,000	-	40,166,723	-	-	-	-	679,388,265	819,554,988
Profit for the year 2009-2010	-	-	-	-	-	-	-	390,002,227	390,002,227
Balance as at June 30, 2010	**100,000,000**	**-**	**40,166,723**	**-**	**-**	**-**	**-**	**1,069,390,492**	**1,209,557,215**
Balance as at July 01, 2010	100,000,000	-	40,166,723	-	-	-	-	1,069,390,492	1,209,557,215
Bonus share issue during the year	1,060,000,000	-	-	-	-	-	-	(1,060,000,000)	-
Profit for the year 2010-2011	-	-	-	-	-	-	-	343,757,733	343,757,733
Revaluation surplus on fixed assets	-	-	-	-	-	-	4,322,220,563	-	4,322,220,563
Adjustment for Depreciation	-	-	-	-	-	-	-	30,786,339	30,786,339
Adjustment for Deferred Tax	-	-	-	-	-	-	-	(82,489,842)	(82,489,842)
Adj. For changes in fair value of investment proper	-	-	-	-	-	-	(393,567)	393,567	-
Balance as at June 30, 2011	**1,160,000,000**	**-**	**40,166,723**	**-**	**-**	**-**	**4,321,826,996**	**301,838,289**	**5,823,832,008**
Balance as at July 01, 2011	1,160,000,000	-	40,166,723	-	-	-	4,321,826,996	301,838,289	5,823,832,008
Revaluation Surplus on land	-	-	-	-	-	-	308,597,541	-	308,597,541
Adjustment for Depreciation on Revalued Assets	-	-	-	-	-	-	(70,864,702)	70,864,702	-
Profit for the year 2011-2012	-	-	-	-	-	-	-	476,128,396	476,128,396
Adjustment of Accumulated Depreciation	-	-	-	-	-	-	-	894,944	894,944
Balance as at June 30, 2012	**1,160,000,000**	**-**	**40,166,723**	**-**	**-**	**-**	**4,559,559,835**	**849,726,331**	**6,609,452,889**
Balance as at July 01, 2012	1,160,000,000	-	40,166,723	-	-	-	4,559,559,835	849,726,331	6,609,452,889
Bonus share issue during the year	-	-	-	-	-	-	-	-	-
New share issued on Premium	396,311,000	1,664,506,200	-	-	-	-	-	-	2,060,817,200
Less: Transaction cost (Detailed in Note # 17)	-	(59,439,631)	-	-	-	-	-	-	(59,439,631)
Profit for the year 2012-2013	-	-	-	-	-	-	-	505,695,794	505,695,794
Share Money deposit	-	-	-	500,000,000	-	-	-	-	500,000,000
Revaluation Surplus on land	-	-	-	-	-	-	-	-	-
Adjustment for Depreciation on Revalued Assets	-	-	-	-	-	-	(70,864,702)	70,864,702	-
Adjustment for Deferred tax	-	-	-	-	-	-	-	-	-
Less: Interim Cash Dividend	-	-	-	-	-	-	-	(85,350,950)	(85,350,950)
TDS on Interim Dividend	-	-	-	-	-	-	-	(13,726,800)	(13,726,800)
Balance as at June 30, 2013	**1,556,311,000**	**1,605,066,569**	**40,166,723**	**500,000,000**	**-**	**-**	**4,488,695,133**	**1,327,209,077**	**9,517,448,502**
Balance as at July 01, 2013	1,556,311,000	1,605,066,569	40,166,723	500,000,000	-	-	4,488,695,133	1,327,209,077	9,517,448,502
Addition due to Amalgamation	-	-	-	-	24,790,876	-	556,246,703	53,079,610	634,117,189
Share money deposit transferred to Long Term Loan	-	-	-	(500,000,000)	-	-	-	-	(500,000,000)
Adjustment due to disbursement of purchase consideration and resultant gain thereon	59,706,000	-	-	-	21,038,719	-	472,506,215	283,977,778	837,228,712
Profit for the year 2013-2014	-	-	-	-	-	-	-	893,890,898	893,890,898
Tax Holiday Reserve	-	-	-	-	45,177,401	-	-	(45,177,401)	-
Dividend payable for the year 2012-13	-	-	-	-	-	-	-	(367,815,550)	(367,815,550)
Interim Cash Dividend for the year 2013-14	-	-	-	-	-	-	-	(323,203,400)	(323,203,400)
Gain/(loss) on Marketable Securities (Unrealized)	-	-	-	-	-	841,041	-	-	841,041
Adjustment of Depreciation on Revaluation	-	-	-	-	-	-	(87,077,493)	87,077,493	-
Adjustment due to disposal	-	-	-	-	-	-	(565,710)	221,500	(344,210)
Capital Reserve transferred to Retained Earnings.	-	-	(40,166,723)	-	-	-	-	40,166,723	-
Balance as at June 30, 2014	**1,616,017,000**	**1,605,066,569**	**-**	**-**	**91,006,996**	**841,041**	**5,429,804,848**	**1,949,426,728**	**10,692,163,182**

C. Statement of Cash Flows

	2013-2014	2012-2013	2011-2012	2010-2011	2009-2010
Cash Flows From Operating Activities:					
Collection from Sales and others	10,151,510,988	8,896,167,780	8,648,752,145	6,938,557,265	5,502,072,722
Payment to Suppliers & Others	(8,499,238,362)	(7,390,616,063)	(7,766,464,127)	(6,100,332,724)	(5,288,669,555)
Financial Expenses	(776,911,191)	(538,786,487)	(526,938,749)	(309,766,701)	(262,464,527)
Workers Profit Participation Fund	(41,808,175)	(33,689,072)	(11,089,248)	-	-
Income Tax	(382,397,340)	(367,371,864)	(239,603,332)	(171,415,191)	(128,512,936)
Net cash provided by operating activities	**451,155,920**	**565,704,294**	**104,656,689**	**357,042,649**	**(177,574,296)**
Cash Flows From Investing Activities:					
Fixed Assets	(2,410,288,500)	(1,919,179,321)	(760,735,581)	(362,966,351)	(138,945,329)
Sale of Fixed Assets	721,500	-	-	-	-
Term Deposit	666,798,260	(1,220,000,000)	-	-	-
Advance to Suppliers for Construction	(40,000,000)	(134,527,355)	(150,057,630)	-	-
Investment in Share	(5,298,280)	-	-	-	(291,467,400)
Advance against Land	-	(74,059,480)	(99,989,741)	(43,035,180)	-
Settlement of obligations of Amalgamating co. (ASPL)	(1,896,892,255)	-	-	-	-
Advance to ASPL against Shares	-	(65,001,394)	(455,018,519)	(409,244,948)	(43,050,218)
Current A/C with the ACME Agrovet & Beverage ltd.	-	-	-	-	48,256,888
Loan to ACMUNIO Int. Ltd.	(25,130,552)	(13,403,149)	(23,703,000)	(58,106,882)	-
Net cash used in investing activities	**(3,710,089,827)**	**(3,426,170,699)**	**(1,489,504,471)**	**(873,353,361)**	**(425,206,059)**
Cash Flows From Financing Activities:					
UNDP Grant	2,373,878	-	(29,540,983)	13,142,438	16,398,545
Loan from Director	-	-	-	-	(5,000,000)
Dividend Paid	(183,373,300)	-	-	-	-
Cash & Cash equivalents received from ASPL	844,137	-	-	-	-
Settlement of Provident Fund Liabilities	(5,193,340)	-	-	-	-
Share Capital	-	396,311,000	-	-	-
Share Money Deposit	-	500,000,000	-	-	-
Share Premium	-	1,605,066,569	-	-	-
Net Increase / (Decrease) in Loans and Overdrafts	1,259,952,933	35,607,605	1,290,180,057	178,418,672	679,004,191
Net Increase / (Decrease) in Long Term Borrowings	2,145,111,849	610,649,098	176,812,362	344,284,450	(40,723,968)
Net cash flow from financing activities	**3,219,716,157**	**3,147,634,272**	**1,437,451,436**	**535,845,560**	**649,678,768**
Increase/(Decrease) in Cash and Cash Equivalents	(39,217,750)	287,167,867	52,603,654	19,534,848	46,898,413
Cash and Cash Equivalents at the Opening	452,650,109	165,482,242	112,878,588	93,343,740	46,445,327
Cash and Cash Equivalents at the Closing	**413,432,359**	**452,650,109**	**165,482,242**	**112,878,588**	**93,343,740**
Net Operating Cash Flow Per Share	**2.85**	**4.69**	**0.90**	**3.08**	**(1.53)**

Internal and External sources of cash

(Amount in BDT)

Particulars	2013-2014	2012-2013	2011-2012	2010-2011	20009-2010
Internal Sources					
Share Capital	1,616,017,000	1,556,311,000	1,160,000,000	1,160,000,000	100,000,000
Share Premium	1,605,066,569	1,605,066,569	-	-	-
Share Money Deposit	-	500,000,000	-	-	-
Retained Earnings	1,949,426,728	1,327,209,077	849,726,331	301,838,289	1,069,390,492
External Sources					
Long Term Loan-Net off Current Maturity	3,018,088,196	1,003,604,234	507,915,714	387,857,802	160,194,313
Loans & Overdrafts	4,874,126,240	3,614,173,307	3,578,565,702	2,288,385,645	2,109,966,973
Current Maturity of Long Term Loans	1,014,864,198	384,236,310	269,275,732	212,521,282	95,900,321

Any material commitments for capital expenditure and expected sources of funds for such expenditure

The Company has not entered into any material commitment for capital expenditure except the cost accumulated against machinery import as at 30 June 2014 is Tk. 250,557,321, for which letter of credit are opened. However, the company has a plan to use the net proceeds from IPO to implement several development projects like Steroid & Hormone, Oncology and Ayurvedic, Modern Herbal & Nutraceuticals which detailed stated in section 'Use of IPO proceeds and projects implementation schedule'.

Causes for any material changes from period to period in revenues, cost of goods sold, other operating expenses and net income;

The Company's net profit after Tax and other business performance indicators show increasing trend due to the management dedication and suitable strategic action to face competition in the industry. Successive strong financial performance is the result of unwavering commitment of the promoters, management efficiency, employees' sincerity, use of appropriate technology, among others.

The following Table shows the year-to-year financial performance of the Company and which is increasing due to the company's long terms vision in this sector, experienced top tier management, favorable economic and government rules and regulations, the commendable repayment culture is contributing for growth of the company.

(Amount in BDT)

Particulars	2013-2014	2012-2013	2011-2012	2010-2011	2009-2010
Revenue	10,217,931,465	8,973,319,332	8,838,091,913	6,996,750,681	5,557,237,718
Cost of Goods Sold	6,237,792,554	5,721,020,810	5,697,479,102	4,540,790,741	3,649,626,560
Other Operating expenses	2,046,213,254	1,882,415,499	1789246835	1,544,960,054	1,300,300,802
Net Profit after tax	**893,890,898**	**505,695,794**	**476,128,396**	**344,151,300**	**227,806,543**

Any seasonal aspects of the issuer's business;

As the products of pharmaceuticals industry are of basic in nature and majorly chronic care related, Bangladesh Pharma market is consistent. However, there may be some insignificant seasonal variation in demand for certain medicine increase seasonally. Therefore, the company's operating results may vary insignificantly over the month of a year.

Any known trends, events or uncertainties that may have material effect on the issuer's future business;

Products of pharmaceuticals industry with related to healthcare needs which one of the fundamental needs of all livings beings. According to IMS total market size of Bangladesh Pharma market in the year 2015 was BDT 12,000 crore. If we calculate per capita consumption of medicine per day for 16 crore population it stands BDT 2.05. Therefore, there is a lot of scope to increase the market significantly, which depends on factors like increase of per capital income, increase health consciousness among mass people. Besides local market, contract manufacturing and emerging overseas market also can play a greater role. On the contrary, factors like natural disaster, entrance of new technology, increase in competition etc can affect the business as well.

Any assets of the company used to pay off any liabilities;

No assets of the Company have been used to pay off any liabilities.

Any loan taken from or given to any related party or connected person of the issuer with details of the same;

Presently, the Company engaged itself in business activities with other companies under common directorship and has provided advance to a concern under common directorship named ACMUNIO International Limited, a manufacturer of all kinds of high quality safety syringes, which are marketed by The ACME Laboratories Ltd. and also were supposed to use by The ACME Laboratories Ltd., itself. Initially ACMUNIO started its commercial manufacturing of Auto Disable (AD) Syringe, comparatively more environment friendly than any other existing syringe manufactured in the country, on January 2011. Considering better quality and uninterrupted supply of packing ingredients The ACME Laboratories Ltd. extended its hand to ACMUNIO International Limited in the form of interest free advances. The balance of the said advances stood at Tk. 120,343,583 as on 30 June 2014. It has been mutually agreed that from now onwards, said advances will be adjusted against submitted bills for supply of syringe to the Company. It has also been agreed that full amount of advances will be adjusted by June 2016.

Apart from the above, an advance was made to additional deputy managing director for acquisition of lands, details of which are disclosed in query # 14 of the auditor's additional disclosure and already been settled the same as at 30 June 2015.

Other than above, no loan was taken from or given to any related party or connected person of the issuer.

Any future contractual liabilities the issuer may enter into within next one year, and the impact, if any, on the financial fundamentals of the issuer;

The company neither has any future contractual liabilities nor has any plan to enter into any contractual liabilities other than normal course of business within next one year that would impact the financial fundamentals of the company.

The estimated amount, where applicable, of future capital expenditure;

The company has a plan to incur capital expenditure by using IPO Proceeds, which have been stated in section '**Use of IPO proceeds and projects implementation schedule'**.

Any VAT, income tax, customs duty or other tax liability which is yet to be paid, including any contingent liabilities stating why the same was not paid prior to the issuance of the prospectus. Updated income tax status for the last 5 years or from commercial operation, which is shorter

VAT

Large Tax Payer Unit (LTU), North Commissionerate and Directorate, Inspection, Intelligence & Investigation under National Board of Revenue (NBR) against 4 (four) claims of VAT and another 1 (one) regarding VAT on VAT exempted medicine.

The ACME Laboratories Ltd. has filed 5 (five) writ petitions in The Honorable High Court Division of the Supreme Court of Bangladesh separately vide no.- 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002 respectively against the said claims. The company reviews status of the same on every reporting date. Details of current status are given below:

SL	Writ No.	Value in BDT	Reason	Expiry Date
01	8650/2008	Non-monitory	Medicine supply to ICDDRB as Exempted.	Valid up to disposal of hearing.
02	785/2009	1,30,97,829.00	Rebate for exemption of medicine	Valid up to disposal of hearing.
03	3948/2004	27,30,765.27	Rebate cancel	Valid up to disposal of hearing.
04	4477/2002	19,07,555.00	Rebate cancel	Valid up to disposal of hearing.
05	4478/2002	6,65,525.24	Difference in rate of custom duty with the department.	Verdict has already been given by the Honorable High court division but formal demand yet to receive from concern authority

Customs duty

There is no outstanding customs duty due to the company.

Income Tax

Accounting Year	Assessment year	Status
2013-14	2014-15	After complying provision of law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax Return was submitted on 31.12.2014. Subsequently the Deputy Commissioner of Taxes issued a letter to audit. Being aggrieved, the Company filed a Writ Petition against the letter before the High Court Division of the Supreme Court of Bangladesh. The court issued a Rule Nisi and stayed the order till disposal from the date 08 March 2016.
2012-13	2013-14	Return was submitted duly under law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax. Subsequently, the Deputy Commissioner of Taxes issued a letter to audit and after conducting audit assessment order was issued by demanding tax liability of Tk. 19,232,808. Against the order, the company appeal the same to the Commissioner of Taxes (Appeal) on dated 20 September 2015. Hearing was duly heard on 25 November 2015 but the order has not yet been issued by the Commissioner Taxes (Appeal).
2011-12	2012-13	As per demand notice u/s 135 dated 20.07.2015 present tax demand is Tk. 22,339,873 which has been paid on dated 24.02.2016.
2010-11	2011-12	The Deputy Commissioner of Taxes, Circle-161, Zone-08 certified that “income tax case for the assessment year 2011-12 has been settled”.
2009-10	2010-11	As per demand notice u/s 135 dated 30.01.2013 present tax demand is Tk. 35,945,126. As per section 173 a letter was submitted by the Company to the DCT on 06.03.2013 to rectify the all-previous years’ orders by adjusting previous years refund and AIT and raised revised demand. Revised order yet to receive.
2008-09	2009-10	As per demand notice u/s 135 dated 08.10.2012 present tax demand is Tk. 45,930,964. As per section 173 a letter was submitted by the Company to the DCT on 06.03.2013 to rectify the all-previous and current years’ orders by adjusting previous years refund and current years AIT and raised revised demand. Revised order yet to receive.

Any financial commitment, including lease commitment, the company had entered into during the past five years or from commercial operation, which is shorter, giving details as to how the liquidation was or is to be effected;

Financial and Lease commitments during last five years

a) **Financial Commitment (Long Term)**

(Amount in BDT)

SL	Bank/NBFI	Type of Loan	Total Amount (Sanctioned)	Rate of Interest%	Sanction Date	Monthly Installment	Outstanding Balance as on 30 June 2014
1	IDLC Finance Ltd.	Term loan	50,000,000.00	13.75	15-Dec-10	2,500,000.00	17,500,000.00
2	IDLC Finance Ltd.	Term loan	100,000,000.00	13.75	15-Dec-10	5,000,000.00	35,000,000.00
3	IDLC Finance Ltd.	Term loan	70,000,000.00	16.00	5-May-11	4,375,000.00	17,500,000.00
4	IDLC Finance Ltd.	Term loan	50,000,000.00	16.00	4-Mar-12	2,500,000.00	27,500,000.00
5	IDLC Finance Ltd.	Term loan	47,490,000.00	16.00	4-Mar-12	2,374,500.00	28,494,000.00
6	IDLC Finance Ltd.	Term loan	40,000,000.00	16.00	4-Jul-12	2,000,000.00	26,000,000.00
7	IDLC Finance Ltd.	Term loan	100,000,000.00	16.00	5-Sep-12	5,000,000.00	65,000,000.00
8	IDLC Finance Ltd.	Term loan	50,000,000.00	16.00	5-Sep-12	2,500,000.00	32,500,000.00
9	IPDC of Bangladesh Ltd.	Term loan	150,000,000.00	14.50	6-Sep-11	3,838,424.00	88,044,962.00
10	IIDFC Ltd.	Term loan	50,000,000.00	15.50	14-Jun-10	2,500,000.00	10,000,000.00
11	IIDFC Ltd.	Term loan	150,000,000.00	15.50	25-Jun-12	7,500,000.00	97,500,000.00
12	ICB	Term loan	500,000,000.00	15.50	28-Jun-12	50,000,000.00	450,000,000.00
13	Trust Bank Ltd.	Term loan	350,000,000.00	13.00	24-Dec-12	17,500,000.00	287,064,168.00
14	Dutch Bangla Bank Ltd.	Term loan	350,000,000.00	13.50	06-Jul-13	17,500,000.00	319,445,361.00
15	Dhaka Bank Ltd.	Term loan	100,000,000.00	14.00	28-May-13	5,555,556.00	91,893,639.00
16	Standard Chartered Bank	Term loan (USD)	1,235,200,000.00	L+4.50	03-Jun-13	61,760,000.00	1,112,233,168.00
17	HSBC	Term loan (USD)	1,300,000,000.00	L+4.50	23-Jun-13	61,436,957.00	1,132,101,526.00

b) **Financial Commitment (Short Term)**

(Amount in BDT)

Bank	Limit of Loan	Rate of Interest (%)	Outstanding Balance as of 30 June 2014
Agrani Bank Ltd. , Ramna Corporate Branch	650,000,000.00	16.00	(18,544,575.15)
Dutch Bangla Bank Ltd. , Local Office Branch	880,000,000.00	13.50	375,390,984.31
Standard Chartered Bank, Bangladesh	1,280,000,000.00	12.00	820,820,160.19
Dhaka Bank Ltd. , Dhanmondi Branch	700,000,000.00	14.00	438,316,591.35
HSBC, Bangladesh	1,420,000,000.00	13.00	1,095,190,245.00
Eastern Bank Ltd. , Gulshan Branch	1,290,000,000.00	14.50	595,291,895.53
Trust Bank Ltd. , Dhanmondi Branch	2,268,000,000.00	13.00	391,554,968.79
The City Bank Ltd. , Dhanmondi Branch	1,200,000,000.00	14.00	967,476,092.42
AB Bank Ltd. , Dhanmondi Branch	650,000,000.00	15.25	252,358,281.00

c) Lease Commitment

The ACME Laboratories Ltd. entered into the following lease commitment during the last five years. The status and outstanding as on 30 June 2014 are presented below:

(Amount in BDT)

SL.	NBFI	Purpose of lease	Total Amount (Sanctioned)	Rate of Interest (%)	Sanction Date	Expiration Date	Monthly / Quarterly Installment	Outstanding Balance as on 30 June 2014
1	IDLC Finance Ltd.	Car	6,415,306.00	13.50	24-Aug-09	25-Aug-13	400,957.00	Nil
2	IDLC Finance Ltd.	Car	9,022,270.00	13.50	27-Jan-10	05-Feb-14	563,892.00	Nil
3	IDLC Finance Ltd.	Car	1,932,780.00	13.60	08-Dec-09	15-Dec-13	120,799.00	Nil
4	IDLC Finance Ltd.	Car	6,278,280.00	13.50	20-Apr-10	25-Apr-14	392,385.00	Nil
5	IDLC Finance Ltd.	Car	5,140,272.00	13.50	20-Apr-10	25-Apr-14	321,267.00	Nil
6	IDLC Finance Ltd.	Car	5,474,027.00	13.50	26-Oct-10	05-Nov-14	342,127.00	684,249.00
7	IDLC Finance Ltd.	Car	10,046,333.00	13.50	13-Jul-10	15-Jul-14	627,896.00	627,893.00
8	IDLC Finance Ltd.	Car	1,748,514.00	13.50	24-Nov-10	25-Nov-14	109,282.00	218,566.00
9	IDLC Finance Ltd.	Car	21,962,939.00	15.00	27-Mar-11	25-Mar-15	1,372,684.00	4,118,047.00
10	IDLC Finance Ltd.	Car	10,157,910.00	16.00	26-Apr-11	05-May-15	634,869.00	2,539,482.00
11	IDLC Finance Ltd.	Car	38,205,010.00	16.00	12-May-11	25-May-15	2,387,813.00	9,551,254.00
12	IDLC Finance Ltd.	Car	5,243,581.00	16.00	22-Jun-11	25-Jun-15	327,724.00	1,310,893.00
13	IDLC Finance Ltd.	Car	1,997,904.00	16.00	22-Jun-11	15-Jul-15	124,869.00	624,345.00
14	IDLC Finance Ltd.	Car	5,624,222.00	16.00	02-Aug-11	05-Aug-15	351,514.00	1,757,568.00
15	IDLC Finance Ltd.	Car	3,041,354.00	16.00	23-Aug-11	05-Sep-15	190,085.00	950,419.00
16	IDLC Finance Ltd.	Car	27,932,820.00	16.00	18-Jan-12	25-Jan-16	1,745,801.00	12,220,611.00
17	IDLC Finance Ltd.	Car	28,144,783.00	16.00	04-Dec-12	05-Dec-16	1,759,049.00	17,590,489.00
18	IDLC Finance Ltd.	Car	6,672,951.00	16.00	04-Dec-12	05-Dec-16	417,059.00	4,170,597.00
19	IDLC Finance Ltd.	Car	6,251,388.00	16.00	28-Nov-13	05-Dec-17	390,712.00	5,469,964.00
20	IDLC Finance Ltd.	Car	5,148,030.00	16.00	18-Nov-13	25-Nov-17	321,752.00	4,504,526.00
21	IDLC Finance Ltd.	Car	5,725,378.00	15.50	30-Apr-14	05-May-18	357,836.00	5,725,378.00
22	IDLC Finance Ltd.	Car	12,849,157.00	15.50	13-Mar-14	25-Mar-18	803,072.00	12,046,085.00
23	IPDC of Bangladesh Ltd.	Car	3,380,000.00	14.50	14-Jul-11	05-Sep-15	286,541.00	1,289,178.00
24	IPDC of Bangladesh Ltd.	Car	3,450,000.00	14.50	14-Jul-11	05-Sep-15	292,475.00	1,315,877.00
25	National Finance Ltd.	Machinery	100,000,000.00	19.00	14-Feb-12	20-Feb-17	2,594,055.00	64,731,754.00

Details of all personnel related schemes for which the company has to make provision for in future years

The ACME Laboratories Ltd. is one of the leading pharmaceutical companies of the country always prioritizes its human resources, as its success immensely depends upon performance of its 6,711 patrons. With the view to go forward by retaining the resource, ACME always offers inspiring propositions along with a classic working environment. Brief of some of the propositions are mentioned below:

A. Long term offerings

Sl. #	Proposition	Proposition in Brief
1	Recognized Contributory Provident Fund	The company and the employee both contribute 10 % of basic salary to the Fund and said fund is administered under a trustee board.
2	Group Insurance (With Health Insurance) insured with Progoti Life Insurance Co. Ltd.	During the year ended 30 June 2014 all permanent employees i.e. 6,711 numbers of employees are insured under the Group Insurance policy.
3	Employee Death Benefit in Service	In case of death in service, the employees contributed one-day basic salary and Board of Directors of the company contributed Tk. 50,000 to the deceased employee's family.
4	Gratuity (non funded)	The company has a policy related to "Payment of gratuity" payable to its eligible Permanent Employees who are serving the company for a considerable duration, at the time of severance of their relationship from the company. Eligibility for getting the said Benefit mainly depends upon the length of service with the organization subject to the compliance of the eligibility criteria as stated in the policy.

B. Periodical/ Timed offerings

Sl.	Proposition	Proposition in Brief
1	Festival Allowances	Each Festival bonus is equivalent to one basic salary
2	Employee Welfare Fund	The company has an Employee Welfare Fund named "Workers Welfare Fund" as prescribed by the Bangladesh Labor Law 2006
3	Annual Appraisal	Appraised according to performances in a very professional way
4	Training participation	For continuous development, arranged at home & abroad
5	Contribution to Worker's Profit Participation Fund (WPPF)	5% of net profit before tax and after charging the contribution to WPPF by the company as per provisions of the Bangladesh Labor Law, 2006 and is payable to beneficiary as defined in the said law

Breakdown of IPO Expenses (Estimated):

Particulars	Rate	Amount in BDT (Approx.)
Issue Management Fee:		
Manager to the issue Fee	@ 0.40% of the Total Issue Size	16,384,000
VAT against Issue Management Fee	@ 15% on the Issue Management Fee	2,457,600
Regulatory Expenses:		
Listing Related Expenses:		
Application Fee for DSE	Fixed	5,000
Annual Listing Fees for Ordinary Shares (DSE & CSE)	@ 0.05% on up to Taka 100 crore of paid-up capital and 0.02% on the above Taka 100 crore of paid-up capital but maximum Tk. 600,000 for each exchanges	1,200,000
Listing Fees for Stock Exchanges (DSE & CSE)	@ 0.25% on up to Taka 10 crore of paid-up capital and 0.15% on the rest amount of paid-up capital but maximum Tk. 10,000,000 for each exchanges	6,548,051
Draft Prospectus Scrutiny Fees for DSE & CSE	Fixed (Tk. 50,000 for each exchanges)	100,000
Electronic Bidding Fee	Fixed	1,250,000
BSEC Fee:		
Application Fee	Fixed	10,000
Consent Fee	@ 0.40% on the public offering amount	16,384,000
IPO Commission/Expenses:		
Underwriting Commission	@ 0.50% on the underwritten amount	7,168,000
Credit Rating Fee		230,000
Auditors' Certification Fee		200,000
Invitation to EIIs through 5 national dailies		362,880
Road show related expenses		1,633,849
Corporate documentary related expenses (Printing of IM and Presentation related expenses)		1,698,187
CDBL Fee and Expenses:		
Security Deposit of Eligible Securities	At actual	500,000
Documentation Fee	At actual	2,500
Annual Fee	At actual	100,000
Transaction fee plus Decartelization fee	@ Tk. 0.00015 of issue size + @ Tk. 0.00015 of Pre-IPO paid up capital	856,803
Connection Fee	At actual	6,000
Printing, Publication and Others:		
Publication of Abridge Version of Prospectus	4 national dailies	700,000
Printing of Prospectus	3,000 copies (approx.) @ Tk. 200.00	600,000
Post Issue Expenses:		
Registrar to the Issue Fees		1,150,000
Lottery conducting expenses and BUET fee		745,000
Data Collection, Data Entry, Data Processing, Printing of Allotment Letters and Refund Warrant Distribution of Allotment Letter and Refund Warrant (including courier) and other related job	Tk. 8.00 per Application	8,000,000
	Total	**68,291,870**

NB: Actual expenses may vary, if above mentioned estimates differ and will be adjusted accordingly

If the issuer has revalued any of its assets, the name, qualification and experiences of the valuer and the reason for the revaluation, showing the value of the assets prior to the revaluation separately for each asset revalued in a manner which shall facilitate comparison between the historical value and the amount after revaluation and giving a summary of the valuation report along with basis of pricing and certificates required under the revaluation guideline of the Commission;

The first revaluation of the company's asset was made on 30 June 2011 by Masih Muhith Haque & Co. Chartered Accountants, a member firm of IGAF Polaris in Bangladesh, the independent Valuer not related to the company.

Summary of Revaluation: The Company made revaluation of land and land developments, factory & office building, vehicles and machinery & equipment as at 30 June 2011 to reflect fair value thereof in terms depreciated current cost, details of which are as follows:

(Amount in BDT)

Sl.#	Particulars of the asset	Name of the Valuer	Qualification of the Valuer	Date of Revaluation	The carrying amount of the asset	Value of assets after revaluation	Revaluation Surplus
1	Land & Land Development	Mashi Muhit Haque & Co. (Statutory auditor at that year was Pinaki & Co.)	Chartered Accountants	30/06/2011	194,590,326	3,155,545,750	2,960,955,424
2	Building				471,676,753	1,756,001,304	1,284,324,551
3	Machinery & Equipment				447,707,833	488,744,084	41,036,251
4	Motor Vehicle				167,066,908	202,971,245	35,904,337
Total					**1,281,041,820**	**5,603,262,383**	**4,322,220,563**

The second revaluation was made as at 31 Dec 2011 for newly registered land only by Masih Muhith Haque & Co. Chartered Accountants.

(Amount in BDT)

Sl	Particulars of the asset	Name of the Valuer	Qualification of the Valuer	Date of Revaluation	The carrying amount of the asset	Value of assets after revaluation	Revaluation Surplus
1	Land and Land Development	Mashi Muhit Haque & Co. (Statutory auditor at that year was Pinaki & Co.)	Chartered Accountants	31/12/2011	35,300,060.00	343,897,600.00	308,597,541.00
Total					**35,300,060.00**	**343,897,600.00**	**308,597,541.00**

Location wise valuation information and considerable facts with regard to valuation of land that was made on 31 December 2011 are presented below:

There was a need of land for the Company and accordingly the company acquired the land. Along with acquisition the Company felt necessity to develop the newly acquired land within a time span of 6 (six) month ending 31 December 2011, tried its best to develop the land in such a way that would ensure the best use of the said land for the purpose it had been acquired by the company.

The said newly acquired land (not previously revalued one) which were revalued within six months of its acquisition, are all situated in various strategic locations where procurement of land itself was a mammoth task. The company was able to get registered those land in its name by the time. However, the process of negotiation has commenced at a considerable time period ahead from the date of registration.

Total area of the aforesaid land under the Company's holding is admeasuring 236.52 decimal out of which various fractions are located at 180.52 decimal on the ***'Dhaka-Aricha High Way'***, 30 decimal in Sylhet at ***'Kadamtali Commercial Area'*** and 26 decimal on '***10Mile Point'*** of ***Dhaka- Rangpur-Dinajpur High Way'.***

CEPHALOSPORIN UNIT

CANTEEN & TRAINING CENTER

Location wise Valuation Information

SL no.	Location of the land	Area of the land	Cost	Revalued amount	Revaluation surplus
1	Dhamrai, Dhaka	180.52	16,520,000	294,247,600	277,727,600
2	Sylhet	30.00	8,191,559	36,000,000	27,808,441
3	Dinajpur	26.00	10,588,500	13,650,000	3,061,500
	Total	**236.52**	**35,300,059**	**343,897,600**	**308,597,541**

The land at Dhaka-Aricha High Way was developed from a low land to above the flood level and particularly on this piece of land the company made a remarkable development. At present ***"Cephalosporin Facility"*** is situated on that piece of land. After making development and starting the construction work of Cephalosporin Facility, value of the said land increased significantly. Availability of this kind of land is out of reach even if a substantial premium is offered to the land owners of the surrounding area over and above the consideration company had paid for acquisition of these lands.

Secondly, the land at Sylhet being situated in the commercial area of Kadamtoli, After building boundary wall and marking for proposed depot of The ACME Laboratories Ltd. value of the said land stepped up and without its fair valuation, real value of the land cannot be brought into the books of accounts which that land possesses.

Thirdly, the situation of land at 10 Mile Point of Dhaka- Rangpur-Dinajpur High Way in itself represents up mark valuation of land due to its locational advantages and without fair valuation, the real value possessed by the land cannot be brought into the books of accounts of the Company.

Finally, we observed that valuation of newly acquired land have been done on the basis of practical and logical consideration and not merely on a presumptive basis and all the land are beyond reach even after paying the huge amount of premium over the consideration paid by the company.

Summary of Revaluation (for The ACME Specialized Pharmaceuticals Ltd., the then subsidiary of The ACME Laboratories Ltd., present Solid Dosages Unit):

M.M. Rahman & Co. Chartered Accountants an independent valuer revalued land, building, vehicles, machineries & equipments, utilities, electrical installation and office equipment of the company as at 30 June 2012 following current cost method. Such revaluation resulted into a revaluation surplus aggregating Tk. 1,093,121,666 the details of which are stated below:

Sl.#	Particulars of the asset	Name of the Valuer	Qualification of the Valuer	Date of Revaluation	The carrying amount of the asset	Value of assets after revaluation	Revaluation Surplus
1	Land	M.M. Rahman & Co. (Statutory auditor at that year was Pinaki & Co.)	Chartered Accountants	30/06/2012	127,182,498	481,500,000	354,317,502
2	Building				583,040,866	1,252,798,532	669,757,666
3	Vehicles				14,298,862	15,883,691	1,584,829
4	Machinery & Equipment				474,557,246	509,755,034	35,197,788
5	Utilities				670,150,091	695,074,967	24,924,876
6	Electrial Installations				84,550,645	90,860,346	6,309,701
7	Office Equipment				7,427,885	8,457,189	1,029,304
Total					**1,961,208,093**	**3,054,329,759**	**1,093,121,666**

The increase in the carrying amount of revalued assets is recognized in the separate component of shareholders' equity under the head "Revaluation Surplus".

Other Fixed Assets were kept outside the scope of the revaluation works. These are expected to be realizable at written down value (WDV) thereof mentioned in the Statement of Financial Position of the company.

Reasons for Valuation: The valuation has been made to reflect fair value of the lands, buildings, vehicles, machinery & equipment, utilities, electrical installation and office equipment of the company.

Work done to date by the Valuer: The above valuer, Masih Muhith Haque & Co., Chartered Accountants, has rendered valuation services to following companies:

i) Jaganath University

ii) Apollo Ispat Complex Limited

iii) PED Steel Alliance Limited

iv) Popular Pharmaceutical Limited

Furher to the above the company revalued of its Investment Property (Non-current Assets) on dated 30 June 2014, Details of the assets are given below:

Sl. #	Particulars of the asset	Name of the Valuer	Qualification of the Valuer	Date of Revaluation	Estimated Fair value as on 01.07.2013	Estimated Fair value as on 30.06.2014 (Tk.)	Revaluation Surplus
1	Investment Property	Mashi Muhit Haque & Co. (Statutory auditor at that year was Pinaki & Co.)	Chartered Accountants	30/06/2014	26,185,000	26,185,000	Nil
Total					**26,185,000**	**26,185,000**	**Nil**

The first valuation of Investment Property was conducted by an Independent valuer Mashi Muhith Haque & Co. Chartered Accountants on dated 30 June 2012, i.e. before the publication of notification regarding valuation guideline by the Bangladesh Securities & Exchange Commission (BSEC) on dated August 18, 2013. Subsequent revaluation for the year ended 30 June 2013 and 2014 was conducted by the same valuer by complying with Bangladesh Accounting Standard 40 'Investment Property'. During the year ended 30 June 2014, there is no change in the fair value of the asset.

All the revaluations of the company mentioned above was conducted before the publication of notification regarding valuation guideline by the Bangladesh Securities & Exchange Commission (BSEC) on dated August 18, 2013. So, certificates required under the revaluation guideline of the Commission is not applicable for the company.

Where the issuer is a holding/subsidiary company, full disclosure about the transactions, including its nature and amount, between the issuer and its subsidiary/holding company, including transactions which had taken place within the last five years of the issuance of the prospectus or since the date of incorporation of the issuer, whichever is later, clearly indicating whether the issuer is a debtor or a creditor

Presently the company has no holding/subsidiary company. However, earstwhile The ACME Specialized Pharmaceuticals Ltd. was a subsidiary of the company until to January 2014 (after that amalgamated). The Transaction between Holding/subsidiary companies and the Issuer within last 5 (five) years as follows:

Name of the Company	Relationship	Nature of Transaction	2009-2010		2010-2011		2011-2012		2012-2013		2013-2014	
			Value of transaction during the year	Balance at year-end. Receivable/(Payable)	Value of transaction during the year	Balance at year-end. Receivable/(Payable)	Value of transaction during the year	Balance at year-end. Receivable/(Payable)	Value of transaction during the year	Balance at year-end. Receivable/(Payable)	Value of transaction during the year	Balance at year-end. Receivable/(Payable)
The ACME Specialized Pharmaceuticals Ltd.	Subsidiary	Investment in Shares	291,467,400	351,467,400	-	351,467,400	-	351,467,400	-	351,467,400	-	-
		Investment	43,050,218	378,538,037	409,244,948	787,782,985	455,018,519	1.242,801,504	65,001,394	1,307,802,898	-	-
		Finished Goods Sale	-	-	-	-	3,039,860	-	-	-		
		Finished Goods Purchase	-	-	-	-	879,099,489	200,160,699	1,147,490,845	-	-	-

Financial Information regarding group:

Sl. No.	Name of the Company	Date of Incorporation	Nature of Business	Accounting Year	Equity capital	Reserves	Sales (Tk.)	Profit after Tax (Tk.)	EPS (Tk.)	Diluted EPS (Tk.)	Net Asset Value (NAV) Tk.	Status of Listing	Information regarding significant adverse factors	Has become sick or is under winding up
01	Sinha Printers Ltd.	07.05.1997	Printing, processing, publishing, packaging and other related business.	2013-14	5,000,000	176,042,798	391,049,968	41,633,550	832.67	832.67	3,620.86	N/A	No	No
				2012-13	5,000,000	143,405,648	314,397,143	19,343,936	386.88	386.88	2,968.11	N/A	No	No
				2011-12	5,000,000	124,061,712	389,102,296	25,918,785	518.38	518.38	2,581.23	N/A	No	No
02	Sinha Fabrics Ltd.	29.03.1997	Garments Industry	2013-14	5,000,000	91,991,240	356,584,000	22,333,200	446.66	446.66	1,939.82	N/A	No	No
				2012-13	5,000,000	69,658,040	496,777,000	35,097,084	701.94	701.94	1,493.16	N/A	No	No
				2011-12	5,000,000	34,560,956	460,619,128	17,585,156	351.70	351.70	791.22	N/A	No	No
03	Sinha Wool Wears Ltd.	29.03.1997	Garments Industry	2013-14	5,000,000	(21,633,434)	1,182,420	(5,248,529)	(104.97)	(104.97)	(332.67)	N/A	Risks and uncertainties discussed in Risk Factor chapter	operating loss
				2012-13		(16,384,905)	5,117,560	(2,209,318)	(44.19)	(44.19)	(227.70)			
				2011-12		(14,175,587)	6055875	(1,915,579)	(38.31)	(38.31)	(183.51)			
04	Sinha Knit Industries Ltd.	17.05.2005	Garments Industry	2013-14	7,500,000	33,797,333	370,607,408	20,738,064	276.51	276.51	550.63	N/A	No	No
				2012-13		13,059,269	412,793,105	18,185,459	242.47	242.47	274.12	N/A	No	No
				2011-12		(5,126,190)	87,440,351	(4,769,865)	(63.60)	(63.60)	31.65	N/A	No	No
05	ACME IT Ltd.	31.03.1999	IT Education	2013-14	2,100,000	(3,048,735)	8,633,464	49,614	2.36	2.36	(45.18)	N/A	No	No
				2012-13		(3,098,349)	11,188,259	33,685	1.60	1.60	(47.54)			
				2011-12		(3,096,304)	13,262,218	141986	6.76	6.76	(47.44)			
06	ACME Overseas Trading Ltd.	23.07.1998	Trading Business	2013-14	2,500,000	1,261,271	57,360,925	(2,379,659)	(95.19)	(95.19)	150.45	N/A	Risks and uncertainties discussed in Risk Factor chapter	operating loss
				2012-13		3,640,930	-	(9,659,129)	(386.37)	(386.37)	245.64			
				2011-12		13,300,059	72106137	-	-	-	632.00			
07	The ACME Specialized Pharmaceuticals Ltd.	27.04.2008	Pharmaceuticals	January,14	650,000,000	2,480,616,199	85,864,052	8,580,396	0.13	0.13	48.16	N/A	Amalagamated with The ACME Laboratories Ltd.	winding up without dissolution due to amalgamation
				2013	650,000,000	2,472,035,803	1,024,531,164	58,306,353	0.94	0.94	50.32			
				2012	500,000,000	2,414,403,073	860,234,842	57,360,968	1.15	1.15	58.29			
				2011	500,000,000	1,082,106,770	123,188,808	(44,556,083)	0.91	0.91	31.64			
08	The ACME Agrovet & Beverages Ltd.	02.01.2003	Manufacturing of fruit juice & other drink, mineral water and trading business.	2013-14	48,000,000	(371,755,785)	233,365,907	76,526	0.16	0.16	(674.49)	N/A	No	No
				2012-13	48,000,000	(371,832,311)	200,503,995	(1,123,033)	(2.34)	(2.34)	(674.65)			
				2011-12	48,000,000	(370,709,278)	163,374,753	(54,442,409)	(113.42)	(113.42)	(672.31)			
09	ACMUNIO International Ltd.	25.01.2007	Manufacturing of syringe	2014	12,000,000	(149,772,163)	11,270,232	(25,823,784)	(215.20)	(215.20)	(1,148.10)	N/A	Risks and uncertainties discussed in Risk Factor chapter	operating loss
				2013	12,000,000	(123,948,379)	13,430,557	(27,172,855)	(226.44)	(226.44)	(932.90)			
				2012	12,000,000	(96,775,524)	19,364,604	(33,249,508)	(277.08)	(277.08)	(706.46)			
10	Kalyar Packaging Ltd.	13.07.2006	Packaging Industry	2013-2014	5,000,000	37,607,374	176,776,650	8,464,475	169.00	169.00	852.15	N/A	No	No
				2012-2013	5,000,000	29,142,899	126,768,775	6,695,241	134	134	682.86	N/A	No	No
				2011-2012	5,000,000	22,447,658	122,821,937	9,565,076	191	191	548.95	N/A	No	No
11	Kalyar Replica Ltd.	06.02.2008	Manufacturer and Converter of Flexible Packing Material	2014	10,000,000	37,591,158	98,751,248	6,817,003	68.17	68.17	475.91	N/A	No	No
				2013	10,000,000	30,774,155	1,030,081,830	9,535,603	95.36	95.36	407.74	N/A	No	No
				2012	10,000,000	21,238,552	865,467,021	10,031,346	100.31	100.31	312.39	N/A	No	No
12	Sanjar Aviation Ltd.	08.07.2008	Travel Agency	2013-2014	5,000,000	(1,130,744)	3,644,563	54,436	1.09	1.09	77.39	N/A	No	No
				2012-2013	5,000,000	(1,201,350)	2,628,196	20,786	0.42	0.42	75.97	N/A	No	No
				2011-2012	5,000,000	(1,234,608)	15,954,318	(122,309)	(2.45)	(2.45)	75.31	N/A	No	No
13	JM Sinha Agriculture Food Processing Ind. Ltd.	05.11.2009	Agro Business	2014	20,000,000	979,511	5,160,469	307,413	1.54	1.54	104.90	N/A	No	No
				2013	20,000,000	672,098	4,124,905	292,044	1.46	1.46	103.36	N/A	No	No
				2012	20,000,000	380,054	3,444,572	160,364	0.80	0.80	101.90	N/A	No	No

The related business transactions within the group and their significance on the financial performance of the issuer

There was no related business transactions within the group which have significance on the financial performance of the issuer except the following transaction

Name of the Company	Relationship	Nature of Transaction	2011-2012		2012-2013		2013-2014	
			Value of transaction during the year	Balance at year-end. Receivable/(Payable)	Value of transaction during the year	Balance at year-end. Receivable/(Payable)	Value of transaction during the year	Balance at year-end. Receivable/(Payable)
The ACME Specialized Pharmaceuticals Ltd.	Subsidiary	Investment in Shares	-	351,467,400	-	351,467,400	-	-
		Investment	455,018,519	1.242,801,504	65,001,394	1,307,802,898	-	-
		Finished Goods Sale	3,039,860	-	-	-		
		Finished Goods Purchase	879,099,489	200,160,699	1,147,490,845	-	-	-
ACMUNIO Int. Limited	Common Director	Advance to ACMUNIO /Current A/C	23,703,000	81,809,882	13,403,149	95,213,031	25,130,552	120,343,583
		Finished Goods Purchase	23,241,702	-	18,344,814	-	43,34,085	-
		Rent on Investment Properties	6,462,000	19,386,000	6,462,000	25,848,000	6,462,000	32,310,000
Sinha Printers Limited	Common Director	Local Supply	389,102,296	(361,724,694)	336,654,355	(434,543,465)	391,049,968	(388,321,732)
		Provide service & others	36,641,407	36,641,407	287,058	36,928,465	329,116	37,257,581
Kalyar Packaging Limited	Common Director	Local Supply	3,904,518	-	4,010,112	(3,781,826)	45,570,985	-
Kalyar Replica Limited	Common Director	Local Supply	138,552	-	1,076,733	-	7,083,759	-

Other than the above, there was no transaction within the group.

Sales or purchase between group companies/ subsidiaries/ associate companies when such sales or purchases exceed in value in the aggregate ten per cent of the total sales or purchases of the issuer and also material items of income or expenditure arising out of such transactions

There were no transactions of The ACME Laboratories Ltd. between group companies/ subsidiaries/ associate companies, which exceed in value in the aggregate ten per cent of the total sales or purchases of the Company.

Where the issuer is a banking company, insurance company, non-banking financial institution or any other company which is regulated and licensed by another primary regulator, a declaration by the board of directors shall be included in the prospectus stating that all requirements of the relevant laws and regulatory requirements of its primary regulator have been adhered to by the issuer

Not applicable.

A report from the auditors regarding any allotment of shares to any person for any consideration otherwise than cash along with relationship of that person with the issuer and rationale of issue price of the shares;

Auditor's Certificate regarding allotment of shares to promoters or sponsor Shareholders for consideration in cash/other than cash

After due verification, we certify that the paid up capital of The ACME Laboratories Limited as at 30 June, 2014 was BDT 1,616,017,000 divided into 161,601,700 ordinary shares of taka 10/- each made up as follows:

Particulars of Allotment	Date of allotment	Consideration		Amount of Share Capital (Taka)
		Cash	Other than Cash	
First (Subscription to the Memorandum and Articles of Association at the time of incorporation)	17-03-1976	600	N/A	6,000
Second	16-05-1976	2,000	27,500	295,000
Third	10-08-1989	300,000	N/A	3,000,000
Fourth	29-11-2006	9,669,900	N/A	96,699,000
Fifth	05-05-2011	106,000,000	Bonus Share	1,060,000,000
Sixth	20-05-2013	39,631,100	N/A	396,311,000
Seventh	26-11-2013	N/A	5,970,600 (Amalgamation)	59,706,000
Total		**155,603,600**	**5,998,100**	**1,616,017,000**

The Company, however has sub divided the face value of its ordinary share from taka 100/- to taka 10/- by passing a special resolution in its extra ordinary general meeting held on 30-11-2011 and necessary amendments in the capital clause of the Memorandum and Articles of Association were made accordingly. Hence, The paid up Capital of the company comes to taka 1,160,000,000.00 divided into 116,000,000 ordinary shares of taka 10.00 each.

The Company applied and obtained approval from Bangladesh Securities and Exchange Commission (BSEC) vide its letter no. SEC/CI/CPLC (Pvt) - 324/2011-346 dated : 04/05/2011 dated for issuance of 106,000,000 bonus shares of taka 10.00 each.

Again the company applied and obtained approval from Bangladesh Securities and Exchange Commission (BSEC) vide it's letter no. SEC/CI/CPLC (Pvt) -360/2012/1993 dated : 17/02/2013 for issuance of 500,00,000 ordinary shares of Tk. 10.00 each against which the company issued 39,631,100 ordinry share of TK. 10 each.

Further, as a natural follow up, the Board of Directors of both the Companies decided to amalgamate the ACME Specialized Pharmaceuticals Limited with the ACME Laboratories Limited. As such applied for the same to Honarable High Court Division of Bangladesh Supreme Court and eventually obtained verdict in favour of amalgamation dated : 20 November 2013. After that, as part of completion of amalgamation procedure the comapnay issued 5,970,600 ordinary shares @ Tk. 10 each as purchase consideration.

Sd/-

Date, Dhaka;
September 17, 2014

PINAKI & COMPANY
Chartered Accountants

Any material information, which is likely to have an impact on the offering or change the terms and conditions under which the offer has been made to the public

There is no material information, which is likely to have an impact on the offering or change the terms and conditions under which the offer has been made to the public.

Business strategies and future plans. Projected statement of financial position, compressive statement of income and earnings per share for the next three accounting years as per the issuers own assessment

Business Strategies

To bring in practice of its mission, ACME set a good number of business strategies like:

1) Ensure health, vigour and happiness for all;
2) Ensure stable and long-term return to our investors;
3) Maintain state-of-the-art manufacturing facilities for ensuring best quality products to the customers;
4) Obtain word class accreditation by proper execution of ISO 9001:2008 standard, WHO cGMP standard and best practices that are proven effective;
5) Expand existing and develop new large scale projects to diverse the product range and related diversification;
6) Strengthening our existing market share, cope with the changing scenario in the pharma industry to ensure higher prescription rates, transparency and improved products and services for our existing and potential customers;
7) Comprehensive marketing and distribution network (Both in domestic and international markets);
8) Excellent relationship with health care professionals, chemists and other concerned stakeholders;
9) Seek new ways of working to improve efficiency and ensure sustainability.

Future plans

From IPO Proceeds

In persuasion of aforesaid strategies ACME and its professional team have been working relentlessly keeping in consideration future as well. ACME has a plan to establish three projects namely Hormone &Steroid Project, Oncology Project and Ayurvedic, Herbal &Neutracuticals Project by using IPO proceeds.

Other than IPO Proceeds

Besides, with an aim to expand its value chain further, ACME applied for three plots in proposed Active Pharmaceuticals Ingredients (API) Park, which will be built by the Government at Munshigonj District. If the plot is available to us, then we have a plan to set up API industry thereon. This will help us to produce active raw materials locally and it substitute the import.

Prospective Financial Information (PFI) for next three years

Following prospective financial information is prepared considering some assumptions like material cost with respect to sales will remain same, Trade price will not change, existing Product mix will remain same, newly launched projects will generate more revenue (LVP & SVP and Liquid and Semisolid), conversion rate of taka against USD will not change significantly, etc. and relate to future events & circumstances. As such, valued investors are advised to note that, the actual results of the entity's operations and financial condition may differ from this PFI.

Projected Statement of Financial Position

ASSETS	TAKA		
	As at 30.06.2016	As at 30.06.2017	As at 30.06.2018
Non-Current Assets :	**16,339,073,455**	**18,612,765,740**	**18,582,499,781**
Property, Plant and Equipment	16,304,561,917	18,578,295,827	18,548,071,493
Intangible Assets	203,625	162,000	120,375
Investment in Shares	8,122,913	8,122,913	8,122,913
Investment Property	26,185,000	26,185,000	26,185,000
Current Assets:	**12,391,920,540**	**10,518,820,297**	**10,919,168,031**
Inventories	3,043,356,175	3,354,800,508	3,594,996,413
Trade Receivable	862,811,876	989,480,289	1,015,143,218
Other Receivable	42,757,406	41,184,980	41,596,830
Advance, Deposits & Pre-Payments	1,063,555,191	1,001,669,649	969,170,435
Advance Income Tax	2,257,967,843	2,903,748,846	3,746,510,503
Material In Transit	422,333,567	475,876,300	551,254,750
Term Deposit	4,244,907,484	1,300,000,000	500,000,000
Cash and Cash Equivalents	454,230,998	452,059,725	500,495,882
TOTAL	**28,730,993,995**	**29,131,586,037**	**29,501,667,812**
EQUITY AND LIABILITIES			
Shareholders' Equity:	**15,691,330,646**	**16,397,653,400**	**17,519,089,268**
Share Capital	2,116,017,000	2,116,017,000	2,116,017,000
Share Premium	5,136,766,569	5,136,766,569	5,136,766,569
Revaluation Surplus	5,210,600,037	5,101,134,244	4,991,668,451
Gain/(Loss) on Marketable Securities (Unrealized)	2,824,633	2,824,633	2,824,633
Tax Holiday Reserve	196,042,851	196,042,851	196,042,851
Retained Earnings	3,029,079,556	3,844,868,103	5,075,769,764
Non Current Liabilities	**3,671,888,036**	**2,609,599,811**	**1,514,023,626**
Long Term Loans- Net off Current Maturity	3,403,577,088	2,183,541,607	900,922,729
Provision For Gratuity	86,664,750	103,997,700	124,797,240
Deferred Tax Liability	181,646,198	322,060,504	488,303,657
Current Liabilities :	**9,367,775,313**	**10,124,332,825**	**10,468,554,917**
Loans & Overdrafts	4,484,477,361	4,609,477,361	4,359,477,361
Current Maturity of Long Term Loans	1,637,536,901	1,620,035,481	1,282,618,878
Trade Payable	392,333,567	405,876,300	552,025,395
Provision for Income Tax	1,983,726,850	2,579,507,853	3,322,269,510
Liability for Expenses and Others	129,094,684	168,829,880	211,557,823
Dividend Payable	740,605,950	740,605,950	740,605,950
TOTAL	**28,730,993,995**	**29,131,586,037**	**29,501,667,812**

Projected Statement of Profit or loss and Other Comprehensive Income and Earning Per Share (EPS)

	TAKA		
	July '15 to June '16 Total	**July '16 to June '17 Total**	**July '17 to June '18 Total**
Revenue	**12,280,491,019**	**13,960,516,156**	**15,947,809,709**
Less: Cost of Goods Sold	7,650,357,543	8,689,766,857	9,918,228,557
Gross Profit/(Loss)	**4,630,133,477**	**5,270,749,299**	**6,029,581,152**
Add: Other Income	36,607,656	115,921,967	42,803,173
	4,666,741,133	**5,386,671,266**	**6,072,384,325**
Less: Selling, Marketing and Distribution Expenses	1,642,688,113	1,764,567,098	2,012,672,310
	3,024,053,020	**3,622,104,168**	**4,059,712,015**
Less: Administrative Expenses	391,070,495	404,387,963	430,380,968
	2,632,982,525	**3,217,716,205**	**3,629,331,047**
Less: Financial Expenses	1,047,815,049	925,435,991	719,732,088
Profit before Contribution to WPPF	**1,585,167,476**	**2,292,280,214**	**2,909,598,959**
Less: Contribution to WPPF	75,484,166	109,156,201	138,552,331
Net Profit before Tax	**1,509,683,310**	**2,183,124,013**	**2,771,046,628**
Less: Current Tax Expense	427,420,827	595,781,003	742,761,657
Less: Deferred Tax (Income)/Expense	55,655,479	140,414,306	166,243,153
Net Profit after Tax	**1,026,607,004**	**1,446,928,704**	**1,862,041,818**
Other Comprehensive Income			
Gain/(loss) on Marketable Securities (Unrealized)	1,000,000	-	-
Total Comprehensive Income for the year	**1,027,607,004**	**1,446,928,704**	**1,862,041,818**
Earning Per Share (on the Equity Share of Taka 10 each)	**5.90**	**6.84**	**8.80**

Discussion on the results of operations shall inter-alia contain the following

A summary of the past financial results after adjustments as given in the auditor's report containing significant items of income and expenditure

There was no significant adjustment given by the auditor's during the last financial year. Summary of the financial results and operations are presented below:

Particulars	2013-2014	2012-2013
Current Assets	6,635,062,802	7,889,442,833
Current Liabilities	8,429,729,474	5,927,783,411
Non-Current Assets	15,544,508,282	8,684,201,210
Non-Current Liabilities	3,057,678,428	1,128,412,130
Revenue	10,217,931,465	8,973,319,332
Gross Profit/(Loss)	3,980,138,911	3,252,298,522
Net Profit after tax	893,890,898	505,695,794
EPS	5.65	4.19
Net Assets Value per share	66.16	61.15

A summary of major items of income and expenditure

Summary of major head wise income and expenditure are given below

Particulars	2013-2014	2012-2013
Revenue	10,217,931,465	8,973,319,332
Gross Profit/(Loss)	**3,980,138,911**	**3,252,298,522**
Other income	108,071,977	20,146,796
	4,088,210,888	**3,272,445,318**
Less: Selling, Marketing and Distribution Expenses	1,499,828,917	1,330,346,506
	2,588,381,971	**1,942,098,812**
Less: Administrative Expenses	546,384,337	552,068,993
	2,041,997,634	**1,390,029,819**
Less: Financial Expenses	776,911,190	538,786,487
Profit before Contribution to WPPF	**1,265,086,444**	**851,243,332**
Less: Contribution to WPPF	60,242,211	40,535,397
Net Profit before tax	**1,204,844,233**	**810,707,935**
Net Profit after tax	**893,890,898**	**505,695,794**

The income and sales on account of major products or services

ACME earns substantial revenue from its pharmaceuticals formulation finished products through continual business.

Particulars	For the year ended 30 June	
	2014	2013
Pharmaceuticals product	10,193,676,707	8,937,132,605
Syrange	4,702,633	18,196,102
Fish Feed	19,552,125	17,990,625
Total	**10,217,931,465**	**8,973,319,332**

In case, other income constitutes more than 10% of the total income, the breakup of the same along with the nature of the income, i.e., recurring or non-recurring

There was no such other income that contstitures 10% of the total income.

If a material part of the income is dependent upon a single customer or a few major customers, disclosure of this fact along with relevant data. Similarly if any foreign customer constitutes a significant portion of the issuer's business, disclosure of the fact along with its impact on the business considering exchange rate fluctuations

The Company's material part of the income is not dependent upon a single customer or a few major customers. The company has foreign customer but it does not constitutes a significant portion of the issuer's business.

In case the issuer has followed any unorthodox procedure for recording sales and revenues, its impact shall be analyzed and disclosed.

The Company has not followed any unorthodox procedure for recording of sales and revenues.

Comparison of recent financial year with the previous financial years on the major heads of the profit and loss statement, including an analysis of reasons for the changes in significant items of income and expenditure

(Amount in BDT)

Particulars	2013-2014	2012-2013	2011-2012
	July'13 to June'14	July'12 to June'13	July'12 to June'13
Revenue	**10,217,931,465**	**8,973,319,332**	**8,838,091,913**
Less: Cost of Goods Sold	6,237,792,554	5,721,020,810	5,697,479,102
Gross Profit/(Loss)	**3,980,138,911**	**3,252,298,522**	**3,140,612,811**
Add: Other Income	108,071,977	20,146,796	17,992,913
	4,088,210,888	**3,272,445,318**	**3,158,605,724**
Less: Selling, Marketing and Distribution Expenses	1,499,828,917	1,330,346,506	1,264,116,205
	2,588,381,971	**1,942,098,812**	**1,894,489,519**
Less: Administrative Expenses	546,384,337	552,068,993	525,130,630
	2,041,997,634	**1,390,029,819**	**1,369,358,889**
Less: Financial Expenses	776,911,190	538,786,487	526,938,749
Profit before Contribution to WPPF	**1,265,086,444**	**851,243,332**	**842,420,140**
Less: Contribution to WPPF	60,242,211	40,535,397	40,115,245
Net Profit before Tax	**1,204,844,233**	**810,707,935**	**802,304,895**
Less: Current Tax expense	426,636,328	304,015,476	(305,940,093)
Less: Deferred Tax (Income)/Expense	(115,682,993)	996,665	(20,236,406)
Net Profit after Tax	**893,890,898**	**505,695,794**	**476,128,396**
Other Comprehensive Income			
Gain/(loss) on Marketable Securities (Unrealized)	841,041	-	-
Total Comprehensive Income for the year	**894,731,939**	**505,695,794**	**389,036,145**
EPS	**5.65**	**4.19**	**4.10**

Unusual or infrequent events or transactions including unusual trends on account of business activity, unusual items of income, change of accounting policies and discretionary reduction of expenses etc.

For the year ended 30 June 2013, revenue increased by 1.53%, which reflects a nominal growth as a result of sluggish industry growth (8.88%). Even though, it appears that growth rate of the pharmaceutical industry as whole was higher during the same period than the growth achieved by ACME. One of the main reasons behind this was ACME's transitional period with regard to transfer of products from old facility to newly constructed modernized facilities after complying all regulatory procedures and also increase/decrease of MRP of different products. As we hoped, in the immediate following year i.e. in the ended year ended 30 June 2014 the Company regained the growth strength andenjoyed 13.87%, growth, which is greater than the industry average(8.48%). Reason behind this was the amalgamation of The ACME Specialized Pharmaceuticals Limited with The ACME Laboratories Limited and introduction of 43 new products.

For the year ended 30 June 2013 and 30 June 2014, other income increased by amounting Tk. 2,153,883 and Tk. 87, 925,181 respectively. Reason behind increase of such income was the Company raised its paid-up capital in May 2013 through issuing 39,631,100 Ordinary Shares @ Tk. 52 each including premium of Tk. 42 each total amounting Tk. 2,060,817,200 for implementing Large & Small Volume Parenteral Project and Liquid & Semisolid Project. Being the money was gradually used to implement the aforesaid projects, certain amount of capital raised was kept as fixed deposit, due to which, the amount of interest FDR increased which were reflected in the head of other income.

With compare to the previous year, during the year 30 June 2014, administration expenses reduced by amounting Tk. 5,684,656 which represent 1.03% reduction. Reason behind this was firstly, after converting into a public limited company, seven payee directors resigned from their position voluntarily and after resignation they are not getting any remuneration. Secondly, remuneration of all executive directors was reduced by the significant amount. All the said decision was effective from 1st January 2014 and passed on 41st Board meeting.

In the above-mentioned years, another unusual area of transaction was recognition of deferred taxes. Due to shortening the temporary difference in the year 2012-2013, deferred tax expenses decreased by Tk. 19,239,741 with compare to previous year. On the contrary, in the year ended 30 June 2014 the Company recognized deferred tax asset amounting Tk. 177,065,444 on un-absorbed depreciation. There is no change in the accounting policies of the Company during last three years.

Significant economic changes that materially affect or are likely to affect income from continuing operations

There is no significant economic change except introduction of new projects that materially affect or are likely to affect income from continuing operations.

Known trends or uncertainties that have had or are expected to have a material adverse impact on sales, revenue or income from continuing operations

Products of pharmaceuticals industry with related to healthcare needs which one of the fundamental needs of all livings beings. There is a lot of scope to increase the market significantly, which depends on factors like increase of per capital income, increase health consciousness among mass people. Besides local market, contract manufacturing and emerging overseas market also can play a greater role. On the contrary, factors like natural disaster, entrance of new technology, increase in competition etc can affect the business as well.

Future changes in relationship between costs and revenues, in case of events such as future increase in labor or material costs or prices that will cause a material change are known;

Any event such as increase in labor or material costs or prices will not affect the operational result of the company, because of, with the passages of time volume and prices of net sales or revenue are also expected to increase in normal course of operation and for introduction of new products or services.

Total turnover of each major industry segment in which the issuer operated

Pharmaceuticals products are met one of the basic needs for all living being. It is one of the fastest growing industries in the world. According to IMS by 2017 demand of pharma products will be USD 1,200 billion, which was USD 965 billion in the year 2012.

According to the same source, in the year 2014 Bangladesh pharma market size was Tk. 10,600 crore with a growth percentage 8.48. For the year ended 30 June 2014 ACME domestic sales was Tk 985.46 crore and export sales was Tk. 36.33 crore totaling Tk. 1021.79 crore with a growth 14.11%, 7.63% and 13.87% respectively. According to IMS in the year 2015 Bangladesh pharma market size was Tk. 12,000 crore. Insiders of the industry apprehend that by the year 2020 Bangladesh pharma size will be Tk. 20,000 crore. They also apprehend that pharma products are going to be added into the Bangladesh export basket in a big way within couple of years.

Therapeutic class wise sales of pharma product in the year 2014 & 2015

(Amount in BDT Crore)

Sl. #	Name of the Therapeutic class	30 June 2015		30 June 2014	
		Sales	Market share	Sales	Market share
1	Alimentary T.& Metabolism	4,145.64	34.68	3,635.51	34.34
2	Systemic Anti-Infectives	2,197.38	18.38	2,045.58	19.32
3	Nervous System	1,242.44	10.39	1,138.74	10.76
4	Cardiovascular System	1,153.32	9.65	988.34	9.34
5	Respiratory System	1,051.38	8.79	881.82	8.33
6	Musculo-Skeletal System	654.66	5.48	576.17	5.44
7	G.U.System & Sex Hormones	354.00	2.96	285.72	2.70
8	Dermatologicals	288.04	2.41	247.00	2.33
9	Blood + B.Forming Organs	247.27	2.07	223.41	2.11

Sl. #	Name of the Therapeutic class	30 June 2015		30 June 2014	
		Sales	Market share	Sales	Market share
10	Sensory Organs	185.12	1.55	160.34	1.51
11	Systemic Hormones	137.41	1.15	119.72	1.13
12	Hospital Solutions	127.06	1.06	128.88	1.22
13	Parasitology	113.56	0.95	109.70	1.04
14	Antineoplast+Immunomodul	34.47	0.29	28.51	0.27
15	Various	22.96	0.19	16.58	0.16
16	Diagnostic Agents	0.13	0.00	0.34	0.00

Sources: IMS Global Health, based on 520 Chemist shop of urban area in Bangladesh

Status of any publicly announced new products or business segment

During the year 2014, the Company started its commercial operations of Cephalosporin unit which is one of the largest state of the art Cephalosporin facilities in the Country, Liquid in hard gelatin products facilities and Parenteral Products facility under BFS technology which is highly automated facility.

In addition to the above, as a part of expansion plan, the company has a plan to establish three projects namely Hormone & Steriod Project, Oncology Project and Ayurvedic, Herbal & Neutracuticals Project by using IPO proceeds detail of which is discussed in the Chapter of 'Use of IPO Proceeds and Implementation Schedule'.

The extent to which the business is seasonal

As the products of pharmaceuticals industry are met the basic need of all living being and majorly chronic care related, Bangladesh Pharma market is consistent. As such, company's business is not seasonal significantly.

Defaults or rescheduling of borrowings with financial institutions/ banks, conversion of loans into equity along with reasons thereof, lock out, strikes and reasons for the same etc.

ACME has not been recognized as defaulter, and never rescheduled any of its borrowings with financial institutions/banks. There is no history of conversion of loan into equity, lock out and strikes.

Details regarding the changes in the activities of the issuer during the last five years which may had a material effect on the profits/loss, including discontinuance of lines of business, loss of agencies or markets and similar factors

During the last five years i.e. 2009-2010 to 2013-2014, the net profit after tax is increased from Tk. 227,806,543 to Tk. 893,890,898 with a Cumulative Average Growth Rate is 40.74% due to launching 4(four) new products facilities like Solid Dosages facilities, Cephalosporin facilities, Liquid in hard gelatin facilities and BFS facilities and introduction of new products in every year.

There is no record of discontinuance of any line of business, loss of agencies or markets and similar factors.

Injunction or restraining order, if any, with possible implications

There is no event in history of Company regarding the injunction or restrain order.

Technology, market, managerial competence and capacity built-up

Technology

ACME is vertically integrated generic pharmaceuticals formulation products manufacturer, marketer, promoter and distributor. Its manufacturing process heavily technology driven, dynamic in nature and using highly sophisticated state-of-the –art cutting edge technology.

ACME has a world-class manufacturing plant, located at Dhamrai, Dhaka. The plant adheres to GMP standard, hygiene and safety. The facilities are unique for Integrated Building Management System (IBMS), World-class Structural Design, Dust-free Environment, well-designed HVAC System, Zero Cross-contamination, Vacuum Transfer Close System, Different Storage Conditions, High-tech Chemical & Microbiological Laboratories, Modern R&D facility, most up-to-date Purified Water Generation plant, Fire Management System and Eco-friendly Effluent Treatment Plant.

ACME maintains Total Quality System, which includes Strict Monitoring, End-to-end Regulation. State-of-the-art Equipment, True Measurements, Equipment Calibration, Trained professionals.

Market

Pharmaceuticals products are met one of the basic needs for all living being. It is one of the fastest growing industries in the world. According to IMS by 2017 demand of pharma products will be USD 1,200 billion, which was USD 965 billion in the year 2012.

According to the same source, in the year 2014 Bangladesh pharma market size was Tk. 10,600 crore with a growth percentage 8.48 (Based on 520 Chemist shop of urban area in Bangladesh). For the year ended 30 June 2014, ACME domestic sales was Tk 985.46 crore and export sales was Tk. 36.33 crore totaling Tk. 1021.79 crore with a growth 14.11%, 7.63% and 13.87% respectively. According to IMS in the year 2015 Bangladesh pharma market size was Tk. 12,000 crore. Insiders of the industry apprehend that by the year 2020 Bangladesh pharma size will be Tk. 20,000 crore. They also apprehend that pharma products are going to be added into the Bangladesh export basket in a big way within couple of years.

The company has good market position with its products mainly; including Tenoloc (Atenolol), Ecosprin (Aspirin), Monas (Montelucast), Fulspec (Meropenem), Nystat (Nystatin) as market leader of its types.

The company currently exports more than 170 pharmaceutical products to different countries in Southeast Asia, Africa and Central America. At present, the company is successfully exporting its quality products to Sri Lanka, Nepal, Bhutan, Myanmar, Thailand, Vietnam, Philippines, Cambodia, Hong Kong, Lao PDR, Iraq, Ethiopia, Kenya, Uzbekistan, Somalia, Guatemala, Belize and Fiji. In addition to human pharmaceuticals, the company is exporting its animal-health products to Myanmar, Sri Lanka and exploring the opportunities of Herbal & Ayurvedic products in South Asia and Africa. The company has further market exploration plan to Europe and Latin America.

Managerial competence

All the members of the management team of the company are highly qualified, trained & skilled professionals, well experienced and extremely devoted. The management team is lead by Mr. Mizanur Rahman Sinha, Managing Director and acts for the best interest of the company.

The expert team of ACME, which consists of 92 Pharmacist and 63 Engineers and a good number of professionals from various disciplines, are seasoned and experienced enough to use the facilities for production to fulfill the demand of target customers.

Successive strong financial performance is the result of unwavering commitment of the promoters, management efficiency, employees' sincerity, use of appropriate technology, among others.

Capacity build up

To keep space with the contemporary technology and customer demand the company continuously investing and deploying enough resources including human resources.

To cope up with the growing market demand and strengthening long term sustainability, during the year 2014, the Company completed and started commercial operations of Cephalosporin unit which is one of the largest state of the art Cephalosporin facilities in the Country, Liquid in hard gelatin products facilities and Parenteral Products facility under BFS technology which is highly automated facility.

Changes in accounting policies in the last three years

There is no change in the accounting policies of the Company during last three years.

Significant developments subsequent to the last financial year: A statement by the directors whether in their opinion there have arisen any circumstances since the date of the last financial statements as disclosed in the prospectus and which materially and adversely affect or is likely to affect the trading or profitability of the issuer, or the value of its assets, or its ability to pay its liabilities within the next twelve months; Statement by the directors whether there have arisen any circumstances since the date of the last financial statements which materially and adversely affect the trading or profitability of the issuer, or the value of its assets, or its ability within the next twelve months

Statement regarding significant developments subsequent to the last financial year

This is to certify that in our opinion there have not arisen any circumstances since the date of the last financial statements as disclosed in the prospectus and which materially and adversely affect or is likely to affect the trading or profitability of The ACME Laboratories Ltd. or the value of its assets, or its ability to pay its liabilities within the next twelve months.

Sd/-
(Afzalur Rahman Sinha)
Chairman
Sd/-
(**Jahanara Mizan Sinha)**
Director

Sd/-
(Mizanur Rahman Sinha)
Managing Director
Sd/-
(Nagina Afzal Sinha)
Director
Sd/-
(Fouzia Haque, FCA)
Independent Director

Sd/-
(**Dr. Jabilur Rahman Sinha)**
Director
Sd/-
(Syed Shahed Reza)
Independent Director

If any quarter of the financial year of the company ends after the period ended in the audited financial statements as disclosed in the prospectus, unaudited financial statements for each of the said quarters duly authenticated by the CEO and CFO of the issuer

After the year ended 30 June 2014, a full year i.e. completed year ended 30 June 2015 completed, for which a full set of Financial Statements are enclosed herewith, page 387-427 under chapter **'Others'**.

Factors that may affect the results of operations

Factors like increase of per capita income, increase health consciousness among mass people, local market, contract manufacturing and emerging overseas market can play a greater role. On the contrary, factors like natural disaster, entrance of new technology, increase in competition etc can affect the business as well.

CHAPTER VII: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview of business

ACME started its journey in the 1954, in the way of its six decades journey it has transform itself from good to better and it has been moving towards the great from better through converting to a public limited Company. Now it is peeping into the Stock Exchanges.

Since very inception of its journey ACME has been enjoying continuous growth and strengthening its position in the Bangladesh and Global phama market. Up to 30 June 2014 ACME introduced 504 human products including herbal products covers 13 dosages form under 17 therapeutics classes and 168 veterinary products including herbal products covers 6 dosages form under 18 therapeutics classes. For the year ended 30 June 2014 its revenue stood at Tk. 10,217,931,465 representing growth 13.87 percent and earned net profit after tax Tk. 893,890,898. It's last five years Cumulative Average Growth Rate of revenue stood at 16.45 percent.

ACME's Business model

ACME's mission statement says "Our holistic approach is to ensure Health, Vigour and Happiness for all by manufacturing ethical drugs and medicines of the highest quality at affordable price and expanding in the local and global market.

We view ourselves as partners with the doctors, healthcare professionals, all other customers, our employees and harmonize with environmental issues."

Core Values

Our company values are the measure for our thinking and actions. They are the core of what ties us together in the past, present and future. We do business on the basis of common values. Our success is based on customer focus, team spirit, desire to win, pro-activity, integrity and excellence. These values determine our actions in our daily dealing with customers and business partners as well as in our teamwork and our collaboration with each other.

Major functional areas

Considering our mission statement, core values and ethos of Bangladesh finished formulation pharmaceuticals industry, ACME has vertically integrated its operations and its value chain covers core activities like selection of molecules, development of formulation, manufacturing the finished products, marketing, distribution and sales operated under the supervision of following functional divisions:

Marketing division

It is one of the core functional divisions. It is the starting point of the whole value chain. It activities cover selection of molecules, preparing marketing brief, designing the product getup, selecting the promotional tools, monitoring market share and market size.

Inspiration of new molecules comes from a variety of sources like following R & D driven company and developed market, different pharmacopeia, IMS data, different healthcare journals and activities of major competitors. For this division ACME employed total 78 talented university graduates including 27 pharmacists most of them are senior and headed by a highly professional marketer.

Production division

Production division is also one of the core functional divisions. It is the supplying point of the value chain. Considering the selected molecules by marketing division and considering the industry regulation this division adapt highly sophisticated cutting-edge technology and other necessary resources including human resources. Its activities includes meet the market demand through producing quality products. This division is highly resourceful and employed 797 professionals including 32 pharmacists.

Quality operation division

Quality division is highly independent one and directly reportable to the Board. It is a supporting division in nature but core of the ACME's brand image. It ensures foolproof quality system from checking sample, vendors' worthiness and in process quality management. Obtainment of accreditation of whole facility is also the responsibility of this division. This division deployed 159 highly talented professional including 44 pharmacists.

Product Development, Research and Development division

This division has been working relentlessly for developing cost effective formulation adhering 100% quality parameters. 18 highly qualified members including 12 pharmacists have been working for this division.

Sales Management Division

A mega forces team has been working almost round the clock for earning bread and butter for the ACME family. Total members of this team are 3,292, they are highly completive and achiever minded.

Distribution Department

ACME's distribution department has been working as a forward linkage wing of its value chain. It deployed a fleet of 100 delivery vehicle and 1,562 sales and collection personnel. It tries to deliver goods to the chemist shop with 24 hours after receiving the orders.

Supply chain Division

Due to integrated in nature of Bangladesh pharma business, efficient supply chain management is one of the Key Result Areas (KRA) here. To make sure all the ingredients and logistics support promptly a very professional team of ACME's supply chain division including 7 pharmacist has been working with full heart.

Besides above, Finance & Accounts, IT, Engineering, Human Resources have been contributing in the ACME's business activities very efficiently.

ACME's Strategies

ACME's key strategic objectives are to:

1) Ensure health, vigour and happiness for all;
2) Ensure stable and long-term return to our investors;
3) Maintain state-of-the-art manufacturing facilities for ensuring best quality products to the customers;
4) Obtain word class accreditation by proper execution of ISO 9001:2008 standard, WHO cGMP standard and best practices that are proven effective;
5) Expand existing and develop new large scale projects to diverse the product range and related diversification;
6) Strengthening our existing market share, cope with the changing scenario in the pharma industry to ensure higher prescription rates, transparency and improved products and services for our existing and potential customers;
7) Comprehensive marketing and distribution network (Both in domestic and international markets);
8) Excellent relationship with health care professionals, chemists and other concerned stakeholders;
9) Seek new ways of working to improve efficiency and ensure sustainability.

SWOT analysis:

It is a common phenomenon that each and every business has its some strength and weakness as well as some opportunities and threats comes before it. But, through proper management, it is possible to convert the weakness into strength and to convert threat into opportunities. ACME's Strength, Weakness, Opportunities and Threats are like follows:

Strength

- Perceived understanding of industry's macro environment over 60 years;
- Highly skilled and qualified white-collar workforces;
- Adaptor of most modern state of the art sophisticated technology;
- Mega sales force comprising of more than three thousand experienced, skilled and devoted persons;
- Country wide extensive distribution channel;
- Application of Corporate Governance;
- Strong brand recognition and outstanding service;

Weaknesses

- Uncovered areas of business (Dosages form);
- Less urban focus than major competitors;
- In most cases follower in new product launching;

Opportunities

- Vast scope of related diversification;
- Emerging overseas market;
- Promising market for contract manufacturing;
- Pharmaceutical market of Bangladesh is booming rapidly, so ACME has a huge scope to do better;
- Establish & Growing market segment.

Threats

- New entrants;
- More competitive with the leading Pharmaceutical;
- Scarcity of core professionals;
- Stringent pricing regulations.

Analysis of the financial statements of last five years with reason(s) of fluctuating revenue/sales, other income, total income, cost of material, finance cost, depreciation and amortization expense, other expense; changes of inventories, net profit before & after tax, EPS etc.

Financial Statements information: **(Amount in BDT)**

Particulars	2013-2014	2012-2013	2011-2012	2010-2011	2009-2010
Revenue	10,217,931,465	8,973,319,332	8,838,091,913	6,996,750,681	5,557,237,718
Other income	108,071,977	20,146,796	17,992,913	12,096,145	19,644,640
Total Income	10,326,003,442	8,993,466,128	8,856,084,826	7,008,846,826	5,576,882,358
Cost of Material	5,381,798,696	5,151,259,859	5,074,477,521	4,004,931,434	3,205,725,987
Finance Cost	776,911,190	538,786,487	526,938,749	309,766,701	262,464,527
Depreciation	311,628,502	228,280,163	217,347,308	123,857,689	110,652,344
Amortization	51,257	70,521	125,508	41,228	-
Other Expenses	2,590,527,353	2,223,825,766	2,194,775,600	1,956,920,444	1,633,549,031
Inventory	2,223,003,434	1,886,267,051	1,781,058,760	1,271,611,575	811,183,318
Changes of Inventory	18%	6%	40%	57%	23%
Net Profit before tax	1,204,844,233	810,707,935	802,304,895	584,141,913	364,490,469
Net Profit after tax	893,890,898	505,695,794	476,128,396	344,151,300	227,806,543
EPS	5.65	4.19	4.10	2.97	1.96

Reason of fluctuation:

Revenue

During the aforesaid years ended at 30 June each the Company enjoyed two digit growth with a range of 13.87% to 26.32% which all in line with or above the industry growth except 2012-2013. For the year ended 30 June 2013, revenue increased by 1.53%, which reflects a nominal growth as a result of sluggish industry growth (8.88%). Even though, it appears that growth rate of the pharmaceutical industry as a whole was higher during the same period than the growth achieved by ACME. One of the main reasons behind this was ACME's transitional period with regard to transfer of products from old facility to newly constructed modernized facilities after complying all regulatory procedures and also increase/decrease of MRP of different products. As we hoped, in the immediate following year i.e. in the year ended 30 June 2014 the Company regained the growth strength andenjoyed 13.87% growth, which is greater than the industry average (8.48%). Reason behind this was the amalgamation of The ACME Specialized Pharmaceuticals Limited with The ACME Laboratories Limited and introduction of 43 new products.

Other Income

Other income also almost consistent over the year except 2012-2013 and 2013-2014. For the year ended 30 June 2013 and 30 June 2014, other income increased by amounting Tk. 2,153,883 and Tk. 87, 925,181 respectively. Reason behind the increase of such income was the Company raised its paid-up capital in May 2013 through issuing 39,631,100 Ordinary Shares @ Tk. 52 each including premium of Tk. 42 each total amounting Tk. 2,060,817,200 for implementing Large & Small Volume Parenteral Project and Liquid & Semisolid Project. Being the money was gradually used to implement the aforesaid projects, certain amount of capital raised was kept as fixed deposit, due to which, the amount of interest FDR increased which were reflected in the head of other income.

Total Income

In-fact, combined effect of revenue and other income are reflected in the total income. As such, aforesaid explanation is applicable here also.

Cost of materials

We see, over the years cost of materials to revenue are consistent.

Finance Cost

As a one of the top ranking pharmaceuticals companies of the country, ACME has been trying to make it more sustainable and more competent one through adapting sophisticated technologies. To do so, in the recent past, the Company has built several new plants and invested huge amount of money, which will generate benefits in coming days, through bank borrowing and capital raising. In consequence, finance cost showing increasing trend over the years.

Depreciation and Amortization

There is significant growth of depreciation in the 2011-2012 and 2013-2014 due to revaluation of fixed assets and amalgamation of The ACME Specialized Pharmaceuticals Company with The ACME Laboratories Limited.

Other Expenses

We see, over the yearstrend of other expenses are consistent.

Changes of Inventory

There is no significant changes of inventory level with relate to its business volume over the years.

Net profit before& afterTax and Earning Per Share (EPS)

The Company has been enjoying revenue growth over the years. Due to reaching at upper scale of economies, ACME's net profit before and after tax showing increasing trend over the years. Besides, in the year ended 30 June 2014 the Company recognized deferred tax asset amounting Tk. 177,065,444 on un-absorbed depreciation, which reflected in the net profit after tax of that year.

By virtue of above reasons, EPS of the Company also reflected accordingly.

Known trends demands, commitments, events or uncertainties that are likely to have an effect on the company's business.

There is a lot of scope to increase the market significantly, which depends on factors like increase of per capita income, increase health consciousness among mass people. Besides local market contract manufacturing and emerging overseas market also can play a greater role. On the contrary, factors like natural disaster, entrance of new technology, increase in competition etc can affect the business as well.

Trends or expected fluctuations in liquidity

The company has been operating with moderate liquidity. The company is currently enjoying working capital facilities in different modes from various banks, through which it is managing liquidity and meeting its import payments for procuring raw materials to carry out the production.

From the cash flow of the company, it has been revealed that the company can generate sufficient fund internally to service its debt burden and other liabilities also. The company generated operating cash flow of Tk. 451.16 mil. for the year ended June 30, 2014 to meets its liquidity and obligation.

Off-balance sheet arrangements those have or likely to have a current or future effect on financial condition

The Company has not any off-balance sheet arrangements except those disclose in the notes no. 48 and 49 in the financial statement of the Company. Details of which as follows-

VAT

Large Tax Payer Unit (LTU), North Commissionerate and Directorate, Inspection, Intelligence & Investigation under National Board of Revenue (NBR) against 4 (four) claims of VAT and another 1 (one) regarding VAT on VAT exempted medicine. The ACME Laboratories Ltd. has filed 5 (five) writ petitions in The Honorable High Court Division of the Supreme Court of Bangladesh separately vide no.- 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002 respectively against the said claims. The company reviews status of the same on every reporting date. Details of current status are given below:

SL	Writ No.	Value in BDT	Reason	Expiry Date
01	8650/2008	Non-monitory	Medicine supply to ICDDRB as Exempted	Valid up to disposal of hearing
02	785/2009	1,30,97,829.00	Rebate for exemption of medicine	Valid up to disposal of hearing
03	3948/2004	27,30,765.27	Rebate cancel	Valid up to disposal of hearing
04	4477/2002	19,07,555.00	Rebate cancel	Valid up to disposal of hearing
05	4478/2002	6,65,525.24	Difference in rate of custom duty with the department	Verdict has already been given by the Honorable High court division but formal demand yet to receive from concern authority

Income Tax

Accounting Year	Assessment year	Status
2013-14	2014-15	After complying provision of law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax Return was submitted on 31.12.2014. Subsequently the Deputy Commissioner of Taxes issued a letter to audit. Being aggrieved, the Company filed a Writ Petition against the letter before the High Court Division of the Supreme Court of Bangladesh. The court issued a Rule Nisi and stayed the order till disposal from the date 08 March 2016.
2012-13	2013-14	Return was submitted duly under law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax. Subsequently, the Deputy Commissioner of Taxes issued a letter to audit and after conducting audit assessment order was issued by demanding tax liability of Tk. 19,232,808. Against the order, the company appeal the same to the Commissioner of Taxes (Appeal) on dated 20 September 2015. Hearing was duly heard on 25 November 2015 but the order has not yet been issued by the Commissioner Taxes (Appeal).
2011-12	2012-13	As per demand notice u/s 135 dated 20.07.2015 present tax demand is Tk. 22,339,873 which has been paid on dated 24.02.2016.
2010-11	2011-12	The Deputy Commissioner of Taxes, Circle-161, Zone-08 certified that "income tax case for the assessment year 2011-12 has been settled".
2009-10	2010-11	As per demand notice u/s 135 dated 30.01.2013 present tax demand is Tk. 35,945,126. As per section 173 a letter was submitted by the Company to the DCT on 06.03.2013 to rectify the all-previous years' orders by adjusting previous years refund and AIT and raised revised demand. Revised order yet to receive.
2008-09	2009-10	As per demand notice u/s 135 dated 08.10.2012 present tax demand is Tk. 45,930,964. As per section 173 a letter was submitted by the Company to the DCT on 06.03.2013 to rectify the all-previous and current years' orders by adjusting previous years refund and current years AIT and raised revised demand. Revised order yet to receive.

Besides, the company provides bank guarantees to various parties in the normal course of business. Since, some the guarantees are required to renew and some of them are settled within the date of Expiry, so there is no scope of current or future effect on financial condition.

CHAPTER VIII: DIRECTORS AND OFFICERS

Name, Father's name, age, residential address, educational qualification, experience and position of each of the directors of the company and any person nominated/represented to be a director, showing the period for which the nomination has been made and the name of the organization which has nominated him;

Particulars of Directors

SL #	Name of the Director's	Father's name	Age	Residential address	Educational qualification	Experience	Position in the company	Name of the Institutions and Duration for Nominated Director
01	Mr. Afzalur Rahman Sinha	Late Hamidur Rahman Sinha	64	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	MBA (USA)	32	Chairman	-
02	Mr. Mizanur Rahman Sinha	Late Hamidur Rahman Sinha	71	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	B.Com	38	Managing Director	-
03	Dr. Jabilur Rahman Sinha	Late Hamidur Rahman Sinha	70	Hazel Wood, House No. 4, Road No. 118, Gulshan-2, Dhaka	M,Sc, PhD. Organic Chemistry	05	Deputy Managing Director	-
04	Mrs. Jahanara Mizan Sinha	Late Habibur Rahman Sinha	65	House No. 6, Road No.14, Sector-4, Uttara Model Town, Dhaka, Bangladesh	HSC.	34	Director	-
05	Mrs. Nagina Afzal Sinha	Aminur Rashid Chowdhury	58	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	BA.	34	Director	-
06	Syed Shahed Reza	Late Syed Ali Reza	62	Apt. # A4, House No. 26, Road No. 130, Gulshan - 01, Dhaka	B.A. (Hon's) and M.A.	01	Independent Director	-
07	Ms. Fouzia Haque, FCA	Md. Serajul Haque, Advocate	47	House No. 7/2, Block-D, Lalmatia, Dhaka.	M.Com (Mgt.) and FCA	01	Independent Director	-

The date on which he first became a director and the date on which his current term of office shall expire

Directorship tenure in the Company

SL #	Name of the Director's	First date of appointment as Director	Date of Expiry current term as Director
01	Mr. Afzalur Rahman Sinha	17-03-1976	19th September 2019
02	Mr. Mizanur Rahman Sinha	17-03-1976 & Appointed as MD on 30-09-1995	19th September 2020
03	Dr. Jabilur Rahman Sinha	17-03-1976	7th November 2017
04	Mrs. Jahanara Mizan Sinha	15-04-1981	Up to the date of AGM of 2016
05	Mrs. Nagina Afzal Sinha	15-04-1981	Up to the date of AGM of 2016
06	Syed Shahed Reza	09-09-2014	08-09-2017
07	Ms. Fouzia Haque, FCA	09-09-2014	08-09-2017

If any director has any type of interest in other businesses, names and types of business of such organizations. If any director is also a director of another company or owner or partner of any other concern, the names of such organizations

Directors' interest in other Business

Sl #	Name of Directors	Directorship/Sponsorship/Ownership with other Company		Position
		Name of Company	Type of Business	
01	Mr. Afzalur Rahman Sinha	The ACME Agrovet & Beverages Limited	Manufacturing of Agro based Products, Foods and Beverages.	Chairman, Managing Director and Director
		Sinha Printers Limited	Printing and Packaging	Managing Director and Director
		ACME IT Limited	IT Education	Managing Director and Director
		The ACME Overseas Trading Limited	Import and Trading Business	Managing Director and Director
		ACMUNIO International Limited	Manufacturing & Marketing of Auto Disable Syringe.	Director
		Sinha Fabrics Limited	Export oriented Garment Manufacturing.	Director
		Sinha Wool Wears Limited	Export oriented Garment Manufacturing.	Director
		Sinha Knit Industries Limited	Export oriented Garment Manufacturing.	Director
02	Mr. Mizanur Rahman Sinha	ACME IT Limited	IT Education	Chairman and Director
		Kalyar Packaging Limited	Printing and Packaging	Chairman and Director
		Kalyar Replica Limited	Foil Printing and Packaging	Chairman and Director
		Sinha Fabrics Limited	Export oriented Garment Manufacturing.	Chairman and Director
		Sinha Wool Wears Limited	Export oriented Garment Manufacturing.	Chairman and Director
		ACME Overseas Trading Limited	Import and Trading Business	Chairman and Director
		Sinha Knit Industries Limited	Export oriented Garment Manufacturing.	Chairman and Director
		ACMUNIO International Limited	Manufacturing & Marketing of Auto Disable Syringe.	Director
		Sinha Printers Limited	Printing and Packaging	Director
		The ACME Agrovet & Beverages Limited.	Manufacturing of Agro based Products, Foods and Beverages.	Director
03	Dr. Jabilur Rahman Sinha	ACMUNIO International Limited	Manufacturing & Marketing of Auto Disable Syringe.	Chairman and Director
		Sinha Printers Limited	Printing and Packaging	Chairman and Director

Sl #	Name of Directors	Directorship/Sponsorship/Ownership with other Company		Position
		Name of Company	Type of Business	
04	Mrs. Jahanara Mizan Sinha	J M Sinha Agriculture Food Processing Industries Limited	Producing Agro Products	Chairman and Director
		Sanjar Aviation Limited	Air Ticketing	Chairman and Director
		The ACME Agrovet & Beverages Limited	Manufacturing of Agro based Products, Foods and Beverages.	Director
		Kalyar Packaging Limited	Printing and Packaging	Director
		Kalyar Replica Limited	Foil Printing and Packaging	Director
		Sinha Printers Limited	Printing and Packaging	Director
05	Mrs. Nagina Afzal Sinha	Sinha Printers Limited	Printing and Packaging	Director
		The ACME Agrovet & Beverages Limited	Manufacturing of Agro based Products, Foods and Beverages.	Director
06	Syed Shahed Reza	Not applicable	Not applicable	Not applicable
07	Ms. Fouzia Haque, FCA	Not applicable	Not applicable	Not applicable

Statement of if any of the directors of the issuer are associated with the securities market in any manner. If any director of the Issuer Company is also a director of any issuer of other listed securities during last three years then dividend payment history and market performance of that issuer

There is no involvement of any director of The ACME Laboratories Ltd. with securities market. No director of the ACME Laboratories Ltd. is a director of any issuer of the listed securities.

Any family relationship (father, mother, spouse, brother, sister, son, daughter, spouse's father, spouse's mother, spouse's brother, spouse's sister) among the directors and top five officers

Family relationship among Directors

Sl. No	Name of the Director	Position in the Company	Relationship
01	Mr. Afzalur Rahman Sinha	Chairman	Brother of Mr. Mizanur Rahman Sinha, MD Brother of Dr. Jabilur Rahman Sinha, DMD
02	Mr. Mizanur Rahman Sinha	Managing Director	Brother of Mr. Afzalur Rahman Sinha, Chairman Brother of Dr. Jabilur Rahman Sinha, DMD
03	Dr. Jabilur Rahman Sinha	Deputy Managing Director	Brother of Mr. Mizanur Rahman Sinha, MD Brother of Mr. Afzalur Rahman Sinha, Chairman
04	Mrs. Jahanara Mizan Sinha	Director	Spouse of Mr. Mizanur Rahman Sinha, MD
05	Mrs. Nagina Afzal Sinha	Director	Spouse of Mr. Afzalur Rahman Sinha, Chairman
06	Syed Shahed Reza	Independent Director	No relation with the company and other directors
07	Ms. Fouzia Haque, FCA	Independent Director	No relation with the company and other directors

Family Relationship among the Directors and Top Five Officers

Sl. No.	Name	Position in the Company	Relationship
1	Mr. Afzalur Rahman Sinha	Chairman	Brother of Mr. Mizanur Rahman Sinha
2	Mr. Mizanur Rahman Sinha	Managing Director	Brother of Dr. Jabilur Rahman Sinha
3	Dr. Jabilur Rahman Sinha	Deputy Managing Director	Brother of Mr. Mizanur Rahman Sinha
4	Mr. Mohammad Dabir Uddin	Additional Deputy Managing Director	Brother in law of Mr. Mizanur Rahman Sinha
5	Mr. Md. Hasibur Rahman	Additional Deputy Managing Director	Brother in law of Mr. Mizanur Rahman Sinha

A very brief description of other businesses of the directors

SL.	Name of the Concerns	Status	Nature of Business
1	The ACME Agrovet & Beverages Ltd.	Common Directorship	Manufacturing of Agro based Products, Foods and Beverages.
2	ACMUNIO International Ltd.	Common Directorship	Manufacturing & Marketing of Auto Disable Syringe.
3	Sinha Printers Ltd.	Common Directorship	Printing and Packaging
4	Sinha Fabrics Ltd.	Common Directorship	Export oriented Garment Manufacturing.
5	Sinha Wool Wears Ltd.	Common Directorship	Export oriented Garment Manufacturing.
6	Kalyar Packaging Ltd.	Common Directorship	Printing and Packaging
7	Kalyar Replica Ltd.	Common Directorship	Foil Printing and Packaging
8	Sinha Knit Industries Ltd.	Common Directorship	Export oriented Garment Manufacturing.
9	ACME IT Ltd.	Common Directorship	IT Education
10	ACME Overseas Trading Ltd.	Common Directorship	Import and Trading Business
11	Sanjar Aviation Ltd.	Common Directorship	Air Ticketing
12	J M Sinha Agriculture Food Processing Industries Ltd.	Common Directorship	Producing Agro Products

Short Bio Data of the Directors

Mr. Afzalur Rahman Sinha, Chairman

Mr. Afzalur Rahman Sinha, a **Freedom Fighter**, was active in the Southwest front during the Liberation War of Bangladesh, graduated from the University of Dhaka with a degree in Science in 1973. He then proceeded to the United States for further studies in Business Administration. During his studies, he worked as an Analytical Chemist at the University of Missouri in the United States. He then returned to Bangladesh in 1982 to join ACME as its Deputy Managing Director. He is also the Director of Sinha Wool Wears Limited, Sinha knit Industries Limited and Sinha Fabrics Limited. He has become Chairman of the company in 2014. He is a sport loving personality and a key organizer and patron to the cricket and hockey and also other sports events. Presently, he is the Director of Bangladesh Cricket Board and the Chairman of Finance Committee of the Bangladesh Cricket Board.

Mr. Mizanur Rahman Sinha, Managing Director

Mr. Mizanur Rahman Sinha obtained his graduation degree in Commerce from University of Dhaka. After graduation, he joined to Habib Bank Limited in 1964 and worked there in different senior positions. In the year 1975 as per the desire of his father i.e. the founder of The ACME Laboratories Ltd, he joined in The ACME Laboratories Ltd. His wholehearted effort and bold leadership made the organization's achievement a milestone in the Pharmaceuticals industry of the country. Besides, he is the founder of Sinha Wool Wears and Sinha Fabrics Limited both of which have achieved a very good export market. He is popular among his fellow countrymen as a devoted social worker and philanthropist for his magnanimous contribution towards the wellbeing of the common masses through development of infrastructure, construction of schools, buildings and roads. He was elected Member of Parliament and State Minister of health and family welfare ministry of government of People's Republic of Bangladesh.

Dr. Jabilur Rahman Sinha, Deputy Managing Director

Dr. Jabilur Rahman Sinha has a B. Sc. in Chemistry from University of Dhaka, and M.Sc. in Pharmaceuticals Chemistry from North Dakota State University, Fargo, North Dakota and a Ph.D. in Organic Medicinal Chemistry from University of Georgia, Athens, Georgia. Dr. J R Sinha has 28 years of research and teaching experience in several academic institutions in the United States. Dr. Sinha has extensive experience in research and teaching in general, organic and analytical Chemistry at several colleges in the United States and has been very successful as professor as revealed by his peer and student evaluation year after year. He has been an active member of American Chemical Society, Rho Chi Honor Society and Sigma Xi Honor Society.

Mrs. Jahanara Mizan Sinha, Director

Mrs. Jahanara Mizan Sinha, wife of Mizanur Rahman Sinha is the Chairman of J M Sinha Agriculture Food Processing Industries Limited. She is also Director of The ACME Agrovet & Beverages Limited, Kalyar Packaging Limited and Kalyar Replica Limited. Besides, her business areas, Mrs. Mizan is a social entrepreneur, which has given her an opportunity to grow and make a difference in the social life in which she lives.

Mrs. Nagina Afzal Sinha, Director

Mrs. Nagina Afzal Sinha is a Director of The ACME Laboratories Ltd. since 1981. She has a proven capability of contributing values in both family and business areas. She is aware of her own traits, rights and also the work situations. Her skills in facing challenges and opportunities enabled the Company to grow rapidly. She is engaged in various social welfare organizations.

Syed Shahed Reza, Independent Director

Syed Shahed Reza has obtained BA (Hons) in Political Science, M.A. in Public Administration from Dhaka University. He started his career in Saudi Arabia as Senior Executive (Finance, Accounts and Administration) at the PARSONS Ltd, an USA based multinational company. Later, he joined Bangladesh Ministry of Foreign Affairs as Secretary and Ambassador to the State of Kuwait and the Republic of Yemen. Presently he is contributing to ACME's Board as an Independent Director.

He is renowned sport personalities and sport organizer. He was awarded by Bangladesh Sports Journalist Association as best sports organizer and also got merit award of Olympic Council of Asia. Currently discharging his responsibility in National Chancellor (Bangladesh Chapter) International Association of Educators for World Peace (IAEWP), he is also Member of different socio-cultural national and international organization. He is the sitting Secretary General of Bangladesh Olympic Association. He is running president of Dhaka Club Ltd.

He has Extensive experience in management, leadership, organizational effectiveness and diplomacy arena at National level.

Ms. Fouzia Haque, FCA, Independent Director

Ms. Fouzia Haque, FCA is a Fellow Member of the Institute of Chartered Accountants of Bangladesh (ICAB). She obtained master degree in Management from the University of Dhaka. Currently she is working as a Partner of Zaman Hoque & Co., Chartered Accountants. She joined in ACME's Board as an Independent Director on 9 September 2014 and also serving as Chairman of Audit Committee of the Company. Previously she served at BRAC, a renowned NGO; BRAC University; Disability and Development in Bangladesh (ADD); ACNABIN, a Chartered Accountants' firm and World Bank at various capacities.

She has Extensive experience in management and leadership. She has strong background in IAS/IFRS, ISA, Internal Control System, Company Law, BSEC Rules &Laws, Corporate Governance, Management Accounting Principles, ERP system and Development of Standard Operating Procedures.

Ms. Haque is well travelled and participated in good number of conferences and training programs at home and in abroad.

Loan status of the issuer, its directors and shareholders who hold 5% or more shares in the paid-up capital of the issuer in terms of the CIB Report of Bangladesh Bank

Credit Information Bureau (CIB) report

It appears from the CIB report of Bangladesh Bank; there are "Stay Order" of the Honorable High Court Division of the Honorable Supreme Court of Bangladesh regarding loan related matters of The ACME Laboratories Ltd. and its Directors.

Name with position, educational qualification, age, date of joining in the company, overall experience (in year), previous employment, salary paid for the financial year of the Chief Executive Officer, Managing Director, Chief Financial Officer, Company Secretary, Advisers, Consultants and all Departmental Heads. If the Chairman, any director or any shareholder received any monthly salary than this information should also be included;

Particulars of Top Executives & Departmental heads of the Company including Consultants & Advisers

Name	Position	Date of Joining in the company	Age	Educational Qualification	Experience in Company	Overall Experience (in year)	Salary paid(2013-14)	Previous employment
Mr. Mizanur Rahman Sinha	Managing Director	17.03.1976	71	B.Com	38	47	2,10,00,000	Agrani Bank Ltd. (formerly Habib Bank Ltd.)
Mr. Md. Hasibur Rahman	Additional Deputy Managing Director, Finance & Accounts, ISO and Internal Audit	01.09.1977	66	B.Com, C.A (Final, Group-I)	36	40	8,087,519	N/A
Mr. Parvez Hashim	Executive Director	02.08.2015	62	M. Pharm (DU)	6 months	37	-	Square Pharmaceutical Ltd.
Mr. Md. Zahangir Alam	Chief Financial Officer	10.07.2000	46	M Com, DU FCMA	16	18	3,308,270	Bashundhara Group
Mr. Md. Rafiqul Islam	Company Secretary	30-10-2014	45	MBA and ACS	1	14	-	International Leasing And Financial Services Ltd.
Mr. AKM Mushiur Rahman Khan	Director, Procurement Planning and Inventory Control	01.06.1996	46	M Com, DU FCMA	19	23	4,315,508	MAWTS (Caritas)
Mr. Tushar Kanti Kundu	Head of HR	03.11.1996	47	M. Sc., MBA (HRM)	18	18	1,547,580	Sir M MacDonald & Partners Limited
Mr. Mohammad Abdul Hamid Miah	DGM, Factory Admin & HR	01.08.2013	51	MA(Eco.), MBA(HRM), Diploma of Business(AU)	2	23	13,12,810	ASM Chemical Ind. Ltd.
Mr. Golam Rabbani Bhuiyan	Director, Sales	07.10.1978	59	HSC	35	35	5,714,801	N/A
Mr. Animesh Pal	Consultant, Marketing & SBMD	09-08-2014	45	M. Pharm, Diploma in Business Administration	1.4	10	-	Beximco Pharmaceuticals Ltd.
Mr. Md. Minar Hossain Khan	General Manager-Marketing	01.01.1986	51	M.Sc, DU	28	28	3,710,522	N/A
Mr. S.M Shafiquzzaman	Head of Production (Human)	10.03.2011	55	M. Pharm	4	24	2,783,027	Orion Infusion Ltd.

Name	Position	Date of Joining in the company	Age	Educational Qualification	Experience in Company	Overall Experience (in year)	Salary paid (2013-14)	Previous employment
Mr. Swapan Kumar Gain	DGM, Production, (Soild Dosage)	16.09.2007	51	M. Pharm	8	23	31,16,138	Globe Pharmaceutical Ltd.
Mr. Bashir Ahmed	Sr. AGM, Production (Cephalosporin)	03.10.2004	43	M. Pharm	11	19	16,62,720	Square Pharmaceutical Ltd.
Mr. Md. Humayun Kabir	Head of International Business	23.10.2005	47	M Pharm DU MBA UK	10	25	2,719,490	Coventry Business School, UK
Mr. S M Rezaul Ahsan	Head of QMS	01.10.2007	38	M.Sc, JU	8	13	1,227,440	N/A
Mr. S.A.B.M Shahadat Ali	Head of Quality Operation	11.05.2011	40	M Pharm	4	17	2,561,418	Beacon Pharma Ltd.
Mr. Md. Abu Sayed Khondoker	Sr. AGM, Engineering	02.08.2006	48	B.Sc, Eng.(Mach)	9	19	2,227,851	RAK Pharmaceutical Ltd.
Mr. Nur Ahmmead Bhuiyan	Sr. AGM, Engineering	03.05.2011	43	B.Sc, Eng. MBA	4	17	2,578,691	Orion Pharmaceutical Ltd.
Syed Nazmul Huda	Head of IT	04.07.1993	49	Masters in Management, Diploma in CSE	22	22	1,232,905	Common Business Associates
Mr. Md. Rubel Miah	Head of Internal Audit	01.01.2012	34	M. Com	4	7	904,190	Bashundhara Group

It is mentionable that the Company has no Advisor during the year 2013-2014.

Apart from this following Chairman, Director, Shareholder of the Company received monthly Salary

Sl. No	Name	Position	Salary paid (2013-14)
1	Mr. Mr. Afzalur Rahman Sinha	Chairman	1,68,00,000
2	Mr. Mizanur Rahman Sinha	Managing Director	2,10,00,000
3	Dr. Jabilur Rahman Sinha	Deputy Managing Director	1,56,00,000
4	Mr. Md. Hasibur Rahman	Shareholder	8,087,519
5	Golam Rabbani Bhuiyan	Shareholder	5,714,801
6	Md. Minar Hossain Khan	Shareholder	3,710,522
7	Abu Reza Khan	Shareholder	3,169,214
8	Suladhar Tarafder	Shareholder	2,888,229
9	Sanowar Habib Sinha	Shareholder	1,648,877
10	Md. Omar Khayam Bhuiyan	Shareholder	756,159
11	Pralay Kumar Paul Chowdhury	Shareholder	664,318
12	Mr. G. K. M Siddiqur Rahman	Shareholder	748,002

Changes in the key management persons during the last three years.

Any change otherwise than by way of retirement in the normal course in the senior key management personnel particularly in charge of production, planning, finance and marketing during the last three years prior to the date of filing the information memorandum (27.10.2011 to 26.10.2014). If the turnover of key management personnel is high compared to the industry, reasons should be discussed

Sl. No.	Name	Designation	Department	Remarks
02.	Mr. Mohd. Abdul Hamid Miah	DGM	Factory Admin	Newly Join
06.	Mr. Animesh Pal	Consultant	Marketing	Newly Join
07.	Mr. Md. Rubel Miah	Manager	Internal Audit	Newly Join
08.	Mr. Motiul Islam	Head of IT	Information Technology	Resigned on 24.08.2014

It appears from above that, turnover of key management personnel is not high compare to the industry.

A profile of the sponsors

SL #	Name of the Sponsor's	Father's name	Age	Personal address	Educational qualification	Exp. in the business	Position /Posts held in the past	Status of the Sponsor in other ventures and position	
								Name of the Company	**Position**
1	Mr. Afzalur Rahman Sinha	Late Hamidur Rahman Sinha	64	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka.	MBA (USA)	32	Chairman	The ACME Agrovet & Beverages Limited	Chairman
								Sinha Printers Limited	MD
								ACME IT Limited	MD
								The ACME Overseas Trading Limited	Director
								ACMUNIO International Limited	Director
								Sinha Fabrics Limited	Director
								Sinha Wool Wears Limited	Director
								Sinha Knit Industries Limited	Director
2	Mr. Mizanur Rahman Sinha	Late Hamidur Rahman Sinha	71	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka.	B.Com	38	Managing Director	ACME IT Limited Kalyar Packaging Limited Kalyar Replica Limited Sinha Fabrics Limited Sinha Wool Wears Limited ACME Overseas Trading Limited Sinha Knit Industries Limited ACMUNIO International Limited Sinha Printers Limited The ACME Agrovet & Beverages Limited.	Chairman Chairman Chairman Chairman Chairman Chairman Chairman Director Director Director
3	Dr. Jabilur Rahman Sinha	Late Hamidur Rahman Sinha	70	Hazel Wood, House No. 4, Road No. 118, Gulshan-2, Dhaka.	M.Sc., PhD, Organic Chemistry	5	Deputy Managing Director	ACMUNIO International Limited Sinha Printers Limited	Chairman Chairman
4	Mr. Nasir-Ur-Rahman Sinha	Late Hamidur Rahman Sinha	74	House No. 7, Road No. 7, Nabodoy R/ A, Mohammadpur, Dhaka-1207.			Shareholder	N/A	N/A
5	Mrs. Parveen Akhter Nasir	W/o. Mr. Nasir-Ur-Rahman Sinha	61	House No. 7, Road No. 7, Nabodoy R/A, Mohammadpur, Dhaka.			Shareholder	N/A	N/A
6	Mrs. Jahanara Mizan Sinha	W/o. Mr. Mizanur Rahman Sinha	65	House No. 6, Road No.14, Sector-4, Uttara Model Town, Dhaka.	HSC	34	Director	J M Sinha Agriculture Food Processing Industries Limited Sanjar Aviation Limited The ACME Agrovet & Beverages Limited Kalyar Packaging Limited Kalyar Replica Limited Sinha Printers Limited	Chairman Chairman Director Director Director Director
7	Mrs. Nagina Afzal Sinha	W/o. Mr. Afzalur Rahman Sinha	58	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka.	BA	34	Director	Sinha Printers Limited The ACME Agrovet & Beverages Limited	Director Director

If the present directors are not the sponsors and control of the issuer was acquired within five years immediately preceding the date of filing prospectus details regarding the acquisition of control, date of acquisition, terms of acquisition, consideration paid for such acquisition etc.

Mr. Mizanur Rahman Sinha and Mrs. Jahanara Mizan Sinha are present directors of the company, are also sponsors. Other three Directors namely Mr. Afzalur Rahman Sinha, Dr. Jabilur Rahman Sinha and Mrs. Nagina Afzal Sinha acquired control of the company before the five years immediately preceding the date of filling prospectus. Hence, the information is not applicable.

If the sponsors/directors do not have experience in the proposed line of business, the fact explaining how the proposed activities would be carried out/managed;

Since all sponsors/directors are experience in the proposed line of business hence, the fact is not applicable.

Interest of the Key management persons

Name	Designation	Salary paid (2013-14)
Mr. Mr. Afzalur Rahman Sinha	Chairman	16,800,000
Mr. Mizanur Rahman Sinha	Managing Director	21,000,000
Dr. Jabilur Rahman Sinha	Deputy Managing Director	15,600,000
Mr. Md. Hasibur Rahman	Additional Deputy Managing Director, Finance & Accounts, ISO and Internal Audit	8,087,519
Mr. Parvez Hashim	Executive Director	N/A
Mr. Md. Zahangir Alam	Chief Financial Officer	3,308,270
Mr. Md. Rafiqul Islam	Company Secretary	N/A
Mr. AKM Mushiur Rahman Khan	Director, Procurement Planning and Inventory Control	4,315,508
Mr. Tushar Kanti Kundu	Head of HR	1,547,580
Mr. Mohammad Abdul Hamid Miah	DGM, Factory Admin & HR	1,312,810
Mr. Golam Rabbani Bhuiyan	Director, Sales	5,714,801
Mr. Animesh Pal	Consultant, Marketing& SBMD	N/A
Mr. Md. Minar Hossain Khan	General Manager-Marketing	3,710,522
Mr. S.M Shafiquzzaman	Head of Production (Human)	2,783,027
Mr. Swapan Kumar Gain	DGM, Production, (Soild Dosage)	3,116,138
Mr. Bashir Ahmed	Sr. AGM, Production (Cephalosporin)	1,662,720
Mr. Md. Humayun Kabir	Head of International Business	2,719,490
Mr. S.A.B.M Shahadat Ali	Head of Quality Operation	2,561,418
Mr. Md. Abu Sayed Khondoker	Sr. AGM, Engineering	2,227,851
Mr. Nur Ahmmead Bhuiyan	Sr. AGM, Engineering	2,578,691

All Interest and facilities enjoyed by the directors, whether pecuniary or non-pecuniary

The Directors did not enjoy any facilities except remuneration, Board attendance fee. Chairman, Managing Director, Deputy Managing Director, and other directors, whose amount for the period from July 2013 to 30 June 2014 is as follows:

Name of Directors	Relationship	Name of theTransaction	Amounts in Taka
Mr. Afzalur Rahman Sinha	Chairman	Remuneration	16,800,000
		Board Atten. Fee	45,000
		Dividend (cash)	17,122,222
Mr. Mizanur Rahman Sinha	Managing Director	Remuneration	21,000,000
		Board Atten. Fee	45,000
		Dividend (cash)	21,377,777
Dr. Jabilur Rahman Sinha	Deputy Managing Director	Remuneration	15,600,000
		Board Atten. Fee	30,000
		Dividend (cash)	7,500,000
Mrs. Jahanara Mizan Sinha	Director	Remuneration	939,000
		Board Atten. Fee	45,000
Mrs. Nagina Afzal Sinha	Director	Remuneration	931,500
		Board Atten. Fee	45,000
Mr. Nasir-Ur-Rahman Sinha	Shareholder**	Remuneration	15,500,000
		Board Atten. Fee	45,000
		Dividend (cash)	12,311,111
Mrs. Parveen Akhter Nasir	Shareholder **	Remuneration	924,000
		Board Atten. Fee	45,000
Mr. Rezaur Rahman Sinha	Shareholder *	Remuneration	6,000,000
Mr. Ansar Uddin Sinha	Shareholder *	Remuneration	7,800,000
Mr. Motiur Rahman Sinha	Shareholder *	Remuneration	6,000,000
Mrs. Tasneem Sinha	Shareholder *	Remuneration	7,800,000
Mr. Tanveer Sinha	Shareholder *	Remuneration	7,200,000
Mrs. Sabrina Sinha	Shareholder *	Remuneration	6,000,000
Mr. Fahim Sinha	Shareholder *	Remuneration	6,000,000

** In the 41st Board Meeting dated 25th June 2014 Mr. Nasir-Ur-Rahman Sinha, former Chairman and Mrs. Parveen Akhter Nasir, former Director resigned from their position and after resignation they are not getting any remuneration.

* In the 41st Board Meeting dated 25th June 2014, the Payee Directors were voluntarily resigned from their position. It is mentionable that by virtue of transfer they possessed some shares on 27 September 2011. After resignation they are not getting any remuneration.

Number of Shares held and percentage of Shareholding (Pre issue)

Sl. No.	Name of the Shareholders	BO ID	Address	No. of Shares	Shareholding (%)
1	Mr. Afzalur Rahman Sinha	1204220058531922	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	17,214,336	10.652
2	Mr. Mizanur Rahman Sinha	1602170058187279	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	20,426,565	12.640
3	Dr. Jabilur Rahman Sinha	1202160016461974	Hazel Wood, House No. 4, Road No. 118, Gulshan-2, Dhaka	4,860,696	3.008
4	Mrs. Jahanara Mizan Sinha	1204220058531949	House No. 6, Road No.14, Sector-4, Uttara Model Town, Dhaka, Bangladesh	10,519,744	6.510
5	Mrs. Nagina Afzal Sinha	1204220058531965	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	11,888,433	7.357

Changes in the Board of Directors in last three years

Sl. No.	Name of the Directors	Date of Joining	Date of retirement	Present Status as on 31.01.2016
01	Mr. Afzalur Rahman Sinha	17-03-1976 (Date of Incorporation)	Continuing	Chairman
02	Mr. Mizanur Rahman Sinha	17-03-1976 (Date of Incorporation)	Continuing	Managing Director
03	Dr. Jabilur Rahman Sinha	17-03-1976 (Date of Incorporation)	Continuing	Deputy Managing Director
04	Mrs. Jahanara Mizan Sinha	15-04-1981	Continuing	Director
05	Mrs. Nagina Afzal Sinha	15-04-1981	Continuing	Director
06	Syed Shahed Reza (Independent Director)	09-09-2014	Continuing	Independent Director
07	Ms. Fouzia Haque, FCA (Independent Director)	09-09-2014	Continuing	Independent Director
08	Mr. Md. Iftikhar-Uz-Zaman (Nominee Director of ICB)	16-03-2015	30-01-2016	Withdrawn nomination by ICB vide letter No. ICB/SD/14.73/67 dated 28-01-2016
09	Mr. Md. Fayekuzzaman (Nominee Director of ICB)	07-10-2013	16-03-2015	Nominee Director withdrawn vide letter No. ICB/SD/14.73/928 dated 11-03-2015
10	Mr. Md. Abdur Rouf (Nominee Director of ICB)	07-10-2013	16-03-2015	Nominee Director withdrawn vide letter No. ICB/SD/14.73/899/2419 dated 04-03-2015
11	Mr. Nasir-Ur-Rahman Sinha	17-03-1976 (Date of Incorporation)	25-06-2014	Voluntary retirement from the post of Chairman & Director due to illness.
12	Mrs. Parveen Akhter Nasir	15-04-1981	25-06-2014	Voluntary retirement from the post of Director due to illness.

Director's engaged with similar business

There is no engagement of any director with similar business.

CHAPTER IX: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

TO WHOM IT MAY CONCERN

This is to certify that the Financial Statements of the ACME Laboratories Ltd. furnished for our audit does not have any transaction during the last five years, or any proposed transaction, between the issuer and any of the following persons:

(i) Any director or sponsor or executive officer of the issuer;
(ii) Any person holding 5% or more of the outstanding shares of the issuer;
(iii) Any related party or connected person of any of the above persons;

Except the transactions described in the following table:

Name of the Company/Person	Relationship	Nature of Transaction	2009-2010		2010-2011		2011-2012		2012-2013		2013-2014	
			Value of transaction during the year	Balance at year end. Receivable/(Payable)	Value of transaction during the year	Balance at year end. Receivable /(Payable)	Value of transaction during the year	Balance at year end. Receivable/(Payable)	Value of transaction during the year	Balance at year end. Receivable/(Payable)	Value of transaction during the year	Balance at year end. Receivable/(Payable)
The ACME Specialized Pharmaceuticals Ltd.	Subsidiary	Investment in Shares	291,467,400	351,467,400	-	351,467,400	-	351,467,400	-	351,467,400	-	-
		Investment	43,050,218	378,538,037	409,244,948	787,782,985	455,018,519	1.242,801,504	65,001,394	1,307,802,898	-	-
		Finished Goods Sale	-	-	-	-	3,039,860	-	-	-		
		Finished Goods Purchase	-	-	-	-	879,099,489	200,160,699	1,147,490,845	-	-	-
ACMUNIO Int. Limited	Common Director	Advance to ACMUNIO /Current A/C	-	-	58,106,882	58,106,882	23,703,000	81,809,882	13,403,149	95,213,031	25,130,552	120,343,583
		Finished Goods Purchase	-	-	-	-	23,241,702	-	18,344,814	-	43,34,085	-
		Rent on Investment Properties	-	6,462,000	-	-	6,462,000	19,386,000	6,462,000	25,848,000	6,462,000	32,310,000
Sinha Printers Limited	Common Director	Local Supply	293,468,557	(173,556,964)	321,067,576	(264,624,540)	389,102,296	(361,724,694)	336,654,355	(434,543,465)	391,049,968	(388,321,732)
		Provide service &others	-	-	-	-	36,641,407	36,641,407	287,058	36,928,465	329,116	37,257,581
Kalyar Packaging Limited	Common Director	Local Supply	-	-	-	-	3,904,518	-	4,010,112	(3,781,826)	45,570,985	-
Kalyar Replica Limited	Common Director	Local Supply	-	-	-	-	138,552	-	1,076,733	-	7,083,759	-
Mr. Md. Hasibur Rahman	Employee and Shareholder (0.037%)	Advance against Land	-	-	-	-	60,000,000	60,000,000	5,000,000	65,000,000	15,000,000	80,000,000

Place: Dhaka
Date: 02 March, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Any transaction or arrangement entered into by the issuer or its subsidiary or associate or entity owned or significantly influenced by a person who is currently a director or in any way connected with a director of either the issuer company or any of its subsidiaries/holding company or associate concerns, or who was a director or connected in any way with a director at any time during the last three years prior to the issuance of the prospectus

The information given in above under the head certain relationships and related transactions (point- a) is applicable in this respect.

Any loans either taken or given from or to any director or any person connected with the director, clearly specifying details of such loan in the prospectus, and if any loan has been taken from any such person who did not have any stake in the issuer, its holding company or its associate concerns prior to such loan, rate of interest applicable, date of loan taken, date of maturity of loan, and present outstanding of such loan.

The company has not taken or given any loan to any director or any person connected with the director.

CHAPTER X: EXECUTIVE COMPENSATION

Remuneration/Salary/Perquisite paid to top 5 (five) salaried officers of the Company

(Amount in BDT)

Sl. #	Name	Designation	Remuneration (July '13 to June '14)
1	Mr. Afzalur Rahman Sinha	Chairman	16,800,000
2	Mr. Mizanur Rahman Sinha	Managing Director	21,000,000
3	Dr. Jabilur Rahman Sinha	Deputy Managing Director	15,600,000
4	Mr. Nasir-Ur-Rahman Sinha*	Shareholder	15,500,000
5	Mr. Mohammad Dabir Uddin	Additional Deputy Managing Director	8,189,332
6	Mr. Md. Hasibur Rahman	Additional Deputy Managing Director	8,087,519

*In the 41st Board Meeting dated 25th June 2014 Mr. Nasir-Ur-Rahman Sinha, former Chairman resigned from his position and after resignation he is not getting any remuneration.

Aggregate Amount of Remuneration paid to all directors and officers as a group during last accounting year (July '13 to June '14)

(As per accounts) (Amount in BDT)

Sl. #	Particulars	Remuneration & Salary
1	Directors	118,494,500.00
2	Officers & Staff	1,375,590,878.00

Monthly salary/perquisite/benefit of shareholder director and approval date of AGM/EGM including terms thereof and payments made last year

The shareholders in its 37th Annual General Meeting (AGM) held on 30th December 2013 fixed monthly remuneration to the Directors who are involved in day-to-day operations of the Company. The amounts of fixed monthly remuneration with effects from 01 January 2014 are stated below:

Name	Designation	Monthly remuneration
Mr. Nasir-Ur-Rahamn Sinha*	Chairman	Tk. 600,000
Mr. Mizanur Rahman Sinha	Managing Director	Tk. 1,000,000
Dr. Jabilur Rahman Sinha	Deputy Managing Director	Tk. 600,000
Mr. Afzalur Rahman Sinha	Deputy Managing Director	Tk. 800,000

*In the 41st Board Meeting dated 25th June 2014 Mr. Nasir-Ur-Rahman Sinha, former Chairman resigned from his position and after resignation he is not getting any remuneration.

Board Meeting attendance fee of Directors including MD and date of approval in AGM/EGM

The shareholders in its 37th Annual General Meeting (AGM) held on 30th December 2013 fixed Board Meeting attendance fee @ Tk. 15,000 per meeting to the Directors who are participated in the Company's board meeting.

Any contract with any director or officer providing for the payment of future compensation;

The Company has no contract with any director/officer for providing the payment of future compensation.

If the issuer intends to substantially increase the remuneration paid to its directors and officers in the current year, appropriate information regarding thereto;

Annual review of the remunerations of the directors and officers will be made depending Board and management decision.

Any other benefit/facility provided to the Directors during the year.

The company has not paid any other benefit/facility to its directors except as stated above.

CSR ACTIVITIES - **Employees and workers' family welfare**

CSR ACTIVITIES -

Poverty reduction, Self Employment Generation, Women's empowerment through Medicinal and Herbal plant cultivation.

CHAPTER XI: OPTIONS GRANTED TO DIRECTORS, OFFICERS AND EMPLOYEES

The company did not grant any options to any director, officer all other officers as a group.
Further to the above, no options are held by any person other than the directors.

CHAPTER XII: TRANSACTION WITH THE DIRECTORS AND SUBSCRIBERS TO THE MEMORANDUM

The names of the directors and subscribers to the memorandum, the nature and amount of anything of value received or to be received by the issuer from the above persons, or by the said persons, directly or indirectly, from the issuer during the last five years along with the description of assets, services or other consideration received or to be received

The Directors and Subscribers to the memorandum have not received any benefits directly or indirectly other than remuneration, dividend and board attendant fee during the last five years.

(Amount in BDT)

Name of the directors and subscribers	Nature of value received	2009-2010	2010-2011	2011-2012	2012-2013	2013-2014
Mr. Afzalur Rahman Sinha	Remuneration	2,40,00,000	2,40,00,000	2,40,00,000	2,40,00,000	16,800,000
	Dividend (Cash)					17,122,222
	Dividend (Bonus)	-	1,272,000 Ordinary Shares	-	-	-
	Board Atten. Fee	-	-	-	-	45,000
Mr. Mizanur Rahman Sinha	Remuneration	3,00,00,000	3,00,00,000	3,00,00,000	3,00,00,000	21,000,000
	Dividend (Cash)					21,377,777
	Dividend (Bonus)	-	1,484,000 Ordinary Shares	-	-	-
	Board Atten. Fee	-	-	-	-	45,000
Dr. Jabilur Rahman Sinha	Remuneration	2,40,00,000	2,40,00,000	2,40,00,000	2,40,00,000	15,600,000
	Dividend (Cash)					7,500,000
	Dividend (Bonus)	-	1,272,000 Ordinary Shares	-	-	-
	Board Atten. Fee	-	-	-	-	30,000
Mr. Nasir-Ur-Rahman Sinha*	Remuneration (Retired on 25.06.14)	2,40,00,000	2,40,00,000	24,000,000	24,000,000	15,500,000
	Dividend (Cash)					12,311,111
	Dividend (Bonus)	-	1,272,000 Ordinary Shares	-	-	-
	Board Atten. Fee	-	-	-	-	45,000
Mrs. Parveen Akhter Nasir*	Remuneration (Retired on 25.06.14)	18,48,000	18,48,000	1,848,000	1,848,000	924,000
	Dividend (Cash)					-
	Dividend (Bonus)	-	954,000 Ordinary Shares	-	-	-
	Board Atten. Fee	-	-	-	-	45,000
Mrs. Jahanara Mizan Sinha	Remuneration	18,78,000	18,78,000	18,78,000	18,78,000	939,000
	Dividend (Cash)					-
	Dividend (Bonus)	-	954,000 Ordinary Shares	-	-	-
	Board Atten. Fee	-	-	-	-	45,000
Mrs. Nagina Afzal Sinha	Remuneration	18,63,000	18,63,000	1863000	1863000	931,500
	Dividend (Cash)					-
	Dividend (Bonus)	-	996,400 Ordinary Shares	-	-	-
	Board Atten. Fee	-	-	-	-	45,000

* In the 41st Board Meeting dated 25th June 2014 Mr. Nasir-Ur-Rahman Sinha, former Chairman and Mrs. Parveen Akhter Nasir, former Director resigned from their position and after resignation they are not getting any remuneration.

If any assets were acquired or to be acquired from the aforesaid persons, the amount paid for such assets and the method used to determine the price shall be mentioned in the prospectus, and if the assets were acquired by the said persons within five years prior to transfer those to the issuer, the acquisition cost thereof paid by them.

The Company has not received any assets, services of other consideration from its directors and subscribers to the memorandum except fund against allotment of shares.

CHAPTER XIII: OWNERSHIP OF THE COMPANY'S SECURITIES

The names, addresses, BO ID Number of all shareholders of the company before IPO, indicating the amount of securities owned and the percentage of the securities represented by such ownership, in tabular form

Name of the Shareholders	BO ID	Address	No. of Securities	Pre-issue %	Post-Issue %
Mr. Afzalur Rahman Sinha	1204220058531922	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	17,214,336	10.652	8.135
Mr. Mizanur Rahman Sinha	1602170058187279	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	20,426,565	12.640	9.653
Dr. Jabilur Rahman Sinha	1202160016461974	Hazel Wood, House No. 4, Road No. 118, Gulshan-2, Dhaka	4,860,696	3.008	2.297
Mrs. Jahanara Mizan Sinha	1204220058531949	House No. 6, Road No.14, Sector-4, Uttara Model Town, Dhaka, Bangladesh	10,519,744	6.510	4.971
Mrs. Nagina Afzal Sinha	1204220058531965	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	11,888,433	7.357	5.618
Mr. Nasir-Ur-Rahman Sinha	1203140008032983	House No. 7, Road No. 7, Nabodoy R/ A, Mohammadpur, Dhaka	6,160,405	3.812	2.911
Mrs. Parveen Akhter Nasir	1203140058498991	House No. 7, Road No. 7, Nabodoy R/A, Mohammadpur, Dhaka	5,401,517	3.342	2.553
Mrs. Hasina Jabil Sinha	1202160016461982	Hazel Wood, House No. 4, Road No. 118, Gulshan-2, Dhaka	4,859,245	3.01	2.296
Mr. Motiur Rahman Sinha	1203140051385761	House No. 7, Road No. 7, Nabodoy R/ A, Mohammadpur, Dhaka	1,400,000	0.866	0.662
Mr. Reza-ur-Rahman Sinha	1203140016549631	House No. 7, Road No. 7, Nabodoy R/ A, Mohammadpur, Dhaka	4,400,000	2.723	2.079
Mr. Ansar Uddin Sinha	1203140020445737	House No. 7, Road No. 7, Nabodoy R/A, Mohammadpur, Dhaka	2,900,000	1.79	1.370

Name of the Shareholders	BO ID	Address	No. of Securities	Pre-issue %	Post-Issue %
Mr. Tanveer Sinha	1204220058532017	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	280,394	0.174	0.133
Ms. Tasneem Sinha	1204220058531981	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	280,394	0.174	0.133
Mr. Fahim Sinha	1204220058531930	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	280,395	0.174	0.133
Ms. Sabrina Sinha	1204220058531973	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	280,394	0.174	0.133
Dr.Mohammad Zillur Rahman	1204220058541799	Plot No. 45&46, Flat No. C&D, Block-A, Bashundhara Project, Badda, Dhaka	2,760,828	1.708	1.305
Mr. Shahriar Rahman	1204220058541812	Plot No. 45&46, Flat No. C&D, Block-A, Bashundhara Project, Badda, Dhaka,	2,679,638	1.658	1.266
Mrs. Farzana Rahman Anwar	1204220058541804	House No. B107, Road No. 4, New DOHS, Mohakhali, Dhaka Cantoment, Dhaka-1206	2,679,529	1.658	1.266
Mr. Imad Uddin Ahmed	1204220058531991	Plot No. 6, Road No. 7, Sector-1, Uttara Model Town, Dhaka	4,059,730	2.512	1.919
Mrs. Merajee Nasim	1204220058531957	Plot No. 6, Road No. 7, Sector-1, Uttara Model Town, Dhaka	4,059,720	2.512	1.919
Ms. Sylvana Sinha	1202160023458535	Hazel Wood, House No. 4, Road No. 118, Gulshan-2, Dhaka	7,288,866	4.51	3.445
Ms. Tanya Quader Sinha	1202160058513919	Hazel Wood, House No. 4, Road No. 118, Gulshan-2, Dhaka	7,288,866	4.51	3.445
Mrs. Khurshid Jahan Dabir (Mrs.Laizu Dabir)	1204220059640631	Plot No. 6, Road No. 7, Sector-1, Uttara Model Town, Dhaka	725	0.0004	0.000
Mr. Md. Hasibur Rahman	1204220059639471	Plot No. 45&46, Flat No. C&D, Block-A, Bashundhara Project, Badda, Dhaka	180	0.0001	0.000
GSP Finance Company (Bangladesh) Limited	1202830004187028	1, Paribagh, Mymensingh Road, Ramna, Dhaka-1000,	769,200	0.476	0.364
Dr. Syed Anwarul Hafiz	1204490000076448	ASRA Apartments, House-23, Road-4, Dhanmondi R/A, Dhaka-1205	500,000	0.309	0.236
Khadim Ceramics Ltd. Unit-2	1202160018312493	House-10, Road-28, Block-K, Banani, Dhaka-1213	500,000	0.309	0.236

Name of the Shareholders	BO ID	Address	No. of Securities	Pre-issue %	Post-Issue %
Alpha Capital Management Ltd.	1605550049519826	National Scout Bhaban (5th Floor), 70/1 Inner Circular Road, Kakrail, Dhaka-1000	500,000	0.309	0.236
Popular Life Insurance Company Limited.	1204680000045409	Peoples Insurance Bhaban (3rd Floor), 36, Dilkusha C/A, Dhaka-1000	1,000,000	0.619	0.473
Dhaka Bank Limited	1201630000001072	Head Office, Biman Bhaban (1st Floor), 100, Motijheel, C/A, Dhaka-1000	500,000	0.309	0.236
Bank Asia Limited	1204490000175597	Corporate Office, Rangs Tower (2nd to 6th Floor), 68 Purana Paltan, Dhaka-1000	1,000,000	0.619	0.473
Green Delta Insurance Company Ltd.	1203620000042986	Head Office: Green Delta Aims Tower (6th Floor), 51-52 Mohakhali, C/A, Dhaka-1212	500,000	0.309	0.236
Southeast Bank Limited	1602290000060633	Eunoos Center (Level-4), 52-53, Dilkusha, C/A, Dhaka-1000	2,884,600	1.785	1.363
Pioneer Insurance Company Limited	1601880004129462	Symphony, Plot No. SE(F) 9, Road No. 142, South Avenue, Gulshan-1, Dhaka-1212	1,000,000	0.619	0.473
Pragati Life Insurance Ltd.	1204080009905096	Pragati Insurance Bhaban, (6th Floor), 20-21 Kawran Bazar, Dhaka-1215	300,000	0.186	0.142
United Commercial Bank Limited	1205590015459615	11/A, Toyenbee Circular Road "Sara Tower" 16th Floor, Motijheel C/A, Dhaka-1000	7,692,300	4.760	3.635
Investment Corporation of Bangladesh	1201530000003501	8, DIT Avenue, (Level-14th to 17th) Dhaka-1000	5,800,000	3.589	2.741
ICB Unit Fund	1201530000003518	8, DIT Avenue, (Level-14th to 17th) Dhaka-1000	5,800,000	3.589	2.741
Bangladesh Shilpa Rin Sangstha (BDBL)	1202180000109618	BDBL Bhaban, 12, Kawran Bazar, Dhaka	1,000,000	0.619	0.473
ICB Capital Management Ltd.	1201530000001725	ICB Capital Management Ltd. BSB Bhaban, (14th Floor), 8, Rajuk Avenue, Dhaka-1000,	1,900,000	1.176	0.898
ICB Securities Trading Company Limited	1201530028713102	BSB Bhaban, 13th Floor, 8 DIT Avenue, Dhaka-1000,	950,000	0.588	0.449
Bangladesh Fund	1605420043478871	ICB Asset Management Co. Ltd. BDBL Bhaban, (Level-17), 8 Rajuk Avenue, Dhaka-1000,	4,800,000	2.970	2.268
Federal Insurance Company Limited	1203310003865475	Chamber Building (2nd Floor), 122-124 Motijheel C/A, Dhaka	500,000	0.309	0.236
Muhammed Ali	1204090046709799	Ivy legacy, House No. 22, Flat No. 3-D, Road No. 108, Gulshan-02, Dhaka	50,000	0.031	0.024

Name of the Shareholders	BO ID	Address	No. of Securities	Pre-issue %	Post-Issue %
Shahnoor Chowdhury	1204090020405505	Ivy legacy, House No. 22, Flat No. 3-D, Road No. 108, Gulshan-02, Dhaka	50,000	0.031	0.024
The ACME Laboratories Ltd. Employees Provident Fund	1203140058536462	Court de la ACME, 1/4, Kallayanpur, Mirpur Road, Dhaka-1207	1,000,000	0.619	0.473
Muhammed Shahidul Islam	1202150045636271	Apt. No. 5-C, House No. 253/A, Road No.18, Mohakhali DOHS, Dhaka Cantonment, Kafrul, Dhaka	100,000	0.062	0.047
ICB Portfolio Khulna	1203650016151687	Investment Corporation of Bangladesh, BDBL Building, 25-26 K.D.A C/A, Khulna	80,000	0.050	0.038
Farzana Abedin	1201950006933721	127/1-A, East Bashabo, Dhaka-1214	20,000	0.012	0.009
Md. Asaduzzaman Mia	1201580000026326	Prime Insurance Co. Ltd. 63 Dilkusha C/A, Dhaka-1000	60,000	0.037	0.028
Partho Kumar Bagchi	1203570011404113	Manager, UCBL, Jhenaidah Branch, Jhenaidah	5000	0.003	0.002
G. K. M. Siddiquer Rahman	1203140049052156	House No. 741/5, Road No.-8, Baitul Aman Housing Society, Adabar, Mohammadpur, Dhaka	10,000	0.006	0.005
Chowdhury Rishad Nighar	1602070000080504	Flat No. A3, Fremonti Terrace, 38-39 Topkhana Road, Dhaka-1000	10,000	0.006	0.005
Dr. Chowdhury Rifat Nighar	1602070000080499	Flat No. A3, Fremonti Terrace, 38-39 Topkhana Road, Dhaka-1000	2,500	0.002	0.001
Dr. Chowdhury Akram Uz Zaman	1602070000049474	Flat No. A3, Fremonti Terrace, 38-39 Topkhana Road, Dhaka-1000	2,500	0.002	0.001
ICB Capital Management Limited – Discretionary Investors Account					
Mr. Md. Ruhul Amin	1201530048491137	105/A, Bara Maghbazar, Dhaka -1217	25,000	0.0161	0.012
Mr. A. S. M. Masudur Rahman	1201530048491137	105/A, Bara Maghbazar, Dhaka -1217	50,000	0.0321	0.024
Mr. Md. Omar Siddique	1201530048491137	Nandan Kuthi, House No. 301, Road No. 2 Middle Peerer Bag, Dhaka-1216.	25,000	0.0161	0.012
Mr. Md. Hasibur Rahman	1201530048491137	Flat-D-2,C-2, House-45,46, Block-A, Bashundhara R/A Gulshan, Badda Dhaka.	60,000	0.0386	0.028
Mr. Sanowar Habib Sinha	1201530048491137	Flat-1301, Building-13, Sakura Japan Garden City, Dhaka1207.	20,000	0.0129	0.009

Name of the Shareholders	BO ID	Address	No. of Securities	Pre-issue %	Post-Issue %
Mr. Sarwar Habib Sinha	1201530048491137	Flat-B-1,1/7, Lalmatia, Block-A, Dhaka	20,000	0.0129	0.009
Mr. Golam Rabbani Bhuiyan	1201530048491137	House No. 11/A-1, Road no-2, Block-D Sec-02, Mirpur Houseing Estate, Mirpur-02, Dhaka	20,000	0.0129	0.009
Mr. Md. Minar Hossain Khan	1201530048491137	Flat-1101, Building-13, Ring Road, Road-24/A, Japan Garden City, Dhaka-1207.	20,000	0.0129	0.009
Mr. Md. Omar Khayam Bhuiyan	1201530048491137	The ACME Laboratories Ltd, Chowmohoni Sales Centre, Kachari Bari, Maszid Road, Chowmohni, Noakhali	20,000	0.0129	0.009
Mr. Suladhar Tarafder	1201530048491137	House-125, Road-02, Mohammadia Housing, Adabor, Mohammadpur, Dhaka-1207.	20,000	0.0129	0.009
Mr. Pralay Kumar Paul Chowdhury	1201530048491137	Road-19, House-62, Rupnagor Abashik, Mirpur, Dhaka-1216.	25,000	0.0161	0.012
Abu Reza Khan	1201530048491137	Flat-1103, Type-E(13), Japan Garden City, Mohammadpur, Dhaka-1207.	20,000	0.0129	0.009
Mr. Mojibur Rahman	1201530048491137	24, Tipu Sultan Road, Dhaka-1100.	*20,000*	0.0129	0.009
Public Issue Under –Book Building Method			***50,000,000***	**-**	***23.629***
Total			**211,601,700**	**100**	**100**

There shall also be a table showing the name and address, age, experience, BO ID Number, TIN number, numbers of shares held including percentage, position held in other companies of all the directors before the public issue;

SL #	Name of the Directors'	Address	Age	Experience	BO ID	E- TIN No.	No. of shares held	Pre-issue %	Name of other Company	Position held
01	Mr. Afzalur Rahman Sinha	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	64	32	1204220058531922	456285609403	17,214,336	10.652	The ACME Agrovet & Beverages Limited Sinha Printers Limited ACME IT Limited The ACME Overseas Trading Limited ACMUNIO International Limited Sinha Fabrics Limited Sinha Wool Wears Limited Sinha Knit Industries Limited	Chairman MD MD M D Director Director Director Director
02	Mr. Mizanur Rahman Sinha	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	71	38	1602170058187279	250831967457	20,426,565	12.640	ACME IT Limited Kalyar Packaging Limited Kalyar Replica Limited Sinha Fabrics Limited Sinha Wool Wears Limited ACME Overseas Trading Limited Sinha Knit Industries Limited ACMUNIO International Limited Sinha Printers Limited The ACME Agrovet & Beverages Limited.	Chairman Chairman Chairman Chairman Chairman Chairman Chairman Director Director Director
03	Dr. Jabilur Rahman Sinha	Hazel Wood, House No. 4, Road No. 118, Gulshan-2, Dhaka	70	05	1202160016461974	297260447491	4,860,696	3.008	ACMUNIO International Limited Sinha Printers Limited	Chairman Chairman
04	Mrs. Jahanara Mizan Sinha	House No. 6, Road No. 14, Sector-4, Uttara Model Town, Dhaka	65	34	1204220058531949	559165700808	10,519,744	6.510	J M Sinha Agriculture Food Processing Industries Limited Sanjar Aviation Limited The ACME Agrovet & Beverages Limited Kalyar Packaging Limited Kalyar Replica Limited Sinha Printers Limited	Chairman Chairman Director Director Director Director
05	Mrs. Nagina Afzal Sinha	House No. 7, Road No. 6, Sector-3, Uttara Model Town, Dhaka	58	34	1204220058531965	871546996065	11,888,433	7.357	Sinha Printers Limited The ACME Agrovet & Beverages Limited	Director Director
06	Syed Shahed Reza, (Independent Director)	Apt. No. A-4, House No. 26, Road No. 130, Gulshan-1, Dhaka	64	38	N/A	291675530156	N/A	N/A	N/A	N/A
07	Ms. Fouzia Haque, FCA, (Independent Director)	House No. 7/2, Block-D, Lalmatia, Dhaka	48	24	N/A	393096259752	N/A	N/A	N/A	N/A

Average cost of acquisition of shares by the Directors certified by auditors

To Whom It May Concern

This is to certify that all the shares of The ACME Laboratories Limited have been alloted to its Directors in face value & in Cash/bonus/other than cash and the average cost of acquisition of equity by the Directors is Tk. 10 each. Necessary Particulars of shareholdings, allotment dates and considerations are given

Date of Allotment	Nature of Transaction	No. of Share Hold.					Consideration	Average Cost of Share/Face Value (Tk.)
		Mr. Mizanur Rahman Sinha	Dr. Jabilur Rahman Sinha	Mr. Afzalur Rahman Sinha	Mrs. Jahanara Mizan Sinha	Mrs. Nagina Afzal Sinha		
17-03-76	By Subscription	50	-	-	50	-	Cash	10
16-05-76	By Allotment	2,500	3,800	1,000	600	2,000	Other than cash	10
07-06-80	By Transfer	950	(50)	2,500	350	(1,000)	Cash	10
10-08-89	By Allotment	60,000	-	60,000	40,000	40,000	Cash	10
28-05-02	By Transfer	400	-	400	-	-	Cash	10
29-11-06	By Allotment	1,335,100	1,195,400	1,135,250	858,350	898,600	Cash	10
05-05-11	By Allotment	14,840,000	12,720,000	12,720,000	9,540,000	9,964,000	Cash	10
27-09-11	By Transfer	(400,000)	-	(400,000)	-	-	Cash	10
26-11-13	By Allotment	2,336,115	301,480	1,443,736	80,394	984,833	Other than cash	10
24-02-15	By Transfer	1,750,000	-	1,750,000	-	-	Cash	10
06-05-15	By Transfer	-	(9,361,384)		-	-	Cash	10
02-06-15	By Transfer	500,000	-	500,000	-	-	Cash	10
01-09-15	By Transmission	1,450	1,450	1,450	-	-	Cash	10
Total		**20,426,565**	**4,860,696**	**17,214,336**	**10,519,744**	**11,888,433**	**-**	**-**

Dated; Dhaka
06 March, 2016

Sd/-
Pinaki and Company
Chartered Accountants

A detail description of capital built up in respect of shareholding (name-wise) of the issuer's sponsors/ directors:

Date of Allotment / Transfer of fully paid up shares	Consideration	Nature of Issue	No of Equity shares	Face Value	Issue Price / Acquisition Price / Transfer Prices	Cumulative no. of Equity shares	% Pre-issue paid up capital	% Post issue paid up capital	Sources of fund
17/03/76	Subscription to the Memorandum and Articles of Association	Ordinary	60	100/-	100/-	60	.00037%	.00028%	Own fund
16/05/76	2750 other than cash & 200 shares in cash	Ordinary	2,950	100/-	100/-	3010	.01862%	.01422%	Own fund
10/08/89	Cash	Ordinary	30,000	100/-	100/-	33010	.20426%	.01564%	Own fund
29/11/06	Cash	Ordinary	9,66,990	100/-	100/-	10,00,000	6.18805%	4.72585%	Own fund
05/05/11	Bonus Shares	Ordinary	1,06,00,000	100/-	100/-	1,16,00,000	71.78142%	54.81997%	Bonus
Denomination from Tk. 100.00 to Tk. 10.00 on 30/11/2011						**11,60,00,000**	**71.78142%**	54.81997%	
20/05/2013	Capital raised	Ordinary	3,96,31,100	10/-	52/-	15,56,31,100	96.30536%	73.5491%	Capital raised
26/11/13	Amalgamation of ASPL with Lab (5:1)	Ordinary	59,70,600	10/-	6:1	16,16,01,700	100%	76.3707%	Amalgamation

Details of share issued by the company at a price lower than the issue price

Date of Allotment	No of Equity shares allotted	Nature of Issue	Face Value	Issue Price	Total amount in BDT at face value	Total amount in BDT at Issue price
17/03/76	60	Ordinary share	Tk. 100*	Tk. 100*	6,000	6,000
16/05/76	2,950	Ordinary share	Tk. 100*	Tk. 100*	295,000	295,000
08-10-89	30,000	Ordinary share	Tk. 100*	Tk. 100*	3,000,000	3,000,000
29/11/06	966,990	Ordinary share	Tk. 100*	Tk. 100*	96,699,000	96,699,000
05-05-11	10,600,000	Ordinary share	Tk. 100*	Tk. 100*	1,060,000,000	1,060,000,000
20/05/13	39,631,100	Ordinary share	Tk. 10	Tk. 52	396,311,000	2,060,817,200
26/11/13	5,970,600	Ordinary share	Tk. 10	Tk. 10	59,706,000	59,706,000

* Before 30 November 2011 the face value of each share of the company was Tk. 100, onwards each share split into 10 equity shares and face value of each share reduced to Tk. 10 each.

History of significant (5% or more) changes in ownership of securities from inception

Date of transfer	Transferor				Receiver			
	Name of the Shareholders	Transferred Quantity	% of transferred	Balance of share holding	Name of the Shareholders	eceived Quantit	% of Received	Balance of share holding
06-02-15	Ansar Uddin Sinha	500,000	0.309	2,900,000	Mizanur Rahman Sinha	500,000	0.309	20,426,565
06-02-15	Ansar Uddin Sinha	500,000	0.309	3,400,000	Afzalur Rahman Sinha	500,000	0.309	17,214,336
05-06-15	Dr. Jabilur Rahman Sinha	7,288,866	4.510	4,860,696	Ms. Sylvana Sinha	7,288,866	4.510	7,288,866
05-06-15	Dr. Jabilur Rahman Sinha	2,072,518	1.282	12,148,112	Ms. Tanya Quader Sinha	2,072,518	1.282	7,288,866
05-06-15	Mrs. Hasina Jabil Sinha	5,216,348	3.228	4,859,245	Ms. Tanya Quader Sinha	5,216,348	3.228	
24-02-2015	Motiur Rahman Sinha	1,500,000	0.928	1,400,000	Mizanur Rahman Sinha	1,500,000	0.928	19,926,565
24-02-2015	Motiur Rahman Sinha	1,500,000	0.928	2,900,000	Afzalur Rahman Sinha	1,500,000	0.928	16,714,336
24-02-2015	Ansar Uddin Sinha	250,000	0.155	3,900,000	Mizanur Rahman Sinha	250,000	0.155	18,426,565
24-02-2015	Ansar Uddin Sinha	250,000	0.155	4,150,000	Afzalur Rahman Sinha	250,000	0.155	15,214,336
10-11-14	Nasir-Ur-Rahman Sinha	296,734	0.184	6,160,405	Motiur Rahman Sinha	296,734	0.184	4,400,000
10-11-14	Nasir-Ur-Rahman Sinha	333,393	0.206	6,455,689	Ansar Uddin Sinha	333,393	0.206	4,400,000
10-11-14	Nasir-Ur-Rahman Sinha	369,873	0.229	6,789,082	Reza-ur-Rahman Sinha	369,873	0.229	4,400,000
10-11-14	Parveen Akhter Nasir	516,698	0.320	5,401,517	Motiur Rahman Sinha	516,698	0.320	4,103,266
10-11-14	Parveen Akhter Nasir	580,532	0.359	5,918,215	Ansar Uddin Sinha	580,532	0.359	4,066,607
10-11-14	Parveen Akhter Nasir	644,052	0.399	6,498,747	Reza-ur-Rahman Sinha	644,052	0.399	4,030,127
20-09-2014	Nasir-Ur-Rahman Sinha	2,153,727	1.333	7,158,955	Motiur Rahman Sinha	2,153,727	1.333	3,586,568
20-09-2014	Nasir-Ur-Rahman Sinha	2,153,727	1.333	9,312,682	Ansar Uddin Sinha	2,153,727	1.333	3,486,075
20-09-2014	Nasir-Ur-Rahman Sinha	2,153,727	1.333	11,466,409	Reza-ur-Rahman Sinha	2,153,727	1.333	3,386,075
20-09-2014	Parveen Akhter Nasir	1,132,348	0.701	7,142,799	Motiur Rahman Sinha	1,132,348	0.701	1,432,841
20-09-2014	Parveen Akhter Nasir	1,132,348	0.701	8,275,147	Ansar Uddin Sinha	1,132,348	0.701	1,332,348
20-09-2014	Parveen Akhter Nasir	1,132,348	0.701	9,407,495	Reza-ur-Rahman Sinha	1,132,348	0.701	1,232,348

EFFLUENT TREATMENT PLANT


EFFLUENT TREATMENT PLANT

CHAPTER - XIV : CORPORATE GOVERNANCE

Dated: 09 October 2014

Board of Directors
The ACME Laboratories Limited.
1/4, Kallayanpur, Mirpur Road,
Dhaka-1207

Subject: CEO/CFO's Certification to the Board.

We have reviewed the Financial Statements of **The ACME Laboratories Limited** for the year ended 30 June 2014 and to the best of our knowledge and belief:

a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.

b) These Statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable Laws

There are to the best of our Knowledge and belief, no transactions entered into by the Company during the year which are fradulent, Illegal or violating the Company's code of Conduct.

Sd/-
Mizanur Rahman Sinha
Managing Director

Sd/-
Md. Zahangir Alam, FCMA
Chief Financial Officer

CERTIFICATE ON COMPLIANCE WITH THE CONDITIONS OF CORPORATE GOVERNANCE GUIDELINES.
To the Members of The ACME Laboratories Limited

This is to certify that The ACME Laboratories Limited has complied with the conditions of Corporate Governance Guidelines imposed by the Bangladesh Securities and Exchange Commission (BSEC) vide their Notification No.SEC/CMRRCD/2006-158/134/ Admin/44 dated 7th August, 2012.

Dated: 14 September, 2014
Dhaka

Sd/-
RAHMAN MUSTAFIZ HAQ & CO.
Chartered Accountants

Status of compliance with the conditions imposed by the Bangladesh Securities and Exchange Commission's Notification No. SEC/CMRRCD/2006-158/134/Admin/44 dated 7th August, 2012.

(Report under Condition No. 7.00)

Condition No.	Title	Compliance Status (Put "√" in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1	**BOARD OF DIRECTORS:**			
1.1	The number of the board members shall not be less than 5 (five) and more than 20 (twenty)	√		
1.2	**Independent Directors**			
1.2(i)	One fifth (1/5) of the total number of Directors	√		
1.2(ii)(a)	Does not hold any share or holds less than 1% shares of the total paid-up shares.	√		
1.2(ii)(b)	Not connected with any sponsor /director/share-holder who holds 1% or more shares of the total paid-up shares on the basis of family relationship	√		
1.2(ii)(c)	Does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary/associated companies	√		
1.2(ii)(d)	Not a member, director or officer of any stock exchange	√		
1.2(ii)(e)	Not a shareholder, director or officer of any member of stock exchange or an intermediary of the capital market	√		
1.2(ii)(f)	Not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the Company's statutory audit firm	√		
1.2(ii)(g)	Not be an independent director in more than 3 (three) listed companies	√		
1.2(ii)(h)	Not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan to a bank or a NBFI	√		
1.2(ii)(i)	Not been convicted for a criminal offence involving moral turpitude	√		
1.2(iii)	Appointed by the Board of Directors and approved by the shareholders in the AGM	√		Appointed by Board of Directors subject to approval in the 38th AGM

Condition No.	Title	Compliance Status (Put "√" in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1.2(iv)	Not remain vacant for more than 90 (ninety) days	√		
1.2(v)	Board shall lay down a code of conduct of all Board members and annual compliance of the code to be recorded	√		
1.2(vi)	Tenure of office of an independent director shall be for a period of 3 (three) years, which may be extended for 1 (one) term only	√		
1.3	**Qualification of Independent Director (ID):**			
1.3(i)	Knowledge of Independent Directors	√		
1.3(ii)	Background of Independent Directors	√		
1.3(iii)	Special cases for qualifications	-	-	N/A
1.4	**Individual Chairman of the Board and CEO**	√		
1.5	**The Directors Report to Shareholders:**			
1.5(i)	Industry outlook and possible future developments in the industry	√		
1.5(ii)	Segment-wise or product-wise performance	√		The company consider the operation on aggregate basis and manage the operations as a single operating segment
1.5(iii)	Risks and concerns	√		
1.5(iv)	Discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin	√		
1.5(v)	Discussion on continuity of any Extra-Ordinary gain or loss			N/A
1.5(vi)	Basis for related party transactions	√		
1.5(vii)	Utilization of proceeds from public issues, rights issues and/or through any others instruments	√		
1.5(viii)	Explanation if the financial results deteriorate after the company goes for IPO, RPO, Rights Offer, and Direct Listing			N/A
1.5(ix)	Explanation about significant variance occurs between Quarterly Financial performance and Annual Financial Statements			N/A
1.5(x)	Remuneration to directors including independent directors	√		

Condition No.	Title	Compliance Status (Put "√" in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1.5(xi)	Fairness of Financial Statement	√		
1.5(xii)	Proper books of accounts of the issuer Company have been maintained	√		
1.5(xiii)	Adoption of appropriate accounting policies and estimates	√		
1.5(xiv)	Followed IAS, BAS, IFRS and BFRS in preparation of financial statements	√		
1.5(xv)	Soundness of internal control system	√		
1.5(xvi)	Ability to continue as a going concern	√		
1.5(xvii)	Significant deviations from the last year's operating results	√		
1.5(xviii)	Key operating and financial data of at least preceding 5 (five) years	√		
1.5(xix)	Reasons for not declared dividend			N/A
1.5(xx)	Number of board meetings held during the year and attendance	√		
1.5(xxi)	**Pattern of shareholding:**			
1.5(xxi)(a)	Parent/Subsidiary/Associated Companies and other related parties	-		N/A
1.5(xxi)(b)	Directors, CEO, CS, CFO, HIA and their spouses and minor children	√		
1.5(xxi)(c)	Executives	√		
1.5(xxi)(d)	10% or more voting interest	√		
1.5(xxii)	**Appointment/re-appointment of director:**			
1.5(xxii)(a)	Resume of the director	√		
1.5(xxii)(b)	Expertise in specific functional areas	√		
1.5(xxii)(c)	Holding of directorship and membership of committees of the board other then this company.	√		
2	**CHIEF FINANCIAL OFFICER (CFO), HEAD OF INTERNAL AUDIT AND COMPANY SECRETARY (CS):**			
2.1	Appointment of Chief Financial Officer, Head of Internal Audit & Company Secretary and defining their roles, responsibilities and duties	√		
2.2	Attendance of CFO and CS at the meeting of the Board of Directors	√		
3	**AUDIT COMMITTEE:**			
3(i)	Constitution of Audit Committee	√		

Condition No.	Title	Compliance Status (Put "√" in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
3(ii)	Assistance of the Audit Committee to Board of Directors	√		
3(iii)	Responsibility of the Audit Committee	√		
3.1	**Constitution of the Audit Committee:**			
3.1(i)	At least 3 (three) members	√		
3.1(ii)	Appointment of members of the Audit Committee at least one ID	√		
3.1(iii)	Qualification of Audit Committee members	√		
3.1(iv)	Term of Service of Audit Committee members	√		
3.1(v)	Secretary of the Audit Committee	√		
3.1(vi)	Quorum of the Audit Committee shall not constitute without at least one Independent Director	√		
3.2	**Chairman of the Audit Committee:**			
3.2(i)	Board of Directors shall select the Chairman: who shall be an Independent Director	√		
3.2(ii)	Chairman of the audit committee: shall remain present in the-AGM	√		
3.3	**Role of Audit Committee:**			
3.3(i)	Oversee the financial reporting process	√		
3.3(ii)	Monitor choice of accounting policies and principles	√		
3.3(iii)	Monitor-Internal Control Risk management process	√		
3.3(iv)	Oversee hiring and performance of external auditors	√		
3.3(v)	Review the annual financial statements before submission to the board for approval	√		
3.3(vi)	Review the quarterly and half yearly financial statements before submission to the board for approval	√		
3.3(vii)	Review the adequacy of internal audit function	√		
3.3(viii)	Review statements of significant related party transactions	√		
3.3(ix)	Review Management Letters/ Letter of Internal Control weakness issued by statutory auditors	√		
3.3(x)	Disclosure about the uses/applications of funds raised by IPO/RPO/Right issue			N/A
3.4	**Reporting of the Audit Committee:**			
3.4.1	**Reporting to the Board of Directors:**			

Condition No.	Title	Compliance Status (Put "√" in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
3.4.1(i)	Activities of Audit Committee	√		
3.4.1(ii)(a)	Conflicts of interests	√		
3.4.1(ii)(b)	Material defect in the internal control system	√		
3.4.1(ii)(c)	Infringement of laws, rules and regulations	√		
3.4.1(ii)(d)	Any other matter	√		
3.4.2	**Reporting to the Authorities**	√		
3.5	**Reporting to the Shareholders and General Investors**	√		
4	**NON-ENGAGEMENT OF EXTERNAL/STATUTORY AUDITORS:**			
4(i)	Appraisal or valuation services or Fairness opinions	√		
4(ii)	Financial information systems design and implementation	√		
4(iii)	Book-keeping	√		
4(iv)	Broker-dealer services	√		
4(v)	Actuarial services	√		
4(vi)	Internal audit services	√		
4(vii)	Services that the Audit Committee determines	√		
4(viii)	Audit firms shall not hold any share of the company they audit.	√		
4(ix)	Audit/certification services on compliance of corporate governance.	√		
5	**SUBSIADIARY COMPANY:**			
5(i)	Composition of the Board of Directors			N/A
5(ii)	At least 1 (one) Independent director to the subsidiary company			N/A
5(iii)	Submission of Minutes to the holding company.			N/A
5(iv)	Review of Minutes by the holding company			N/A
5(v)	Review of Financial Statement by the holding company			N/A
6	**DUTIES OF CHIEF EXECUTIVE OFFICER (CEO) AND CHIEF FINANCIAL OFFICER (CFO):**			
6(i)(a)	Reviewed the materially untrue of the financial statement	√		

Condition No.	Title	Compliance Status (Put "√" in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
6(i)(b)	Reviewed about compliance of the accounting standard	√		
6(ii)	Reviewed about fraudulent, illegal or violation of the company's code of conduct	√		
7	**REPORTING AND COMPLIANCE OF CORPORATE GOVERNANCE:**			
7(i)	Obtain certificate -about compliance of conditions of Corporate Governance Guidelines	√		
7(ii)	Annexure attached in the directors report	√		

Issuer's Audit Committee

In accordance with the currently accepted Best Practice and Corporate Governance Guidelines adopted by Bangladesh Securities and Exchange Commission (BSEC), the Board appointed Audit Committee comprises of the following Non-Executive and Independent Directors of the Company:

- Ms. Fouzia Haque, FCA, Independent Director (Chairman of the Audit Committee)
- Dr. Jabilur Rahman Sinha, Deputy Managing Director (Member of the Audit Committee)
- Syed Shahed Reza, Independent Director (Member of the Audit Committee)

Terms of reference of Audit Committee

The main objective of the Audit Committee is to assist the Board of Directors to effectively carry on its responsibilities relating to financial and other relevant affairs of the Company. The Committee is empowered to monitor, review and examine the following:-

- Oversee the financial reporting process.
- Monitor implementation/ following the accounting policies and principles.
- Monitor Internal Control Risk Management Process.
- Oversee hiring and performance of external auditors.
- Review along with the management, the Annual Financial Statements before submission to the Board for approval.
- Review along with the management, the Quarterly and Half Yearly Financial Statements before submission to the Board for approval.
- Review the adequacy of Internal Audit team performance in terms of internal audit report.
- Review statement of significant related party transactions submitted by the management.
- Review Management Letters/ Letter of Internal Control weakness issued by statutory auditors.
- When money is raised through Initial Public Offering (IPO)/Repeat Public Offering (RPO)/Rights Issue, the company shall disclose to the Audit Committee about the uses/applications of funds by major category (capital expenditure, sales and marketing expenses, working capital, etc.), on a quarterly basis, as a part of their quarterly declaration of financial results. Further, on an annual basis, the company shall prepare a statement of funds utilized for the purposes other than those stated in the offer document/prospectus.

Remuneration Committee

The company does not have any remuneration committee.

CHAPTER XV: VALUATION REPORT OF SECURITIES PREPARED BY THE ISSUE MANAGER

The valuation report of securities offered is prepared and justified by the issue manger on the basis of the financial and all other information pertinent to the issue

Qualitative and Quantative factors for valuation

Qualitative Justification

1. One of the top ranking Pharmaceutical Companies of the Country and has been running successfully since 1954.
2. Enjoying consistent earnings and EPS
3. Consistently paying dividend at higher rate
4. Highly state of the art technology adaptor and huge long term assets based company
5. Highly structured and professionally run company
6. Substantial retained earnings amounting to BDT 1,949.43 million as on 30 June 2014

Quantitative Justification

76 (Seventy Six) Eligible Institutional Investors (EIIs) in 6 (six) categories have given their indicative prices out of which 46 (Forty Six) EIIs in 6 (six) categories have given support to the proposed indicative price of Tk. 71.00 (Seventy One) each along with their intended quantity as against the requirement of minimum 20 (twenty) offers covering 10% of the total issue size as specified in "Indicative Price Supported by the Eligible Institutional Investors (EIIs)" under the head of Features of IPO of this Prospectus.

Determination of Share Price

The ACME Laboratories Ltd. has conducted a Road Show on 13 October 2014 for Price Discovery under Book-building Method. Total 76 (Seventy Six) Eligible Institutional Investors (EIIs) in 6 (six) categories have given their indicative prices.

The Issuer in consultation with the Issue Manager quote the indicative price at BDT 71.00 (Seventy One)based on these indicative prices as the price is supported by 46 (Forty Six) EIIs in 6 (six) categories against the requirement of at least 20 (twenty) EIIs including at least 3(Three) quotations covering 10% of the total issue size as per Rule 8(B)(16)(4)(b) of the Securities and Exchange Commission (Public Issue) Rules, 2006.

Analyzing macro environment, sectoral prospect, present market scenario and micro level other qualitative and quantitative factors of The ACME Laboratories Ltd., sectoral P/E driven earning based valuation would be the most appropriate valuation method for highly state of the art technology adapted and huge long term assets based company like The ACME Laboratories Ltd.. Besides, valuation based on Net Asset Value of the Company also found lucrative one.

Therefore, Primary Valuation method for the Company is considered on the basis of earnings based valuation and Net Assets Value based valuation per share.

Method-1: Net Assets Value at historical or current costs

Method-1(a): Net Assets Value per Share at current cost as at 30 June 2015	
Particulars	**Amount**
Share capital	1,616,017,000
Share premium	1,605,066,569
Revaluation reserve	5,320,065,830
Gain/(Loss) on Marketable Securities (Unrealized)	1,824,633
Tax Holiday Reserve	139,860,882
Retained earnings	2,689,794,678
Total Shareholders' Equity	**11,372,629,592**
Number of shares	161,601,700
Net Asset Value per share at current cost as at June 30, 2015 (as per audited report)	**70.37**

Method-1(b): Net Assets Value per Share at historical cost as at 30 June 2015	
Particulars	**Amount**
Share capital	1,616,017,000
Share premium	1,605,066,569
Gain/(Loss) on Marketable Securities (Unrealized)	1,824,633
Tax Holiday Reserve	139,860,882
Retained earnings	2,689,794,678
Total Shareholders' Equity	**6,052,563,762**
Number of shares	161,601,700
Net Asset Value per share at historical cost as at June 30, 2015 (as per audited report)	**37.45**

Method-2: Earnings based value per share as at 30 June 2015				
Financial Year	**No. of Share**	**Net Profit after Tax**	**Weight (%)**	**Weighted Average Profit**
2015	161,601,700	921,917,143	22.734	209,589,402
2014	161,601,700	893,890,898	22.734	203,217,892
2013	155,631,100	505,695,794	21.894	110,717,745
2012	116,000,000	476,128,396	16.319	77,698,668
2011	116,000,000	344,151,300	16.319	56,161,527
Total	**710,834,500**	**2,219,866,388**	**100.00**	**657,385,233**
No. of shares				**161,601,700**
Weighted average EPS (657,385,233/161,601,700)				4.07
DSE 3 months average Sectoral P/E (October'15 to December' 15)				**27.11**
Earning Based Value per share (Sectoral P/E)				**110.34**

Particulars	**Oct.'15**	**Nov.'15**	**Dec'15**	**Average**
Sectoral P/E (Pharmaceuticals)	26.94	27.04	27.34	27.11

Method-3: Average Market Price Per Share of Similar Stock

Similar companies information in the Pharmaceuticals sector

Sl. No.	Name	EPS	NAV	Net Profit after Tax (mn)	Average P/E
1	ACI	14.4	103.93	573.45	39.01
2	BEACONPHAR	0.17	12.58	38.6	89.87
3	BXPHARMA	3.96	54.16	1,528.3	21.25
4	CENTRALPHL	1.52	16.27	143.42	13.81
5	IBNSINA	5.67	30.26	127.28	26.39
6	ORIONPHARM	4.25	67.5	994.09	8.66
7	RENATA	31.87	150.86	1,687.49	38.69
8	SQURPHARMA	9.6	49.86	5,983.81	26.44

January 2015 to December 2015														
Sl. No.	**Name**	**Jan**	**Feb**	**Mar**	**Apr**	**May**	**June**	**Jul**	**Aug**	**Sep**	**Oct**	**Nov**	**Dec**	**1 year average price**
1	ACI	356	436	535.2	534	527	517.1	585.2	547	580.6	556	507.40	561.6	**520.26**
2	BEACONPHAR	16.3	15.7	14.6	13.5	13.9	14.7	15.8	15.2	15.8	14.9	14.10	15	**14.96**
3	BXPHARMA	56.3	57.4	56.3	44.8	57.5	62.8	69.7	65.8	71.5	71.3	77.00	84.1	**64.54**
4	CENTRALPHL	28	27.4	25.7	21.6	28.4	27.8	27.8	28.3	27.7	23.2	21.00	21	**25.66**
5	IBNSINA	94.1	106.7	103.7	94.9	91.1	88.7	103.8	134.6	182	164	127.70	149.6	**120.08**
6	ORIONPHARM	43.4	43.7	42	33	38.5	40.8	39.4	37.3	38.1	34.8	33.90	36.8	**38.48**
7	RENATA	998.3	1143	1150	1030	894	999	1244	1208	1250	1206.4	1,248.60	1233.1	**1,133.64**
8	SQURPHARMA	254.3	263.8	263.1	246	246.6	262.2	272.7	252.9	249.4	243	254.10	253.7	**255.15**
Average Market Price Per Share of Similar Stock														**271.59**

Summary of the Calculation:

Sl. #	Particulars	Amount in BDT
Method-1 (a)	Net Assets Value per Share at current cost as at 30 June 2015	70.37
Method-1 (b)	Net Assets Value per Share at historical cost as at 30 June 2015	37.45
Method-2	Earnings based value per share as at 30 June 2015	110.34
Method-3	Average Market Price Per Share of Similar Stock	271.59
	Average Price of the above four methods	**122.44**

Sources of Information:

1. *Annual Report of Issuer Company*
2. *Monthly review published by Dhaka Stock Exchange Ltd.*

List of Indicative price supported by the Eligible Institutional Investors (EIIs)

List of 46 (Forty Six) Eligible Institutional Investors (EIIs) giving support to the indicative price of BDT 71.00 (Seventy One) along with intended quantity:

SL.#	Name of the Eligible Institutional Investors (EIIs)	Category	No. of Shares Subscribed	Indicative Price (BDT)
01	RACE Asset Management PCL	**Asset Management Company 2,65,000**	10,000	71.00
02	Alliance Capital Asset Management Ltd.		2,50,000	80.00
03	Prime Finance Asset Management Company Ltd.		5,000	80.00
04	Prime Insurance Company Ltd.	**Insurance Company 61,26,300**	10,00,000	80.00
05	Popular Life Insurance Company Ltd.		10,00,000	80.00
06	Fareast Islami Life Insurance Co. Ltd.		10,00,000	80.00
07	Asia Insurance Ltd.		10,00,000	80.00
08	Prime Islami Life Insurance Ltd.		5,00,000	80.00
09	Rupali Insurance Company Ltd.		20,000	80.00
10	Pioneer Insurance Company Ltd.		31,300	80.00

11	Republic Insurance Company Ltd.	**Insurance Company 61,26,300**	25,000	80.00
12	Green Delta Insurance Co. Ltd.		1,25,000	80.00
13	Karnaphuli Insurance Company Ltd.		1,25,000	80.00
14	Meghna Life Insurance Co. Ltd.		2,00,000	80.00
15	Federal Insurance Company Ltd.		1,00,000	80.00
16	Sandhani Life Insurance Co. Ltd.		10,00,000	75.00
17	Dhaka Bank Ltd.	**Commercial Bank 21,90,000**	10,00,000	80.00
18	Bangladesh Commerce Bank Ltd.		10,00,000	80.15
19	The City Bank Ltd.		1,00,000	80.00
20	United Commercial Bank Ltd.		25,000	80.00
21	Trust Bank Ltd.		10,000	80.00
22	Eastern Bank Ltd.		50,000	80.00
23	Standard Bank Ltd.		5,000	80.00
24	Fareast Finance & Investment Ltd.	**Non-Banking Financial Institution (NBFI) 26,60,000**	10,00,000	80.00
25	Bay Leasing &Investment Ltd.		10,00,000	80.00
26	International Leasing And Financial Services Ltd.		10,000	80.00
27	Prime Finance &Investment Ltd.		1,00,000	81.00
28	Phonix Finance &Investment Ltd.		2,50,000	80.00
29	Sandhani Life Finance Limited		3,00,000	73.00
30	Southeast Bank Capital Services Ltd.	**Merchant Bank 19,10,000**	10,00,000	80.00
31	IL Capital Ltd.		1,00,000	80.00
32	City Bank Capital Resources Ltd.		2,00,000	80.00
33	PLFS Investments Ltd.		10,000	80.00
34	Swadesh Investment Management Ltd.		2,00,000	80.00
35	Alpha Capital Management Ltd.		2,00,000	80.00
36	Imperial Capital Limited		80,000	78.00
37	AFC Capital Limited		70,000	79.00
38	Banco Finance and Investment Ltd.		50,000	75.00
39	DBL Securities Ltd.	**Stock Dealer 15,65,000**	5,00,000	80.00
40	PFI Securities Ltd.		2,00,000	80.00
41	Prime Islami Securities Ltd.		5,000	80.00
42	IIDFC Securities Ltd.		2,50,000	80.90
43	Social Islami Bank Securities Ltd.		10,000	85.00
44	Galaxy Capital Ltd.		50,000	80.00
45	Island Securities Ltd.		50,000	86.00
46	Mona Financial Consultancy and Securities Ltd.		5,00,000	74.00
TOTAL			**1,47,16,300**	

CHAPTER XVI: DEBT SECURITIES

The Company has not issued or is planning to issue any debt security within six months.

CHAPTER XVII: PARTIES INVOLVED AND THEIR RESPONSIBILITIES

Issue manager

ICB Capital Management Ltd.

The issuer has appointed **ICB Capital Management Ltd. as** issue manager, registered with the Bangladesh Securities and Exchange Commission, for the purpose of making the public offer under book building method. The issue managers shall be entitled to fees and be responsible for the issue including preparation and disclosures made in the prospectus, road show and all other responsibilities given in the due diligence certificate and relevant securities laws.

Underwriters

The company has appointed the following institutions as underwriter

1. ICB Capital Management Ltd.
2. Prime Finance Capital Management Ltd.
3. Southeast Bank Capital Services Ltd.
4. Swadesh Investment Management Ltd.
5. IDLC Investments Ltd.
6. EBL Investments Ltd.
7. First Security Islami Capital & Investment Ltd.
8. IL Capital Ltd.
9. PLFS Investments Ltd.
10. Roots Investment Limited
11. Sonali Investment Ltd.
12. BetaOne Investment Ltd.

The responsibility of the underwriter is to take up the un-subscribed securities against the Initial Public Offering.

Auditor

The auditor of the company is Pinaki & Company, Chartered Accountants.

Auditor's responsibility is to express an opinion on the financial statements based on their audit. An auditor conducting an audit in accordance with BSAs is responsible for obtaining reasonable assurance that the financial statements taken as a whole are free from material misstatement, whether caused by fraud or error. Owing to the inherent limitations of an audit, there is an unavoidable risk that some material misstatements of the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the BSAs

Cost and Management Accountants

Not applicable for the companies.

Valuers

The value of the company is Masih Muhith Haque & Co., Chartered Accountants and M.M. Rahman & Co. Chartered Accountants.

The responsibility of the valuer is to value the investment property in accordance with International Valuation Standards (IVSs) and condition and guidelines for valuation of assets by Bangladesh Securities and Exchange Commission (BSEC).

An independent valuer Masih Muhith Haque & Co. Chartered Accountants conducted the valuation of Property, Plant & Equipment of the company as at 30 June 2011. The same valuer also conducted the valuation of Investment Property of the company from the year 30 June 2012 to 30 June 2014.

M.M. Rahman & Co. Chartered Accountants an independent valuer revalued land, building, vehicles, machineries & equipments, utilities, electrical installation and office equipment of erstwhile The ACME Specialized Pharmaceuticals Ltd. as at 30 June 2012 following current cost method.

All the revaluations of the company mentioned above was conducted before the publication of notification regarding valuation guideline by the Bangladesh Securities & Exchange Commission (BSEC) on dated August 18, 2013. So, certificates required under the revaluation guideline of the Commission is not applicable for the company.

Credit rating Company

The Credit Rating Information & Services Ltd. (CRISL) has conducted credit rating of the company
The responsibility of the Credit Rating Company is to reaffirm the long-term rating and short term rating of the company based on its financial and other relevant quantitative and qualitative information up to the date of rating.

CHAPTER XVIII: MATERIAL CONTRACTS

(a) Major agreements entered into by the Issuer.

a. Underwriting Agreements between the Company and the Underwriters.
b. Issue Management Agreement between the Company and ICB Capital Management Limited.
c. Registrar to the Issue Agreement with Prime Finance Capital Management Limited
d. Credit Rating Agreement between the Company and CRISL.

Copies of the aforementioned contracts and documents and a copy of Memorandum and Articles of Association of the Company and the Consent Order from the Bangladesh Securities and Exchange Commission may be inspected on any working day during office hours at the Company's Registered Office

Fees Payable to different parties

Manager(s) to the Issue fee

ICB Capital Management Limited is the Manager to the Issue. The Issue Manager will get 0.40% of the Issue size as issue management fee.

Registrar to the Issue fee

Prime Finance and Capital Investment Limited is the Registrar to the Issue. The Registrar to the Issue will get Tk. 11.50 lac as Registrar to the Issue fee.

Commission for the Underwriters

The company shall pay to the underwriters an underwriting commission at the rate of 0. 50% of the IPO amount of the issue value of shares underwritten by them out of the Public Issue.

Credit Rating fee

The Credit rating of the Company is conducted by the Credit Rating Information & Services Ltd. (CRISL) and they got Tk. 230,000 as credit rating fee.

CHAPTER XIX: OUTSTANDING LITIGATIONS, FINE OR PENALTY

There is no outstanding litigation against the issuer or any of its Directors and fine or penalty imposed by any authority:

(i) Litigation involving Civil Laws
(ii) Litigation involving Criminal Laws
(iii) Litigation involving Securities, Finance and Economic Laws
(iv) Litigation involving Labor Laws
(v) Litigation involving Taxation (Income tax, VAT, Customs Duty and any other taxes/duties)
(vi) Litigation involving any other Laws

Outstanding cases filed by the Company or any of its directors

(i) Litigation involving Civil Laws: No cases filed by the company or any of its directors
(ii) Litigation involving Criminal Laws: No cases filed by the company or any of its directors
(iii) Litigation involving Securities, Finance and Economic Laws:

We were informed by our lenders that, The ACME Laboratories Ltd. was shown as defaulter borrower in the CIB report prepared and circulated by the Bangladesh Bank. Being aggrieved, the Company filed Writ Petition against the report before the High Court Division of the Supreme Court of Bangladesh and the court stayed the order.

(iv) Litigation involving Labor Laws: No cases filed by the company or any of its directors
(v) Litigation involving Taxation Litigation involving any other Laws:

Income Tax

Accounting Year	Assessment year	Status
2013-14	2014-15	After complying provision of law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax Return was submitted on 31.12.2014. Subsequently the Deputy Commissioner of Taxes issued a letter to audit. Being aggrieved, the Company filed a Writ Petition against the letter before the High Court Division of the Supreme Court of Bangladesh. The court issued a Rule Nisi and stayed the order till disposal from the date 08 March 2016.

Accounting Year	Assessment year	Status
2012-13	2013-14	Return was submitted duly under law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax. Subsequently, the Deputy Commissioner of Taxes issued a letter to audit and after conducting audit assessment order was issued by demanding tax liability of Tk. 19,232,808. Against the order, the company appeal the same to the Commissioner of Taxes (Appeal) on dated 20 September 2015. Hearing was duly heard on 25 November 2015 but the order has not yet been issued by the Commissioner Taxes (Appeal).
2011-12	2012-13	As per demand notice u/s 135 dated 20.07.2015 present tax demand is Tk. 22,339,873 which has been paid on dated 24.02.2016.
2010-11	2011-12	The Deputy Commissioner of Taxes, Circle-161, Zone-08 certified that "income tax case for the assessment year 2011-12 has been settled".
2009-10	2010-11	As per demand notice u/s 135 dated 30.01.2013 present tax demand is Tk. 35,945,126. As per section 173 a letter was submitted by the Company to the DCT on 06.03.2013 to rectify the all-previous years' orders by adjusting previous years refund and AIT and raised revised demand. Revised order yet to receive.
2008-09	2009-10	As per demand notice u/s 135 dated 08.10.2012 present tax demand is Tk. 45,930,964. As per section 173 a letter was submitted by the Company to the DCT on 06.03.2013 to rectify the all-previous and current years' orders by adjusting previous years refund and current years AIT and raised revised demand. Revised order yet to receive.

VAT

Large Tax Payer Unit (LTU), North Commissionerate and Directorate, Inspection, Intelligence & Investigation under National Board of Revenue (NBR) against 4 (four) claims of VAT and another 1 (one) regarding VAT on VAT exempted medicine. The ACME Laboratories Ltd. has filed 5 (five) writ petitions in The Honorable High Court Division of the Supreme Court of Bangladesh separately vide no.- 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002 respectively against the said claims. The company reviews status of the same on every reporting date. Details of current status are given below:

SL	Writ No.	Value in BDT	Reason	Expiry Date
01	8650/2008	Non-monitory	Medicine supply to ICDDR,B as Exempted	Valid up to disposal of hearing
02	785/2009	1,30,97,829.00	Rebate for exemption of medicine	Valid up to disposal of hearing
03	3948/2004	27,30,765.27	Rebate cancel	Valid up to disposal of hearing
04	4477/2002	19,07,555.00	Rebate cancel	Valid up to disposal of hearing
05	4478/2002	6,65,525.24	Difference in rate of custom duty with the department	Verdict has already been given by the Honorable High court division but formal demand yet to receive from concern authority

CHAPTER XX: RISK FACTORS AND MANAGEMENT'S PERCEPTIONS ABOUT THE RISKS

In the business world return and risks has reciprocal relationship. Thus, The ACME Laboratories Ltd. would be subject to risk of a typical nature for similar pharmaceutical companies. The majority of these risks are commercial and business risks that can be mitigated effectively. Before making any investment decision, Investors should take the risk factors into consideration. Such major risk factors are described in brief as under:

Internal risk factors may include, among others

Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge on obligation. Credit risk information helps users of financial statements to assess the credit quality of the entity's financial assets and level & sources of impairment loss.

Management Perception

Management has a credit policy in place and exposure to credit risk is monitored on an on-going basis. To mitigate the credit risk the management of the company follows robust credit control and collections policies. The company has dedicated credit collections team.

Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure as far as possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses including financial obligations through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient fund to make the expected payment within due date. In extreme stressed conditions, the company may get support from the related company in the form of short-term financing.

Management Perception

Effective liquidity risk management requires both a top-down and a bottom-up approach. Strategy, principles and objectives are set at board and management levels. ACME conducts liquidity management in a manner that maintains stability and flexibility in day-to-day funding activities. Our liquidity risk management starts by managing daily payment of cheques, daily cash inflow and outflow, maturity of deposits and our access to other funding sources as and when required.

Risk associated with the issuer's interest in subsidiaries, joint ventures and associates

Right now, The ACME Laboratories Limited has no subsidiaries, joint ventures and associates concern**.**

Management Perception

Since ACME has no subsidiaries, joint ventures and associates concern**.** So, it out of this sort of risk.

Significant revenue generated from limited number of customers, losing any one or more of which would have a material adverse effect on the issuer

Management Perception

Since ACME's market is diverse from urban to the very remote rural of the country and it has not limited customers from whom it generates significant amount of revenue, it is almost free from this sort of risk.

Dependency on a single or few suppliers of raw materials, failure of which may affect production adversely;

Management Perception

We are not depended on a single or few suppliers of raw materials. ACME has a good number of vendors for each and every ingredient and services, the company has more than one approved vendors. It uses to conduct vendor audit and its concerned professionals are very conscious regarding the vendor issue. Further, we assume that sourcing of raw material would be comparatively easier in times to come as due to globalization, the world economy opened much more than it was in older days and world is becoming like a global village. Hence the risk is not applicable for us.

More than 20% revenue of the Company comes from sister concern or associate or subsidiary

Management Perception

The Company does not earn any revenue from its any sister concern or associate or subsidiary. So, for ACME there is no possibility to faces this sort of risk.

Negative earnings, negative cash flows from operating activities, declining turnover or profitability, during last five years, if any;

Management Perception

The Company does not have any negative earnings, negative cash flows from operating activities, declining turnover or profitability during last five years except negative cash flows from operating activities during the year ended 30 June 2010 amounting Tk. 177,574,296. However, we have overcome the situations and from onwards 30 June 2011 as per audited accounts the same shows positive inflows.

Loss making associate/subsidiary/group companies of the issuer

ACME has no associate and subsidiary company. But, it has 12 (twelve) number of related parties under the ground of common directorship among which 3 (three) namely Sinha Wool wears Ltd., ACME Overseas Trading Ltd. and ACMUNIO International Ltd. are still suffering operating losses. The amount of net loss for the year ended 30 June 2014 for Sinha Wool wears Ltd. is Tk. 5,248,529, For ACME Overseas Trading Ltd. is Tk. 2,379,659 and for ACMUNIO International Ltd for the year ended 31 December 2014 is Tk. 25,823,784 respectively.

Management Perception

ACME has no investment in all of the related parties. Truly, it is the matter of concerned Directors. As such, ACME has no risk.

Financial weakness and poor performance of the Company or any of its subsidiary or associates

Management Perception

ACME has no subsidiary or associate concerns. Besides, ACME is a highly competent, resourceful, and profitable company. The Company's net profit after Tax and other business performance indicators show increasing trend due to the management dedication and suitable strategic action to face competition in the industry. Successive strong financial performance is the result of unwavering commitment of the promoters, management efficiency, employees' sincerity, use of appropriate technology, among others. Over the year, company's financial performance is improving due to its long terms vision in this sector, experienced top tier management, favorable economic and government rules and regulations, the commendable repayment culture is contributing for growth of the company. As such, possibility of liquidity and going concern risks are significantly minimum.

Decline in value of any investment

Management Perception

ACME has investment in shares of several listed companies amounting Tk. 6,139,321 in the note 8 of Audited Financial Statements as at 30 June 2014 from which it earned unrealized profit amounting Tk. 841,041. Considering the facts, it is evident that ACME is not under the preview of this risk**.**

Risk associated with useful economic life of plant and machinery, if purchased in second hand or reconditioned

Management Perception

ACME dose not purchase or use any second hand or recondition plant and machinery. Therefore, it is not applicable for ACME.

Adverse effect on future cash flow if interest free loan given to related party or such loans taken from directors may recall

Management Perception

ACME did not provide any loan to its related party. As such, this risk is not applicable.

Potential conflict of interest, if the sponsors or directors of the issuer are involved with one or more ventures which are in the same line of activity or business as that of the Company and if any supplier of raw materials or major customer is related to the same sponsors or directors;

Management Perception

No ACME's sponsor or director is engaged in same line of business of the issuer Company. No supplier of raw materials or major customer is related to the same sponsors or directors. So, such risk is not relevant to ACME.

Related party transactions entered into by the company those may adversely affect competitive edge;

Management Perception

ACME did not engage any such transaction, which may adversely affect competitive edge.

Any restrictive covenants in any shareholders' agreement, sponsors' agreement or any agreement for debt or preference shares or any restrictive covenants of banks in respect of the loan/ credit limit and other banking facilities

Management Perception

There are no restrictive covenants in any covenants in any shareholders' agreement, sponsors' agreement or any agreement for debt or preference shares except some restrictive covenants of banks like changes in ownership structure, changes in sponsor Directors and some mortgage agreements that are mentioned in page no 107 of the prospectus.

Business operations may be adversely affected by strikes, work stoppages or increase in wage demands by employees

Management Perception

The ACME Laboratories Ltd. is one of the leading pharmaceutical companies of the country always prioritizes its Human Resources, as its success immensely depends upon performance of its 6,711 patrons. With the view to go forward by retaining the resource, ACME always offers inspiring propositions along with a classic working environment. Considering the facts, it is apparent that risk of strikes, work stoppages or increase in wage demands by employees is very remote for ACME.

Seasonality of the business of the issuer

Management Perception

As the products of pharmaceuticals industry are of basic in nature and majorly chronic care related, Bangladesh Pharma market is consistent. So the risk of variability of company's operating results is varying insignificant over the month of a year.

Expiry of any revenue-generating contract that may adversely affect the business

Management Perception

ACME has no long-term revenue-generating contract with any customer. So, there is no chance to affect the business adversely on this ground.

Excessive dependence on debt financing which may adversely affect the cash flow

As per ratio analysis certified by auditors as at 30 June 2014 debt is 1.07 times of Equity, which indicates that, The ACME Laboratories Ltd. excessive dependence on debt financing. It may adversely affect the cash flows.

Management Perception

As per credit rating report for the year ended 30 June 2015, The ACME Laboratories has been awarded by CRISL 'A+' for long term refers adequate safety for timely repayment of financial obligations and 'ST-3' for short term refers good certainty of timely payment and company liquidity factors & fundamentals are sound.

Moreover, during last four years the company has been enjoying positive cash flows from operating activities.

Excessive dependence on any key management personnel absence of whom may have adverse effect on the Company's business performance

Management Perception

ACME has been running its business over six decades with name and fame. It is a structured Company. It practices strong human resources management and corporate governance principles. Succession planning is always in our mind and Company is running very professionally. As such, there is very remote possibility of adversely affect the business due to excessive dependence on key management personnel.

Enforcement of contingent liabilities, which may adversely affect financial condition

A contingent liability is where there is significant uncertainty about a number of aspects regarding the liability. A contingent liability arises where an event that occurred in the past may lead to the entity having a liability in the future, but the financial impact of the event will only be confirmed by the outcome of some future event not wholly within the entity's control.

VAT

The Company has contingent liability of Tk. 18,401,674 against 5 (five) claims to Large Tax Payer Unit (LTU), North Commissionerate and Directorate, Inspection, Intelligence & Investigation under National Board of Revenue (NBR). Out of which against 4 (four) claims of VAT amounting Tk. 17,736,149 are yet to settle and against 1(one) claim of VAT amounting Tk. 665,525 already been imposed on the Company, waiting for formal demand from the concerned authority to settle the matter, for which Company accounted for necessary provision in its financial statement. For the remaining amount, i.e. Tk. Tk. 17,736,149 the Company did not create any provision. If the said amount imposed on the Company in future, its financial position will be adversely affected by that amount.

Income Tax

Accounting Year	Assessment year	Status
2013-14	2014-15	After complying provision of law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax Return was submitted on 31.12.2014. Subsequently the Deputy Commissioner of Taxes issued a letter to audit. Being aggrieved, the Company filed a Writ Petition against the letter before the High Court Division of the Supreme Court of Bangladesh. The court issued a Rule Nisi and stayed the order till disposal from the date 8 March 2016.
2012-13	2013-14	Return was submitted duly under law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax. Subsequently, the Deputy Commissioner of Taxes issued a letter to audit and after conducting audit assessment order was issued by demanding tax liability of Tk. 19,232,808. Against the order, the company appeal the same to the Commissioner of Taxes (Appeal) on dated 20 September 2015. Hearing was duly heard on 25 November 2015 but the order has not yet been issued by the Commissioner Taxes (Appeal).

Disputed tax liabilities with regard to the assessment year 2013-2014 is Tk. 19,232,808 against which the company appealed to the Commissioner of Taxes (Appeal) on dated 20 September 2015. Hearing was duly heard on 25 November 2015 but the order has not yet been issued by the Commissioner Taxes (Appeal). The Company did not create any provision against the demand.

With regard to the assessment year 2014-2015 concerned tax authority issued a letter to audit the return. Being aggrieved, the Company filed a Writ Petition against the letter before the High Court Division of the Supreme Court of Bangladesh and the court stayed the order till disposal. No disputed demand yet to raise. As such, the Company did not create any provision for this assessment year.

Management Perception

VAT

The ACME Laboratories Ltd. has filed 5 (five) writ petitions in The Honorable High Court Division of The Honorable Supreme Court of Bangladesh separately vide no.- 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002 respectively against the said claims. Among these, against the writ no. 4478/2002 the Company kept necessary provision for payment and waiting for formal demand from the concerned authority. If the judgment of remaining writs go against the Company, it will be paid accordingly.

Income Tax

The ACME Laboratories Ltd. has filed a writ petition to the Honorable High Court Division of The Honorable Supreme Court of Bangladesh with regard to the Income Taxes for the assessment year 2014-2015. Besides, for the assessment year 2013-2014, the Company appeared a hearing before Commissioner of Taxes (Appeal) on 25.11.2015 against a claim of Tk. 19,232,808, but judgment yet to receive. If anything goes against the Company, it will be accommodated accordingly.

Insurance coverage not adequately protect against certain risks of damages

Management Perception

As a part of risk management process, ACME transfers risks through insurance for inventory, plant & machinery, building covering fire & lighting damage, Group insurance coverage for permanent employees, riot & strike damage, malicious damage, aircraft damage, explosion and impact damage. So, risk of damages is mitigated.

Absence of assurance that directors will continue its engagement with Company after expiry of lock in period;

Management Perception

All running director of the Company gave their kind consent that they shall serve the Company. Further, since the Company follows corporate governance principles and other relevant laws of the land, absence of assurance that director will continue its engagement will not affect the business.

Ability to pay any dividends in future will depend upon future earnings, financial condition, cash flows, working capital requirements and capital expenditure

Management Perception

The Company's net profit after Tax and other business performance indicators show increasing trend due to the management dedication and suitable strategic action to face competition in the industry.

Successive strong financial performance is the result of unwavering commitment of the promoters, management efficiency, employees' sincerity, use of appropriate technology, among others. Over the year company's financial performance is improving due to its long terms vision in this sector, experienced top tier management, favorable economic and government rules and regulations, the commendable repayment culture is contributing for growth of the Company. Company follows prudent financial management. Company has a good record of paying dividend last three years. Besides, as at 30 June 2014 Company's retained earnings stood at Tk. 1,949,426,728. As shown in page 158 of the prospectus under business strategies and future plan that the company's net profit after tax for the next three accounting year are positive. So, risk is minimum.

History of non operation, if any and short operational history of the issuer and lack of adequate background and experience of the sponsors

Management Perception

The ACME Laboratories Ltd. started its journey in the year 1954 and converted into a private limited company on 17 March 1976 vides registration no C-4745/163 of 1975-76 under the Companies Act-1913. Since commencement of its operation, it has no history of non-operation till now. The company is running by a professional team and its sponsors have adequate business background and experience, which reduce the non-operating risk.

Risks related to engagement in new type of business, if any

Management Perception

Right now, ACME has no plan to engage in new type of business.

Risk in investing the securities being offered with comparison to other available investment options;

Management Perception

Investment in share market is risky. But, it is not true for investment in companies which basic fundamentals are strong. It also depends on the sector in which the Company belongs to. If investors make investment in good company and better sector, there is a possibility to earn higher dividend as well as capital gain. As far as the financial performances are concern, ACME is fundamentally strong Company. Further, as per Monthly Review December 2015 of Dhaka Stock Exchange, we found that market capitalization rate is 15.90% and sectoral PE ratio is 27.34. So, investment in ACME's share may be a better option for investors.

Any penalty or action taken by any regulatory authorities for non-compliance with provisions of any law

Management Perception

No penalty or action taken by any regulatory authorities for non-compliance with provisions of any law;

Litigations against the issuer for Tax and VAT related matters and other government claims, along with the disclosures of amount, period for which such demands or claims are outstanding, financial implications and the status of the case

Litigation against the Company for Income Tax

Accounting Year	Assessment Year	Status
2013-14	2014-15	After complying provision of law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax Return was submitted on 31.12.2014. Subsequently the Deputy Commissioner of Taxes issued a letter to audit. Being aggrieved, the Company filed a Writ Petition against the letter before the High Court Division of the Supreme Court of Bangladesh. The court issued a Rule Nisi and stayed the order till disposal from the date 8 March 2016.
2012-13	2013-14	Return was submitted duly under law of Universal Self Assessment Scheme (u/s 82BB) of Income Tax Ordinance, 1984 Income Tax. Subsequently, the Deputy Commissioner of Taxes issued a letter to audit and after conducting audit assessment order was issued by demanding tax liability of Tk. 19,232,808. Against the order, the company appeal the same to the Commissioner of Taxes (Appeal) on dated 20 September 2015. Hearing was duly heard on 25 November 2015 but the order has not yet been issued by the Commissioner Taxes (Appeal).
2011-12	2012-13	As per demand notice u/s 135 dated 20.07.2015 present tax demand is Tk. 22,339,873 which has been paid on dated 24.02.2016.
2010-11	2011-12	The Deputy Commissioner of Taxes, Circle-161, Zone-08 certified that "income tax case for the assessment year 2011-12 has been settled".
2009-10	2010-11	As per demand notice u/s 135 dated 30.01.2013 present tax demand is Tk. 35,945,126. As per section 173 a letter was submitted by the Company to the DCT on 06.03.2013 to rectify the all-previous years' orders by adjusting previous years refund and AIT and raised revised demand. Revised order yet to receive.
2008-09	2009-10	As per demand notice u/s 135 dated 08.10.2012 present tax demand is Tk. 45,930,964. As per section 173 a letter was submitted by the Company to the DCT on 06.03.2013 to rectify the all-previous and current years' orders by adjusting previous years refund and current years AIT and raised revised demand. Revised order yet to receive.

Among the above disputes, with regard to the assessment year 2012-13 and 2011-2012 already been settled. For the remaining the assessment years total demand raised amounting Tk. 101,108,898 before adjusting AIT and refund amounting Tk. 13,001,697 i.e. net demand stood at Tk. 88,107,201 for which the Company has made an additional provision of Tk. 10,000,000 in the books of account for the year ended 30 June 2014.

Litigation against the Company for VAT

Large Tax Payer Unit (LTU), North Commissionerate and Directorate, Inspection, Intelligence & Investigation under National Board of Revenue (NBR) against 4 (four) claims of VAT and another 1 (one) regarding VAT on VAT exempted medicine. The ACME Laboratories Ltd. has filed 5 (five) writ petitions in The Honorable High Court Division of the Supreme Court of Bangladesh separately vide no.- 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002 respectively against the said claims. The company reviews status of the same on every reporting date. Details of current status are given below:

SL	Writ No.	Value in BDT	Reason	Expiry Date
01	8650/2008	Non-monitory	Medicine supply to ICDDRB as Exempted.	Valid up to disposal of hearing.
02	785/2009	1,30,97,829.00	Rebate for exemption of medicine	Valid up to disposal of hearing.
03	3948/2004	27,30,765.27	Rebate cancel	Valid up to disposal of hearing.
04	4477/2002	19,07,555.00	Rebate cancel	Valid up to disposal of hearing.
05	4478/2002	6,65,525.24	Difference in rate of custom duty with the department.	Verdict has already been given by the Honorable High court division but formal demand yet to receive from concern authority

Other government claims

ACME has no other government claims

Management Perception

Income Tax

The ACME Laboratories Ltd. has filed a writ petition to The Honorable High Court Division of The Honorable Supreme Court of Bangladesh with regard to the Income Taxes for the assessment year 2014-2015. Besides, for the assessment year 2013-2014, the Company appeared a hearing before Commissioner of Taxes (Appeal) on 25 November 2015 against disputed amount of Tk. 19,232,808, but judgment yet to receive. For the remaining issues, the Company applied to adjust the claims against the advance taxes and refunds. After making necessary adjustments, if any demands arise by the Income Tax authority, company will follow accordingly.

VAT

The ACME Laboratories Ltd. has filed 5 (five) writ petitions in The Honorable High Court Division of The Honorable Supreme Court of Bangladesh separately vide no.- 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002 respectively against the said claims. Among these, against the writ no. 4478/2002 the Company kept necessary provision for payment and waiting for formal demand from the concerned authority. If the judgments of remaining writs go against the Company, it will be paid accordingly.

Registered office or factory building or place of operation is not owned by the issuer

Management Perception

ACME has own registered office and factory building. Besides, ACME operates 20 depots including central depots. Among 20 depots ACME owned building in 9 depots and others 11 are rented and of these 11 rented depots ACME has own vacant land in 9 depots of another places in the same cities.

Lack of renewal of existing regulatory permissions/licenses

Management Perception

A dedicated team supervises renewal processes of all the regularity permission/licenses. So, risk with regard to lack of renewal of existing regulatory permissions/licenses is very remote.

Failure in holding AGM or declaring dividend or payment of interest by any listed securities of the Company or any of its subsidiaries or associates

Management Perception

ACME has no listed securities or any of its subsidiaries or associates. Hence, this risk is not applicable for ACME.

Issuances of securities at lower than the IPO offer price within one year

Management Perception

ACME has no plan to issue any sort of securities within one year of IPO. As such, this issue is not applicable for ACME.

Refusal of application for public issue of any securities of the issuer or any of its subsidiaries or associates at any time by the Commission.

Management Perception

ACME has no subsidiary or associates. No refusal of application for public issue of any securities of the ACME's at any time by the commission.

External risk factors

Interest rate risks

Interest rate risk is the risk that Company faces due to unfavorable movement in the interest rates. Changes in the government's monetary policy, along with increased demand for loans/investments tend to increase the interest rates. Such rises in interest rates mostly affect Companies having floating rate loans or Companies investing in debt securities.

Management Perception

In order to manage this risk and overcome it, the Company shall exercise prudence in its cash flow management, supported by continued strength in sales and marketing. ACME is very careful in forecasting the prices of raw materials and manages its costs in an effective manner. To maintain effective rate of return ACME also follow knowledge and information based products mix, so as to ensure that the debt repayments are met on schedule, even if the interest rates were to rise.

Exchange rate risks

Exchange rate risk occurs due to changes in foreign currency exchange rates. As the Company has taken foreign currency loan, imports major raw materials and some packing materials from abroad and earns most of the revenue in local currency, unfavorable volatility or fluctuation may affect the profitability of the Company. On the other hand, if exchange rate decreased against local currency opportunity will be created for generating more profit.

Management Perception

ACME earns some of its revenue in US dollars, thereby creating in built hedging scopes. Besides, in case of significant BDT devaluation in order to keep the cost to minimum, appropriate and responsible hedging mechanisms may be applied. However, if the price of the US dollar appreciates too sharply against the BDT, this will be a nationwide phenomenon experienced by the entire industry. In such a scenario, there will be a market adjustment in end product prices, subject to approval of concerned authority.

Industry risks

The pharmaceutical industry has witnessed challenges such as intellectual property rights, a historic fuel price peak, and material cost increase across the globe. It stands as one of the most challenging and dynamic industries to operate as on date. Fortunately, Bangladesh is only least developed country who demonstrates significant competencies in pharmaceuticals industry and it requires huge medicine for its present 160 million (approx.) population and requires huge quantity of medicine. As such, local pharmaceutical industry is not in a trouble; rather the said industry has ample opportunities to grow.

Management Perception

As the per capita income and per person consumption of medicine is increasing over the years, management is optimistic about growth opportunities of pharmaceutical industry in Bangladesh. The company is trying to adopt sophisticated state of art manufacturing facilities and making efforts to catch the opportunity of regulated global market.

Economic and political risks

Bangladesh is prone to serious unrest in the political condition which produces Hartal, Road-Block and many other barriers to the business. This could also propel the cost of the product upwards.

Management Perception

Although the country has passed a political turmoil until the end of last year, a sound political atmosphere is prevailing from early this year which is expected to continue in future. Both the ruling and opposition parties are committed to the betterment of the country. Last democratic national assembly election and local council polls are instances of peaceful political situation in Bangladesh.

Market and technology-related risks

Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the Company. Mostly, the risk arises from falling demand for the pharmaceutical products which would harm the performance of

the Company. On the other hand, strong marketing and brand management would help the Company increase its customer base.

Management Perception

The products of pharmaceuticals industry are of basic nature and have a wide market as they are giving a good market share to The ACME Laboratories Ltd. at present. Hence, it will hardly be the case that there will be a lack of demand for the products. Moreover, as explained earlier, the pharmaceuticals industry is only increasing year-on-year and ACME is following fool-proof scientific integrated marketing policy. Hence, has marginal probability for shrinkage.

Technology Related Risk

Pharmaceutical industry is dynamic nature and heavily driven by technology. Hence, technology always plays a vital role here. Adaptation of better technology can help to gain remarkable competencies that certainly create competitive advantages like increase productivity; reduce costs, better perception of customers. Firms are exposed to technology risks when there are better technologies available in the market than the one used by the Company which may cause operational inefficiency.

Management Perception

As a one of the leading pharmaceutical firm of the country, there are clear intent regarding adaptation of technology here and the management is aware of technological changes and always trying to adopt new technology according to its needs. Furthermore, routine and proper maintenance of the equipment carried out by the Company ensures longer service life for the existing equipment and facilities. Finally, ACME is committed to hold its leading edge and maintaining quality and brand image.

Potential or Existing Government Regulations

The Company operates under the Drugs Ordinance 1982, Companies Act 1994, Directorate General of Drug Administration (DGDA) Regulations, Income Tax Ordinance 1984, Income Tax Rules 1984, Customs Act 1969, Value Added Tax (VAT) Act 1991, and Value Added Tax (VAT) Rules 1991 and other rules and regulations of the country. Any abrupt changes of the policies made by the regulatory authorities may adversely affect the business of the Company.

Management Perception

Since product of pharmaceuticals industry is essential one for lives and it is import substitute industry and value addition is remarkable, we see the government regulations are mostly investment friendly for this sector particularly. As ACME is one of the top ranking pharmaceutical companies of the country, it is doing business following all the rules and regulations. Change in regulations will bring changed strategies for doing the business by the dynamic management of the Company. Besides this, many of the patented drugs/molecules will be off patented and it will be an opportunity for the manufacturer to freely manufacture and distribute without any restriction.

Potential Changes in Global and National Policies

Changes of Government policies may affect business. 49 LDCs including Bangladesh are not required to provide patent protection, give exclusive marketing rights to companies with patented products or comply with the "mailbox" program – create a process to receive complaints about pharmaceutical product patent right violations until 2016. While it is possible that the deadline may be extended, its implementation in 2016 will have significant impact on the LDC who have not implemented the TRIPS standards.

Management Perception

Pharmaceuticals, over the years have been proved as a thrust sector for the country growing at a considerable pace each year. Bangladesh, through its international affiliates and other 48 LDCs shall definitely lobby for extension of this deadline. In addition, ACME is continuously trying to adopt right technology and build infrastructure to meet TRIPS standards.

Statutory clearances and approvals those are yet to be received by the issuer

Management perception

All the required statutory clearances and approvals, those are required for day to day running business is obtained.

Competitive condition of the business

Management perception

Pharmaceutical sector is one of the highest priority sectors in Bangladesh. With an annual two-digit growth rate the Bangladesh pharmaceutical industry is now heading towards self–sufficiency in meeting local demand. There are more than 437 registered small, medium, large, local and multinational companies operating in the country producing around 97% of the total internal demand.

Complementary and supplementary products/services which may have an impact on business of the issuer;

Management perception

Basically, Pharmaceuticals products meet fundamental of all living being. As such, it has no supplementary products.

Other Risks

Long Cash Conversion Cycle

Management Perception

Pharmaceuticals industry in Bangladesh itself is vertically integrated i.e. same company conducting business in three distinct functional areas like manufacturing, distribution of finished goods and eventually promoting the same. As such, its cash conversion cycle naturally longer than other industries. However, in order to manage and overcome it, the company shall exercise prudence in its working capital management, supported by continued

strength in supply chain management, sales and marketing with regard to management of Trade Payable, Trade Receivable and Inventory.

Advance against Land

The ACME Laboratories Ltd. has given & recorded Tk. 95,250,000/- as Advance against Land in note no 13 in its Financial Statements for the year ended on 30th June 2014 which have been given to various parties over the years for procuring land of strategic importance, located in surrounding area of the existing factory premises at Dhamrai near Dhaka and Sales Center at Brahmanbaria in Bangladesh based on duly executed contract with the parties for searching and remains successful in procuring then for development of it.

Management Perception

These lands are being acquired keeping in view the proposed future expansion plan of the business. For advancing the money, company has entered into formal written agreements with third parties, and advances are given to the third parties through proper banking channel. Mentionable here that for the Advance against land at Dhamrai registration for 190 decimals already been completed on dated 29 June 2015 for amounting Tk. 80,000,000 and regarding Brahmanbaria land registration process is in final stage.

Non Collection of Rent on Investment Property

ACMUNIO International Limited, a manufacturer of all kinds of high quality safety syringes, which are marketed by The ACME Laboratories Ltd. and also were supposed to use by The ACME Laboratories Ltd., itself. Initially ACMUNIO started its commercial manufacturing of Auto Disable (AD) Syringe, comparatively more health hazard free than any other conventional syringe manufactured in the country, on January 2011. Considering better quality and uninterrupted supply of packing ingredients The ACME Laboratories Ltd. extended its hand to ACMUNIO International Limited by renting one of its pre-fabricated building situated at Hemayetpur, Savar. However, due to its poor financial condition at the start-up stage the company was not able to pay the rentals of its office building in time.

Management Perception

Initially ACMUNIO started its commercial manufacturing of Auto Disable (AD) Syringe, comparatively more health hazard free than any other conventional syringe manufactured in the country, on January 2011. But due to very new features, said products were not able to convert consumers' behavior in favor of it. As a result, ACMUNIO was unable to pay its factory building rent in time. By this time considering the market scenario, ACMUNIO International changed its business proposition and commenced commercial manufacturing of usual disposable syringe on November 2014 and supplying its product to ACME. It has been mutually agreed that from now onwards, accrued rent will be adjusted against submitted bills for supply of syringe to the Company. It has also been agreed that outstanding amount will be adjusted by June 2016.

Advance to ACMUNIO International Limited

ACMUNIO International Limited, a manufacturer of all kinds of high quality safety syringes, which are marketed by The ACME Laboratories Ltd. and also were supposed to use by The ACME Laboratories Ltd., itself. Initially ACMUNIO started its commercial manufacturing of Auto Disable (AD) Syringe, comparatively more health hazard free than any other conventional syringe manufactured in the country, on January 2011. Considering better quality and uninterrupted supply of packing ingredients The ACME Laboratories Ltd. extended its hand to ACMUNIO International Limited by providing working capital in the form of interest free advance. However, due to its poor financial condition at the start-up stage the company was not able to pay the advances in time.

Management Perception

Initially ACMUNIO started its commercial manufacturing of Auto Disable (AD) Syringe, comparatively more health hazard free than any other conventional syringe manufactured in the country, on January 2011. But due to very new features, said products were not able to convert consumers' behavior in favor of it. As a result, ACMUNIO was unable to repay the advances in time. Considering the market scenario, ACMUNIO International changed its business proposition and commenced commercial manufacturing of usual disposable syringe on November 2014 and has been supplying its product to the company. It has been mutually agreed that from now onwards, said advances will be adjusted against submitted bills for supply of syringe to the Company. It has also been agreed that full amount of advances will be adjusted by June 2016.

Limited Control over Product Pricing

Worldwide pharmaceutical industry is heavily regulated including its product pricing. It cannot changes its products price as it wishes and sometimes it is not possible to increase finished product price even if price of input factors increase. As such, revenue and profit margin of the Company may change due to price controls imposed by the government.

Management Perception

Like many other countries pharmaceuticals products price is heavily regulated by the government. Basically in our country pharmaceuticals products are divided in two categories one is essential products for which Maximum Retail Price (MRP) are approved Directorate General of Drug Administration and another one is non-essential (INN) products for which Indicative Price (IP) are approved by the Directorate General of Drug Administration. In case of IP, the Company has discretion to submit any reasonable price considering demand and supply factors in market place and to get approval accordingly. If any abnormal increase of input factors happens, the company considers it as systematic risk and will move together with the industry as whole for logical price compensation.

Risks related with Completion of the Projects

Management Perception

Pharmaceutical is a technical, compliance oriented and highly regulated industry. Considering all the circumstances, establishment of a plant/project, from starting of construction to producing of goods, takes two to three years, which may create expectation gap with the investors' planned time frame of return. ACME is one of the top ranking pharmaceuticals companies in Bangladesh and has been running its business for last six decades. To make its business more sustainable and competent one, it has a plan to step into uncovered dosages forms through executing three projects by using IPO proceeds. All of which will bring benefits for the Company in the long-term.

CHAPTER XXI: DESCRIPTION OF THE ISSUE

Issue Size

Number of securities to be issued

The Company will offer 5,00,00,000 Ordinary Shares, of this 50,000,000 ordinary shares 50% (i.e. 25,000,000 Ordinary Shares) are reserved for Eligible Institutional Investors and 10% (i.e. 5,000,000 Ordinary Shares) for Mutual Fund at a cut off price of Tk. 85.20 and remaining 40% (i.e. 20,000,000 Ordinary Shares) to General investors including 10% of NRB and ক্ষতিগ্রস্থ ক্ষুদ্র বিনিয়োগকারী at a discounted price of Tk. 77.00 per share.

Authorized capital and paid-up capital

Particulars	Amount
Authorized Capital 500,000,000 Ordinary Shares of Taka 10 each	Tk. 5,000,000,000.00
Issued, Subscribed and Paid up Capital **Before IPO** 161,601,700 Ordinary Shares of Taka 10 each	Tk. 1,616,017,000.00
Initial Public Offering through Book Building Method 50,000,000 Ordinary Shares @ Tk. 10 each	Tk. 500,000,000.00
Post IPO Paid up Capital	**Tk. 2,116,017,000.00**

Face value, Premium and offer price per unit of securities

Face value per share	Tk. 10 each
Offer Price per share to Eligible Investors (EIs)	Tk. 85.20 with a premium of Tk. 75.20
Offer Price per share to General Public	Tk. 77.00 with a premium of Tk. 67.00

Number of securities to be entitled for each category of applicants

Category	Particulars	Number of Shares	Issue Price per Share	Amount in BDT
Eligible Investors (EIs)	10% of IPO i.e. 5,000,000 Ordinary Shares shall be reserved for Mutual Funds	5,000,000	Tk. 85.20	426,000,000
	50% of IPO i.e. 25,000,000 Ordinary Shares shall be reserved for Other Eligible Investors (EIs)	25,000,000		2,130,000,000
General Public	10% of IPO i.e. 5,000,000 Ordinary Shares shall be reserved for Non Resident Bangladeshis (NRBs)	5,000,000	Tk. 77.00	385,000,000
	30% of IPO i.e. 15,000,000 Ordinary Shares shall be reserved for ক্ষতিগ্রস্থ ক্ষুদ্র বিনিয়োগকারী and General Public	15,000,000		1,155,000,000
Total		**50,000,000**		**4,096,000,000**

- In case of over-subscription under Eligible Investors (EIs) categories mentioned above shall be allotted security on pro-rata basis at the cut-off price.
- In case of over subscription in the general public category, the issuer and the issue manager shall jointly conduct an open lottery.
- In case of under-subscription in any category by up to 35% in an initial public offer, the unsubscribed portion of securities shall be taken up by the underwriter(s):

Application for Subscription

1. Application for shares may be made for a minimum lot for 100 ordinary shares to the value of Tk. 7,700.00 (Seven Thousand Seven Hundred) only. Prospectus may be obtained from the Registered Office of the Company, members of Dhaka Stock Exchange Limited, Chittagong Stock Exchange Limited. Applications/buy Instruction must not be for less than 100 shares. Any application/buy Instruction not meeting this criterion will not be considered for allotment purpose.
2. Joint application form for more than two (2) persons will not be accepted. In the case of joint application, each party must sign the application form.
3. An applicant for public issue of securities shall submit application/buy instruction to the Stockbroker/ Merchant Banker where the applicant maintains customer account, within the cut-off date (i.e. subscription closing date).
4. The application/buy instruction may be submitted in prescribed paper or electronic form, which shall contain the Customer ID, Name, BO Account Number, Number of Securities applied for, Total Amount and Category of the Applicant.
5. Application/buy instruction must be in full name of individuals or limited companies or trusts or societies and not in the name of firms, minors or persons of unsound mind. Application/buy instruction from insurance, financial and market intermediary companies and limited companies must be accompanied by Memorandum and Articles of Association.

6. An applicant cannot submit more than two applications, one in his/her own name and the other jointly with another person. In case, an applicant submits more than two applications, all applications will be treated as invalid and will not be considered for allotment purpose. In addition, 15% (fifteen) of the application money will be forfeited by the Commission and the balance amount will be refunded to the applicant.

7. The applicants who have applied for more than two applications using same bank account, their application will not be considered for lottery and the Commission will forfeit 15% of the subscription money.

8. Making of any false statement in the application or supplying of incorrect information therein or suppressing any relevant information in the application shall make the application liable to rejection and subject to forfeiture of 25% of the application money and/or forfeiture of share (unit) before or after issuance of the same by the issuer. The said forfeited application money or share (unit) will be deposited in account of the Bangladesh Securities and Exchange Commission (BSEC). This is in addition to any other penalties as may be provided for by the law.

9. An IPO applicant shall ensure his/her BO account remains operational till the process of IPO (including securities allotment or refund of IPO application/buy instruction) is completed. If any BO account mentioned in the application/buy instruction is found closed, the allotted security may be forfeited by BSEC.

10. Bangladeshi Nationals (including non-resident Bangladeshi Nationals working abroad) and foreign nationals shall be entitled to apply for the share.

11. Non-resident Bangladeshi (NRB) and Foreign applicants shall submit bank drafts (FDD), issued in favor of the Issuer for an amount equivalent to the application money, with their application to the concerned Stockbroker/Merchant Banker. A Non-resident Bangladeshi (NRB) and Foreign applicant may also submit a single draft against 02(two) applications made by him/her, i.e. one in his/her own name and the other jointly with another person. The draft (FDD) shall be issued by the Bank where the applicant maintains NITA/Foreign Currency account debiting the same account. No banker shall issue more than two drafts from any NITA/Foreign Currency account for any public issue. At the same time, the applicant shall make the service charge available in respective customer account maintained with the Stockbroker/Merchant Banker.

12. The bank draft (FDD) shall be issued considering TT Clean exchange rate of Sonali Bank Ltd. on the date of publication of abridged version of prospectus.

13. The IPO subscription money collected from investors (other than non-resident Bangladeshis in US Dollar or UK Pound sterling or EURO) by the Stock Borkers/Merchant Bankers will be remitted to the **'The ACME Laboratories Ltd.'** (IPO) interest bearing SND Account No. 02-1111195-01 of Standard Chartered Bank, Bangladesh for this purpose.

14. The Application money collected from Eligible Investors (EIs) by the lead banker to the issue will be remitted to the **'The ACME Laboratories Ltd.'** (IPO) interest bearing escrow Account No. 02-1111195-03 of Standard Chartered Bank, Bangladesh for this purpose.

15. The subscription money collected from Non-Resident Bangladeshis in US Dollar or UK Pound sterling or EURO shall be deposited to three FC accounts opened by the Company for IPO purpose as follows:

Sl. #	Name of the FC Accounts	Currency	Account No.	Bank & Branch
1.	FC Account	US Dollar	01-1111195-01	Standard Chartered Bank, Bangladesh
2.	FC Account	UK Pound Sterling	01-1111195-02	Standard Chartered Bank, Bangladesh
3.	FC Account	EURO	01-1111195-03	Standard Chartered Bank, Bangladesh

16. **ক্ষতিগ্রস্থ ক্ষুদ্র বিনিয়োগকারীগণ সকল পাবলিক ইস্যুতে একক অথবা যৌথ হিসাবের যে কোনটি অথবা উভয়টি হতে সংরক্ষিত কোটায় আবেদন করতে পারবেন। তবে তারা ইচ্ছা করলে ক্ষতিগ্রস্থ সংরক্ষিত কোটায়ও আবেদন না করে সাধারণ বিনিয়োগকারীদের জন্য নির্ধারিত কোটায় আবেদন করতে পারবেন।**

APPLICATIONS NOT IN CONFORMITY WITH THE ABOVE REQUIREMENTS ARE LIABLE TO BE REJECTED.

LIST OF EIIS ALLOTMENT:

As per the Bangladesh Securities and Exchange Commission (Public Issue) Rules 2015, 50% (Excluding Mutual Fund's quota) of the proposed issue of 50,000,000 Ordinary Shares i.e. 25,000,000 Ordinary Shares were allotted to intuitional bidders. Following is the list of EIIs who participated in the bid at and above cut-off price were allotted the shares on pro-rata basis:

Sl. No.	Name of Eligible Institutional Investors	BOID	Allotted Volume	Allotted Value	% of outstanding shares post offering
1	Sonali Investment Limited	1605180039866810	102,624	8,743,564.80	0.05
2	"CROSS FREIGHT LIMITED" EMPLOYEES PROVIDENT FUND	1204030059705612	114,965	9,795,018.00	0.05
3	"GLOBAL AVIATION SERVICES LIMITED" EMPLOYEES PROVIDENT FUND	1204030059705655	116,248	9,904,329.60	0.05
4	A. L. Securities Ltd.	1203500045200605	22,757	1,938,896.40	0.01
5	AB & Co. Ltd	1201940007747374	22,577	1,923,560.40	0.01
6	ADAMS SECURITIES LTD	1203830038476101	66,706	5,683,351.20	0.03
7	AFC CAPITAL LIMITED	1201950040900165	25,656	2,185,891.20	0.01
8	ANCHOR SECURITIES LTD	1202950048476574	76,122	6,485,594.40	0.04
9	ANW SECURITIES LTD.	1205300050885551	154,963	13,202,847.60	0.07
10	ARENA SECURITIES LTD.	1202850003772483	67,475	5,748,870.00	0.03
11	ASENZ SECURITIES LTD.	1204100019226122	256,561	21,858,997.20	0.12
12	ASIA INSURANCE LIMITED	1201500003782844	256,561	21,858,997.20	0.12
13	Adil Securities Ltd	1202060000039196	2,565	218,538.00	0.00
14	Alliance Capital Asset Management Limited	1201470060935343	256,561	21,858,997.20	0.12
15	Alliance Financial Services Limited	1203670000017861	15,034	1,280,896.80	0.01
16	Alpha Capital Management Limited.	1605550049519826	256,561	21,858,997.20	0.12
17	B & B ENTERPRISE	1202790028773976	51,312	4,371,782.40	0.02
18	BANCO FINANCE AND INVESTMENT LIMITED	1202150015857032	22,577	1,923,560.40	0.01
19	BDBL Securities Limited	1202180045048887	256,561	21,858,997.20	0.12
20	BE RICH LIMITED	1204180017222163	6,414	546,472.80	0.00
21	BEXIMCO SECURITIES LIMITED	1201930016160034	256,561	21,858,997.20	0.12

Sl. No.	Name of Eligible Institutional Investors	BOID	Allotted Volume	Allotted Value	% of outstanding shares post offering
22	BLI CAPITAL LIMITED	1605650050408172	256,561	21,858,997.20	0.12
23	BMSL Investment Limited	1203110040416300	256,561	21,858,997.20	0.12
24	BRAC BANK LIMITED	1201820021984509	256,561	21,858,997.20	0.12
25	BRAC EPL Investments Limited	1604650000060261	256,561	21,858,997.20	0.12
26	BRAC EPL Stock Brokerage Limited	1201820000005731	128,280	10,929,456.00	0.06
27	BRB Securities Limited	1203910038355843	111,604	9,508,660.80	0.05
28	Banco Securities Ltd	1202150033195699	105,190	8,962,188.00	0.05
29	Bangladesh Commerce Bank Limited	1203000004128342	256,561	21,858,997.20	0.12
30	Bangladesh Development Bank Limited	1202180060983803	256,561	21,858,997.20	0.12
31	Bank Asia Limited	1301650000175597	205,249	17,487,214.80	0.10
32	Bank Asia Securities Limited	1204490045011859	128,280	10,929,456.00	0.06
33	Bay Leasing & Investment Ltd.	1201500000007492	256,561	21,858,997.20	0.12
34	CAPM (Capital & Asset Portfolio Management) Company Limited	1605270048618617	10,262	874,322.40	0.00
35	CAPM Advisory Limited	1605290048619978	64,140	5,464,728.00	0.03
36	CMSL Securities Ltd	1201750000001535	25,656	2,185,891.20	0.01
37	Chittagong Shares & Securities Limited	1203230050895631	256,561	21,858,997.20	0.12
38	Citizen Securities & Investment Limited	1202150051858499	256,561	21,858,997.20	0.12
39	City Bank Capital Resources Limited	1204500046667286	256,561	21,858,997.20	0.12
40	City Brokerage Limited	1204500028949639	256,561	21,858,997.20	0.12
41	Commerce Bank Securities and Investment Limited	1203000044662073	25,656	2,185,891.20	0.01
42	Continental Insurance Limited	1203510009734492	11,288	961,737.60	0.01
43	D.N. Securities Ltd.	1203860013501896	23,347	1,989,164.40	0.01
44	DBL Securities Limited	1201630043531874	256,561	21,858,997.20	0.12
45	DESA SECURITIES LIMITED	1203920014940996	1,488	126,777.60	0.00
46	DLIC Securities Ltd.	1205730053939461	256,561	21,858,997.20	0.12
47	Delta Brac Housing Finance Corporation Ltd	1203620020217413	256,561	21,858,997.20	0.12

Sl. No.	Name of Eligible Institutional Investors	BOID	Allotted Volume	Allotted Value	% of outstanding shares post offering
48	Delta Life Insurance Co. Ltd	1603420000842934	256,561	21,858,997.20	0.12
49	EBL INVESTMENTS LIMITED	1201950048415426	256,561	21,858,997.20	0.12
50	EBL Securities Limited (Former LRK Securities Limited)	1201950000015755	128,280	10,929,456.00	0.06
51	EMINENT SECURITIES LTD.	1201710030210546	256,561	21,858,997.20	0.12
52	EXPO Traders Limited	1203600019188321	33,353	2,841,675.60	0.02
53	Eastern Bank Limited	1201950030178336	12,828	1,092,945.60	0.01
54	Eastern Shares & Securities Ltd	1203640007850771	105,190	8,962,188.00	0.05
55	Ershad Securities Ltd.	1202320027911837	115,452	9,836,510.40	0.05
56	Expo Freight Limited Employee's Provident Fund	1204030031916200	256,535	21,856,782.00	0.12
57	FAREAST FINANCE & INVESTMENT LIMITED	1204690000134328	256,561	21,858,997.20	0.12
58	FAS Capital Management Limited	1604630040382971	25,656	2,185,891.20	0.01
59	Far East Shares & Securities Limited	1204200017263638	256,561	21,858,997.20	0.12
60	Fareast Islami Life Insurance Co. Ltd	1205790011903928	256,561	21,858,997.20	0.12
61	Fareast Islami Securities Ltd.	1205790055232286	25,656	2,185,891.20	0.01
62	Fareast Stocks & Bonds Limited.	1204690031201818	38,484	3,278,836.80	0.02
63	Federal Insurance Company Ltd.	1203310003865475	25,656	2,185,891.20	0.01
64	First Capital Securities Ltd.	1204430039584103	256,561	21,858,997.20	0.12
65	GALAXY CAPITAL LIMITED	1204800033270280	25,656	2,185,891.20	0.01
66	GLOBAL SECURITIES LTD.	1203880028811091	128,280	10,929,456.00	0.06
67	Green Delta Insurance Company Limited	1203620000042986	32,070	2,732,364.00	0.02
68	Greenland Equities Limited	1202190030807625	256,561	21,858,997.20	0.12
69	Hallmark Securities Ltd.	1204020023309987	192,421	16,394,269.20	0.09
70	Hazrat Amanat Shah Securities Ltd	1204570028771356	43,538	3,709,437.60	0.02
71	Howlader Equity Services Ltd.	1202260030433948	2,565	218,538.00	0.00
72	IDLC Employees' Provident Fund	1602510057011151	45,155	3,847,206.00	0.02
73	IDLC Finance Limited	1602510000744624	256,561	21,858,997.20	0.12
74	IDLC Investments Limited	1602510045047740	180,670	15,393,084.00	0.09

Sl. No.	Name of Eligible Institutional Investors	BOID	Allotted Volume	Allotted Value	% of outstanding shares post offering
75	IDLC SECURITIES LIMITED	1203680008053444	150,550	12,826,860.00	0.07
76	IDLC Securities Limited Employees Provident Fund	1602510057009290	4,515	384,678.00	0.00
77	IL Capital Limited	1605520058255619	256,561	21,858,997.20	0.12
78	IMPERIAL CAPITAL LIMITED	1201950060942951	20,525	1,748,730.00	0.01
79	INTER CONTINENTAL SECURITIES LIMITED	1301030034950845	17,959	1,530,106.80	0.01
80	INTERNATIONAL LEASING AND FINANCIAL SERVICES LIMITED	1204220018130161	256,561	21,858,997.20	0.12
81	ISLAMI BANK BANGLADESH LIMITED	1603700044716333	256,561	21,858,997.20	0.12
82	ISLAND SECURITIES LTD	1201960028837738	256,561	21,858,997.20	0.12
83	Impress Capital Limited	1201820055033647	24,065	2,050,338.00	0.01
84	Incepta Pharmaceuticals Employees Provident Fund	1204030053698676	256,561	21,858,997.20	0.12
85	Indicate Securities Consultants Limited	1204380019701075	25,656	2,185,891.20	0.01
86	International Leasing Securities Ltd.	1204220030590007	256,561	21,858,997.20	0.12
87	International Securities Co Ltd	1201850000007904	41,050	3,497,460.00	0.02
88	Investment Promotion Services Ltd.	1202010004761820	75,172	6,404,654.40	0.04
89	Islami Bank Securities Ltd	1603700032969047	256,561	21,858,997.20	0.12
90	Janata Capital and Investment Limited	1201530034513871	12,828	1,092,945.60	0.01
91	KABIR SECURITIES LIMITED	1203330029280914	128,280	10,929,456.00	0.06
92	KAZI EQUITIES LTD.	1201730029204716	62,857	5,355,416.40	0.03
93	Kazi Firoz Rashid Securities Ltd.	1202450000545359	25,656	2,185,891.20	0.01
94	Khurshid Alam Securities Limited	1202560029259822	192,421	16,394,269.20	0.09
95	LANKABANGLA INVESTMENTS LIMITED	1201830043239232	256,561	21,858,997.20	0.12
96	LR Global Bangladesh Asset Management Company Limited	1203620039158453	59,009	5,027,566.80	0.03
97	Lanka Bangla Finance Limited	1201830000012221	256,561	21,858,997.20	0.12
98	LankaBangla Asset Management Company Ltd.	1204030045890257	256,561	21,858,997.20	0.12
99	LankaBangla Finance Limited Employees Provident Fund	1204030053199415	256,561	21,858,997.20	0.12
100	LankaBangla Securities Limited	1201830000007813	256,561	21,858,997.20	0.12
101	LankaBangla Securities Limited Employees Provident Fund	1201830060975261	256,561	21,858,997.20	0.12

Sl. No.	Name of Eligible Institutional Investors	BOID	Allotted Volume	Allotted Value	% of outstanding shares post offering
102	M. ZUBAIR SECURITIES LTD.	1202890003832461	256,561	21,858,997.20	0.12
103	MIDAS Financing Limited	1201830000101207	256,561	21,858,997.20	0.12
104	MTB Capital Limited	1605070043537970	7,696	655,699.20	0.00
105	MTB Securities Ltd.	1601880000161286	25,656	2,185,891.20	0.01
106	MUNTAHA SHARES & CAPITAL LIMITED	1204950040989661	2,565	218,538.00	0.00
107	Meenhar Securities Ltd	1201780019220259	102,624	8,743,564.80	0.05
108	Meghna Cement Mills Ltd- Staff Provident Fund	1201510014775878	15,009	1,278,766.80	0.01
109	Merchant Securities Ltd	1203310005907344	256,561	21,858,997.20	0.12
110	Midway Securities Ltd.	1201890029057248	256,561	21,858,997.20	0.12
111	Mika Securities Ltd	1203260005126048	256,561	21,858,997.20	0.12
112	Mirpur Securities Ltd.	1203970028927180	16,548	1,409,889.60	0.01
113	Mona Financial Consultancy & Securities Ltd.	1201470000000763	256,561	21,858,997.20	0.12
114	Multi Securities & Services Limited	1202830003717284	225,773	19,235,859.60	0.11
115	Multi Securities & Services Ltd. Employees Provident Fund	1202830041434061	23,090	1,967,268.00	0.01
116	NCC BANK LTD.	1202090000048338	256,561	21,858,997.20	0.12
117	NCCB Securities and Financial Services Limited	1202090044996438	25,656	2,185,891.20	0.01
118	NLI SECURITIES LIMITED	1205720053777852	12,828	1,092,945.60	0.01
119	NORTH WEST SECURITIES LTD	1202130038287396	179,593	15,301,323.60	0.08
120	NRB BANK LIMITED	1201820053754332	256,561	21,858,997.20	0.12
121	National Finance Limited	1202020044198628	256,561	21,858,997.20	0.12
122	National Life Insurance Company Limited	1204080000268934	256,561	21,858,997.20	0.12
123	PFCML EMPLOYEES (CONTRIBUTORY) PROVIDENT FUND	1204690060969830	59,009	5,027,566.80	0.03
124	PFI Securities Limited	1201740018057708	51,312	4,371,782.40	0.02
125	PLFS INVESTMENTS LIMITED	1202880018300497	76,968	6,557,673.60	0.04
126	PRILINK SECURITIES LTD.	1203300005828888	256,561	21,858,997.20	0.12
127	PRUDENTIAL CAPITAL LTD.	1204250037999816	256,561	21,858,997.20	0.12
128	Parkway Securities Ltd.	1201520020432993	128,280	10,929,456.00	0.06

Sl. No.	Name of Eligible Institutional Investors	BOID	Allotted Volume	Allotted Value	% of outstanding shares post offering
129	Parom Securities Ltd.	1205890060789530	256,561	21,858,997.20	0.12
130	Phoenix Finance & Investments Limited	1203410014915119	256,561	21,858,997.20	0.12
131	Pioneer Insurance Company Limited	1601880004129462	8,030	684,156.00	0.00
132	Pragati Insurance Ltd	1201830000019025	25,656	2,185,891.20	0.01
133	Prime Bank Investment Limited	1602110007884745	143,674	12,241,024.80	0.07
134	Prime Finance & Investment Limited	1205000000017151	25,656	2,185,891.20	0.01
135	Prime Finance Asset management Company Limited	1201740048615458	2,565	218,538.00	0.00
136	Prime Insurance Co. Ltd	1201740000210297	256,561	21,858,997.20	0.12
137	Prime Islami Securities Limited	1205000045323294	5,131	437,161.20	0.00
138	RACE ASSET MANAGEMENT PCL	1201950053747157	2,565	218,538.00	0.00
139	RAK Capital Ltd.	1301030030642865	25,656	2,185,891.20	0.01
140	RELIANCE FINANCE LTD	1203850015056676	256,561	21,858,997.20	0.12
141	RELIANCE INSURANCE LIMITED	1203680000008794	51,312	4,371,782.40	0.02
142	RUPALI INSURANCE COMPANY LIMITED	1203620004744209	5,131	437,161.20	0.00
143	Rapid Securities Ltd	1201900000011350	15,393	1,311,483.60	0.01
144	Reliance Brokerage Services Limited	1203850038318433	256,561	21,858,997.20	0.12
145	Republic Insurance Company Limited	1204350033155748	256,561	21,858,997.20	0.12
146	Riverstone Capital Limited	1202830060966133	15,034	1,280,896.80	0.01
147	Rose Securities Ltd	1202540019187226	25,656	2,185,891.20	0.01
148	S.N.SECURITIES LTD	1301030039490358	12,186	1,038,247.20	0.01
149	SADEQUE FINANCE MANAGEMENT LTD.	1204910044087087	282	24,026.40	0.00
150	SBL Capital Management Limited	1604530021647727	5,131	437,161.20	0.00
151	SIBL SECURITIES LIMITED	1205200044789105	51,312	4,371,782.40	0.02
152	STOCK AND BOND LTD	1203510028786331	15,393	1,311,483.60	0.01
153	Sandhani Life Finance Ltd.	1605610032935344	256,561	21,858,997.20	0.12
154	Sandhani Life Insurance Co. Ltd. Employee`s Provident Fund	1201470040729859	256,561	21,858,997.20	0.12
155	Sandhani Life Insurance Company Ltd	1201470000004349	256,561	21,858,997.20	0.12

Sl. No.	Name of Eligible Institutional Investors	BOID	Allotted Volume	Allotted Value	% of outstanding shares post offering
156	Shahjahan Securities Limited	1202870045211540	64,140	5,464,728.00	0.03
157	Shakil Rizvi Stock Ltd.	1201510028774467	102,624	8,743,564.80	0.05
158	Shanta Asset Management Ltd.	1203490060953009	256,561	21,858,997.20	0.12
159	Shanta Securities Ltd.	1203490029025239	256,561	21,858,997.20	0.12
160	Sigma Capital Management Limited	1601880060608197	256,561	21,858,997.20	0.12
161	Southeast Bank Capital Services Limited	1602290040732747	256,561	21,858,997.20	0.12
162	Southeast Bank Limited	1602290000060633	256,561	21,858,997.20	0.12
163	Square Securities Management Ltd.	1201560000061025	256,561	21,858,997.20	0.12
164	Standard Bank Limited	1602070044983338	1,282	109,226.40	0.00
165	Standard Bank Securities Limited	1205600051708405	25,656	2,185,891.20	0.01
166	Stock And Security Linkway Limited	1204840036203021	1,026	87,415.20	0.00
167	Swadesh Investment Management Limited	1204380000164777	51,312	4,371,782.40	0.02
168	The City Bank Limited	1204500000803683	102,624	8,743,564.80	0.05
169	Total Communication Ltd.	1203220004814607	32,070	2,732,364.00	0.02
170	Trust Bank Investment Limited	1205660051158541	256,561	21,858,997.20	0.12
171	Trust Bank Securities Limited	1205660050869603	30,095	2,564,094.00	0.01
172	UNICAP SECURITIES LIMITED	1201910000012968	179,593	15,301,323.60	0.08
173	UniCap Securities Employees Contributory Provident Fund	1201910053946845	17,959	1,530,106.80	0.01
174	United Enterprises & Co. Ltd	1204780038832511	256,561	21,858,997.20	0.12
175	Uttara Finance and Investments Limited	1203770012801322	256,561	21,858,997.20	0.12
176	VANGUARD SHARES & SECURITIES LTD.	1301030000143363	256,561	21,858,997.20	0.12
177	VISION CAPITAL MANAGEMENT LTD	1204280029275995	256,561	21,858,997.20	0.12
178	Western Security Investment Management Ltd.	1202930033641081	51,312	4,371,782.40	0.02
Total			**25,000,000**	**2,130,000,000.00**	

Holding structure of different classes of securities before and after the issue

Sl. No.	Category of Shareholders	No. of Ordinary Shares Hold		Percentage of Holding	
		Pre-IPO	Post-IPO	Pre-IPO	Post-IPO
1	Sponsors	121,970,600	121,970,600	75.48	57.64
2	Institutional	38,476,100	63,476,100	23.81	30.00
3	Mutual fund	-	5,000,000	-	2.36
4	Individual	1,155,000	16,155,000	0.71	7.64
5	Non Resident Bangladeshis (NRBs)	-	5,000,000	-	2.36

Objective of the issue including financing requirements and feasibility in respect of enhanced paid-up capital

ACME has an expansion plan to develop three new projects as mentioned below in its existing factory site by using IPO Proceeds of Tk. 409.60 and balance Tk. 21.68 crore will be financed company own sources.

SL.	Projects	Amount (BDT in crore)
01	Steroid and Hormone	135.80
02	Oncology	114.10
03	Ayurvedic, Modern Herbal and Nutraceuticals	174.55
Total		**424.45**
IPO Expenses		6.83
Total		**431.28**

Apart from above Tk. 6.83 crore will be used for IPO expenses out of total IPO proceeds. The feasibility report in respect enhance paid up capital as prepared Mr. Faruque Ahmed, FCMA is enclosed below:

Capacity of the Project *:*

(Thousand pcs. Per year)

Particulars	Steroid & Hormone	Oncology	Ayurvedic, Modern Herbal and Nutraceuticals	Total
Capsule	46,370	-	18,362	64,732
Hard Gelatin Capsule	-	-	3,441	3,441
Soft Gelatin Capsule	-	-	8,353	8,353
Cream	1,759	-	360	2,119
Eye Drops	465	-	-	465
Dry Syrup	-	-	16,595	16,595
Injection	5,730	1,309	-	7,039
Lotion	256	-	-	256
Liquid	-	-	2,426	2,426
Nasal Spray	397	-	-	397
Ointment	1,236	-	873	2,109
Solution	572	-	-	572
Sachet	-	-	22,713	22,713
Tablet	365,232	1,248	31,711	398,191
Pill	169,832	-	-	169,832
Tooth Powder	-	-	396	396
Emulsion	-	-	165	165
Rub	-	-	200	200
Gel	-	-	264	264
Oil	-	-	198	198
Probiotic	-	-	2,153	2,153
Inhaler (MDI)	914	-	-	914

Particulars	Steroid & Hormone	Oncology	Ayurvedic, Modern Herbal and Nutraceuticals	Combined
Cost of the Project (in Crore):	135.80	114.10	174.55	424.45
Total Equity of the Project: (in Crore)	135.80	114.10	174.55	424.45
Net Present Value (@ 13%): (in Crore)	78.36	60.27	82.45	229.79
Internal Rate of Return:	24.30%	22.89%	22.75%	23.79
Payback period of the project:	4.12	4.37	4.40	4.20

Projected Statement of Financial Position

ASSETS	TAKA		
	As at 30.06.2016	As at 30.06.2017	As at 30.06.2018
Non-Current Assets :	**16,339,073,455**	**18,612,765,740**	**18,582,499,781**
Property, Plant and Equipment	16,304,561,917	18,578,295,827	18,548,071,493
Intangible Assets	203,625	162,000	120,375
Investment in Shares	8,122,913	8,122,913	8,122,913
Investment Property	26,185,000	26,185,000	26,185,000
Current Assets:	**12,391,920,540**	**10,518,820,297**	**10,919,168,031**
Inventories	3,043,356,175	3,354,800,508	3,594,996,413
Trade Receivable	862,811,876	989,480,289	1,015,143,218
Other Receivable	42,757,406	41,184,980	41,596,830
Advance, Deposits & Pre-Payments	1,063,555,191	1,001,669,649	969,170,435
Advance Income Tax	2,257,967,843	2,903,748,846	3,746,510,503
Material In Transit	422,333,567	475,876,300	551,254,750
Term Deposit	4,244,907,484	1,300,000,000	500,000,000
Cash and Cash Equivalents	454,230,998	452,059,725	500,495,882
TOTAL	**28,730,993,995**	**29,131,586,037**	**29,501,667,812**
EQUITY AND LIABILITIES			
Shareholders' Equity:	**15,691,330,646**	**16,397,653,400**	**17,519,089,268**
Share Capital	2,116,017,000	2,116,017,000	2,116,017,000
Share Premium	5,136,766,569	5,136,766,569	5,136,766,569
Revaluation Surplus	5,210,600,037	5,101,134,244	4,991,668,451
Gain/(Loss) on Marketable Securities (Unrealized)	2,824,633	2,824,633	2,824,633
Tax Holiday Reserve	196,042,851	196,042,851	196,042,851
Retained Earnings	3,029,079,556	3,844,868,103	5,075,769,764
Non Current Liabilities	**3,671,888,036**	**2,609,599,811**	**1,514,023,626**
Long Term Loans- Net off Current Maturity	3,403,577,088	2,183,541,607	900,922,729
Provision For Gratuity	86,664,750	103,997,700	124,797,240
Deferred Tax Liability	181,646,198	322,060,504	488,303,657
Current Liabilities :	**9,367,775,313**	**10,124,332,825**	**10,468,554,917**
Loans & Overdrafts	4,484,477,361	4,609,477,361	4,359,477,361
Current Maturity of Long Term Loans	1,637,536,901	1,620,035,481	1,282,618,878
Trade Payable	392,333,567	405,876,300	552,025,395
Provision for Income Tax	1,983,726,850	2,579,507,853	3,322,269,510
Liability for Expenses and Others	129,094,684	168,829,880	211,557,823
Dividend Payable	740,605,950	740,605,950	740,605,950
TOTAL	**28,730,993,995**	**29,131,586,037**	**29,501,667,812**

Projected Statement of Profit or loss and Other Comprehensive Income and Earning Per Share (EPS)

	TAKA		
	July '15 to June '16 Total	**July '16 to June '17 Total**	**July '17 to June '18 Total**
Revenue	**12,280,491,019**	**13,960,516,156**	**15,947,809,709**
Less: Cost of Goods Sold	7,650,357,543	8,689,766,857	9,918,228,557
Gross Profit/(Loss)	**4,630,133,477**	**5,270,749,299**	**6,029,581,152**
Add: Other Income	36,607,656	115,921,967	42,803,173
	4,666,741,133	**5,386,671,266**	**6,072,384,325**
Less: Selling, Marketing and Distribution Expenses	1,642,688,113	1,764,567,098	2,012,672,310
	3,024,053,020	**3,622,104,168**	**4,059,712,015**
Less: Administrative Expenses	391,070,495	404,387,963	430,380,968
	2,632,982,525	**3,217,716,205**	**3,629,331,047**
Less: Financial Expenses	1,047,815,049	925,435,991	719,732,088
Profit before Contribution to WPPF	**1,585,167,476**	**2,292,280,214**	**2,909,598,959**
Less: Contribution to WPPF	75,484,166	109,156,201	138,552,331
Net Profit before Tax	**1,509,683,310**	**2,183,124,013**	**2,771,046,628**
Less: Current Tax Expense	427,420,827	595,781,003	742,761,657
Less: Deferred Tax (Income)/Expense	55,655,479	140,414,306	166,243,153
Net Profit after Tax	**1,026,607,004**	**1,446,928,704**	**1,862,041,818**
Other Comprehensive Income			
Gain/(loss) on Marketable Securities (Unrealized)	1,000,000	-	-
Total Comprehensive Income for the year	**1,027,607,004**	**1,446,928,704**	**1,862,041,818**
Earning Per Share (on the Equity Share of Taka 10 each)	**5.90**	**6.84**	**8.80**

CHAPTER XXII: USE OF PROCEEDS AND PROJECT IMPLEMENTATION SCHEDULE

The ACME Laboratories Ltd. intended to issue 50,000,000 Ordinary Shares of Tk. 10 each, out of which 50% i.e. 25,000,000 Ordinary Shares are reserved for Eligible Institutional Investors and 10% i.e. 5,000,000 Ordinary Shares for Mutual Funds at a cut off price of Tk. 85.20 per share. Remaining 40% i.e. 20,000,000 Ordinary Shares are reserved for General Public at a discounted price of Tk. 77.00 per share under Book Building Method. ACME has a succeeding expansion plan to develop three new projects to its existing factory site located at Dhulivita, Dhamrai on 10.08 acres of land under same boundary. The underline costs are estimated. These may vary up to implementation of the projects. Utilization of the proceeds of IPO is as follows:

Sl. No	Projects	Cost Breakdown	Amount (in BDT crore)
01	**Steroid and Hormone**	Civil Construction	33.58
		Machinery & Equipment	59.86
		Utility	33.96
		Warehouse	3.95
		Vehicle	0.50
		Consultancy	2.63
		Contingencies	1.32
		Sub-total	**135.80**
02	**Oncology**	Civil Construction	33.58
		Machinery & Equipment	36.70
		Utility	35.00
		Warehouse	5.00
		Vehicle	0.50
		Consultancy	2.21
		Contingencies	1.11
		Sub-total	**114.10**
03	**Ayurvedic, Modern Herbal and Nutraceuticals**	Civil Construction	41.75
		Machinery & Equipment	85.72
		Utility	40.40
		Warehouse	1.10
		Vehicle	0.50
		Consultancy	3.39
		Contingencies	1.69
		Sub-total	**174.55**
	Total Cost of the Projects		**424.45**
04	**IPO Expenses**		**6.83**
	Grand Total		**431.28**

01. Detail Cost Break down of Steroid & Hormone Project

01.1 Civil Construction				
Particulars	**Area**	**Unit**	**Rate in BDT**	**Total Amount (In BDT crore)**
Architectural Design-Drawings including elevation and section of building, layout plan of column, beam, brick wall, toilet portion, stair, case, details of doors, windows, parapet and drop walls.	90,000	Sft	6	0.054
Structural design-drawings for sub structure	90,000	Sft	3	0.027
Structural design-drawings for super structure	90,000	Sft	4	0.036
Earth work in excavation of all kinds of soils of foundation trenches including leveling, ramming and preparing the base, bailing out water and shoring if necessary including pal siding up to required height if necessary, cutting earth up to 12'-0" depth by Mechanically or manually, removing the spoils, etc. to a lead not exceeding 60m.	106,222	Cft	10	0.106
One layer of brick flat soling in foundation or in floor with 1st class or picked bricks including preparation of bed and filling the interstices with local sand (Excluding cost of all materials & equipments).	18,243	Sft	30	0.055
Laying polythene sheet as per requirement.	3,704	Sft	5	0.002
Pile Boring	14,199	Rft	1,800	2.556
Pile Casting	55,731	Cft	290	1.616
Pile Cap Casting	8,212	Cft	290	0.238
Labor for breaking of pile head of cast-in-situ bored pile or pre-cast pile up to required length				
a) Cast-in-site pile up to 24" dia	2,886	Cft	80	0.023
b) Strengthening cleaning, clearing of pile M.S. Rod including removing of rust etc. all complete.	177	Pcs	500	0.009
Mass concrete any proportion in foundation or floor with cement, sand (F.M.1.2) and picked jhama chips.	9,096	Cft	30	0.027
Earth or Sand filling in foundation trenches and plinth with fine sand having minimum F.M. 0.80 in 150mm layers including leveling, watering and consolidating each layer up to finished level with mechanical compaction up to finished level. (Excluding cost of all materials)	231,594	Cft	14	0.324

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
Brick work with 1st class bricks in cement mortar (1:6) or (1:4) in foundation and plinth Level				
a) 10" Brick Work	33,126	Cft	150	0.497
b) 5" Brick Work	22,680	Sft	70	0.159
Fabrication and fixing of details as per design deformed bar reinforcement of any grade in concrete including straightening and cleaning rust, if any bending and binding in position with G.I. wires including supply of G.I. wire etc. all complete in all respects. (Excluding cost of all materials)				
a) Foundation to 5th Floor (Labour Cost)	505	M. Ton	5,800	0.293
b) Foundation to 5th Floor	504,837	Kg	85	4.291
c) Pilling	293,023	Kg	85	2.491
d) Pile Cap	14,083	Kg	85	0.120
e) Grade Beam	54,970	Kg	85	0.467
f) Machinery hire charges in all floors	505	M. Ton	600	0.030
Reinforced cement concrete works (1:1.5:3) A. Labour cost for casting and shuttering including curing. **a) Foundation to Ground Floor**				
1. In individual and continuous footing of columns, raft, pile cap, floor slab at ground level.	14,572	Cft	50	0.073
2. In pedestal, column, capital, lift wall and wall.	4,689	Cft	88	0.041
3. All kinds of Beams	5,285	Cft	85	0.045
4. In roof slab of all types, cantilever slab, stair case slab and step.	1,139	Cft	75	0.009
5. In sunshade, cornice, railing, drop wall, louver, fins and lintel.	114	Cft	120	0.001
b) 1st Floor to 5th Floor				
1. In pedestal, column, capital, lift wall and wall.	12,141	Cft	98	0.119
2. All kinds of Beams	14,060	Cft	93	0.131
3. In roof slab of all types, cantilever slab, stair case slab and step.	48,856	Cft	80	0.391
4. In sunshade, cornice, railing, drop wall, louver, fins and lintel.	593	Cft	130	0.008
B. Rental value of steel shutter in all places except in column beam joint and some special places with wood if required. Payment to be made on R.C.C. volume at any height upto 5th floor				
a) In individual and continuous footing of columns, raft, pile cap, floor slab at ground level.	8,212	Cft	25	0.021
b) In pedestal, column, capital, lift wall and wall.	16,830	Cft	88	0.148
c) All kinds of Beams.	19,345	Cft	78	0.151
d) In roof slab of all types, cantilever slab, stair case slab and step.	43,729	Cft	65	0.284
e) In sunshade, cornice, railing, drop wall, louver, fins and lintel.	708	Cft	120	0.008

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
C. Rental value of machinery and equipment including operating and maintenance. Payment to be made on R.C.C. volume at any height up to 5th floor for all kinds of concrete work.	109,796	Cft	8	0.088
D. Rental value of staging and scaffolding materials up to required height. Measurement of staging & scaffolding, materials will be up to every 10'-0" height or part thereof in all respect.	148,387	Sft	30	0.445
E. Labour rate for staging, fitting, fixing for any work as and where required up to every 10'-0" height as per instruction of the Engineer-in-charge.	128,017	Sft	17	0.218
F. Up to 2" thick patent stone flooring including compacting, curing etc. all complete.	51,193	Sft	195	0.998
G. Labour rate for scaffolding ,fitting fixing at any where required up to every 10'-0'' height.	155,724	Sft	8	0.125
H. Chipping R.C.C surfaces at any height and any places including watering and cement grouting to receive cement mortar as per instruction of the Engineer-in-charge.	179,008	Sft	2	0.036
Aluminum Work (Door & Window)	10,047	Sft	262	0.263
Paint Work	242,822	Sft	13	0.316
Net cement finishing to all surfaces including curing complete	18,684	Sft	5	0.009
Rate of RCC Casting was Done by Ready Mixed Concrete	45,156	Cft	253	1.142
Interior Design by Studio 45 LS	1	Job		0.250
Aluminum Composite Panel	10,310	Sft	510	0.526
Zinc Coated Composite Panel	20,501	Sft	871	1.786
Curtain Wall Glazing	5,275	Sft	663	0.350
MS Structure for extended Column, Slab & Wall	2,826	Sft	340	0.096
Tempering Charge for 60mm Reflective Glass	5,275	Sft	76	0.040
Spider Glass Wall	306	Sft	1,401	0.043
Glass Door Handle	8	Rft	7,600	0.006
Tempered Laminated Glass Canopy	773	Sft	2,340	0.181
Sliding Window	1,015	Sft	250	0.025
SS Railing With 10mm Tempered Glass	329	Sft	1,150	0.038
Auto Sensor Door	1	Job		0.055
Aluminium Ellipse Louver	218	Sft	1,105	0.024
Wall Tiles	10,094	Sft	150	0.151
Floor Tiles	14,185	Sft	180	0.255

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
Stair Tiles	1,674	Sft	156	0.026
Stone Fitting	3,135	Sft	900	0.282
Sandwich panel	51,000	Sft	1,500	7.650
Painting (Self leveling epoxy)	80,000	Sft	250	2.000
Fire Protection : Fire fighting by fire hydrant hose reel, Fire extinguisher (different type) Fire Detection: Smoke detection Heat detection Fire alarm system All are control by BMS (Building Management System)				0.800
Plumbing : PVC & UPVC Pipe, MS Pipe and others accessories				0.500
Civil Construction Total :				**33.58**

01.2 Machinery & Equipment					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Tablet & Capsule					
Rapid Mixture Granulator, Wet Granulator	1	100kg/Batch	Belgium	187,500	1.575
60 kg FBD (Flued Bed Dryer)	1	60kg	Belgium	62,500	0.525
Dry mill	1	100kg	India	35,000	0.294
Vibratory Sifter	2	100kg	India	31,500	0.265
IBC (Intermediate Bulk Container) Blender	1	100kg	India	62,500	0.525
IBC (Intermediate Bulk Container) Bin	10	100kg	India	62,500	0.525
IBC (Intermediate Bulk Container) Bin Washing & Drying	1	100kg	India	26,250	0.221
Tablet Press Machine	2	600000 /HR	Korea	1,000,000	8.400
Capsule Filling+Polishing	2	60000/HR	China	375,000	3.150
Vacuum Transfer	4	100kg/H	India	25,000	0.210
Coating Machine	2	100kg	India	315,000	2.646
Blister Machine (Primary Packing)	2	10000strip/H	Vietnam	625,000	5.250
Injectable					
Sterile Compounding	1	100liter	India	106,250	0.893
Mobile LAF (Laminar Air Flow)	1	2'x8'	India	12,500	0.105
Container Washing m/c	1	15000ampoul/h	Korea	187,500	1.575
Sterilization Tunnel	1	15000ampoul/h	Korea	647,500	5.439
Sterile Filling/Sealing m/c	1	15000ampoul/h	Korea	500,000	4.200
Inspection table	1	15000ampoul/h	Korea	1,250	0.011
Sterile Labeling m/c	1	15000ampoul/h	India	62,500	0.525
Fixed LAF (Laminar Air Flow)	1	2'x8'	India	2,500	0.021
Autoclave	1	1000 liter	Sweden	265,625	2.231

Particulars	Qty.	Capacity	Country of Origin	Total Amount in USD	Total Amount (In BDT crore)
Cream & Ointment					
Compounding vessel	3	300 liter	Germany	225,000	1.890
Planetary mixer	1	300 liter	Germany	31,250	0.263
Filling Machine	1	12000/hr	Italy	562,500	4.725
Nasal spray (steroid) line					
Bottle Washing	1	10000/hr	India	50,000	0.420
DHS (Dry Heat Sterilizer)	1	50000/load	Denmark	125,000	1.050
Processing Vessel	1	400 L	Germany	75,000	0.630
Buffer tank with 4 wheel	1	100 L	Germany	37,500	0.315
Filling & crimping machine automatic	1	10000/hr	Canada	62,500	0.525
Sticker Labeling machine auto	1	10000/hr	India	37,500	0.315
Batch coding & mini carton	1	10000/hr	India	3,750	0.032
Image printer	1	5,5m/s	Japan	10,000	0.084
Master carton self adhesive closer	1	100 /h	India	6,250	0.053
MDI inhaler (steroid) line					
Preparation Vessel	2	200 L	India	150,000	1.260
Can Cleaner	1	2000/hr	Germany	125,000	1.050
Filling Machine	2	40 container/min	Korea	75,000	0.630
Vacuum Crimper	1	40can/min	Korea	12,500	0.105
Propellant Filler	1	40can/min	Korea	25,000	0.210
Spray checking and sticker labeling	1	40can/min	Korea	12,500	0.105
Eye drop					
Compounding Vessel	2	100 liter	India	150,000	1.260
Filling & Sealing Machine	2	80 container/Min	China	125,000	1.050
Lotion					
Mixture	2	100kg	India	125,000	1.050
Filling Machine	2	60/min	China	75,000	0.630
QC & Microbiology	1	01 Lot	China	375,000	3.000
Laundry					
Dress Washing & Drying Machine	2	30 kg	China	55,000	0.462
Sterile Dress Holding Cabinet	2	4'x8'	China	20,000	0.168
Machinery & Equipment Total :					**59.86**

01.3 Utility					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Heating, Ventilating and Air Conditioning System (HVAC)- Air Handling Unit, Chiller, Pump, Ducting and other parts & Accessories.	1	200 ton	Malaysia	2,500,000	21.000
Building Management System (BMS)- Access Control, Alam Monitor, Control Panel, CCTV set up cost, Security Automation, PA System, Security and Observation.	1	HVAC + Fire seystem	Bangladesh	375,000	3.000
Central Vacuum	2	100cfm	China	10,000	0.086

Particulars	Qty.	Capacity	Country of Origin	Total Amount in USD	Total Amount (In BDT crore)
Air Compressor	1	55kw	Usa	25,000	0.210
Purified Water & Water for Injection Generation	1	3000 liter	Sweden	500,000	4.200
Purified Water & Water for Injection Distribution	1	30 point	Sweden	500,000	4.200
Lift	4	14 persons	Korea	150,000	1.260
Utility Total :					**33.96**

01.4 Warehouse					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Dispensing Booth	2	5'x7'x4'	India	62,500	0.525
Weighting balances	3	200kg -3 g,	Japan	7,500	0.063
Rack	1	200 ton/Rack	Uae	125,000	1.050
01.4 Warehouse					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Fork lift	2	1000kg	China	75,000	0.630
Reach truck	1	1000kg	Germany	75,000	0.630
Pallet	1	1000kg	Korea	125,000	1.050
Warehouse Total :					**3.95**

01.5 Vehicle					
Microbus	1		Bangladesh		0.300
Car	1		Bangladesh		0.200
Vehicle Total :					**0.50**

01.6 Consultancy and Contingencies	
Consultancy Fees	**2.630**
Goods Manufacturing Practice (GMP) - Validate the Machine Layout, Process Layout, Airflow, Water flow, Building Layout etc.	1.100
Electrical (Drawing & Design)	0.450
Plumbing (Drawing & Design)	0.300
Heating, Ventilating and Air Conditioning System (HVAC) - Calculate & Measure Data regarding Airflow Management, Temperature Management of the Plant.	0.780
Contingencies	1.324
Consultancy and Contingencies Total	**3.95**

Total Cost for Steroid & Hormone Project	**135.80**

02. Detail Cost Break Down of Oncology Project

02. 1 Civil Construction				
Particulars	**Area**	**Unit**	**Rate in BDT**	**Total Amount (In BDT crore)**
Architectural Design-Drawings including elevation and section of building, layout plan of column, beam, brick wall, toilet portion, stair, case, details of doors, windows, parapet and drop walls.	90,000	Sft	6	0.054
Structural design-drawings for sub structure	90,000	Sft	3	0.027
Structural design-drawings for super structure	90,000	Sft	4	0.036
Earth work in excavation of all kinds of soils of foundation trenches including leveling, ramming and preparing the base, bailing out water and shoring if necessary including pal siding up to required height if necessary, cutting earth up to 12'-0" depth by Mechanically or manually, removing the spoils, etc. to a lead not exceeding 60m.	106,222	Cft	10	0.106
One layer of brick flat soling in foundation or in floor with 1st class or picked bricks including preparation of bed and filling the interstices with local sand (Excluding cost of all materials & equipments).	18,243	Sft	30	0.055
Laying polythene sheet as per requirement.	3,704	Sft	5	0.002
Pile Boring	14,199	Rft	1,800	2.556
Pile Casting	55,731	Cft	290	1.616
Pile Cap Casting	8,212	Cft	290	0.238
Labor for breaking of pile head of cast-in-situ bored pile or pre-cast pile up to required length				
a) Cast-in-situ pile up to 24" dia	2,886	Cft	80	0.023
b) Strengthening cleaning, clearing of pile M.S. Rod including removing of rust etc. all complete.	177	Pcs	500	0.009
Mass concrete any proportion in foundation or floor with cement, sand (F.M.1.2) and picked jhama chips.	9,096	Cft	30	0.027
Earth or Sand filling in foundation trenches and plinth with fine sand having minimum F.M. 0.80 in 150mm layers including leveling, watering and consolidating each layer up to finished level with mechanical compaction up to finished level. (Excluding cost of all materials)	231,594	Cft	14	0.324
Brick work with 1st class bricks in cement mortar (1:6) or (1:4) in foundation and plinth Level				
a) 10" Brick Work	33,126	Cft	150	0.497

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
b) 5" Brick Work	22,680	Sft	70	0.159
Fabrication and fixing of details as per design deformed bar reinforcement of any grade in concrete including straightening and cleaning rust, if any bending and binding in position with G.I. wires including supply of G.I. wire etc. all complete in all respects. (Excluding cost of all materials)				
a) Foundation to 5th Floor (Labour Cost)	505	M. Ton	5,800	0.293
b) Foundation to 5th Floor	504,837	Kg	85	4.291
c) Pilling	293,023	Kg	85	2.491
d) Pile Cap	14,083	Kg	85	0.120
e) Grade Beam	54,970	Kg	85	0.467
f) Machinery hire charges in all floors	505	M. Ton	600	0.030
Reinforced cement concrete works (1:1.5:3) A. Labour cost for casting and shuttering including curing. **a) Foundation to Ground Floor**				
1. In individual and continuous footing of columns, raft, pile cap, floor slab at ground level.	14,572	Cft	50	0.073
2. In pedestal, column, capital, lift wall and wall.	4,689	Cft	88	0.041
3. All kinds of Beams	5,285	Cft	85	0.045
4. In roof slab of all types, cantilever slab, stair case slab and step.	1,139	Cft	75	0.009
5. In sunshade, cornice, railing, drop wall, louver, fins and lintel.	114	Cft	120	0.001
b) 1st Floor to 5th Floor				
1. In pedestal, column, capital, lift wall and wall.	12,141	Cft	98	0.119
2. All kinds of Beams	14,060	Cft	93	0.131
3. In roof slab of all types, cantilever slab, stair case slab and step.	48,856	Cft	80	0.391
4. In sunshade, cornice, railing, drop wall, louver, fins and lintel.	593	Cft	130	0.008
B. Rental value of steel shutter in all places except in column beam joint and some special places with wood if required. Payment to be made on R.C.C. volume at any height upto 5th floor				
a) In individual and continuous footing of columns, raft, pile cap, floor slab at ground level.	8,212	Cft	25	0.021
b) In pedestal, column, capital, lift wall and wall.	16,830	Cft	88	0.148
c) All kinds of Beams.	19,345	Cft	78	0.151
d) In roof slab of all types, cantilever slab, stair case slab and step.	43,729	Cft	65	0.284
e) In sunshade, cornice, railing, drop wall, louver, fins and lintel.	708	Cft	120	0.008
C. Rental value of machinery and equipment including operating and maintenance. Payment to be made on R.C.C. volume at any height up to 5th floor for all kinds of concrete work.	109,796	Cft	8	0.088

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
D. Rental value of staging and scaffolding materials up to required height. Measurement of staging & scaffolding, materials will be up to every 10'-0" height or part thereof in all respect.	148,387	Sft	30	0.445
E. Labour rate for staging, fitting, fixing for any work as and where required up to every 10'-0" height as per instruction of the Engineer-in-charge.	128,017	Sft	17	0.218
F. Up to 2" thick patent stone flooring including compacting, curing etc. all complete.	51,193	Sft	195	0.998
G. Labour rate for scaffolding ,fitting fixing at any where required up to every 10'-0'' height.	155,724	Sft	8	0.125
H. Chipping R.C.C surfaces at any height and any places including watering and cement grouting to receive cement mortar as per instruction of the Engineer-in-charge.	179,008	Sft	2	0.036
Aluminum Work (Door & Window)	10,047	Sft	262	0.263
Paint Work	242,822	Sft	13	0.316
Net cement finishing to all surfaces including curing complete	18,684	Sft	5	0.009
Rate of RCC Casting was Done by Ready Mixed Concrete	45,156	Cft	253	1.142
Interior Design by Studio 45 LS	1	Job		0.250
Aluminum Composite Panel	10,310	Sft	510	0.526
Zinc Coated Composite Panel	20,501	Sft	871	1.786
Curtain Wall Glazing	5,275	Sft	663	0.350
MS Structure for extended Column, Slab & Wall	2,826	Sft	340	0.096
Tempering Charge for 60mm Reflective Glass	5,275	Sft	76	0.040
Spider Glass Wall	306	Sft	1,401	0.043
Glass Door Handle	8	Rft	7,600	0.006
Tempered Laminated Glass Canopy	773	Sft	2,340	0.181
Sliding Window	1,015	Sft	250	0.025
SS Railing With 10mm Tempered Glass	329	Sft	1,150	0.038
Auto Sensor Door	1	Job		0.055
Aluminium Ellipse Louver	218	Sft	1,105	0.024
Wall Tiles	10,094	Sft	150	0.151
Floor Tiles	14,185	Sft	180	0.255
Stair Tiles	1,674	Sft	156	0.026
Stone Fitting	3,135	Sft	900	0.282
Sandwich panel	51,000	Sft	1,500	7.650
Painting (Self leveling epoxy)	80,000	Sft	250	2.000

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
Fire Protection : Fire fighting by fire hydrant hose reel, Fire extinguisher (different type) Fire Detection: Smoke detection Heat detection Fire alarm system All are control by BMS (Building Management System)				0.800
Plumbing : PVC & UPVC Pipe, MS Pipe and others accessories				0.500
Civil Construction Total :				**33.58**

02.2 Machinery & Equipment					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Tablet & Capsule					
Rapid Mixture Granulator, Wet Granulator	1	100kg/Batch	Belgium	187,500	1.575
60 kg FBD (Flued Bed Dryer)	1	60kg	Belgium	62,500	0.525
Dry mill	1	100kg	India	35,000	0.294
Vibratory Sifter	2	100kg	India	31,500	0.265
IBC (Intermediate Bulk Container) Blender	1	100kg	India	62,500	0.525
IBC (Intermediate Bulk Container) Bin	3	120kg	India	19,875	0.167
IBC (Intermediate Bulk Container) Bin Washing & Drying	1	100kg	China	26,250	0.221
Tablet Press	2	600000 /HR	India	1,000,000	8.400
Capsule Filling+Polishing	2	60000/HR	China	375,000	3.150
Vacuum Transfer	3	100kg/H	India	18,750	0.158
Coating Machine	1	100kg	Germany	157,500	1.323
Blister	1	10000strip/H	Vietnam	312,500	2.625
Injectable					
Sterile Compounding	1	100 liter	India	106,250	0.893
Mobile LAF (Laminar Air Flow)	1	2'x8'	India	12,500	0.105
Container Washing m/c	1	15000amoul/h	Korea	187,500	1.575
Sterilization Tunnel	1	15000amoul/h	Korea	562,500	4.725
Sterile Filling/Sealing m/c	1	15000amoul/h	Korea	500,000	4.200
Inspection table	1	15000amoul/h	Korea	1,250	0.011
Sterile Labeling m/c	1	15000amoul/h	India	62,500	0.525
Fixed LAF (Laminar Air Flow)	1	2'x8'	India	2,500	0.021
Autoclave	1	1000 liter	Sweden	250,000	2.100
QC & Microbiology	1	01 Lot	China	312,500	2.625
Laundry					
Dress Washing & Drying Machine	2	30 kg	China	55,000	0.462
Sterile Dress Holding Cabinet	3	4'x7'	China	28,125	0.236
Machinery & Equipment Total :					**36.70**

02.3 Utility					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Heating, Ventilating and Air Conditioning System (HVAC)- Air Handling Unit, Chiller, Pump, Ducting etc.	1	200 ton	Malaysia	2,500,000	21.000
Building Management System (BMS)- Access Control, Alam Monitor, Control Panel, CCTV set up cost, Security Automation, PA System, Security and Observation.	1	HVAC +Fire seystem	Bangladesh	375,000	3.000
Central Vacuum	2	100cfm	Malaysia	10,000	0.084
Air Compressor	1	55kw	Usa	25,000	0.210
Purified Water & Water for Injection Generation	1	3200 liter	Sweden	562,500	4.725
Purified Water & Water for Injection Distribution	1	32 point	Sweden	562,500	4.725
Lift	4	14 persons	Korea	150,000	1.260
Utility Total :					**35.00**

02.4 Warehouse					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Dispensing Booth	2	5'x7'x4'	India	62,500	0.525
Weighting balances	5	200kg -3 g,	Japan	20,000	0.168
Rack	1	200 ton/Rack	Uae	125,000	1.050
Fork lift	3	1000kg	China	112,500	0.945
Reach truck	2	1000kg	Japan	150,000	1.260
Pallet	1	1000kg	Malaysia	125,000	1.050
Warehouse Total :					**5.00**

02.5 Vehicles					
Microbus	1		Bangladesh		0.300
Car	1		Bangladesh		0.200
Vehicles Total :					**0.50**

02.6 Consultancy and Contingencies	
Consultancy Fees	**2.214**
Goods Manufacturing Practice (GMP) - Validate the Machine Layout, Process Layout, Airflow, Water flow, Building Layout etc.	1.100
Electrical (Drawing & Design)	0.450
Plumbing (Drawing & Design)	0.300
Heating, Ventilating and Air Conditioning System (HVAC) - Calculate & Measure Data regarding Airflow Management, Temperature Management of the Plant.	0.364
Contingencies	1.108
Consultancy and Contingencies Total :	**3.32**
Total Cost for Oncology Project	**114.10**

03. Detail Cost Break down of Ayurvedic, Modern Herbal & Nutraceuticals Project

03.1 Civil Construction				
Particulars	**Area**	**Unit**	**Rate in BDT**	**Total Amount (In BDT crore)**
Architectural Design-Drawings including elevation and section of building, layout plan of column, beam, brick wall, toilet portion, stair, case, details of doors, windows, parapet and drop walls.	120,000	Sft	6	0.072
Structural design-drawings for sub structure	120,000	Sft	3	0.036
Structural design-drawings for super structure	120,000	Sft	4	0.048
Earth work in excavation of all kinds of soils of foundation trenches including leveling, ramming and preparing the base, bailing out water and shoring if necessary including pal siding up to required height if necessary, cutting earth up to 12'-0" depth by Mechanically or manually, removing the spoils, etc. to a lead not exceeding 60m.	141,290	Cft	10	0.141
One layer of brick flat soling in foundation or in floor with 1st class or picked bricks including preparation of bed and filling the interstices with local sand (Excluding cost of all materials & equipments).	24,266	Sft	30	0.073
Laying polythene sheet as per requirement.	4,926	Sft	5	0.002
Pile Boring	18,887	Rft	1,800	3.400
Pile Casting	74,130	Cft	290	2.150
Pile Cap Casting	10,923	Cft	290	0.317
Labor for breaking of pile head of cast-in-situ bored pile or pre-cast pile up to required length				
a) Cast-in-situ pile up to 24" dia	3,839	Cft	80	0.031
b) Strengthening cleaning, clearing of pile M.S. Rod including removing of rust etc. all complete.	236	Pcs	500	0.012
Mass concrete any proportion in foundation or floor with cement, sand (F.M.1.2) and picked jhama chips.	23,818	Cft	30	0.071
Earth or Sand filling in foundation trenches and plinth with fine sand having minimum F.M. 0.80 in 150mm layers including leveling, watering and consolidating each layer up to finished level with mechanical compaction up to finished level. (Excluding cost of all materials)	308,051	Cft	14	0.431
Brick work with 1st class bricks in cement mortar (1:6) or (1:4) in foundation and plinth Level				
a) 10" Brick Work	44,062	Cft	150	0.661
b) 5" Brick Work	30,167	Sft	70	0.211

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
Fabrication and fixing of details as per design deformed bar reinforcement of any grade in concrete including straightening and cleaning rust, if any bending and binding in position with G.I. wires including supply of G.I. wire etc. all complete in all respects. (Excluding cost of all materials)				
a) Foundation to 5th Floor (Labour Cost)	672	M. Ton	5,800	0.390
b) Foundation to 5th Floor	671,501	Kg	85	5.708
c) Pilling	389,760	Kg	85	3.313
d) Pile Cap	18,732	Kg	85	0.159
e) Grade Beam	73,117	Kg	85	0.621
f) Machinery hire charges in all floors	672	M. Ton	600	0.040
Reinforced cement concrete works (1:1.5:3) A. Labour cost for casting and shuttering including curing. **a) Foundation to Ground Floor**				
1. In individual and continuous footing of columns, raft, pile cap, floor slab at ground level.	19,382	Cft	50	0.097
2. In pedestal, column, capital, lift wall and wall.	6,237	Cft	88	0.055
3. All kinds of Beams	7,029	Cft	85	0.060
4. In roof slab of all types, cantilever slab, stair case slab and step.	1,515	Cft	75	0.011
5. In sunshade, cornice, railing, drop wall, louver, fins and lintel.	152	Cft	120	0.002
b) 1st Floor to 5th Floor				
1. In pedestal, column, capital, lift wall and wall.	16,150	Cft	98	0.158
2. All kinds of Beams	18,702	Cft	93	0.174
3. In roof slab of all types, cantilever slab, stair case slab and step.	64,985	Cft	80	0.520
4. In sunshade, cornice, railing, drop wall, louver, fins and lintel.	789	Cft	130	0.010
B. Rental value of steel shutter in all places except in column beam joint and some special places with wood if required. Payment to be made on R.C.C. volume at any height upto 5th floor				
a) In individual and continuous footing of columns, raft, pile cap, floor slab at ground level.	10,923	Cft	25	0.027
b) In pedestal, column, capital, lift wall and wall.	22,387	Cft	88	0.197
c) All kinds of Beams.	25,731	Cft	78	0.201
d) In roof slab of all types, cantilever slab, stair case slab and step.	58,166	Cft	65	0.378
e) In sunshade, cornice, railing, drop wall, louver, fins and lintel.	941	Cft	120	0.011
C. Rental value of machinery and equipment including operating and maintenance. Payment to be made on R.C.C. volume at any height up to 5th floor for all kinds of concrete work.	146,043	Cft	8	0.117

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
D. Rental value of staging and scaffolding materials up to required height. Measurement of staging & scaffolding, materials will be up to every 10'-0" height or part thereof in all respect.	197,374	Sft	30	0.592
E. Labour rate for staging, fitting, fixing for any work as and where required up to every 10'-0" height as per instruction of the Engineer-in-charge.	170,280	Sft	17	0.289
F. Up to 2" thick patent stone flooring including compacting, curing etc. all complete.	68,094	Sft	195	1.328
G. Labour rate for scaffolding ,fitting fixing at any where required up to every 10'-0'' height.	207,133	Sft	8	0.166
H. Chipping R.C.C surfaces at any height and any places including watering and cement grouting to receive cement mortar as per instruction of the Engineer-in-charge.	238,119	Sft	2	0.048
Aluminum Work (Door & Window)	13,363	Sft	262	0.350
Paint Work	322,986	Sft	13	0.420
Net cement finishing to all surfaces including curing complete	24,852	Sft	5	0.012
Rate of RCC Casting was Done by Ready Mixed Concrete	58,621	Cft	253	1.483
Interior Design by Studio 45 LS	1	Job		0.260
Aluminum Composite Panel	13,713	Sft	510	0.699
Zinc Coated Composite Panel	27,270	Sft	871	2.375
Curtain Wall Glazing	7,017	Sft	663	0.465
MS Structure for extended Column, Slab & Wall	3,759	Sft	340	0.128
Tempering Charge for 60mm Reflective Glass	7,017	Sft	76	0.053
Spider Glass Wall	407	Sft	1,401	0.057
Glass Door Handle	13	Rft	7,600	0.010
Tempered Laminated Glass Canopy	1,028	Sft	2,340	0.241
Sliding Window	1,350	Sft	250	0.034
SS Railing With 10mm Tempered Glass	438	Sft	1,150	0.050
Auto Sensor Door	1	Job		0.055
Aluminium Ellipse Louver	290	Sft	1,105	0.032
Wall Tiles	13,426	Sft	150	0.201
Floor Tiles	18,868	Sft	180	0.340
Stair Tiles	2,227	Sft	156	0.035
Stone Fitting	3,839	Sft	900	0.346
Sandwich panel	52,500	Sft	1,500	7.875
Painting (Self leveling epoxy)	104,000	Sft	250	2.600

Particulars	Area	Unit	Rate in BDT	Total Amount (In BDT crore)
Fire Protection : Fire fighting by fire hydrant hose reel, Fire extinguisher (different type) Fire Detection: Smoke detection Heat detection Fire alarm system All are control by BMS (Building Management System)				0.800
Plumbing : PVC & UPVC Pipe, MS Pipe and others accessories				0.500
Civil Construction Total :				**41.75**

03.2 Machinery & Equipment					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Herbs Processing					
Herbs Extraction Plant	2	5000 L/ batch	Italy	625,000	5.250
Herbs processing plant	1	5000L/Batch	Italy	437,500	3.675
Herbs Softener	1	700Liter /Batch	China	43,875	0.369
Herbs Cutting machine	1	100kg/Hr	China	24,375	0.205
Herbs Washing Machine	1	500 kg/hr	China	24,375	0.205
Herbs Crushing Machine	1	200kg/hr	China	29,250	0.246
Herbs Grinding Machine	1	200kg/hr	China	19,500	0.164
Vacuum Dryer	1	300kg/hr	China	58,500	0.491
Pulverizer	1	200kg/hr	China	34,125	0.287
Spray Dryer	1	5000 L/ batch	China	938	0.008
Granulation					
Fluid Bed Dryer	1	300 kg	India	200,000	1.680
Rapid Mixer Granulator	1	300 kg	India	200,000	1.680
Co Mill	1	500 kg/hr	India	18,750	0.158
Vibratory Sifter	1	500 kg/hr	India	18,750	0.158
Roller Compactor	1	500 kg/hr	India	100,000	0.840
Blender	1	500 kg	India	75,000	0.630
Tablet Pressing					
Tablet Press machine	1	30,000 tab/hr	Korea	250,000	2.100
Coating machine	1	100 kg	Korea	250,000	2.100
Lifting Column	1	300 kg	India	97,500	0.819
Tablet Bin	8	150 kg	India	54,600	0.459
Capsule Filling					
Capsule Filling machine	1	35,000 Cap/hr	Korea	250,000	2.100
Lifting Column	1	300 kg	India	97,500	0.819
Capsule bin	8	150 kg	India	54,600	0.459
Syrup Filling					
Bottle Washing machine	2	20,000 bot/hr	Italy	200,000	1.680
Bottle Dryer	1	40,000 bot/batch	India	93,750	0.788
Syrup Manufacturing Vessel	2	5000 L	India	500,000	4.200
Syrup Storage Vessel	2	5000 L	India	487,500	4.095
Sugar melting vessel	1	3000 L	Germany	100,000	0.840
Sugar storage vessel	1	3000 L	Germany	125,000	1.050

Particulars	Qty.	Capacity	Country of Origin	Total Amount in USD	Total Amount (In BDT crore)
CMC melting vessel	2	3000 L	Germany	150,000	1.260
Turn Table	1	150 BPM	Italy	687,500	5.775
Inspection Machine (before Filling)	2	150 BPM	India		
Syrup Filling machine	2	20,000 bot/hr	India		
Capping Machine	2	20,000 bot/hr	India		
Inspection Machine (after capping)	2	120 BPM	India		
Labeling machine	2	20,000 bot/hr	India		
Ink Jet Printer	2	5.5m/s	Bangladesh	17,500	0.140
Cream & Ointment					
Emulsifier	1	200 L	Germany	150,000	1.260
Oil Phase vessel	1	150 L	Germany		
Wax Phase Vessel	1	150 L	Germany		
Tube Filling machine	1	2500 tube/hr	China		
Rub filling machine	1	1 kg/hr	China		
Ink Jet Printer	1	5.5m/s	Bangladesh	8,750	0.070
Sachet Filling					
Sachet Filling Machine	1	125 kg/hr	China	150,000	1.260
Ink Jet Printer	1	5.5m/s	Bangladesh	8,750	0.070
Bin	5	150 kg	India	34,125	0.287
Common Use					
Clean Room Equipments	1	01 lot	Malaysia	48,750	0.410
SS Furniture & Utensils	1	01 lot	Bangladesh	75,000	0.600
IPQC instruments	1	01 lot	Bangladesh	62,500	0.500
IPQC Furniture	1	01 lot	Bangladesh	31,250	0.250
Bin washing & drying machine	1	Flow rate 10 ton/H	Taiwan	48,750	0.410
De-blistering machine	1	20 - 40 strip/Min	Taiwan	4,875	0.041
Batch Printing machine	1	250 PPH	India	4,875	0.041
Leaflet folding machine	1	300PPM	India	4,875	0.041
Soft Gelatin					
Soft Gelatin Filling Machine	1	20,000 cap/hr	Korea	125,000	1.050
Drying Machine	1	50 kg	Korea	48,750	0.410
Bin	5	175 kg	India	34,375	0.289
Hard Gelatin					
Hard Gelatin Filling Machine	1	20,000 cap/hr	China	125,000	1.050
Bin	5	175 kg	India	34,375	0.289
Primary Packing					
Blister Pack machine for Tablet	1	7000 strips/hr	Vietnam	375,000	3.150
Blister Pack machine for Capsule	1	7000 strips/hr	Vietnam	375,000	3.150
Blister Pack machine for Gelatin	1	7000 strips/hr	Germany	237,500	1.995
Blister Pack machine for Tube	1	7000 strips/hr	Germany	237,500	1.995
Container Filling Line (Tab/Cap)	1	150 cont/min	Korea	375,000	3.150
Container Filling Line (cream/oil)	1	120 tube / min	India	375,000	3.150
Secondary Packing					
Conveyor belt	8	30 RPM	Bangladesh	30,000	0.240
Ink Jet Printer	8	5.5 m/s	Bangladesh	70,000	0.560
Sticker labeling machine	2	120BPM	India	37,500	0.315
Shrink Warf machine	1	60 - 80 pack/min	India	37,500	0.315
SS Table	8	4'x6'	Bangladesh	2,500	0.020
SS Cabinet	8	5'x6'x1.5'	Bangladesh	4,000	0.032
Hydraulic trolley	5	5 Ton	Bangladesh	12,500	0.100
Vacuum Cleaner	5	90 Liter	Bangladesh	12,500	0.100
QC Instruments					
Validation instruments	1	01 lot	Bangladesh	125,000	1.000
Lab Furniture	1	01 lot	Bangladesh	50,000	0.400

Particulars	Qty.	Capacity	Country of Origin	Total Amount in USD	Total Amount (In BDT crore)
QC Instruments	1	01 lot	Bangladesh	1,250,000	10.000
Others					
Laundry equipments	1	01 lot	Bangladesh	62,500	0.500
Office and others furniture	1	01 lot	Bangladesh	62,500	0.500
Contingency	1	01 lot	Bangladesh	250,000	2.000
Machinery & Equipment Total :					**85.72**

03.3 Utility					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Heating, Ventilating and Air Conditioning System (HVAC)- Air Handling Unit, Chiller, Pump, Ducting etc.	1	500 Ton	Malaysia	2,812,500	22.500
Lift	1	14 persons	Korea	150,000	1.200
Canteen Furniture & Facility	1	01 lot	Uae	12,500	0.100
Air Compressor	1	10 m3/min	Usa	100,000	0.800
Generator	1	2 MW 1 nos.	Usa	750,000	6.000
Boiler	1	2 Ton	Korea	250,000	2.000
Water System	1	7,000 L	Spain	250,000	2.000
Fork Lift	1	800kg	China	25,000	0.200
Electrical Work	1	01 lot	Bangladesh	625,000	5.000
Split type A/C	1	100 ton	Bangladesh	75,000	0.600
Utility Total :					**40.40**

03.4 Warehouse					
Particulars	**Qty.**	**Capacity**	**Country of Origin**	**Total Amount in USD**	**Total Amount (In BDT crore)**
Racks	1	02 ton	Bangladesh	62,500	0.500
Pallets	1	1000kg	Malaysia	12,500	0.100
Balance	1	150 kg	Bangladesh	62,500	0.500
Warehouse Total :					**1.10**

03.5 Vehicles					
Microbus	1		Bangladesh		0.300
Car	1		Bangladesh		0.200
Vehicles Total :					**0.50**

03.6 Consultancy and Contingencies	
Consultancy Fees	**3.390**
Goods Manufacturing Practice (GMP) - Validate the Machine Layout, Process Layout, Airflow, Water flow, Building Layout etc.	1.100
Electrical (Drawing & Design)	0.450
Plumbing (Drawing & Design)	0.300
Heating, Ventilating and Air Conditioning System (HVAC) - Calculate & Measure Data regarding Airflow Management, Temperature Management of the Plant.	1.540
Contingencies	1.690
Consultancy and Contingencies Total :	**5.08**

Total Cost for Ayurvedic, Modern Herbal & Nutraceuticals Project	**174.55**

Terms of Contract

As per Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 there is no contract covering any of the activities for which the proceeds of sale of securities are to be used, such as contracts for the purchase of land or contracts for the construction of buildings.

Sd/-	Sd/-	Sd/-
(Md. Zahangir Alam, FCMA)	**(Mizanur Rahman Sinha)**	**(Afzalur Rahman Sinha)**
Chief Financial Officer	Managing Director	Chairman

Where the sponsors' contribution or privately placed fund has been brought prior to the public issue and has already been deployed by the issuer, indication of use of such funds in the cash flow statement;

Indication of use of privately placed fund in the statement of cash flows

Tk. 2,001,377,569 (net of placement expenses) has been raised through private placement prior to the public issue on dated 20 May 2013, this fund has already deployed by the issuer in the following manner.

Accounting Year	Items	Amount in BDT	Reflected in Cash Flows
30 June 2013	Investment in Term Deposit	1,220,000,000	Company have made short term investment in FDR to several financial institutions namely in trust bank Tk. 35 crore, in Dhaka Bank Tk. 15 crore, in DBH Tk. 20 Crore, in ICB Tk. 15 crore and Tk. 2 Core in Bank Asia. Details of which are stated in the note no. 16 of the Audited Financial Statements for the year ended 30 June 2013 In the statement of Cash Flows, same figure is shown as Term Deposit under the head of Investing Activities.
	Acquisition of Property, Plant & Equipment	781,377,569	In the statement of Cash Flows, the figure is included in total amount of fixed assets acquisition under the head of Investing Activities.
30 June 2014	Investment in Term Deposit	553,201,740	Short term investment in FDR amounting Tk. 553,201,740 is remained unused and balance amounting Tk. 666,798,260 has been encased during the year ended 30 June 2014 and same figure is shown as encashment of FDR under the head of Investing Activities
	Acquisition of Property, Plant & Equipment	666,798,260	In the statement of Cash Flows, the figure is included in total amount of fixed assets acquisition under the head of Investing Activities.

If one of the objects is an investment in a joint venture, a subsidiary, an associate or any acquisition, details of the form of investment, nature of benefit expected to accrue to the issuer as a result of the investment, brief description of business and financials of such venture;

The Company has no objects to investment in such type of ventures by using Use of IPO proceeds.

If IPO proceeds are not sufficient to complete the project, then source of additional fund must be mentioned. In this connection, copies of contract to meet the additional funds are required to be submitted to the Commission. The means and source of financing, including details of bridge loan or other financial arrangement, which may be repaid from the proceeds of the issue along with utilization of such funds;

The Company has been running its business with name and fame for last six decades and enjoying profit growth over the years. For the year ended 30 June 2014, Company's net profit after tax stood at Tk. 893,890,898. Therefore, the additional fund required to complete the proposed three expansion projects will be arranged from its organic sources of cash generation.

A schedule mentioning the stages of implementation and utilization of funds received through public offer in a tabular form, progress made so far, giving details of land acquisition, civil works, installation of plant and machinery, the approximate date of completion of the project and the projected date of full commercial operation etc. The schedule shall be signed by the Chief Executive Officer or Managing Director, Chief Financial Officer and Chairman on behalf of Board of Directors of the issuer;

Sl. No	Projects	Progress made so far		Approximate date of Completion of the Projects	Projected date of full commercial Operation
01	Steroid and Hormone	Land Acquisition	No land is required to acquired, it will be established in the own land of the ACME Laboratories Ltd.	To be completed within 2 years of receive IPO fund.	Within Six months of completion of the projects
		Civil works	Civil works will be started after receiving IPO Fund.		
		Installation of Plant & Machinery	Installation of plant & Machinery will be started after receiving IPO Fund.		
02	Oncology	Land Acquisition	No land is required to acquired, it will be established in the own land of the ACME Laboratories Ltd.	To be completed within 2.5 years of receive IPO fund.	Within Six months of completion of the projects
		Civil works	Civil works will be started after receiving IPO Fund.		
		Installation of Plant & Machinery	Installation of plant & Machinery will be started after receiving IPO Fund.		

Sl. No	Projects	Progress made so far		Approximate date of Completion of the Projects	Projected date of full commercial Operation
03	Ayurvedic, Modern Herbal and Nutraceuticals	Land Acquisition	No land is required to acquired, it will be established in the own land of the ACME Laboratories Ltd.	To be completed within 2.5 years of receive IPO fund.	Within Six months of completion of the projects
		Civil works	Civil works will be started after receiving IPO Fund.		
		Installation of Plant & Machinery	Installation of plant & Machinery will be started after receiving IPO Fund.		

Sd/-	Sd/-	Sd/-
(Md. Zahangir Alam, FCMA)	**(Mizanur Rahman Sinha)**	**(Afzalur Rahman Sinha)**
Chief Financial Officer	Managing Director	Chairman

If there are contracts covering any of the activities of the issuer for which the proceeds of sale of securities are to be used, such as contracts for the purchase of land or contracts for the construction of buildings, the issuer shall disclose the terms of such contracts, and copies of the contracts shall be enclosed as annexure to the prospectus;

There is no such contract yet to be engaged by the Company.

If one of the objects of the issue is utilization of the issue proceeds for working capital, basis of estimation of working capital requirement along with the relevant assumptions, reasons for raising additional working capital substantiating the same with relevant facts and figures and also the reasons for financing short with long term investments and an item wise break-up of last three years working capital and next two years projection;

Not applicable for the company

Where the issuer proposes to undertake one or more activities like diversification, modernization, expansion, etc., the total project cost activity-wise or project wise, as the case may be;

The company has a plan to implement three new projects by using IPO proceeds, which have been mentioned in use of IPO Proceeds and project implementation schedule.

Where the issuer is implementing the project in a phased manner, the cost of each phase, including the phases, if any, which have already been implemented;

The company has a plan to implement three new projects by using IPO proceeds after receiving the funds, which have been mentioned in use of IPO Proceeds and project implementation schedule.

The details of all existing or anticipated material transactions in relation to utilization of the issue proceeds or project cost with sponsors, directors, key management personnel, associates and group companies;

There is no such material transaction with sponsors, directors, key management personnel, associates and group companies in relation to utilization of the issue proceeds.

Summary of Feasibility report with cost of the project, means of finance, weakness and threats

Summary

Under The Entity: **The ACME Laboratories Ltd.**

Type of the Industry: **Pharmaceuticals**

Location of the Project **Dhulivita, Dhamrai, Dhaka.**

Capacity of the Project *:* ***(Thousand pcs. Per year)***

Particulars	Steroid & Hormone	Oncology	Ayurvedic, Modern Herbal and Nutraceuticals	Total
Capsule	46,370	-	18,362	64,732
Hard Gelatin Capsule	-	-	3,441	3,441
Soft Gelatin Capsule	-	-	8,353	8,353
Cream	1,759	-	360	2,119
Eye Drops	465	-	-	465
Dry Syrup	-	-	16,595	16,595
Injection	5,730	1,309	-	7,039
Lotion	256	-	-	256
Liquid	-	-	2,426	2,426
Nasal Spray	397	-	-	397
Ointment	1,236	-	873	2,109
Solution	572	-	-	572
Sachet	-	-	22,713	22,713
Tablet	365,232	1,248	31,711	398,191
Pill	169,832	-	-	169,832
Tooth Powder	-	-	396	396
Emulsion	-	-	165	165
Rub	-	-	200	200
Gel	-	-	264	264
Oil	-	-	198	198
Probiotic	-	-	2,153	2,153
Inhaler (MDI)	914	-	-	914

Particulars	Steroid & Hormone	Oncology	Ayurvedic, Modern Herbal and Nutraceuticals	Combined
Cost of the Project (in Crore):	135.80	114.10	174.55	424.45
Total Equity of the Project: (in Crore)	135.80	114.10	174.55	424.45
Net Present Value (@ 13%): (in Crore)	78.36	60.27	82.45	229.79
Internal Rate of Return:	24.30%	22.89%	22.75%	23.79
Payback period of the project:	4.12	4.37	4.40	4.20

Means of finance

The aforesaid projects will be established through using IPO Proceeds.

Sd/-
(Mohammad Faruque Ahmed, FCMA)

CHAPTER XXIII: LOCK- IN PROVISION OF SHARES

Ordinary shares of the issuer shall be subject to lock-in, from the date of issuance of prospectus or commercial operation, whichever comes later, in the following manner:

(1) All shares held, at the time of according consent to the public offer, by sponsors, directors and shareholders holding 5% or more shares, other than alternative investment funds, for 03(three) years;

(2) All shares allotted, before 02(two) years of according consent to the public offer, to any person, other than alternative investment funds, for 03(three) years;

(3) In case any existing sponsor or director of the issuer transfers any share to any person, other than existing shareholders, within preceding 12 (twelve) months of submitting an application for raising of capital or initial public offer (IPO), all shares held by those transferee shareholders, for 03(three) years;

(4) 25% of the shares allotted to eligible investors, for 03 (three) months and other 25% of the shares allotted to them, for 06 (six) months;

(5) All shares held by alternative investment funds, for 01(one) year; and

(6) Shares allotted, within two years of according consent to the public offer, to any person other than the shares mentioned in sub-rules (1), (2), (3), (4), and (5) above, for 01(one) year.

Provided that ordinary shares converted from any other type of securities shall also be subject to lock-in as mentioned above.

Statement of securities to be locked

Shareholder wise statement of securities to be locked is stated below:

SL. #	Name in Full	Position with the Company	BO Account Number	Number of shares held and to be locked in	% of share held	Date of Acquisition	Lock-in period from the date of issuance of prospectus
01.	Mr. Nasir-Ur-Rahman Sinha	Shareholder	1203140008032983	6,160,405	3.812	17.03.1976 16.05.1976 10.08.1989 20.05.2002 29.11.2006 05.05.2011 26.11.2013 01.09.2015	3 (Three) Years
02.	Mr. Mizanur Rahman Sinha	Managing Director	1602170058187279	20,426,565	12.640	17.03.1976 16.05.1976 07.06.1980 10.08.1989 20.05.2002 29.11.2006 05.05.2011 26.11.2013 24.02.2015 02.06.2015 01.09.2015	3 (Three) Years
03	Mrs. Parveen Akhter Nasir	Shareholder	1203140058498991	5,401,517	3.34	17.03.1976 16.05.1976 07.06.1980 10.08.1989 29.11.2006 05.05.2011 26.11.2013	3 (Three) Years
04	Mrs. Jahanara Mizan Sinha	Director	1204220058531949	10,519,744	6.510	17.03.1976 16.05.1976 07.06.1980 10.08.1989 29.11.2006 05.05.2011 26.11.2013	3 (Three) Years
05	Dr. Jabilur Rahman Sinha	Deputy Managing Director	1202160016461974	4,860,696	3.008	16.05.1976 29.11.2006 05.05.2011 26.11.2013 01.09.2015	3 (Three) Years

SL. #	Name in Full	Position with the Company	BO Account Number	Number of shares held and to be locked in	% of share held	Date of Acquisition	Lock-in period from the date of issuance of prospectus
06	Mrs. Hasina Jabil Sinha	Shareholder	1202160016461982	4,859,245	3.01	16.05.1976 29.11.2006 05.05.2011 26.11.2013	3 (Three) Years
07	Mr. Afzalur Rahman Sinha	Chairman	1204220058531922	17,214,336	10.652	16.05.1976 07.06.1980 10.08.1989 28.05.2002 29.11.2006 05.05.2011 26.11.2013 24.02.2015 02.06.2015 01.09.2015	3 (Three) Years
08	Mrs. Nagina Afzal Sinha	Director	1204220058531965	11,888,433	7.357	16.05.1976 10.08.1989 29.11.2006 05.05.2011 26.11.2013	3 (Three) Years
09	Dr. Mohammad Zillur Rahman	Shareholder	1204220058541799	2,760,828	1.708	15.09.2011 01.09.2015	3 (Three) Years
10	Mr. Shahriar Rahman	Shareholder	1204220058541812	2,679,638	1.658	15.09.2011 01.09.2015	3 (Three) Years
11	Ms. Farzana Rahman Anwar	Shareholder	1204220058541804	2,679,529	1.658	15.09.2011 01.09.2015	3 (Three) Years
12	Mr. Reza-ur-Rahman Sinha	Shareholder	1203140016549631	4,400,000	2.72	27.09.2011 20.09.2014 11.10.2014	3 (Three) Years
13	Mr. Motiur Rahman Sinha	Shareholder	1203140051385761	1,400,000	0.87	27.09.2011 26.11.2013 20.09.2014 11.10.2014	3 (Three) Years
14	Mr. Ansar Uddin Sinha	Shareholder	1203140020445737	2,900,000	1.79	27.09.2011 20.09.2014 11.10.2014	3 (Three) Years
15	Mr. Tanveer Sinha	Shareholder	1204220058532017	280,394	0.17	27.09.2011 26.11.2013	3 (Three) Years
16	Ms. Tasneem Sinha	Shareholder	1204220058531981	280,394	0.17	27.09.2011 26.11.2013	3 (Three) Years
17	Mr. Imad Uddin Ahmed	Shareholder	1204220058531991	4,059,730	2.51	27.09.2011	3 (Three) Years

SL. #	Name in Full	Position with the Company	BO Account Number	Number of shares held and to be locked in	% of share held	Date of Acquisition	Lock-in period from the date of issuance of prospectus
18	Mrs. Merajee Nasim	Shareholder	1204220058531957	4,059,720	2.51	27.09.2011	3 (Three) Years
19	Mr. Fahim Sinha	Shareholder	1204220058531930	280,395	0.17	27.09.2011 26.11.2013	3 (Three) Years
20	Ms. Sabrina Sinha	Shareholder	1204220058531973	280,394	0.17	27.09.2011 26.11.2013	3 (Three) Years
21	Ms. Sylvana Sinha	Shareholder	1202160023458535	7,288,866	4.51	06-05-2015	3 (Three) Years
22	Ms. Tanya Quader Sinha	Shareholder	1202160058513919	7,288,866	4.51	06-05-2015	3 (Three) Years
23	Mrs. Khurshid Jehan Dabir (Mrs.Laizu Dabir)	Shareholder	1204220059640631	725	0.0004	01.09.2015	3 (Three) Years
24	Mr. Md. Hasibur Rahman	Shareholder	1204220059639471	180	0.0001	01.09.2015	3 (Three) Years
25	GSP Finance Company (Bangladesh) Limited	Shareholder	1202830004187028	769,200	0.48	20-05-2013	3 (Three) Years
26	Dr. Syed Anwarul Hafiz	Shareholder	1204490000076448	500,000	0.31	20-05-2013	3 (Three) Years
27	Khadim Ceramics Ltd. Unit-2	Shareholder	1202160018312493	500,000	0.31	20-05-2013	3 (Three) Years
28	Alpha Capital Management Ltd.	Shareholder	1605550049519826	500,000	0.31	20-05-2013	3 (Three) Years
29	Popular Life Insurance Company Limited	Shareholder	1204680000045409	1,000,000	0.62	20-05-2013	3 (Three) Years
30	Dhaka Bank Limited	Shareholder	1201630000001072	500,000	0.31	20-05-2013	3 (Three) Years
31	Bank Asia Limited	Shareholder	1204490000175597	1,000,000	0.62	20-05-2013	3 (Three) Years
32	Green Delta Insurance Company Ltd.	Shareholder	1203620000042986	500,000	0.31	20-05-2013	3 (Three) Years
33	Southeast Bank Limited	Shareholder	1602290000060633	2,884,600	1.76	20-05-2013	3 (Three) Years
34	Pioneer Insurance Company Limited	Shareholder	1601880004129462	1,000,000	0.62	20-05-2013	3 (Three) Years
35	Pragati Life Insurance Ltd.	Shareholder	1204080009905096	300,000	0.19	20-05-2013	3 (Three) Years
36	United Commercial Bank Limited	Shareholder	1205590015459615	7,692,300	4.76	20-05-2013	3 (Three) Years
37	Investment Corporation of Bangladesh	Shareholder	1201530000003501	5,800,000	3.59	20-05-2013	3 (Three) Years
38	ICB Unit Fund	Shareholder	1201530000003518	5,800,000	3.59	20-05-2013	3 (Three) Years
39	Bangladesh Shilpa Rin Sangstha (BDBL)	Shareholder	1202180000109618	1,000,000	0.62	20-05-2013	3 (Three) Years
40	ICB Capital Management Ltd.	Shareholder	1201530000001725	1,900,000	1.18	20-05-2013	3 (Three) Years
41	ICB Securities Trading Company Limited	Shareholder	1201530028713102	950,000	0.59	20-05-2013	3 (Three) Years

SL. #	Name in Full	Position with the Company	BO Account Number	Number of shares held and to be locked in	% of share held	Date of Acquisition	Lock-in period from the date of issuance of prospectus
42	Bangladesh Fund	Shareholder	1605420043478871	4,800,000	2.97	20-05-2013	3 (Three) Years
43	Federal Insurance Company Limited	Shareholder	1203310003865475	500,000	0.31	20-05-2013	3 (Three) Years
44	ICB Capital Management Limited – DIA	Shareholder	1201530048491137	Total # 3,45,000 Shares			3 (Three) Years
DIA-1	Md. Ruhul Amin - ICML A/C	Shareholder	1201530048491137	25,000	0.015	20-05-2013	3 (Three) Years
DIA-2	A. S. M. Masudur Rahman - ICML A/C	Shareholder	1201530048491137	50,000	0.031	20-05-2013	3 (Three) Years
DIA-3	Md. Omar Siddique - ICML A/C	Shareholder	1201530048491137	25,000	0.015	20-05-2013	3 (Three) Years
DIA-4	Md. Hasibur Rahman - ICML A/C	Shareholder	1201530048491137	60,000	0.037	20-05-2013	3 (Three) Years
DIA-5	Sanowar Habib Sinha - ICML A/C	Shareholder	1201530048491137	20,000	0.012	20-05-2013	3 (Three) Years
DIA-6	Sarwar Habib Sinha - ICML A/C	Shareholder	1201530048491137	20,000	0.012	20-05-2013	3 (Three) Years
DIA-7	Golam Rabbani Bhuian - ICML A/C	Shareholder	1201530048491137	20,000	0.012	20-05-2013	3 (Three) Years
DIA-8	Md. Minar Hossain Khan - ICML A/C	Shareholder	1201530048491137	20,000	0.012	20-05-2013	3 (Three) Years
DIA-9	Md. Omar Khayam Bhuiyan - ICML A/C	Shareholder	1201530048491137	20,000	0.012	20-05-2013	3 (Three) Years
DIA-10	Suladhar Tarafder - ICML A/C	Shareholder	1201530048491137	20,000	0.012	20-05-2013	3 (Three) Years
DIA-11	Pralay Kumar Paul Chowdhury - ICML A/C	Shareholder	1201530048491137	25,000	0.015	20-05-2013	3 (Three) Years
DIA-12	Abu Reza Khan - ICML A/C	Shareholder	1201530048491137	20,000	0.012	20-05-2013	3 (Three) Years
DIA-13	Mojibur Rahman - ICML A/C	Shareholder	1201530048491137	20,000	0.012	20-05-2013	3 (Three) Years
45	Muhammed Ali	Shareholder	1204090046709799	50,000	0.03	20-05-2013	3 (Three) Years
46	Shahnoor Chowdhury	Shareholder	1204090020405505	50,000	0.03	20-05-2013	3 (Three) Years
47	The ACME Laboratories Ltd. Employees Provident Fund	Shareholder	1203140058536462	1,000,000	0.62	20-05-2013	3 (Three) Years
48	Muhammed Shahidul Islam	Shareholder	1202150045636271	100,000	0.06	20-05-2013	3 (Three) Years
49	ICB Portfolio Khulna	Shareholder	1203650016151687	80,000	0.05	20-05-2013	3 (Three) Years

SL. #	Name in Full	Position with the Company	BO Account Number	Number of shares held and to be locked in	% of share held	Date of Acquisition	Lock-in period from the date of issuance of prospectus
50	Farzana Abedin	Shareholder	1201950006933721	20,000	0.01	20-05-2013	3 (Three) Years
51	Md. Asaduzzaman Mia	Shareholder	1201580000026326	60,000	0.04	20-05-2013	3 (Three) Years
52	Partho Kumar Bagchi	Shareholder	1203570011404113	5,000	0.003	20-05-2013	3 (Three) Years
53	G.K.M. Siddiquer Rahman	Shareholder	1203140049052156	10,000	0.006	20-05-2013	3 (Three) Years
54	Chowdhury Rishad Nighar	Shareholder	1602070000080504	10,000	0.006	20-05-2013	3 (Three) Years
55	Dr. Chowdhury Rifat Nighar	Shareholder	1602070000080499	2,500	0.002	20-05-2013	3 (Three) Years
56	Dr. Chowdhury Akram Uz Zaman	Shareholder	1602070000049474	2,500	0.002	20-05-2013	3 (Three) Years
Total No. of shares				**=16,16,01,700=**			

CHAPTER XXIV: MARKETS FOR THE SECURITIES BEING OFFERED

The issuer shall apply to

SL #	Name of the Exchange	Logo	Address
1	Dhaka Stock Exchange Limited (DSE)		9/F, Motijheel C/A, Dhaka-1000.
2	Chittagong Stock Exchange Limited (CSE)		CSE Building, 1080 Sheikh Mujib Road, Chittagong.

Within 7 (seven) working days from the date of consent accorded by the Commission to issue prospectus.

Declaration about Listing of Shares with the Stock Exchange(s)

If none of the Stock Exchange(s), if for any reason, grant listing within 75 days from the closure of subscription, any allotment in terms of this prospectus shall be void and the company shall refund the subscription money within fifteen days from the date of refusal for listing by the stock exchange, or from the date of expiry of the said 75 (seventy five) days, as the case may be.

In case of non-refund of the subscription money within the aforesaid fifteen days, the company directors, in addition to the issuer company, shall be collectively and severally liable for refund of the subscription money, with interest at the rate of 2% (two percent) per month above the bank rate, to the subscribers concerned.

The issue manager, in addition to the issuer company, shall ensure due compliance of the above mentioned conditions and shall submit compliance report thereon to the Commission within seven days of expiry of the aforesaid fifteen days time period allowed for refund of the subscription money.

Trading and Settlement

Trading and Settlement Regulation of the stock exchanges shall apply in respect of trading and settlement of the shares of the company.

The issue shall be placed in "N" Category with DSE & CSE.

CHAPTER XXV: DESCRIPTION OF SECURITIES OUTSTANDING OR BEING OFFERED

(description by giving All types of securities outstanding or being offered with date/ proposed date of such issue and to whom those are offered, number of securities and issue/offer price)

Dividend, Voting, Preemption Right

Voting right

The share capital of the Company is divided into Ordinary Shares, carrying equal rights to vote and eligible to receive dividend in terms of the relevant provisions of the Companies Act, 1994 and the Articles of Association of the Company. All shareholders shall have the usual voting right in person or by proxy in connection with, among others, election of directors & Auditors and other usual agenda of General Meeting-Ordinary or Extra Ordinary. On a show of hand, every shareholder present in person and every duly authorized representative of a shareholder present at a General Meeting shall have one vote and on a poll every shareholder present in person or by attorney or proxy shall have one vote for every share held by him or her.

In case of any additional issue of shares for raising further capital the existing shareholders shall be entitled to Right Issue of in terms of the guidelines issued by the BSEC from time to time.

Dividends on Transferred Shares

A transfer of share shall not pass the right to any dividend declared thereon before the registration of the transfer.

Appointment of proxy

The instrument appointing a proxy shall be in writing under the hand of the appointee or his attorney of is such appointee is a company or corporation, under its common seal or under the hand of a person duly authorized by such company or corporation in that behalf, or under the hand of its attorney who may be the appoint. No person shall be appointed a proxy who is a member of the company and qualified to vote save that a corporation being a member of the company may appoint as its representative any person whether member of the company or not.

Deposit of instrument of Appointment

The instrument appointing a proxy and the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of the power of attorney, shall deposited at the registered office of the Company not less than forty-eight hours before the time for holding the meeting at which the person named in the instrument proposes to vote and in default the instrument of proxy shall not be treated as valid.

Transfer of Shares

In terms of the provision of the Companies Act, 1994, Articles of Association of the company and other relevant rules in force, the shares of the Company are transferable. No shares shall be transferred to an infant or a person of unsound mind.

Conversion of shares in stock & Liquidation Right

The company may convert its share into stock as per enforceable law of the country.

Dividend Policy

Subject to the rights of members entitled to shares if any with preferential or special rights attached thereto as to dividends and subject to the provision of these presents as to the reserve fund and depreciation fund the net profits of the Company in respect of any year or other period shall be applied in the payment of dividend on the ordinary shares of the Company but so that a partly paid up share as the amount paid thereon bears to the nominal amount of cash share. The Company in general meeting may declare a dividend to be paid to the members according to their respective rights and interest in the profits and may fix the time for payment.

Interim Dividend

The Directors may from time to time pay to the members such interim dividend as in their judgment the position of the Company justifies.

Reserve and Dividend

The Directors shall in every year calculate the net profits of the company for that year remaining after deduction of all general expenses (including provisions for payment of taxes and allocation to any appropriate reserves) and dividend may be paid from the balance of net profits available. The profits of the company shall be divisible among the members in proportion to the shares held by them respectively.

Limitation on the payment of dividend

There is no limitation on the payment of dividend.

Other Rights of Stock holders

The shareholders shall have the right to receive all periodical reports and statements audited as well as un-audited published by the company from time to time. The Directors shall present the financial statements as required under the law and International Accounting Standards (IAS) as well as International Financial Reporting Standards (IFRS) as adopted in Bangladesh. Financial Statements will be prepared in accordance with Accounting Standards (IAS) as well as IFRS as adopted in Bangladesh, consistently applied throughout the subsequent periods and present with the objective of providing maximum disclosure as per law and International Accounting Standard to the shareholders regarding the Financial and operational position of the Company.

In case of any declaration of Stock dividend by issue of bonus shares, all shareholders shall be entitled to it in proportion to their shareholdings on the date of book closure for the purpose. The shareholders holding not less than 10% of the issued / fully paid up capital of the company shall have the right to requisition of the Extra-Ordinary General Meeting of the Company as provided under Section 84 of the Companies Act, 1994.

CHAPTER - XXVI : FINANCIAL STATEMENTS

AUDITOR'S REPORT

TO THE SHAREHOLDERS OF THE ACME LABORATORIES LTD.

We have audited the accompanying financial statements of **The ACME Laboratories Ltd.** which comprises the Statement of Financial Position as at June 30, 2014 and the related Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows for the year then ended and a summary of significant accounting policies and other explanatory notes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Bangladesh Financial Reporting Standards (BFRS), the companies Act 1994 and other applicable laws and regulations, This responsibility includes designing, implementing, and maintaining internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Bangladesh Standards on Auditing (BSA). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

In our opinion, the financial statements prepared in accordance with Bangladesh Financial Reporting Standards (BFRS), give a true and fair view of the state of the company's affairs as at June 30, 2014 and of the results of its operations and its cash flows for the year then ended and comply with the companies Act 1994 and other applicable laws and regulations.

We also report that:

(i) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;

(ii) In our opinion, proper books of account as required by law have been kept by the company so far as it appeared from our examination of those books and proper returns adequate for the purpose of our audit have been received;

(iii) The Company's Statement of Financial Position and Statement of Comprehensive Income and its Cash Flows dealt with by the report are in agreement with the books of account and returns;

(iv) The expenditure incurred was for the purpose of the company's business;

Dhaka
Dated: September 17, 2014

Sd/-
Pinaki & Company
Chartered Accountant

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Statement of Financial Position

As at June 30, 2014

Continuation Sheet....

ASSETS	NOTES	TAKA	
		As at 30.06.2014	As at 30.06.2013
Non-Current Assets :		**15,544,508,282**	**8,684,201,210**
Property, Plant and Equipment	6	15,511,897,086	8,306,210,678
Intangible Assets	7	286,875	338,132
Investment in Shares	8	6,139,321	351,467,400
Investment Property	9	26,185,000	26,185,000
Current Assets:		**6,635,062,802**	**7,889,442,833**
Inventories	10	2,223,003,434	1,886,267,051
Trade Receivable	11	644,867,067	471,021,187
Other Receivable	12	74,526,105	76,067,715
Advance, Deposits & Pre-Payments	13	1,097,408,239	2,347,694,271
Advance Income Tax	14	1,334,147,374	1,273,276,904
Material In Transit	15	294,476,484	162,465,596
Term Deposit	16	553,201,740	1,220,000,000
Cash and Cash Equivalents	17	413,432,359	452,650,109
TOTAL		**22,179,571,084**	**16,573,644,043**
EQUITY AND LIABILITIES			
Shareholders Equity:		**10,692,163,182**	**9,517,448,502**
Share Capital	18	1,616,017,000	1,556,311,000
Share Premium	19	1,605,066,569	1,605,066,569
Revaluation Surplus	6.a	5,429,804,848	4,488,695,133
Capital Reserve	20	-	40,166,723
Share Money Deposit		-	500,000,000
Gain/(Loss) on Marketable Securities (Unrealized)	8.1	841,041	-
Tax Holiday Reserve		91,006,996	-
Retained Earnings	21	1,949,426,728	1,327,209,077
Non Current Liabilities		**3,057,678,428**	**1,128,412,130**
Long Term Loans- Net off Current Maturity	22	3,018,088,196	1,003,604,234
Provision For Gratuity	23	30,465,330	-
Deferred Tax Liability	24	9,124,902	124,807,896
Current Liabilities :		**8,429,729,474**	**5,927,783,411**
Loans & Overdrafts	25	4,874,126,240	3,614,173,307
Current Maturity of Long Term Loans	26	1,014,864,198	384,236,310
UNDP Grant	27	-	-
Trade Payable	28	528,302,125	506,963,399
Provision for Income Tax	29	1,245,658,922	1,168,807,914
Liability for Expenses and Others	30	160,054,589	154,524,731
Dividend Payable	31	606,723,400	99,077,750
TOTAL		**22,179,571,084**	**16,573,644,043**

The annexed notes 1 to 54 form an integral part of the financial statements.

As per our annexed report of even date.

Sd/-
Managing Director

Sd/-
Director

Sd/-
PINAKI & COMPANY
Chartered Accountants

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Statement of Comprehensive Income

For the Year Ended 30 June 2014

Continuation Sheet....

	NOTES	TAKA July '13 to June '14 Non-Tax Holiday Unit	TAKA Feb.'14 to June'14 Tax Holiday Unit (50% Tax exemption)	TAKA July '13 to June '14 Total	TAKA July '12 to June '13 Non-Tax Holiday Unit
Revenue	**32**	**9,168,072,945**	**1,049,858,520**	**10,217,931,465**	**8,973,319,332**
Less: Cost of Goods Sold	**33**	5,709,287,076	528,505,478	6,237,792,554	5,721,020,810
Gross Profit/(Loss)		**3,458,785,869**	**521,353,042**	**3,980,138,911**	**3,252,298,522**
Add: Other Income	**34**	108,071,977	-	108,071,977	20,146,796
		3,566,857,846	**521,353,042**	**4,088,210,888**	**3,272,445,318**
Less: Selling, Marketing and Distribution Expense	**35**	1,348,054,041	151,774,876	1,499,828,917	1,330,346,506
		2,218,803,805	**369,578,166**	**2,588,381,971**	**1,942,098,812**
Less: Administrative Expenses	**36**	493,812,572	52,571,765	546,384,337	552,068,993
		1,724,991,233	**317,006,401**	**2,041,997,634**	**1,390,029,819**
Less: Financial Expenses	**37**	697,086,146	79,825,044	776,911,190	538,786,487
Profit before Contribution to WPPF		**1,027,905,087**	**237,181,357**	**1,265,086,444**	**851,243,332**
Less: Contribution to WPPF	**38**	48,947,861	11,294,350	60,242,211	40,535,397
Net Profit before Tax		**978,957,226**	**225,887,007**	**1,204,844,233**	**810,707,935**
Less: Current Tax expense	**39**	388,509,276	38,127,052	426,636,328	304,015,476
Less: Deferred Tax (Income)/Expense	**39**	(115,682,993)	-	(115,682,993)	996,665
Net Profit after Tax		**706,130,943**	**187,759,955**	**893,890,898**	**505,695,794**
Other Comprehensive Income					
Gain/(loss) on Marketable Securities (Unrealized)	**8.1**	841,041	-	841,041	-
Total Comprehensive Income for the year		**706,971,984**	**187,759,955**	**894,731,939**	**505,695,794**
Earning Per Share (on the Equity Share of Taka 10 each)	**40**			**5.65**	**4.19**

The annexed notes 1 to 54 form an integral part of the financial statements.

As per our annexed report of even date.

Sd/-
Managing Director

Sd/-
Director

Sd/-
PINAKI & COMPANY
Chartered Accountants

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Statement of Changes in Equity

For the Year Ended 30 June 2014

Continuation Sheet....

(Amount in Taka)

Particulars	Share capital	Share Premium	Capital Reserve**	Share money Deposit *	Tax Holiday Reserve	Gain/(Loss) on Marketable securities (Unrealized)	Revaluation Surplus	Retained earnings	Total
Balance as at July 01, 2012	1,160,000,000	-	40,166,723	-	-	-	4,559,559,835	849,726,331	6,609,452,889
New share issued on Premium	396,311,000	1,664,506,200	-	-	-	-	-	-	2,060,817,200
Less: Transaction cost (Detailed in Note # 19)	-	(59,439,631)	-	-	-	-	-	-	(59,439,631)
Profit for the year 2012-2013	-	-	-	-	-	-	-	505,695,794	505,695,794
Share Money deposit	-	-	-	500,000,000	-	-	-	-	500,000,000
Adjustment for Depreciation on Revalued Assets	-	-	-	-	-	-	(70,864,702)	70,864,702	-
Adjustment for Accumulated Depreciation	-	-	-	-	-	-	-	-	-
Less: Interim Cash Dividend	-	-	-	-	-	-	-	(85,350,950)	(85,350,950)
TDS on Interim Dividend	-	-	-	-	-	-	-	(13,726,800)	(13,726,800)
Balance as at June 30, 2013	**1,556,311,000**	**1,605,066,569**	**40,166,723**	**500,000,000**	**-**	**-**	**4,488,695,133**	**1,327,209,077**	**9,517,448,502**
Balance as at July 01, 2013	1,556,311,000	1,605,066,569	40,166,723	500,000,000	-	-	4,488,695,133	1,327,209,077	9,517,448,502
Addition due to Amalgamation	-	-	-	-	24,790,876	-	556,246,703	53,079,610	634,117,189
Share money deposit transferred to Long Term Loan	-	-	-	(500,000,000)	-	-	-	-	(500,000,000)
Adjustment due to disbursement of purchase consideration and resultant gain	59,706,000	-	-	-	21,038,719	-	472,506,215	283,977,778	837,228,712
Profit for the year 2013-2014	-	-	-	-	-	-	-	893,890,898	893,890,898
Tax Holiday Reserve	-	-	-	-	45,177,401	-	-	(45,177,401)	-
Dividend payable for the year 2012-13	-	-	-	-	-	-	-	(367,815,550)	(367,815,550)
Interim Cash Dividend for the year 2013-14	-	-	-	-	-	-	-	(323,203,400)	(323,203,400)
Gain/(loss) on Marketable Securities (Unrealized)	-	-	-	-	-	841,041	-	-	841,041
Adjustment of Depreciation on Revaluation	-	-	-	-	-	-	(87,077,493)	87,077,493	-
Adjustment due to disposal	-	-	-	-	-	-	(565,710)	221,500	(344,210)
Capital reserve tranferred to retained earnings	-	-	(40,166,723)	-	-	-	-	40,166,723	-
Balance as at June 30, 2014	**1,616,017,000**	**1,605,066,569**	**-**	**-**	**91,006,996**	**841,041**	**5,429,804,848**	**1,949,426,728**	**10,692,163,182**

* Represents Taka 500,000,000 sanctioned and disbursed by Investment Corporation of Bangladesh (ICB) which was initially recognized as advance against share money deposit as per the agreed terms, i.e. the Company was supposed to issue equity shares against the advances at the time of public issue initiated by the company within one year from the date of disbursement. If the Company is not able to fulfill the condition as stated above, the said advance will be derecognized as Share Money Deposit and recognized as Term loan."
Since the company has not able to comply the agreed condition as stated above, the Company during the year derecognized the amount of Share Money Deposit and recognized it as a Term loan with agreed rate of interest repayable in ten half yearly equated installments.

** Capital Reserve amounting Tk. 40,166,723 was recognized in the year 2008-09, after completion of final settlement of tax under section 82(C). In fact, it was a free reserve in nature & as such, during the year the management of the company has decided to transfer the said amount to retained earnings.

The annexed notes 1 to 54 form an integral part of the financial statements.

As per our annexed report of even date.

Sd/-
Managing Director

Sd/-
Director

Sd/-
PINAKI & COMPANY
Chartered Accountants

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Statement of Cash Flows
For the Year Ended 30 June 2014

Continuation Sheet....

PARTICULARS	TAKA	
	July '13-June '14	July '12-June '13
Cash Flows From Operating Activities:		
Collection from Sales and others	10,151,510,988	8,896,167,780
Payment to Suppliers & Others	(8,499,238,362)	(7,390,616,063)
Workers Profit Participation Fund	(41,808,175)	(33,689,072)
Cash generated from operating activities	1,610,464,451	1,471,862,645
Financial Expenses	(776,911,191)	(538,786,487)
Income Tax	(382,397,340)	(367,371,864)
Net cash generated through operating activities	**451,155,920**	**565,704,294**
Cash Flows From Investing Activities:		
Fixed Assets acqusition	(2,410,288,500)	(1,993,238,801)
Sale of Fixed Assets	721,500	-
Term Deposit	666,798,260	(1,220,000,000)
Advance to Suppliers for Construction	(40,000,000)	(134,527,355)
Investment in Shares	(5,298,280)	-
Advance to ASPL against Shares	-	(65,001,394)
Settlement of obligations of Amalgamating co. (ASPL)	(1,896,892,255)	-
Loan to ACMUNIO Int. Ltd.	(25,130,552)	(13,403,149)
Net cash used in investing activities	**(3,710,089,827)**	**(3,426,170,699)**
Cash Flows From Financing Activities:		
UNDP Grant	2,373,878	-
Share Capital	-	396,311,000
Share Money Deposit	-	500,000,000
Dividend Paid	(183,373,300)	-
Cash & Cash equivalents received from ASPL	844,137	-
Share Premium	-	1,605,066,569
Settlement of Provident Fund Liabilities	(5,193,340)	-
Net Increase / (Decrease) in Loans and Overdrafts	1,259,952,933	35,607,605
Net Increase / (Decrease) in Long Term Borrowings	2,145,111,849	610,649,098
Net cash flow from financing activities	**3,219,716,157**	**3,147,634,272**
Increase/(Decrease) in Cash and Cash Equivalents	(39,217,750)	287,167,867
Cash and Cash Equivalents at the Opening	452,650,109	165,482,242
Cash and Cash Equivalents at the Closing	**413,432,359**	**452,650,109**
Net Operating Cash Flow Per Equity Share	**2.85**	**4.69**

The annexed notes 1 to 54 form an integral part of the financial statements.

As per our annexed report of even date.

Sd/-
PINAKI & COMPANY
Chartered Accountants

Sd/-
Managing Director

Sd/-
Director

About the company

1.0 About the company

The ACME Laboratories was founded in the year 1954 as a Proprietorship Firm and it was converted into a Private Limited Company on 17th March, 1976 vide registration no. C-4745/163 of 1975-76 under the Companies Act-1913. Further, it was converted into a public limited company on 30th November 2011.

Amalgamation of "The ACME Specialized Pharmaceuticals Limited with The ACME Laboratories Limited:"

The Supreme Court of Bangladesh, High Court Division, vide its judgment dated 20.11.13 approved the scheme of amalgamation of the "The ACME Specialized Pharmaceuticals Limited" (the Transferor Company) with "The ACME Laboratories Limited" (the Transferee Company) whereby the entire undertaking of the Transferor Company as a going concern together with all the assets and liabilities relating there to be transferred to and vest in the Transferee Company.

In accordance with the Scheme of Amalgamation

- The Transferee Company issued and allotted one new ordinary share of The ACME Laboratories Limited for every five ordinary shares of Taka 10/- each held by the shares holders of the Transferor Company.
- No new ordinary shares were issued and allotted to the ACME Laboratories Limited in respect of its holding in the Transferor Company and such ordinary shares stand cancelled.
- The Board of Directors of the Transferee Company and the Transferor Company in its respective meetings held on 27.12.2013 resolved that the books of account of the Transferor Company to be closed through transferring all balances to the books of the Transferee Company by /as of 31.01.2014.
- The difference in the value of the net assets of the Transferor Company and the paid up value of the shares issued and allotted has been accounted for in the books of the Transferee Company as per the accepted accounting principles as on transfer date i.e. 31.01.2014.

  In accordance with the applicable BAS, the accounts of the Transferor Company have been amalgamated in the books of accounts of the amalgamated company as per "Predecessor Value Method" as of the transfer date.

1.1 Address of registered office and factories

The Registered office of the company is situated at 1/4, Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh and the industrial units are established at Dhulivita, Dhamrai, Dhaka, Bangladesh.

2.0 Nature of business of the company and Tax Holiday Period

The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products which includes human drugs dosages form like tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, sachet products; veterinary drugs dosages form like bolus, liquid, injection, water soluble powder, premix and herbal drugs dosages form like liquid, capsule, tablet, cream & ointment. The products of the company are sold in domestic and international markets.

The erstwhile 'The ACME Specialized Pharmaceuticals Limited' (Present Solid Dosages Unit) was engaged in manufacturing of non-penicillin & non-cephalosporin solid dosages generic pharmaceuticals formulation products including dosages form like tablet, capsule and dry syrup, liquid in hard gelatine, , sachet products and was enjoying Tax Holiday period from September 29, 2011 to September 28, 2016.

As a Consequence of the amalgamation, business of the Solid Dosages Unit has been transferred as a going concern to The ACME Laboratories Limited, however the said unit of The company would continue to enjoy the tax holiday for the remaining period i.e. from February 01, 2014 till September 28, 2016.

3.0 Share Capital

Particulars	30th June, 2014	30th June, 2013
Authorized Capital		
500,000,000 Ordinary Shares @ Tk. 10/- each	5,000,000,000	5,000,000,000
Total	**5,000,000,000**	**5,000,000,000**
Issued, Subscribed and fully paid up:		
155,631,100 Ordinary Shares @ Tk.10/- each. (As on 1st July 2012, 116,000,000 Ordinary shares @ Tk. 10 each)	1,556,311,000	1,160,000,000
Add: Issued during the year 2012-1013, 39,631,100 Ordinary Shares @Tk. 10 each.	-	396,311,000
Add: Issued during the year as purchase consideration. (5,970,600 Ordinary Shares @ Tk. 10 each.)	59,706,000	-
Total 161,601,700 (As on 30th June 2013- 155,631,100) Ordinary Shares @ Tk. 10 each	**1,616,017,000**	**1,556,311,000**

4.0 Basis of Preparation of Financial Statements

4.1 Basis of measurement

a. The financial statements have been prepared on the historical cost basis except Land, Building and Plant, Vehicle & Machinery which was revalued by an independent valuer Mashi Muhit & Co. Chartered Accountants, Dhaka, Bangladesh as on 30th June 2011 after considering the fair value of the entire class of property, plant and equipment and other fixed assets to which that assets belong to on the basis of fair market value/current cost accounting /index adjusted replacement cost methods , as applicable. Further on 31st December 2011 the company revalued newly registered land based on the valuation report of the same valuer and disclosed in note: 6.a. The financial statements however, do not take into consideration the effects of inflation. The accounting policies, unless otherwise stated, have been consistently applied by the company and are consistent with those of the previous year.

The revaluation surplus, as per prudency, is not available for distribution as dividend to the shareholders.

4.2 Statement of compliance

These financial statements have been prepared in accordance with Framework, applicable International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) as adopted by the Institute of Chartered Accountants of Bangladesh as Bangladesh Accounting Standards (BASs) and Bangladesh Financial Reporting Standards (BFRSs), Companies Act 1994 and other relevant laws and regulations applicable in Bangladesh.

4.3 Presentation of financial statements

The Financial Statements are presented in accordance with guidelines provided by BAS 1: Presentation of Financial Statements.

The Financial Statements comprise of:

i) A Statement of Financial Position as at 30th June 2014.
ii) A Statement of Comprehensive Income for the year ended 30th June 2014
iii) A Statement of Change in Equity for the year ended 30th June 2014.
iv) A Statement of Cash Flows for the year ended 30th June 2014
v) Notes, comprising a summary of significant accounting policies and explanatory information.

4.4 Reporting Period

The Financial Statements cover the accounting year commencing from 1st July 2013 to 30th June 2014.

4.5 Authorisation for Issue

The financial Statements have been authorised for issue by the board of directors in their meeting held on September 09, 2014.

4.6 Functional and presentation currency

The financial statement are prepared and presented in Bangladeshi Currency (Taka), which is the functional currency of the company. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

4.7 Comparative information

Comparative information has been disclosed is the standalone figures of the financial year 2012-2013 for all numerical information in the financial statements and also the narrative and descriptive information where ever it is relevant for understanding of the current year's financial statement.

Figures for the comparative year have been regrouped/rearranged where ever considered necessary to ensure better comparability with the current year.

4.8 Use of estimates and judgements

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the reported value of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the result of which forms the basis of making the judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. However, the estimates and underlying assumptions are reviewed on an on-going basis and the revision is recognized in the year in which the estimates are revised. No such revision however was carried out during the year under report except in the useful life of two classes of noncurrent assets. There is no material impact of change of estimates on the financial results of the company.

4.9 Going concern

The Company has adequate resources to continue in operation for foreseeable future. For this reason, the board of directors continue to adopt going concern basis in preparing the financial statements. The current credit facilities and resources of the Company provide sufficient funds to meet the present requirements of its existing businesses and operations.

4.10 Application of Bangladesh Financial Reporting Standards (BFRS)

Name of the Accounting Standards	Ref. No.	Status of Application
First-time Adoption of BFRSs	BFRS-1	Not applicable
Share-based payment	BFRS-2	Not applicable
Business Combination	BFRS-3	Applied
Insurance Contracts	BFRS-4	Not applicable
Non-current assets Held for Sales and Discontinued Operations	BFRS-5	Not applicable
Exploration for and Evaluation of Mineral Resources	BFRS-6	Not applicable
Financial Instruments : Disclosure	BFRS-7	Applied
Operating Segments	BFRS-8	Not applicable
Financial Instruments	BFRS-9	Applied
Consolidated Financial Statements	BFRS-10	Not applicable
Joint Arrangements	BFRS-11	Not applicable
Disclosure of Interests in Other Entities	BFRS-12	Not applicable
Fair Value Measurement	BFRS-13	Applied.
Regulatory Deferral Accounts	BFRS-14	Not applicable
Revenue from Contracts with Customers	BFRS-15	Not applicable
Presentation of Financial Statements	BAS-1	Applied
Inventories	BAS-2	Applied
Statement of Cash Flows	BAS-7	Applied
Accounting Policies, Changes in Accounting Estimates and Errors	BAS-8	Applied
Events after the Reporting Period	BAS-10	Applied
Construction Contacts	BAS-11	Not applicable
Income Taxes	BAS-12	Applied
Property, Plant and Equipment	BAS-16	Applied
Leases	BAS-17	Applied
Revenue Recognition	BAS-18	Applied
Employee Benefits	BAS-19	Applied
Accounting for Govt. Grants and Disclosure of Government Assistants	BAS-20	Applied
The effects of Changes in Foreign Exchange Rates	BAS-21	Applied
Borrowing Costs	BAS-23	Applied
Related Party Disclosures	BAS-24	Applied
Consolidated Financial Statements and Accounting for Investment in Subsidiary	BAS-27	Applied
Accounting for Investment in Associates	BAS-28	Not applicable
Interests in Joint Venture	BAS-31	Not applicable
Earnings Per Share	BAS-33	Applied
Provisions, Contingent Liabilities and Contingent Assets	BAS-37	Applied
Intangible Assets	BAS-38	Applied
Financial Instruments: Recognition & Measurement	BAS-39	Applied
Investment Property	BAS-40	Applied
Agriculture	BAS-41	Not applicable

5.0 Significant Accounting Policies

5.1 Revenue recognition

(a) Sales of Goods: In compliance with the requirements of BAS-18 'Revenue Recognition', revenue is recognized for local sales of Pharmaceuticals Drugs and Medicines at the time of delivery to chemists/ Institutions and Exports of Pharmaceuticals Drugs and Medicines at the time of delivery to Custom Port. i.e. when the significant risk and rewards of ownership is transferred to the buyer, whereby there is no continuing management involvement with the goods and the amount of revenue can be measured reliably.
(b) Rental income is recognized when accrued on a time proportion basis.
(c) Interest income is recognized when accrued on a time proportion basis.

5.2 Sales

Turnover comprises the invoice value of goods supplied by the Company, representing domestic and Export sales. Revenue from sales is exclusive of VAT.

5.3 Property, Plant and Equipment

i) Recognition and measurement
This has been stated at cost or revalued amount less accumulated depreciation in compliance with the requirement of BAS 16: Property Plant and Equipment. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the assets to its present locations and working conditions for its intended use inclusive of inward freight, duties and non-refundable taxes.

ii) Maintenance activities
The company incurs maintenance costs for all its major items of Property, Plant and Equipment. Repair and maintenance costs are charged as expenses as and when incurred.

iii) Depreciation
Land is held on a freehold basis and is not depreciated considering its unlimited useful life. In respect of all other fixed assets depreciation is provided on a straight line method to amortize the cost of the asset after commissioning over their expected useful life. In respect of addition to property, plant and equipment, depreciation is charged from the date of capitalisation up to the date immediately preceding the date of disposal.

The rate at which assets are depreciated per annum depending on the nature and estimated useful life of assets are given below:

Category of Assets	Rate
Building	5%
Machinery and Equipments	7.5%
Furniture and Fixtures	10%
Motor Vehicles	10%
Utilities, Engineering and Electrical Installations	7.5%
Office Equipments	20%
Books and Periodicals	10%

iv) Retirement and Disposal
On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is recognized in the Statement of Comprehensive Income, which is determined with reference to the net book value of the assets and net sales proceeds.

5.4 Intangible assets

Intangible assets are stated at cost less provision for amortization and impairments. The cost of acquiring and developing computer software for internal use and internet sites for external use are capitalized as intangible fixed assets where the software or site support a significant business system and the expenditure lead to the creation of a durable asset.
Amortization is recognized in Statement of Comprehensive Income under the head of Administrative Expenses on a straight line basis @ 7.5% over the estimated useful lives of intangible assets, from the date that they are available for use.

5.5 Leased assets

In compliance with BAS 17: "Leases", Lease in terms of which the company assumes substantially all the risks and rewards of ownership are classified as finance leases and all other leases are classified as operating lease.

Upon initial recognition, the lease assets is measured at an amount equal to the lower of its fair value and the present value of the minimum lease payment. Subsequent to initial recognition, the assets is accounted for in accordance with accounting policy applicable to the assets.

Though there are financing in the name of lease financing however, as per the substance of the agreement, these financing are not in the nature of lease financing, hence has been grouped as 'Long Term Loan' and its current maturity as 'Current Maturity of Long Term Loans'.

5.6 Financial instruments

A financial instrument is any contract that gives rise to financial assets and a financial liability or equity instrument of another entity.

i) Financial assets
Financial assets of the company include cash and cash equivalents, accounts receivable, other receivables and equity instrument of another entity. The company initially recognized receivable on the date they are originated. All other financial assets are recognized initially on the date at which the company becomes a party to the contractual provision of the transaction. The company derecognizes a financial asset when, and only when the contractual rights or probabilities of receiving the cash flow from the assets expire or it transfer the right to receive the contractual cash flows on the financial assets in a transaction in which substantially all the risk and rewards of ownership of the financial assets are transferred.

Trade Receivable
Trade receivable are created at original invoice amount less any provisions for doubtful debts. Provision is made where there is evidence of a risk of non-payments, taking into consideration aging, previous experience and general economic conditions. When a trade receivable is determined to be uncollected, it is written off firstly against any provision available and then to the Statement of Comprehensive Income. Subsequent recoveries of amounts previously provided for and/or written off are credited to the Statement of Comprehensive Income. During the year under audit, the company has no uncollectable trade receivable to be written off and for which it created any provision.

Cash and cash equivalents
Cash and cash equivalents are comprised of cash in hand and cash at bank that are readily convertible to known amount of cash and that are subject to an insignificant risk of change in value.

ii) Financial Liability
Financial liabilities are recognized initially on the transaction date at which the company becomes a party to the contractual provisions of the liability. The company derecognises the financial liabilities when its contractual obligations are discharged or cancelled or expired. Financial liabilities includes payable for expense, liability for capital expenditure and other current liabilities.

5.7 Impairment

i) Financial assets

Accounts receivable and others receivables are assessed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flow of that asset, that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indicates that a debtor or issuer will enter bankruptcy etc.

ii) Non-Financial assets

An asset is impaired when its carrying amount exceeds its recoverable amount. The company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exits, the company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less cost to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount by recognizing an impaired loss if, and only if, the recoverable amount of the assets is lesser than its carrying amount. Impaired loss is recognized immediately in Statement of Comprehensive Income unless the asset is carried at revalued amount. Any impaired loss of a revalued asset shall be treated as a revaluation decrease.

5.8 Investment in shares

Though there is no exempted taxable income of the Tax Holiday unit, however, the company used to invest on estimated basis for purchasing shares of listed companies through stock exchange. The investments are recognized at cost including transaction cost. Further, the entity has presented the subsequent changes in other comprehensive income.

5.9 Inventories

Inventories are carried at the lower of cost and net realizable value as prescribed by BAS 2: 'Inventories'. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present location and condition. Cost of material consumption is determined on first in first out basis. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sales.

Type of Stock	Basis of Valuation
Raw Materials	At cost on First in First Out basis
Packing Materials	At cost on First in First Out basis
Work-in-Process	At cost
Finished Goods	At lower of cost or net realizable value
Printing Stationary	At cost on First in First Out basis
Spare & Accessories	At cost on First in First Out basis

5.10 Provisions

Provisions and accrued expenses are recognized in the financial statements in line with the Bangladesh Accounting Standard (BAS) 37 "Provisions, Contingent Liabilities and Contingent Assets" when:

- The company has a legal or constructive obligation as a result of past events.
- It is probable that an outflow of economic benefit will be required to settle the obligations.
- A reliable estimate can be made of the amount of the obligations.

5.11 Income tax expense

Income tax expense comprised of current and deferred tax. Income tax expense is recognized in the statement of Comprehensive Income and accounted for in accordance with requirement of BAS 12: Income Taxes.

Current tax
Current tax is the expected tax payable on the taxable income for the period/year and any adjustment to tax payable in respect of previous years.

Deferred tax
The company has recognized deferred tax using balance sheet method in compliance with the provision of BAS 12: Income Taxes. The policy of recognition of deferred tax assets/liabilities is based on temporary differences (taxable or deductible) between the carrying amount (Book Value) of assets and liabilities for financial reporting purpose and its tax base, and accordingly, deferred tax income or expense has been considered to determine net profit after tax and Earnings per Share (EPS).

5.12 Loans – Long Term and Short Term from Banks, Financial Institutions and Others.

i) Borrowing cost
Interest and other cost incurred by the company in connection with the Borrowings of fund are recognized as expenses in the year in which they are incurred unless such borrowing cost related to acquisition/ construction of assets in progress that are capitalized as per BAS 23: 'Borrowing costs'.

ii) Charges on the Assets of the Company
There are Fixed and Floating charges over:

- All the Plant, Machinery and Equipments (both present and future) ;

- Floating assets (both present and future) including but not limited to book debts , bills receivable , goodwill and other floating assets both tangible and intangible and all documents title , undertakings, contracts ,engagements securities and other documents whatsoever related to such assets of the Company in favour of various bankers securing the various kinds of loans taken by the company from them through a pari-passu agreement dated 23.04.2014 amongst the bankers for sharing the security. The names of the participating bankers in the charges through pari-passu agreement are stated here under:

- Agrani Bank Limited.
- The Hongkong and Shanghai Banking Corporation Limited.
- Standard Chartered Bank.
- Dutch Bangla Bank Limited.
- Dhaka Bank Limited.
- Trust Bank Limited.

5.13 UNDP Grant

UNDP Grant has been credited out of the grant received from UNDP to finance acquisition of HPF based Metered Dose Inhaler Production Machinery for the ACME Laboratories Ltd. As per decision of the Board of Directors, grant is subject to set off against the book value of Production Machinery by deducting the grant from the asset's carrying amount following the principle of BAS 20: Accounting for Government Grants and Disclosure of Government Assistance.

5.14 Employee benefits

The company maintains defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective agreements/trust deeds.

The company has accounted for and disclosed employee benefits in compliance with the provision of BAS19: 'Employee Benefits'.

The cost of employee benefit is charged off as revenue expenditure in the year to which the contributions relate.

The company's employee benefits include the following:

i) Defined Contribution Plan (Provident Fund)
The company got recognition from Commissioner of Taxes its provident fund scheme (Defined Contribution Plan) vide order no.: নথি নং পি,এফ অনুমোদন/৩২/ক:অ:-৩/২০১০-২০১১, তারিখ: ২৩/০৩/২০১১ Bs for employees of the company eligible to be members of the fund in accordance with the rules of the provident fund constituted under an irrevocable trust. All permanent employees contribute to the provident fund and the company also makes equal contribution.

The company recognizes contribution to defined contribution plan as an expense when an employee has rendered services in exchange for such contribution. The legal and constructive obligation is limited to the amount it agrees to contribute to the fund.

ii) Defined Benefit Plan (Gratuity)
The Company has formulated a policy related to "Payment of Gratuity "payable to its eligible Permanent Employees who are serving the company for a considerable duration, at the time of severance of their relationship from the Company. Eligibility for getting the said Benefit mainly depends upon the length of service with the organization subject to compliance of the eligibility criteria as prescribed by the management in the policy and accordingly the company has made necessary provision (non funded) in the books of accounts.

iii) Short-term employee Benefits
Short-term employee benefits include salaries, bonuses etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

iv) Contribution to Worker's Profit Participation Fund (WPPF)
This represents 5% of net profit before tax and before charging the contribution to WPPF by the company as per provisions of the Bangladesh Labor Law, 2006 and is payable to beneficiary as defined in the said law.

v) Insurance Schemes
Employees of the company are covered under group hospitalization and group term life insurance including accidental benefits. Summary of the plans are stated here under:

A. Group Hospitalization Insurance Plan

In this scheme, the company covers its employees under hospitalization and other medical expenses related with hospitalization of the employees from salary Grade K and above. The hospitalization benefits are provided to employees as per three tier system and each tier of benefits covering from different group of employees based on salary grade in the company. The company pay annual premium to the insurance company for this cover of their employees.

B. Group Term Life Insurance Including Accidental Death Benefit:

In this policy, all the permanent and salaried employees of the company are covered. If an insured employee dies irrespective of the cause of death, insurance company upon receipt of written proof pays to the employer the sum insured in respect of that employee as per the terms of the contract between the insurance company and the employer.

In respect of Fourth class (i.e. Driver, Peon, Cleaner, Guard, Electrician, Loader, Packing Man, Worker and Helper etc.) married employees, if he leaves behind not more than two children then additional sum equivalent to 15% of sum insured is being paid to them.

Employee Position

During the year there were 6,711 employees employed in the company with remuneration above Tk. 3,000 per month, among them 4,306 employees employed for the full year and remaining 2,405 employees employed less than full year.

5.15 Investment Property

For Investment Property, the company follows fair value model as subsequent measurement. A gain or loss arising from a change in the fair value of investment property is recognized in Statement of Comprehensive Income for the year in which it arises.

5.16 Share Premium

As per BAS-32, Para-37, an entity typically incurs various costs in issuing or acquiring its own equity instruments. Those costs might include registration and other regulatory fees amounts paid to legal, accounting and other professional advisers, printing costs and stamp duties. The transaction costs of an equity transaction are accounted for as a deduction from equity (net of any related income tax benefit) to the extent they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided. The costs of an equity transaction that is abandoned are recognized as an expense.

The company shows share premium account balance after netting off relevant transaction costs. The balance in share premium account shall be utilized in accordance with provisions of Section 57(2) the Companies Act 1994 and as directed by the Bangladesh Securities and Exchange Commission in this respect.

5.17 Research Development and Experimental Cost:

In compliance with the requirements of BAS-38 "Intangible Assets", research, development and experimental costs are usually absorbed as revenue charges to the Statement of Comprehensive Income as and when incurred, as being not that much material in the company's and /local context.

5.18 Earnings per Share (EPS)

This has been calculated in compliance with the requirement of BAS 33: Earnings per Share, by dividing the basic earnings by the weighted average number of ordinary shares outstanding during the year.

Basic Earnings per Share (Numerator/Denominator)

Earnings (Numerator)

This represents earning for the year attributable to ordinary shareholders.

No. of Ordinary shares (Denominator)

This represents weighted average number of ordinary share outstanding during the year.

Diluted Earnings per Share

As per the existing conditions of the loans taken by the company from various financial institutions or other contracts with various parties including employees, there is no condition related to conversion or stipulation related to share based payments for material and services supplied by them to the company. Hence, the Diluted EPS of the company is same as Basic EPS.

5.19 Foreign Currency Transactions

Foreign currency transactions are recorded at the applicable rate of exchange ruling at the transaction date. The monetary assets and liabilities, if any denominated in foreign currencies at the financial position date are translated at the applicable rate of exchanges ruling at that date. Exchange differences are accounted as expenditure/income in compliance with the provision of BSA 21: The Effects of Changes in Foreign Exchange Rates.

5.20 Directors' Responsibility Statement

The Board of Directors takes the responsibility for the preparation and presentation of these financial Statements.

5.21 Corporate Social Responsibility (CSR)

In continuation of benevolent activities like helping poor meritorious students of their studies and assisting needy poorer section of people in availing livelihood since inception of the company and also donating lump sum amount of money to the Salvation For the Deserving (SFD), an NGO registered under the Societies Act since 2003. The company has this year decided to extend these activities in a form of Corporate Social Responsibility in collaboration with project SDC (A Samriddhi Project implement by HELVETAS Swiss Intercooperation) and would allocate funds for the purpose under the head Corporate Social Responsibility (CSR).

5.22 Segmental Reporting

As required by BFRS – 8 'Operating Segments', if an entity operates and engages in different economic environments and activities then the entity has to disclose information, to enable users of its financial statements to evaluate the nature and financial effects of the business so carried out.

The company consider the operation on aggregate basis and manage the operations as a single operating segment. Hence it is felt that such segment reporting is not required to be disclosed.

5.23 Contingent Liabilities and Contingents Assets

Contingent liabilities and assets are present or possible obligations or on liabilities or assets, arising from past events and existence of which depends upon the occurrence or non-occurrence of one or more uncertain future events which are not within the control of the company or which amount of the obligations cannot be measured with sufficient reliability. In accordance with BAS-37, they are disclosed in the note # 48 hereunder.

5.24 Statement of Cash Flows

Statement of Cash Flows has been prepared in accordance with BAS-7 'Statement of Cash Flows' by using direct method.

5.25 Risk Management

Operational Risk

ACME relies on suppliers for ingredients and various third parties for certain manufacturing-related services to produce material that meets appropriate content, quality and stability standards of the company products and, after approval it is being released for commercial distribution. ACME may not be able to produce its drug substance or drug product to appropriate standards without the required supports from its suppliers and vendors. Again if it fails to maintain important manufacturing and service relationships, may not find a replacement supplier or required vendor or develop company's own capabilities which could delay or impair company's ability to obtain regulatory approval for its products and substantially increase company's costs or deplete profit margins, if any.

Management Perception

ACME has a good number of vendors and for each and every ingredients and services, the company have more than one approved vendors. It uses to conduct vendor audit and its concerned professionals are very conscious regarding the vendor issue. Further, none of the supplier accounts for significant amount of total purchases.

Industry Risks

The pharmaceutical industry has witnessed challenges such as intellectual property rights, a historic fuel price peak, and material cost increase across the globe. It stands as one of the most challenging and dynamic industries to operate as on date. Fortunately, Bangladesh is only least developed country who demonstrates significant competencies in pharmaceuticals industry and it requires huge medicine for its present 160

million (approx.) population and requires huge quantity of medicine. As such, local pharmaceutical industry is not in a trouble, rather the said industry has ample opportunities to grow.

Management Perception

As the per capita income and per person consumption of medicine is increasing over the years, management is optimistic about growth opportunities of pharmaceutical industry in Bangladesh. The company is trying to adopt sophisticated state of art manufacturing facilities and making efforts to catch the opportunity of regulated global market.

Market Risks

Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the Company. Mostly, the risk arises from falling demand for the pharmaceutical products which would harm the performance of the Company. On the other hand, strong marketing and brand management would help the Company increase their customer base.

Management Perception

The products of pharmaceuticals industry are of basic nature and have a wide market as they are giving a good market share to The ACME Laboratories Limited at present. Hence, it will hardly be the case that there will be a lack of demand for the products. Moreover, as explained earlier, the pharmaceuticals industry is only increasing year-on-year and ACME is following fool-proof scientific integrated marketing policy. Hence, has marginal probability for shrinkage.

Currency risk

Exchange rate risk occurs due to changes in foreign currency exchange rates. As the Company has taken foreign currency loan, imports major raw materials and some packing materials from abroad and earns most of the revenue in local currency, unfavourable volatility or fluctuation may affect the profitability of the Company. On the other hand, if exchange rate decreased against local currency opportunity will be created for generating more profit.

Management Perception

ACME earns some of its revenue in US dollars, thereby creating to built-up hedging scopes. Besides, in case of significant BDT devaluation in order to keep the cost to minimum, appropriate and responsible hedging mechanisms may be applied. However, if the price of the US dollar appreciates too sharply against the BDT, this will be a nationwide phenomenon experienced by the entire industry. In such a scenario, there will be a market adjustment in end product prices, subject to approval of concerned authority.

Interest rate risk

Interest rate risk is the risk that Company faces due to unfavourable movement in the interest rates. Changes in the government's monetary policy, along with increased demand for loans/investments tend to increase the interest rates. Such rises in interest rates mostly affect Companies having floating rate loans or Companies investing in debt securities.

Management Perception

In order to manage this risk and overcome it, the Company shall exercise prudence in its cash flow management, supported by continued strength in sales and marketing. ACME is very careful in forecasting the prices of raw materials and manages its costs in an effective manner. To maintain effective rate of return ACME also follow knowledge and information based products mix, so as to ensure that the debt repayments are met on schedule, even if the interest rates were to rise.

Technology Related Risks Potential

Pharmaceutical industry is dynamic nature and heavily driven by technology. Hence, technology always plays a vital role here. Adaptation of better technology can help to gain remarkable competencies that certainly create competitive advantages like increase productivity; reduce costs, better perception of customers. Firms are exposed to technology risks when there are better technologies available in the market than the one used by the Company which may cause operational inefficiency.

Management Perception

As one of the leading pharmaceutical firm of the country, there are clear intent regarding adaptation of technology here and the management is aware of technological changes and always trying to adopt new technology according to its needs. Furthermore, routine and proper maintenance of the equipment carried out by the Company ensures longer service life for the existing equipment and facilities. Finally, ACME is committed to hold its leading edge and maintaining quality and brand image.

Potential or Existing Government Regulations

The Company operates under the Drugs Ordinance 1982, Companies Act 1994, Directorate General of Drug Administration (DGDA) Regulations, Income Tax Ordinance 1984, Income Tax Rules 1984, Customs Act 1969, Value Added Tax (VAT) Act 1991, Value Added Tax (VAT) Rules 1991 and other rules and regulations of the country. Any abrupt changes of the policies made by the regulatory authorities may adversely affect the business of the Company.

Management Perception

Since product of pharmaceuticals industry is essential one for lives and it is an import substitute industry and value addition is remarkable, we see the government regulations are mostly investment friendly for this sector particularly. As ACME is one of the top ranking pharmaceutical companies of the country, it is doing business following all the rules and regulations. Change in regulations will bring changed strategies for doing the business by the dynamic management of the Company. Besides this, many of the patented drugs/molecules will be off patented and it will be an opportunity for the manufacturer to freely manufacture and distribute without any restriction.

Potential Changes in Global and National Policies

Changes of Government policies may affect business. 49 LDCs including Bangladesh are not required to provide patent protection, give exclusive marketing rights to companies with patented products or comply with the "mailbox" program – create a process to receive complaints about pharmaceutical product patent right violations until 2016. While it is possible that the deadline may be extended, its implementation in 2016 will have significant impact on the LDC who have not implemented the TRIPS standards.

Management Perception

Pharmaceuticals, over the years have been proved as a thrust sector for the country growing at a considerable pace each year. Bangladesh, through its international affiliates and other 48 LDCs shall definitely lobby for extension of this deadline. In addition, ACME is continuously trying to adopt right technology and build infrastructure to meet TRIPS standards.

Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge on obligation. Credit risk information helps users of financial statements asses the credit quality of the entity's financial assets and level and sources of impairment loss. Management has a credit policy in place and exposure to credit risk is monitored on an on-going basis. As at 3oth June 2014 substantial part of

the receivables are subject to insignificant credit risk. Risk exposures from other financial assets i.e. Cash at bank and other external receivables are nominal.

Management Perception

To mitigate the credit risk the management of the company follows robust credit control and collections policies. The company has dedicated credit collections team.

Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure as far as possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses including financial obligations through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient fund to make the expected payment within due date. In extreme stressed conditions the company may get support from the related company in the form of short term financing.

Management Perception

Effective liquidity risk management requires both a top-down and a bottom-up approach. Strategy, principles and objectives are set at board and management levels. ACME conducts liquidity management in a manner that maintains stability and flexibility in day-to-day funding activities. Our liquidity risk management starts by managing daily payment of cheques, daily cash inflow and outflow, maturity of deposits and our access to other funding sources as and when required.

5.26 General Comments & Observations

a) Previous year's figures have been regrouped/reclassified wherever considered necessary to confirm to current year's presentation. Figures have been rounded off to the nearest taka, as the currency represented in this financial statement.
b) All shares have been fully called and paid up.
c) The company has not incurred any expenditure in foreign currency against royalties and technical fees.
d) No foreign exchange remitted to the relevant shareholders during the year under audit.
e) No amount of money was expended by the company for compensating any members of the Board for special service rendered.
f) No brokerage was paid against sales during the year under audit.
g) There was no bank guarantee issued by the company on behalf of directors.

Property, Plant and Equipment * - Schedule A

Amount in Taka

Particulars of Assets	Historical Cost as on 01.07.13	Addition due to Amalgamation (Cost)	Revaluation Surplus as on 01.07.13	Addition due to Amalgamation (Revaluation)	Addition During the period (Cost)	Disposal		Machinery in transit/CWIP Adjustment	Total as on 30.06.14	Rate	DEPRECIATION								Written Down value as on 30.06.2014
						Cost	Revaluation				Accumulated Dep. As on 01.07.13 on Cost	Accumulated Dep. Addition due to Amalgamation on Cost	Accumulated Dep. as on 01.07.13 on Revaluation	Accumulated Dep. Addition due to Amalgamation on Revaluation	Depriciation on Revaluation during the year	Depriciation on Historical Cost during the year	Disposal: Accumulated Dep. on Cost	Disposal: Accumulated dep. On Revaluation	Total as on 30.06.14	
Land and land development	246,147,536	127,182,498	3,269,552,965	354,317,502	32,594,660	-	-	-	4,029,795,161		-				-	-	-	-	-	4,029,795,161
Building	787,477,166	583,040,866	1,283,930,984	669,757,666	1,182,377,834	-	-	-	4,506,584,516	5%	199,370,168	68,021,435	128,393,098	53,022,482	78,149,831	54,641,924	-	-	581,598,938	3,924,985,578
Machinary & Equipment	576,887,575	485,516,206	8,404,561	35,197,788	1,303,525,162	-	-	-	2,409,531,292	7.5%	256,414,876	110,747,547	1,260,682	5,572,983	1,730,270	59,634,337	-	-	435,360,695	1,974,170,597
Furniture & Fixture	144,693,055	46,060,190	-	-	24,671,398	-	-	-	215,424,643	10%	78,334,872	19,307,369			-	16,055,670	-	-	113,697,911	101,726,732
Motor Vehicle	357,116,498	14,298,862	35,904,337	1,584,829	39,565,425	(1,933,338)	(720,000)		445,816,613	10%	176,033,260	6,112,802	7,180,670	501,863	3,659,689	33,476,406	(1,247,694)	(154,290)	225,562,706	220,253,907
Utilities,Electrical Installation & Eng.	371,231,640	784,170,975	32,085,001	31,234,577	271,300,626	-	-	-	1,490,022,819	7.5%	176,645,134	180,304,653	4,812,952	4,945,475	3,382,454	52,016,316	-	-	422,106,984	1,067,915,835
Office Equipment	61,293,121	8,895,971	546,689	1,029,304	6,413,593	-	-	-	78,178,678	20%	25,451,772	3,593,999	82,002	325,946	155,249	8,290,355	-	-	37,899,323	40,279,355
Books and Periodicals	3,977,901	807,499	-	-	508,257	-	-		5,293,657	10%	2,433,416	392,667	-	-	-	436,001	-	-	3,262,084	2,031,573
Sub Total	**2,548,824,492**	**2,049,973,067**	**4,630,424,537**	**1,093,121,666**	**2,860,956,955**	**(1,933,338)**	**(720,000)**	**-**	**13,180,647,379**		**914,683,498**	**388,480,472**	**141,729,404**	**64,368,749**	**87,077,493**	**224,551,009**	**(1,247,694)**	**(154,290)**	**1,819,488,641**	**11,361,158,738**
Machinery In Transit	294,065,336	1,963,808,654	-	-	748,744,861	-	-	(1,566,238,286)	1,440,380,565		-	-	-	-	-	-	-	-	-	1,440,380,565
Construction work in progress	1,889,309,216	309,986,928	-	-	1,706,653,327	-	-	(1,195,591,688)	2,710,357,783		-	-	-	-	-	-	-	-	-	2,710,357,783
Sub Total	**2,183,374,552**	**2,273,795,582**	**-**	**-**	**2,455,398,188**	**-**	**-**	**(2,761,829,974)**	**4,150,738,348**		**-**				**-**	**-**	**-**	**-**	**-**	**4,150,738,348**
Total Taka :-	**4,732,199,044**	**4,323,768,649**	**4,630,424,537**	**1,093,121,666**	**5,316,355,143**	**(1,933,338)**	**(720,000)**	**(2,761,829,974)**	**17,331,385,727**		**914,683,498**	**388,480,472**	**141,729,404**	**64,368,749**	**87,077,493**	**224,551,009**	**(1,247,694)**	**(154,290)**	**1,819,488,641**	**15,511,897,086**
Previous year	**2,813,812,841**	**-**	**4,630,424,537**	**-**	**2,016,107,915**	**(14,356,639)**	**-**	**(83,365,072)**	**9,362,623,582**		**758,634,925**	**-**	**70,864,072**	**-**	**70,864,702**	**157,415,461**	**(1,366,256)**	**-**	**1,056,412,904**	**8,306,210,678**

* Refer note # 5.12 regarding creation of charges in favour of bankers as per syndication agreement.

ALLOCATION OF DEPRECIATION:		**On Cost**	**On Revaluation**	**Total**
Factory Overhead	48%	107,784,484	41,797,197	149,581,681
Selling & Distribution Expenses	28%	62,874,283	24,381,698	87,255,981
Administrative Expenses	24%	53,892,242	20,898,598	74,790,840
		224,551,009	**87,077,493**	**311,628,502**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013

6 Property Plant and Equipment: Tk. 15,511,897,086

Details of Property, Plant and Equipment and Depreciation as at June 30, 2014 are shown in the annexed Schedule - A. This is arrived at as follows:

	14,372,322,836	4,829,920,756
Opening Balance (At Cost)	4,732,199,044	2,813,812,841
Add:		
Addition of cost due to Amalgamation	4,323,768,649	-
Addition of cost during the year	5,316,355,143	2,016,107,915
	5,723,546,203	4,630,424,537
Opening Balance (Revaluation)	4,630,424,537	4,630,424,537
Add: Addition due to amalgamation	1,093,121,666	-
Less: Adjustment of CIP and Machinery in transit	(2,761,829,974)	-
Less: Disposal/Adjustment	(2,653,338)	(97,721,711)
	(2,764,483,312)	(97,721,711)
Closing balance	17,331,385,727	9,362,623,582
Less: Accumulated Depreciation	1,819,488,641	1,056,412,904
Opening balance	1,056,412,902	829,498,997
Addition due to amalgamation	452,849,221	-
Depreciation charged during the year	311,628,502	228,280,163
Adjustment due to Disposal	(1,401,984)	(1,366,256)
Carrying Value	**15,511,897,086**	**8,306,210,678**

Allocation of depreciation charge for the year has been made in the accounts as follows:

Factory Overhead	149,581,681	108,743,848
Selling and Distribution Expenses	87,255,981	64,076,563
Administrative Expenses	74,790,840	55,459,752
Total	**311,628,502**	**228,280,163**

6.a Revaluation Surplus: Tk. 5,429,804,848

Mashi Muhit Haque & Co. Chartered Accountants, Dhaka, Bangladesh the valuer revalued the Land, Building, Machinary & Equipment and Motor Vehicle of the Company as at 30 June 2011 at " Current Cost Method". Further on 31st December 2011 the company revalued newly registered land based on the valuation report of the same valuer. Due to these revaluation, a revaluation surplus aggregating Tk.4,630,818,104 has arisen. Current balance is shown below:

Revaluation surplus	5,722,826,203	4,630,424,537
- Opening Balance	4,630,424,537	4,630,424,537
Add :		
Addition of revulation due to amalgamation	1,093,121,666	-
Adjustment of revaluation due to disposal	(720,000)	-
Less: Accumulated depreciation on revaluation	293,021,355	141,729,404
- Opening Balance	141,729,404	70,864,702
-Addition due to amalgamation	64,368,749	-
- Charged during the year	87,077,492	70,864,702
- Adjustment due to disposal	(154,290)	-
	5,429,804,848	**4,488,695,133**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars		Taka	
			As at 30-06-2014	As at 30-06-2013
7	**Intangible Assets :Tk. 286,875**			
	This amount consists of as follows:			
	Application Software	(Details in note # 7.1)	940,285	940,285
	Less: Amortization		653,410	602,153
	Accumulated balance		602,153	531,632
	During the year		51,257	70,521
			286,875	**338,132**

7.1 Application Software: Tk. 286,875

Details have been given below :

Year of Acquisition	Amount (Tk.)	Rate of write Off	Total Write off		Closing Balance
			Opening balance	During the year	
2000-01	385,285	7.50%	375,653	9,632	-
2007-08	400,000	7.50%	180,000	30,000	190,000
2009-10	155,000	7.50%	46,500	11,625	96,875
Total	**940,285**		**602,153**	**51,257**	**286,875**

8 Investment in Shares: Tk. 6,139,321

This represents investment in share capital of erstwhile The ACME Specialized Pharmaceuticals Ltd. (ASPL) and other public limited companies.

Investment in ASPL shares *		-	351,467,400
Other Public Limited Co.'s securities	(note # 8.1)	6,139,321	-
		6,139,321	**351,467,400**

* As per scheme of amalgamation of ASPL with the company, the holding of the transferee company in ASPL stands cancelled.

8.1 Other Public Limited Co's Securities

Particulars	No. of shares hold	FV	Average cost per unit	Total cost	Market Price as on 30.06.2014	Unrealized gain/(loss) as on 30.06.2014
AB Bank	20000	10	26.12	522,446	508,000	(14,446)
Eastern Bank Limited	20000	10	29.17	583,480	576,000	(7,480)
Pioneer Insurance	21000	10	50.00	1,050,013	1,047,900	(2,113)
Southeast Bank	25000	10	20.18	504,509	487,500	(17,009)
EXIM Bank	25000	10	10.26	256,530	252,500	(4,030)
BRAC Bank	28000	10	27.00	755,908	736,400	(19,508)
Trust Bank	25000	10	14.60	365,027	370,000	4,973
Delta Brac Housing	20000	10	63.02	1,260,367	1,240,000	(20,367)
Square Pharma	3203	10	0.00	-	903,887	903,887
Square Textile	199	10	0.00	-	17,134	17,134
				5,298,280	**6,139,321**	**841,041**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013

9 Investment Property : Tk. 2,61,85,000

The comapany has an Investment Property (Building) which have been rented to ACMUNIO International Ltd. As per BAS-40: Investment Property, the company is following fair value model as subsequent measurement and any gain or loss arising from a change in fair value of Investment Property is recognized in Statement of Comprehensive Income for the year in which it arises.

The details are hereunder:

Opening balance	26,185,000	26,185,000
Add/Less: Changes in fair value	-	-
Closing Balance	**26,185,000**	**26,185,000**

10 Inventories: Tk. 2,223,003,434

This consists of as follows:

Raw Materials	824,926,270	694,987,665
Packing Materials	545,143,710	404,785,640
Work-in-Process	375,336,272	356,784,193
Finished Goods	375,693,869	332,745,359
Printing Stationary	18,866,704	21,700,383
Spare & Accessories	83,036,609	75,263,811
Total	**2,223,003,434**	**1,886,267,051**

Refer note # 5.12 regarding creation of charges in favour of bankers as per syndication agreement.

11 Trade Receivable : Tk. 644,867,067

The accounts receivable both domestic and exports occurred in the ordinary course of business are unsecured but considred good by the management. The above accounts receivable is as follows:

Domestic	574,255,442	396,956,360
Exports	70,338,597	74,307,328
	644,594,038	471,263,688
Foreign exchange Unrealised Gain/(Loss)	273,029	(242,501)
	644,867,067	**471,021,187**

There was no amounts due from the directors (Including Managing Director, Managing Agent, Manager and other Officers of the Company) and any of them severally or jointly with any other person (s).

Refer note # 5.12 regarding creation of charges in favour of bankers as per syndication agreement.

11.1 Trade Receivable: Tk. 644,867,067

Ageing of the above receivables are given below:

	Upto 6 Months	Above 6 Months	Total	
Domestic	574,255,442	-	574,255,442	396,956,360
Exports	70,338,597	-	70,338,597	74,307,328
			644,594,038	471,263,688
Foreign exchange Unrealised Gain/(Loss)			273,029	(242,501)
			644,867,067	**471,021,187**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013
12	**Other Receivable: Tk. 74,526,105**		
	(Unsecured but considered good)		
	This consists of as follows:		
	Rent on Investment Property	32,310,000	25,848,000
	Sinha Printers Ltd. against Goods and Services	37,257,581	36,928,465
	Interest Receivable on FDRs	4,958,524	13,291,250
		74,526,105	**76,067,715**
13	**Advances, Deposits and Prepayment : Tk 1,097,408,239**		
	The followings items are unsecured but considered as good and this consists of as follows :		
	Advances:		
	Advances against salary	57,757,291	42,806,736
	Motor Cycle advance to employees	238,546,633	245,970,768
	Employee advances (Others)	48,503,038	-
	Advance to ASPL against Shares	-	1,307,802,898
	ACMUNIO Int. Ltd.	120,343,583	95,213,031
	Advance to Suppliers	116,607,407	55,225,110
	Advance to Suppliers for Construction	324,584,985	284,584,985
	Advance against Land	95,250,000	217,084,401
	Others	7,733,061	-
	Deposit :		
	Security deposit and earnest money	11,673,501	12,573,531
	Lease Deposit	4,780,055	21,497,806
	Presumptive Tax on Share Premium	13,064,814	13,064,814
	Bank Guarantee/LC Margin	11,604,600	-
	Advance VAT	30,733,050	31,392,912
	Others	4,710,353	13,176,010
	Prepayments :		
	Office Rent	5,429,450	5,149,433
	Insurance	6,086,418	2,151,836
		1,097,408,239	**2,347,694,271**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013
14	**Advance Income Tax: Tk 1,334,147,374**		
	The breakup of the above amount is as under		
	Opening Balance as per last A/C	1,273,276,904	905,905,040
	Less: Adjsutment of Current Tax Provision against Advance Income Tax		
	- For the assessment year 2011-2012	(218,905,630)	-
	- For the assessment year 2010-2011	(136,683,926)	-
	Payment during the year:		
	AIT collected by customs Authority	95,433,002	58,514,240
	AIT collected by Bank from export bills	1,948,536	1,844,291
	AIT deducted against supply of medicine	9,809,089	9,582,469
	AIT collected by BRTA Authority	2,676,500	2,559,500
	AIT deducted on bank Interest on FDRs	10,543,922	195,231
	Paid by pay order:		
	for the assessment year 2012-13	-	154,422,433
	for the assessment year 2013-14	91,066,045	140,253,700
	for the assessment year 2014-15	170,920,246	-
	Addition of advance Income Tax due to amalgamation	34,062,686	-
		1,334,147,374	**1,273,276,904**
15	**Material in Transit: Tk. 294,476,484**		
	Raw Materials	254,312,276	123,320,205
	Packing Materials	20,008,993	34,616,319
	Spare Parts	20,155,215	4,529,073
		294,476,484	**162,465,596**
16	**Term Deposit: Tk. 553,201,740**		
	As a part of efficient treasury management, the comapany have made some short term deposits with various Commercial Banks which are stated below:		
	Trust Bank Limited	387,365,775	350,000,000
	Dhaka Bank Limited	165,835,965	150,000,000
	Delta Brac Housing	-	200,000,000
	Investment Corporation of Bangladesh (ICB)	-	500,000,000
	Bank Asia Limited	-	20,000,000
		553,201,740	**1,220,000,000**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013
17	**Cash and Cash Equivalents: Tk. 413,432,359**		
	This is made up as follows :		
	Cash in Hand	296,664,128	224,784,484
	Cash at Bank :		
	Agrani Bank, Ramna Branch, STD A/C	15,403,313	9,742,391
	Agrani Bank, Dhamrai Branch, C/D A/C	1,469,840	128,685
	Dhaka Bank Ltd, Dhanmondi Br. A/C No 2051001807	209,529	456,652
	National Bank Ltd, Dhanmondi Br. CD A/C	349,591	1,677,701
	Uttara Bank Ltd, Satmosjid Road Br. CD A/C	22,012,108	15,816,212
	Marcantile Bank Ltd, Hemaetpur Br. CD A/C	32,130,061	43,948,898
	Agrani Bank ,Ramna Br. F/C A/C	(4,069,819)	(1,525,723)
	SCB F/C A/C, HO	2,457,628	1,726,081
	Commercial Bank of Ceylon	-	18,786
	Sonali Bank, Local office	246,197	1,761,332
	Islami Bank,Shymoli Br.	-	48,481
	NCCBL, Shymoli Br.	1,349,336	(449,391)
	EBL C/D A/C, Gulshan Branch	9,958,746	6,525,192
	Dutch Bangla Bank, Barisal Br.	280,043	6,223
	Sonali Bank, Kallayanpur Br.	111,565	83,065
	Dutch Bangla Bank, Rajshahi Br.	187,009	203,837
	Dutch Bangla Bank, Jessore Br.	245,793	506,837
	Dutch Bangla Bank, Khulna Br.	541,232	265,614
	Dutch Bangla Bank, Mymensingh Br.	2,426,666	46,273
	Dutch Bangla Bank, Dinajpur Br.	284,980	237,404
	Agrani Bank, Ramna Br.	-	41,612
	Dutch Bangla Bank, Ring Road Br.	181,284	182,984
	Dutch Bangla Bank, Narayangong Br.	484,387	7,414
	Dutch Bangla Bank, B.Baria, Branch	736,350	235,115
	Prime Bank-CD A/C, Satmasjid Road	-	837,161
	Dutch Bangla Bank	1,030	1,030
	Dutch Bangla Bank, Patherhat Branch	14,300	-
	HSBC F/C A/C, Main Branch	33,628	-
	HSBC F/C (USD) A/C, Main Branch	11,202,335	-
	United Commercial Bank Limited UCBL-CD AC, Gulshan Branch	90,839	285,803
	DBBL Chakoria Branch	203,510	130,000
	The City Bank Ltd., Dhanmondi Branch	78,175	3,210
	Trust Bank Ltd., Dhanmondi Branch	761,363	1,611,722
	Dutch Bangla Bank, Faridpur Br.	167,529	361,399
	Dutch Bangla,Bogra Br.	365,680	680,370
	SCB snd A/C, HO	3,165,666	142,151,090
	SCB DSRA A/C, HO	13,683,268	-
	Dutch Bangla, Rangpur Br.	3,350	112,165
	Cash at BO account	1,720	-
		413,432,359	**452,650,109**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013
18	**Share Capital : Tk. 161,601,700**		
	This is arrived at as follows :		
a)	**Authorized Capital : Tk 5,000,000,000**		
	500,000,000 Ordinary Shares @ Tk. 10/-each	5,000,000,000	5,000,000,000
b)	**Issued, Subscribed and Paid - up Capital:**		
	155,631,100 Ordinary Shares @ Tk. 10/- each (last year 116,000,000 Ordinary Shares)	1,556,311,000	1,160,000,000
	Add: Issued 39,631,100 Ordinary Shares @ Tk. 10/- each in the year 2012-'13	-	396,311,000
	Add: Issued during the year 5,970,600 Ordinary Shares @ Tk. 10/- each	59,706,000	-
		1,616,017,000	**1,556,311,000**
c)	**The movement of Ordinary Shares during the year is as under**		
		No. of Share	**No. of Share**
	Opening Balance	155,631,100	116,000,000
	Share issued during the year	5,970,600	39,631,100
	Closing Balance.	161,601,700	155,631,100

d) Composition of Share holding of Ordinary Shares :

Name of the Shareholders	2013-2014		2012-2013	
	No. of Shares	%	No. of Shares	%
Mr. Nasir-Ur-Rahman Sinha	13,620,136	8.43%	13,419,150	8.62%
Mr. Mizanur Rahman Sinha	18,175,115	11.25%	15,839,000	10.18%
Dr. Jabilur Rahman Sinha	14,220,630	8.80%	13,919,150	8.94%
Mr. Afzalur Rahman Sinha	14,962,886	9.26%	13,519,150	8.69%
Mrs. Parveen Akhter Nasir	10,539,843	6.52%	10,439,350	6.71%
Mrs. Jahanara Mizan Sinha	10,519,744	6.51%	10,439,350	6.71%
Mrs. Nagina Afzal Sinha	11,888,433	7.36%	10,903,600	7.01%
Mrs. Hasina Jabil Sinha	10,075,593	6.23%	9,975,100	6.41%
Others (who holds less than 5% share)	57,599,320	35.64%	57,177,250	36.74%
Total	**161,601,700**	**100%**	**155,631,100**	**100%**

19 Share Premium: Tk. 1,605,066,569

In the year 2012-2013, the company issued 39,631,100 Ordinary Shares of Tk. 10 each at issue price of Tk. 52 with a premium of Tk. 42 each.

Opening balance	1,605,066,569	-
Add : Amount received during the year	-	1,664,506,200
Less: Transaction cost	-	59,439,631
Fees to the issue Manager	-	7,777,778
VAT on fees to the issue Manager	-	1,166,667
Tax on Share Premium	-	49,935,186
BSEC Fees	-	560,000
Closing balance	**1,605,066,569**	**1,605,066,569**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013
20	**Capital Reserve: Tk. 0**		
	The amount realized on sale of land in the year 2008-2009, has been derived as under:		
	Sales proceeds of the land	80,150,000	80,150,000
	Less: Cost of the land	9,259,110	9,259,110
	Gain on sale of land befor netting of tax	70,890,890	70,890,890
	Less: Tax on sales proceeds	4,007,500	4,007,500
	Net gain on sale of land	66,883,390	66,883,390
	Disposition of Gain:		
	Net gain from sale of land	66,883,390	66,883,390
	Less: Gain shown in Statement of Comprehensive Income during the year 2008-09	26,716,667	26,716,667
	Amount shown as Capital Reserve	40,166,723	40,166,723
	Less: Amount transferred to Retained Earnings	40,166,723	-
		-	**40,166,723**

Capital Reserve amounting Tk. 40,166,723 was recognized in the year 2008-09, after completion of final settlement of tax under section 82(C). In fact, it was a free reserve in nature. As such, during the year the management of the company has decided to transfer the said amount to retained earnings.

21	**Retained Earnings: Tk. 1,949,426,728**		
	Opening balance	1,327,209,077	849,726,331
		1,358,414,002	576,560,496
	Add: Net profit after tax for the year	893,890,898	505,695,794
	Adjustment for Depreciation on Revalued Assets	87,077,493	70,864,702
	Adjustment of Revaluation surplus due to disposal	221,500	-
	Adjustment due to disbursement of purchase consideration and resultant gain thereon	283,977,778	-
	Capital reserve	40,166,723	
	Addition due to amalgamation	53,079,610	-
		736,196,351	99,077,750
	Less: Tax Holiday Reserve	45,177,401	-
	Interim Cash Dividend declared during the year	323,203,400	99,077,750
	Final dividend declared for the year 2012-2013	367,815,550	-
	Closing balance	**1,949,426,728**	**1,327,209,077**
22	**Long Term Loans - Net off Current Maturity: Tk. 3,018,088,196**		
	This represents long term borrowings from financial institutions which are as follows:		
	Name of Financial Institution		
	Standered Chartered Bank	18,225,115	11,944,699
	Trust Bank (MTL)	226,030,241	327,666,082
	Dhaka Bank MTL	73,907,803	100,516,667
	Dutch Bangla Bank (MTL)	249,445,361	-
	IDLC	183,708,976	305,858,403
	SCB-Foreign Loan (Net of foreign currency gain/loss)	865,193,168	-
	ICB*	350,000,000	-
	IIDFC	67,500,000	107,500,000
	IPDC	52,994,901	85,386,629
	NFL	44,172,675	64,731,754
	HSBC-Foreign Loan (Net of foreign currency gain/loss)	886,909,956	-
		3,018,088,196	**1,003,604,234**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013

* Represents Taka 500,000,000 sanctioned and disbursed by Investment Corporation of Bangladesh (ICB) which was initially recognized as advance against share money deposit as per the agreed terms, i.e. the Company was supposed to issue equity shares against the advances at the time of public issue brought by the company within one year from the date of disbursement. If the Company is not able to fulfill the condition as stated above, the said advance will be derecognized as Share Money Deposit and recognized as Term loan.

Since the company has not able to comply the agreed condition as stated above, the Company during the year derecognized the amount of

Share Money Deposit and recognized it as a Term loan with agreed rate of interest repayable in ten half yearly equated installments.

23 Provision for Gratuity: Tk. 30,465,330

The ACME Laboratories Limited	27,059,047	-
Addition due to amalgamation	3,406,283	-
	30,465,330	**-**

24 Deferred Tax Liability/(Assets): Tk. 9,124,902

This represents provision made/assets created related to deferred income tax for taxable/deductable temporary differences which is arrived at as follows:

Opening Balance	124,807,896	123,811,231
Add : Deferred Tax Liability/(Assets) created during the year		
Increase in Deferred tax liability	70,853,117	996,665
On account of taxable temporary difference of taxable unit	61,193,400	996,665
On account of taxable temporary difference of Tax holiday unit	9,659,717	-
Creation of Deferred Tax Assets	(186,536,110)	-
on account of Unabsobed Depreciaiton of Tax holiday unit *	(177,065,444)	-
on account of Provision for Gratuity	(9,470,666)	-
	9,124,902	**124,807,896**

Deferred Tax Asset- Carry forward of unabsorbed depreciation of Tax Holiday Unit:
Para 9 of the Third Schedule of the Income Tax Ordinance, 1984 specifies that:

* the aggregate of the allowances for depreciation allowed under this ordinance or the Income Tax Act, 1922(XI of 1922), in respect of any asset, shall not exceed the original cost of the asset.

* where full effect cannot be given to depreciation allowances under this Schedule in the year it is admissible , there being no income chargeable for that year or such income being less than the allowance admissible ,then, subject first to carrying forward of loss, if any, under section 38, the allowances or part thereof to which effect has not been given shall added to the amount of allowance for the following year or if no allowance is admissible for such following year, shall be deemed to be allowance admissible for such year and so on for succeeding years till such time as the entire allowance on this account is adjusted against the profits.

In view of the aforesaid provision, the company has carried forward the unabsorbed depreciation amounting to Taka 505,901,269 (Taka 367,065,444 related to Assessment year 2012-13, Taka 100,018,337 related to Assessment year 2013-14 and Taka 38,832,067 related to Assessment year 2014-15) related to its tax holiday unit (নথি নং -১১(৬২) কর মওকুফ ও প্রত্যাপণ/২০১১/ তারিখ: ১২/০১/২০১২ ইং) which was a separate company till 31.01.2014 to adjust it against taxable profits for future assessment years till it gets fully absorbed. The company has accordingly created a deferred tax asset amounting to Taka 177,065,444 applying the substantively enacted rate based on the provisions of BAS-12 "Income Taxes".

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013

25 Loans & Overdrafts : Tk. 4,874,126,240

This represents various facilities availed from bank which are as follows :

Name of the Bank		
Agrani Bank	(18,544,575)	283,417,041
Dutch Bangla Bank	375,390,984	510,424,329
Standard Chartered Bank	777,091,756	695,425,798
Dhaka Bank Ltd. LTR A/C	72,918,444	56,328,097
Dhaka Bank Ltd. C/C Hypo A/C	335,304,815	294,537,414
Dhaka Bank Ltd. STL A/C	30,093,333	34,059,510
Citi Bank. Overdraft	-	(44,584)
HSBC O/D, LTR, RL	1,095,190,245	538,224,956
EBL, Overdraft,LTR,RL	595,291,896	210,150,563
Trust Bank Ltd., OD,LTR,STL	391,554,969	356,466,943
The City Bank Ltd., O/D A/C, LTR, STL A/C	967,476,092	537,977,397
AB Bank Ltd., O/D, LTR, RL A/C	252,358,281	97,205,844
	4,874,126,240	**3,614,173,307**

26 Current Maturity of Long Term Loans: Tk. 1,014,864,198

This represents current portion of long term loans from financial Institution which are repayable within next 12 months from the balance Sheet date :

Standered Chartered Bank (MTL)	25,503,290	30,283,931
Trust Bank	61,033,927	87,288,001
EBL	-	2,674,100
IDLC	149,895,380	152,587,970
IIDFC	40,000,000	62,500,000
IPDC	37,655,116	31,875,464
NFL	20,559,079	17,026,844
Foreign Loan SCB	247,040,000	-
HSBC Foreign Loan	245,191,570	-
ICB	100,000,000	-
Dhaka Bank	17,985,836	-
Dutch Bangla Bangla Bank	70,000,000	-
	1,014,864,198	**384,236,310**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars		Taka	
			As at 30-06-2014	As at 30-06-2013
27	**UNDP Grant: Tk. 0**			
	This consists of:			
	Opening balance		-	-
	Add: Addition during the year		2,373,878	14,513,643
			2,373,878	14,513,643
	Less: Utilization		-	13,962,581
			2,373,878	551,062
	Less: Transfer to Other Income		2,373,878	551,062
			-	-
28	**Trade Payables: Tk. 528,302,125**			
	This consists of :			
	Trade Creditors		528,302,125	506,963,399
			528,302,125	**506,963,399**
29	**Provision for Income Tax: Tk. 1,245,658,922**			
	Opening Balance		1,168,807,914	864,792,438
	Add: Addition due to amalgamation		5,804,236	-
	Add: Provision for the year		416,636,328	304,015,476
	Add: Provision related to prior years		10,000,000	-
	Less: Adjsutment of Current Tax Provision against Advance Income Tax			
	- For the assessment year 2011-2012		(218,905,630)	-
	- For the assessment year 2010-2011		(136,683,926)	-
	Closing Balance		**1,245,658,922**	**1,168,807,914**
30	**Liability for Expenses and Others: Tk. 160,054,589**			
	This comprise of :			
	Salary & Allowances		28,603,514	74,647,122
	Power & Electricity		3,681,082	2,171,781
	Postage & Telephone		1,392,185	1,458,785
	Gas Bill		7,799,019	1,865,991
	Office rent		224,599	224,599
	Audit Fee		500,000	200,000
	WASA Bill		1,076,850	1,121,558
	Other Expenses		1,820,953	5,830,711
	Interest payable		22,402,271	-
	Workers profit participation fund	30.a	84,214,886	65,059,739
	Employees deduction		4,016,023	-
	VAT payable		-	1,166,667
	Tax Deducted at Source			
	- On directors' remuneration		546,292	-
	- On employees' salary		604,458	-
	- Others		3,172,457	777,778
			160,054,589	**154,524,731**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
As at June 30, 2014

Continuation Sheet....

No.	Particulars	Taka	
		As at 30-06-2014	As at 30-06-2013

30.a Workers Profit Participation Fund: Tk. 84,214,886

The company makes a regular allocation of 5% on net profit before tax to this funds and payment is made to the workers as per provisions of Labour Law 2006, Chapter-15.

Opening balance	65,059,739	58,213,414
Add: Addition due to amalgamation	721,111	-
Add: Addition during the year	60,242,211	40,535,397
Less: Payment during the year	41,808,175	33,689,072
Closing balance	**84,214,886**	**65,059,739**

31 Dividend Payable: Tk. 606,723,400

In the line of proposed appropriation of profit, the Board of Directors proposed and recommended for declaration of Interim cash dividend a the rate of 20% for the year 2013-2014. This will involve an amount of Tk. 323,203,400 has been paid to the Shareholders.

Opening balance (Interim dividend for 2012-2013)	99,077,750	-
Add: Final dividend declared for the year 2012-2013 (Gross)	367,815,550	99,077,750
Add: Interim dividend decalred for the year 2013-2014	323,203,400	-
Less: Dividend paid to Promoter shareholders	64,480,000	-
Less: Dividend paid to other than promoter shareholders	118,893,300	-
Net Dividend Payable	**606,723,400**	**99,077,750**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No.	Particulars		Taka			
			July '13 to June '14	Feb.'14 to June'14	July '13 to June '14	July '12 to June '13
			Taxable Unit	Tax Holiday Unit	Total	Taxable Unit
32	**Revenue : Tk. 10,217,931,465**					
	This is made up as follows:					
	Gross Turnover					
	Domestic					
	Own Products (with VAT)		8,489,442,448	1,228,334,468	9,717,776,916	7,524,111,266
	ASPL Products (Erstwhile Subsidiary Co. now amalagamated)		1,460,306,873	-	1,460,306,873	1,975,362,063
			9,949,749,321	1,228,334,468	11,178,083,789	9,499,473,329
	Manufactured by Others :					
	Syrange		4,702,633	-	4,702,633	18,196,102
	Fish Feed		19,552,125	-	19,552,125	17,990,625
			9,974,004,079	**1,228,334,468**	**11,202,338,547**	**9,535,660,056**
	Exports					
	Own Products		363,269,096	-	363,269,096	337,528,776
	Total Gross Turnover		**10,337,273,175**	**1,228,334,468**	**11,565,607,643**	**9,873,188,832**
	Less: VAT		1,169,200,230	178,475,948	1,347,676,178	899,869,500
	Net Turnover		**9,168,072,945**	**1,049,858,520**	**10,217,931,465**	**8,973,319,332**

The summarized quantities are as follows

Name of Category	Unit	Opening	Production/ Purchase	Sales	Closing
Capsule	Pcs	14,782,615	327,784,997	326,918,398	15,649,214
Cream	Tube	209,436	4,238,375	4,222,253	225,558
Dry Syrup	Bottles	295,894	6,711,595	6,731,469	276,020
Eye/Ear/Nosal Drop	Phials	358,026	7,606,854	7,615,877	349,003
Injection	Pcs	4,475,719	38,618,239	38,764,901	4,329,057
Liquid	Bottles	2,879,123	51,760,497	51,612,110	3,027,510
Ointment	Tube	69,125	1,639,817	1,651,498	57,444
Tablet	Pcs	61,462,258	1,965,994,209	1,963,782,748	63,673,719
Powder	Pcs	43,254	576,662	575,426	44,490
Inhaler (DPI)	Cans	1,389,321	24,530,350	24,320,272	1,599,399
Suppository	Pcs	498,754	15,296,715	15,197,135	598,334
Inhaler(MDI)	Cans	21,451	409,920	410,041	21,330
Injection (vet)	Pcs	2,471,369	8,995,662	10,258,740	1,208,291
Liquid (Vet.)	Bottles	158,741	3,025,308	3,015,699	168,350
Bolus	Pcs	7,358,456	98,757,805	98,712,162	7,404,099
Primix	Pcs	2,539,159	13,255,094	11,811,432	3,982,821
Water Soluble Pow	Pcs	234,357	3,228,048	3,251,067	211,338
Syringe	Pcs	354,845	1,008,300	1,289,936	73,209
Fish Feed	Kg	26,489	606,200	621,390	11,299

33	**Cost of Goods Sold: Tk. 6,237,792,554**					
	This is arrived at as follows :					
	Raw Materials Consumed	33.a	2,663,042,738	321,035,398	2,984,078,136	2,378,519,086
	Packing Materials Consumed	33.b	1,390,252,656	173,433,642	1,563,686,298	1,322,164,974
	Work in Process (Opening)		356,784,193	-	356,784,193	255,296,856
	Work in Process (Closing)		(324,256,819)	(51,079,453)	(375,336,272)	(356,784,193)
	Consumption during the year		**4,085,822,768**	**443,389,587**	**4,529,212,355**	**3,599,196,723**
	Factory Overheads	33.c	752,593,592	103,400,266	855,993,858	569,760,951
	Cost of Production		**4,838,416,360**	**546,789,853**	**5,385,206,213**	**4,168,957,674**
	Purchase of Finished Goods		872,031,409	-	872,031,409	1,176,929,755
	Purchase of Finished Goods through amalgamation			23,503,442	23,503,442	-
	Opening Stock of Finished Goods		332,745,359	-	332,745,359	707,878,740
	Finished Goods Available		**6,043,193,128**	**570,293,295**	**6,613,486,423**	**6,053,766,169**
	Closing Stock of Finished Goods		(333,906,052)	(41,787,817)	(375,693,869)	(332,745,359)
	Cost of Goods Sold		**5,709,287,076**	**528,505,478**	**6,237,792,554**	**5,721,020,810**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No.	Particulars	Taka			
		July '13 to June '14	Feb.'14 to June'14	July '13 to June '14	July '12 to June '13
		Taxable Unit	Tax Holiday Unit	Total	Taxable Unit

33.a Raw Materials Consumed: Tk. 2,984,078,136

This is arrived at as follows :

Opening Stock of Raw Materials	694,987,665	-	694,987,665	504,743,728
Purchase during the year	2,721,311,552	392,705,189	3,114,016,741	2,568,763,023
- Through amalagamation	-	89,230,829	-	-
- From outside	-	303,474,360	-	-
Closing Stock of Raw Materials	(753,256,479)	(71,669,791)	(824,926,270)	(694,987,665)
Raw Material Consumed	**2,663,042,738**	**321,035,398**	**2,984,078,136**	**2,378,519,086**

Item wise summaried quantity and total number of ingredients are as follows

Particulars	Pcs	Quantity (kg)		Quantity (Liter)		Quantity (Pcs)	
	Cap Shell	Active	Excepients	Active	Excepients	Active	Excepients
Opening Balance	339,575,770	2,648,814	892,470	250	7,800	-	-
Purchase	515,634,660	4,721,345	4,042,738	135	40,931	24,000	299,359,000
Available for use	855,210,430	7,370,159	4,935,208	385	48,731	24,000	299,359,000
Closing Balance	398,429,439	2,854,892	915,676	197	13,186	-	-
Consumtion	456,780,991	4,515,267	4,019,532	188	35,545	24,000	299,359,000

33.b Packing Materials Consumed: Tk. 1,563,686,298

This is arrived at as follows :

Opening Stock of Packing Materials	404,785,640	-	404,785,640	234,585,478
Purchase during the year	1,496,521,392	207,522,976	1,704,044,368	1,492,365,136
- Through amalagamation	-	9,879,052	-	-
- From outside	-	197,643,924	-	-
Closing Stock of Packing Materials	(511,054,376)	(34,089,334)	(545,143,710)	(404,785,640)
	1,390,252,656	**173,433,642**	**1,563,686,298**	**1,322,164,974**

The Total quantity of Packing Materials are stated as under :

Name of Category	Unit	Opening	Purchase Yearly	Consumption yearly	Closing balance Yearly
Ampoule	Pcs	19,372,652	32,920,365	25,967,470	26,325,547
Bottle	Pcs	24,739,557	64,107,599	61,976,220	26,870,936
Carton	Pcs	17,954,213	100,871,014	94,882,187	23,943,040
Plastic Item	Pcs	11,287,777	89,311,230	95,034,714	5,564,293
Cap	Pcs	27,094,291	69,900,801	72,864,671	24,130,421
Catch Cover	Pcs	13,093,222	24,428,191	17,840,787	19,680,626
Inner Leaflet	Pcs	4,384,703	81,455,160	73,966,132	11,873,731
Label	Pcs	1,299,096	63,517,601	63,211,247	1,605,450
Shipping Box Label	Pcs	1,202,224	5,798,652	5,365,434	1,635,442
PVC/PVDC	Pcs	259,652	574,442	496,988	337,106
Shipping Box	Pcs	573,316	7,021,777	7,559,335	35,758
Tube	Pcs	1,628,002	6,884,374	5,878,802	2,633,574
Al. Foil- Blister	Pcs	6,822	76,438	76,100	7,160
Al. Foil- Strip	Pcs	52,751	650,926	631,697	71,980
Inner Board	Pcs	6,775	1,420,550	1,367,678	59,647
Vial	Pcs	7,952,793	21,432,988	23,370,327	6,015,454
Sticker Label	Pcs	6,109,362	20,142,929	18,322,536	7,929,755

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No.	Particulars	Taka			
		July '13 to June '14 Taxable Unit	Feb.'14 to June'14 Tax Holiday Unit	July '13 to June '14 Total	July '12 to June '13 Taxable Unit
33.c	**Factory Overheads : Tk. 855,993,858**				
	This is made up as follows :				
	Salary & Allowances	240,364,514	34,867,543	275,232,057	185,494,965
	Daily Wages	59,879,833	16,500,309	76,380,142	82,896,614
	Gratuity	13,005,229	23,720	13,028,949	2,576,055
	Group Insurance Premium	590,413	10,567	600,980	527,369
	Postage & Telephone	1,612,130	203,542	1,815,672	1,347,654
	Fuel, Power & Electricity	133,890,701	-	133,890,701	85,802,604
	Conveyance	1,549,713	387,345	1,937,058	387,275
	Company's Contribution to RPF	12,462,230	-	12,462,230	8,123,953
	Gas Bill	19,427,837	5,670,969	25,098,806	12,713,374
	Factory Staff Uniform	1,559,341	734,569	2,293,910	1,241,422
	Carriage Inward	2,368,855	232,767	2,601,622	2,183,670
	Repairs & Maintenance	76,855,647	8,800,929	85,656,576	25,331,086
	Medical Expenses	29,682	3,765	33,447	14,271
	Insurance	8,055,810	-	8,055,810	4,571,565
	Local Tax	2,001,000	425,000	2,426,000	375,000
	Printing & Stationery	15,873,149	1,550,987	17,424,136	10,784,779
	Design, Blocks & Layout	-	-	-	303,970
	Research & Analysis	1,479,945	150,675	1,630,620	1,246,706
	Welfare & Recreation	7,662,529	1,798,544	9,461,073	5,887,031
	Entertainment	3,692,158	10,789	3,702,947	3,568,092
	Canteen Expenses	5,887,352	1,476,854	7,364,206	4,804,702
	Spare Parts	23,917,954	102,457	24,020,411	20,304,973
	Contribution to CSR Activities	937,839	105,690	1,043,529	-
	Travelling and Conveyance	230,843	20,453	251,296	529,974
	Depreciation	119,258,889	30,322,792	149,581,681	108,743,848
		752,593,592	**103,400,266**	**855,993,858**	**569,760,951**
34	**Other Income: Tk. 108,071,977**				
	This is arrived at as follows :				
	Rent on Investment Property	6,462,000	-	6,462,000	6,462,000
	Other Lease Rent	228,000	-	228,000	228,000
	Income/(loss) from sale of Motor vehicle	(185,645)	-	(185,645)	(1,452,746)
	Interest Bank's STD and SND A/C	842,831	-	842,831	1,796,691
	Foreign Exch. fluctuation Gain/(Loss) against Receivable (Unrealized)	2,031,861	-	2,031,861	(242,501)
	Foreign Exch. fluctuation Gain/(Loss) against Collection on Export Bill	55,448	-	55,448	(2,115,360)
	Commission	-	-	-	1,628,400
	Interest on FDR	96,263,653	-	96,263,653	13,291,250
	Unutilized amount of UNDP Grant	2,373,829	-	2,373,829	551,062
		108,071,977	**-**	**108,071,977**	**20,146,796**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No.	Particulars	Taka			
		July '13 to June '14 Taxable Unit	Feb.'14 to June'14 Tax Holiday Unit	July '13 to June '14 Total	July '12 to June '13 Taxable Unit

35 Selling, Marketing and Distribution Expenses: Tk. 1,499,828,917

This is arrived at as follows :

Salary & Allowances	810,496,942	92,811,993	903,308,935	856,676,877
Daily Basis Salary	6,407,803	731,778	7,139,581	3,570,537
Gratuity	31,619,507	-	31,619,507	9,389,900
Company's Contribution to RPF	38,829,938	4,434,419	43,264,358	30,852,221
Office Rent	7,661,521	874,954	8,536,475	6,613,009
Electricity & WASA, Gas	8,641,223	986,837	9,628,060	9,517,678
Postage & Telephone	15,610,672	1,787,616	17,398,288	13,780,305
Fuel for Generator	2,226,779	254,300	2,481,079	2,651,394
Vehicle Expenses	21,397,043	3,585,575	24,982,618	13,897,785
Printing & Stationery	36,561,108	4,175,317	40,736,424	39,035,576
TA/DA	60,827,770	6,965,537	67,793,307	65,121,118
Travelling Kits	10,098,133	1,153,217	11,251,350	223,383
Carriage Outward	39,869,281	4,553,113	44,422,394	54,612,944
Seminar & Conference	11,583,733	1,322,874	12,906,607	4,796,957
Medical Expenses	1,047,234	119,595	1,166,829	593,839
Sales Promotion Expenses	70,443,860	8,066,699	78,510,559	70,130,647
New Products Induction expense	633,684	72,367	706,052	80,830
Group & Health Insurance Premium	1,058,478	120,879	1,179,357	3,762,461
Export Expenses	14,245,411	1,626,841	15,872,252	9,576,943
Welfare & Recreation	2,025,369	231,299	2,256,669	1,082,244
Free Sample	46,489,719	5,307,917	51,797,636	46,276,644
Insurance	5,281,248	603,124	5,884,372	6,617,733
Fees & Renewals	11,107,843	1,268,527	12,376,370	6,834,260
Repair & Maintenance	3,172,191	362,267	3,534,458	3,657,488
Entertainment	11,098,832	1,270,954	12,369,786	5,862,824
Repacking Materials	882,058	100,732	982,790	1,054,345
Countibution to CSR Activities	418,977	47,848	466,825	-
Depreciation	78,317,686	8,938,295	87,255,981	64,076,563
	1,348,054,041	**151,774,876**	**1,499,828,917**	**1,330,346,506**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No.	Particulars	Taka			
		July '13 to June '14 Taxable Unit	Feb.'14 to June'14 Tax Holiday Unit	July '13 to June '14 Total	July '12 to June '13 Taxable Unit
36	**Administrative Expenses: Tk. 546,384,337**				
	This is made up as follows :				
	Directors Remuneration	106,339,050	12,155,450	118,494,500	197,239,000
	Salary & Allowances	178,250,530	18,799,356	197,049,886	167,306,964
	Directors sitting fee	390,000	-	390,000	-
	Group & Health Insurance Premium	416,758	47,594	464,352	1,393,224
	Postage & Telephone	4,984,969	569,289	5,554,258	5,508,859
	Electricity ,Gas & WASA	11,416,791	1,303,810	12,720,601	11,771,219
	Fuel for Genaretor & Vehicle	9,381,362	1,071,361	10,452,723	6,337,658
	Conveyance	3,276,807	374,215	3,651,022	5,000,053
	Refreshment Expenses	4,808,151	357,779	5,165,930	3,053,933
	Office General Expenses	15,241,392	1,740,583	16,981,975	18,615,425
	Vehicle Expenses	12,063,321	1,377,644	13,440,965	6,687,349
	Advertisement for Recuritment & Others	3,040,070	347,179	3,387,249	5,649,622
	Printing & Stationary	17,074,451	807,910	17,882,361	15,248,794
	Intangible Assets Write off	51,257	-	51,257	70,521
	Newspaper & Periodicals	295,174	33,709	328,883	137,480
	AGM Expenses	1,111,995	126,991	1,238,986	-
	Expenses for Legal Procedure	1,844,615	210,657	2,055,272	643,330
	Gratuity	10,835,572	-	10,835,572	3,565,258
	Company's Contribution to RPF	7,318,690	835,802	8,154,492	7,250,450
	Professional Fee	5,442,100	621,493	6,063,593	12,613,698
	Audit Fee	500,000	-	500,000	200,000
	Medical Expenses	1,308,764	149,462	1,458,226	194,142
	Uniform and liveries	721,755	82,425	804,180	702,010
	Travelling Eepenses	2,651,991	645,463	3,297,454	1,823,315
	Foreign Business travelling	163,827	18,709	182,536	-
	Repair and maintenance	11,421,028	1,304,293	12,725,321	8,345,065
	Insurance	1,247,398	142,454	1,389,852	1,159,200
	Municipal Tax	1,548,262	176,813	1,725,075	6,210,270
	Fees and Renewals	4,852,048	435,340	5,287,388	3,184,676
	Merger Expenses	560,940	64,060	625,000	-
	Welfare and recreation	1,556,667	177,773	1,734,440	1,203,881
	Daily basis salary	5,500,033	819,426	6,319,459	5,493,846
	Countibution to CSR Activities	1,067,362	113,329	1,180,691	-
	Depreciation	67,129,444	7,661,396	74,790,840	55,459,752
		493,812,572	**52,571,765**	**546,384,337**	**552,068,993**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No.	Particulars	Taka			
		July '13 to June '14 Taxable Unit	Feb.'14 to June'14 Tax Holiday Unit	July '13 to June '14 Total	July '12 to June '13 Taxable Unit
37	**Financial Expenses: Tk. 776,911,190**				
	This is arrived at as follows :				
	Interest on Cash Credit	119,541,815	13,689,027	133,230,842	144,862,724
	Interest on Overdraft	99,731,654	11,420,516	111,152,170	98,651,913
	Interest on MTL & LTR	56,645,445	6,486,609	63,132,054	86,893,212
	Interest on Revolving & STL	314,178,433	35,977,343	350,155,776	130,699,455
	Interest on Lease Finance	67,309,932	7,707,825	75,017,757	51,034,309
	Interest on Term Loan	15,323,171	1,754,694	17,077,865	8,226,175
	Interest on Accepted Import Loan	5,535,270	633,857	6,169,127	-
	Bank Charge	18,820,427	2,155,173	20,975,600	18,418,699
		697,086,146	**79,825,044**	**776,911,190**	**538,786,487**
38	**Contribution to workers profit participation fund: Tk. 60,242,211**				
	This repesent 5% of net profit before tax after charging contribution as per provision of the section 15 of Bangladesh Labour Law 2006				
39	**Income Tax Expenses: Tk. 310,953,335**				
	This is arrived at as follows :				
	Current Tax Expenses				
	Current Tax for the year under review	378,509,276	38,127,052	416,636,328	304,015,476
	Tax expense related to prior years	10,000,000	-	10,000,000	-
		388,509,276	38,127,052	426,636,328	304,015,476
	Deferred Tax Expenses/(Income)				
	Deferred Tax Expenses/(Income)	(115,682,993)	-	(115,682,993)	996,665
		(115,682,993)	-	(115,682,993)	996,665
		272,826,283	**38,127,052**	**310,953,335**	**305,012,141**

Brief computation of Income Tax Expense and Effective Tax Rate

	Income Year 2013-'14 (Assessment Year 2014-'15)		
	Non-Tax Holiday Unit	Tax Holiday Unit	Total (In Taka)
Net Profit before tax as per Comprehensive Income Statement (a)	978,957,226	225,887,007	1,204,844,233
Taxable profit as per computation (b)	1,103,313,520	217,868,868	1,321,182,388
Corporate Tax Rate			35%
Tax Liability thereon	379,374,583	38,127,052	417,501,635
Adjustment recognized for current tax of prior years	10,000,000	-	10,000,000
Total tax Liability (c)			427,501,635
Adjustment for deferred tax assets			(115,682,993)
Income tax expense recognized in Finanacial Statements (d)			**311,818,642**
Effective Tax Rate [(c) /(a)]			**35.48%**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No.	Particulars	Taka	
		July '13 to June '14	July '12 to June '13

40 Basic/Diluted Earnings Per Share (EPS) Tk 5.65

The computation is given below :

Net Profit After Tax	893,890,898	505,695,795
Weighted average number of shares outstanding during the year (40.2)	158,084,771	120,560,291
Basic Earnings Per Share	**5.65**	**4.19**
Diluted Earnings Per Share	**5.65**	**4.19**

Refer Policy notes 5.18

40.1 Number of Ordinary Share outstanding : 161,601,700

This is arrived at as follows :

Opening number of ordinary shares outstanding	155,631,100	116,000,000
Add : Ordinary shares issued during the year	5,970,600	39,631,100
	161,601,700	155,631,100

40.2 Weighted average number of Shares Outstanding

This is arrived at as follows :

Opening number of shares outstanding	155,631,100	116,000,000
Add: Weighted average number of ordinary share issued (59,70,600 * 150/365)	2,453,671	4,560,291
(Previous year: 3,96,31,100 * 42/365)	**158,084,771**	**120,560,291**

41 Related Party Disclosures:

The company carried out a number of transactions with related parties in the normal course of business and on arms lenth basis. The nature of the transactions and their relative value is shown below:

Name of the Related Parties	Relation	Nature of Transaction	Value of Transactions	Balance at 30.06.2014 Receivable/(Payable)
ACMUNIO Int. Ltd.	Common Directors	Advance to ACMUNIO Int. Ltd.	25,130,552	120,343,583
		Finished Goods Purchase	4,334,085	-
		Rent as Investment Property	6,462,000	32,310,000
Sinha Printers ltd.	Do	Local Supply received	391,049,968	(388,321,732)
		Provide Service & others	329,116	37,257,581
Kalyar Packaging Ltd.	Do	Local Supply	45,570,985	-
Kalyar Replica Ltd.	Do	Local Supply	7,083,759	-

42 Particulars of Disposal of Plant and Equipment

This is arrived at as follows :

	Dhk-MET MA 50-0167	Dhk-Metro GA 27-8384	
Value of Vehicle (Cost + Revaluation)	1,200,000	1,453,338	1,952,746
Less: Acc. Depreciation	720,000	681,984	-
Less: Cash proceeds	221,500	500,000	500,000
Less: Adjustment of Revaluation Surplus	480,000	85,710	-
Loss/(Gain) from Sale of Vehicle	**(221,500)**	**185,644**	**1,452,746**

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No.	Particulars	Taka	
		July '13 to June '14	July '12 to June '13
43	**Payments/Receipts in Foreign Currency**	Amounts in BDT	Amounts in BDT
	Payments		
	Import of Machinery,Spares and Equipments	784,166,032	97,947,521
	Import of Raw & Packing Materials	2,120,940,942	1,339,962,127
	Foreign Currency Loans	291,574,222	-
		3,196,681,196	1,437,909,648
	Receipts		
	UNDP grant	2,373,829	14,513,643
	Exports	363,269,096	337,528,776
	Foreign Currency Loans	2,447,608,561	-
		2,813,251,486	352,042,419
44	**Directors Remuneration and Sitting Allowance**		
	Directors Remuneration (Including MD's Remuneration Tk. 21,000,000)	118,494,500	197,239,000
	Directors Sitting Allowance (Including MD's Sitting Allowance Tk. 45,000)	390,000	-
		118,884,500	197,239,000

45 Board Meetings and Attendance

The number of Board Meeting and attendance of Directors during the year 2013-2014 were as follows

Name of Directors	Position	No. of Meetings held	No. of Meetings attended
Mr. Nasir- Ur- Rahman Sinha	Chairman (Upto 25.06.2014)	9	8
Mr. Mizanur Rahman Sinha	Managing Director	9	9
Mr. Fayekuzzaman	Nominated Director	9	4
Dr. Jabilur Rahman Sinha	Deputy Managing Director	9	4
Mr. Afzalur Rahman Sinha	Deputy Managing Director	9	9
Mr. Md. Abdour Rouf	Nominated Director	9	4
Mrs. Parveen Akter Nasir	Director	9	9
Mrs. Jahanara Mizan Sinha	Director	9	9
Mrs. Nagina Afzal Sinha	Director	9	9

46	**Audit Fees**	500,000	200,000

47 Events After the Reporting Period:

The company has commenced operations in the following units and commercial launching date of products manufactured by the units are here under-

SL #	Name of the units	Commercial Launching date/month
1	Liquid in hard geltin product	September, 2014
2	Sachet Products	September, 2014
3	Blow Fill Seal (BFS)	October, 2014

The prospective financial impact of the above said events occuring after reporting period canot be quantified hence no disclosure of quantative impact has been made.

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.

Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No. Particulars

48 Contingent Liability

The Company has contingent liability of Tk. 18,401,674 to Large Tax Payer Unit (LTU), North Commissionerate and Directorate, Inspection, Intelligence & Investigation under National Board of Revenue (NBR) against 4 (four) claims of VAT to be imposed or not on the company. The ACME Laboratories Ltd. has filed 5 (five) writ petitions in The Honorable High Court Division of the Supreme Court of Bangladesh separately vide no.- 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002 respectively against the said claims. The company is hopeful that the writ petitions would be decided in its favour.

49 Un Expired Bank Guarantees

Details of unexpired Bank Guarantees of Tk. 171,268,699 given in the normal course of business on behalf of the company to various parties as on 30 June 2014 are as here under:

SL #	Name of the Bank	Date of Expiry	Amount in Taka
1	Dutch Bangla Bank Limited	17.10.2016	430,700
2	Dutch Bangla Bank Limited	24.05.2017	931,030
3	Dutch Bangla Bank Limited	30.10.2014	1,018,000
4	Agrani Bank Limited	15.10.2016	1,093,820
5	Agrani Bank Limited	11.09.2018	1,547,350
6	Estern Bank Limited	05.10.2014	1,264,068
7	Trust Bank Limited	25.06.2015	14,364,430
8	Trust Bank Limited	29.09.2014	143,644,301
9	Trust Bank Limited	21.02.2015	6,975,000
			171,268,699

50 Claim not Acknowledged as Debts

There is no claim against the company which have not been acknowledged as debt as at 30 June 2014

51 Capital Expenditure Commitment

The estimated amount of capital expenditure commitement of the company mainly in the form of Letter of Credit opened in favour of suppliers as at 30 June 2014 is Tk. 250,557,321.

52 Production Capacity and Actual Production (Quantity in Thousand)

Name of Category	Unit	Production Capacity		Actual Production		Actual Production	
		2013-14	2012-13	2013-14	%	2012-13	%
Human							
Tablet	Pcs	3,086,237	1,411,000	1,953,640	63.30	1,695,264	120.15
Capsule	Pcs	630,486	224,100	319,640	50.70	271,001	120.93
Liquid	Bottle	62,250	62,250	46,571	74.81	39,622	63.65
Dry Syrup	Bottle	18,409	7,470	6,712	36.46	5,562	74.46
Ointment	Tube	3,984	3,984	1,640	41.16	1,356	34.04
Cream	Tube	17,928	17,928	4,238	23.64	3,225	17.99
Suppository	Pcs	14,940	14,940	15,297	102.39	12,973	86.83
Inhaler (DPI)	Cans	22,410	22,410	24,530	109.46	19,445	86.77
Inhaler (MDI)	Canister	498	498	410	82.31	341	68.47
Eye/Ear/Nasal Drop	Phials	6,640	6,640	7,607	114.56	6,265	94.35
Injection (Amps)	Pcs	24,900	24,900	24,244	97.37	18,176	73.00
Injection (Vial)	Pcs	18,424	13,280	14,374	78.02	10,676	80.39
Veterinary							
Bolus	Pcs	174,300	174,300	98,758	56.66	86,434	49.59
Liquid	Pcs	4,980	4,980	3,025	60.75	2,681	53.84
Premix	Pcs	14,940	14,940	13,255	88.72	12,045	80.62
WSP	Pcs	5,976	5,976	3,228	54.02	2,722	45.55
Injection	Vial	12,700	12,700	8,996	70.83	6,438	50.69
Herbal & Ayurbedic							
Capsule	Pcs	32,370	32,370	8,145	25.16	4,629	14.30
Liquid	Pcs	7,470	7,470	5,189	69.46	4,410	59.04
Tablet	Pcs	29,880	29,880	12,354	41.35	8,343	27.92

Note: Capacity is calculated considering 240 days per year; 2 shifts per day and 8 hours per shifts.

পিনাকী এন্ড কোম্পানী
Pinaki & Company

The ACME Laboratories Ltd.
Notes to the Financial Statement
For the year ended 30 June 2014

Continuation Sheet....

No. Particulars

53 Income Tax Assessments

Income tax assessments for some of the previous financial years of the company are in progress at various stages with the assessing tax authorities. The initial tax demands raised by income tax authorities have been contested by filling appeals, petitions as per section 173 for correction of the appeal orders, giving effect to advance income tax payments made and other tax credits claimed by the company and tax demands barred by time limitation etc. In the opinion of the management, there will not be any significant tax liability which would ultimately be devolved on the company after giving effect to the aforesaid adjustments/credits. However, to guard against any possible future liabilities, the management has made an additional provision of Tk. 10,000,000 in the books of account to take care of.

54 VAT Return and Auditing status as at 30.06.2014

The Company is depositing VAT & filing VAT returns on monthly basis with the concerned department. The department has conducted and completed their audit upto the financial year 2012-13 in May 2014 and there is no adverse findings of the department during the course of audit.

Annexure-D

The ACME Laboratories Limited

Statement of Ratio Analysis

The following ratios have been computed from the Audited Financial Statements of the The ACME Laboratories Limited for the year ended 30th June 2015, 2014, 2013, 2012 and 2011 :

Sl.	Name of the Ratios	30.06.2015	30.06.2014	30.06.2013	30.06.2012	30.06.2011
		Result	Result	Result	Result	Result
	Liquidity Ratios					
1	Current ratio (Time)	1.03	0.79	1.33	1.05	1.05
2	Quick ratio (Time)	0.63	0.49	0.98	0.66	0.64
3	Debt to Equity Ratio (Time)	1.05	1.07	0.74	0.93	0.68
4	Time Interest earned	2.37	2.55	2.50	2.52	2.89
	Activity/Operating Ratios					
1	Acct. Receivable Turnover Ratio	16.73	18.31	20.76	28.45	35.51
2	Inventory Turnover Ratio (Time)	2.72	2.73	2.76	3.73	4.36
3	Fixed Assets Turnover Ratio (Times)	0.73	0.86	1.20	1.43	2.01
4	Assets Turnover Ratio (Times)	0.51	0.53	0.61	0.78	1.00
	Profitability Ratios					
1	Gross profit margin Ratio (%)	37.42	38.95	36.24	35.54	35.10
2	Operating Income Ratio (%)	20.51	18.93	15.26	15.29	13.02
3	Net Profit Ratio (%)	8.02	8.74	5.64	5.38	4.91
4	Return on Asset (%)	4.06	4.61	3.45	4.22	4.89
5	Return on Equity (%)	8.11	8.36	5.31	7.20	5.90
6	EPS	5.70	5.65	4.19	4.10	2.97
7	EBITDA Margin	26.10%	22.45%	17.58%	17.50%	14.54%
	Coverage Ratio					
1	Debt to Total Assets ratio	0.51	0.52	0.43	0.48	0.41
2	Debt Service Coverage Ratio	0.41	0.29	0.30	0.31	0.32
	Cash Flow					
1	Net Operating Cash Flow Per Share	6.50	2.85	4.69	0.90	3.08
2	Net Operating Cash Flow Per Share/EPS	1.14	0.51	1.12	0.22	1.04

We have examined the calculation of the above ratios of The ACME Laboratories Ltd. for the year ended 30th June 2015, 2014, 2013, 2012 and 2011 and found them correct.

Sd/-

Date, Dhaka;
March 2, 2016

Pinaki & Company
Chartered Accountants

Statement regarding the explanation of difference to the calculation of ratio

It has been observed that Debt Service Coverage ratio for the year ended 30 June 2015 and 2014 'shown in Annexure D' is different from Credit Rating Information and Services Limited (CRISL) Report. However, it happened because of using different formula to calculate the said ratio. To make visible the reason both the formulas are mentioned below side by side:

Name of the Ration	AMCE's Formula	CRISL's Formula
Debt Service Coverage Ratio	Net Operating Income	EBT +Finance Cost + Depreciation
	Finance Cost + Current Maturity of Long Term Loan (Current Year) + Loan and Overdraft	Current Maturity of Long Term Loan (Previous Year) + Finance Cost

Date, Dhaka
March 10, 2016

Sd/-
(Mizanur Rahman Sinha)
Managing Director
The ACME Laboratories Limited.

Industry average ratios compare with The ACME Laboratories Ltd.

SL #	Name of the Ratio	30.06.2014		30.06.2013		30.06.2012		30.06.2011		30.06.2010	
		ACME	Industry Avg.	ACME	Industry Avg.	ACME	Industry Avg.	ACME	Industry Avg.	ACME	Industry Avg.
Liquidity Ratios											
1	Current ratio (Time)	0.79	1.95	1.33	1.61	1.05	1.75	1.05	1.78	0.94	2.24
2	Quick ratio (Time)	0.49	1.20	0.98	1.01	0.66	0.99	0.64	1.06	0.65	1.43
3	Debt to Equity Ratio (Time)	1.07	0.44	0.74	2.06	0.93	0.49	0.68	0.63	2.50	0.73
4	Time Interest earned	2.55	15.37	2.50	8.96	2.52	9.01	2.89	7.67	2.39	5.28
Activity/Operating Ratios											
1	Acct. Receivable Turnover Ratio	18.31	138.37	20.76	166.72	28.45	227	35.51	241.64	42.15	293.33
2	Inventory Turnover Ratio (Time)	2.73	4.15	2.76	3.85	3.73	4.11	4.36	4.43	4.97	4.61
3	Fixed Assets Turnover Ratio (Times)	0.86	1.90	1.20	1.84	1.43	1.80	2.01	1.71	4.69	1.69
4	Assets Turnover Ratio (Times)	0.53	0.82	0.61	0.73	0.78	0.75	1.00	0.87	1.54	0.89
Profitability Ratios											
1	Gross profit margin Ratio (%)	38.95	45.25	36.24	45.51	35.54	44.86	35.10	43.42	34.33	43.46
2	Operating Income Ratio (%)	18.93	21.42	15.26	20.79	15.29	22.77	13.02	21.18	10.93	20.59
3	Net Income Ratio (%)	8.74	12.47	5.64	11.01	5.38	11.64	4.91	12.34	4.10	9.31
4	Return on Asset (%)	4.61	7.29	3.45	6.11	4.22	6.69	4.89	7.35	5.37	6.51
5	Return on Equity (%)	8.36	11.13	5.31	9.56	7.20	8.97	5.90	10.97	19.00	10.19
6	EPS	5.65	4.14	4.19	3.30	4.10	3.31	2.97	3.92	1.96	4.07
7	EBITDA Margin (%)	22.45	32.07	17.58	32.22	17.50	35.02	14.54	36.28	13.27	33.49
Coverage Ratio											
1	Debt to Total Assets ratio	0.52	0.29	0.43	0.42	0.48	0.32	0.41	0.37	0.71	0.39
2	Debt Service Coverage Ratio	0.29	2.99	0.30	1.01	0.31	0.92	0.32	0.68	0.26	0.79
Cash Flow											
1	Net Operating Cash Flow Per Share	2.85	5.68	4.69	4.06	0.90	4.37	3.08	4.13	(1.53)	5.81
2	Net Operating Cash Flow Per Share/EPS	0.51	1.37	1.12	1.23	0.22	1.32	1.04	1.05	(0.78)	1.43

Note:

The stand-alone ratio of The ACME Laboratories Ltd. have been calculated based on Audited Financial Statements and Industry average ratios are calculated on the basis of financial data collected from Annual Report of following five publicly traded Companies corresponding accounting years:

Sl #	Name of the Company	Considered Accounting years	Remarks
01	Square Pharmaceuticals Ltd.	For the year ended 31 March 2010, 2011, 2012, 2013 and 2014.	
02	Beximco Pharmaceuticals Limited	For the year ended 31 December 2010, 2011, 2012, 2013 and 2014.	Annual Report for the ended 31 December 2015 yet to be published.
03	Beacon Pharmaceuticals Limited	For the year ended 30 June 2010, 2011, 2012, 2013 and 2014.	
04	Central Pharmaceuticals Ltd.	For the year ended 30 June 2010, 2011, 2012, 2013 and 2014.	
05	The IBN SINA Pharmaceutical Industries Ltd.	For the year ended 31 December 2010, 2011, 2012, 2013 and 2014.	Annual Report for the ended 31 December 2015 yet to be published.

For wider range of data, we communicated with Bangladesh Bureau of Statistics, Bangladesh Association of Pharmaceutical Industries and Bangladesh Bank. But, we were informed that none of them maintains such ratios with regard to industry concern.

Analysis:

Industry average ratios are calculated considering five listed companies only including leader of the industry. It is to be noted that, right now, substantial number of companies of the industry are out of capital market. Further, as far as the revenue is concern, industry's top leader earns almost double revenue with compare to the second highest listed company of the industry (as indicated in the page no. 87 under the head Competitive conditions in the business). However, in case of Earnings Per Share (EPS), stand-alone EPS of ACME is better than the industry average except in the year 2010-2011 and 2009-2010.

As at 30.06.2013, ACME'S debt to equity ratio shows better than the industry ratios, in case of other years industry average ratios are favorable.

ACME's stand-alone inventory turnover ratio is favorable than industry average in the year 2009-2010, but in other years industry average ratios are favorable than ACME's stand-alone ratio.

In case of fixed assets turnover ratio, ACME's stand-alone ratios are favorable in the years 2010-2011 and 2009-2010, but in other years industry average ratios are favorable than ACME's stand-alone ratio.

In case of assets turnover ratios, ACME's ratios are favorable in the years 2011-2012, 2010-2011 and 2009-2010, and in other years end industry average ratios are favorable.

Again, in case of return on equity, ACME's ratio is favorable in the year 2009-2010 and other years end industry average ratios are favorable.

In case of net operating cash flow per share, ACME's ratio is favorable in the year 2012-2013 and in case of other years end industry average ratios are favorable.

Besides, aforesaid ratio, all other industry average ratios are favorable than stand-alone ratios.

The ACME Laboratories Limited

Auditors' Report under section-135 (1) and Para-24 (1) of part II of Schedule-III of the Companies Act 1994 for the year ended June 30, 2015

We have examined the Financial Statements of The ACME Laboratories Limited for the year ended 30th June 2015, 2014, 2013, 2012 and 2011 of section 135 under para 24(1) of part II of the third schedule of the Companies Act 1994, we report that;

A. Statement of Financial Position

Particulars	As at 30.06.2015	As at 30.06.2014	As at 30.06.2013	As at 30.06.2012	As at 30.06.2011
ASSETS					
Non-Current Assets :	**16,060,787,303**	**15,544,508,282**	**8,684,201,210**	**6,993,694,379**	**6,140,710,979**
Property, Plant and Equipment	16,027,234,140	15,511,897,086	8,306,210,678	6,615,633,325	5,762,752,567
Intangible Assets	245,250	286,875	338,132	408,654	528,472
Investment in Shares	7,122,913	6,139,321	351,467,400	351,467,400	351,467,400
Preliminary Expenses	-	-	-	-	5,690
Investment Property	26,185,000	26,185,000	26,185,000	26,185,000	25,956,850
Current Assets:	**7,198,984,638**	**6,635,062,802**	**7,889,442,833**	**5,738,665,873**	**3,669,103,044**
Inventories	2,484,869,763	2,223,003,434	1,886,267,051	1,781,058,760	1,271,611,575
Trade Receivable	729,654,988	644,867,067	471,021,187	393,373,660	228,023,633
Other Receivable	40,721,339	74,526,105	76,067,715	56,095,089	14,340,585
Advance, Deposits & Pre-Payments	986,392,966	1,097,408,239	2,347,694,271	2,126,780,980	1,202,554,410
Advance Income Tax	1,820,547,016	1,334,147,374	1,273,276,904	905,905,040	666,301,708
Material In Transit	285,524,549	294,476,484	162,465,596	309,970,102	173,392,545
Term Deposit	419,003,619	553,201,740	1,220,000,000	-	-
Cash and Cash Equivalents	432,270,398	413,432,359	452,650,109	165,482,242	112,878,588
TOTAL ASSETS	**23,259,771,941**	**22,179,571,084**	**16,573,644,043**	**12,732,360,252**	**9,809,814,023**
EQUITY AND LIABILITIES					
Shareholders' Equity:	**11,372,629,592**	**10,692,163,182**	**9,517,448,502**	**6,609,452,889**	**5,823,832,008**
Share Capital	1,616,017,000	1,616,017,000	1,556,311,000	1,160,000,000	1,160,000,000
Share Premium	1,605,066,569	1,605,066,569	1,605,066,569	-	-
Revaluation Surplus	5,320,065,830	5,429,804,848	4,488,695,133	4,559,559,835	4,321,826,996
Capital Reserve	-	-	40,166,723	40,166,723	40,166,723
Share Money Deposit	-	-	500,000,000	-	-
Gain/(Loss) on Marketable Securities (Unrealized)	1,824,633	841,041	-	-	-
Tax Holiday Reserve	139,860,882	91,006,996	-	-	-
Retained Earnings	2,689,794,678	1,949,426,728	1,327,209,077	849,726,331	301,838,289
Non Current Liabilities:	**4,904,881,207**	**3,057,678,428**	**1,128,412,130**	**631,726,945**	**491,432,627**
Long Term Loan- Net off Current Maturity	4,721,113,988	3,018,088,196	1,003,604,234	507,915,714	387,857,802
Provision For Gratuity	57,776,500	30,465,330	-	-	-
Deferred Tax Liability	125,990,719	9,124,902	124,807,896	123,811,231	103,574,825
Current Liabilities :	**6,982,261,142**	**8,429,729,474**	**5,927,783,411**	**5,491,180,418**	**3,494,549,388**
Loans & Overdrafts	3,099,847,325	4,874,126,240	3,614,173,307	3,578,565,702	2,288,385,645
Current Maturity of Long Term Loans	1,609,081,078	1,014,864,198	384,236,310	269,275,732	212,521,282
UNDP Grant		-	-	-	29,540,983
Trade Payable	432,244,843	528,302,125	506,963,399	615,283,214	283,312,919
Provision for Income Tax	1,556,306,023	1,245,658,922	1,168,807,914	864,792,438	558,852,345
Liability for Expenses and Others	133,076,893	160,054,589	154,524,731	163,263,332	121,936,214
Dividend Payable	151,704,980	606,723,400	99,077,750	-	-
TOTAL EQUITY AND LIABILITIES	**23,259,771,941**	**22,179,571,084**	**16,573,644,043**	**12,732,360,252**	**9,809,814,023**

Sd/-
Managing Director

Sd/-
Director

Sd/-
Pinaki & Company
Chartered Accountants

B. Statement of Profit or Loss & Other Comprehensive Income for the year ended 30th June;

Particulars	2015	2014	2013	2012	2011
Revenue	**11,496,413,631**	**10,217,931,465**	**8,973,319,332**	**8,838,091,913**	**6,996,750,681**
Less: Cost of Goods Sold	7,194,997,972	6,237,792,554	5,721,020,810	5,697,479,102	4,540,790,741
Gross Profit/(Loss)	**4,301,415,659**	**3,980,138,911**	**3,252,298,522**	**3,140,612,811**	**2,455,959,940**
Add: Other Income	41,127,977	108,071,977	20,146,796	17,992,913	12,096,145
	4,342,543,636	**4,088,210,888**	**3,272,445,318**	**3,158,605,724**	**2,468,056,085**
Less: Selling, Marketing and Distribution Expenses	1,555,756,698	1,499,828,917	1,330,346,506	1,264,116,205	1,090,284,975
	2,786,786,938	**2,588,381,971**	**1,942,098,812**	**1,894,489,519**	**1,377,771,110**
Less: Administrative Expenses	387,355,878	546,384,337	552,068,993	525,130,630	454,675,079
	2,399,431,060	**2,041,997,634**	**1,390,029,819**	**1,369,358,889**	**923,096,031**
Less: Financial Expenses	982,529,496	776,911,190	538,786,487	526,938,749	309,766,701
Profit before Contribution to WPPF	**1,416,901,564**	**1,265,086,444**	**851,243,332**	**842,420,140**	**613,329,330**
Less: Contribution to WPPF	67,471,503	60,242,211	40,535,397	40,115,245	29,187,417
Net Profit before Tax	**1,349,430,061**	**1,204,844,233**	**810,707,935**	**802,304,895**	**584,141,913**
Less: Current Tax expense	310,647,101	426,636,328	304,015,476	305,940,093	218,905,630
Less: Deferred Tax (Income)/Expense	116,865,817	(115,682,993)	996,665	20,236,406	21,084,983
Net Profit after Tax	**921,917,143**	**893,890,898**	**505,695,794**	**476,128,396**	**344,151,300**
Other Comprehensive Income					
Gain/(loss) on Marketable Securities (Unrealized)	983,592	841,041	-	-	-
Total Comprehensive Income for the year	**922,900,735**	**894,731,939**	**505,695,794**	**476,128,396**	**344,151,300**
EPS	**5.70**	**5.65**	**4.19**	**4.10**	**2.97**

Sd/-
Managing Director

Sd/-
Director

Sd/-
Pinaki & Company
Chartered Accountants

C. Statement of Cash Flows for the year ended 30th June;

	2015	2014	2013	2012	2011
Cash Flows From Operating Activities:					
Collection from Sales and others	11,482,235,909	10,151,510,988	8,896,167,780	8,648,752,145	6,938,557,265
Payment to Suppliers & Others	(8,889,653,916)	(8,499,238,362)	(7,390,616,063)	(7,766,464,127)	(6,100,332,724)
Financial Expenses	(982,529,496)	(776,911,191)	(538,786,487)	(526,938,749)	(309,766,701)
Workers Profit Participation Fund	(73,568,003)	(41,808,175)	(33,689,072)	(11,089,248)	-
Income Tax	(486,399,642)	(382,397,340)	(367,371,864)	(239,603,332)	(171,415,191)
Net cash provided by operating activities	**1,050,084,852**	**451,155,920**	**565,704,294**	**104,656,689**	**357,042,649**
Cash Flows From Investing Activities:					
Fixed Assets	(971,816,955)	(2,410,288,500)	(1,919,179,321)	(760,735,581)	(362,966,351)
Sale of Fixed Assets	4,310,000	721,500	-	-	-
Term Deposit	134,198,121	666,798,260	(1,220,000,000)	-	-
Advance to Suppliers for Construction	-	(40,000,000)	(134,527,355)	(150,057,630)	-
Investment in Share	-	(5,298,280)	-	-	-
Dividend received	217,549	-	-	-	-
Advance against Land	-	-	(74,059,480)	(99,989,741)	(43,035,180)
Settlement of obligations of Amalgamating co. (ASPL)	-	(1,896,892,255)			
Advance to ASPL against Shares	-	-	(65,001,394)	(455,018,519)	(409,244,948)
Loan to ACMUNIO Int. Ltd.	(23,698,315)	(25,130,552)	(13,403,149)	(23,703,000)	(58,106,882)
Net cash used in investing activities	**(856,789,600)**	**(3,710,089,827)**	**(3,426,170,699)**	**(1,489,504,471)**	**(873,353,361)**
Cash Flows From Financing Activities:					
UNDP Grant	-	2,373,878	-	(29,540,983)	13,142,438
Dividend Paid	(697,420,970)	(183,373,300)	-	-	-
Cash & Cash equivalents received from ASPL	-	844,137	-	-	-
Settlement of Provident Fund Liabilities	-	(5,193,340)	-	-	-
Share Capital	-	-	396,311,000	-	-
Share Money Deposit	-	-	500,000,000	-	-
Share Premium	-	-	1,605,066,569	-	-
Net Increase / (Decrease) in Loans and Overdrafts	(1,774,278,915)	1,259,952,933	35,607,605	1,290,180,057	178,418,672
Net Increase / (Decrease) in Long Term Borrowings	2,297,242,672	2,145,111,849	610,649,098	176,812,362	344,284,450
Net cash flow from financing activities	**(174,457,213)**	**3,219,716,157**	**3,147,634,272**	**1,437,451,436**	**535,845,560**
Increase/(Decrease) in Cash and Cash Equivalents	18,838,039	(39,217,750)	287,167,867	52,603,654	19,534,848
Cash and Cash Equivalents at the Opening	413,432,359	452,650,109	165,482,242	112,878,588	93,343,740
Cash and Cash Equivalents at the Closing	**432,270,398**	**413,432,359**	**452,650,109**	**165,482,242**	**112,878,588**
Net Operating Cash Flow Per Share	**6.50**	**2.85**	**4.69**	**0.90**	**3.08**

Sd/-
Managing Director

Sd/-
Director

Sd/-
Pinaki & Company
Chartered Accountants

D. Dividend and Others

1. The Company was incorporated on 17 March 1976 and Converted into Public Limited Company on 30-11-2011

2. Dividend Declared:

Year	Cash Dividend	Stock Dividend	Total Dividend
2014-2015	35%	0%	35%
2013-2014	35%	0%	35%
2012-2013	30%	0%	30%
2011-2012	0%	0%	0%
2010-2011	0%	0%	0%

3. The Statement of Asset and Liabilities (Statement of Financial Position) as at 30th June 2015, 2014, 2013, 2012, and 2011 of the Company have been duly certified by us.

4. The Statement of Operating Results (Statement of Profit or Loss and Other Comprehensive Income) for the year ended 30th June 2015, 2014, 2013, 2012 and 2011 of the Company have been duly certified by us.

5.The Statement of Cash Flows for the year ended 30th June 2015, 2014, 2013, 2012 and 2011 of the company have been duly certified by us.

6.The company did not prepare any financial Statements for any period subsequent to 30th June 2015.

7. Figures related to previous years have been re arranged wherever considered necessary.

Sd/-
Pinaki & Company
Chartered Accountants

Date, Dhaka;
March 2, 2016

Worksheet Analysis
For the year ended and as at 30 June 2014

Particulars	Unadjusted Trial Balance		Adjustments		Adjusted Trial Balance		Statement of Profit or Loss and Other Comprehensive Income		Statement of Changes in Equity		Statement of Financial Position	
	Debit	Credit	Debit	Credit	Debit	Credit	Debit	Credit	Debit	Credit	Debit	Credit
Property, Plant and Equipment at Revalued Amount	17,331,385,727	-	-	-	17,331,385,727	-	-	-	-	-	17,331,385,727	-
Intangible Assets at Cost	940,285	-	-	-	940,285	-	-	-	-	-	940,285	-
Investment in Shares	5,298,280	-	841,041	-	6,139,321		-	-	-	-	6,139,321	-
Investment Property	26,185,000	-	-	-	26,185,000	-	-	-	-	-	26,185,000	-
Inventories	2,223,003,434	-	-	-	2,223,003,434	-	-	-	-	-	2,223,003,434	-
Trade Receivable	644,594,038	-	273,029	-	644,867,067	-	-	-	-	-	644,867,067	-
Other Receivable	74,526,105	-	-	-	74,526,105	-	-	-	-	-	74,526,105	-
Advance, Deposits & Pre-Payments	1,097,408,239	-	-	-	1,097,408,239	-	-	-	-	-	1,097,408,239	-
Advance Income Tax	1,334,147,374	-	-	-	1,334,147,374	-	-	-	-	-	1,334,147,374	-
Material In Transit	294,476,484	-	-	-	294,476,484	-	-	-	-	-	294,476,484	-
Term Deposit	553,201,740	-	-	-	553,201,740	-	-	-	-	-	553,201,740	-
Cash and Cash Equivalents	413,432,359	-	-	-	413,432,359	-	-	-	-	-	413,432,359	-
Share Capital	-	1,616,017,000	-	-	-	1,616,017,000	-	-	-	-	-	1,616,017,000
Share Premium	-	1,605,066,569	-	-	-	1,605,066,569	-	-	-	-	-	1,605,066,569
Revaluation Surplus	-	5,516,882,341	87,077,493	-	-	5,429,804,848	-	-	-	-	-	5,429,804,848
Gain/(Loss) on Marketable Securities (Unrealized)	-	-	-	841,041	-	841,041	-	-	-	-	-	841,041
Tax Holiday Reserve	-	45,829,595	-	45,177,401	-	91,006,996	-	-	-	-	-	91,006,996
Retained Earnings	-	1,336,839,138	45,177,401	87,077,493	-	1,378,739,230	-	-	323,203,400	2,272,630,128	-	1,949,426,728
Long Term Loans- Net off Current Maturity	-	3,018,088,196	-	-	-	3,018,088,196	-	-	-	-	-	3,018,088,196
Provision For Gratuity	-	30,465,330	-	-	-	30,465,330	-	-	-	-	-	30,465,330
Deferred Tax Liability	-	124,807,895	115,682,993	-	-	9,124,902	-	-	-	-	-	9,124,902
Loans & Overdrafts	-	4,874,126,240	-	-	-	4,874,126,240	-	-	-	-	-	4,874,126,240
Current Maturity of Long Term Loans	-	1,014,864,198	-	-	-	1,014,864,198	-	-	-	-	-	1,014,864,198
Trade Payable	-	528,302,125	-	-	-	528,302,125	-	-	-	-	-	528,302,125
Provision for Income Tax	-	819,022,594	-	426,636,328	-	1,245,658,922	-	-	-	-	-	1,245,658,922
Liability for Expenses and Others	-	99,312,378	-	60,742,211	-	160,054,589	-	-	-	-	-	160,054,589
Dividend Payable	-	283,520,000	-	-	-	283,520,000	-	-		323,203,400	-	606,723,400
Revenue	-	10,217,931,465	-	-	-	10,217,931,465	-	10,217,931,465	-	-	-	-
Cost of Goods Sold excluding Depreciation	6,088,210,873	-	-	-	6,088,210,873	-	6,088,210,873	-	-	-		-
Other Income	-	107,798,948	-	273,029	-	108,071,977	-	108,071,977	-	-	-	
Selling, Marketing and Distribution Expenses	1,412,572,936	-	-	-	1,412,572,936	-	1,412,572,936	-	-	-	-	-
Administrative Expenses	471,042,240	-	-	-	471,042,240	-	471,042,240	-	-	-	-	-
Financial Expenses	776,911,190	-	-	-	776,911,190	-	776,911,190	-	-	-	-	-
Contribution to WPPF	-	-	60,242,211	-	60,242,211	-	60,242,211	-	-	-	-	-
Current Tax expense	-	-	426,636,328	-	426,636,328	-	426,636,328	-	-	-	-	-
Deferred Tax (Income)/Expense	-	-	-	115,682,993	-	115,682,993	-	115,682,993	-	-	-	-
Accumulated Depreciation	-	1,507,860,139	-	311,628,502	-	1,819,488,641	-		-	-	-	1,819,488,641
Accumulated Amortization	-	602,153	-	51,257	-	653,410	-		-	-	-	653,410
Amortization	-	-	51,257	-	51,257	-	51,257		-	-	-	-
Depreciation	-	-	311,628,502	-	311,628,502	-	311,628,502		-	-	-	-
Audit Fees	-	-	500,000	-	500,000	-	500,000		-	-	-	-
	32,747,336,305	**32,747,336,305**	**1,048,110,255**	**1,048,110,255**	**33,547,508,673**	**33,547,508,673**	9,547,795,537	10,441,686,435	-	-	-	-
Net Profit after Tax							893,890,898	-	-	-	-	-
							10,441,686,435	**10,441,686,435**	-	-	-	-
Transferred to Dividend Payable									323,203,400	-	-	-
Transferred to Retained Earnings									1,949,426,728	-	-	-
									2,595,833,528	**2,595,833,528**	-	-
											23,999,713,135	**23,999,713,135**

Financial Spread Sheet Analysis

Statement of Financial Position

Particulars	As at 30.06.2014		As at 30.06.2013		As at 30.06.2012		As at 30.06.2011		As at 30.06.2010	
	Amount (BDT)	% on Total Asset	Amount (BDT)	% on Total Asset	Amount (BDT)	% on Total Asset	Amount (BDT)	% on Total Asset	Amount (BDT)	% on Total Asset
Non-Current Assets :	**15,544,508,282**	**70.08**	**8,684,201,210**	**52.40**	**6,993,694,379**	**54.93**	**6,140,710,979**	**62.60**	**1,548,636,643**	**36.55**
Property, Plant and Equipment	15,511,897,086	69.94	8,306,210,678	50.12	6,615,633,325	51.96	5,762,752,567	58.74	1,197,143,553	28.25
Intangible Assets	286,875	0.00	338,132	0.00	408,654	0.00	528,472	0.01	20,000	0.00
Investment in Shares	6,139,321	0.03	351,467,400	2.12	351,467,400	2.76	351,467,400	3.58	351,467,400	8.29
Preliminary Expenses	-	-	-	-	-	-	5,690	0.00	5,690	0.00
Investment Property	26,185,000	0.12	26,185,000	0.16	26,185,000	0.21	25,956,850	0.26	-	-
Current Assets:	**6,635,062,802**	**29.92**	**7,889,442,833**	**47.60**	**5,738,665,873**	**45.07**	**3,669,103,044**	**37.40**	**2,688,889,318**	**63.45**
Inventories	2,223,003,434	10.02	1,886,267,051	11.38	1,781,058,760	13.99	1,271,611,575	12.96	811,183,318	19.14
Trade Receivable	644,867,067	2.91	471,021,187	2.84	393,373,660	3.09	228,023,633	2.32	166,006,224	3.92
Other Receivable	74,526,105	0.34	76,067,715	0.46	56,095,089	0.44	14,340,585	0.15	6,462,000	0.15
Advance, Deposits & Pre-Payments	1,097,408,239	4.95	2,347,694,271	14.17	2,126,780,980	16.70	1,202,554,410	12.26	1,276,005,733	30.11
Advance Income Tax	1,334,147,374	6.02	1,273,276,904	7.68	905,905,040	7.11	666,301,708	6.79	-	-
Material In Transit	294,476,484	1.33	162,465,596	0.98	309,970,102	2.43	173,392,545	1.77	335,888,303	7.93
Term Deposit	553,201,740	2.49	1,220,000,000	7.36	-	-	-	-	-	-
Cash and Cash Equivalents	413,432,359	1.86	452,650,109	2.73	165,482,242	1.30	112,878,588	1.15	93,343,740	2.20
TOTAL ASSET	**22,179,571,084**	**100.00**	**16,573,644,043**	**100.00**	**12,732,360,252**	**100.00**	**9,809,814,023**	**100.00**	**4,237,525,961**	**100.00**
EQUITY AND LIABILITIES										
Shareholders Equity:	**10,692,163,182**	**48.21**	**9,517,448,502**	**57.43**	**6,609,452,889**	**51.91**	**5,823,832,008**	**59.37**	**1,209,557,215**	**28.54**
Share Capital	1,616,017,000	7.29	1,556,311,000	9.39	1,160,000,000	9.11	1,160,000,000	11.82	100,000,000	2.36
Share Premium	1,605,066,569	7.24	1,605,066,569	9.68		-		-		-
Revaluation Surplus	5,429,804,848	24.48	4,488,695,133	27.08	4,559,559,835	35.81	4,321,826,996	44.06		-
Capital Reserve	-	-	40,166,723	0.24	40,166,723	0.32	40,166,723	0.41	40,166,723	0.95
Share Money Deposit	-	-	500,000,000	3.02	-	-	-	-	-	-
Gain/(Loss) on Marketable Securities (Unrealized)	841,041	0.00	-	-	-	-	-	-	-	-
Tax Holiday Reserve	91,006,996	0.41	-	-	-	-	-	-	-	-
Retained Earnings	1,949,426,728	8.79	1,327,209,077	8.01	849,726,331	6.67	301,838,289	3.08	1,069,390,492	25.24
Non Current Liabilities	**3,057,678,428**	**13.79**	**1,128,412,130**	**6.81**	**631,726,945**	**4.96**	**491,432,627**	**5.01**	**160,194,313**	**3.78**
Long Term Loan- Net off Current Maturity	3,018,088,196	13.61	1,003,604,234	6.06	507,915,714	3.99	387,857,802	3.95	160,194,313	3.78
Provision For Gratuity	30,465,330	0.14	-	-	-	-	-	-	-	-
Deferred Tax Liability	9,124,902	0.04	124,807,896	0.75	123,811,231	0.97	103,574,825	1.06	-	-
Current Liabilities :	**8,429,729,474**	**38.01**	**5,927,783,411**	**35.77**	**5,491,180,418**	**43.13**	**3,494,549,388**	**35.62**	**2,867,774,433**	**67.68**
Loans & Overdrafts	4,874,126,240	21.98	3,614,173,307	21.81	3,578,565,702	28.11	2,288,385,645	23.33	2,109,966,973	49.79
Current Maturity of Long Term Loans	1,014,864,198	4.58	384,236,310	2.32	269,275,732	2.11	212,521,282	2.17	95,900,321	2.26
UNDP Grant	-	-	-	-	-	-	29,540,983	0.30	16,398,545	0.39
Trade Payable	528,302,125	2.38	506,963,399	3.06	615,283,214	4.83	283,312,919	2.89	227,239,956	5.36
Provision for Income Tax	1,245,658,922	5.62	1,168,807,914	7.05	864,792,438	6.79	558,852,345	5.70	339,946,715	8.02
Liability for Expenses and Others	160,054,589	0.72	154,524,731	0.93	163,263,332	1.28	121,936,214	1.24	78,321,923	1.85
Dividend Payable	606,723,400	2.74	99,077,750	0.60	-	-	-	-	-	-
TOTAL EQUITY AND LIABILITY	**22,179,571,084**	**100.00**	**16,573,644,043**	**100.00**	**12,732,360,252**	**100.00**	**9,809,814,023**	**100.00**	**4,237,525,961**	**100.00**

Statement of Comprehensive Income

Particulars	2013-2014		2012-2013		2011-2012		2010-2011		2009-2010	
	Amount (BDT)	% on Sales	Amount (BDT)	% on Sales	Amount (BDT)	% on Sales	Amount (BDT)	% on Sales	Amount (BDT)	% on Sales
Total Revenue	**10,217,931,465**	**100.00**	**8,973,319,332**	**100.00**	**8,838,091,913**	**100.00**	**6,996,750,681**	**100.00**	**5,557,237,718**	**100.00**
Domestic Sales	9,854,662,369	96.44	8,635,790,556	96.24	8,645,975,391	97.83	6,742,610,671	96.37	5,332,867,274	95.96
Export Sales	363,269,096	3.56	337,528,776	3.76	192,116,522	2.17	254,140,010	3.63	224,370,444	4.04
Less: Cost of Goods Sold	**6,237,792,554**	**61.05**	**5,721,020,810**	**63.76**	**5,697,479,102**	**64.47**	**4,540,790,741**	**64.90**	**3,649,626,560**	**65.67**
Gross Profit	**3,980,138,911**	**38.95**	**3,252,298,522**	**36.24**	**3,140,612,811**	**35.53**	**2,455,959,940**	**35.10**	**1,907,611,158**	**34.33**
Add: Other Income	**108,071,977**	**1.06**	**20,146,796**	**0.22**	**17,992,913**	**0.20**	**12,096,145**	**0.17**	**19,644,640**	**0.35**
Interest income	96,263,653	0.94	13,291,250	0.15	-	-	-	-	12,547,240	0.23
Other Non Operational Income	11,808,324	0.12	6,855,546	0.08	17,992,913	0.20	12,096,145	0.17	7,097,400	0.13
Less: Operating Expenses	**2,046,213,254**	**20.03**	**1,882,415,499**	**20.98**	**1,789,246,835**	**20.24**	**1,544,960,054**	**22.08**	**1,300,300,802**	**23.40**
Selling, Marketing and Distribution Expenses	1,499,828,917	14.68	1,330,346,506	14.83	1,264,116,205	14.30	1,090,284,975	15.58	881,562,057	15.86
Administrative Expenses	546,384,337	5.35	552,068,993	6.15	525,130,630	5.94	454,675,079	6.50	418,738,745	7.54
Less: Non-operating Expenses										
Contribution to WPPF	60,242,211	0.59	40,535,397	0.45	40,115,245	0.45	29,187,417	0.42	-	-
EBIT	**1,981,755,423**	**19.39**	**1,349,494,422**	**15.04**	**1,329,243,644**	**15.04**	**893,908,614**	**12.78**	**626,954,996**	**11.28**
Less: Financial Expenses	**776,911,190**	**7.60**	**538,786,487**	**6.00**	**526,938,749**	**5.96**	**309,766,701**	**4.43**	**262,464,527**	**4.72**
Less: Income Tax Expeses	**310,953,335**	**3.04**	**305,012,141**	**3.40**	**326,176,499**	**3.69**	**239,990,613**	**3.43**	**136,683,926**	**2.46**
Current Tax Expenses	426,636,328	4.18	304,015,476	3.39	305,940,093	3.46	218,905,630	3.13	136,683,926	2.46
Deferred Tax (Income)/Expenses	(115,682,993)	(1.13)	996,665	0.01	20,236,406	0.23	21,084,983	0.30	-	-
EAT	**893,890,898**	**8.75**	**505,695,794**	**5.64**	**476,128,396**	**5.39**	**344,151,300**	**4.92**	**227,806,543**	**4.10**
Other Comprehensive Income	**841,041**	**0.01**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
Total Comprehensive Income for the year	**894,731,939**	**8.76**	**505,695,794**	**5.64**	**476,128,396**	**5.39**	**344,151,300**	**4.92**	**227,806,543**	**4.10**
EPS	**5.65**		**4.19**		**4.10**		**2.97**		**1.96**	
EBITDA Margin	**22.45%**		**17.58%**		**17.50%**		**14.54%**		**13.27%**	

Statement of Cash Flows

Particulars	2013-2014	2012-2013	2011-2012	2010-2011	2009-2010
Net cash provided by operating activities	451,155,920	565,704,294	104,656,689	357,042,649	(177,574,296)
Net cash used in investing activities	(3,710,089,827)	(3,426,170,699)	(1,489,504,471)	(873,353,361)	(425,206,059)
Net cash flow from financing activities	3,219,716,157	3,147,634,272	1,437,451,436	535,845,560	649,678,768
Increase/(Decrease) in Cash and Cash Equivalents	**(39,217,750)**	**287,167,867**	**52,603,654**	**19,534,848**	**46,898,413**
Cash and Cash Equivalents at the Opening	452,650,109	165,482,242	112,878,588	93,343,740	46,445,327
Cash and Cash Equivalents at the Closing	**413,432,359**	**452,650,109**	**165,482,242**	**112,878,588**	**93,343,740**
Net Operating Cash Flow Per Share	2.85	4.69	0.90	3.08	(1.53)
Net Operating Cash Flow Per Share/EPS	0.51	1.12	0.22	1.04	(0.78)

Earnings Per Share (EPS) on fully diluted basis (with the total existing number of shares) in addition to the weighted average number of shares basis

Earnings Per Share (EPS) on fully diluted basis (with the total existing no. of shares)

Particulars	Amount in BDT
Net profit after Tax for the year ended 30 June 2014	893,890,898
Number of Ordinary Shares outstanding	161,601,700
EPS	**5.53**

Earnings Per Share (EPS) on weighted average number of shares basis

Particulars	Amount in BDT
Net profit after Tax for the year ended 30 June 2014	893,890,898
Number of Ordinary Shares outstanding	158,084,771
EPS	**5.65**

All extra-ordinary income or non-recurring income coming from other than core operations should be shown separately while showing the Net Profit as well as the Earnings Per Share

Net Profit after tax excluding extra-ordinary income or non-recurring income from other than core operations:

Particulars	Amount in BDT
Net profit after Tax for the year ended 30 June 2014	893,890,898
Less: Other Income	108,071,977
Net profit after tax except other income	**785,818,921**

Earnings Per Share (EPS) excluding extra-ordinary income or non-recurring income coming from other than core operations:

Particulars	Amount in BDT
Net profit after Tax for the year ended 30 June 2014	893,890,898
Less: Other Income	108,071,977
Net profit after tax except other income	**785,818,921**
Number of Ordinary Shares outstanding	161,601,700
Earnings Per Share (EPS) on fully diluted basis	**4.86**

Net asset value (with and without considering revaluation surplus/reserve) per unit of the securities being offered at the date of the latest audited statement of financial position;

Net Assets Value per share with revaluation surplus as at 30 June 2014:

Particulars	Amount in BDT
Total assets	22,179,571,084
Less: Total Liabilities	11,487,407,902
Net Assets Value	10,692,163,182
Number of Ordinary Shares outstanding	161,601,700
Net Assets Value per share	**66.16**

Net Assets Value per share without revaluation surplus as at 30 June 2014:

Particulars	Amount in BDT
Total assets	22,179,571,084
Less: Total Liabilities	11,487,407,902
Net Assets Value with Revaluation Surplus	10,692,163,182
Less: Revaluation Surplus	5,429,804,848
Net Assets Value per share Without Revaluation Surplus	5,262,358,334
Number of Ordinary Shares outstanding	161,601,700
Net Assets Value per share	**32.56**

Auditor's Certificates

Statement of Long Term and Short Term Borrowings Including Borrowing from Related Party or Connected Persons with rate of interest and interest paid/accrued

After due verification, we certify that the Long Term and Short Term Borrowings Including Borrowing from Related Party or Connected Persons of The ACME Laboratories Limited for the last five years made up as follows:

For the Year ended June 30, 2014 :

Name Of the Institutions	Nature of Relationship	Nature of Borrowings	Balance as on 30 June 2014	Interest Rate (%)	Interest Paid (BDT)	Interest Accrued (BDT)
Dutch Bangla Bank Ltd.	Lender	Long term	319,445,361	14.50%		
Standard Chartered Bank	Lender	Long term	1,155,961,573	3 months L+4.50%, 14.00%		
Dhaka Bank Ltd.	Lender	Long term	91,893,639	14.00%		
HSBC	Lender	Long term	1,132,101,526	3 months L+4.50%		
Trust Bank Ltd.	Lender	Long term	287,064,168	13.00%		
IDLC	Lender	Long term	333,604,356	13.50%-16.00%		
IIDFC	Lender	Long term	107,500,000	15.50%		
IPDC	Lender	Long term	90,650,017	14.50%		
National Finance Ltd.	Lender	Long term	64,731,754	19.00%		
Investment Corporation of Bangladesh	Lender	Long term	450,000,000	15.50%		
Sub Total			**4,032,952,394**		776,911,190	Nil
Agrani Bank Limited	Lender	Short Term	(18,544,575)	16.00%		
Dutch Bangla Bank Ltd.	Lender	Short Term	375,390,984	15.00%		
Standard Chartered Bank	Lender	Short Term	777,091,756	13.50%		
Dhaka Bank Ltd.	Lender	Short Term	438,316,592	14.00%		
HSBC	Lender	Short Term	1,095,190,245	13.25% - 13.75%		
Trust Bank Ltd.	Lender	Short Term	391,554,969	14.00%		
Eastern Bank Ltd	Lender	Short Term	595,291,896	14.50%		
The City Bank Ltd	Lender	Short Term	967,476,092	14.00%		
AB Bank Ltd	Lender	Short Term	252,358,281	15.25%-15.50%		
Sub Total			**4,874,126,240**			
Grand Total			**8,907,078,634**		**776,911,190**	Nil

For the Year ended June 30, 2013:

Name Of the Institutions	Nature of Relationship	Nature of Borrowings	Balance as on 30 June 2013	Interest Rate (%)	Interest Paid (BDT)	Interest Accrued (BDT)
Standard Chartered Bank	Lender	Long term	42,228,630	15.00%		
Dhaka Bank Ltd.	Lender	Long term	100,516,667	15.50%		
Eastern bank Ltd.	Lender	Long term	2,674,100	15.50%		
Trust Bank Ltd.	Lender	Long term	414,954,083	15.00% - 15.50%		
IDLC	Lender	Long term	458,446,373	13.50%-18.00%		
IIDFC	Lender	Long term	170,000,000	16.50%		
IPDC	Lender	Long term	117,262,093	16.00%		
National Finance Ltd.	Lender	Long term	81,758,598	19.00%		
Sub Total			**1,387,840,544**			
Agrani Bank Limited	Lender	Short Term	283,417,041	16.00%	538,786,487	Nil
Dutch Bangla Bank Ltd.	Lender	Short Term	510,424,329	15.00%		
Standard Chartered Bank	Lender	Short Term	695,425,798	15.00%		
Dhaka Bank Ltd.	Lender	Short Term	384,925,021	15.50%		
HSBC	Lender	Short Term	538,224,956	14.25% - 14.50%		
Trust Bank Ltd.	Lender	Short Term	356,466,943	15.00%		
Eastern Bank Ltd	Lender	Short Term	210,150,563	15.50%		
The City Bank Ltd	Lender	Short Term	537,977,397	15.50%		
AB Bank Ltd	Lender	Short Term	97,205,844	15.25%-15.50%		
CITI Bank N.A.	Lender	Short Term	(44,584)			
Sub Total			**3,614,173,307**			
Grand Total			**5,002,013,851**		**538,786,487**	**Nil**

For the Year ended June 30, 2012:

Name Of the Institutions	Nature of Relationship	Nature of Borrowings	Balance as on 30 June 2012	Interest Rate (%)	Interest Paid (BDT)	Interest Accrued (BDT)
Standard Chartered Bank	Lender	Long term	74,189,756	15.00%		
IDLC	Lender	Long term	378,280,407	13.50%-18.00%		
ULC	Lender	Long term	1,904,824	15.80%		
IIDFC	Lender	Long term	82,500,000	18.00%		
IPDC	Lender	Long term	144,456,382	16.00%		
National Finance Ltd.	Lender	Long term	95,860,077	19.00%		
Sub Total			**777,191,446**			
Agrani Bank Limited	Lender	Short Term	320,360,923	16.00%		
Dutch Bangla Bank Ltd.	Lender	Short Term	515,881,716	14.50%	526,938,749	Nil
Standard Chartered Bank	Lender	Short Term	750,468,511	15.00%		
Dhaka Bank Ltd.	Lender	Short Term	190,371,712	17.00%		
HSBC	Lender	Short Term	474,613,674	13.00% - 13.50%		
Trust Bank Ltd.	Lender	Short Term	633,036,439	15.00%		
Eastern Bank Ltd	Lender	Short Term	242,016,747	15.50%		
The City Bank Ltd	Lender	Short Term	224,410,030	15.50%		
AB Bank Ltd	Lender	Short Term	227,459,151	14.50%-15.00%		
CITI Bank N.A.	Lender	Short Term	(53,201)			
Sub Total			**3,578,565,702**			
Grand Total			**4,355,757,148**		**526,938,749**	Nil

For the Year ended June 30, 2011:

Name Of the Institutions	Nature of Relationship	Nature of Borrowings	Balance as on 30 June 2011	Interest Rate (%)	Interest Paid (BDT)	Interest Accrued (BDT)
Standard Chartered Bank	Lender	Long term	138,006,045	13.00%		
IDLC	Lender	Long term	335,753,392	13.50%-18.00%		
ULC	Lender	Long term	4,119,647	15.80%		
IIDFC	Lender	Long term	122,500,000	15.00%		
Sub Total			**600,379,084**			
Agrani Bank Limited	Lender	Short Term	277,086,638	14.00%		
Dutch Bangla Bank Ltd.	Lender	Short Term	521,722,170	14.50%	309,766,701	Nil
Standard Chartered Bank	Lender	Short Term	710,330,574	13.00%		
Dhaka Bank Ltd.	Lender	Short Term	229,634,532	15.00%		
HSBC	Lender	Short Term	337,790,017	12.50% - 12.75%		
Eastern Bank Ltd	Lender	Short Term	20,078,353	14.00%		
CITI Bank N.A.	Lender	Short Term	191,743,361	12.75% - 13.00%		
Sub Total			**2,288,385,645**			
Grand Total			**2,888,764,729**		**309,766,701.00**	Nil

For the Year ended June 30, 2010:

Name Of the Institutions	Nature of Relationship	Nature of Borrowings	Balance as on 30 June 2010	Interest Rate (%)	Interest Paid (BDT)	Interest Accrued (BDT)
Standard Chartered Bank	Lender	Long term	34,912,751	13.25% - 13.50%		
IDLC	Lender	Long term	51,131,164	13.50%-15.90%		
ULC	Lender	Long term	7,550,719	15.80%		
IIDFC	Lender	Long term	162,500,000	13.25% - 13.75%		
Sub Total			**256,094,634**			
Agrani Bank Limited	Lender	Short Term	287,318,270	13.00%	262,464,527	Nil
Dutch Bangla Bank Ltd.	Lender	Short Term	313,028,158	12.00%		
Standard Chartered Bank	Lender	Short Term	780,365,960	13.00% - 13.25%		
Dhaka Bank Ltd.	Lender	Short Term	182,923,352	12.50%		
CITI Bank N.A.	Lender	Short Term	546,331,233	11.50% - 13.50%		
Sub Total			**2,109,966,973**			
Grand Total			**2,366,061,607**		**262,464,527**	Nil

The ACME Laboratories Ltd. does not have any Long Term and Short Term Borrowings from related Party or Connected Persons for the Period from 1st July 2009 to 30th June 2014.

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of Principal Terms of Secured Short Term Loans and Assets on which charge have been Created against those Loans.

Particulars	2014	2013	2012	2011	2010
Names of lenders	Agrani Bank Limited	Agrani Bank Limited	Agrani Bank Limited	Agrani Bank Limited	Agrani Bank Limited
Purpose	Working Capital	Working Capital	Working Capital	Working Capital	Working Capital
Status of Asset Charged	Land Mortgaged and Hypothecation charged on pari-passu basis	Land Mortgaged and Hypothecation charged on pari-passu basis	Land Mortgaged and Hypothecation charged on pari-passu basis	Land Mortgaged and Hypothecation charged on pari-passu basis	Land Mortgaged and Hypothecation charged on pari-passu basis
Sanctioned Amount	650,000,000	650,000,000	650,000,000	650,000,000	450,000,000
Rate of Interest	16.00%	16.00%	16.00%	14.00%	13.00%
Primary Security/Collateral/Other Security	Personal Gurantee	Personal Gurantee	Personal Gurantee	Personal Gurantee	Personal Gurantee
Re-payment schedule					
Status (Current Balance)	**(18,544,575)**	**283,417,041**	**320,360,923**	**277,086,638**	**287,318,270**

Particulars	2014	2013	2012	2011	2010
Names of lenders	Dutch Bangla Bank Limited	Dutch Bangla Bank Limited	Dutch Bangla Bank Limited	Dutch Bangla Bank Limited	Dutch Bangla Bank Limited
Purpose	Working Capital	Working Capital	Working Capital	Working Capital	Working Capital
Status of Asset Charged	Hypothecation charged on pari-passu basis	Hypothecation charged	Hypothecation charged	Hypothecation charged	Hypothecation charged
Sanctioned Amount	880,000,000	880,000,000	880,000,000	880,000,000	700,000,000
Rate of Interest	15.00%	15.00%	14.50%	14.50%	12.00%
Primary Security/ Collateral/Other Security	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee
Re-payment schedule					
Status (Current Balance)	**375,390,984**	**510,424,329**	**515,881,716**	**521,722,170**	**313,028,158**

Particulars	2014	2013	2012	2011	2010
Names of lenders	Standard Chartered Bank	Standard Chartered Bank	Standard Chartered Bank	Standard Chartered Bank	Standard Chartered Bank
Purpose	Working Capital	Working Capital	Working Capital	Working Capital	Working Capital
Status of Asset Charged	Hypothecation charged on pari-passu basis	Hypothecation charged on pari-passu basis	Hypothecation charged on pari-passu basis	Hypothecation charged on pari-passu basis	Hypothecation charged on pari-passu basis
Sanctioned Amount	1,230,000,000	1,230,000,000	1,230,000,000	1,230,000,000	930,000,000
Rate of Interest	13.50%	15.00%	15.00%	13.00%	13.00% - 13.25%
Primary Security/Collateral/Other Security	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee
Re-payment schedule					
Status (Current Balance)	**777,091,756**	**695,425,798**	**750,468,511**	**710,330,574**	**780,365,960**

Particulars	2014	2013	2012	2011	2010
Names of lenders	Dhaka Bank Limited	Dhaka Bank Limited	Dhaka Bank Limited	Dhaka Bank Limited	Dhaka Bank Limited
Purpose	Working Capital	Working Capital	Working Capital	Working Capital	Working Capital
Status of Asset Charged	Hypothecation charged on pari-passu basis	Hypothecation charged	Hypothecation charged	Hypothecation charged	Hypothecation charged
Sanctioned Amount	700,000,000	700,000,000	470,000,000	470,000,000	440,000,000
Rate of Interest	14.00%	15.50%	17.00%	15.00%	12.50%
Primary Security/Collateral/Other Security	Personal Gurantee and undated cheque	Personal Gurantee and undated cheque	Personal Gurantee	Personal Gurantee	Personal Gurantee
Re-payment schedule					
Status (Current Balance)	**438,316,592**	**384,925,021**	**190,371,712**	**229,634,532**	**182,923,352**

Particulars	2014	2013	2012	2011	2010
Names of lenders	HSBC	HSBC	HSBC	HSBC	HSBC
Purpose	Working Capital	Working Capital	Working Capital	Working Capital	
Status of Asset Charged	Hypothecation charged on pari-passu basis	Hypothecation charged on pari-passu basis	Hypothecation charged on pari-passu basis	Hypothecation charged on pari-passu basis	
Sanctioned Amount	1,200,000,000	1,200,000,000	680,000,000	680,000,000	
Rate of Interest	13.25% - 13.75%	14.25% - 14.50%	13.00% - 13.50%	12.50% - 12.75%	
Primary Security/Collateral/Other Security	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	
Re-payment schedule					
Status (Current Balance)	1,095,190,245	538,224,956	474,613,674	337,790,017	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	Eastern Bank Limited	Eastern Bank Limited	Eastern Bank Limited	Eastern Bank Limited	Eastern Bank Limited
Purpose	Working Capital	Working Capital	Working Capital	Working Capital	
Status of Asset Charged	Hypothecation charged	Hypothecation charged	Hypothecation charged	Hypothecation charged	
Sanctioned Amount	1,290,000,000	550,000,000	550,000,000	550,000,000	
Rate of Interest	14.50%	15.50%	15.50%	14.00%	
Primary Security/Collateral/Other Security	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	
Re-payment schedule					
Status (Current Balance)	595,291,896	210,150,563	242,016,747	20,078,353	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	Trust Bank Limited	Trust Bank Limited	Trust Bank Limited	Trust Bank Limited	Trust Bank Limited
Purpose	Working Capital	Working Capital	Working Capital		
Status of Asset Charged	Hypothecation charged on pari-passu basis	Hypothecation charged	Hypothecation charged		
Sanctioned Amount	2,000,000,000	2,000,000,000	1,450,000,000		
Rate of Interest	14.00%	15.00%	15.00%		
Primary Security/Collateral/Other Security	Personal Gurantee	Personal Gurantee	Personal Gurantee		
Re-payment schedule					
Status (Current Balance)	**391,554,969**	**356,466,943**	**633,036,439**	**-**	**-**

Particulars	2014	2013	2012	2011	2010
Names of lenders	The City Bank Limited	The City Bank Limited	The City Bank Limited	The City Bank Limited	The City Bank Limited
Purpose	Working Capital	Working Capital	Working Capital		
Status of Asset Charged	Land Mortgaged and Hypothecation charged	Land Mortgaged and Hypothecation charged	Land Mortgaged and Hypothecation charged		
Sanctioned Amount	1,200,000,000	700,000,000	700,000,000		
Rate of Interest	14.00%	15.50%	15.50%		
Primary Security/Collateral/Other Security	Personal Gurantee and Undated Cheque	Personal Gurantee and Undated Cheque	Personal Gurantee and Undated Cheque		
Re-payment schedule					
Status (Current Balance)	**967,476,092**	**537,977,397**	**224,410,030**		

Particulars	2014	2013	2012	2011	2010
Names of lenders	AB Bank Limited	AB Bank Limited	AB Bank Limited	AB Bank Limited	AB Bank Limited
Purpose	Working Capital	Working Capital	Working Capital		
Status of Asset Charged	Hypothecation charged	Hypothecation charged	Hypothecation charged		
Sanctioned Amount	650,000,000	650,000,000	650,000,000		
Rate of Interest	15.25%-15.50%	15.25%-15.50%	14.50%-15.00%		
Primary Security/Collateral/Other Security	Personal Gurantee	Personal Gurantee	Personal Gurantee		
Re-payment schedule					
Status (Current Balance)	**252,358,281**	**97,205,844**	**227,459,151**	-	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	CITI N.A.	CITI N.A.	CITI N.A.	CITI N.A.	CITI N.A.
Purpose		Working Capital	Working Capital	Working Capital	Working Capital
Status of Asset Charged				Hypothecation charged on pari-passu basis	Hypothecation charged on pari-passu basis
Sanctioned Amount				760,000,000	760,000,000
Rate of Interest				12.75% - 13.00%	11.50% - 13.50%
Primary Security/Collateral/Other Security				Personal Gurantee	Personal Gurantee
Re-payment schedule					
Status (Current Balance)	-	**(44,584)**	**(53,201)**	**191,743,361**	**546,331,233**

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of Principal Terms of Secured Long Term Loans and Assets on which charge have been Created against those Loans.

Particulars	2014	2013	2012	2011	2010
Names of lenders	Dutch Bangla Bank Limited	Dutch Bangla Bank Limited	Dutch Bangla Bank Limited	Dutch Bangla Bank Limited	Dutch Bangla Bank Limited
Purpose	To pay off short term liability of other banks				
Status of Asset Charged	Hypothecation charged on pari-passu basis				
Sanctioned Amount	350,000,000				
Rate of Interest	14.50%				
Primary Security/Collateral/Other Security	Personal Gurantee, 20 Post dated and 1 undated cheque				
Re-payment schedule	20 Installment				
Status (Current Balance)	**319,445,361**				

Particulars	2014	2013	2012	2011	2010
Names of lenders	Standard Chartered Bank	Standard Chartered Bank	Standard Chartered Bank	Standard Chartered Bank	Standard Chartered Bank
Purpose	Import capital machinery and pay off liabilities with other banks	Capital Machinery & Construction	Capital Machinery & Construction	Capital Machinery & Construction	Capital Machinery & Construction
Status of Asset Charged	Land Mortgaged and Hypothecation charged on pari-passu basis	Land Mortgaged and Hypothecation charged on pari-passu basis	Land Mortgaged and Hypothecation charged on pari-passu basis	Land Mortgaged and Hypothecation charged on pari-passu basis	Land Mortgaged and Hypothecation charged on pari-passu basis
Sanctioned Amount	USD 16,000,000 + BDT 50,000,000	150,000,000	150,000,000	150,000,000	150,000,000
Rate of Interest	3 months L+4.50%, 14.00%	15.00%	15.00%	13.00%	13.25% - 13.50%
Primary Security/Collateral/Other Security	Personal Gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee	Personal Gurantee and Corporate gurantee
Re-payment schedule	20-24 Installment	18-24 Installment	18-24 Installment	18-24 Installment	18-24 Installment
Status (Current Balance)	**1,155,961,573**	**42,228,630**	**74,189,756**	**138,006,045**	**34,912,751**

Particulars	2014	2013	2012	2011	2010
Names of lenders	Dhaka Bank Limited	Dhaka Bank Limited	Dhaka Bank Limited	Dhaka Bank Limited	Dhaka Bank Limited
Purpose	To pay off short term liability of other banks	To pay off short term liability of other banks			
Status of Asset Charged	Hypothecation charged	Hypothecation charged			
Sanctioned Amount	100,000,000	100,000,000			
Rate of Interest	14.00%	15.50%			
Primary Security/Collateral/Other Security	Personal Gurantee, Post dated and undated cheque	Personal Gurantee, Post dated and undated cheque			
Re-payment schedule	18 Installment	18 Installment			
Status (Current Balance)	**91,893,639**	**100,516,667**	-	-	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	HSBC	HSBC	HSBC	HSBC	HSBC
Purpose	Import & refinancing of existing loan for capital machinery				
Status of Asset Charged	Import & refinancing of existing loan for capital machinery				
Sanctioned Amount	USD 16,000,000				
Rate of Interest	3 months L+4.50%				
Primary Security/Collateral/Other Security	Personal Gurantee and Corporate gurantee				
Re-payment schedule	20 Installment				
Status (Current Balance)	**1,132,101,526.00**	-	-	-	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	Eastern Bank Limited	Eastern Bank Limited	Eastern Bank Limited	Eastern Bank Limited	Eastern Bank Limited
Purpose		Capital Machinery			
Status of Asset Charged		Hypothecation charged			
Sanctioned Amount		40,000,000			
Rate of Interest		15.50%			
Primary Security/Collateral/Other Security		Personal Gurantee and Corporate gurantee			
Re-payment schedule					
Status (Current Balance)	-	**2,674,100.00**			

Particulars	2014	2013	2012	2011	2010
Names of lenders	Trust Bank Limited	Trust Bank Limited	Trust Bank Limited	Trust Bank Limited	Trust Bank Limited
Purpose	To pay off short term liability of other banks and Capital Macinery	To pay off short term liability of other banks and Capital Macinery			
Status of Asset Charged	Hypothecation charged on pari-passu basis	Hypothecation charged			
Sanctioned Amount	450,000,000	450,000,000			
Rate of Interest	13.00%	15.00% - 15.50%			
Primary Security/Collateral/Other Security	Personal Gurantee	Personal Gurantee			
Re-payment schedule	10 - 20 Installments	10 - 20 Installments			
Status (Current Balance)	**287,064,168**	**414,954,083**	**-**	**-**	**-**

Particulars	2014	2013	2012	2011	2010
Names of lenders	IDLC Finance Limited	IDLC Finance Limited	IDLC Finance Limited	IDLC Finance Limited	IDLC Finance Limited
Purpose	Renovation, Expansion, construction of depo & Procurement of Vehicle	Renovation, Expansion, construction of depo & Procurement of Vehicle	Renovation, Expansion, construction of depo & Procurement of Vehicle	Renovation, Expansion, construction of depo & Procurement of Vehicle	Procurement of Vehicle
Status of Asset Charged	Land Mortgaged and Charge creation with RJSC	Land Mortgaged and Charge creation with RJSC	Land Mortgaged and Charge creation with RJSC	Land Mortgaged and Charge creation with RJSC	
Sanctioned Amount	703,715,301.00	718,294,162.00	5,162,600,149.00	380,173,719.00	67,336,405.00
Rate of Interest	13.50%-16.00%	13.50%-18.00%	13.50%-18.00%	13.50%-18.00%	13.50%-15.90%
Primary Security/Collateral/Other Security	Personal & corporate gurantee, Lease deposit,post dated & undated cheque	Personal & corporate gurantee, Lease deposit,post dated & undated cheque	Personal & corporate gurantee, Lease deposit,post dated & undated cheque	Personal & corporate gurantee, Lease deposit,post dated & undated cheque	Personal & corporate gurantee, Lease deposit,post dated & undated cheque
Re-payment schedule	16-20 Installment	16-20 Installment	16-20 Installment	16-20 Installment	16-20 Installment
Status (Current Balance)	333,604,356.00	458,446,373.00	378,280,407.00	335,753,392.00	51,131,164.00

Particulars	2014	2013	2012	2011	2010
Names of lenders	ULC	ULC	ULC	ULC	ULC
Purpose			Procurement of Vehicle	Procurement of Vehicle	Procurement of Vehicle
Status of Asset Charged					
Sanctioned Amount			10,000,000	10,000,000	10,000,000
Rate of Interest			15.80%	15.80%	15.80%
Primary Security/Collateral/Other Security			Lease Assets and Lease advance	Lease Assets and Lease advance	Lease Assets and Lease advance
Re-payment schedule			16 Installment	16 Installment	16 Installment
Status (Current Balance)	**-**	**-**	**1,904,824.00**	**4,119,647.00**	**7,550,719.00**

Particulars	2014	2013	2012	2011	2010
Names of lenders	IIDFC	IIDFC	IIDFC	IIDFC	IIDFC
Purpose	Launching New product and Expanding production capacity	Capital Machinery, Launching New product, Expanding production capacity construcrion of depo and working capital	Capital Machinery, construcrion of depo and working capital	Capital Machinery, construcrion of depo and working capital	Capital Machinery, construcrion of depo and working capital
Status of Asset Charged					
Sanctioned Amount	150,000,000	350,000,000	200,000,000	200,000,000	200,000,000
Rate of Interest	15.50%	16.50%	18.00%	15.00%	13.25% - 13.75%
Primary Security/Collateral/Other Security	Personal Gurantee, Corporate gurantee, Security deposit, post dated and undated cheque	Personal Gurantee, Corporate gurantee, Security deposit, Lease Assete, post dated and undated cheque	Personal Gurantee, Corporate gurantee, Lease Assete, post dated and undated cheque	Personal Gurantee, Corporate gurantee, Lease Assete, post dated and undated cheque	Personal Gurantee, Corporate gurantee, Lease Assete, post dated and undated cheque
Re-payment schedule	20 Installment	20 Installment	20 Installment	20 Installment	20 Installment
Status (Current Balance)	**107,500,000.00**	**170,000,000.00**	**82,500,000.00**	**122,500,000.00**	**162,500,000.00**

Particulars	2014	2013	2012	2011	2010
Names of lenders	IPDC	IPDC	IPDC	IPDC	IPDC
Purpose	Procurement of Vehicle, to meet working capital and enhance distribution network	Procurement of Vehicle, to meet working capital and enhance distribution network	Procurement of Vehicle, to meet working capital and enhance distribution network		
Status of Asset Charged	Land Mortgaged and Charge creation with RJSC	Land Mortgaged and Charge creation with RJSC	Land Mortgaged and Charge creation with RJSC		
Sanctioned Amount	200,000,000	200,000,000	200,000,000		
Rate of Interest	14.50%	16.00%	16.00%		
Primary Security/Collateral/Other Security	Personal Gurantee, Lease Assete, post dated and undated cheque	Personal Gurantee, Lease Assete, post dated and undated cheque	Personal Gurantee, Lease Assete, post dated and undated cheque		
Re-payment schedule	16 - 57 Installment	16 - 57 Installment	16 - 57 Installment		
Status (Current Balance)	**90,650,017.00**	**117,262,093.00**	**144,456,382.00**	-	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	ILFSL	ILFSL	ILFSL	ILFSL	ILFSL
Purpose					
Status of Asset Charged					
Sanctioned Amount					
Rate of Interest					
Primary Security/Collateral/Other Security					
Re-payment schedule					
Status (Current Balance)	-	-	-	-	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	FAREAST	FAREAST	FAREAST	FAREAST	FAREAST
Purpose					
Status of Asset Charged					
Sanctioned Amount					
Rate of Interest					
Primary Security/Collateral/Other Security					
Re-payment schedule					
Status (Current Balance)	-	-	-	-	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	LANKABANGLA	LANKABANGLA	LANKABANGLA	LANKABANGLA	LANKABANGLA
Purpose					
Status of Asset Charged					
Sanctioned Amount					
Rate of Interest					
Primary Security/Collateral/Other Security					
Re-payment schedule					
Status (Current Balance)	-	-	-	-	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	NFL	NFL	NFL	NFL	NFL
Purpose	Capital Machinery	Capital Machinery	Capital Machinery		
Status of Asset Charged	Lease Assets	Lease Assets	Lease Assets		
Sanctioned Amount	100,000,000	100,000,000	100,000,000		
Rate of Interest	19.00%	19.00%	19.00%		
Primary Security/Collateral/Other Security	Personal Gurantee, Corporate gurantee, post dated and undated cheque	Personal Gurantee, Corporate gurantee, post dated and undated cheque	Personal Gurantee, Corporate gurantee, post dated and undated cheque		
Re-payment schedule	60 Installment	60 Installment	60 Installment		
Status (Current Balance)	64,731,754.00	81,758,598.00	95,860,077.00	-	-

Particulars	2014	2013	2012	2011	2010
Names of lenders	ICB	ICB	ICB	ICB	ICB
Purpose	Expansion				
Status of Asset Charged	Land Mortgaged and charge creation with RJSC				
Sanctioned Amount	500,000,000				
Rate of Interest	15.50%				
Primary Security/Collateral/Other Security	Personal Gurantee , Corporate gurantee, post dated and undated cheque				
Re-payment schedule	10 Installment				
Status (Current Balance)	**450,000,000.00**	-	-	-	-

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of Unsecured Loans with Terms & Conditions

This is to certify that The ACME Laboratories Limited has not taken any unsecured loan from any person/body/related party from 01 July 2009 to 30th June 2014.

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of Inventories

Items	June 30, 2014	June 30, 2013	June 30, 2012	June 30, 2011	June 30, 2010
Raw Materials	824,926,270	694,987,665	504,743,728	330,435,382	7,586,896
Packing Materials	545,143,710	404,785,640	234,585,478	114,678,183	6,075,456
Work-In-Process	375,336,272	356,784,193	255,296,856	5,412,225	4,436,786
Finished Goods	375,693,869	332,745,359	707,878,740	821,085,785	793,084,180
Printing Stationery	18,866,704	21,700,383	18,521,010	-	-
Spare and Accessories	83,036,609	75,263,811	60,032,948	-	-
Total	**2,223,003,434**	**1,886,267,051**	**1,781,058,760**	**1,271,611,575**	**811,183,318**

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of Trade Receivables

Particulars	Amount in BDT				
	June 30, 2014	**June 30, 2013**	**June 30, 2012**	**June 30, 2011**	**June 30, 2010**
General	644,867,067	471,021,187	393,373,660	228,023,633	166,006,224
From Related Party	-	-	-	-	-
From Connected Persons	-	-	-	-	-
Total	**644,867,067**	**471,021,187**	**393,373,660**	**228,023,633**	**166,006,224**

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of any Loan Given by the Issuer Including Loans to Related Party or Connected Persons

This is to certify that The ACME Laboratories Limited had not given any loan to related Party or connected persons from 01 July 2009 to 30 June 2014.

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of Other Income

Particulars	Amount in BDT				
	June 30, 2014	June 30, 2013	June 30, 2012	June 30, 2011	June 30, 2010
Interest Income	96,263,653	13,291,250	-	-	12,547,240
Dividend Income	-	-	-	-	-
Discount received	-	-	-	-	-
Other Non-Operating Income	11,808,324	6,855,546	17,992,913	12,096,145	7,097,400
Total	**108,071,977**	**20,146,796**	**17,992,913**	**12,096,145**	**19,644,640**

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of Turnover

Particulars	Amount in BDT				
	June 30, 2014	June 30, 2013	June 30, 2012	June 30, 2011	June 30, 2010
In Cash	-	-	-	-	-
Through Banking Channel	10,217,931,465	8,973,319,332	8,838,091,913	6,996,750,681	5,557,237,718
Total	**10,217,931,465**	**8,973,319,332**	**8,838,091,913**	**6,996,750,681**	**5,557,237,718**

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of related Party Transaction

Name of the Company/person	Relationship	Nature of Transaction	2009-2010		2010-2011		2011-2012		2012-2013		2013-2014	
			Value of transaction during the year	Balance at year end. Receivable/(Payable)	Value of transaction during the year	Balance at year end. Receivable /(Payable)	Value of transaction during the year	Balance at year end. Receivable/(Payable)	Value of transaction during the year	Balance at year end. Receivable/(Payable)	Value of transaction during the year	Balance at year end. Receivable/(Payable)
The ACME Specialized Pharmaceuticals Ltd.	Subsidiary	Investment in Shares	291,467,400	351,467,400	-	351,467,400	-	351,467,400	-	351,467,400	-	-
		Investment	43,050,218	378,538,037	409,244,948	787,782,985	455,018,519	1.242,801,504	65,001,394	1,307,802,898	-	-
		Finished Goods Sale	-	-	-	-	3,039,860	-	-	-		
		Finished Goods Purchase	-	-	-	-	879,099,489	200,160,699	1,147,490,845	-	-	-
ACMUNIO Int. Limited	Common Director	Advance to ACMUNIO /Current A/C	-	-	58,106,882	58,106,882	23,703,000	81,809,882	13,403,149	95,213,031	25,130,552	120,343,583
		Finished Goods Purchase	-	-	-	-	23,241,702	-	18,344,814	-	43,34,085	-
		Rent on Investment Properties	-	6,462,000	-	-	6,462,000	19,386,000	6,462,000	25,848,000	6,462,000	32,310,000
Sinha Printers Limited	Common Director	Local Supply	293,468,557	(173,556,964)	321,067,576	(264,624,540)	389,102,296	(361,724,694)	336,654,355	(434,543,465)	391,049,968	(388,321,732)
		Provide service &others	-	-	-	-	36,641,407	36,641,407	287,058	36,928,465	329,116	37,257,581
Kalyar Packaging Limited	Common Director	Local Supply	-	-	-	-	3,904,518	-	4,010,112	(3,781,826)	45,570,985	-
Kalyar Replica Limited	Common Director	Local Supply	-	-	-	-	138,552	-	1,076,733	-	7,083,759	-
Mr. Md. Hasibur Rahman	Employee and Shareholder (0.037%)	Advance against Land	-	-	-	-	60,000,000	60,000,000	5,000,000	65,000,000	15,000,000	80,000,000

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Reconciliation of Business Income Shown in Tax Return with Net Income Shown in Audited Financial Statements

Particulars	2013-14		2012-13	2011-12	2010-11	2009-10
	Taxable Unit	Tax Exempted Unit	Taxable Unit	Taxable Unit	Taxable Unit	Taxable Unit
Income shown in Audited Financial Statements	978,957,226	225,887,007	810,707,935	802,304,895	583,748,346	364,490,469
Less: Other Income	108,071,977	-	20,146,796	17,992,913	11,702,578	19,644,640
Add: Accounting Depreciation	264,706,019	46,922,483	-	-	-	-
Add: Inadmissible Item	121,549,165	6,971,158	-	-	-	-
	1,257,140,433	**279,780,648**	**790,561,139**	**784,311,982**	**572,045,768**	**344,845,829**
Less: Admissible Expenses	94,490,120	6,947,439	-	-	-	-
Less: Depreciation	167,408,770	54,964,342	-	-	-	-
	995,241,543	**217,868,867**	**790,561,139**	**784,311,982**	**572,045,768**	**344,845,829**
Add: Other Income	108,071,977	-	20,146,796	17,992,913	11,702,578	19,644,640
Income Shown in Tax Return	**1,103,313,520**	**217,868,867**	**810,707,935**	**802,304,895**	**583,748,346**	**364,490,469**

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Note: As per auditor's accounts 2010-11, the profit after tax was shown amounting Tk. 583,748,346. But as per auditor's certificate under section 135(1) and para 24(1) of part II of schedule –III of the Companies act 1994, the reported profit was shown amounting Tk. 584,141,913. The difference amounting Tk. 393,567 was arisen due to prior year adjustment in the year ended 30 June 2012.

Auditors' Discloser Regarding Confirmation That All Receipts and Payments of the Issuer above Tk. 5, 00,000/- (Five Lac) were made through Banking Channel

This is to certify that all receipts and payments excepting adjustment entries (specimen sheet enclosed) of The ACME Laboratories Limited above Tk. 5,00,000/- (Five lac) were made through banking channel for the year ended 30th June 2010 to 30th June 2014.

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Specimen sheet

The ACME Laboratories Ltd.

Adjusting Entries Tk. 500,000 and above

Sl. No.	Date	Vr. No	Purpose	Amount (Tk.)
01	20.04.2010	42	Foreign Business Travelling	520,200.00
02	11.04.2011	19	Welfare & Recreation	682,500.00
03	27.09.2012	2	Seminar & Conference	987,250.00
04	26.11.2012	3	Entertainment	660,800.00
05	01.04.2014	10	Sales Promotional Expense	550,000.00

Auditors' Discloser Regarding Confirmation that Bank Statements of the Issuer are in Conformity with Its Books of Accounts

This is to certify that Bank Statements of the ACME Laboratories Limited are in conformity with its books of accounts for the year ended 30th June 2010 to 30th June 2014.

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Statement of Payment Status of Tax, VAT and Other Taxes/ Duties

Particulars	Payment Status				
	2013-14	2012-13	2011-12	2010-11	2009-10
TAX	382,397,340	367,371,864	239,603,332	171,415,191	128,512,936
VAT	1,454,890,617	933,816,142	1,075,432,645	1,044,451,740	850,755,148
Other Taxes/Duties	119,231,250	75,579,632	66,577,348	60,752,923	51,804,513

Place: Dhaka
Date: 08 February, 2016

Sd/-
Pinaki & Company
Chartered Accountants

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

REPORT: RR/7621/15

This is a credit rating report as per the provisions of the Credit Rating Companies Rules 1996. CRISL's entity rating is valid one year for long-term rating and 6 months for short term rating. CRISL's Bank loan rating (blr) is valid one year for long term facilities and up-to 365 days (according to tenure of short term facilities) for short term facilities. After the above periods, these ratings will not carry any validity unless the entity goes for surveillance.

CRISL followed Corporate Rating Methodology published in CRISL website www.crislbd.com

Date of Rating: October 15, 2015		**Valid up to: October 14, 2016**
	Long Term	**Short Term**
Entity Rating	A+	ST-3
Outlook	Positive	
Bank Facilities Rating		
Bank/FI	Mode of Exposures (Figures in million)	Ratings
DBBL	WCLL* of Tk. 630.00	*blr* A+
	TLO** of Tk. 1,074.61	*blr* A+
Trust Bank Ltd.	WCLL* of Tk. 2,338.00	*blr* A+
	TLO** of Tk. 218.72	*blr* A+
SCB	WCLL* of Tk. 3,030.00	*blr* A+
	TLO** of Tk. 864.64	*blr* A+
EBL	WCLL* of Tk. 1,490.00	*blr* A+
IPDC	TLO** of Tk. 171.29	*blr* A+
HSBC	WCLL* of Tk. 3,558.98	*blr* A+
	TLO** of Tk. 885.05	*blr* A+
Dhaka Bank Ltd.	WCLL* of Tk. 700.00	*blr* A+
	TLO** of Tk. 73.44	*blr* A+
IDLC	TLO** of Tk. 227.93	*blr* A+
IIDFC	TLO** of Tk. 330.00	*blr* A+
Lanka Bangla Finance	TLO** of Tk. 950.00	*blr* A+
UFL	LFO*** of Tk. 170.00	*blr* A+
ILFSL	LFO*** of Tk. 450.00	*blr* A+
FFIL	LFO*** of Tk. 475.00	*blr* A+
Agrani Bank Ltd.	WCLL* of Tk. 650.00	*blr* A+
The City Bank Ltd.	WCLL* of Tk. 1,580.00	*blr* A+
AB Bank Ltd.	WCLL* of Tk. 900.00	*blr* A+

**WCLL-Working Capital Loan Limit; **TLO-Term Loan Outstanding; ***LFO-Lease Finance outstanding; DBBL-Dutch Bangla Bank Ltd.; SCB-Standard Chartered Bank; EBL-Eastern Bank Ltd.; ULCL-United Finance Ltd.; FFIL-Fareast Finance & Investment Ltd.; ILFSL-International Leasing and Financial Services Ltd.*

Address:
CRISL
Nakshi Homes
(4th & 5th Floor)
6/1A, Segunbagicha,
Dhaka-1000
Tel: 9530991-4
Fax: 88-02-953-0995
Email:
crisldhk@crislbd.com

Analysts:

Md. Shohel Khan
shohel@crislbd.com

Dil Khadija Banu
beli@crislbd.com

Entity Rating
Long Term: A+
Short Term: ST-3

Outlook: Positive

Rating based on financials up to June 30, 2015

THE ACME LABORATORIES LIMITED

ACTIVITY
Manufacturer of Pharmaceutical products

DATE OF INCORPORATION
1954

CHAIRMAN
Afzalur Rahman Sinha

MANAGING DIRECTOR
Mizanur Rahman Sinha

EQUITY
Tk. 11,372.63 million

TOTAL ASSETS
Tk. 23,259.77 million

1.0 RATIONALE

CRISL has reaffirmed the Long term rating to 'A+' (pronounced as single A plus) and Short term rating to 'ST-3' of 'The ACME Laboratories Limited' (ALL) based on its financials and other relevant quantitative and qualitative information up to the date of rating.

These ratings reflect that the company has been operating with average business and financial performance, State-Of-The-Art technology, sound production facilities, good number of products in the market, regular loan repayment history etc. These rating strengths are partially offset by moderately debt based capital structure, long cash conversion cycle, risk of foreign exchange, competition, TRIPS Agreement expiration etc.

ALL, the flagship company of renowned ACME Group, is a front footed pharmaceutical company, which has been involved in the manufacturing and marketing of Pharmaceutical finished products since 1954. The company mainly engaged in manufacturing human, herbal & ayurvedic products and veterinary products. Over its period of operation, the company has launched more than 700 products in different dosage forms in the market. Moreover, after meeting local demand, it entered into the foreign market in the year 1999. During 2014-15, the average capacity and capacity utilization of ALL increased to some extent. The company distributes the products through its own distribution channel throughout the country. The reported turnover of the company stood at Tk. 11,496.41 mil. and Tk. 10,217.93 mil. in FY 2014-15 and FY 2013-14 respectively with a growth of 12.51%. The profit after tax of ALL stood at Tk. 921.92 mil. and Tk. 893.89 mil. in FY 2014-15 and FY 2013-14 respectively.

Entities rated in this category are adjudged to offer adequate safety for timely repayment of financial obligations. This level of rating indicates a corporate entity with an adequate credit profile. Risk factors are more variable and greater in periods of economic stress than those

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

rated in the higher categories. The Short Term rating indicates good certainty of timely payment. Liquidity factors and company fundamentals are sound. Although ongoing funding needs may enlarge total financing requirements, access to capital and financial markets is good.

CRISL also placed the company with "Positive Outlook" with an expectation of no extreme changes in economic or company situation within the rating validity period.

2.0 CORPORATE PROFILE

2.1 The Genesis

The ACME Laboratories Limited (ALL), the flagship company of renowned ACME Group, is a front footed pharmaceutical company in Bangladesh. Initially in 1954, the company was a proprietorship concern engaged in manufacturing few oral liquid products. Later on, the enterprise converted into a private limited company in the year 1976 and started substantial Balancing, Modernization, Replacement and Expansion (BMRE) in its production unit. At that time, the company was engaged in manufacturing human products only. In 1999, ALL started launching animal health products and herbal & ayurvedic products in the year 2004. At present, the company is consistently building upon its portfolio of products, currently producing more than700 products in different dosage forms encompassing broad therapeutic categories. As on June 30, 2015, it has 494 human products, 37 herbal & ayurvedic products and 170 veterinary products. After meeting local demand, it entered into the foreign market in the year 1999. The company had obtained ISO 9001:1994 certifications in the year of 1999 and gradually upgraded to ISO 9001:2008 certificates in the year of 2011 for maintaining the quality of the product. Initially, ALL had a one subsidiary namely the ACME Specialized Pharmaceutical Ltd. but on 31st January 2014, this subsidiary amalgamated with the ACME Laboratories Ltd. The company was sponsored by a prominent entrepreneur Late Hamidur Rahman Sinha. At present ALL is a public limited company and is operating with a paid up capital of Tk. 1,616.02 mil. as on June 30, 2015 against authorized capital of Tk. 5000.00 mil. The corporate office of the company is located at 1/4, Kallayanpur, Mirpur Road, Dhaka-1207 and the plant is located at Dhamrai, Dhaka.

2.2 Ownership Pattern

Ownership pattern of ALL is diversified among Sponsors & Directors, institutional shareholders and others. Right now, ALL had total of 161,601,700 ordinary shares of Tk. 10.00 each owned by 68 shareholders. The Sponsors & Directors held 75.48%of the total shares followed by other individual Shareholders including several financial institutions held 24.52%. A summary of the present ownership structure and owners details are delineated below:

Diversified ownership pattern

Name	Designation	Educational Qualification	No of Shares	Share holding (%)
Mr. Afzalur Rahman Sinha	Chairman	MBA (USA)	17,214,336	10.65
Mr. Mizanur Rahman Sinha	Managing Director	B. Com	20,426,565	12.64
Dr. Jabilur Rahman Sinha	Deputy Managing Director	M.Sc. Phd, Organic Chemistry (USA)	4,860,696	3.01
Mrs. JahanaraMizan Sinha	Director	Under graduation	10,519,744	6.51
Mrs. Nagina Afzal Sinha	Director	B.A	11,888,433	7.36
Mr. Nasir –Ur- Rahman Sinha	Shareholder	M.A. (D.U)	6,160,405	3.81
Mrs. Parveen Akhter Nasir	Shareholder	B.A	5,401,517	3.34
Mrs. Hasina Jabil Sinha	Shareholder	B.Sc	4,859,245	3.01
Other Sponsor Shareholders	Shareholder	-	40,639,659	25.15
Institutional (placement) Shareholders	Shareholder	-	38,476,100	23.81
Other individual (placement) Shareholders	All Shareholder	-	1,155,000	0.71
Total			161,601,700	100

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

2.3 Products & Market Position

Wide range of products

The company is consistently adding new products in its portfolio. In 2014-15, ALL added 61 new products in the product portfolio. As earlier mentioned that, the company has been operating with a diversified product ranges in human, veterinary and herbal segment. Presently, the company has total 494 human products in the form of tablets, capsules, dry syrup, eye/ear/nasal drop, creams, injectables, liquid, ointments, inhalers, suppository, liquid in hard gelatin, oral saline, IV infusions etc. The products have been designed and produced to act on various areas of human health including physical and mental disorder. The company also has total 170 veterinary products in the form of liquid, injection, WSP, Premix, Bolus etc and 37 herbal &ayurvedic products in the form of capsule, liquid & tablet. There are around 65 new products in the pipeline, which will be launched within 2015–2016 financial year under the existing established facility.

The company has good market position with its products mainly; including Tenoloc (Atenolol), Ecosprin (Aspirin), Monas (Montelucast), Fulspec (Meropenem), Nystat (Nystatin) (Generic Name) as market leader of its types. As per IMS report as on 31st May, 2015, the company is holding 9th position among 258 market players with a market share of 3.89%.

The company currently exports more than 200 pharmaceutical products to different countries in Southeast Asia, Africa and Central AmericaAt present, the company is successfully exporting its quality products to Sri Lanka, Nepal, Bhutan, Myanmar, Thailand, Vietnam, Philippines, Cambodia, Hong Kong, Mongolia, Lao PDR, Iraq, Ethiopia, Kenya, Nigeria, Uzbekistan, Somalia, Guatemala, Belize, Fiji etc. In addition to human pharmaceuticals, the company is exporting its animal-health products to Myanmar, Sri Lanka etc and exploring the opportunities of Herbal &Ayurvedic products in South Asia and Africa. The company has further market exploration plan to USA, Europe and Latin America.

3.0 PHARMACEUTICALS INDUSTRY PREVIEW

Prospective industry

The pharmaceutical sector in Bangladesh, one of the fastest growing sectors of the economy, is poised to transform the country into a global hub of quality medicines. The $ 1450 million sector with 258manufacturers is continuously expanding with new products. Beginning in the 1950s, a few multinationals and local entrepreneurs set up manufacturing facilities in the then East Pakistan. Now there are 258 small, medium and large local and multinational pharmaceutical companies operating in Bangladesh. Of the companies, the leading market players (Square, Beximco, Eskayef, Incepta, ACME, Opsonin, Renata, ACI, Aristopharma Ltd and Drug International) take up nearly 75 percent of the total market. Out of 258companies, 200 have their own manufacturing facilities of which five are multinationals.

The Pharmaceutical Industry in Bangladesh is paying the second largest revenue to the Government's exchequer. Currently, the market size of the local pharmaceutical industry is around Tk. 11,972 crore. Bangladesh has ample scope for its pharmaceutical companies to become one of the most competitive players in global market in the days to come due to the availability of cheap manpower and utility services.

The pharmaceutical industries of Bangladesh manufacture about 8,000 generic drugs under 26,813 registered brands in different dosages and strengths. The government also controls the price of 209 generic drugs in specified dosage forms along with imported medicines and 41 APIs (Active Pharmaceutical Ingredients) produced in the country. Although the pharmaceutical industry of Bangladesh has advanced much, but backward linkage of this industry is not very strong and sufficient. The industry has succeeded in securing its place in the world market in a very short span of time, but almost all of its necessary raw materials need to be imported from abroad. The sector is gradually getting involved in producing of APIs (Active Pharmaceutical Ingredients). Twenty-one different companies now locally manufacture 41 API's. However, compared to huge local demand, more API industries need to be set up. The API Park will inject fresh momentum into the pharmaceutical industry.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

Besides this, some top edge companies already started producing anti-cancer and antiretroviral drugs previously being imported from abroad. The pharmaceutical market size as per BMI is: Tk.138.81 billion (US$1.78 billion) in 2013 and Tk.154.62 billion (US$1.99 billion) in 2014; +11.4 per cent in local currency and +11.9 per cent in US dollars.

Among the 258 licensed pharmaceutical companies, almost 94 percent of pharma business is controlled by 30 companies and almost 98.0 percent of the over BDT 11,758Crore pharma market of the country is catered by a total of 50 companies. It is indeed appreciable that after meeting 97.0 percent of the local demand, we are presently exporting to about 87 destinations of the world including stringently regulated markets in Europe along with the mild regulated countries like the Philippines, Vietnam, Singapore, Sri Lanka and 49 LDCs in Asia pacific and Africa.

The number of exporting firms ranged from 35 to 47, according to available sources. Our yearly pharmaceutical exports are Tk.7.33 billion in 2014 (+19.0 over 2013) against Tk.6.20 billion in 2013 (+15 per cent over 2012).

The LDC's have been enjoying a patent-free regime till 2016 as per WTO/TRIPS agreement. As per latest development, WTO member states have to legislate and enforce the minimum standards for the protection of intellectual property such as copyrights, patents, designs, trademarks. As such local pharmaceutical manufacturers will have to cease production, distribution and sale of medicines that come under this intellectual property rights agreement as elsewhere in the world. But WTO could not specify the number of products classified under patent protection rights that may be 25.0 per cent of the total branded generics and this will initiate a major change in the industry scenario. First, price control will be lifted. Producers will have to pay for their patented products, as well as license fees. But stipulated agreement clauses for export of patented products may create problems, as Bangladesh cannot export patented products without patent owners' approval, which will be more costly. In addition, foreign firms will get free access to local market, and multinationals can produce several products in Bangladesh that are not allowed now.

However, it may be noted that 75 per cent of the drugs in the WHO list are not subject to patent protection. And many of the products in Bangladesh are generics, and thus not subject to WTO patent protection jurisdictions. However, costs of licensing fees, impeded access to export markets, withdrawal of local protection may cause a considerable hike in import costs. This is why, forward-looking local drug manufacturers will have to adapt their product portfolio as required or else suffer a steep drop-off in sales. However, the global 'patent cliff' may mitigate this to some extent if we could develop reverse engineering mechanism like India/China along with internationally accredited bio-equivalence test laboratories in Bangladesh to comply with the original kinetics and dynamics of pharmaceutical products under the drug regulatory acts.

As implementation of the much dreaded TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) has been haunting the global pharmaceutical industries for years, twenty drugs, including cholesterol-lowering Atorvastatin Lipitor of Pfizer, blockbuster blood thinner Plavix of Bristol-Myers and Sanofi, Eli Lilly's atypical antipsychotic Zyprexa and Takeda's diabetes medication Actos will become generic drugs in the years ahead.

By the year 2016, the world's best-selling drugs, with about $255.0 billion in global annual sales, are set to go off-patent, as recent data from London-based research firm Evaluate Pharma has revealed. Once the blockbusters lose their patent protection, lower-price generics are expected to decimate as much as 90.0 per cent of the sales of innovator companies.

Under the changing circumstances, leading pharma companies will have to look for new ways and strategies to fill the gap instead of relying on traditional patent blockbuster models. All industry players will have to embrace the generic market model as an increasingly important part of the overall pharmaceutical lifecycle in conformity with the economies of LDCs like Bangladesh.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

4.0 BUSINESS ANALYSIS

4.1 Production Facilities and Environment Compliance

Sound production facilities

ALL has established its production facilities with well-equipped production units in its Factories. The company has established its manufacturing plant in such a way that it has been designed, built and validated by active support experts with compliance to the cGMP concept and local Drugs Administration regulation. The production plant is divided in five areas- i) Solid Dosages unit; ii) LVP, Liquid & Semisolid unit, iii) Cephalosporin unit iv) General unit and v) Herbal, Nutraceuticals & Ayurvedic unit. The company has divided and dedicated manufacturing facilities for Human, Herbal &Ayurvedic and veterinary products. ALL has established production unit for Human products in the form of Tablet, Capsule, Liquids, Dry Syrup, Ointment, Cream, Suppository, Inhaler, Eye/Ear/Nasal Drop, Injection, Liquid in hard gelatin, Oral saline, IV infusion etc and for Veterinary products in the form of Bolus, Liquid, Premix, WSP and Injection and for Herbal &Ayurvedic products in the form of Capsule, Liquid and Tablet. The yearly production capacity of human product in the form of tablet is 3,368.59 million Pcs; capsule 630.49 million Pcs; dry syrup 18.41 million bottle; liquid 87.23 million bottle; cream 17.93 million tube; suppository 32.66 million Pcs; eye/ear/nasal drop 10.14 million Phials; injection (Amps) 35.38 million Pcs; injection (Vial) 15.35 million Pcs; ointment 6.16 million Tube; inhaler (DPI) 66.69 million cans; inhaler (MDI) 1.46 million canister, infusion 4.68 million Pcs and sachet 28.20 million Pcs. On the other hand, yearly production capacity of veterinary products in the form of bolus 217.45 million Pcs; liquid 5.21 million phials; premix 27.59 Pcs; WSP 8.58 million Pcs & injection 12.49 million vial and herbal &ayurbedic products in the form of capsule 32.37 million Pcs; liquid 8.71 million Pcs and tablet 29.88 million Pcs.

Most of the machineries have been sourced from Germany, Switzerland, UK, USA, Taiwan, China and India. The production processes are mostly highly automatic along with some being manual. The expert team of ACME, which consists of more than 155 Pharmacist and 62 Engineers and a good number of professionals from various disciplines, are seasoned and experienced enough to use the facilities for production to fulfill the demand of target customers. Moreover, the company has its own transportation facilities for the smooth delivery of goods around the country. All the units enjoy required physical infrastructural facilities including power, water, gas and good road communications facilities. The company maintains a high degree of quality control from the stage of raw material procurement, production process, storage of final product and marketing the final product. Factory compound is occupied with separate building for administration, core production and storage, quality control and other ancillary facilities. The production, QA and QC buildings are accommodated with cGMP (current Good Manufacturing Practices) compliant machineries and systems. Highly sophisticated HVAC systems are used to condition, monitor and supply clean air to the working zone according to the manufacturing zone concept, capture and control any dust, vapor, gas or fume generated, as well as treat re-circulated and/or exhausted air. Temperature and moisture level are maintained at the desired level through this system. To comply with the instructions of Directorate of Environment (DoE) as well as with GMP guidelines, the plant has been facilitated with effluent treatment plant (ETP), emission control, etc. Factory of ACME is located at Dhamrai, Dhaka; about 40 Km north-west to Dhakaon 16acres land. Unit wise production facilities are delineated below:

4.1.1 Solid Dosages Facility

Solid Dosages Unit (SDU) is State Of The Art and professionally managed facility for manufacturing oral solid dosages forms. Total facility area is 2,19,162 sft. It is a dedicated building for non-penicillin, non-cephalosporin and non-steroid products. The finest and largest solid dosage forms manufacturing facility is constructed by active guidance of European Consultant. Facilities and processes are of the highest quality which has been designed to achieve quality products with vision to export in global market. Manufacturing Capabilities includes Tablet, Capsule, Pellets/ Powder for Suspension, Sachets, Liquid in Hard Gelatin Capsule. On the other hand, Packaging Capabilities Includes Blister with HAPA Foil Printing, Strip, Blister, Sachet and Bottle Filling.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

4.1.2 LVP, Liquid & Semisolid Facility

In order to meet the growing demand of healthcare, ACME has already established a technologically advanced plant which will produce Large Volume Parenteral (LVP), Small Volume Parenteral (SVP), Liquid, Cream and Ointment. The LVP & SVP facility ensure highest quality standard during manufacture. The whole manufacturing process provides absolute sterile manufacturing condition, no human physical contact with the product and a class 100 clean room. This is a highly sophisticated fully integrated production process where in one continuous operation the container is blown, formed, filled with the solution and sealed. The entire process takes place in a completely sterile environment within the machine, without human intervention which eliminates any risk of contamination. The Quality Control laboratory at the plant ensures intensive quality control checks at all the stages of production process.

4.1.3 Cephalosporin Facility

To prevent cross-contamination between products as well as to safeguard the workers' health and environmental safety is the prime responsibility of the pharmaceutical manufacturer. Therefore, it is mandatory to manufacture cephalosporin products in separate and dedicated self-contained areas with separate air handling facilities. True to its quality slogan Perpetual Quest for Excellence, ACME has set up a new dedicated State-Of-The-Art cephalosporin plant to offer world-class healthcare products. The Cephalosporin plant is built on a plinth area of 17,000 square feet. The building height is 76 feet and it comprises of six floors. Manufacturing Capabilities includes Tablet, Capsule, Pellets/ Powder for Suspension. On the other hand Packaging Capabilities includes blister with HAPA Foil Printing, Strip, Blister and Bottle Filling.

4.1.4 General Facility

General Unit (GU) is State Of The Art facility and professionally managed manufacturing facility. Manufacturing Capabilities for human products includes Tablet, Capsule, Injections, Liquid, Powder for Suspension, Cream & Ointment, Inhaler, Eye, Ear & Nasal drops and Suppository. General Units also produces a good number of dosage forms for animal health which includes Injection, Liquid, Bolus, Premix, Water soluble powder, Cream and Ointment. Packing capabilities of this unit includes Strip, Blister, Sachet, Vial Filling, Bottle & Tube Filling.

4.1.5 Herbal, Nutraceuticals & Ayurvedic Facilities

Herbal, Nutraceuticals & Ayurvedic manufacturing facilities emerged the year 2004 and after meeting all regulatory requirements production and marketing of Ayurvedic items started in the same year. In this facility State-of-the-art extraction system that runs from starting of herbal raw materials feeding to finished product packaging without human contact Manufacturing capabilities of this unit includes Liquid, Tablet, Capsule, Powder, Semisolid, Cream and Ointment.

In order to generate electricity the company has 7 gas generators with a capacity 8.91MW (1.6 MW 3 nos. 1.03 MW 3 nos, 1.02 MW 1no.) and 7 diesel generators with capacity 7.736 MW (1.6 MW 3 nos. 1.056 MW 1 no., 0.4 MW 1 no. 0.36 MW 1 no.). In addition the company has REB connection that is mainly used for off time lighting purpose. Water is drawn by own deep Tube well and stored in central storage tank (300,000 liter capacity) for distribution throughout the site. The gas required for both official and manufacturing purpose is supplied from Titas Gas Transmission & Distribution Company Limited.

4.2 Quality Control Mechanisms

Strict quality control mechanisms

The ACME Laboratories Ltd. maintains state-of-the-art manufacturing facilities and strict quality control procedure for ensuring best quality products to the customers at every steps of the pharmaceutical product manufacturing starting from sourcing of materials to dispatching of finished products. The Company's quality slogan is -"Perpetual Quest for Excellence". Current Good Manufacturing Practice (cGMP), Good Laboratory Practices (GLP), Standard Operating Procedures (SOP) and best practices that are proven effective are followed in every step of manufacturing, packaging & laboratory operations. ACME has three (3) most modern Quality Control (QC) laboratories which are well equipped with the most modern & sophisticated equipments like High Performance Liquid Chromatography (HPLC), UV-Visible Spectrophotometer, Gas Chromatography (GC), Total Organic Carbon analyzer (TOC), Fourier Transform Infrared Spectrophotometer (FTIR), Atomic Absorption Spectrophotometer (AAS), Aerodynamic particle size analyzer, Single stage cascade impact or, Kinetic LAL Analyzer, API

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

(analytical profile index) for microbial identification, Dissolution Tester with auto sampler and several other instruments & accessories to meet the world class standards like ISO, WHO, cGMP, UK MHRA, US FDA, PICS etc for ensuring the highest quality of the products. The total quality operational activities are accomplished by three departments – Quality Assurance, Quality Control and Research & Development (R&D), which are comprised of competent, trained and highly qualified professionals like Pharmacists, Chemists, Biochemists, Molecular Biologists & Microbiologists.

4.3 Supply Chain Management

4.3.1 Procurement

The company is maintaining a fully automated purchasing system for supply chain management. It starts from planning process which is supported by some basic components like sales target from sales department, materials reports from Warehouse, finished product in factory warehouse including different sales centers and in-process stock from production division. The process also certainly ensures that the inventory will be maintained in a proper level with minimum chances of overstock or under stock. As an ISO certified organization the company has the written Standard Operating Procedures (SOP) for all its operation which certainly ensures process capability for its operations.

The Company is engaged in formulating pharmaceutical products which requires numerous raw materials like active pharmaceutical ingredients (API), excipients, primary & secondary packing & packaging components. For quality control and laboratory management process various chemicals and reagents are also required to purchase from different sources. Most of the raw materials are imported from foreign sources with a few from local market due to certain country regulations. On the other hand, maximum primary packing components are imported from world market including a few from local sources. Besides the above, all sort of secondary packaging materials and ancillary items are procured from local markets.

Raw materials (Active & Excipients) are mainly imported from world market like Roquette France/Italy, MolkereiMeggle, Germany, DMV Fonterra Excipients, Germany/USA, BASF Germany / USA, Dr. Paul Lohamann GmbH, Germany, AIE Pharmaceuticals, USA, Daewong Korea, GATT fosse France, IPOCHEM Poland, NCPC Pharmaceutical Co Ltd. China, Zhejiang GuobangPh Co Ltd. China, Zhejiang xinxing Pharmaceutical co Ltd., China , CSPC China, Zhejiang HuayiPh Co Ltd., China, Nectar Life Sciences Ltd. India, Aurobindo Pharma Ltd. India, Morepen laboratories Ltd. India, Aarti Drugs Ltd. India, IPCA Laboratories Ltd. India, Dr. Reddy's Laboratories India etc. These are some reference name only although the company deals with almost 300 (three hundred) manufacturers and suppliers across the world. Due to the country regulations the company has to purchase some ingredients like Paracetamol, Flucloxacillin, Amoxycillin, Cloxycillinetc from local sources like Beximco Pharmaceuticals Ltd., Gonoshasthaya Pharmaceuticals Ltd., NIP Chemicals, Globe Pharmaceuticals Ltd., Square Pharmaceuticals Ltd. etc and major primary components like Alu / Alu bottom foil, Glass vial, Infusion bottles, Capsule shells, DPI Device, Aluminium Canister, Metered Valve , Actuators , PVC Film, PVC/PVDC films are imported from Korea Aluminium Ltd Korea, SGD Asia Pacific , Shangdong Pharnaceuticals Glass Co. Ltd., Viscose Closure, UK, Sam-A Aluminium, Korea, ACG Associated Capsules Pvt Ltd., Dinesh remedies, Caprihans Ltd. India, YanzhouKaier Co Ltd. China, Dong Won Systems Co Ltd. Korea, Coaster Italy, Scanchem International Ltd. India etc. Rest other primary components like Plastic container, Ampoule, Glass bottles, Printed Aluminium Foils etc are purchased from available local sources like Padma Group, Bengal Glass, Liza plastic, Bismillah Plastic, Luna Plastic, Leos Plastic, Packstone Ltd., Fairbiz, Metro Foils, Pinacle Foils etc of Bangladesh.

4.3.2 Distribution and Marketing System

Wide distribution network

The company has a well-trained sales team and also has well established distribution channel all over the country. The company has one central warehouse at Hemayetpur, Savar, Dhaka where all finished products are kept for distribution. To make its quality products available at every corner of the country, ALL has a strong distribution network consisting of 20 depots throughout the country with its own 104 delivery vans to supply its products.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

Since 1954, being constantly focused on the diverse requirements of the customers, ACME has expanded its business into different therapeutic areas through ensuring different flexible options in terms of both acute and chronic care treatment needs. To keep pace with the trend of globalization and exploit the benefits of modern IT infrastructure ACME has adopted versatile approach that will help maximize customer satisfaction. ACME wants to gain competitive edge through increasing its understanding of customers' needs and offering services that will be unmatched in this industry. Its endeavor is to become a truly value focused and market oriented company with vestiges of genuine customer care and corporate citizenship. Its real intent is to establish new and innovative tracts of therapeutic care that are always consistent and commensurate with the rising needs of therapeutic areas from the perspectives of domestic market.

5.0 CORPORATE GOVERNANCE

Corporate governance is a term that refers broadly to the rules, procedure and laws by which businesses are operated, regulated, and controlled in order to ensure the interest of the stakeholders of a corporate body. This is central to the continued strong performance of the business in a manner which is sustainable in the long term and gains the continued confidence of investors. Furthermore for the company, good governance is about managing the business effectively and responsibly and in a way which is honest, transparent and shows accountability.

The Company has a two-tier senior management, comprising the Board of Directors and the Audit Committee.

5.1 Board of Directors

8 members Board

The Board of ALL comprises of 8 Directors including Chairman, Managing Director & one nominee Director from Investment Corporation of Bangladesh and 2 Independent Directors. Mr. Afzalur Rahman Sinha is the Chairman of the Board; Mr. Mizanur Rahman Sinha is the Managing Director, Dr. Jabilur Rahman Sinha is Deputy Managing Directors and others Directors are Mrs. JahanaraMizan Sinha, Mrs. Nagina Afzal Sinha, Mr. Md. Iftikhar-Uz-Zaman (nominated by ICB) and two Independent Directors are Syed Shahed Reza & Ms. Fouzia Haque, FCA. Besides, the Directorship role, Mr. Mizanur Rahman Sinha acts as the Managing Director and looks after overall operations including Sales and Marketing, Production and Supply Chain Management. The Board is involved in both operational level as well as policy matters of the company. The Board formulates strategic objectives and policies for the company, provides leadership and supervises management actions in implementing objectives of the company. During FY 2014-15 and FY 2013-14, the Board conducted 10 and 9 meetings respectively.

5.2 Corporate Management

Experienced management team

The operation of ALL is being looked after by an experienced management team having wide exposures in this sector. Mr. Mizanur Rahman Sinha, the Managing Director of the company leads the team with the assistance of a host of senior professionals. The management team consists of qualified professionals with wide experience in pharmaceuticals industry. Summary status of corporate management team is stated in the following:

Name	Designation	Educational Qualification	Experience in Company	Total experience
Mr. Mizanur Rahman Sinha	Managing Director	B.Com	38	47
Mr. Md. Hasibu rRahman	ADMD (Finance & Accounts), ISO & Internal Audit	B.Com, CA (Final Group-I)	36	40
Mr. Parvez Hashim	Executive Director (Plant Operation)	M. Pharm	1 month	37
Mr. Golam Rabbani Bhuiyan	Director, Sales	Below graduation	36	36
Mr. A.K.M. Mushiur Rahman Khan	Director, PPIC	M.Com- DU, FCMA	18	22

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

Mr. Animesh Pal	Consultant, Brand Management	M. Pharm, Diploma in Business Administration	01	17
Mr. Md. Zahangir Alam	Chief Financial Officer	M Com- DU, FCMA	14	16
Mr. A.K.M Mahbubur Rahman	Head of Production (Veterinary)	M.Sc(RU)	06	45
Mr. Swapan Kumar Gain	Head of Production (Solid Dosages)	M. Pharm (DU)	08	22
Mr. Md. Humayun Kabir	Head of International Business	M. Sc (DU), MBA (UK)	10	22
Mr. S. M. Shafiquzzaman	Head of Production (General)	M. Pharm (DU)	04	23
Mr. S.A.B.M Shahadat Ali	Head of Quality Operation	M. Pharm (USTC)	04	16
Mr. Mohammad Abdul Hamid Miah	Head of Factory Admin & HR	M.A (RU), MBA	02	26
Mr. Bashir Ahmed	Head of Production (Cephalosporin)	M. Pharm (DU)	11	18
Mr. Md. Abu Sayed Khondoker	Head of Engineering (Solid)	B. Sc, Eng. Mech (DUET)	09	19
Mr. Nur Ahammead Bhuiyan	Head of Engineering (General)	B.Sc, Eng. (DUET) MBA	04	16
Mr. Tushar Kanti Kundu	Head of HR	M. Sc (DU), MBA, L.L.B	19	19
Mr. Md. Rafiqul Islam	Company Secretary	MBA (Mkt.), ACS	01	14
Mr. Syed Nazmul Huda	Head of IT	M.Com, Diploma in CSE	22	22
Mr. S. M. Rezaul Ahsan	Head of QMS&OD	M.Sc (JU), MBA	13	13
Mr. Md. Rubel Miah	Head of Internal Audit	M.Com (NU), CA (PE-II)	04	06
Ms. Molla Sabiha Sultana	Project Coordinator, CSR	M. Sc (BAU)	1 month	15

Mr. Rahman has successfully been operating the company since inception. With a dedicated and experienced corporate team, he has successfully built up a sound corporate structure and good brand image through wide range of healthcare products in the market. The overall operation of ALL has been carried out through a number of division including H.R, PPIC, Marketing, IT , Finance & Accounts, International Business, QMS, Internal Audit, Production, Quality Operation and Engineering. Most of the Divisional at Head Office and Factory level are headed by senior and experienced Executives.

5.3 Audit Committee

3 members audit committee

The Audit Committee currently consists of three members. Committee is chaired by an Independent Director named Ms. Fouzia Haque, FCA and other members' are- Dr. Jabilur Rahman Sinha & Mr. Md. Iftikhar-Uz-Zaman (Nominated by ICB). The Committee assists the Board of Directors of the Company and conducts its business considering the terms and references mentioned in the Corporate Governance Guideline vide notification no. SEC/CMRRCD/2006-158/134/Admin/44 issued by the Bangladesh Securities and Exchange Commission. The Audit Committee is responsible to the Board of Directors.

5.4 Human Resources Management

The company has sound human resource policy to ensure the congenial working environment and better career path. The compensation structure has been framed with the objective to attract and retain high quality personnel. ALL has service rules covering various policies on employment conditions, performance appraisal, training and development, salary and other perquisites, leave etc. The company provides some long-term benefits to their employees like Recognized Provident Fund, Gratuity, bonuses etc. Total human resource strength of the company employed 7,603 employees during the year 30 June, 2015.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

5.5 Management Information System

ALL has separate IT division headed by Mr. Nazmul Huda consisting of IT Infrastructure dept. & Business IT dept. IT Infrastructure dept. has 21 personnel headed by Mr. Amalesh Sen Gupta and Business IT dept. has 8 personnel headed by Mr. Bishnu Pada Sen. The company has developed MIS system for sales & marketing, inventory management, supply chain, finance & accounts and management information system.

6.0 BUSINESS PERFORMANCE

Average business performance

Indicators	June-2015	June-2014
Gross Turnover (Tk. in mil.)	13,175.14	11,565.61
Net Turnover (Tk. in mil.)	11,496.41	10,217.93
Export Sale (Tk. in mil.)	438.64	363.27
Local Sale (Tk. in mil.)	12,736.50	11,202.34
Cost of Goods Sold (Tk. mil.)	7,195.00	6,237.79
Gross Profit (Tk. in million)	4,301.42	3,980.14
Operating Profit (Tk. in mil.)	2,358.30	1,933.93
Profit After Tax (Tk. in mil.)	921.92	893.89
Change in Turnover (%)	12.51	4.17
Change in Export Sales (%)	20.75	7.63
Change in Local Sales (%)	12.21	4.14
Change in Cost of goods sold (%)	15.35	-2.57
Change in Profit After Tax (%)	3.14	67.55

Overall business performance of ALL has been found to be average over the years. The reported turnover of the company stood at Tk. 11,496.41 mil. in FY 2014-15 against Tk. 10,217.93 mil. in FY 2013-14 indicating a growth of 12.51%.The above revenue growth was due to increase in selling price as well as volume. The revenue pie is largely shared by its local sale which is about 96.18% of total sale and the rest 3.82% has been from export in FY2014-15. Moreover, the gross revenue of the ALL is constituted of The ACME Laboratories own products of Tk. 11,032.09 mil., other products (syringe& fish feed) of Tk.25.68 mil. and exports product of Tk.438.64 mil. The cost of goods sold (COGS) stood at Tk. 7,195.00 mil. in FY 2014-15 against Tk. 6,237.79 mil. in FY 2013-14. The net profit after tax of the company reached to Tk. 921.92 mil. in FY 2014-15 compared to Tk. 893.89mil. in FY 2013-14. The net profit after tax has increased by 3.14% in FY 2014-15 compared to FY2013-14 due to increase in turnover and decrease in admin expense.

7.0 FINANCIAL PERFORMANCE

Average financial performance

Indicators	June-2015	June-2014
Return on Average Asset After Tax (ROAA %)	4.06	4.24
Return on Average Equity After Tax (ROAE %)	8.36	8.59
Return on Average Capital Employed (ROACE %)	6.14	6.65
Gross Profit Margin%	37.42	38.95
Operating Profit Margin%	20.51	18.93
Net Profit Margin%	8.02	8.74
Cost to Revenue Ratio (%)	62.58	61.05
Administrative Exp to Revenue Ratio %	3.37	5.35
Selling & Distribution Cost to Revenue Ratio %	13.53	14.68
Finance Cost to Revenue Ratio %	8.55	7.60

The financial performance of ALL has been found to be average. While analyzing the performance of ALL, it has been revealed that the company fetched a gross profit of Tk. 4,301.42 mil. in FY 2014-15 against Tk. 3,980.14 mil. in FY 2013-14; therefore, its gross profit margin stood at 37.42% in FY2014-15 and 38.95% in FY2013-14 respectively. After deducting all expenditure, the net profit margin in FY 2014-15 stood at 8.02% against 8.74% in FY 2013-14. The profitability of a company can also be measured in terms of Return on Average Assets (ROAA), Return on Average Equity (ROAE) and Return on Average Capital Employed (ROACE). The above indicators of the company were also found to be moderate.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

The cost efficiency of the company highly depends on the raw materials price. The overall cost efficiency of the company increased in FY2014-15. The efficiency ratio (cost in comparison to revenue) stood at 62.58% in FY 2014-15 against 61.05% in FY2013-14. The raw material cost has been about 82.08% of the total cost of goods sold and manufacturing overhead cost has been 17.92% of the total cost of goods sold. However, the finance cost to revenue ratio also increased in FY 2013-14 due to increase in finance expense. The finance cost to revenue ratio stood at 8.55% in FY 2014-15 compared to 7.60% in FY 2013-14.

8.0 CAPITAL STRUCTURE AND SOLVENCY

Moderately debt based capital structure

Indicators	June-2015	June-2014
Leverage Ratio (X) with revaluation	1.05	1.07
Leverage Ratio (X) without revaluation	1.96	2.18
Bank Borrowing to Equity (X)	0.83	0.83
Equity Multiplier(X)	2.05	2.07
Long Term Leverage Ratio(X)	0.43	0.29
Short Term Leverage Ratio(X)	0.61	0.79
Internal Capital Generation (%)	6.16	8.59
Net Asset Value Per Share(Tk.10) with revaluation	70.37	66.16
Net Asset Value Per Share(Tk.10) without revaluation	37.45	32.56

ALL is a moderately debt based company operating with a leverage ratio of 1.05 times as on June 2015 and 1.07 times as on June 2014 when considering revaluation surplus. But without revaluation surplus, the company has been operating with levered company and leverage ratio stood at 1.96 times in FY2014-15 and 2.18 times in FY2013-14 respectively. The total capital employed in FY 2014-15 stood at Tk. 16,277.51 mil. consisting of non-current assets of Tk. 16,060.79 mil. and net current asset of Tk. 216.72 mil. The above capital employed has been financed by shareholders' equity of Tk. 11,372.63 mil., non-current liabilities of Tk. 4,904.88 mil. The equity pie composed of 14.21% paid up capital (Tk. 1,616.02 mil.), share premium 14.11% (Tk. 1,605.07 mil.), revaluation surplus 46.78% (Tk. 5,320.07 mil.), retained earnings 23.65% (Tk.2,689.79 mil.) and other reserves 1.25% (Tk.141.68 mil.). However, considering all outside liabilities, total debt to equity ratio of the company reached to 51:49 in FY 2014-15. In the leverage of ALL (i.e. outside liability to equity), the contribution of short term loan had significant influence over the long term loan because of high dependency on short term loan. At FY 2014-15, the short term leverage stood at 0.61 times against long term leverage of 0.43 times. In considering the regular income of ALL the internal capital generation stood at 6.16% in FY2014-15 against 8.59% in FY2013-14.

(BDT in Million)

Indicators/Components	June-2015	June-2014
Current assets	7,198.98	6,635.06
Less Current liabilities	6,982.26	8,429.73
Net Current Asset	216.72	-1,794.67
Add Non-current assets	16,060.79	15,544.51
CAPITAL EMPLOYED	**16,277.51**	**13,749.84**
FINANCED BY		
Equity:		
Paid up capital	1,616.02	1,616.02
Share Premium	1,605.07	1,605.07
Revaluation surplus	5,320.07	5,429.80
Retained Earnings	2,689.79	1,949.43
Other Reserve	141.68	91.85
Total Equity	11,372.63	10,692.16
Long Term Liabilities	4,904.88	3,057.68
Total Equity & Non-Current Liabilities	**16,277.51**	**13,749.84**

While analyzing the leverage of the company, against the equity of Tk. 11,372.63 mil. total outside liabilities reached to Tk. 11,887.14 mil. Its Bank borrowing to equity stood at 0.83 times both in FY2014-15 and FY 2013-14. The Net Asset Value (NAV) per share of Tk. 10 with

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

revaluation stood at Tk. 70.37in FY 2014-15 against Tk. 66.16 in FY 2013-14. The Net Asset Value (NAV) per share of Tk. 10 without revaluation stood at Tk. 37.45 in FY 2014-15against Tk. 32.56 in FY 2013-14.

9.0 LIQUIDITY AND FUND FLOW ANALYSIS

Indicators	June-2015	June-2014
Current Ratio (X)	1.03	0.79
Quick Ratio (X)	0.63	0.49

Moderate liquidity

The company has been operating with moderate liquidity. As the company depends on the import based raw materials, it requires significant inventory with long cash conversion cycle. Generally, ALL maintains raw materials inventory for four to five months and it takes 20 to 25 days to collect its receivables against which it can stagger its payable payment up to 25to 30days. Liquidity in terms of current ratio increased in FY2014-15 due to increase in current assets (particularly inventory, trade receivable and advance, deposits & prepayments) and decreased in current liabilities (particularly short term loan and trade & others payables) compared to previous year. The current ratio of the company stood at 1.03 times in FY 2014-15 against 0.79times in FY 2013-14. The same was reflected in the terms of quick ratio which increased to 0.63 times in FY2014-15 against 0.49 times in FY2013-14. However, the company is currently enjoying working capital facilities in different modes from various banks, through which it is managing liquidity and meeting its import payments for procuring raw materials to carry out the production

While analyzing the cash flow of the company, it has been revealed that the company can generate moderate fund internally to service its debt burden and other liabilities also. The company generated operating cash flow of Tk. 1,050.08 mil. as on June 30, 2015. However, after meeting capital expenditure of Tk.971.82 mil., its free operating cash flow stood at positive.

10.0 BANKING RELATIONSHIP AND CREDIBILITY

10.1 Liability Position

The total outstanding bank loan of ALL was Tk.9,829.22million (Tk. 5,905.42 million long term loans and Tk. 3,923.80 million short term revolving credit line). A summarized loan position of the company stands as follows:

(Tk. in million)

Bank Name	Details of Exposures					Repayment Status
	Mode	Sanction/ Limit	Disbursed/ Availed as funded	Outstanding as on 31.08.15		
				Long Term	Short Term	
DBBL	CC(Hypo)/OD/LTR	450.00	-	-	311.03	Regular
	LC/LG	180.00	-	-	21.14	Regular
	Term loan	1,200.00	1,200.00	1,074.61		
Trust Bank Ltd.	L/C/BG	900.00	-	-	472.07	Regular
	LTR/OD/ Time loan	1,438.00	-		857.49	Regular
	Term loan	480.00	480.00	218.72		Regular
SCB	Term loan	1,285.20	1,285.20	864.64	879.37	Regular
	LC/Acceptance	1,800.00	-	-	188.18	Regular
	OD/LATR/ STL	1,230.00	-	-	466.93	Regular

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

EBL	OD/DL/LATR	1,050.00	-	-	1,019.21	Regular
	LC/Acceptance/BG/Import loan	440.00	-	-	105.28	Regular
IPDC	Term loan	325.00	325.00	171.29	-	Regular
HSBC	Term loan	1,300.00	1,237.21	885.05	-	Regular
	OD/DL/IL	1,390.00	-	-	500.84	Regular
	LC/ Acceptance	2,168.98	-	-	173.85	Regular
Dhaka Bank Ltd.	Term loan	100.00	100.00	73.44	-	Regular
	CC(Hypo)/LTR	530.00	-	-	397.40	Regular
	LC	170.00	-	-	42.46	Regular
IDLC	Term Loan	497.96	497.96	227.93	-	Regular
IIDFC	Term loan	450.00	450 .00	330.00	-	Regular
Lanka Bangla Finance	Lease finance	1000.00	1000.00	950.00	-	Regular
ULCL	Lease finance	200.00	200.00	170.00		Regular
ILFSL	Lease finance	500.00	500.00	450.00		Regular
FFIL	Lease finance	500.00	500.00	475.00		
Agrani Bank Ltd.	CC (Hypo)/LTR	450.00	-	-	(22.41)	Regular
	L/C	200.00	-	-	-	Regular
The City Bank	OD/STL/Import loan	1,180.00	1,180.00	-	393.55	Regular
	L/C	400.00	-	-	4.02	Regular
AB Bank	L/C	350.00	-		-	Regular
	OD/LTR/Time loan	550.00	-		(0.21)	Regular
Total		22,315.14	8,955.37	5,905.42	3,923.80	

10.2 Security Arrangements against the Loan Facilities

Securities against loan under each bank given as below:

S.I. No.	Name of the Bank/FIs	Security Package
1.	Dutch-Bangla Bank Limited	**Security**: i. Registered hypothecation by way of 1st ranking pari passu charge with RJSC among other lenders on entire Stocks of the company. ii. Registered hypothecation by way of 1st ranking pari passu charge with RJSC among other lenders on Trade/market receivables of the. iii. Registered hypothecation by way of 1st ranking pari passu charge with RJSC among other lenders on fixed assets comprising of plant, machinery & equipment (installed/to be installed in the factory premises) of the company. iv. Personal Guarantee of Directors. v. Corporate Guarantee of ACME Overseas Trading Ltd. vi. Two undated cheques of covering entire term loan amount for BDT 350 million and BDT 850 million with interest. vii. Post dated Cheques for loan installments of each term loan of BDT 350 million and BDT 850 million.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

2.	Trust Bank Limited	**Security**: i. Hypothecation of machinery, equipment and stocks. ii. Charge with RJSC on machinery & equipments (imported & to be imported), stocks, raw materials and book debts on Pari-Passu security sharing basis covering the total facilities with other lenders of The ACME Laboratories Ltd. iii. Trust receipt in case of LTR iv. Personal Guarantee of Directors of the company.
3.	Standard Chartered Bank	**Security**: i. Demand Promissory Note and Letter of Continuation for BDT 1,280 million. ii. Registered first charge over Stocks & Book Debts on pari passu basis with other lenders where Standard Chartered Bank's shares would not be less than BDT 2,630 million. iii. Registered first charge over Plant & Machinery on pari passu basis with other lenders where Standard Chartered Bank's shares would not be less than BDT 2,630 million. iv. Registered Mortgage over land & building of the central warehouse at Savar for BDT 100 million covering the entire credit facilities. v. Personal Guarantee of Directors vi. Registered Mortgage over Land & Building of Cephalosporin Project of the company on pari passu basis with other Term Lenders for BDT 1,350 million. vii. Registered Mortgage over Land & Building of Mizanur Rahman Sinha & The ACME Laboratories Limited on pari passu basis with other Term Lenders where Standard Chartered Bank's shares would not be less than BDT 1,350 million.
4.	Eastern Bank Limited	**Security:** i. Margin @10% on LG (1-5 years/close ended) & @100% on LG (Open ended) in the form of cash/EBL deposits. ii. Registered hypothecation over existing & future Plant & Machinery of the company. iii. Registered hypothecation over Inventory & Book Debts of the company. iv. Personal guarantee of Directors.
5.	IPDC of Bangladesh Limited	**Security:** i. Registered mortgage of 21.00 decimal land along with 6 storied building at Narayangonj and 26.60 decimal land along with 5 storied building at Bogra. ii. Registered Irrevocable General Power of Attorney in favor of IPDC to sell the mortgage properties. iii. Hypothecation of the floating assets of the company registered with RJSC on ranking basis. iv. Personal guarantee of Directors. v. Two undated cheques of covering entire term loan amount for BDT 150 million and BDT 125 million. vi. Post dated cheques for loan installments of each term loan of BDT 150 million and BDT 125 million. vii. Demand promissory note along with letter of continuation.
6.	HSBC Limited	**Security:** i. Demand Promissory Note for BDT 2,720 million. ii. First charge over the Borrower's Stocks and Book Debts/Receivable with the RJSC on Pari Passu basis with other lenders and HSBC's share is BDT 2,720 million. iii. First charge over the Borrower's Plant and Machinery with the RJSC on Pari Passu basis with other lenders and HSBC's share is BDT 2,720 million. iv. Registered Mortgage over 90 decimal and 238 decimal land and structures thereon at Dhamrai, Dhaka on Pari Passu basis with other lenders and HSBC's share is BDT 1,350 million. v. Personal guarantee of directors. vi. Corporate Guarantee executed by The ACME Agrovet and Beverages Limited.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

7.	Dhaka Bank Limited	**Security:** i. Hypothecation of machinery, equipment and stock ii. First Ranking Pari-Passu Charge on Machinery & Equipment (imported & to be imported), Stocks, Raw Materials and Book Debts i.e. Fixed and Floating assets of the company with RJSC with other lenders. iii. Personal Guarantee of Directors of the company. iv. Trust receipt in case of LTR. v. Post dated cheques for loan installments of term loan BDT 100 million.
8.	IIDFC	**Security:** i. Two undated security cheque for the full finance amount of BDT 150.00 & BDT 50.00 mil. respectively ii. Insurance of the machinery in favour of IIDFC Ltd. amount BDT 20.91 mil. iii. Personal guarantee of all Directors iv. Corporate guarantee of The ACME Agrovet and Beverages Ltd. v. Post dated Cheque vi. Security Deposit of BDT 2.00 million vii. Demand promissory note viii. Undertaking as per IIDFC format
9.	Agrani Bank Ltd.	**Security:** i. First ranking Pari Passu charge on machinery & equipment, stocks, raw materials and book debts of the ACME Laboratories Ltd. with RJSC with other lenders ii. Registered mortgage of land measuring 105.50 decimals iii. Personal guarantee of all Directors iv. Personal Guarantee of owner of the company v. Mortgage against CC (Hypo)
10.	United Finance Ltd.	**Security:** i. Personal guarantee ii. Vehicles registration in favor of IDLC
11.	IDLC	**Security:** i. Personal guarantee ii. Vehicles registration in favor of IDLC- iii. Post-dated cheque against installment iv. Undated Cheque v. Corporaye guarantee vi. Hypothecation of floating charges on stock and receivable
12.	The City Bank Ltd.	**Security:** i. Registered mortgage of 133.50 decimal land along with construction thereon, situated at Hemayetpur, Savar, Dhaka with MV of Tk.22.66 crore ii. Registered hypothecation on fixed and floating assets of the company iii. Personal Guarantee of all the Directors of the company iv. Undated Security Cheque
13.	AB Bank Ltd.	**Security:** i. Registered charge by way of hypothecation with RJSC over all floating assets covering the bank's full exposure ii. Personal Guarantee of all directors iii. Margin against L/C
14.	Fareast Finance & Investment Ltd.	**Security:** i. Personal Guarantee of all sponsors Directors ii. Corporate Guarantee of the ACME Agrovet and Beverage Ltd. iii. Charge on fixed and floating assets of the company
15.	Lanka Bangla Finance	**Security:** i. Personal Guarantee of Directors ii. Corporate Guarantee of the ACME Agrovet and Beverage Ltd. iii. 20 post-dated cheques iv. Hypothecation/charge on all present and future fixed and floating assets

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

16.	International Leasing and Financial Services Ltd.	**Security:** i. Personal Guarantee of Directors ii. An undated cheque of Tk.694,170,000 iii. Demand promissory note

10.3 Payment Efficiency

Indicators	June-2015	June-2014
Debt Service Coverage Ratio (X)	1.50	1.37
Interest Service Coverage Ratio (X)	2.40	2.55

Regular loan repayment history

The loan payment history of the company has been found to be good. The creditworthiness of the company is also supported by its debt servicing capacity as well as interest coverage capability. Both debt service coverage ratio and interest service coverage ratio of ALL were found to be good. The Debt service coverage ratio stood at1.50 times in FY2014-2015 against 1.37 times in FY2013-2014 and interest coverage ratio stood at 2.40 times in FY2014-15 against 2.55 times in FY2013-14.

11.0 RISK ANALYSIS

11.1 Operational & Maintenance Risk

The company has reduced operational and maintenance risk through establishment of in-house expertise or experienced workforce for its factory operation and head office management (including departmental management). The management set up is matured and is running under the direct leadership of the Managing Director. The factory plants and machineries are automated and are run by educated and skilled work forces. The company has arranged adequate safety measures to minimize/avoid accidents.

11.2 Quality Control Risk

Pharmaceutical products are usually exposed to high quality control risk. Each product is required to be marketed through a stringent compliance procedure. Each product is required to have the flexibility to cope with the new regulations and also continuous quality improvement capacity to face the global demand. Especially local market is highly competitive due to presence of both quality local producers and many global giants. Any deviation from the standard may result in serious market image crisis and might also create regulatory barrier. By considering this, CRISL views that, ALL, like other players in the industry, is exposed to quality control risk.

11.3 Raw Material Supply Risk

Pharmaceuticals industry in Bangladesh is fully dependent on imported raw materials as backward linkage is yet to be developed. To mitigate the supplies risk due to single supplier dependency, ALL imports raw material from various countries and also from local vendors. It has its own quality assurance policy in line with the international standard. However, import based supplies are likely to be affected by any uncontrollable event or country risk.

11.4 Power Supply Risk

ALL has good power supply arrangement to ensure un-interrupted production. Power supply is facilitated by internally installed diesel and gas burn generator to produce electricity. ALL seems to be at a favorable position in this regard.

11.5 Competition Risk

Pharmaceutical products are usually exposed to high market risk. Local market is highly competitive due to presence of both quality local producers and many global giants. ALL is in continuous process to diverse market both locally and internationally. The company's present thrust towards foreign buyers may assist it to minimize product liability/over production risk; rather it will induce the company to do more expansion of existing production capacity including diversification of product line.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

11.6 Foreign Exchange Risk

The company is also at foreign exchange risk as it pays to foreign suppliers in foreign currency for raw materials. When value of foreign currency rises, it has to spend more Bangladeshi currency to procure raw material, affecting cost of production, growth of sales/revenue and overall profitability. In the recent years, the exchange rates of $US and Euro are volatile and thus the company is exposed to foreign currency risk.

11.7 TRIPS Agreement Expiration Risk

With the incorporation of Doha Ministerial Declaration of 14 March, 2001 in the TRIPS Guidelines, the least developed countries (LDC) were given exemption from pharmaceutical product patents until 2016. Due to TRIPS relaxation, Bangladesh can produce drugs without patent or license cost up to 2016. If the present relaxation of TRIPS is withdrawn after 2016, producers will have to pay more for patented products as well as license fees. Billions in revenues will be lost due to patent expiry and price control will be lifted. CRISL views that, ALL, like other players in the industry, is exposed to TRIPS expiration risk.

12.0 OBSERVATION SUMMARY

Rating Comforts:	**Rating Concerns:**
▪ Average business and financial performance ▪ Wide distribution network ▪ Experienced corporate management ▪ Sound production facilities ▪ State-Of-The-Art technology ▪ Good number of products in the market ▪ Adequate ETP facility ▪ Regular loan repayment history	▪ Moderate debt based capital structure ▪ Moderate liquidity ▪ Increase in cost of goods sold ▪ Long cash conversion cycle ▪ TRIPS Agreement expiration risk ▪ Foreign currency risk ▪ Competition risk
Business Opportunity:	**Business Challenges:**
▪ Cheap skilled human resource base ▪ Launching of new products ▪ Establishment of backward supply linkage ▪ Exploring more export markets ▪ Immense opportunity of penetration in foreign market ▪ Friendly government drug policy	▪ Limited scope of local raw material sources ▪ Severe competition in local market ▪ Maintenance of international standard

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

13.0 PROSPECTS

Pharmaceutical industry is considered to be a highly competitive market in Bangladesh due to presence of both multinational giant companies as well as international standard local companies. Once local companies were primarily in back end positions due to technically disadvantageous production facilities and expertise but with the passage of time local pharmacists have built their expertise to capture the global standard. Besides, local companies have been enjoying Government support and cheap labor cost in this sector. The above position has reversed the dependency on foreign companies to local companies and now almost 96% of the requirements are met by the local pharmaceutical companies. ALL, as one of the leading pharmaceutical companies, has contributed significantly in developing this sector as well as changed the market position. It has been continuously adapting most recent state of the art sophisticated cutting-edge technology and expanding its horizons vertically as well as horizontally. The Company perpetually has been pursuing proven best corporate practices. The product range of ALL includes more than 700 diversified products. The company developed its value with its long range of quality products in local and export market. CRISL believes that, good capital base, sound infrastructural facilities, strong Group image and experience sponsor will assist the Company to achieve its position as the leader of the sector and would earn much needed foreign exchange through enhanced export for the country in future.

END OF THE REPORT

(Information used herein is obtained from sources believed to be accurate and reliable. However, CRISL does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Rating is an opinion on credit quality only and is not a recommendation to buy or sell any securities. All rights of this report are reserved by CRISL. Contents may be used by news media and researchers with due acknowledgement)

[We have examined, prepared, finalized and issued this report without compromising with the matters of any conflict of interest. We have also complied with all the requirements, policy procedures of the BSEC rules as prescribed by the Bangladesh Securities and Exchange Commission.]

14.0 CORPORATE INFORMATION

Date of Incorporation **:1976**

Commencement of Business **: 1976 (but the company started operation in the year 1954 as a Sole proprietorship business)**

Board of Directors	Mr. Afzalur Rahman Sinha	Chairman
	Mr. Mizanur Rahman Sinha	Managing Director
	Dr. Jabilur Rahman Sinha	Deputy Managing Director
	Mrs. Jahanara Mizan Sinha	Director
	Mrs. Nagina Afzal Sinha	Director
	Mr. Md. Iftikhar-Uz-Zaman	Director (Nominated by ICB)
	Mr. Syed Shahed Reza	Independent Director
	Ms. Fouzia Haque, FCA	Independent Director
Auditor	**Pinaki& Company** *Chartered Accountants* *(An Independent Associate Member of Thakur, VaidyanathAiyur& Co., Chartered Accountants, New Delhi, India)*	
Key Management		
	Mr. Mizanur Rahman Sinha	Managing Director
	Mr. Md. Hasibur Rahman	ADMD (Finance & Accounts), ISO & Internal Audit
	Mr. Parvez Hashim	Executive Director (Plant Operation)

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

	Mr. Golam Rabbani Bhuiyan	Director, Sales
	Mr. A.K.M. Mushiur Rahman Khan	Director, PPIC
	Mr. Animesh Pal	Consultant, Brand Management
	Mr. Md. Zahangir Alam	Chief Financial Officer
	Mr. A.K.M Mahbubur Rahman	Head of Production (Veterinary)
	Mr. Swapan Kumar Gain	Head of Production (Solid Dosages)
	Mr. Md. Humayun Kabir	Head of International Business
	Mr. S. M. Shafiquzzaman	Head of Production (General)
	Mr. S.A.B.M Shahadat Ali	Head of Quality Operation
	Mr. Mohammad Abdul Hamid Miah	Head of Factory Admin & HR
	Mr. Bashir Ahmed	Head of Production (Cephalosporin)
	Mr. Md. Abu Sayed Khondoker	Head of Engineering (Solid)
	Mr. Nur Ahammead Bhuiyan	Head of Engineering (General)
	Mr. Tushar Kanti Kundu	Head of HR
	Mr. Md. Rafiqul Islam	Company Secretary
	Mr. Syed Nazmul Huda	Head of IT
	Mr. S. M. Rezaul Ahsan	Head of QMS & OD
	Mr. Md. Rubel Miah	Head of Internal Audit
	Ms. Molla Sabiha Sultana	Project Coordinator, CSR

Capital History:

Year	Authorized Capital(M.Tk)	Issued, Subscribed and Paid-up Capital (M. Tk.)	Rate of Increase	Source of Paid-up Capital
2008-09	1,000.00	100.00	-	Share holders equity
2009-10	1,000.00	100.00	-	Share holders equity
2010-11	5,000.00	1,160.00	1060%	Share holders equity
2011-12	5,000.00	1,160.00	-	Share holders equity
2012-13	5,000.00	1,556.00	34.14%	Share holders equity
2013-14	5,000.00	1,616.02	3.86%	Share holders equity
2014-15	5,000.00	1,616.02	-	Share holders equity

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

CRISL RATING SCALES AND DEFINITIONS
LONG-TERM RATINGS OF CORPORATE

RATING	DEFINITION
AAA Triple A (Highest Safety)	**Investment Grade** Entity rated in this category is adjudged to be of best quality, offer highest safety and have highest credit quality. Risk factors are negligible and risk free, nearest to risk free Government bonds and securities. Changing economic circumstances are unlikely to have any serious impact on this category of companies.
AA+, AA, AA- (Double A) (High Safety)	Entity rated in this category is adjudged to be of high quality, offer higher safety and have high credit quality. This level of rating indicates a corporate entity with a sound credit profile and without significant problems. Risks are modest and may vary slightly from time to time because of economic conditions.
A+, A, A- Single A (Adequate Safety)	Entity rated in this category is adjudged to offer adequate safety for timely repayment of financial obligations. This level of rating indicates a corporate entity with an adequate credit profile. Risk factors are more variable and greater in periods of economic stress than those rated in the higher categories.
BBB+, BBB, BBB- Triple B (Moderate Safety)	Entity rated in this category is adjudged to offer moderate degree of safety for timely repayment of financial obligations. This level of rating indicates that a company is under-performing in some areas. Risk factors are more variable in periods of economic stress than those rated in the higher categories. These entities are however considered to have the capability to overcome the above-mentioned limitations.
BB+, BB, BB- Double B (Inadequate Safety)	**Speculative Grade** Entity rated in this category is adjudged to lack key protection factors, which results in an inadequate safety. This level of rating indicates a company as below investment grade but deemed likely to meet obligations when due. Overall quality may move up or down frequently within this category.
B+, B, B- Single B (Risky)	Entity rated in this category is adjudged to be with high risk. Timely repayment of financial obligations is impaired by serious problems which the entity is faced with. Whilst an entity rated in this category might be currently meeting obligations in time through creating external liabilities.
CCC+,CCC, CCC- Triple C (Vulnerable)	Entity rated in this category is adjudged to be vulnerable and might fail to meet its repayments frequently or it may currently meeting obligations in time through creating external liabilities. Continuance of this would depend upon favorable economic conditions or on some degree of external support.
CC+,CC, CC- Double C (High Vulnerable)	Entity rated in this category is adjudged to be very highly vulnerable. Entity might not have required financial flexibility to continue meeting obligations; however, continuance of timely repayment is subject to external support.
C+,C,C- Single C (Extremely Speculative)	Entity rated in this category is adjudged to be with extremely speculative in timely repayment of financial obligations. This level of rating indicates entities with very serious problems and unless external support is provided, they would be unable to meet financial obligations.
D (Default)	**Default Grade** Entity rated in this category is adjudged to be either already in default or expected to be in default.

Note: For long-term ratings, CRISL assigns + (Positive) sign to indicate that the issue is ranked at the upper-end of its generic rating category and - (Minus) sign to indicate that the issue is ranked at the bottom end of its generic rating category. Long-term ratings without any sign denote mid-levels of each group.

SHORT-TERM RATINGS OF CORPORATE

ST-1	**Highest Grade** Highest certainty of timely payment. Short-term liquidity including internal fund generation is very strong and access to alternative sources of funds is outstanding. Safety is almost like risk free Government short-term obligations.
ST-2	**High Grade** High certainty of timely payment. Liquidity factors are strong and supported by good fundamental protection factors. Risk factors are very small.
ST-3	**Good Grade** Good certainty of timely payment. Liquidity factors and company fundamentals are sound. Although ongoing funding needs may enlarge total financing requirements, access to capital markets is good. Risk factors are small.
ST-4	**Moderate Grade** Moderate liquidity and other protection factors qualify an entity to be in investment grade. Risk factors are larger and subject to more variation.
ST-5	**Non-Investment/Speculative Grade** Speculative investment characteristics. Liquidity is not sufficient to ensure discharging debt obligations. Operating factors and market access may be subject to a high degree of variation.
ST-6	**Default** Entity is in default or is likely to default in discharging its short-term obligations. Market access for liquidity and external support is uncertain.

CREDIT RATING REPORT
On
THE ACME LABORATORIES LIMITED

CRISL RATING SCALES AND DEFINITIONS
BANK LOAN/ FACILITY RATING SCALES AND DEFINITIONS- LONG-TERM

RATING	DEFINITION
blr **AAA** (*blr* Triple A) (Highest Safety)	**Investment Grade** Bank Loan/ Facilities enjoyed by banking clients rated in this category are adjudged to have highest credit quality, offer highest safety and carry almost no risk. Risk factors are negligible and almost nearest to risk free Government bonds and securities. Changing economic circumstances are unlikely to have any serious impact on this category of loans/ facilities.
blr **AA+**, *blr* **AA**, *blr* **AA-** (Double A) (High Safety)	Bank Loan/ Facilities enjoyed by banking clients rated in this category are adjudged to have high credit quality, offer higher safety and have high credit quality. This level of rating indicates that the loan / facilities enjoyed by an entity has sound credit profile and without any significant problem. Risks are modest and may vary slightly from time to time because of economic conditions.
blr **A+**, *blr* **A**, *blr* **A-** Single A (Adequate Safety)	Bank Loan/ Facilities rated in this category are adjudged to carry adequate safety for timely repayment/ settlement. This level of rating indicates that the loan / facilities enjoyed by an entity have adequate and reliable credit profile. Risk factors are more variable and greater in periods of economic stress than those rated in the higher categories.
blr **BBB+**, *blr* **BBB**, *blr* **BBB-** Triple B (Moderate Safety)	Bank Loan/ Facilities rated in this category are adjudged to offer moderate degree of safety for timely repayment /fulfilling commitments. This level of rating indicates that the client enjoying loans/ facilities under-performing in some areas. However, these clients are considered to have the capability to overcome the above-mentioned limitations. Cash flows are irregular but the same is sufficient to service the loan/ fulfill commitments. Risk factors are more variable in periods of economic stress than those rated in the higher categories.
blr **BB+**, *blr* **BB**, *blr* **BB-** Duble B (Inadequate Safety)	**Speculative/ Non investment Grade** Bank Loan/ Facilities rated in this category are adjudged to lack key protection factors, which results in an inadequate safety. This level of rating indicates loans/ facilities enjoyed by a client are below investment grade. However, clients may discharge the obligation irregularly within reasonable time although they are in financial/ cash problem. These loans / facilities need strong monitoring from bankers side. There is possibility of overcoming the business situation with the support from group concerns/ owners. Overall quality may move up or down frequently within this category.
blr **B+**, *blr* **B**, *blr* **B-** Single B (Somewhat Risk)	Bank Loan/ Facilities rated in this category are adjudged to have weak protection factors. Timely repayment of financial obligations may be impaired by problems. Whilst a Bank loan rated in this category might be currently meeting obligations in time, continuance of this would depend upon favorable economic conditions or on some degree of external support. Special monitoring is needed from the financial institutions to recover the installments.
blr **CCC+**, *blr* **CCC**, *blr* **CCC-** Triple C (Risky)	**Risky Grade** Bank Loan/ Facilities rated in this category are adjudged to be in vulnerable status and the clients enjoying these loans/ facilities might fail to meet its repayments frequently or it may currently meeting obligations through creating external support/liabilities. Continuance of this would depend upon favorable economic conditions or on some degree of external support. These loans / facilities need strong monitoring from bankers side for recovery.
blr **CC+**, *blr* **CC**, *blr* **CC-** Double C (High Risky)	Bank Loan/ Facilities rated in this category are adjudged to carry high risk. Client enjoying the loan/ facility might not have required financial flexibility to continue meeting obligations; however, continuance of timely repayment is subject to external support. These loans / facilities need strong monitoring from bankers side for recovery.
blr **C+**, *blr* **C**, *blr* **C-** (Extremely Speculative)	Bank Loan/ Facilities rated in this category are adjudged to be extremely risky in timely repayment/ fulfilling commitments. This level of rating indicates that the clients enjoying these loan/ facilities are with very serious problems and unless external support is provided, they would be unable to meet financial obligations.
blr **D** (Default)	**Default Grade** Entities rated in this category are adjudged to be either already in default or expected to be in default.

SHORT-TERM RATINGS

blr ST-1	**Highest Grade** Highest certainty of timely payment. Short-term liquidity including internal fund generation is very strong and access to alternative sources of funds is outstanding, Safety is almost like risk free Government short-term obligations.
blr ST-2	**High Grade** High certainty of timely payment. Liquidity factors are strong and supported by good fundamental protection factors. Risk factors are very small.
blr ST-3	**Good Grade** Good certainty of timely payment. Liquidity factors and company fundamentals are sound. Although ongoing funding needs may enlarge total financing requirements, access to capital markets is good. Risk factors are small.
blr ST-4	**Satisfactory Grade** Satisfactory liquidity and other protection factors qualify issues as to invest grade. Risk factors are larger and subject to more variation.
blr ST-5	**Non-Investment Grade** Speculative investment characteristics. Liquidity is not sufficient to insure against disruption in debt service. Operating factors and market access may be subject to a high degree of variation.
blr ST-6	**Default** Institution failed to meet financial obligations

CHAPTER XXVIII: PUBLIC ISSUE APPLICATION PROCEDURE

Step-1 (Applicant)

1. An applicant for public issue of securities shall submit application/buy instruction to the Stockbroker/ Merchant Banker where the applicant maintains customer account, within the cut-off date (i.e. the subscription closing date), which shall be the **25th (twenty fifth) working day** from the date of publication of abridged version of prospectus.

2. The application/buy instruction may be submitted in prescribed paper or electronic form, which shall contain the Customer ID, Name, BO Account Number, Number of Securities applied for, Total Amount and Category of the Applicant. At the same time:

    a) Other than non-resident Bangladeshi (NRB) and Foreign applicants shall make the application money and service charge available in respective customer account maintained with the Stockbroker/Merchant Banker. No margin facility, advance or deferred payment is permissible for this purpose. In case the application is made through a margin account, the application money shall be deposited separately and the Stockbroker/Merchant Banker shall keep the amount segregated from the margin account, which shall be refundable to the applicant, if become unsuccessful.

    b) Non-resident Bangladeshi (NRB) and Foreign applicants shall submit bank drafts (FDD), issued in favor of the Issuer for an amount equivalent to the application money, with their application to the concerned Stockbroker/Merchant Banker. A Non-resident Bangladeshi (NRB) and Foreign applicant may also submit a single draft against 02(two) applications made by him/her, i.e. one in his/her own name and the other jointly with another person. The draft (FDD) shall be issued by the Bank where the applicant maintains NITA/Foreign Currency account debiting the same account. No banker shall issue more than two drafts from any NITA/Foreign Currency account for any public issue. At the same time, the applicant shall make the service charge available in respective customer account maintained with the Stockbroker/Merchant Banker.

Step-2 (Intermediary)

3. The Stockbroker/Merchant Banker shall maintain a separate bank account only for this purpose namely "Public Issue Application Account". The Stockbroker/Merchant Banker shall:

    a) post the amount separately in the customer account (other than NRB and Foreign applicants), and upon availability of fund, block the amount equivalent to the application money;

    b) accumulate all the application/buy instructions received up to the cut-off date, deposit the amount in the "Public Issue Application Account" maintained with its bank within the first banking hour of **next working day** of the cut-off date. In case of application submitted by the Stock-dealer or the Merchant Banker's own portfolio, the application amount should also be transferred to the "Public Issue Application Account";

c) instruct the banker to block the account for an amount equivalent to the aggregate application money and to issue a certificate in this regard.

4. Banker of the Stockbroker/Merchant Banker shall block the account as requested for, issue a certificate confirming the same and handover it to the respective Stockbroker/Merchant Banker.

5. For Non-resident Bangladeshi (NRB) and Foreign applicants, the Stockbroker/Merchant Banker shall prepare a list containing the draft information against the respective applicant's particulars.

6. The Stockbroker/Merchant Banker shall prepare category wise lists of the applicants containing Customer ID, Name, BO Account Number and Number of Securities applied for, and **within 03 (three) working days** from the cut-off date, send to the respective Exchange, the lists of applicants in electronic (text format with tilde '~' separator) format, the certificate(s) issued by its banker, the drafts received from Non-resident Bangladeshi (NRB) and Foreign applicants and a copy of the list containing the draft information.

7. **On the next working day**, the Exchanges shall provide the Issuer with the information received from the Stockbroker/Merchant Bankers, the drafts submitted by Non-resident Bangladeshi (NRB) and Foreign applicants and the list containing the draft information. Exchanges shall verify and preserve the bankers' certificates in their custody.

8. The application/buy instructions shall be preserved by the Stockbroker/Merchant Bankers up to 6 months from listing of the securities with exchange.

Step-3 (Issuer)

9. The Issuer shall prepare consolidated list of the applications and send the applicants' BOIDs in electronic (text) format in a CDROM to CDBL for verification. The Issuer shall post the consolidated list of applicants on its website and websites of the Exchanges. CDBL shall verify the BOIDs as to whether the BO accounts of the applicants are active or not.

10. **On the next working day**, CDBL shall provide the Issuer with an updated database of the applicants containing BO Account Number, Name, Addresses, Parents' Name, Joint Account and Bank Account information along with the verification report.

11. After receiving verification report and information from CDBL, the Issuer shall scrutinize the applications, prepare category wise consolidated lists of valid and invalid applications and submit report of final status of subscription to the Commission and the Exchanges **within 10 (ten) working days** from the date of receiving information from the Exchanges.

12. The Issuer and the issue manager shall conduct category wise lottery with the valid applications **within 03 (three) working days** from the date of reporting to the Commission and the Exchanges, if do not receive any observation from the Commission or the Exchanges.

13. The Issuer and issue manager shall arrange posting the lottery result on their websites within **06 (six) hours** and on the websites of the Commission and Exchanges within **12 (twelve) hours** of lottery.

14. Within **02 (two) working days** of conducting lottery, the Issuer shall:

a) send category wise lists of the successful and unsuccessful applicants in electronic (text format with tilde '~' separator) format to the respective Exchange.

b) send category wise lists of unsuccessful applicants who are subject to penal provisions as per conditions of the Consent Letter issued by the Commission in electronic (text format with tilde '~' separator) format to the Commission and Exchanges mentioning the penalty amount against each applicant.

c) issue allotment letters in the names of successful applicants in electronic format with digital signatures and send those to respective Exchange in electronic form.

d) send consolidated allotment data (BOID and number of securities) in electronic text format in a CDROM to CDBL to credit the allotted shares to the respective BO accounts.

Step-4 (Intermediary)

15. **On the next working day**, Exchanges shall distribute the information and allotment letters to the Stockbroker/Merchant Bankers concerned in electronic format and instruct them to:

a) remit the amount of successful (other than NRB and Foreign) applicants to the Issuer's respective Escrow Account opened for subscription purpose, and unblock the amount of unsuccessful applicants;

b) send the penalty amount of other than NRB and Foreign applicants who are subject to penal provisions to the Issuer's respective Escrow Accounts along with a list and unblock the balance application money;

16. **On the next working day** of receiving the documents from the Exchanges, the Stockbrokers/Merchant Banker shall request its banker to:

a) release the amount blocked for unsuccessful (other than NRB and foreign) applicants;

b) remit the aggregate amount of successful applicants and the penalty amount of unsuccessful applicants (other than NRB and foreign) who are subject to penal provisions to the respective 'Escrow' accounts of the Issuer opened for subscription purpose.

17. **On the next working day** of receiving request from the Stockbrokers/Merchant Bankers, their bankers shall unblock the amount blocked in the account(s) and remit the amount as requested for to the Issuer's 'Escrow' account.

18. **Simultaneously**, the stockbrokers/Merchant Bankers shall release the application money blocked in the customer accounts; inform the successful applicants about allotment of securities and the unsuccessful applicants about releasing their blocked amounts and send documents to the Exchange evidencing details of the remittances made to the respective 'Escrow' accounts of the Issuer. The unblocked amounts of unsuccessful applicants shall be placed as per their instructions. The Stockbroker/Merchant Banker shall be entitled to recover the withdrawal charges, if any, from the applicant who wants to withdraw the application money, up to an amount of Tk.5.00 (five) per withdrawal.

19. All drafts submitted by NRB or Foreign applicants shall be deposited in the Issuer's respective 'Escrow' accounts and refund shall be made by the Issuer by refund warrants through concerned stockbroker or merchant banker or transfer to the applicant's bank account through banking channel within 10 (ten) working days from the date of lottery.

Miscellaneous:

20. The Issuer, Issue Manager(s), Stockbrokers and Merchant Bankers shall ensure compliance of the above.

21. The bank drafts (FDD) shall be issued considering TT Clean exchange rate of Sonali Bank Ltd. on the date of publication of abridged version of prospectus.

22. Amount deposited and blocked in the "Public Issue Application Account" shall not be withdrawn or transferred during the blocking period. Amount deposited by the applicants shall not be used by the Stockbrokers/Merchant Bankers for any purpose other than public issue application.

23. The Issuer shall pay the costs related to data transmission, if claimed by the Exchange concerned up to an amount of Tk.2,00,000.00 (taka two lac) for a public issue.

24. The Stockbroker/Merchant Bankers shall be entitled to a service charge of Tk.5.00 (taka five) only per application irrespective of the amount or category. The service charge shall be paid by the applicant at the time of submitting application.

25. The Stockbroker/Merchant Banker shall provide the Issuer with a statement of the remittance and drafts sent.

26. The Issuer shall accumulate the penalty amount recovered and send it to the Commission through a bank draft/payment order issued in favor of the Bangladesh Securities and Exchange Commission.

27. The concerned Exchange are authorized to settle any complaints and take necessary actions against any Stockbroker/Merchant Banker in case of violation of any provision of the public issue application process with intimation to the Commission.

All eligible Stock Brokers and Merchant Bankers shall receive the IPO Subscription.

শেয়ারবাজারে বিনিয়োগ ঝুঁকিপূর্ণ।
জেনে ও বুঝে বিনিয়োগ করুন।

Interested persons are entitled to a prospectus, if they desire, and that copies of prospectus may be obtained from the issuer and the issue manager

The ACME Laboratories Ltd.

APPLICATION FOR PUBLIC ISSUE

Date	:	
Name of applicant	:	
Client Code	:	
BO ID No.	:	
Category of applicant	:	
Name of the Company/Fund	:	
Number of Shares/Units	:	
Total amount	:	
Amount in word	:	
Mode of payment	:	
Cheque/Draft information	:	

Signature of Applicant(s)

Signature of Authorized Officer

CHAPTER XXIX: OTHERS

Auditors' Additional Disclosure relating to the Financial Statements for the year ended 30 June 2014

With reference to the letter no. BSEC/CI/BB-03/2014/177; dated: May 11, 2015 of Bangladesh Securities and Exchange Commission and subsequent follow-up letter dated: May 11, 2015 issued by the Company, we have a pleasure to provide hereunder the additional disclosures relating to the Financial Statements of The ACME Laboratories Ltd. for the year ended 30 June 2014:

Query No. 01

Whether the company has complied with the provisions of Securities and Exchange Rules, 1987;

Auditors' Disclosure:

Normally in each and every report of the public listed company we mention particularly the phrase "BSEC rules 1987". But how this has been slipped off in this case is a matter of our concern also. However, we appreciate your observation regarding missing of this particular phrase. We understand that this has been an inadvertent mistake on our Part. In our opinion, the financial statements of the Company as at 30th June 2014 have been prepared in accordance with BAS/BFRS and complying with the provision of BSEC Rules 1987.

Query No. 02

Mention amount of Income Tax paid in the Statement of Cash Flows;

Auditors' Disclosure:

The details breakup of Income Tax paid during the year amounting Tk. 382,397,340 shown in Statement of Cash Flows is presented for your kind reference:

Particulars	Amount (Tk.)
Paid by Treasury Challan/Pay Order	261,986,291
AIT collected by Customs Authority	95,433,002
AIT collected by Bank from Export Bills	1,948,536
AIT deducted against supply of Medicine	9,809,089
AIT collected by BRTA Authority	2,676,500
AIT deducted by bank against Interest on FDR's	10,543,922
Total cash payment during the year	**382,397,340**

Query No. 03

In the Statement of Cash Flows it shows that loan to ACMUNIO International Limited is Tk. 25,130,552. However, the Company in the draft prospectus discloses that advance was given to ACMUNIO International Limited. Explain this inconsistency;

Auditors' Disclosure:

The ACMUNIO International Limited manufactures high quality safety syringes. Such syringes are both used and marketed by The ACME Laboratories Limited. Taking into consideration the very nature of health hazard free product, the Company provided financial assistance in the form of advance in order to ensure uninterrupted and better quality supply.

The said Advance was inadvertently termed as Loan at Statement of Cash Flows.

Query No. 04

Explain the 'Predecessor Value Method' as disclosed in note 1;

Auditors' Disclosure:

In absence of any guideline in the BFRS-3 'Business Combination' for incorporation of balances of the taken over company under common control, it requires that entities should develop an accounting policy for themselves while facing this kind of situation.

The Predecessor Values Method is one of the accounting policies which have been usually chosen by the entities. Financial statements under this method are required to be prepared using "Predecessor's Book Values" without any step upto fair values. It is likely to be a difference between any consideration given and the aggregate book value of the assets and liabilities (as of the date of transaction) of the acquired entity. This difference is recorded as an adjustment to Equity which may be recorded in retained earnings or as a separate Reserve.

The ACME Laboratories Limited followed the 'Predecessor Value Method' for amalgamation of its subsidiary, The ACME Specialized Pharmaceuticals Limited, with it and details of the said transactions have been shown in Statement of Changes in Equity.

Query No. 05

Explain the reason of showing same value of 'Investment Property' as shown in note 9 of the audited report 30 June 2014;

Auditors' Disclosure:

The Company has made revaluation based on the valuation reportissued by the independent valuer namely MASIH MUHITH HAQUE & CO, Chartered Accountants, on every reporting date. The aforesaid valuation report determined the same value as incorporated in the Financial Statements as at 30 June 2014. Since the valuer did not consider any gain or loss attributable to that of the property under reference, there did not appear any gain or loss to that effect which is noted in **Paragraph 35 of Bangladesh Accounting Standard 40 "Investment Property"**.

Query No. 06

Provide names, addresses and amount of confirmation of balances of Trade Receivable of more than 1 (one) crore as shown in note 11;

Auditors' Disclosure:

There do not exist any party under Trade Receivable from whom an amount of Tk. 1 (One) crore and above is receivable to the company. As such, providing information regarding names, addresses and amount is not applicable.

Query No. 07

State whether you have obtained balance confirmation certificates from all the parties of trade receivable. If not, requested to collect the balance confirmation certificates from who have more than 1 (one) crore trade receivable involved in note 11;

Auditors' Disclosure:

As per our normal professional practice, we issue letters to parties selected on random sample basis and procure confirmation to that affects. In the audit under reference, we could receive confirmation from certain parties which are kept in our audit file. Normally, the practice of replying balance confirmation letter sent to the partiesin general is very poor.

However, save for the export, there is no single party in the list of Trade Receivable exceeding Tk. 5 (five) Lacs. Requirement of fresh confirmation is not applicable from the parties, as none of them owes to the company an amount Tk. 1(One) crore and more.

Query No. 08

Reason of Receivable from Sinha Printers Limited and subsequent status thereon;

Auditors' Disclosure:

Sinha Printers Limited, a primary source for supplier of packing materials, used to receive some common services and others from The ACME Laboratories Limited, which appeared as receivable from Sinha Printers Limited in the financial statement. Balance of such receivable as at 30 June 2014 stood at Tk. 37,257,581 which was subsequently adjusted against Trade Payable owing to Sinha Printers Limited by The ACME Laboratories Limited.

Query No. 09

Non-movement of Motor Cycle Advance within 1 year, if any;

Auditors' Disclosure:

For Smooth and quick movement of Medical Representatives the company provides Motor Cycle Advance on realizable basis against salary and other allowances.

Because of revolving in nature and the easy rate of realization against a significant amount of advance the movement of advance shows a slow recovery trend. However, there is no event of non-movement of said advance within 1 year.

Query No. 10

Provide names, addresses and amount of confirmation of balances of Advance to suppliers and Advance to suppliers for construction as shown in note 13;

Auditors' Disclosure:

Details of Advance to suppliers and Advance to suppliers for construction are furnished below:

A) Advance to Suppliers:

SL #	Party Name	Address	Outstanding Balance as at 30 June 2014
1	Sun Rise Chemical	8, Armanian Street, Motahar plaza (Mitford), Dhaka 1100	364,094
2	Jamuna Distillery Ltd.	KA-244, ProgotiSharoni , Kuril Baridhara, Dhaka-1229	640,000
3	Century Art Publicity	26, 31 PuranaPolton, Dhaka	270,000
4	Desh Rent-A-Car	House-122, Road 13/A(new Dhanmondi R/A Dhaka 1209	5,027,391
5	Chemie International	64/ka, Pc culture Housing Society, Shyamoli, Dhaka-1207	418,865
6	Pioneer Insurance Company Ltd.	Symphony (5th floor), Plot-SE (F) 9, Road-142, South Avenue, Gulshan, Dhaka-1212	1,000,000
7	HQ Technologies	H# 11, Road# 1, Block# C, Dhaka Uddan, Mohammadpur Dhaka 1207	24,534,469
8	Shaheen Enterprises	House# 72 (1st floor), Road# 3, Janata Housing, Adabor Ring Road, Mohammodpur, Dhaka	21,712,867
9	Sarwar Enterprise	E-234, HuzuriatolaDhamrai, Dhaka	21,992,614
10	Tacnokit Corporation	Navana DH Tower Suite-501 (5th Floor) Plot 6, Panthapath, Kawran Bazar Dhaka-1215.	20,359,072
11	Masstech Complex	H# 11, Road# 1, Block# C Dhaka Uddan, Mohammadpur, Dhaka 1207	20,288,035
Total			**116,607,407**

B) Advance to Suppliers for Construction:

SL #	Party Name	Address	Outstanding Balance as at 30 June 2014
1	Ashraf & Son's	New 28/1 (Old-49) Majid Khanpur Main Road, Narayangonj	16,267,012
2	Amanullah Enterprise	15/Ga, Mirbagh, Mirertech, Dhaka	910,325
3	Arko Engineers Limited	Road-25/A, House-9/B Banani, Dhaka-1213	1,000,000
4	Arman Engineering	218/c New Elephant Road, (1st Floor) Dhaka-1205	39,833,155
5	Automation Engineering & Controls Ltd.	Modern Mansion (5th Floor) 53, Mothijheel C/A Dhaka-1000	5,611,779
6	BSRM Steels Ltd.	35, PuranaPalton line (2nd Floor) VIP Road, Dhaka	1,180,000
7	Build Asia	Dhaka Trade Center (level-12). 99, KaziNazrul Islam Avenue, Kawran Bazar C/A Dhaka 1215	41,621,796
8	Buildtrade Engineering Ltd.	Dhaka Trade Center (6th Floor) 99, KaziNazrul Islam Avenue Kawran bazaar, Dhaka-1215	34,610,465
9	Car Selection	86/1, Inner circular VIP Road, Dhaka-1100	6,000,000
10	Confidence Trade Limited	09-05 Navana tower 45, Gulshan Avenue Dhaka-1212	31,976,199
11	Himel Engineers	1053/2-A, East Monipur, Mirpur, Dhaka-1216	5,299,893
12	Jamuna Erection & Engineering Works	Aukpara, Dairy farm, Asulia, Savar, Dhaka-1212	2,027,550
13	Joongbo Multimode Chemicals Ltd.	419/420, Tejgaon Industrial Area, Dhaka 1208	929,936
14	New-Tech International	House-4, Road-4, Section-7 Uttara, Dhaka 1100	1,315,000
15	Nitol Motors Limited	Nitol Center, 71, Mohakhali C/A Dhaka-1205	5,050,000
16	R. M. Car & Automobiles	35/1, Kakrail, Dhaka	1,000,000
17	Reza Enterprise	BejoraDhakkinpara, Shazahanpur, Bogra	659,432
18	RupayanProkaushli Ltd.	53/1, New Elephant Road, (1st Floor) Dhanmondi Dhaka-1205	71,151,248
19	Saka International Ltd.	80, Satmoszid Road, Dhanmondi, Dhaka-1209	24,647,834
20	Studio45	110, Tejgaon Industrial Area (2nd floor) Dhaka-1208	4,228,992
21	United Car Complex	28/B, Kakrail, VIP Road, Dhaka	2,050,000
22	Xebec Trading Services	Happy Rahman Plaza (1st floor). 25, 26, 27 KaziNazrul Islam Avenue Banglamotor, Dhaka	6,560,569
23	S.N.B Bricks	Kalampur, Dhamrai, Dhaka	10,973,513
24	M/S. Khan Enterprise	Hujuritola, Dhamrai, Dhaka	9,680,287
Total			**324,584,985**

Query No. 11

State whether you have obtained balance confirmation certificates from all the parties of Advance to suppliers and advance to suppliers for construction as shown in note 13. If not, requested to collect the balance confirmation certificates from the parties having outstanding balance more than Tk. 1.00crore;

Auditors' Disclosure:

As per our normal professional practice, we obtain confirmation at random basis.In case of audit under reference, we procured balance confirmation certificate from all the parties aboveTk. 1 (one) crore and even some of the parties below Tk. 1 (One) crore.

Query No. 12

It is learnt that an amount of Tk. 32,310,000 is not collected from ACMUNIO International Limited since 1st July, 2009. Comment with reason whether this amount appears to you as good;

Auditors' Disclosure:

Considering the initial financial constraints of The ACMUNIO International Ltd. vis-a-vis Prospective Commercial advantage to be availed from the unit, The ACME Laboratories Ltd. made a balancing arrangement to recover earlier dues by way of adjustment within June 2016 against the supply billsas supply being continued between both the companies and expected that it remains in the times to come.

Since the whole matter is within the reach of the company and receivable to the company, said amount appears to be good to us.

Query No. 13

Explain "presumptive tax" as shown in note 13 and adjustment procedure of the same;

Auditors' Disclosure:

In the year 2012-2013, the Company applied for raising its Paid up Capital by issuing 50,000,000 Ordinary Shares of Tk. 10 each. In this regard, with refer to the section 53(L) of Income Tax Ordinance 1984, Bangladesh Securities and Exchange Commission issued a letter of intent and advised to pay taxes in advances @ 3% on premium, if any. After discussion and consent with the Manager to the issue, the Company fixed the issue price of Tk. 52 including premium of Tk. 42 per Ordinary Share. Accordingly, the Company paid advance tax amounting Tk. 63,000,000 vide Challan # T-2, dated: 11 February 2013, Sonali Bank-Kakrail Branch, Dhaka.

Subsequently, the Company issued 39,631,100 numbers of Ordinary Shares of Tk. 10 each at an issue price of Tk. 52 including premium of Tk. 42 per Ordinary Share for which equivalent tax amount stood Tk.49, 935,186. Consequently, balance of advance tax amounting Tk. 13,064,814 remain unadjusted which has been shown as advance presumptive tax. However, By this time, as per section 146 of Income Tax Ordinance 1984, the Company filed a prayer to the Commissioner of Taxes, Zone-03; and to the Deputy Commissioner of Taxes, Circle- 161, Zone – 08, Dhaka for adjustment against the normal income tax liability of the company/refund of said advance tax.

Query No. 14

Provide break-up and name wise schedule of advance against land as shown in note 13;

Auditors' Disclosure:

The ACME Laboratories Limited has given & recorded Tk. 95,250,000 as Advance against Land in note no. 13 in its Financial Statements as at 30 June 2014 which have been given to various parties for procuring land of strategic importance, located in surrounding area of the existing factory premises at Dhamrai near Dhaka and Sales Center at Brahmanbaria in Bangladesh. These lands are being acquired keeping in view the proposed future expansion of the business plans of the Company.

In this regard, Company has entered into formal written agreements with relevant parties.

Details of advances given against lands are furnished below:

Serial No	Name	Location of land	Area in decimal	Amount (Tk.)
01	Mr. Md. Hasibur Rahman*	Dhamrai	190.00	80,000,000
02	Mr. Md. ShajahanKabir	Brahmanbaria	47.10	15,250,000
Total			**237.10**	**95,250,000**

*Mr. Md. Hasibur Rahman is an employee as well as shareholder of the Company (0.037%)

Query No. 15

It appears from note 22 that share money deposit in the name of ICB was converted into Term Loan. Mention the rate of interest payable to ICB;

Auditors' Disclosure:

Investment Corporation of Bangladesh (ICB) sanctioned and disbursed Tk. 500,000,000 which was initially recognized as advance against share money deposit as per the agreed terms, i.e. the Company was supposed to issue Ordinary

Shares against the said advance within one year at the IPO price subject to approval by the concerned authority, otherwise the said advance shall be converted into Term Loan.

Since the Company could not fulfill the aforesaid condition, the said advance converted into Term Loan initially @ 17% interest Per Annum and repayable in ten half yearly equal installments. However, subsequently the rate of interest was reduced to 15.50% with effect from 05 December 2013.

Query No. 16

Whether Liability for Power &Electricity (Tk. 3,681,082.00), Gas Bill (Tk. 7,799,019.00), WASABill (Tk. 1,076,850.00), as shown in note 30 are subsequently fully paid;

Auditors' Disclosure:

As a consistent practice followed by the Company, the amount remained outstanding as at 30 June 2014 with respect to Power & Electricity, Gas Bill and WASA Bill have been fully paid in the subsequent period.

Query No. 17

Subsequent status of 'Dividend payable' as shown in note 31;

Auditors' Disclosure:

The subsequent status of Dividend Payable as at 30 April 2015 is as follows:

Particulars	Promoters (Tk.)	Non-promoters (Tk.)	Total (Tk.)
Dividend Payable as at 30 June 2014	527,461,200	79,262,200	606,723,400
Add: Final Dividend For the year 2013-2014	182,955,900	59,446,650	242,402,550
Less: Paid up to 30 April 2015	524,666,088	138,708,850	663,374,938
Dividend Payable as at 30 April 2015	**185,751,012**	**-**	**185,751,012**

Query No. 18

It appears from note 32 that revenue from others (Syringes and Fish feed) is Tk. 24,254,758.00.Mentioned related cost against this revenue;

Auditors' Disclosure:

Revenue generation form Syringes and Fish feed during the year ended 30 June 2014 and their corresponding Cost of Goods Sold are presented below:

Particulars	Syringes (Tk.)	Fish Feed(Tk.)	Total (Tk.)
Revenue	4,702,633	19,552,125	24,254,758
Less: Cost of Goods Sold	4,334,085	12,139,475	16,473,560
Profit	**368,548**	**7,412,650**	**7,781,198**

Query No. 19

Break up of Welfare & Recreation (Tk. 7,662,529.00) as shown in note 33;

Auditors' Disclosure:

The detail break up of Welfare & Recreation expenses as incurred during the year ended 30 June 2014 has been shown in Note # 33 are as follows:

Particulars	Amount (Tk.)
Free Medicine to Employees	4,020,782
Milad, Mahfil and Doa etc.	3,641,747
Total	**7,662,529**

Query No. 20

The reason why Capacity utilization is more than production capacity as shown in note 52;

Auditors' Disclosure:

Production capacity is calculated considering 240 days per year, 2 shifts per day and 8 hours per shift. Conversely, if needed, to meet the market demand, the Company runs three shifts production in a day. That's why in some production areas actual utilization of capacity shows more than 100%.

Query No. 21

Whether all plants and machineries used by company is reconditioned or second-hand;

Auditors' Disclosure:

During the course of our audit, we have examined the relevant papers of plant and machinery and observed that, no re-conditioned or second-hand plant & machinery is used by The ACME Laboratories Limited (including those acquired as a result of amalgamation of The ACME Specialized Pharmaceuticals Limited).

Query No. 22

Whether Workers Profit Participation Fund is properly invested as per requirement of laws with details description;

Auditors' Disclosure:

To comply with the Labor Law 2006, as amended in the year 2013 effective from July 2013, the Company allocated Tk. 60,242,211 to Workers' Profit Participation Fund, Workers' Welfare Fund and Workers' Welfare Foundation Fund and as per section 240(3) of the said Laws, recovered interest amounting Tk. 3,131,770 on the same and eventually made payment as on 10 March 2015 to the Board of Trustees constituted for the same.

It is mentionable that, the Board of Trustees allocated the said amount among the beneficiaries and invested as under:

Workers' Profit Participation Fund (80%)	Tk. 50, 699,185 (Paid to the beneficiaries on 16 March 2015)
Workers' Welfare Fund (10%)	Tk. 6,337,398 (Out of this BDT 5,000,000 invested in Bangladesh Shanchayapatra on 22 April 2015)
Workers' Welfare Foundation Fund (10%)	Tk. 6,337,398 (Paid to fund on 5 April 2015)

Query No. 23

Comparative information for the year ended 30 June 2014 in note 41 is not provided in the related party transaction;

Auditors' Disclosure:

The Company carried out a number of transactions with related parties in the normal course of business considering arms length transaction motive. The nature of transactions and amount with comparative figure are given below:

Name of the Related Parties	Relation	Nature of Transaction	Value of transactions [in Taka]	Balance at 30.06.2014 Receivable/ (Payable) [in Taka]	Balance at 30.06.2013 Receivable/ (Payable) [in Taka]
ACMUNIO Int. Ltd.	Common Directors	Advance to ACMUNIO	25,130,552	120,343,583	95,213,031
		Finished Goods Purchase	4,334,085	-	-
		Rent as Investment Property	6,462,000	32,310,000	25,848,000
The ACME Specialized pharmaceuticals Ltd.	Do	Investment in shares	-	-	351,467,400
		Investment	-	-	1,307,802,898
		Finished Goods Sale	-	-	-
		Finished Goods Purchase	-	-	-

Name of the Related Parties	Relation	Nature of Transaction	Value of transactions [in Taka]	Balance at 30.06.2014 Receivable/ (Payable) [in Taka]	Balance at 30.06.2013 Receivable/ (Payable) [in Taka]
Sinha Printers ltd.	Do	Local Supply received	391,049,968	(388,321,732)	(434,543,465)
		Provide Service & others	329,116	37,257,581	36,928,465
Kalyar Packaging Ltd.	Do	Local Supply	45,570,985	-	(3,781,826)
Kalyar Replica Ltd.	Do	Local Supply	7,083,759	-	-
Mr. Md. Hasibur Rahman	Employee and Shareholder (0.037%)	Advance against Land	15,000,000	80,000,000	65,000,000

Query No. 24

Whether you have made physical verification of inventories;

Auditors' Disclosure:

As a part of our standard audit procedure, we used to do physical verification of Inventory in case of medium to large manufacturing company on test basis keeping in view the 'Principles of Materiality'.

During the currency of audit under reference of The ACME Laboratories Limited, we have followed the same as a standard practice.

Query No. 25

The company has recognized of Deferred Tax Assets on account of un-absorbed depreciation of tax holiday unit of Tk. 177,065,444.00, which appears to be non compliance of paragraph 22 and 42 of BAS 8. Explain.

Auditors' Disclosure:

In this regard, we want to draw your kind attention to the note no. 1.0 and note no. 2.0, page no. 142 -143 of draft prospectus, whereby the Company stated following information:

Amalgamation of "The ACME Specialized Pharmaceutical Limited (ASPL) with The ACME Laboratories Limited:"
The Honorable Supreme Court of Bangladesh, High Court Division, vide its judgment dated 20.11.13 approved the scheme of amalgamation of the "The ACME Specialized Pharmaceuticals Limited" (the Transferor Company) with "The ACME Laboratories Limited" (the Transferee Company) whereby the *entire undertaking of the Transferor Company as a going concern together with all the assets and liabilities relating there to be transferred to and vest in the Transferee Company.*

In accordance with the Scheme of Amalgamation, The Board of Directors of the Transferee Company and the Transferor Company in its respective meetings held on 27.12.2013 resolved that the books of account of the Transferor Company to be closed through transferring all balances to the books of the Transferee Company by /as of 31.01.2014.

The erstwhile 'The ACME Specialized Pharmaceuticals Limited' (Present Solid Dosages Unit) was engaged in manufacturing of non-penicillin & non-cephalosporin solid dosages generic pharmaceuticals formulation products including dosages form like tablet, capsule, dry syrup, liquid in hard gelatin, sachet products and was enjoying Tax Holiday period from September 29, 2011 to September 28, 2016.

As a Consequence of the amalgamation, business of the Solid Dosages Unit has been transferred as a going concern to The ACME Laboratories Limited, however the said unit of The company would continue to enjoy the tax holiday for the remaining period i.e. from February 01, 2014 till September 28, 2016.

From the aforesaid facts, it is clear that on 01.02.2014The ACME Laboratories Limited took all the assets and liabilities of The ACME Specialized Pharmaceuticals Limited (Present Solid Dosages Unit) through its (ASPL) dissolution without winding up. As such, there is no scope of providing retrospective effects relating to deferred tax adjustment, the matter has been adjusted in this year's financial statements.

Sd/-
PINAKI & COMPANY
Chartered Accountants

Date, Dhaka;
June 8, 2015

Statement of supplementary compliance by the ACME Laboratories Limited regarding The Companies Act 1994 Schedule XI Part Two Para 8.

(a) Value of Imports Calculated on CIF basis by the Company during the Financial year 2013-2014 in respect of Raw Materials, Component and Spare Parts and Capital Goods is as follows:

S.L	Year	Particulars	Import		
			Unit	Quantity	Amount (in BDT)
i	2013-2014	Raw materials	Gram	541,095	32,830,095
i	2013-2014	Raw materials	Kg	939,690	1,596,611,604
i	2013-2014	Raw materials	Ltr	900	6,860,337
i	2013-2014	Raw materials	Pc	114,765,000	39,048,472
i	2013-2014	Raw materials (ASPL)	Kg	21,086	13,512,921
					1,688,863,428
ii	2013-2014	Component and Spare Parts	Pc	14,659	19,370,403
iii	2013-2014	Capital Goods			764,795,629

(b) The Company does not have any expenditure in foreign currency during the financial year on account of royalty, Know-how, Professional Consultation fees, Interest and Other matters;

(c) Value of Both Imported and Indigenous raw Materials, Spare Parts and Consumption thereon;

Particulars	Raw Material		Total	Spare Parts		Total
	Imported Value (in BDT)	Indigenous Value (in BDT)		Imported Value (in BDT)	Indigenous Value (in BDT)	
Opening Balance	486,322,436	208,665,229	694,987,665	3,046,561	72,217,250	75,263,811
Purchase during the Year	1,688,863,428	1,425,153,313	3,114,016,741	19,370,403	4,650,008	24,020,411
Closing Balance	(305,355,314)	(519,570,956)	(824,926,270)	(7,524,494)	(75,512,115)	(83,036,609)
Consumed during the year	**1,869,830,550**	**1,114,247,586**	**2,984,078,136**	**14,892,470**	**1,355,143**	**16,247,613**
Percentage to total Consumption	**63%**	**37%**	**100%**	**92%**	**8%**	**100%**

(d) No amount is remitted during the year in foreign currencies on account of dividends with a specific mention of the number of non-residents shareholders, the number of shares held by them on which the dividends were due and the year to which the dividends, related.

(e) Earnings in foreign exchange Classified under the following heads are as follows:

i) Total Export for the year ended 30th June, 2014 is BDT 363,269,096.00 in which BDT 308,778,732 is calculated on FOB basis

ii) Royalty, Know how, Professional and Consultation Fees; are not applicable in this case.

iii) Interest and Dividend; is not applicable in this case

iv) Other Income; indicating the nature thereon is not applicable in this case.

Place: Dhaka
Date : 10 March, 2016

Sd/-
Pinaki & Company
Chartered Accountants

Additional Disclosures of the Management

Statement Regarding Participation of the Representatives from the Stock Exchanges in the road show as observers

This is to certify that according to our records and knowledge following representatives had participated from the Stock Exchanges in the road show as observers:

SL #	Name	Designation	Representing Institution
01	Mr. Md. Rabiul Islam	Sr. Executive	Dhaka Stock Exchange Ltd.
02	Mr. Md. Nasir Uddin	Sr. Officer, Compliance Monitoring	Chittagong Stock Exchange Ltd.

Statement Regarding Realization of Outstanding Rent on Investment Property Amounting Tk. 32,310,000

As per Audited Financial Statements for the year ended 30 June 2014 outstanding rent on investment property stood Tk. 32,310,000 which was shown at note no. 12. Management of The ACME Laboratories Ltd. recently have communicated the matter to the authority of ACMUNIO International Ltd. In this regard, Board of Directors of ACMONIO International Ltd. have passed a resolution that outstanding factory rent will be adjusted against submitted bills for supply of syringe to The ACME Laboratories Ltd. They (ACMUNIO) have also decided that outstanding amount of rent will be adjusted by June 2016.

Statement Regarding Explaining the Reason of Increase FDR Interest Income

It appears that for the year ended on 30 June 2014, interest income on FDR increased to Tk. 96,263,653 which was Tk. 13,291,250 for the year ended 30 June 2013. The reason behind increase of such interest is the Company raised its paid up capital in May 2013 through issuing 39,631,100 Ordinary Shares@ Tk. 52 including a premium of Tk. 42 total amounting Tk. 2,060,817,200 for implementing Large & Small Volume Parenteral Project and Liquid & Semisolid project. Being the money was gradually used to implement the aforesaid projects, certain amount of capital raised was kept as fixed deposit, due to which, the amount of interest on FDR increased during the reporting period.

Statement Regarding Fluctuation of Net Assets Value (NAV)

There are two reasons behind this significant change of Net Assets Value (NAV) per share. Firstly, during the financial year 2010-11 the Company issued 10,600,000 Ordinary Shares @ Tk. 100 each as stock dividend. Consequently, number of Ordinary Shares increased from 1000,000 to 11,600,000. Secondly, the Company changed the denomination of face value of Ordinary Shares from Tk. 100 each to Tk. 10 each. As a result, again number of Ordinary Shares had increased from 11,600,000 to 116,000,000.

Due to aforesaid events, as at 30 June 2011 NAV per share stood Tk. 50.21 which was Tk. 1,209.56 as at 30 June 2010 considering face value per share Tk. 100, if we consider face value per share Tk. 10, NAV as at 30 June 2010 would stand Tk. 120.956 per share. After that, in the way of wealth maximization NAV per share gradually increased and stood Tk. 66.16 as at 30 June 2014.

Sd/-
Mizanur Rahman Sinha
Managing Director
The ACME Laboratories Ltd.

Date, Dhaka
June 08, 2015

Date: 18 February 2016

Statement regarding any material change including raising of paid-up capital after the date of audited financial Statements

This is to certify that, "The ACME Laboratories Ltd." has not made any material change including raising of paid-up capital after the date of audited financial Statements (30 June 2014) as included in the prospectus.

Sd/-	Sd/-
(Md. Zahangir Alam, FCMA)	**(Mizanur Rahman Sinha)**
Chief Financial Officer	Managing Director

Date: 18 February 2016

Statement regarding Cost Audit

This is to certify that, as per provision of the Companies Act 1994, Cost Audit by Professional Accountant is not applicable for "The ACME Laboratories Ltd.".

Sd/-	Sd/-	Sd/-
(Md. Zahangir Alam, FCMA)	**(Nasrin Sultana)**	**(Mizanur Rahman Sinha)**
Chief Financial Officer	Chief Executive Officer	Managing Director
The ACME Laboratories Ltd.	ICB Capital Management Limited	The ACME Laboratories Ltd.

AUDITOR'S REPORT

TO THE SHAREHOLDERS OF THE ACME LABORATORIES LTD.

We have audited the accompanying financial statements of The ACME Laboratories Ltd. which comprises the Statement of Financial Position as at June 30, 2015 and the related Statement of Profit or Loss and other comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows for the year then ended and a summary of significant accounting policies and other explanatory notes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Bangladesh Financial Reporting Standards (BFRS), the companies Act 1994, the Bangladesh Securities and Exchange Rules 1987 and other applicable laws and regulations, This responsibility includes designing, implementing, and maintaining internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Bangladesh Standards on Auditing (BSA). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

In our opinion, the financial statements prepared in accordance with Bangladesh Financial Reporting Standards (BFRS), give a true and fair view of the state of the company's affairs as at June 30, 2015 and of the results of its operations and its cash flows for the year then ended and comply with the Bangladesh Securities and Exchange Rules 1987, the companies Act 1994 and other applicable laws and regulations.

We also report that:

(i) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;

(ii) In our opinion, proper books of account as required by law have been kept by the company so far as it appeared from our examination of those books and proper returns adequate for the purpose of our audit have been received;

(iii) The Company's Statement of Financial Position and Statement of Profit or Loss and other comprehensive Income and its statements of Cash Flows dealt with by the report are in agreement with the books of account and returns;

(iv) The expenditure incurred was for the purpose of the company's business;

Sd/-
Pinaki & Company
Chartered Accountants

Dhaka
Dated: September 20, 2015

Continuation Sheet...

The ACME Laboratories Ltd.

Statement of Financial Position

As at June 30, 2015

ASSETS	NOTES	TAKA	
		As at 30.06.2015	As at 30.06.2014
Non-Current Assets :		**16,060,787,303**	**15,544,508,282**
Property, Plant and Equipment	6	16,027,234,140	15,511,897,086
Intangible Assets	7	245,250	286,875
Investment in Shares	8	7,122,913	6,139,321
Investment Property	9	26,185,000	26,185,000
Current Assets:		**7,198,984,638**	**6,635,062,802**
Inventories	10	2,484,869,763	2,223,003,434
Trade Receivable	11	729,654,988	644,867,067
Other Receivable	12	40,721,339	74,526,105
Advance, Deposits & Pre-Payments	13	986,392,966	1,097,408,239
Advance Income Tax	14	1,820,547,016	1,334,147,374
Material In Transit	15	285,524,549	294,476,484
Term Deposit	16	419,003,619	553,201,740
Cash and Cash Equivalents	17	432,270,398	413,432,359
TOTAL		**23,259,771,941**	**22,179,571,084**
EQUITY AND LIABILITIES			
Shareholders' Equity:		**11,372,629,592**	**10,692,163,182**
Share Capital	18	1,616,017,000	1,616,017,000
Share Premium	19	1,605,066,569	1,605,066,569
Revaluation Surplus	6.a	5,320,065,830	5,429,804,848
Gain/(Loss) on Marketable Securities (Unrealized)	8.1	1,824,633	841,041
Tax Holiday Reserve		139,860,882	91,006,996
Retained Earnings	20	2,689,794,678	1,949,426,728
Non Current Liabilities		**4,904,881,207**	**3,057,678,428**
Long Term Loans- Net off Current Maturity	21	4,721,113,988	3,018,088,196
Provision For Gratuity	22	57,776,500	30,465,330
Deferred Tax Liability	23	125,990,719	9,124,902
Current Liabilities :		**6,982,261,142**	**8,429,729,474**
Loans & Overdrafts	24	3,099,847,325	4,874,126,240
Current Maturity of Long Term Loans	25	1,609,081,078	1,014,864,198
Trade Payable	26	432,244,843	528,302,125
Provision for Income Tax	27	1,556,306,023	1,245,658,922
Liability for Expenses and Others	28	133,076,893	160,054,589
Dividend Payable	29	151,704,980	606,723,400
TOTAL		**23,259,771,941**	**22,179,571,084**

The annexed notes 1 to 51 form an integral part of the financial statements.

As per our annexed report of even date.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Pinaki & Company
Chartered Accountants

Continuation Sheet...

The ACME Laboratories Ltd.

Statement of Profit or Loss and Other Comprehensive Income

For the Year Ended 30 June 2015

	NOTES	TAKA	TAKA	TAKA	TAKA
		July '14 to June '15	July '14 to June '15	July '14 to June '15	July '13 to June '14
		Non-Tax Holiday Unit	Tax Holiday Unit (50% Tax exemption)	Total	Total
Revenue	30	**8,822,686,137**	**2,673,727,494**	**11,496,413,631**	**10,217,931,465**
Less: Cost of Goods Sold	31	5,656,961,523	1,538,036,449	7,194,997,972	6,237,792,554
Gross Profit/(Loss)		**3,165,724,614**	**1,135,691,045**	**4,301,415,659**	**3,980,138,911**
Add: Other Income	32	40,910,030	217,947	41,127,977	108,071,977
		3,206,634,644	**1,135,908,992**	**4,342,543,636**	**4,088,210,888**
Less: Selling, Marketing and Distribution Expenses	33	1,193,887,688	361,869,010	1,555,756,698	1,499,828,917
		2,012,746,956	**774,039,982**	**2,786,786,938**	**2,588,381,971**
Less: Administrative Expenses	34	297,256,899	90,098,979	387,355,878	546,384,337
		1,715,490,057	**683,941,003**	**2,399,431,060**	**2,041,997,634**
Less: Financial Expenses	35	753,993,136	228,536,360	982,529,496	776,911,190
Profit before Contribution to WPPF		**961,496,921**	**455,404,643**	**1,416,901,564**	**1,265,086,444**
Less: Contribution to WPPF	36	45,785,568	21,685,935	67,471,503	60,242,211
Net Profit before Tax		**915,711,353**	**433,718,708**	**1,349,430,061**	**1,204,844,233**
Less: Current Tax expense	37	268,161,434	42,485,667	310,647,101	426,636,328
Less: Deferred Tax (Income)/Expense	37	72,719,007	44,146,810	116,865,817	(115,682,993)
Net Profit after Tax		**574,830,912**	**347,086,231**	**921,917,143**	**893,890,898**
Other Comprehensive Income					
Gain/(loss) on Marketable Securities (Unrealized)		983,592	-	983,592	841,041
Total Comprehensive Income for the year		**575,814,504**	**347,086,231**	**922,900,735**	**894,731,939**
Earning Per Share (on the Equity Share of Taka 10 each)	38			**5.70**	**5.65**

The annexed notes 1 to 51 form an integral part of the financial statements.

As per our annexed report of even date.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Pinaki & Company
Chartered Accountants

Continuation Sheet...

The ACME Laboratories Ltd.

Statement of Changes in Equity

For the Year Ended 30 June 2015

(Amount In Taka)

Particulars	Share capital	Share Premium	Capital Reserve	Share money Deposit	Tax Holiday Reserve	Gain/(Loss) on Marketable securities (Unrealized)	Revaluation Surplus	Retained earnings	Total
Balance as at July 01, 2013	1,556,311,000	1,605,066,569	40,166,723	500,000,000	-	-	4,488,695,133	1,327,209,077	9,517,448,502
Addition due to Amalgamation	-	-	-	-	24,790,876	-	556,246,703	53,079,610	634,117,189
Share money deposit transferred to Long Term Loan	-	-	-	(500,000,000)	-	-	-	-	(500,000,000)
Adjustment due to disbursement of purchase consideration and resultant gain thereon	59,706,000	-	-	-	21,038,719	-	472,506,215	283,977,778	837,228,712
Profit for the year 2013-2014	-	-	-	-	-	-	-	893,890,898	893,890,898
Tax Holiday Reserve	-	-	-	-	45,177,401	-	-	(45,177,401)	-
Final Dividend for the year 2012-13	-	-	-	-	-	-	-	(367,815,550)	(367,815,550)
Interim Cash Dividend for the year 2013-14	-	-	-	-	-	-	-	(323,203,400)	(323,203,400)
Gain/(loss) on Marketable Securities (Unrealized)	-	-	-	-	-	841,041	-	-	841,041
Adjustment of Depreciation on Revaluation Surplus	-	-	-	-	-	-	(87,077,493)	87,077,493	-
Adjustment due to disposal	-	-	-	-	-	-	(565,710)	221,500	(344,210)
Capital reserve transferred to retained earnings	-	-	(40,166,723)	-	-	-	-	40,166,723	-
Balance as at June 30, 2014	**1,616,017,000**	**1,605,066,569**	**-**	**-**	**91,006,996**	**841,041**	**5,429,804,848**	**1,949,426,728**	**10,692,163,182**
Balance as at July 01, 2014	1,616,017,000	1,605,066,569	-	-	91,006,996	841,041	5,429,804,848	1,949,426,728	10,692,163,182
Profit for the year 2014-2015	-	-	-	-	-	-	-	921,917,143	921,917,143
Tax Holiday Reserve	-	-	-	-	48,853,886	-	-	(48,853,886)	-
Final Dividend for the year 2013-14	-	-	-	-	-	-	-	(242,402,550)	(242,402,550)
Gain/(loss) on Marketable Securities (Unrealized)	-	-	-	-	-	983,592	-	-	983,592
Adjustment of Depreciation on Revaluation Surplus	-	-	-	-	-	-	(109,502,243)	109,502,243	-
Adjustment due to disposal	-	-	-	-	-	-	(236,775)	205,000	(31,775)
Balance as at June 30, 2015	**1,616,017,000**	**1,605,066,569**	**-**	**-**	**139,860,882**	**1,824,633**	**5,320,065,830**	**2,689,794,678**	**11,372,629,592**

The annexed notes 1 to 51 form an integral part of the financial statements.

As per our annexed report of even date.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Pinaki & Company
Chartered Accountants

Continuation Sheet...

The ACME Laboratories Ltd.

Statement of Cash Flows

For the Year Ended 30 June 2015

PARTICULARS	TAKA	
	July '14-June '15	July '13-June '14
Cash Flows From Operating Activities:		
Collection from Sales and others	11,482,235,909	10,151,510,988
Payment to Suppliers & Others	(8,889,653,916)	(8,499,238,362)
Workers Profit Participation Fund	(73,568,003)	(41,808,175)
Cash generated from operation	2,519,013,990	1,610,464,451
Financial Expenses	(982,529,496)	(776,911,191)
Income Tax Paid	(486,399,642)	(382,397,340)
Net cash from operating activities	**1,050,084,852**	**451,155,920**
Cash Flows From Investing Activities:		
Acqusition of Property, Plant and Equipment	(971,816,955)	(2,450,288,500)
Sale proceeds of Property, Plant & Equipments	4,310,000	721,500
Encashment of Fixed Deposit Receipt	134,198,121	666,798,260
Dividend received	217,549	-
Investment in share	-	(5,298,280)
Settlement of obligations of amalgamating company	-	(1,896,892,255)
Advance to ACMUNIO Int. Ltd.	(23,698,315)	(25,130,552)
Net cash used in investing activities	**(856,789,600)**	**(3,710,089,827)**
Cash Flows From Financing Activities:		
Share Capital	-	-
UNDP Grant	-	2,373,878
Dividend Paid	(697,420,970)	(183,373,300)
Cash and Cash Equivalent of amalgamating company	-	844,137
Settlement of Provident Fund Liabilities	-	(5,193,340)
Net Increase / (Decrease) in Loans and Overdrafts	(1,774,278,915)	1,259,952,933
Net Increase / (Decrease) in Long Term Borrowings	2,297,242,672	2,145,111,849
Net cash used in financing activities	**(174,457,213)**	**3,219,716,157**
Increase/(Decrease) in Cash and Cash Equivalents	18,838,039	(39,217,750)
Cash and Cash Equivalents at the Opening	413,432,359	452,650,109
Cash and Cash Equivalents at the Closing	**432,270,398**	**413,432,359**
Net Operating Cash Flow Per Equity Share	**6.50**	**2.85**

The annexed notes 1 to 51 form an integral part of the financial statements.

As per our annexed report of even date.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Pinaki & Company
Chartered Accountants

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

1.00 About the company

The ACME Laboratories was founded in the year 1954 as a Proprietorship Firm and it was converted into a Private Limited Company on 17th March, 1976 vide registration no. C-4745/163 of 1975-76 under the Companies Act-1913. Further, it was converted into a public limited company on 30thNovember 2011.

Amalgamation of "The ACME Specialized Pharmaceutical Limited with The ACME Laboratories Limited:"

The Supreme Court of Bangladesh, High Court Division, vide its judgment dated 20.11.13 approved the scheme of amalgamation of the "The ACME Specialized Pharmaceuticals Limited" (the Transferor Company) with "The ACME Laboratories Limited" (the Transferee Company) whereby the entire undertaking of the Transferor Company as a going concern together with all the assets and liabilities relating there to be transferred to and vest in the Transferee Company.

In this regard, the Board of Directors of the Transferee Company and the Transferor Company in its respective meetings held on 27.12.2013 resolved that the books of account of the Transferor Company to be closed through transferring all balances to the books of the Transferee Company by /as of 31.01.2014.

1.01 Address of registered office and factories

The Registered office of the company is situated at 1/4, Kallayanpur, Mirpur Road, Dhaka-1207, Bangladesh and the industrial units are established at Dhulivita, Dhamrai, Dhaka, Bangladesh.

2.00 Nature of business of the company and Tax Holiday Period:

The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products which includes human drugs dosages form like tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs dosages form like bolus, liquid, injection, water soluble powder, premix and herbal drugs dosages form like liquid, capsule, tablet, cream & ointment. The products of the company are sold in domestic and international markets.

The erstwhile 'The ACME Specialized Pharmaceuticals Limited' (Present Solid Dosages Unit) was engaged in manufacturing of non-penicillin& non-cephalosporin solid dosages generic pharmaceuticals formulation products including dosages form like tablet, capsule and dry syrup, liquid in hard gelatine, , sachet products and was enjoying Tax Holiday period from September 29, 2011 to September 28, 2016.

As a Consequence of the amalgamation, business of the Solid Dosages Unit has been transferred as a going concern to The ACME Laboratories Limited, however the said unit of The company would continue to enjoy the tax holiday for the remaining period i.e. from February 01, 2014 till September 28, 2016.

The ACME Laboratories Ltd.

Notes to the Financial Statements
As at June 30, 2015

3.00 Share Capital:

Particulars	30th June, 2015	30th June, 2014
Authorized Capital		
500,000,000 Ordinary Shares @ Tk. 10/- each	5,000,000,000	5,000,000,000
Total	**5,000,000,000**	**5,000,000,000**
Issued, Subscribed and fully paid up:		
161,601,700 Ordinary Shares @ Tk.10/- each. (As on 1 July 2013, 155,631,100 Ordinary Shares @ Tk. 10 each)	1,616,017,000	1,556,311,000
Add: Issued during the year as purchase consideration. (5,970,600 Ordinary Shares @ Tk. 10 each.)	-	59,706,000
Total 161,601,700 Ordinary Shares @ Tk. 10 each	**1,616,017,000**	**1,616,017,000**

4.00 Basis of Preparation of Financial Statements

4.01 Basis of measurement

The financial statements have been prepared on the historical cost basis except Land and Land Development, Building, Machinery & Equipment, Utilities, Electrical Installation & Engineering, Office Equipment and Motor Vehicle which was revalued by an independent valuer Mashi Muhit & Co. Chartered Accountants, Dhaka, Bangladesh as on 30th June 2011 after considering the fair value of the entire class of property, plant and equipment and other fixed assets to which that assets belong to on the basis of fair market value/current cost accounting /index adjusted replacement cost methods , as applicable. Further on 31st December 2011 the company revalued newly registered land based on the valuation report of the same valuer and disclosed in note: 6.a. The financial statements however, do not take into consideration the effects of inflation. The accounting policies, unless otherwise stated, have been consistently applied by the company and are consistent with those of the previous year.

The revaluation surplus, as per prudency, is not available for distribution as dividend to the shareholders.

4.02 Statement of compliance

These financial statements have been prepared in accordance with Framework, applicable International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) as adopted by the Institute of Chartered Accountants of Bangladesh as Bangladesh Accounting Standards (BASs) and Bangladesh Financial Reporting Standards (BFRSs), Companies Act 1994, Bangladesh Securities and Exchange Rules 1987 and other relevant laws and regulations applicable in Bangladesh.

4.03 Presentation of financial statements

The Financial Statements are presented in accordance with guidelines provided by BAS 1: 'Presentation of Financial Statements'.

The Financial Statements comprise of:

(i) A Statement of Financial Position as at 30 June 2015.

(ii) A Statement of Profit or Loss and Other Comprehensive Income for the year ended 30 June 2015
(iii) A Statement of Change in Equity for the year ended 30 June 2015.
(iv A Statement of Cash Flows for the year ended 30 June 2015
(v) Notes to the Financial Statements, comprising a summary of significant accounting policies and explanatory information.

4.04 Reporting Period

The Financial Statements cover the accounting year commencing from 1 July 2014 to 30 June 2015.

4.05 Authorisation for Issue

The financial Statements have been authorised for issue by the board of directors in their meeting held on 20 September 2015.

4.06 Functional and presentation currency

The financial statement are prepared and presented in Bangladeshi Currency (Taka), which is the functional currency of the company. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

4.07 Comparative information

Comparative information has been disclosed in respect of the financial year 2013-2014 for all numerical information in the financial statements and also the narrative and descriptive information where ever it is relevant for understanding of the current year's financial statement.

Figures for the comparative year have been regrouped/rearranged where ever considered necessary to ensure better comparability with the current year.

4.08 Use of estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the reported value of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the result of which forms the basis of making the judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. However, the estimates and underlying assumptions are reviewed on an on-going basis and the revision is recognized in the year in which the estimates are revised. No such revision however was carried out during the year under report except in the useful life of two classes of noncurrent assets. There is no material impact of change of estimates on the financial results of the company.

4.09 Going concern

The Company has adequate resources to continue in operation for foreseeable future. For this reason, the board of directors continue to adopt going concern basis in preparing the financial statements. The current credit facilities and resources of the Company provide sufficient funds to meet the present requirements of its existing businesses and operations.

4.10 Application of Bangladesh Financial Reporting Standards (BFRS) and Bangladesh Accounting Standards (BAS)

Name of the Accounting Standards	Ref. No.	Status of Application
Business Combination	BFRS-3	Applied
Financial Instruments : Disclosure	BFRS-7	Applied
Financial Instruments	BFRS-9	Applied
Fair Value Measurement	BFRS-13	Applied
Presentation of Financial Statements	BAS-1	Applied
Inventories	BAS-2	Applied
Statement of Cash Flows	BAS-7	Applied
Accounting Policies, Changes in Accounting Estimates and Errors	BAS-8	Applied
Events after the Reporting Period	BAS-10	Applied
Income Taxes	BAS-12	Applied
Property, Plant and Equipment	BAS-16	Applied
Leases	BAS-17	Applied
Revenue Recognition	BAS-18	Applied
Employee Benefits	BAS-19	Applied
Accounting for Govt. Grants and Disclosure of Government Assistants	BAS-20	Applied
The effects of Changes in Foreign Exchange Rates	BAS-21	Applied
Borrowing Costs	BAS-23	Applied
Related Party Disclosures	BAS-24	Applied
Financial Instruments: Presentation	BAS-32	Applied
Earnings Per Share	BAS-33	Applied
Provisions, Contingent Liabilities and Contingent Assets	BAS-37	Applied
Intangible Assets	BAS-38	Applied
Financial Instruments: Recognition & Measurement	BAS-39	Applied
Investment Property	BAS-40	Applied

5.00 Significant Accounting Policies

5.01 Revenue recognition

(a) **Sales of Goods:** In compliance with the requirements of BAS-18 'Revenue Recognition', revenue is recognized for local sales of Pharmaceuticals Drugs and Medicines at the time of delivery to chemists/Institutions and Exports of Pharmaceuticals Drugs and Medicines at the time of delivery to Custom Port. i.e. when the significant risk and rewards of ownership is transferred to the buyer, whereby there is no continuing management involvement with the goods and the amount of revenue can be measured reliably.

(b) Rental income is recognized when accrued on a time proportion basis.
(c) Interest income is recognized when accrued on a time proportion basis.

5.02 Sales

Turnover comprises the invoice value of goods supplied by the Company, representing domestic and Export sales. Revenue from sales is exclusive of VAT.

5.03 Property, Plant and Equipment:

i) Recognition and measurement

This has been stated at cost or revalued amount less accumulated depreciation in compliance with the requirement of BAS 16: Property Plant and Equipment. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the assets to its present locations and working conditions for its intended use inclusive of inward freight, duties and non-refundable taxes.

ii) Maintenance activities

The company incurs maintenance costs for all its major items of Property, Plant and Equipment. Repair and maintenance costs are charged as expenses as and when incurred.

iii) Depreciation

Land is held on a freehold basis and is not depreciated considering its unlimited useful life. In respect of all other fixed assets depreciation is provided on a straight line method to amortize the cost of the asset after commissioning over their expected useful life. In respect of addition to property, plant and equipment, depreciation begins from the date of available for use up to the date immediately preceding the date of disposal.

The rate at which assets are depreciated per annum depending on the nature and estimated useful life of assets are given below:

Category of Assets	Rate
Building	5%
Machinery and Equipments	7.5%
Furniture and Fixtures	10%
Motor Vehicles	10%
Utilities, Engineering and Electrical Installations	7.5%
Office Equipments	20%
Books and Periodicals	10%

iv) Retirement and Disposal

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is recognized in the Statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets and net sales proceeds.

5.04 Intangible assets

Intangible assets are stated at cost less provision for amortization and impairments. The cost of

acquiring and developing computer software for internal use and internet sites for external use are capitalized as Intangible Assets where the software or site support a significant business system and the expenditure lead to the creation of a durable asset.

Amortization is recognized in the Statement of Profit or Loss and Other Comprehensive Income under the head of Administrative Expenses on a straight line basis @ 7.5% over the estimated useful lives of intangible assets, from the date that they are available for use.

5.05 Leased assets

In compliance with BAS 17: "Leases", Lease in terms of which the company assumes substantially all the risks and rewards of ownership are classified as finance leases and all other leases are classified as operating lease.

Upon initial recognition, the lease assets is measured at an amount equal to the lower of its fair value and the present value of the minimum lease payment. Subsequent to initial recognition, the assets is accounted for in accordance with accounting policy applicable to the assets.

Though there are financing in the name of lease financing however, as per the substance of the agreement, these financing are not in the nature of lease financing, hence has been grouped as 'Long Term Loan' and its current maturity as 'Current Maturity of Long Term Loans'.

5.06 Financial instruments

A financial instrument is any contract that gives rise to financial assets and a financial liability or equity instrument of another entity.

i) Financial assets

Financial assets of the company include cash and cash equivalents, accounts receivable, other receivables and equity instrument of another entity. The company initially recognized receivable on the date they are originated. All other financial assets are recognized initially on the date at which the company becomes a party to the contractual provision of the transaction. The company derecognizes a financial asset when, and only when the contractual rights or probabilities of receiving the cash flow from the assets expire or it transfer the right to receive the contractual cash flows on the financial assets in a transaction in which substantially all the risk and rewards of ownership of the financial assets are transferred.

Trade Receivable

Trade receivable are created at original invoice amount less any provisions for doubtful debts. Provision is made where there is evidence of a risk of non-payments, taking into consideration aging, previous experience and general economic conditions. When a trade receivable is determined to be uncollected, it is written off firstly against any provision available and then to the Statement of Profit or Loss and Comprehensive Income. Subsequent recoveries of amounts previously provided for and/or written off are credited to the Statement of Profit or Loss and Other Comprehensive Income. During the year under audit, the company has no uncollectable trade receivable to be written off and for which it created any provision.

Cash and cash equivalents

Cash and cash equivalents are comprised of cash in hand and cash at bank that are readily convertible to known amount of cash and that are subject to an insignificant risk of change in value.

ii) Financial Liability

Financial liabilities are recognized initially on the transaction date at which the company becomes a party to the contractual provisions of the liability. The company derecognises the financial liabilities when its contractual obligations are discharged or cancelled or expired. Financial liabilities include payable for expense, liability for capital expenditure and other current liabilities.

5.07 Impairment

i) Financial assets

Trade receivable and others receivables are assessed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flow of that asset, that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indicates that a debtor or issuer will enter bankruptcy etc.

ii) Non-Financial assets

An asset is impaired when its carrying amount exceeds its recoverable amount. The company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exits, the company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less cost to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount by recognizing an impaired loss if, and only if, the recoverable amount of the assets is lesser than its carrying amount. Impaired loss is recognized immediately in the Statement of Profit or Loss and Other Comprehensive Income unless the asset is carried at revalued amount. Any impaired loss of a revalued asset shall be treated as a revaluation decrease.

5.08 Investment in shares

According to the relevant laws of the Land, the company used to invest in shares of listed companies through stock exchange, by using the income generated in Tax Holiday Unit. The investments are recognized at cost including transaction cost. Further, the entity has presented the subsequent changes in other comprehensive income.

5.09 Inventories

Inventories are carried at the lower of cost and net realizable value as prescribed by BAS 2: 'Inventories'. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present location and condition. Cost of material consumption is determined on first in first out basis. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sales.

Type of Stock	Basis of Valuation
Raw Materials	At cost on First in First Out basis
Packing Materials	At cost on First in First Out basis
Work-in-Process	At cost
Finished Goods	At lower of cost or net realizable value
Printing Stationary	At cost on First in First Out basis
Spare & Accessories	At cost on First in First Out basis

5.10 Provisions

Provisions and accrued expenses are recognized in the financial statements in line with the Bangladesh Accounting Standard (BAS) 37 "Provisions, Contingent Liabilities and Contingent Assets" when:

- The company has a legal or constructive obligation as a result of past events.
- It is probable that an outflow of economic benefit will be required to settle the obligations.
- A reliable estimate can be made of the amount of the obligations.

5.11 Income tax expense

Income tax expense comprised of current and deferred tax. Income tax expense is recognized in the Statement of Profit or Loss and Other Comprehensive Income and accounted for in accordance with requirement of BAS 12: Income Taxes.

Current tax

Current tax is the expected tax payable on the taxable income for the period/year and any adjustment to tax payable in respect of previous years.

Deferred tax

The company has recognized deferred tax using balance sheet method in compliance with the provision of BAS 12: Income Taxes. The policy of recognition of deferred tax assets/liabilities is based on temporary differences (taxable or deductible) between the carrying amount (Book Value) of assets and liabilities for financial reporting purpose and its tax base, and accordingly, deferred tax income or expense has been considered to determine net profit after tax and Earnings per Share (EPS).

5.12 Loans – Long Term and Short Term from Banks, Financial Institutions and Others.

i) Borrowing cost

Interest and other cost incurred by the company in connection with the Borrowings of fund are recognized as expenses in the year in which they are incurred unless such borrowing cost related to acquisition/construction of assets in progress that are capitalized as per BAS 23: 'Borrowing costs'.

ii) Charges on the Assets of the Company:

There are Fixed and Floating charges over:

- All the Plant, Machinery and Equipments (both present and future) ;
- Floating assets (both present and future)including but not limited to book debts , bills receivable , goodwill and other floating assets both tangible and intangible and all documents title , undertakings, contracts ,engagements securities and other documents whatsoever related to such assets of the Company in favour of various bankers securing the various kinds of loans taken by the company from them through a pari-passu agreement dated 23 April 2014 amongst the bankers for sharing the security. The names of the participating bankers in the charges through pari-passu agreement are stated here under:

    - Agrani Bank Limited.
    - The Hongkong and Shanghai Banking Corporation Limited.
    - Standard Chartered Bank.
    - Dutch Bangla Bank Limited.
    - Dhaka Bank Limited.
    - Trust Bank Limited.

5.13 Employee benefits

The company maintains defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective agreements/trust deeds.

The company has accounted for and disclosed employee benefits in compliance with the provision of BAS19: 'Employee Benefits'.

The cost of employee benefit is charged off as revenue expenditure in the year to which the contributions relate.

The company's employee benefits include the following:

i) Defined Contribution Plan (Provident Fund):

The company got recognition from Commissioner of Taxesits provident fund scheme (Defined Contribution Plan) vide order no.: নথি নংপি,এফঅনুমোদন/৩২/ক:অ:-৩/২০১০-২০১১, তারিখ: ২৩/০৩/২০১১ Bsfor employees of the company eligible to be members of the fund in accordance with the rules of the provident fund constituted under an irrevocable trust. All permanent employees contribute to the provident fund and the company also makes equal contribution.

The company recognizes contribution to defined contribution plan as an expense when an employee has rendered services in exchange for such contribution. The legal and constructive obligation is limited to the amount it agrees to contribute to the fund.

ii) Defined Benefit Plan (Gratuity):

The Company has formulated a policy related to "Payment of Gratuity "payable to its eligible Permanent Employees who are serving the company for a considerable duration, at the time of severance of their relationship from the Company. Eligibility for getting the said Benefit mainly depends upon the length of service with the organization subject to compliance of the eligibility criteria as prescribed by the management in the policy and accordingly the company has made necessary provision (non funded) in the books of accounts.

iii) Short-term employee Benefits

Short-term employee benefits include salaries, bonuses etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

iv) Contribution to Worker's Profit Participation Fund (WPPF)

This represents 5% of net profit before tax and before charging the contribution to WPPF by the company as per provision of the section 15 of the Bangladesh Labor (Amendment) Act, 2013 and is payable to beneficiary as defined in the said law.

v) Insurance Schemes

Employees of the company are covered under group hospitalization and group term life insurance including accidental benefits. Summary of the plans are stated here under:

A. Group Hospitalization Insurance Plan:

In this scheme, the company covers its employees under hospitalization and other medical expenses related with hospitalization of the employees from salary Grade K and above. The hospitalization

benefits are provided to employees as per three tier system and each tier of benefits covering from different group of employees based on salary grade in the company. The company pay annual premium to the insurance company for this cover of their employees.

B. Group Term Life Insurance Including Accidental Death Benefit:

In this policy, all the permanent and salaried employees of the company are covered. If an insured employee dies irrespective of the cause of death, insurance company upon receipt of written proof pays to the employer the sum insured in respect of that employee as per the terms of the contract between the insurance company and the employer.

In respect of Fourth class (i.e. Driver, Peon, Cleaner, Guard, Electrician, Loader, Packing Man, Worker and Helper etc.) married employees, if he leaves behind not more than two children then additional sum equivalent to 15% of sum insured is being paid to them.

Employee Position:

During the year there were 7,603 employees employed in the company with remuneration above Tk. 3,000 per month, among them 5,396 employees employed for the full year and remaining 2,207 employees employed less than full year.

5.14 Investment Property

For Investment Property, the company follows fair value model as subsequent measurement. A gain or loss arising from a change in the fair value of investment property is recognized in Statement of Profit or Loss and Other Comprehensive Income for the year in which it arises.

5.15 Share Premium

As per BAS-32, Para-37, an entity typically incurs various costs in issuing or acquiring its own equity instruments. Those costs might include registration and other regulatory fees amounts paid to legal, accounting and other professional advisers, printing costs and stamp duties. The transaction costs of an equity transaction are accounted for as a deduction from equity (net of any related income tax benefit) to the extent they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided. The costs of an equity transaction that is abandoned are recognized as an expense.

The company shows share premium account balance after netting off relevant transaction costs. The balance in share premium account shall be utilized in accordance with provisions of Section 57(2) the Companies Act 1994 and as directed by the Bangladesh Securities and Exchange Commission in this respect.

5.16 Research Development and Experimental Cost:

In compliance with the requirements of BAS-38 "Intangible Assets", research, development and experimental costs are usually absorbed as revenue charges to the Statement of Profit or Loss and Other Comprehensive Income as and when incurred, as being not that much material in the company's and /local context.

5.17 Earnings per Share (EPS)

This has been calculated in compliance with the requirement of BAS 33: Earnings per Share, by dividing the basic earnings by the weighted average number of ordinary shares outstanding during the year.

Basic Earnings per Share (Numerator/Denominator)

Earnings (Numerator)

This represents earning for the year attributable to ordinary shareholders.

No. of Ordinary shares (Denominator)

This represents weighted average number of ordinary share outstanding during the year.

Diluted Earnings per Share

As per the existing conditions of the loans taken by the company from various financial institutions or other contracts with various parties including employees, there is no condition related to conversion or stipulation related to share based payments for material and services supplied by them to the company. Hence, the Diluted EPS of the company is same as Basic EPS.

5.18 Foreign Currency Transactions

Foreign currency transactions are recorded at the applicable rates of exchange ruling at the transaction date. The monetary assets and liabilities, if any, denominated in foreign currencies at the financial position date are translated at the applicable rates of exchanges ruling at that date. Exchange differences are accounted as revenue expenditure/income in compliance with the provision of BSA 21: The Effects of Changes in Foreign Exchange Rates.

5.19 Directors' Responsibility Statement

The Board of Directors takes the responsibility for the preparation and presentation of these financial Statements.

5.20 Triple Bottom Line Practice in ACME

In ACME, we believe that there is more to business than just making profit. Long term business success and sustainability relies on economic value, environmental health, and social progress. Our values are rooted in the concept of the 'Triple Bottom Line' (TBL) and we assume ourselves accountable in relationship to Profit, Planet and People. We strongly believe that earning profit can't be the only goal of any organization, well-being of the people and environment are also equally important, hence ACME has adopted Triple Bottom Line concept as its business philosophy.

5.21 Segmental Reporting:

As required by BFRS – 8 'Operating Segments', if an entity operates and engages in different economic environments and activities then the entity has to disclose information, to enable users of its financial statements to evaluate the nature and financial effects of the business so carried out.

The company consider the operation on aggregate basis and manage the operations as a single operating segment. Hence it is felt that such segment reporting is not required to be disclosed.

5.22 Contingent Liabilities and Contingents Assets:

Contingent liabilities and assets are present or possible obligations or on liabilities or assets, arising from past events and existence of which depends upon the occurrence or non-occurrence of one or more uncertain future events which are not within the control of the company or which amount of the obligations cannot be measured with sufficient reliability. In accordance with BAS-37, they are disclosed in the note # 47 hereunder.

5.23 Statement of Cash Flows:

Statement of Cash Flows has been prepared in accordance with BAS-7 'Statement of Cash Flows' by using direct method.

5.24 Events after the reporting period:

Events after the reporting period that provide additional information about the company's position at the date of statement of financial position or those that indicate the going concern assumption is not appropriate are reflected in the financial statements. Events after the reporting period that are not adjusting events are disclosed when material.

5.25 Risk Management

Efficient and effective Risk management is a part and parcel of today's business. As such, The ACME Laboratories Ltd. would be subject to systematic risks of the industry and market as well. The majority of these risks are commercial and business risks in nature that can be mitigated effectively. Such major risk factors and management approaches on the same are described in brief as under:

Operational Risk

ACME relies on suppliers for ingredients and various third parties for certain manufacturing-related services to produce material that meets appropriate content, quality and stability standards of the company products and after approval it is being released for commercial distribution. ACME may not be able to produce its drug substance or drug product to appropriate standards without the required supports from its suppliers and vendors. Again, if it fails to maintain important manufacturing and service relationships, may not find a replacement supplier or required vendor or develop company's own capabilities which could delay or impair company's ability to obtain regulatory approval for its products and substantially increase company's costs or deplete profit margins, if any.

Management Perception

ACME has a good number of vendors and for each and every ingredient and service, the company have more than one approved vendors. It uses to conduct vendor audit and its concerned professionals are very conscious regarding the vendor issue. Further, none of the supplier accounts for significant amount of total purchases.

Interest Rate Risk

Interest rate risk is the risk that Company faces due to unfavourable movement in the interest rates. Changes in the government's monetary policy, along with increased demand for loans/investments tend to increase the interest rates. Such rises in interest rates mostly affect Companies having floating rate loans or Companies investing in debt securities.

Management Perception

In order to manage this risk and overcome it, the Company shall exercise prudence in its cash flow management, supported by continued strength in sales and marketing. ACME is very careful in forecasting the prices of ingredients and manages its costs in an effective manner. To maintain effective rate of return ACME also follow knowledge and information based products mix, so as to ensure that the debt repayments are met on schedule, even if the interest rates were to rise.

Exchange Rate Risk

Exchange rate risk occurs due to changes in foreign currency exchange rates. As the Company has taken foreign currency loan, imports major raw materials and some packing materials from abroad and earns most of the revenue in local currency, unfavourable volatility or fluctuation may affect the profitability of the Company. On the other hand, if exchange rate decreased against local currency opportunity will be created for generating more profit.

Management Perception

ACME earns some of its revenue in US dollars, thereby creating to built-up auto hedging scopes. Besides, in case of significant BDT devaluation, to keep the cost to minimum, appropriate and responsible hedging mechanisms may be applied. However, if the price of the US dollar appreciates too sharply against the BDT, this will be a nationwide phenomenon experienced by the entire industry. In such a scenario, there will be a market adjustment in end product prices, subject to approval of concerned authority.

Industry Risk

The pharmaceutical industry has witnessed challenges such as intellectual property rights, a historic fuel price peak, and material cost increase across the globe. It stands as one of the most challenging and dynamic industries to operate as on date. Fortunately, Bangladesh is only least developed country who demonstrates significant competencies in pharmaceuticals industry and it requires huge medicine for its present 160 million (approx.) populations and requires huge quantity of medicine. As such, local pharmaceutical industry is not in a trouble; rather the said industry has ample opportunities to grow.

Management Perception

As the per capita income and per person consumption of medicine has been increasing over the years, management is optimistic about growth opportunities of pharmaceutical industry in Bangladesh. The company is trying to adopt sophisticated state of art cutting edge technology driven manufacturing facilities and making efforts to catch the opportunity of regulated global market.

Market Risk

Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the Company. Mostly, the risk arises from falling demand for the pharmaceutical products which would harm the performance of the Company. On the other hand, strong marketing and brand management system would help the Company to increase its customer and market base.

Management Perception

The products of pharmaceuticals industry are of basic nature and have a wide market as they are giving a good market share to The ACME Laboratories Ltd. at present. Hence, it will hardly be the case that there will be a lack of demand for the products. Moreover, as explained earlier, the pharmaceuticals industry is only increasing year-on-year basis and ACME is following fool-proof scientific integrated marketing policy. Hence, has marginal probability for shrinkage of the market.

Technology Related Risk

Pharmaceutical industry is dynamic in nature and heavily driven by technology. Hence, technology always plays a vital role here. Adaptation of better technology can help to gain remarkable core competencies that certainly create competitive advantages like increase productivity; reduce costs, better perception of customers. Firms are exposed to technology risks when there are better technologies available in the market than the one used by the Company which may cause operational inefficiency.

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

Management Perception

As a one of the leading pharmaceutical firm of the country, there are clear intent regarding adaptation of technology here and the management is aware of technological changes and always trying to adopt new technology according to its needs. Furthermore, routine and proper maintenance of the equipment carried out by the Company ensures longer service life for the existing equipment and facilities. Finally, ACME is committed to hold its leading edge and maintaining quality and brand image.

Potential or Existing Government Regulations

The Company operates under the Drugs Ordinance 1982, Companies Act 1994, Directorate General of Drug Administration (DGDA) Regulations, Income Tax Ordinance 1984, Income Tax Rules 1984, Customs Act 1969, Value Added Tax (VAT) Act 1991, and Value Added Tax (VAT) Rules 1991 and other rules and regulations of the country. Any abrupt changes of the policies made by the regulatory authorities may adversely affect the business of the Company.

Management Perception

Since product of pharmaceuticals industry is essential one for lives and it is an import substitute industry and degree of value addition is remarkable, we see the government regulations are mostly investment friendly for this sector particularly. As ACME is one of the top ranking pharmaceutical companies of the country, it is doing business following all the rules and regulations of the land. Change in regulations will bring changed strategies for doing the business by the dynamic management of the Company. Besides, many of the patented drugs/molecules will be off patented and it will be an opportunity for the manufacturer to freely manufacture, promote and distribute without any restriction.

Potential Changes in Global and National Policies

Changes of Government policies may affect business. 49 LDCs including Bangladesh are not required to provide patent protection, give exclusive marketing rights to companies with patented products or comply with the "mailbox" program – create a process to receive complaints about pharmaceutical product patent right violations until 2016. While it is possible that the deadline may be extended, its implementation in 2016 will have significant impact on the LDC who have not implemented the TRIPS standards.

Management Perception

Pharmaceuticals, over the years have been proved as a thrust sector for the country and growing at a considerable pace each year. Bangladesh, through its international affiliates and other 48 LDCs shall definitely lobby for extension of this deadline. In addition, ACME is continuously trying to adopt right technology and build infrastructure to meet TRIPS standards.

History of Non-operation

The ACME Laboratories started its journey in the year 1954 and converted into a private limited company on 17 March 1976 vide registration no. C-4745/163 of 1975-76 under the Companies Act-1913. Since commencement of its operation, it has no history of non-operation till now. The Company is running by a professional team and pursues continuous fool-proof market promotion system, which reduce the non-operating risk.

Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge on obligation. Credit risk information helps users of financial statements asses the credit quality of the entity's financial assets and level and sources of impairment loss. Management has a credit

policy in place and exposure to credit risk is monitored on an on-going basis. As at 30 June 2015 substantial part of the receivables are subject to insignificant credit risk. Risk exposures from other financial assets i.e. cash at bank and other external receivables are nominal.

Management Perception

To mitigate the credit risk the management of the Company follows robust credit control and collections policies. The company has dedicated credit collections team who are responsible the any dues and they have been demonstrating remarkable performances.

Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (Cash and Cash equivalents) is to ensure as far as possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without incurring unacceptable losses or bringing damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses including financial obligations through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient fund to make the expected payment within due date.

Management Perception

Effective liquidity risk management requires both a top-down and a bottom-up approach. Strategy, principles and objectives are set at Board and management levels. ACME conducts liquidity management in a manner that maintains stability and flexibility in day-to-day funding activities. Our liquidity risk management starts by managing daily payment of cheques, daily cash inflow and outflow, maturity of deposits and our access to other funding sources as and when required.

5.26 General Comments & Observations:

a) Previous year's figures have been regrouped/reclassified wherever considered necessary to confirm to current year's presentation. Figures have been rounded off to the nearest taka, as the currency represented in this financial statement.

b) All shares have been fully called and paid up.

c) The company has not incurred any expenditure in foreign currency against royalties.

d) No foreign exchange remitted to the relevant shareholders during the year under audit.

e) No amount of money was expended by the company for compensating any members of the Board for special service rendered.

f) No brokerage was paid against sales during the year under audit.

g) There was no bank guarantee issued by the company on behalf of directors.

Property, Plant and Equipment * - Schedule A

Amount in Taka

Particulars of Assets	Historical Cost as at 01.07.14	Revaluation Surplus as at 01.07.14	Addition During the year (Cost)	Disposal		Adjustment of Machinery in transit/CWIP	Total as at 30.06.15	Rate	DEPRECIATION							Written Down value as at 30.06.2015
				Cost	Revaluation Surplus				Accumulated Dep. as at 01.07.14 on Cost	Accumulated Dep. as at 01.07.14 on Revaluation Surplus	Depriciation on Revaluation Surplus during the year	Depriciation on Historical Cost during the year	Disposal		Total as at 30.06.15	
													Accumulated Dep. on Cost	Accumulated dep. On Revaluation Surplus		
Land and land development	405,924,694	3,623,870,487	115,000,000	-	-	-	4,144,795,161		-	-	-	-	-	-	-	4,144,795,161
Building	2,552,895,866	1,953,688,650	266,975,981	-	-	-	4,773,560,497	5%	322,033,526	259,565,411	97,684,444	136,063,753	-	-	815,347,134	3,958,213,363
Machinery & Equipment	2,365,928,943	43,602,349	1,198,077,704	-	-	-	3,607,608,996	7.5%	426,796,760	8,563,935	3,268,856	237,257,741	-	-	675,887,292	2,931,721,704
Furniture & Fixture	215,424,643		32,817,837	-	-	-	248,242,480	10%	113,697,911	-	-	21,289,196	-	-	134,987,107	113,255,373
Motor Vehicle	409,047,447	36,769,166	36,308,455	(6,587,233)	(364,500)	-	475,173,335	10%	214,374,774	11,187,932	3,483,419	37,489,520	(6,587,233)	(127,725)	259,820,687	215,352,648
Utilities, Electrical Installation & Eng.	1,426,703,241	63,319,578	86,534,312	-	-	-	1,576,557,131	7.5%	408,966,103	13,140,881	4,751,738	105,777,345	-	-	532,636,067	1,043,921,064
Office Equipment	76,602,685	1,575,993	14,586,983	-	-	-	92,765,661	20%	37,336,126	563,197	313,786	20,236,182	-	-	58,449,291	34,316,370
Books and Periodicals	5,293,657		347,928	-	-	-	5,641,585	10%	3,262,084	-	-	501,701	-	-	3,763,785	1,877,800
Sub Total	**7,457,821,176**	**5,722,826,203**	**1,750,649,200**	**(6,587,233)**	**(364,500)**	**-**	**14,924,344,846**		**1,526,467,284**	**293,021,356**	**109,502,243**	**558,615,438**	**(6,587,233)**	**(127,725)**	**2,480,891,363**	**12,443,453,483**
Machinery in Transit	1,440,380,565	-	644,079,500	-	-	(1,288,056,174)	796,403,891		-	-	-	-	-	-	-	796,403,891
Construction work in progress	2,710,357,783	-	346,075,559	-	-	(269,056,576)	2,787,376,766		-	-	-	-	-	-	-	2,787,376,766
Sub Total	**4,150,738,348**	**-**	**990,155,059**	**-**	**-**	**(1,557,112,750)**	**3,583,780,657**		**-**		**-**	**-**	**-**	**-**	**-**	**3,583,780,657**
Total Taka :-	**11,608,559,524**	**5,722,826,203**	**2,740,804,259**	**(6,587,233)**	**(364,500)**	**(1,557,112,750)**	**18,508,125,503**		**1,526,467,284**	**293,021,356**	**109,502,243**	**558,615,438**	**(6,587,233)**	**(127,725)**	**2,480,891,363**	**16,027,234,140**

ALLOCATION OF DEPRECIATION:	On Cost	On Revaluation	Total
Factory Overhead	467,487,186	104,738,033	572,225,219
Selling, Marketing and Distribution Expenses	46,080,119	2,603,928	48,684,047
Administrative Expenses	45,048,133	2,160,282	47,208,415
	558,615,438	**109,502,243**	**668,117,681**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars	Taka	
		As at 30-06-2015	As at 30-06-2014
6	**Property, Plant and Equipment: Tk. 16,027,234,140**		
	Details of Property, Plant and Equipment and Depreciation as at June 30, 2015 are shown in the annexed Schedule - A. This is arrived at as follows:		
		14,349,363,783	14,372,322,836
	Opening Balance (At Cost)	11,608,559,524	4,732,199,044
	Add:		
	Addition of cost due to Amalgamation	-	4,323,768,649
	Addition of cost during the year	2,740,804,259	5,316,355,143
		5,722,826,203	5,723,546,203
	Opening Balance (Revaluation Surplus)	5,722,826,203	4,630,424,537
	Add: Addition due to amalgamation	-	1,093,121,666
	Less: Adjustment of CIP and Machinery in transit	(1,557,112,750)	(2,761,829,974)
	Less: Adjustment due to Disposal	(6,951,733)	(2,653,338)
		(1,564,064,483)	(2,764,483,312)
	Closing balance	18,508,125,503	17,331,385,727
	Less: Accumulated Depreciation	2,480,891,363	1,819,488,641
	Opening balance	1,819,488,640	1,056,412,902
	Addition due to amalgamation	-	452,849,221
	Depreciation charged during the year	668,117,681	311,628,502
	Adjustment due to Disposal	(6,714,958)	(1,401,984)
	Carrying Value	**16,027,234,140**	**15,511,897,086**
	Allocation of depreciation charge for the year has been made in the accounts as follows:		
	Factory Overhead	572,225,219	149,581,681
	Selling, Marketing and Distribution Expenses	48,684,047	87,255,981
	Administrative Expenses	47,208,415	74,790,840
	Total	**668,117,681**	**311,628,502**
6.a	**Revaluation Surplus: Tk. 5,320,065,830**		
	Mashi Muhit Haque & Co. Chartered Accountants, Dhaka, Bangladesh the valuer revalued the Land and Land Development, Building, Machinery & Equipment, Utilities, Electrical Installation & Engineering, Office Equipment and Motor Vehicle of the Company as at 30 June 2011 at " Current Cost Method". Further on 31st December 2011 the company revalued newly registered land under the same method by the same valuer. Due to these revaluation, a revaluation surplus aggregating Tk.4,630,818,104 has arisen. Current balance is shown below:		
	Revaluation surplus	5,722,461,703	5,722,826,203
	- Opening Balance	5,722,826,203	4,630,424,537
	Add :		
	Addition of revaluation due to amalgamation	-	1,093,121,666
	Adjustment of revaluation surplus due to disposal	(364,500)	(720,000)
	Less: Accumulated depreciation on revaluation surplus	402,395,873	293,021,355
	- Opening Balance	293,021,355	141,729,404
	-Addition due to amalgamation	-	64,368,749
	- Charged during the year	109,502,243	87,077,492
	- Adjustment due to disposal	(127,725)	(154,290)
		5,320,065,830	**5,429,804,848**

No.	Particulars		Taka	
			As at 30-06-2015	As at 30-06-2014
7	**Intangible Assets :Tk. 245,250**			
	This amount consists of as follows:			
	Application Software	(Details in note # 7.1)	940,285	940,285
	Less: Accumulated Amortization		695,035	653,410
	Opening balance		653,410	602,153
	During the year		41,625	51,257
			245,250	**286,875**

7.1 Application Software: Tk. 245,250

Details have been given below :

Year of Acquisition	Amount (Tk.)	Rate of write Off	Total Write off			Closing Balance as at 30.06.2015
			Opening balance	During the year	Total	
2000-01	385,285	7.50%	385,285	-	385,285	-
2007-08	400,000	7.50%	210,000	30,000	240,000	160,000
2009-10	155,000	7.50%	58,125	11,625	69,750	85,250
Total	**940,285**		**653,410**	**41,625**	**695,035**	**245,250**

8 Investment in Shares: Tk. 7,122,913

This represents investment in shares of Publicly listed Companies.

Public Limited Co.'s securities	(Details in note # 8.1)	7,122,913	6,139,321
		7,122,913	**6,139,321**

8.1 Public Limited Co's Securities

Particulars	No. of shares hold	FV	Average cost per unit	Total cost	Market Price as at 30.06.2014	Market Price as at 30.06.2015	Unrealized gain/(loss) as at 30.06.2015
AB Bank Ltd.	22,500	10	23.22	522,446	508,000	519,750	(2,696)
Eastern Bank Ltd.	20,000	10	29.17	583,480	576,000	514,000	(69,480)
Pioneer Insurance Co. Ltd.	26,250	10	40.00	1,050,013	1,047,900	874,125	(175,888)
Southest Bank Ltd.	25,000	10	20.18	504,509	487,500	430,000	(74,509)
EXIM Bank Ltd.	27,500	10	9.33	256,530	252,500	253,000	(3,530)
BRAC Bank Ltd.	28,000	10	27.00	755,908	736,400	1,150,800	394,892
Trust Bank Ltd.	27,500	10	13.27	365,027	370,000	599,500	234,473
Delta Brac Housing Ltd.	20,000	10	63.02	1,260,367	1,240,000	1,802,000	541,633
Square Pharma Ltd.	3,683	10	-	-	903,887	963,105	963,105
Square Textile Ltd.	218	10	-	-	17,134	16,633	16,633
				5,298,280	**6,139,321**	**7,122,913**	**1,824,633**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars	Taka	
		As at 30-06-2015	As at 30-06-2014

9 Investment Property : Tk. 26,185,000

The Company has an Investment Property (Building) which have been rented to ACMUNIO International Ltd. As per BAS-40: Investment Property, the company is following fair value model as subsequent measurement and any gain or loss arising from a change in fair value of Investment Property is recognized in Statement of profit or loss and other comprehensive Income for the year in which it arises. During the year the company has conducted valuation by its internal valuer who has sufficient knowledge regarding the location and category of the Investment Property.

The details are here under:

Opening balance	26,185,000	26,185,000
Add/Less: Changes in fair value	-	-
Closing Balance	**26,185,000**	**26,185,000**

10 Inventories: Tk. 2,484,869,763

This consists of as follows:

Raw Materials	690,584,842	824,926,270
Packing Materials	688,717,291	545,143,710
Work-in-Process	392,224,068	375,336,272
Finished Goods	573,035,786	375,693,869
Printing Stationery	37,471,715	18,866,704
Spare & Accessories	102,836,061	83,036,609
Total	**2,484,869,763**	**2,223,003,434**

Refer note # 5.12 regarding creation of charges in favour of bankers as per syndication agreement.

11 Trade Receivable : Tk. 729,654,988

The trade receivable both domestic and exports occurred in the ordinary course of business are unsecured but considered good by the management. The above trade receivable is as follows:

Domestic	685,518,418	574,255,442
Exports	43,908,015	70,338,597
	729,426,433	644,594,038
Foreign exchange Unrealised Gain/(Loss)	228,555	273,029
	729,654,988	**644,867,067**

There was no amounts due from the directors (Including Managing Director, Managing Agent, Manager and other Officers of the Company) and any of them severally or jointly with any other person (s).

Refer note # 5.12 regarding creation of charges in favour of bankers as per syndication agreement.

11.1 Trade Receivable: Tk. 729,654,988

Ageing of the above receivables are given below:

	Upto 6 Months	Above 6 Months	Total	Total
Domestic	685,518,418	-	685,518,418	574,255,442
Exports	43,908,015	-	43,908,015	70,338,597
			729,426,433	644,594,038
Foreign exchange Unrealised Gain/(Loss)			228,555	273,029
			729,654,988	**644,867,067**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars	Taka	
		As at 30-06-2015	As at 30-06-2014
12	**Other Receivable: Tk. 40,721,339**		
	(Unsecured but considered good)		
	This consists of as follows:		
	Rent on Investment Property	37,156,500	32,310,000
	Sinha Printers Ltd. against Goods and Services	-	37,257,581
	Interest Receivable on FDRs	3,564,441	4,958,524
	Dividend Receivable on Marketable Securities	398	-
		40,721,339	**74,526,105**
13	**Advances, Deposits and Prepayment : Tk 986,392,966**		
	The followings items are unsecured but considered as good and this consists of as follows :		
	Advances:		
	Advances against salary	63,466,623	57,757,291
	Motor Cycle advance to employees	223,938,533	238,546,633
	Employee advances (Others)	54,429,351	48,503,038
	ACMUNIO Int. Ltd.	144,041,898	120,343,583
	Advance to Suppliers	167,854,352	116,607,407
	Advance to Suppliers for Construction	192,710,431	324,584,985
	Advance against Land	15,250,000	95,250,000
	Others	6,532,169	7,733,061
	Deposit :		
	Security deposit and earnest money	13,486,031	11,673,501
	Lease Deposit	2,186,000	4,780,055
	Presumptive Tax on Share Premium	13,064,814	13,064,814
	Bank Guarantee/LC Margin	11,604,600	11,604,600
	Advance VAT	61,203,886	30,733,050
	Others	4,210,353	4,710,353
	Prepayments :		
	Office Rent	5,178,450	5,429,450
	Insurance	7,235,475	6,086,418
		986,392,966	**1,097,408,239**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars	Taka	
		As at 30-06-2015	As at 30-06-2014
14	**Advance Income Tax: Tk 1,820,547,016**		
	The breakup of the above amount is as under		
	Opening Balance as per last A/C	1,334,147,374	1,273,276,904
	Less: Adjustment of Current Tax Provision against Advance Income Tax		
	- For the assessment year 2011-2012	-	(218,905,630)
	- For the assessment year 2010-2011	-	(136,683,926)
	Payment during the year:		
	AIT collected by customs Authority	95,250,919	95,433,002
	AIT collected by Bank from export bills	1,800,276	1,948,536
	AIT deducted against supply of medicine	5,898,376	9,809,089
	AIT collected by BRTA Authority	3,076,000	2,676,500
	AIT deducted on bank Interest	4,830,561	10,543,922
	AIT deducted from Dividend Received	43,510	-
	Paid by Pay Order/Cheque:		
	for the assessment year 2012-13	3,020,000	-
	for the assessment year 2013-14	-	91,066,045
	for the assessment year 2014-15	140,305,033	170,920,246
	for the assessment year 2015-16	232,174,967	-
	Addition of advance Income Tax due to amalgamation	-	34,062,686
		1,820,547,016	**1,334,147,374**
15	**Material in Transit: Tk. 285,524,549**		
	Raw Materials	226,982,203	254,312,276
	Packing Materials	50,518,104	20,008,993
	Spare Parts	8,024,242	20,155,215
		285,524,549	**294,476,484**
16	**Term Deposit: Tk. 419,003,619**		
	As a part of efficient treasury management, the company have made some short term deposits with various Commercial Banks which are stated below:		
	Trust Bank Limited	419,003,619	387,365,775
	Dhaka Bank Limited	-	165,835,965
		419,003,619	**553,201,740**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars	Taka	
		As at 30-06-2015	As at 30-06-2014
17	**Cash and Cash Equivalents: Tk. 432,270,398**		
	This is made up as follows :		
	Cash in Hand	305,996,749	296,664,128
	Cash at Bank :		
	Agrani Bank, Ramna Branch, STD A/C	15,775,722	15,403,313
	Agrani Bank, Dhamrai Branch, C/D A/C	3,033,318	1,469,840
	Dhaka Bank Ltd, Dhanmondi Br.	57,478	209,529
	National Bank Ltd, Dhanmondi Br. CD A/C	48,901	349,591
	Uttara Bank Ltd, Satmosjid Road Br. CD A/C	25,740,763	22,012,108
	Marcantile Bank Ltd, Hemaetpur Br. CD A/C	44,646,880	32,130,061
	Agrani Bank ,Ramna Br. F/C A/C	6,283,434	(4,069,819)
	Standard Chartered Bank F/C A/C, HO	22,622	2,457,628
	Sonali Bank, Local office	277,054	246,197
	National Credit and Commerce Bank Ltd., Shymoli Br.	7,582,424	1,349,336
	Eastern Bank Limited C/D A/C, Gulshan Branch	3,425,007	9,958,746
	Dutch Bangla Bank Ltd., Barisal Br.	9,031	280,043
	Sonali Bank, Kallayanpur Br.	110,065	111,565
	Dutch Bangla Bank Ltd., Rajshahi Br.	6,680	187,009
	Dutch Bangla Bank Ltd., Jessore Br.	626,500	245,793
	Dutch Bangla Bank Ltd., Khulna Br.	336,440	541,232
	Dutch Bangla Bank Ltd., Mymensingh Br.	23,344	2,426,666
	Dutch Bangla Bank Ltd., Dinajpur Br.	156,855	284,980
	Dutch Bangla Bank Ltd., Ring Road Br.	179,354	181,284
	Dutch Bangla Bank Ltd., B.B Road Br.,Narayangonj	296,158	484,387
	Dutch Bangla Bank Ltd., B.Baria, Branch	563	736,350
	Dutch Bangla Bank Ltd.	-	1,030
	Dutch Bangla Bank Ltd., Patherhat Branch	752,046	14,300
	HSBC F/C A/C, Main Branch	2,748	33,628
	HSBC F/C (USD) A/C, Main Branch	6,914,388	11,202,335
	United Commercial Bank Limited UCBL-CD AC, Gulshan Branch	498,846	90,839
	Dutch Bangla Bank Ltd, Chakoria Branch	408,160	203,510
	The City Bank Ltd., Dhanmondi Branch	55,990	78,175
	Trust Bank Ltd., Dhanmondi Branch	354,337	761,363
	Dutch Bangla Bank Ltd., Faridpur Br.	25,485	167,529
	Dutch Bangla Bank Ltd., Bogra Br.	29,357	365,680
	Standard Chartered Bank SND A/C, HO	866,523	3,165,666
	Standard Chartered Bank DSRA A/C, HO	3,390,099	13,683,268
	Dutch Bangla Bank Ltd., Rangpur Br.	130,415	3,350
	Dutch Bangla Bank Ltd., Hemayetpur Branch	59,337	-
	EXIM Bank Ltd., Hemayetpur Branch	336,981	-
	Bank Asia Ltd., Hemayetpur Branch	266,252	-
	Trust Bank Ltd. F/c A/C	3,542,872	-
	Cash at BO account	1,220	1,720
		432,270,398	**413,432,359**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars	Taka	
		As at 30-06-2015	As at 30-06-2014

18 Share Capital : Tk. 161,601,700

This is arrived at as follows :

a) Authorized Capital : Tk 5,000,000,000

500,000,000 Ordinary Shares @ Tk. 10/-each	5,000,000,000	5,000,000,000

b) Issued, Subscribed and Paid - up Capital:

161,601,700 Ordinary Shares @ Tk.10/- each. (As at 01.07.13, 155,631,100 Ordinary Shares)	1,616,017,000	1,556,311,000
Add: Issued during the year (5,970,600 Ordinary Shares issued in the year 2013-2014)	-	59,706,000
	1,616,017,000	**1,616,017,000**

c) The movement of Ordinary Shares during the year is as under

	No. of Share	No. of Share
Opening Balance	161,601,700	155,631,100
Share issued during the year	-	5,970,600
Closing Balance.	161,601,700	161,601,700

d) Composition of Share holding of Ordinary Shares:

Name of the Shareholders	2014-2015		2013-2014	
	No. of Shares	%	No. of Shares	%
Mr. Nasir-Ur-Rahman Sinha	6,160,405	3.81%	13,620,136	8.43%
Mr. Mizanur Rahman Sinha	20,426,565	12.64%	18,175,115	11.25%
Dr. Jabilur Rahman Sinha	4,860,696	3.01%	14,220,630	8.80%
Mr. Afzalur Rahman Sinha	17,214,336	10.65%	14,962,886	9.26%
Mrs. Parveen Akhter Nasir	5,401,517	3.34%	10,539,843	6.52%
Mrs. Jahanara Mizan Sinha	10,519,744	6.51%	10,519,744	6.51%
Mrs. Nagina Afzal Sinha	11,888,433	7.36%	11,888,433	7.36%
Mrs. Hasina Jabil Sinha	4,859,245	3.01%	10,075,593	6.23%
Institutional Shareholders	38,476,100	23.81%	38,476,100	23.81%
Others	41,794,659	25.86%	19,123,220	11.83%
Total	**161,601,700**	**100%**	**161,601,700**	**100%**

Above mentioned composition of shareholding represents the position as at 01 September 2015.

19 Share Premium: Tk. 1,605,066,569

In the year 2012-2013, the company issued 39,631,100 Ordinary Shares of Tk. 10 each at issue price of Tk. 52 with a premium of Tk. 42 each.

Opening balance	1,605,066,569	1,605,066,569
Add : Amount received during the year	-	-
Less: Transaction cost	-	-
Closing balance	**1,605,066,569**	**1,605,066,569**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars	Taka	
		As at 30-06-2015	As at 30-06-2014
20	**Retained Earnings: Tk. 2,689,794,678**		
	Opening balance	1,949,426,728	1,327,209,077
		1,031,624,386	1,358,414,002
	Add: Net profit after tax for the year	921,917,143	893,890,898
	Adjustment for Depreciation on Revaluation Surplus	109,502,243	87,077,493
	Adjustment of Revaluation surplus due to disposal	205,000	221,500
	Adjustment due to disbursement of purchase consideration and resultant gain thereon	-	283,977,778
	Transfer from Capital Reserve	-	40,166,723
	Addition due to amalgamation	-	53,079,610
		291,256,436	736,196,351
	Less: Tax Holiday Reserve	48,853,886	45,177,401
	Interim Cash Dividend declared during the year 2013-2014	-	323,203,400
	Final dividend declared for the year 2013-2014	242,402,550	367,815,550
	Closing balance	**2,689,794,678**	**1,949,426,728**
21	**Long Term Loans - Net off Current Maturity: Tk. 4,721,113,988**		
	This represents long term borrowings from financial institutions which are as follows:		
	Name of Financial Institution		
	Standard Chartered Bank Ltd.	216,005	18,225,115
	Trust Bank Ltd. (MTL)	213,830,194	226,030,241
	Dhaka Bank Ltd. MTL	51,908,940	73,907,803
	Dutch Bangla Bank Ltd. (MTL)	934,246,841	249,445,361
	IDLC	226,642,333	183,708,976
	SCB-Foreign Loan (Net of foreign currency gain/loss)	622,440,000	865,193,168
	ICB	-	350,000,000
	IIDFC	262,500,000	67,500,000
	IPDC	105,056,694	52,994,901
	ULC	140,000,000	-
	ILFSL	375,000,000	-
	Fareast Finance and Investment Ltd.	375,000,000	-
	Lanka Bangla Finane Ltd.	750,000,000	-
	National Finance Ltd.	-	44,172,675
	HSBC-Foreign Loan (Net of foreign currency gain/loss)	664,272,981	886,909,956
		4,721,113,988	**3,018,088,196**
22	**Provision for Gratuity: Tk. 57,776,500**		
	Opening Balance	30,465,330	-
	Addition due to amalgamation	-	3,406,283
	Add: Provision during the year	84,652,887	27,059,047
	Less: Paid during the year	57,341,717	-
		57,776,500	**30,465,330**
23	**Deferred Tax Liability/(Assets): Tk. 125,990,719**		
	This represents provision made/assets created related to deferred income tax for taxable/deductable temporary differences which is arrived at as follows:		
	Opening Balance	9,124,902	124,807,896
	Add : Deferred Tax Liability/(Assets) created during the year		
	Increase in Deferred tax liability	126,424,727	70,853,117
	On account of taxable temporary difference of taxable unit	82,277,917	61,193,400
	On account of taxable temporary difference of Tax holiday unit	44,146,810	9,659,717
	Creation of Deferred Tax Assets	(9,558,910)	(186,536,111)
	on account of Unabsorbed Depreciation of Tax holiday unit	-	(177,065,445)
	on account of Provision for Gratuity	(9,558,910)	(9,470,666)
		125,990,719	**9,124,902**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars	Taka	
		As at 30-06-2015	As at 30-06-2014

24 Loans & Overdrafts : Tk. 3,099,847,325

This represents various facilities availed from bank which are as follows :

Name of the Bank		
Agrani Bank	(7,406,415)	(18,544,575)
Dutch Bangla Bank	137,756,243	375,390,984
Standard Chartered Bank	503,346,739	777,091,756
Dhaka Bank Ltd. LTR A/C	92,721,024	72,918,444
Dhaka Bank Ltd. C/C Hypo A/C	264,361,396	335,304,815
Dhaka Bank Ltd. STL A/C	30,070,000	30,093,333
HSBC O/D, LTR, RL	606,158,381	1,095,190,245
EBL, Overdraft,LTR,RL	1,118,134,010	595,291,896
Trust Bank Ltd., OD,LTR,STL	80,603,307	391,554,969
The City Bank Ltd., O/D A/C, LTR, STL A/C	274,312,215	967,476,092
AB Bank Ltd., O/D, LTR, RL A/C	(209,575)	252,358,281
	3,099,847,325	**4,874,126,240**

25 Current Maturity of Long Term Loans: Tk. 1,609,081,078

This represents current portion of long term loans from financial Institution which are repayable within next 12 months from the balance Sheet date :

Standard Chartered Bank Ltd. (MTL)	18,873,131	25,503,290
Trust Bank Ltd.	117,472,328	61,033,927
Eastern Bank Ltd.	-	-
IDLC	148,113,043	149,895,380
IIDFC	90,000,000	40,000,000
IPDC	72,938,207	37,655,116
ULC	40,000,000	-
ILFSL	100,000,000	-
Fareast Finance and Investment Ltd.	100,000,000	-
Lanka Bangla Finane Ltd.	200,000,000	-
National Finance Ltd.	-	20,559,079
SCB-Foreign Loan (Net of foreign currency gain/loss)	248,976,000	247,040,000
HSBC Foreign Loan (Net of foreign currency gain/loss)	251,713,370	245,191,570
ICB	-	100,000,000
Dhaka Bank Ltd.	21,532,160	17,985,836
Dutch Bangla Bangla Bank Ltd.	199,462,839	70,000,000
	1,609,081,078	**1,014,864,198**

26 Trade Payable: Tk. 432,244,843

This consists of :

Trade Creditors	432,244,843	528,302,125
	432,244,843	**528,302,125**

27 Provision for Income Tax: Tk. 1,556,306,023

Opening Balance	1,245,658,922	1,168,807,914
Add: Addition due to Amalgamation	-	5,804,236
Add: Provision for the year	310,647,101	416,636,328
Add: Provision related to prior years	-	10,000,000
Less: Adjustment of Current Tax Provision against Advance Income Tax		
- For the assessment year 2011-2012	-	(218,905,630)
- For the assessment year 2010-2011	-	(136,683,926)
Closing Balance	**1,556,306,023**	**1,245,658,922**

The ACME Laboratories Ltd.

Notes to the Financial Statements

As at June 30, 2015

No.	Particulars		Taka	
			As at 30-06-2015	As at 30-06-2014
28	**Liability for Expenses and Others: Tk. 133,076,893**			
	This comprise of :			
	Salary & Allowances		32,491,093	28,603,514
	Power & Electricity		1,327,436	3,681,082
	Postage & Telephone		2,012,310	1,392,185
	Gas Bill		5,531,596	7,799,019
	Office rent		224,599	224,599
	Audit Fee		500,000	500,000
	WASA Bill		57,840	1,076,850
	Other Expenses		12,813,633	1,820,953
	Interest payable		-	22,402,271
	Workers Profit Participation Fund	28.a	78,118,386	84,214,886
	Employee Deduction		-	4,016,023
	Tax Deducted at Source			
	- On directors' remuneration		-	546,292
	- On employees' salary		-	604,458
	- Others		-	3,172,457
			133,076,893	**160,054,589**
28.a	**Workers Profit Participation Fund: Tk. 78,118,386**			
	The company makes a regular allocation of 5% on net profit before tax to this funds and payment is made to the workers as per provision of the section 15 of the Bangladesh Labour (Amendment) Act, 2013.			
	Opening balance		84,214,886	65,059,739
	Add: Addition due to amalgamation		-	721,111
	Add: Addition during the year		67,471,503	60,242,211
	Less: Payment during the year		73,568,003	41,808,175
	Closing balance		**78,118,386**	**84,214,886**
29	**Dividend Payable: Tk. 151,704,980**			
	The Board of Directors proposed 35% cash dividend which was duly approved in 38th AGM by the shareholders for the year 2013-2014. This will involve an amount of Tk. 565,605,950. The details are stated below:			
	Opening balance (Interim dividend for 2012-2013)		606,723,400	99,077,750
	Add: Final dividend declared for the year 2013-2014 (Gross)		242,402,550	367,815,550
	Add: Interim dividend declared for the year 2013-2014		-	323,203,400
	Less: Dividend paid to the shareholders		558,712,120	64,480,000
	Less: Dividend paid to other than promoter shareholders		138,708,850	118,893,300
	Net Dividend Payable		**151,704,980**	**606,723,400**

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No.	Particulars	Taka			
		July '14 to June '15	July '14 to June '15	July '14 to June '15	July '13 to June '14
		Non Tax Holiday Unit	Tax Holiday Unit (50% Tax exemption)	Total	Total
30	**Revenue : Tk. 11,496,413,631**				
	This is made up as follows:				
	Gross Turnover				
	Domestic				
	Own Products (with VAT)	9,621,670,641	3,089,145,886	12,710,816,527	9,717,776,916
	ASPL Products (Erstwhile Subsidiary Co. now amalgamated)	-	-	-	1,460,306,873
		9,621,670,641	3,089,145,886	12,710,816,527	11,178,083,789
	Manufactured by Others :				
	Syringe	10,791,437	-	10,791,437	4,702,633
	Fish Feed	14,889,000	-	14,889,000	19,552,125
		9,647,351,078	**3,089,145,886**	**12,736,496,964**	**11,202,338,547**
	Exports				
	Own Products	321,221,254	33,431,865	354,653,119	363,269,096
	Manufactured by Others	83,991,530	-	83,991,530	-
		405,212,784	**33,431,865**	**438,644,649**	**363,269,096**
	Total Gross Turnover (Domestic & Exports)	**10,052,563,862**	**3,122,577,751**	**13,175,141,613**	**11,565,607,643**
	Less: VAT	1,229,877,725	448,850,257	1,678,727,982	1,347,676,178
	Net Turnover	**8,822,686,137**	**2,673,727,494**	**11,496,413,631**	**10,217,931,465**

The summarized quantities are as follows:

Name of Category	Unit	Opening	Production/ Purchase	Sales	Closing
Capsule	Pcs	15,649,214	357,285,647	356,784,393	16,150,468
Cream	Tube	225,558	4,919,829	4,647,837	497,550
Dry Syrup	Bottles	276,020	7,915,639	7,057,832	1,133,827
Eye/Ear/Nasal Drop	Phials	349,003	9,091,471	8,229,250	1,211,224
Injection	Pcs	4,329,057	39,693,881	40,993,881	3,029,057
Liquid	Bottles	3,027,510	58,418,942	56,777,123	4,669,329
Ointment	Tube	57,444	1,894,000	1,760,921	190,523
Tablet	Pcs	63,673,719	2,210,933,688	2,202,432,432	72,174,975
Powder	Pcs	44,490	658,562	636,518	66,534
Inhaler (DPI)	Cans	1,599,399	27,738,082	27,750,540	1,586,941
Suppository	Pcs	598,334	21,770,000	21,716,856	651,478
Inhaler(MDI)	Cans	21,330	486,813	433,486	74,657
Injection (vet)	Pcs	1,208,291	11,305,272	10,946,034	1,567,529
Liquid (Vet.)	Bottles	168,350	3,747,586	3,237,282	678,654
Bolus	Pcs	7,404,099	118,482,000	118,294,458	7,591,641
Premix	Pcs	3,982,821	14,448,052	14,050,177	4,380,696
W S Powder	Pcs	211,338	3,836,000	3,798,769	248,569
Syringe	Pcs	73,209	1,949,047	2,013,386	8,870
Fish Feed	Kg	11,299	415,758	423,931	3,126
Infusion	Pcs	-	2,001,000	1,595,664	405,336
Sachet	Pcs	-	8,223,000	7,899,604	323,396

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No.	Particulars		Taka			
			July '14 to June '15	July '14 to June '15	July '14 to June '15	July '13 to June '14
			Non Tax Holiday Unit	Tax Holiday Unit (50% Tax exemption)	Total	Total
31	**Cost of Goods Sold: Tk. 7,194,997,972**					
	This is arrived at as follows :					
	Raw Materials Consumed	31.a	3,165,919,498	766,887,788	3,932,807,286	2,984,078,136
	Packing Materials Consumed	31.b	1,634,933,139	442,609,109	2,077,542,248	1,563,686,298
	Work in Process (Opening)		324,256,819	51,079,453	375,336,272	356,784,193
	Work in Process (Closing)		(327,656,434)	(64,567,634)	(392,224,068)	(375,336,272)
	Consumption during the year		**4,797,453,022**	**1,196,008,716**	**5,993,461,738**	**4,529,212,355**
	Factory Overheads	31.c	965,491,832	323,807,812	1,289,299,644	855,993,858
	Cost of Production		**5,762,944,854**	**1,519,816,528**	**7,282,761,382**	**5,385,206,213**
	Purchase of Finished Goods		109,578,507	-	109,578,507	872,031,409
	Purchase of Finished Goods through amalgamation		-	-	-	23,503,442
	Opening Stock of Finished Goods		333,906,052	41,787,817	375,693,869	332,745,359
	Finished Goods Available		**6,206,429,413**	**1,561,604,345**	**7,768,033,758**	**6,613,486,423**
	Closing Stock of Finished Goods		(549,467,890)	(23,567,896)	(573,035,786)	(375,693,869)
	Cost of Goods Sold		**5,656,961,523**	**1,538,036,449**	**7,194,997,972**	**6,237,792,554**

31.a Raw Materials Consumed: Tk. 3,932,807,286

This is arrived at as follows :

Opening Stock of Raw Materials	753,256,479	71,669,791	824,926,270	694,987,665
Purchase during the year	3,072,791,502	725,674,356	3,798,465,858	3,114,016,741
Closing Stock of Raw Materials	(660,128,483)	(30,456,359)	(690,584,842)	(824,926,270)
Raw Material Consumed	**3,165,919,498**	**766,887,788**	**3,932,807,286**	**2,984,078,136**

Item wise summarized quantity and total number of ingredients are as follows:

Particulars	Pcs	Quantity (kg)		Quantity (Liter)		Quantity (Pcs)	
	Cap Shell	Active	Excepients	Active	Excepients	Active	Excepients
Opening Balance	398,429,439	2,854,892	915,676	197	13,186	-	-
Purchase	294,425,831	4,990,086	4,691,024	147	41,939	28,000	3,095,400
Available for use	692,855,270	7,844,978	5,606,700	344	55,125	28,000	3,095,400
Closing Balance	338,665,023	2,426,658	783,262	243	12,471	-	-
Consumption	354,190,247	5,418,320	4,823,438	101	42,654	28,000	3,095,400

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No.	Particulars	Taka			
		July '14 to June '15	July '14 to June '15	July '14 to June '15	July '13 to June '14
		Non Tax Holiday Unit	Tax Holiday Unit (50% Tax exemption)	Total	Total

31.b Packing Materials Consumed: Tk. 2,077,542,248

This is arrived at as follows :

Opening Stock of Packing Materials	511,054,376	34,089,334	545,143,710	404,785,640
Purchase during the year	1,801,537,529	419,578,300	2,221,115,829	1,704,044,368
Closing Stock of Packing Materials	(677,658,766)	(11,058,525)	(688,717,291)	(545,143,710)
	1,634,933,139	**442,609,109**	**2,077,542,248**	**1,563,686,298**

The Total quantity of Packing Materials are stated as under :

Name of Category	Unit	Opening	Purchase	Consumption	Closing
Ampoule	Pcs	26,325,547	42,968,672	41,124,030	28,170,189
Bottle	Pcs	26,870,936	84,456,718	77,470,275	33,857,379
Carton	Pcs	23,943,040	111,312,495	105,087,305	30,168,230
Plastic Item	Pcs	5,564,293	127,231,563	108,606,823	24,189,033
Cap	Pcs	24,130,421	94,354,748	91,080,839	27,404,330
Catch Cover	Pcs	19,680,626	24,417,947	22,300,984	21,797,589
Inner Leaflet	Pcs	11,873,731	90,627,429	89,125,262	13,375,898
Label	Pcs	1,605,450	84,759,079	79,014,059	7,350,470
Shipping Box Label	Pcs	1,635,442	7,266,157	5,981,694	2,919,905
PVC/PVDC	Pcs	337,106	470,152	581,966	225,292
Shipping Box	Pcs	35,758	8,370,775	8,346,135	60,398
Tube	Pcs	2,633,574	7,533,232	7,348,503	2,818,303
Al. Foil- Blister	Pcs	7,160	136,755	122,232	21,683
Al. Foil- Strip	Pcs	71,980	1,230,308	822,594	479,694
Inner Board	Pcs	59,647	1,811,717	1,709,598	161,766
Vial	Pcs	6,015,454	9,739,141	9,175,123	6,579,472
Sticker Label	Pcs	7,929,755	28,749,602	23,891,749	12,787,608

31.c Factory Overheads : Tk. 1,289,299,644

This is made up as follows :

Salary & Allowances	219,556,608	66,461,610	286,018,218	275,232,057
Daily Wages	67,286,580	20,368,207	87,654,787	76,380,142
Gratuity	16,363,233	4,887,719	21,250,952	13,028,949
Group Insurance Premium	626,371	189,608	815,979	600,980
Postage & Telephone	2,208,150	668,426	2,876,576	1,815,672
Fuel, Power & Electricity	57,164,600	17,304,199	74,468,799	133,890,701
Conveyance	1,945,766	588,999	2,534,765	1,937,058
Company's Contribution to RPF	10,043,447	3,040,235	13,083,682	12,462,230
Gas Bill	45,366,514	13,732,821	59,099,335	25,098,806
Factory Staff Uniform	3,071,650	794,226	3,865,876	2,293,910
Carriage Inward	9,733,664	2,946,461	12,680,125	2,601,622
Repairs & Maintenance	25,774,661	7,802,204	33,576,865	85,656,576
Medical Expenses	108,056	32,709	140,765	33,447
Insurance	8,890,714	2,691,293	11,582,007	8,055,810
Local Tax	853,990	258,510	1,112,500	2,426,000
Printing & Stationery	13,626,301	4,228,464	17,854,765	17,424,136
Design, Blocks & Layout	675,996	204,629	880,625	-
Research & Analysis	1,433,587	433,959	1,867,546	1,630,620
Welfare & Recreation	6,201,361	1,877,203	8,078,564	9,461,073
Entertainment	3,052,523	924,024	3,976,547	3,702,947
Canteen Expenses	6,038,009	1,827,756	7,865,765	7,364,206
Spare Parts	47,177,058	14,280,887	61,457,945	24,020,411
Service Charge	3,990,540	-	3,990,540	
Contribution to CSR Activities	-	-	-	1,043,529
Travelling and Conveyance	261,683	79,214	340,897	251,296
Depreciation	414,040,770	158,184,449	572,225,219	149,581,681
	965,491,832	**323,807,812**	**1,289,299,644**	**855,993,858**

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No.	Particulars	Taka			
		July '14 to June '15	July '14 to June '15	July '14 to June '15	July '13 to June '14
		Non Tax Holiday Unit	Tax Holiday Unit (50% Tax exemption)	Total	Total
32	**Other Income: Tk. 41,127,977**				
	This is arrived at as follows :				
	Rent on Investment Property	6,462,000	-	6,462,000	6,462,000
	Other Lease Rent	228,000	-	228,000	228,000
	Income/(loss) from sale of Motor vehicle	4,104,995	-	4,104,995	(185,645)
	Interest Bank's STD and SND A/C	685,509	-	685,509	842,831
	Translation Gain/(Loss) for Foreign currency fluctuation	(13,591,519)	-	(13,591,519)	2,031,861
	Settlement Gain/(Loss) for Foreign currency fluctuation	(3,204,969)	-	(3,204,969)	55,448
	Interest on FDR	46,226,014	-	46,226,014	96,263,653
	Unutilized amount of UNDP Grant	-	-	-	2,373,829
	Dividend income on marketable securities	-	217,947	217,947	-
		40,910,030	**217,947**	**41,127,977**	**108,071,977**
33	**Selling, Marketing and Distribution Expenses: Tk. 1,555,756,698**				
	This is arrived at as follows :				
	Salary & Allowances	765,700,453	232,084,865	997,785,318	903,308,935
	Daily Basis Salary	4,225,516	1,280,760	5,506,276	7,139,581
	Gratuity	38,727,014	11,738,211	50,465,225	31,619,507
	Company's Contribution to RPF	31,614,490	9,582,396	41,196,886	43,264,358
	Office Rent	6,003,370	1,819,630	7,823,000	8,536,475
	Electricity, WASA & Gas	6,540,151	1,982,329	8,522,480	9,628,060
	Postage & Telephone	13,455,939	4,078,514	17,534,453	17,398,288
	Fuel for Generator	1,410,908	427,648	1,838,556	2,481,079
	Vehicle Expenses	20,778,539	6,298,004	27,076,543	24,982,618
	Printing & Stationery	30,860,351	9,353,815	40,214,166	40,736,424
	TA/DA	53,616,395	16,251,203	69,867,598	67,793,307
	Travelling Kits	5,504,368	1,668,382	7,172,750	11,251,350
	Carriage Outward	26,014,202	7,884,940	33,899,142	44,422,394
	Seminar & Conference	4,216,780	1,278,112	5,494,892	12,906,607
	Medical Expenses	772,911	234,271	1,007,182	1,166,829
	Sales Promotion Expenses	58,346,679	17,684,959	76,031,638	78,510,559
	New Products Induction expense	1,122,705	340,294	1,462,999	706,052
	Group & Health Insurance Premium	3,317,508	1,005,541	4,323,049	1,179,357
	Export Expenses	10,084,027	3,056,482	13,140,509	15,872,252
	Welfare & Recreation	1,568,168	475,314	2,043,482	2,256,669
	Free Sample	44,815,066	13,583,509	58,398,575	51,797,636
	Insurance	5,711,267	1,731,093	7,442,360	5,884,372
	Fees & Renewals	8,627,593	2,615,036	11,242,629	12,376,370
	Repair & Maintenance	2,783,880	843,798	3,627,678	3,534,458
	Entertainment	10,052,009	3,046,778	13,098,787	12,369,786
	Repacking Materials	657,261	199,217	856,478	982,790
	Contribution to CSR Activities	-	-	-	466,825
	Depreciation	37,360,138	11,323,909	48,684,047	87,255,981
		1,193,887,688	**361,869,010**	**1,555,756,698**	**1,499,828,917**

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No.	Particulars	Taka			
		July '14 to June '15	July '14 to June '15	July '14 to June '15	July '13 to June '14
		Non Tax Holiday Unit	Tax Holiday Unit (50% Tax exemption)	Total	Total
34	**Administrative Expenses: Tk. 387,355,878**				
	This is made up as follows :				
	Directors Remuneration	22,101,120	6,698,880	28,800,000	118,494,500
	Salary & Allowances	140,608,879	42,618,746	183,227,625	197,049,886
	Directors sitting fee	1,367,891	414,609	1,782,500	390,000
	Group & Health Insurance Premium	875,178	265,268	1,140,446	464,352
	Postage & Telephone	3,714,557	1,125,888	4,840,445	5,554,258
	Electricity ,Gas & WASA	11,182,887	3,389,549	14,572,436	12,720,601
	Fuel for Generator & Vehicle	4,112,789	1,246,592	5,359,381	10,452,723
	Conveyance	3,051,618	924,949	3,976,567	3,651,022
	Refreshment Expenses	3,137,028	950,838	4,087,866	5,165,930
	Office General Expenses	4,417,197	1,338,859	5,756,056	16,981,975
	Vehicle Expenses	9,613,547	2,913,879	12,527,426	13,440,965
	Advertisement for Recruitment & Others	1,602,502	485,721	2,088,223	3,387,249
	Printing & Stationary	10,026,684	3,039,102	13,065,786	17,882,361
	Intangible Assets Write off	31,943	9,682	41,625	51,257
	Newspaper & Periodicals	384,827	116,641	501,468	328,883
	AGM Expenses	160,778	48,732	209,510	1,238,986
	Expenses for Legal Procedure	1,790,603	542,734	2,333,337	2,055,272
	Gratuity	9,927,631	3,009,079	12,936,710	10,835,572
	Company's Contribution to RPF	6,524,155	1,977,480	8,501,635	8,154,492
	Professional Fee	6,380,672	1,933,991	8,314,663	6,063,593
	Audit Fee	383,700	116,300	500,000	500,000
	Medical Expenses	138,270	41,910	180,180	1,458,226
	Uniform and liveries	494,082	149,757	643,839	804,180
	Travelling Expenses	2,721,652	824,937	3,546,589	3,297,454
	Foreign Business travelling	-	-	-	182,536
	Repair and maintenance	8,541,273	2,588,871	11,130,144	12,725,321
	Insurance	1,270,814	385,186	1,656,000	1,389,852
	Municipal Tax	-	-	-	1,725,075
	Fees and Renewals	2,497,638	757,038	3,254,676	5,287,388
	Merger Expenses	-	-	-	625,000
	Welfare and recreation	1,067,105	323,441	1,390,546	1,734,440
	Daily basis salary	2,377,904	720,746	3,098,650	6,319,459
	Contribution to CSR Activities	524,237	158,897	683,134	1,180,691
	Depreciation	36,227,738	10,980,677	47,208,415	74,790,840
		297,256,899	**90,098,979**	**387,355,878**	**546,384,337**

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No.	Particulars	Taka			
		July '14 to June '15	July '14 to June '15	July '14 to June '15	July '13 to June '14
		Non Tax Holiday Unit	Tax Holiday Unit (50% Tax exemption)	Total	Total

35 Financial Expenses: Tk. 982,529,496

This is arrived at as follows :

Interest on Cash Credit	79,316,120	24,040,825	103,356,945	133,230,842
Interest on Overdraft	51,445,597	15,593,232	67,038,829	111,152,170
Interest on MTL & LTR	33,070,930	10,023,845	43,094,775	63,132,054
Interest on Revolving & STL	299,006,112	90,629,165	389,635,277	350,155,776
Interest on Lease Finance	59,180,194	17,937,598	77,117,792	75,017,757
Interest on Term Loan	37,421,425	11,342,485	48,763,910	17,077,865
Interest on Accepted Import Loan	182,793,475	55,404,955	238,198,430	6,169,127
Interest on WPPF	2,403,320	728,450	3,131,770	-
Bank Charge	9,355,963	2,835,805	12,191,768	20,975,600
	753,993,136	**228,536,360**	**982,529,496**	**776,911,190**

36 Contribution to workers profit participation fund: Tk. 67,471,503

This represent 5% of net profit before tax after charging contribution as per provision of the section 15 of the Bangladesh Labour (Amendment) Act, 2013.

37 Income Tax Expenses: Tk. 427,512,918

This is arrived at as follows :

Current Tax Expenses				
Current Tax for the year under review	268,161,434	42,485,667	310,647,101	416,636,328
Tax expense related to prior years	-	-	-	10,000,000
	268,161,434	42,485,667	310,647,101	426,636,328
Deferred Tax Expenses/(Income)				
Deferred Tax Expenses/(Income)	72,719,007	44,146,810	116,865,817	(115,682,993)
	72,719,007	44,146,810	116,865,817	(115,682,993)
	340,880,441	**86,632,477**	**427,512,918**	**310,953,335**

Brief computation of Income Tax Expense and Effective Tax Rate

	Income Year 2014-'15 (Assessment Year 2015-'16)		
	Non-Tax Holiday Unit	Tax Holiday Unit	Total (In Taka)
Net Profit before tax as per Comprehensive Income Statement (a)	915,711,353	433,718,708	1,349,430,061
Taxable profit as per computation (b)	-	-	-
Corporate Tax Rate			35%
Tax Liability thereon	268,161,434	42,485,667	310,647,101
Adjustment recognized for current tax of prior years	-	-	-
Total tax Liability (c)			310,647,101
Adjustment for deferred tax assets			116,865,817
Income tax expense recognized in Financial Statements (d)			**427,512,918**
Effective Tax Rate [(c) /(a)]			**23.02%**

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No.	Particulars	Taka	
		July '14 to June '15	July '13 to June '14
		Total	Total
38	**Basic/Diluted Earnings Per Share (EPS) Tk 5.70**		
	The computation is given below :		
	Net Profit After Tax	921,917,143	893,890,898
	Weighted average number of shares outstanding during the year (38.2)	161,601,700	158,084,771
	Basic Earnings Per Share	**5.70**	**5.65**
	Diluted Earnings Per Share	**5.70**	**5.65**
	Refer Policy notes 5.17		
38.1	**Number of Ordinary Share outstanding : 161,601,700**		
	This is arrived at as follows :		
	Opening number of ordinary shares outstanding	161,601,700	155,631,100
	Add : Ordinary shares issued during the year	-	5,970,600
		161,601,700	161,601,700
38.2	**Weighted average number of Shares Outstanding**		
	This is arrived at as follows :		
	Opening number of shares outstanding	161,601,700	155,631,100
	Add: Weighted average number of ordinary shares issued (Previous year 5,970,600 * 150/365)	-	2,453,671
		161,601,700	**158,084,771**

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No. Particulars

39 Related Party Disclosures:

The company carried out a number of transactions with related parties in the normal course of business and on arms length basis. The nature of the transactions and their relative value is shown below:

Name of the Related Parties	Relation	Nature of Transactions	Value of Transactions	Balance at 30.06.2015 Receivable/(Payable)
ACMUNIO Int. Ltd.	Common Directors	Advance to ACMUNIO Int. Ltd.	23,698,315	144,041,898
		Finished Goods Purchase	16,193,227	-
		Rent as Investment Property	6,462,000	37,156,500
Sinha Printers ltd.	Do	Local Supply received	381,793,998	(391,042,580)
		Provide Service & others	348,296	-
Kalyar Packaging Ltd.	Do	Local Supply	62,486,680	-
Kalyar Replica Ltd.	Do	Local Supply	3,755,407	-

40 Details regarding Disposal of Motor Vehicles

Particulars	Cost/Revaluation	Accumulated Depreciation on (cost/revaluation surplus)	Net Book Value	Sales price	Disposition of total Gain/ (Loss)		
					Charged to Profit/Loss A/C	Charged to Changes in Equity	Total
Vehicle -Bha-14-0109	2,357,339	2,357,339	1	1,225,000	1,224,999	-	1,224,999
Vehicle -kha-12-0202	1,025,000	1,025,000	1	770,000	769,999	-	769,999
Vehicle -Ga-17-4413	1,105,394	1,105,394	1	840,000	839,999	-	839,999
Vehicle -Cha-51-4223	650,000	650,000	1	720,000	719,999	-	719,999
Vehicle -Ga-15-8672	1,085,000	1,085,000	1	550,000	549,999	-	549,999
Vehicle -Ma-51-1335	729,000	492,225	236,775	205,000	-	236,775	236,775
Total	**6,951,733**	**6,714,958**	**236,780**	**4,310,000**	**4,104,995**	**236,775**	**4,341,770**

41 Payments/Receipts in Foreign Currency

	Taka	
	July '14 to June '15	July '13 to June '14
	Amounts in BDT	Amounts in BDT
Payments		
Import of Machinery, Spare parts and Equipments	699,255,480	784,166,032
Import of Raw & Packing Materials	2,019,717,820	2,120,940,942
Foreign Currency Loans	495,952,144	291,574,222
	3,214,925,444	**3,196,681,196**
Receipts		
UNDP grant	-	2,373,829
Exports	465,075,231	363,269,096
Foreign Currency Loans	24,803,828	2,447,608,561
	489,879,059	**2,813,251,486**

42 Directors Remuneration and Sitting Allowance

Directors Remuneration (Including MD's Remuneration Tk. 12,000,000)	28,800,000	118,494,500
Directors Sitting Allowance (Including MD's Sitting Allowance Tk. 166,660)	1,782,500	390,000
	30,582,500	**118,884,500**

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No. Particulars

43 Board Meetings and Attendance

The number of Board Meeting and attendance of Directors during the year 2014-2015 were as follows:

Name of Directors	Position	No. of Meetings held	No. of Meetings attended
Mr. Afzalur Rahman Sinha	Chairman	10	10
Mr. Mizanur Rahman Sinha	Managing Director	10	10
Dr. Jabilur Rahman Sinha	Deputy Managing Director	10	5
Mrs. Jahanara Mizan Sinha	Director	10	10
Mrs. Nagina Afzal Sinha	Director	10	10
Syed Shahed Reza	Independent Director	10	8
Ms. Fouzia Haque FCA	Independent Director	10	10
Mr. Md. Fayekuzzaman	Nominee Director (Upto 11.03.2015)	10	8
Mr. Md. Abdour Rouf	Nominee Director (Upto 04.03.2015)	10	7
Mr. Md. Iftikhar-uz-zaman	Nominee Director (From 04.03.2015)	10	3

44 Audit Fees

500,000	500,000

45 Events After the Reporting Period:

There was no event after the reporting period that requires either disclosure of or adjustment to these financial statements other than changes in shareholding position which is disclosed in note no. 18.d. 'Composition of share holding of Ordinary Shares'.

46 Contingent Liability

The Company has contingent liability of Tk. 21,736,149 to Large Tax Payer Unit (LTU), North Commissionerate and Directorate, Inspection, Intelligence & Investigation under National Board of Revenue (NBR) against 4 (four) claims of VAT to be imposed or not on the company. The ACME Laboratories Ltd. has filed 4 (four) writ petitions in The Honorable High Court Division of the Supreme Court of Bangladesh separately vide no.- 8650/2008, 785/2009, 3948/2004, 4477/2002 and 2477/2015 respectively against the said claims. The company is hopeful that the writ petitions would be decided in its favour.

47 Un Expired Bank Guarantees

Details of unexpired Bank Guarantees of Tk. 29,603,266 given in the normal course of business on behalf of the company to various parties as at 30 June 2015 are as here under:

SL #	Name of the Bank	Date of Expiry	Amount in Taka
1	Dutch Bangla Bank Ltd.	17.10.2016	430,700
2	Dutch Bangla Bank Ltd.	24.05.2017	931,030
3	Dutch Bangla Bank Ltd.	18.09.2015	1,274,720
4	Agrani Bank Ltd.	15.10.2016	1,093,820
5	Agrani Bank Ltd.	11.09.2018	1,547,350
6	Eastern Bank Ltd.	19.02.2016	623,000
7	Trust bank Ltd.	02.07.2015	2,200,000
8	Trust bank Ltd.	02.07.2015	1,250,000
9	Trust bank Ltd.	02.07.2015	500,000
10	Trust bank Ltd.	02.07.2015	300,000
11	Trust bank Ltd.	02.09.2015	1,200,000
12	Trust bank Ltd.	02.09.2015	700,000
13	Trust bank Ltd.	31.07.2015	6,400,000
14	Trust bank Ltd.	31.07.2015	6,000,000
15	Trust bank Ltd.	30.08.2015	1,050,000
16	Trust bank Ltd.	30.08.2015	110,000
17	Trust bank Ltd.	15.04.2016	787,200
18	Trust bank Ltd.	30.04.2016	1,993,365
19	Trust bank Ltd.	30.04.2016	547,780
20	Trust bank Ltd.	19.05.2016	664,301
			29,603,266

The ACME Laboratories Ltd.

Notes to the Financial Statements

For the Year Ended 30 June 2015

No. Particulars

48 Claim not Acknowledged as Debts

There is no claim against the company which have been acknowledged as debt as at 30 June 2015.

49 Capital Expenditure Commitment

The estimated amount of capital expenditure commitment of the company mainly in the form of Letter of Credit opened in favour of suppliers as at 30 June 2015 is Tk. 49,647,745.

50 Production Capacity and Actual Production (Quantity in Thousand)

Name of Category	Unit	Production Capacity		Actual Production		Actual Production	
		2014-15	2013-14	2014-15	%	2013-14	%
Human							
Tablet	Pcs	3,368,590	3,086,237	2,199,808	65.30	1,953,640	63.30
Capsule	Pcs	630,486	630,486	348,051	55.20	319,640	50.70
Liquid	Bottle	87,234	62,250	51,959	59.56	46,571	74.81
Dry Syrup	Bottle	18,409	18,409	8,574	46.58	6,712	36.46
Ointment	Tube	6,158	3,984	1,894	30.76	1,640	41.16
Cream	Tube	17,928	17,928	4,920	27.44	4,238	23.64
Suppository	Pcs	32,660	14,940	21,770	66.66	15,297	102.39
Inhaler (DPI)	Cans	66,690	22,410	27,738	41.59	24,530	109.46
Inhaler (MDI)	Canister	1,457	498	487	33.41	410	82.31
Eye/Ear/Nasal Drop	Phials	10,136	6,640	9,091	89.69	7,607	114.56
Injection (Amps)	Pcs	35,380	24,900	30,518	86.26	24,244	97.37
Injection (Vial)	Pcs	15,350	18,424	9,176	59.78	14,374	78.02
Infusion	Pcs	4,680	-	2,001	42.76		
Sachet	Pcs	28,201	-	8,223	29.16		
Veterinary							
Bolus	Pcs	217,445	174,300	118,482	54.49	98,758	56.66
Liquid	Pcs	5,212	4,980	3,748	71.90	3,025	60.75
Premix	Pcs	27,587	14,940	14,448	52.37	13,255	88.72
WSP	Pcs	8,579	5,976	3,836	44.71	3,228	54.02
Injection	Vial	12,487	12,700	11,305	90.54	8,996	70.83
Herbal & Ayurbedic							
Capsule	Pcs	32,370	32,370	9,235	28.53	8,145	25.16
Liquid	Pcs	8,708	7,470	6,460	74.18	5,189	69.46
Tablet	Pcs	29,880	29,880	11,126	37.24	12,354	41.35

Note: Capacity is calculated considering 240 days per year; 2 shifts per day and 8 hours per shifts.

51 VAT Return and Auditing status as at 30.06.2015

The Company is depositing VAT & filing VAT returns on monthly basis with the concerned department. The department has conducted and completed their audit upto the financial year 2013-14 in June 2015 and there is no adverse findings of the department during the course of audit.

GREAT

2011...

BETTER

(1976-2010)

GOOD

(1954-1975)

Good to Great

The ACME Laboratories Ltd.

www.acmeglobal.com

Corporate Office
Court de la ACME
1/4, Kallayanpur, Mirpur Road, Dhaka - 1207
Phone : +88 02 900 4194-6
Fax : +88 02 901 6872
E-mail: headoffice@acmeglobal.com

Plant
Dhamrai, Dhaka, Bangladesh
Phone : +88 02 773 0881-2
+88 02 773 0816-7
Fax : +88 02 773 0141
E-mail: plant@acmeglobal.com